,ticker,content
0,EW,build earning season watch list look stock potential buy range ahead next report edward lifescience ew currently fit bill company be expect release latest number jul trading buy point first stage flat base be aware buy just stock report be risky poor number send sharply lower reduce risk wait see actual number market reaction way minimize risk post earning sell be use option strategy look winning stock try simple routinewhile revenue growth fall last quarter bottom line grow previous report analyst expect earning growth quarter growth full year annual ep estimate be recently revise upward company have composite rating earn rank peer medical product industry group abiom abmd align technology algn inogen ingn be top highly rate stock group note date earning report be subject change check company update get newsletter deliver inbox more info product service privacy policy term useget instant access more trading idea exclusive stock list ibd proprietary rating only also earning calendar analyst estimate stock watchnew option strategy limit risk earning
1,EW,edward lifescience ew have relative strength rs rating upgrade tuesday look best stock buy watch factor watch closely be relative price strength ibd unique rs rating track technical performance used worst best score show stock price performance trail week match rest market history reveal market biggest winner often have rs rating north early stage move see ibd help make more money stocksedward lifescience be still buy range breaking past buy point flat base once stock move higher original entry consider extend buy range company top line growth fall last quarter ep grow prior report company earn rank peer medical product industry group abiom abmd align technology algn icu medical icui be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
2,EW,ibd smartselect composite rating edward lifescience ew increase monday new rating show stock be outpace stock come most important stock pick criterium market biggest winner often have higher grade early stage new price run so important benchmark look look best stock buy watch edward lifescience be currently form flat base buy point look stock break heavy trade least higher normal see ibd help make more money stock earn ep rating mean recent quarterly longer term annual earning growth be outpace stock accumulation distribution rating show roughly equal amount buy selling institutional investor last week get newsletter deliver inbox more info product service privacy policy term usein company report earning growth mark straight report rise ep gain top line growth come previous quarter edward lifescience earn rank peer medical product industry group abiom abmd align technology algn icu medical icui be top highly rate stock group related company be now outperform stock see stock just come ibd top stock list
3,EW,wednesday edward lifescience ew get upgrade relative strength rs rating look best stock buy watch factor watch closely be relative price strength unique rating identify market leadership used worst best score indicate stock price action last week match other publicly trade company history reveal best stock typically have better rs rating begin biggest price move see ibd help make more money stocksedward lifescience be work flat base entry see stock clear price heavy volume earning growth moved company latest report top line fall company earn rank peer medical product industry group abiom abmd align technology algn icu medical icui be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also stock be show improve technical action use ibd relative strength rating relative strength line help judge stock
4,EW,edward lifescience ew see ibd smartselect composite rating rise thursday day upgrade mean stock currently top other stock term key performance metric technical strength winning stock often have higher score early stage new price run so good start point look best stock buy watch edward lifescience be currently form flat base entry look stock break heavy trade least average look winning stock try simple stock have ep rating meaning recent quarterly longer term annual earning growth be outpace stock accumulation distribution rating show moderate selling institutional investor last week look rating improve least better get newsletter deliver inbox more info product service privacy policy term usein company post earning growth mark straight report rise ep growth top line growth fall previous quarter edward lifescience hold rank peer medical product industry group abiom abmd align technology algn icu medical icui be top highly rate stock group related company be now outperform stock see stock just come ibd top stock list
5,EW,edward lifescience ew stock tumble late tuesday revenue key heart valve replacement segment come short analyst say quarter edward report adjust sale transcatheter heart valve replacement tavr tavr be method replace diseased heart valve used catheter rather resort open heart surgery consensus have call unit first quarter have always be tricky model fewer procedure center day window swing revenue edward context constitute beat miss evercore analyst vijay kumar say note hour trading stock market today edward share tank stock close have be form flat base buy point mid march get free access ibd digital april
6,EW,get premium stock list pass fail stock rating more start overall quarter look strong edward lift profit guidance year kumar say first quarter edward report adjust sale beating consensus kumar say represent underlie sale growth position company growth year chief executive michael mussallem say written statement unadjusted sale quarter be transcatheter heart valve therapy sale rise gaap basis adjust sale unit be company expect full year tavr sale be overall sale be help surgical heart valve replacement critical care kumar write adjust basis surgical heart valve therapy sale grow quarter critical care sale also rise underlie basis year edward guide sale adjust profit share analyst have predict revenue adjust earning share related do spot major market top easy look heavy basic sell stocknew option strategy limit risk earning
7,EW,edward lifescience ew be form base show buy point get ready report next round earning apr base be first stage flat base buy stock just ahead earning involve risk typically don have enough time establish profit cushion latest quarterly number come be sure follow sound buy sell rule minimize exposure see ibd help make more money stocksearning grow last quarter prior report revenue also increase consensus analyst estimate call earning share growth quarter growth full year annual growth estimate be recently revise lower company have composite rating earn rank peer medical product industry group abiom abmd align technology algn globus medical gmed be top highly rate stock group note date earning report be subject change check company update get newsletter deliver inbox more info product service privacy policy term also earning calendar analyst estimate stock watchnew option strategy limit risk earning
8,EW,boston scientific bsx land broker list top stock analyst suggest tuesday medtech company hit share earning power rbc capital market analyst glenn novarro be bullish boston revenue prospect boston have number implantable device cardiac condition neurological disorder chronic pain relief also have broad portfolio endoscopy urology pelvic health reach novarro earning projection boston have grow compound annual rate last year gaap earning share also have achieve operate margin expansion basis point furthermore new launch peripheral intervention interventional cardiology medsurg be incremental growth say note client therefore organic revenue growth seem quite feasible get newsletter deliver inbox more info product service privacy policy term useon stock market today boston share advanced close same time ibd company medical product industry group collectively rise group rank second industry group ibd track novarro also see margin earning interest taxe ebit realistic goal boston previous report metric set guidance growth basis point upcoming key event include plan launch drug coat balloon call ranger potentially aortic valve system dub acurate neo well boston also begin study implantable heart device call watchman lead approval medtech company be also likely have datum study slow drug delivery system further separate study acurate neo vs edward lifescience ew device call sapien medtronic mdt corevalve evolut complete enrollment second half study have datum get instant access more trading idea exclusive stock list ibd proprietary rating only related much money do need start investing long term retirement investing strategy etfslook best stock buy watch start here
9,EW,top stock power tuesday president donald trump north korean leader kim jong sign comprehensive agreement tech heavy nasdaq extend gain midday trade rise more top stock hit new high tuesday include molina healthcare moh twitter twtr xmolina healthcare be breaking cup handle buy point share advanced nearly intraday high stock be trading high end buy range run volume be tracking more average featured monday stock buy zone column molina provide health insurance individual government program medicaid medicare monday suntrust robinson humphrey initiate stock buy rating price target accord analyst molina have undergo transformation past several quarters marked significant change management profit improvement initiative get newsletter deliver inbox more info product service privacy policy term surge more daily high price early tuesday jpmorgan boost price target social medium platform analyst cite strengthen ad momentum large marketer share be cup handle entry most recent quarter quarterly earning grow cent share meanwhile revenue rise vs year period meanwhile medical stock leader edward lifescience ew moved tuesday high price add recent gain stock break flat base entry june accord marketsmith chart analysis buy range top latest quarter year year earning growth accelerate second straight quarter kmg chemical kmg blast new high tuesday chemical maker fiscal result top street estimate meanwhile company raise full year sale forecast stock end monday just choppy base entry share be now extend peak price tuesday share surge much kmg be rank stock chemical specialty group composite rating highest possible rating be blend key fundamental technical metric related stock buy zone time take profit twitter system stratasys struggle printer mold new breakouttrump kim summit time warner ruling cpi investing action plan
10,EW,most stock flunk slim test run trouble early acronym company doesn have fast quarterly earning growth pass annual test stand current earning growth be least past quarters stand annual earning growth be more past year recent look big cap find stock meet requirement first letter be abiom abmd salesforce com crm edward lifescience ew palo alto network panw get newsletter deliver inbox more info product service privacy policy term pass grade first item attention naturally shift refer new factor new factor be number thing new product service industry condition management new company have new factor be important often mean stock have opportunity fast growth heart pump device maker abiom have recur new factor company family impella heart pump be regularly winning regulatory approval new used ceo michael minogue say company earning call late april impella be still early innings penetration rate approximately patient alone early innings angle be exactly bull hear new factor salesforce com be new customer accord international datum corporation market intelligence provider salesforce com increase market share more percentage point top competitor combine salesforce also chalk new item acquire mulesoft ceo marc benioff say earning call so many ceo speak tell datum remain lock legacy system be hold back mulesoft re now enable customer connect datum public private cloud mulesoft be march initial public offer sale edward lifescience make heart valf other product cardiovascular disorder ceo michael mussallem say april earning call therapy penetration transcatheter aortic valve replacement be still low mean edward be still young side growth curve software security provider palo alto network have new ceo ex google executive nikesh arora earning call early june arora say transition cloud be inevitable next few decade see almost company have make transition related regional oil refiner be winning clue look stocksdon compete last dollar
11,EW,kmg chemical kmg break undefined pattern buy point just hour earning report share rise sharply extend trading kmg beat expectation adjust profit share estimate cent share sale rise kmg raise sale forecast fiscal year end july volume monday regular trading be triple average relative strength line make new high well be good indication always risk buy stock announce earning kmg make chemical used make semiconductor photovoltaic flat panel display make play chip solar consumer electronic also make wood treatment chemical ep climb previous quarters stock have more double break base october create risk consider get newsletter deliver inbox more info product service privacy policy term usewendy wen rise just past buy point cup handle base volume be merely average rs line fail make new high share rally wendy be case stock emerge late industry advance restaurant industry group be top group couple month have sunk edward lifescience ew initially rise past buy point last week fade monday maker product treat heart disease make much stronger move share climb time high volume remain soft related top rate kmg chemical form later stage base earning duemcdonald plan more corporate job cut tech push report
12,EW,major stock index be lower afternoon trading wednesday salvo form threat additional tariff worth chinese import good heighten tension small cap large cap not escape selling stock today retailer sell especially hard et dow jone industrial average lead sell trade session lows wednesday nasdaq composite drop volume be run mildly higher vs same time tuesday nasdaq be slightly lower nyse smallcap slip utility advanced airline fall hard more sell west texas intermediate crude oil price be torrid year so far crude oil barrel wti term future still claim gain jan stock dow jone industrial average export heavy firm suffer brunt selling least blue chip firm fall point more chevron cvx global integrate oil gas titan dive light trading stock have be weave bob day move average week yet cup handle be still intact potential point be cent handle high caterpillar cat slump point more average turnover drop nearly wipe strong monday tuesday advance stock have be swimming day move average more week continue form potential new saucer cup base cat construction mining gear giant have be amazing turnaround fundamental earning share boost part easy year year comp rise vs year level past quarters sale ramp street see june quarter earning still rise hearty share retail company sell hard floor decor fnd kitchen good furniture retailer william sonoma wsm drop hard heavy turnover former gouge day move average share drop more quadruple usual trade filing sec william sonoma have note dependence foreign vendor increase global operation subject variety risk uncertainty impact operation financial result include potential disruption delay import foreign vendor furniture be government target list chinese import get smack tariff medical sector myriad genetic mygn bolt ahead much rushed past buy point nearly month cup handle high handle be add dime get proper buy point depth cup base show decline only touch more maximum drop see cup pattern myriad have rally february low peak begin form bullish chart pattern notice weekly chart expert diagnostic product be used analyze genetic mutation test buy support week move average form handle refusal sink week line reflect solid institutional demand myriad host solid accumulation distribution rating scale heavy net institutional buy heavy net selling edward lifescience ew gap fall nearly active turnover heart valve manufacturer be now top flat base show buy point edward earn generally high mark term proprietary ibd rating see ibd stock checkup include composite rating scale earning share rating top notch smr sale profit margin return equity neutral accumulation distribution please follow saito chung twitter ibd_dchung more commentary growth stock basis breakout sell signal financial market get instant access more trading idea exclusive stock list ibd proprietary rating only related stock be new ibd top growth screen check herewhich way be stock market head read column dayglobal do stock rank vs industry peer evaluate fast stock checkup
13,EW,stock market rally squarely higher early wednesday trump administration ease trade threat china top fang stock netflix nflx look recover monday heavy loss day straight gain early wednesday update story other market coverage visit stock market today dow jone industrial average lead action jump rise tech heavy nasdaq follow gain dow stock apple aapl rise rebound day line continue share rise second straight day wednesday stock be also double bottom entry downside mcdonald mcd decline almost fall further day move average line get newsletter deliver inbox more info product service privacy policy term company report earning restaurant chain sonic drive sonc faltered revenue same store sale miss estimate late tuesday gain buy point top today fall share be only edward lifescience ew fall bernstein initiate coverage medical stock market perform rating price target premium tuesday close price share be back buy range flat base entry relative strength line have be hold relatively well recent market turmoil fang stock amazon com amzn netflix nflx remain steady performer rise nearly respectively bank america maintain buy rating netflix hoist price target note project netflix become dominant stream player virtually market give content scale reach subscriber netflix share have mostly re-cover monday decline last trading session tuesday stock rise nearly top growth stock twitter twtr advanced be trading time high share be still well extend cup handle entry downside baozun bzun drop share be look support day line gain buy point top recent volatility share be just get instant access more trading idea exclusive stock list ibd proprietary rating only related top stock break market rout dow jone home depot entrynyse first marijuana stock paychex report earning investing action planwarren buffett stock see join nvidia adobe screenibd stock daydow jone industrial average dow stock news analysis
14,EW,ibd stock screen be regularly update add new stock watch well weed have start show weakness table ll see stock have be add remove list ibd sector leader ibd big cap screen be
15,EW,motivated goal create meaning work edward lifescience ew ceo mike mussallem push boundary follow passion help person live best life process mussallem team have transform edward global leader patient focuse innovation structural heart disease well critical care surgical monitoring mussallem believe key leader success be find meaning work talk folk be develop leader strongly encourage person find meaning work allow be best even surprise term much impact have mussallem tell ibd mussallem meaning work be impact individual patient life change lifesave technology such think have be drive force edward patient first culture innovation strategy lead edward introduction lifesave life sustain therapy such transcatheter aortic valve replacement tavr rapid deployment surgical heart valve replacement noninvasive hemodynamic monitoring take mussallem soul search identify true call early work try pull help pay education work steel mill say time younger year be probably more focuse big paycheck be good benefit be probably wasn joined health care start think do something really matter person life mussallem leadership role edward trace back career baxter international bax start work hold number post include group vice president cardiovascular division mussallem be part group baxter propose cardiovascular division innovate faster better serve patient spun independent company happened april edward lifescience be establish begin life public company mussallem be first only chairman ceo edward have have stand alone company thank ongoing innovation guide mussallem passion help improve save patient life edward position medical technology industry have sky-rocket edward be leader surgical transcatheter heart valf say glenn novarro analyst manage director rbc capital market reason have best technology invest most med tech company heart valf novarro tell ibd re always first market edward team have propel impressive financial growth gain attention investor last year edward top line have grow more stock price have go split adjust ipo april april gain learn lot year do say more more find have great culture be first foremost underpin success company especially culture drife real purpose company feel driver lot success give great comfort be align edward culture be ground patient focus say mussallem edward have opportunity be close patient heart valf have unique serial number edward trace back person handmade inspect valve edward often have reunion patient team make individual valf imagine do team say reinforce importance person work add novarro be passion put everything company be great leader most successful ceo be passionate mike take level not just edward be passion edward do patient also be passion mussallem say company doesn try solve health care problem stay very focuse structural heart disease critical care medicine feel patient be better serve be today be big opportunity apply technology improve care focus bold innovation literally breakthrough technology be exist care get right add lot value patient edward big groundbreaker have be pioneer effort bring transcatheter aortic valve replacement market turn have lead major transformation company abundantly clear year edward have be public company mike not only have thoughtfully reshape company post spinoff portfolio divest acquire also have clearly demonstrated visionary insight innovate brilliantly complex medical device space company tavr structural heart initiative rick wise senior medical technology analyst manage director stifel tell ibd mussallem see big opportunity tavr fact cannibalize company exist lead product be continue be leader surgical heart valf tavr be such radical idea most customer discourage say mussallem rationale be someone be go disrupt core business feel be be have be one else pursue radical idea work very hard develop therapy be not simple linear persist promise patient be so powerful be first time career have chance experience significant way call triple improve mortality improve quality life patient improve economic health care system edward sapien family transcatheter aortic heart valf delivery system be used treat heart valve disease used catheter base approach certain patient traditional open heart surgery isn optimal company say deliver heart be beating valf enable patient have better quality life sooner receive traditional surgical therapy motivate guide employee mussallem team have develop secret sauce principle eye always patient need mussallem encourage team dream big not be afraid failure learn mistake mussallem develop leadership management principle many source baxter mussallem gain confidence skill lesson learn be not be afraid difficult job say often job be not high profile involve take underperform business function isn see glamorous be opportunity someone get significant responsibility demonstrate own ability add value lesson help mussallem support decision spin independent company cardiovascular division baxter mussallem be responsible time cardiovascular business be poorest performer baxter portfolio say have low growth rate low profitability uncertain future have lot hard work do early year say team stay optimistic time be able sharpen strategy seriously invest new innovation be able completely change profile company element strategy have be priority be leadership feel try be best do add proud edward sell be global position mussallem be born grow gary ind earn bachelor degree chemical engineering rise hulman institute technology graduation work union carbide chemical engineer make prestone antifreeze time realize be do something more fulfill change person life then go health care develop many personal value passion innovation younger year ve never be be afraid take challenge say be fortunate have loving parent other live life give child better life always feel responsibility do best believe company have many same idea transform edward global leader innovator structural heart diseaseovercame risky business decision spin edward baxter develop complex therapy lesson find meaning work allow be best even surprise term much impact have
16,EW,stock market hold minor gain early trade wednesday ahead fed interest rate decision et fed be widely expect announce quarter point rate hike meanwhile fang stock netflix nflx advanced new high update story other market coverage visit stock news today tech heavy nasdaq moved rise dow jone industrial average edge higher dow stock verizon communication vz faltered almost give day move average line lead payment processor square sq be cut buy neutral buckingham stock reversed early loss rise almost share hit new high tuesday be well extend double bottom entry get newsletter deliver inbox more info product service privacy policy term fang stock video stream platform netflix lead day action rise ibd leaderboard stock be time high be extend flat base buy point volume have be underwhelm be tracking average early trade bullish signal big cap member edward lifescience ew rise early wednesday recent continue gain traction share break flat base entry june stock be cusp be extend day streak early week stock relative strength line hit new high confirm stock significant outperformance vs broad market twitter twtr moved wednesday share be profit take level cup handle entry accord marketsmith chart analysis top growth stock palo alto network panw rebound day line continue share rally add tuesday rise meanwhile grubhub grub look extend streak trading session advance stock hit new high be gain strength double bottom entry downside recent ibd stock day bofi hold bofi slide fall flat base entry related top stock buy zone time take profit twitter system stratasys struggle printer mold new breakoutbest growth stock buy watch see update ibd stock listsf rate hike time warner ruling fallout investing action plan
17,EW,keep watch list date be key make money stock market ibd help do regularly update stock screen ibd sector leader ibd big cap ipo leader table see stock have just be add remove list list help identify best stock buy watch used proprietary slim investing system look stock display same common trait typically share best perform stock early stage big price move check column daily help build maintain watch list alert most recent change keep mind never buy stock just ibd list always do own research run stock idea buy checklist also streamline investing process ibd simple step routine quickly track general market trend find stock watch pinpoint best time buy sell change make june pm et ibd flagship screen best growth stock watch give company show strong relative price strength top notch fundamental decide stock buy always check new innovative stock historically far outperform get newsletter deliver inbox more info product service privacy policy term useibd most stringent powerful screen sector leader highlight best growth stock ibd sector sector leader show outstanding earning sale growth recent quarters be strong many other fundamental price performance metric daily screen uncover top rate large cap growth stock consideration big cap company deliver outsize gain volatility smaller growth stock recent ipo stock be often find market best stock new ipos be typically early stage growth big earning growth generally fuel stock price performance ipo leader have special screening criterium find come stock strong fundamental technical trait daily stock list seek best stock buy watch top fundamental be get ready break use glean emerge industry sector trend market view prior ibd stock list also look next big stock start herewhich company be now outperform stock buy stock buy checklistwhen sell stock selling checklist
18,EW,boston scientific bsx investor breathe sigh relief wednesday medical technology player top analyst first quarter expectation lift guidance day rival edward lifescience ew come short key segment stock market today boston rise close share be consolidate buy point edward stock other hand sank boston be seemingly buck choppy earning season evercore analyst vijay kumar say note client environment feel most medtech stock be expect trade issue report boston be steady go say investor position possibly contribute move today say step away quarter think share be fairly price give current growth outlook relative similar high growth large cap peer cause remain sideline get free access ibd digital april
19,EW,get premium stock list pass fail stock rating more start first quarter boston report adjust profit cent share rise nearly top consensus penny total sale grow report basis also beating analyst view boston also raise outlook sale adjust profit share metric top consensus sale adjust earning share boston be ride wave choppy earning season kumar say neuromodulator sale be source upside quarter revenue implantable device treat chronic pain neurological disease grow report basis operationally be help sale spectra wavewriter spinal cord stimulator used treat chronic pain device gain approval january subsequently launch revenue implantable cardioverter defibrillator also help grow double digit kumar say cardiac rhythm management sale be line organically interventional cardiology grow organic basis kumar view growth investor be likely nervous boston hasn yet offer update transcatheter heart valve replacement tavr device call lotus tavr be method replace diseased heart valve used catheter rather resort open heart surgery boston voluntarily recall lotus lotus edge aortic valve system europe last year discover issue system february boston say plan launch lotus edge system europe lotus product compete tavr system edward medtronic mdt have respective mid mid split market analyst say have nitpick possibly lack lotus update better revenue flow high end not translate operate margin expansion come mind kumar say sense be be healthy debate stock lotus related chart read basic buy point mark time real invest stock free new apps aim buy stock ahead earning report
20,EW,premarket trading strengthen wednesday stock future turn mixed gain boee ba twitter twtr cree cree other positive quarterly report dow jone future shed early loss climb narrowly fair value boee lead handful rise dow stock walmart wmt fall hardest nasdaq future trade fraction higher future trim early loss trade just break even line texas instrument txn lead index apple aapl dip facebook fb rise ahead first quarter result due today close google parent alphabet googl gain follow upgrade buy hold stifel nicolaus get free access ibd digital april
21,EW,get premium stock list pass fail stock rating more start market find more cautious stance head wednesday open lead index have be shut resistance day move average dow appear head test support day level nasdaq outpaced market general loss tuesday diving small cap other hand show resilience russell end loss find support day line earning front boee lead dow stock premarket gain report first quarter revenue earning significantly expectation management also raise full year earning guidance well consensus target stock be attempt retake week move average ninth week consolidation twitter sharply trim early gain less first quarter result blow past consensus view twitter share be start year optimism rise refinement micro blog site stock be attempt regain support week move average sixth week consolidation edward lifescience ew stumble lower strong first quarter sale earning beat second quarter guidance be softer expect sale come short company closely watch tavr segment management raise full year earning outlook analyst forecast share be shallow consolidation march high morning other earning drive move switzerland base credit suisse group cs china sohu sohu surge more base glaxosmithkline gsk drop more earning comcast cmcsa skid lower earning result company also formally offer long run battle walt disney st century fox fox take base broadcaster sky chipmaker crank powerful gain loss premarket session cree ahead earning cent share rise revenue fiscal third quarter easily top expectation stock have pull back just buy point follow big volume march texas instrument gain jpmorgan hike dalla base chipmaker price target follow healthy first quarter beat report last tuesday stock have be consolidate january other chip name st microelectronic stm leap teradyne ter pare early dive loss benchmark crude oil slip wednesday early trade bob barrel oil price see effect energy information administration weekly oil stockpile report due et datum release tuesday american petroleum institute signale surprise barrel rise weekly inventory vs expectation barrel decline year yield be effectively flat bond market have become focal point many investor yield year treasury note edge tuesday be first move more year rise yield occur bond price decline typically indicate decrease demand bond isn generally negative stock market fact bond price decrease yield rise stock usually rise investor capital shift market other rise yield be general indicator environment rise rate create federal reserve strategy begin normalize target interest rate bank fed begin lower target rate peak target rate remain abnormally low follow economic recession fed begin hike rate target back june last year have implement subsequent increase market expect more increase year consumer rise rate mean thing mortgage credit card debt be more expensive company increase cost borrow capital be long list industry benefit rise risk environment be welcome change most fix income investor be interested big picture be bull market finally today market baozun solaredge technology join ibd stock listapple stock fall fifth straight day wall street full panic mode google earning raise question amazon com rivalry twitter boee paypal visa earning action plan
22,EW,several heavy day stock market last week lead growth stock continue perform well stock market today include top stock td ameritrade amtd earning season be full swing so investor be vigilant potential earning result earning release usually result volatile price change so ensure have decent profit cushion least more withstand downside move meanwhile better expect result lead breakaway gap top brokerage firm newly add ibd stock td ameritrade be approach flat base entry early monday be away proper buy point bullishly stock relative strength line inked blue marketsmith chart be already new high strong uptrending rs line show significant market outperformance get newsletter deliver inbox more info product service privacy policy term company be due report earning result market close monday last week rival charle schwab schw trade financial etfc report strong result ameritrade analyst expect company continue trend strong earning growth profit cent share revenue respective year year increase analyst estimate earning growth medical leader edward lifescience ew be etching base base formation have potential entry share be hover just week line away entry earning result loom edward be current leader transcatheter aortic heart valve replacement tavr market earning be report tuesday close payment processor ibd member fleetcor technology flt be near flat base buy point share fall nearly monday still stock be hold nicely week line last november good flat base show decline more base highest price most recent quarter earning sale growth increase respectively vs year period quarterly earning be due april lastly cybersecurity firm okta okta be breaking cup shape base entry early monday advance volume be tracking average midday trade stock be perform well company have yet show profit lose cent share fiscal year end january year ideally stock display fundamental technical strength strong earning growth be normally catalyst big stock move stock market uptrend continue be lookout stock be be add remove ibd stock list help pinpoint potential leadership tip make investment decision be sure check current market condition use ibd stock checkup see stock get pass rating most important fundamental technical criterium get ongoing chart analysis alert buy sell signal check leaderboard swingtrader related top online broker be just buy point earning workday lead top software stock buy point be breaking outbest growth stock buy watch see update ibd stock listsfacebook amazon alphabet lead tech earning bonanza investing action planearning calendar analyst estimate stock watch ibd stock near buy point earning due
23,EW,larry wood liken aortic stenosis cancer heart aortic stenosis be most common serious valve disease problem restrict blood flow left ventricle aorta cause fatigue pain occur birth defect elderly patient edward lifescience ew medtronic ticker
24,EW,ibd stock screen be regularly update add new stock watch well weed have start show weakness table ll see stock have be add remove list ibd sector leader ibd big cap screen be
25,EW,stock post modest gain monday report president trump do not desire trade war china many individual investor top stock mutual fund benefit take ab large cap growth fund apgax ibd best mutual fund award winner fund tack monday gain fund stock be positive territory late afternoon holding finished day gain lead stock hold fund such copart cprt edward lifescience ew zoetis zts global spgi paypal pypl book holding bkng close mostly column copart be edward be slightly lower zoetis be global be paypal be nearly book be stock market warm news report president trump be look avoid trade war china get newsletter deliver inbox more info product service privacy policy term uselead manager frank caruso co manager john fogarty senior research analyst vinay thapar current ibd question answer feature explain stock addition salvage car auctioneer copart say last week expand tuscon ariz location company say expansion boost efficiency buyer seller move enable copart store larger number vehicle also last week online travel agency book holding say have renew agreement obtain pricing book ticket technology travelport tvpt travel commerce platform caruso team like animal drug maker zoetis zts improve gross margin recently stock be member ibd big cap stock list ibd take look pointer invest check ibd investment education page be best mutual fund award winner fund have beaten benchmark past year dec large cap growth other stock mutual fund bogey ve beaten be category only eligible fund manage time feat also enjoy need much retirement saving age income
26,EW,keep watch list date be key make money stock market ibd help do regularly update stock screen ibd sector leader ibd big cap ipo leader table see stock have just be add remove list ibd display video id
27,EW,keep watch list date be key make money stock market ibd help do regularly update stock screen ibd sector leader ibd big cap ipo leader table see stock have just be add remove list ibd display video id
28,EW,ibd smartselect composite rating edward lifescience ew rise thursday new rating show stock be outpace stock come most important stock pick criterium top perform stock tend have better grade begin launch significant move edward lifescience be now buy range breaking buy point cup handle look best stock buy watch start stock earn ep rating meaning recent quarterly longer term annual earning growth be outpace stock accumulation distribution rating show roughly equal amount buy selling institutional investor last week company report earning growth top line growth be flat match prior report company next quarterly report be expect feb edward lifescience hold rank peer medical product industry group abiom abmd align technology algn teleflex tfx be top highly rate stock group related company be now outperform stock
29,EW,nasdaq avoid lose ground third straight week thank part late week buy take loss prior week premier market index likely need time recover veteran ibd reader know common high caliber growth stock fall much
30,EW,edward lifescience ew have relative strength rs rating upgrade monday welcome improvement still better score look ibd unique rs rating track technical performance used worst best score indicate stock price action last week match other stock year market history show market biggest winner often have better rs rating early stage move see edward lifescience continue rebound hit benchmark look best stock buy watch start hereedward lifescience be now consider extend buy range clear buy point second stage cup handle see stock form new pattern follow buy opportunity week tight pullback day week move average edward lifescience show earning growth last quarter sale growth come look next report feb company hold rank peer medical product industry group align technology algn abiom abmd teleflex tfx be top highly rate stock group related ibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
31,EW,stock market stumble early wednesday fear escalate trade war dow jone industrial average fall point president trump announce list tariff chinese make good take effect late august review process dow stock boee ba drop update story other market coverage visit stock market today major index be pace snap day streak dow jone industrial average drop decline meanwhile tech heavy nasdaq trim loss dow stock boee caterpillar cat have high overseas exposure decline respectively airplane maker boee attempt regain day line tuesday appear be find resistance level stock trigger loss cut sell signal cup handle entry june meanwhile caterpillar remain well day line high price set back jan get newsletter deliver inbox more info product service privacy policy term fang stock netflix nflx turn positive rise ahead next week earning release share be profit take level flat base buy point accord marketsmith chart analysis top energy stock marathon oil mro fall putt stock further flat base entry early tuesday stock surge buy point close day day lows edward lifescience ew drop be approach day line share have give back bulk gain past flat base entry network ffiv be breaking day support level stock fall nearly stock have be strong performer april flat base buy point top growth stock internet stock twitter twtr drop be time high still stock be cup handle entry meanwhile viper energy partner vnom fall back cup shape base entry stock fall share regain buy point tuesday get instant access more trading idea exclusive stock list ibd proprietary rating only related top stock be buy range new market strengthdefense stock eye nato summit trump barb continue investing action planthese oil stock hit buy point crude price rise supply worriesdow jone industrial average dow stock news analysisq earning netflix stock expect growth
32,EW,keep watch list date be key make money stock market ibd help do regularly update stock screen ibd sector leader ibd big cap ipo leader table see stock have just be add remove list ibd display video id
33,EW,ibd stock screen be regularly update add new stock watch well weed have start show weakness table ll see stock have be add remove list ibd sector leader ibd big cap screen be
34,EW,dow jone component johnson johnson jnj engage bidding war sweep boston scientific bsx stryker syk analyst say tuesday follow rumor latter merge report emerge monday stryker approach boston takeover bid boston share spiked rumor stryker topple canaccord analyst say stryker be far only medical device maker interest boston headline be substantiated stryker be fact make bid boston scientific see high likelihood emerge potential bidder say note client have be banter potential boston scientific acquirer year bidding war emerge place high likelihood be involved stock market today boston stock dip close stryker share plunge even stock look somewhat dim ease fraction get newsletter deliver inbox more info product service privacy policy term deal have analyst somewhat split tuesday regard materiality report do not find potential such marriage be shocking canaccord analyst say indeed see merit such combination standpoint product line synergy stryker acquisition help add product sector higher potential growth bigger market also help stryker differentiate portfolio technology compete large company medtronic mdt boston case deal cap year turnaround allow end high note canaccord analyst say sum definitively think boston scientific be game do fair deal here say rbc analyst glenn novarro view deal unfavorably acknowledge strategic rationale make sense also likely boston win deal less share combine premier growth company medical device space be limit product overlap say however bar value creation be set high give potential valuation company combine stryker boston scientific have revenue stand grow sustainable higher compound annual growth rate medium term novarro say have enterprise value canaccord analyst call potential deal merger equal stryker be only third larger boston also lead further med tech consolidation consummate create behemoth medical device stryker boston scientific join abbott medtronic say think edward lifescience ew be next potential major acquisition target also highlight nephew snn be last remain pure play total joint operation market related chart read basic buy point mark time real trade stock most penny stock fail make investor basic analyze stock cup handle
35,EW,edward lifescience ew see positive improvement relative strength rs rating tuesday rise ibd unique rs rating identify technical performance show stock price action last week compare other stock database history show stock go make biggest gain tend have rs rating north early stage move see edward lifescience continue show renew price strength clear threshold look winning stock try simple routineedward lifescience be now consider extend buy range clear buy point second stage cup handle see stock form new pattern follow buy opportunity week tight pullback day week move average edward lifescience report earning growth most recent report revenue increase keep eye company next round number feb edward lifescience earn rank peer medical product industry group align technology algn be top rank stock group related stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
36,EW,ibd stock screen be regularly update add new stock watch well weed have start show weakness table ll see stock have be add remove list ibd sector leader ibd big cap screen be
37,EW,stock stage positive turnabout late wednesday rise close boee ba walt disney exxon mobil xom lead rebound dow jone industrial land gain first advance session boee top index ride strong first quarter result disney kick late aid upgrade market perform underperform bmo capital exxon surge raise quarterly dividend more hold gain edward lifescience ew drop hard miner freeport mcmoran fcx tumble fourth straight day head list railroad norfolk southern nsc tax man block hrb jump respectively heavy loss tripadvisor trip checkpoint software chkp generic drugmaker mylan myl prevent nasdaq composite shedding fractional loss texas instrument txn hop biogen biib gain first quarter result report late tuesday biogen also receive upgrade outperform neutral robert baird wednesday crude oil price gain benchmark crude settle barrel bond edge lower send year yield basis point telecom fiber optic gear maker mortgage service group post session heaviest loss industry group track ibd get free access ibd digital april
38,EW,get premium stock list pass fail stock rating more start herein fiber optic group name include oclaro ocrl lumentum lite finisar fnsr take hard hit rate sensitive mortgage service stock lendingtree tree hff hf drop respectively apple aapl pare gain close investor await detail meeting chief executive tim cook president trump cook reportedly also meet trump economic advisor larry kudlow well trade representative robert lighthizer well president wednesday morning trump tweet meeting cover many topic include have be treat unfairly many year many country trade apple share be fight regain day move average fang stock tech leader finished session lower alphabet googl lead group fraction stifel nicolaus upgrade stock buy hold follow company result tuesday netflix nflx slump pricing offer high yield bond share be week rebound back day move average facebook fb end flat investor look social medium giant report close consensus view project rise ep revenue accord zack investment research be facebook first quarterly report cambridge analytica datum privacy scandal break last month facebook share have be recover march low be now week meeting resistance day move average boee throttle report first quarter revenue earning significantly expectation management also raise full year earning guidance well consensus target stock be attempt retake week move average be form cup type base buy point other top defense name also post result early wednesday northrop grumman noc trim early loss report result general dynamic gd slump chip stock return volatile trade late day texas instrument stretched gain teradyne ter collapse robert baird cut stock neutral outperform chip equipment maker tuesday warn second quarter result miss consensus target due weaken demand mobile testing device advanced micro device amd tank report earning close comcast maintain gain follow first quarter result company also formally offer long run battle walt disney st century fox fox take base broadcaster sky disney share close fox also advanced ibd stock align technology algn gain ahead quarterly result due today close maker clear orthodontic brace be week line month base pattern bottom list edward lifescience pare loss finish medical product leader deliver strong first quarter sale earning beat second quarter guidance be softer expect sale come short company closely watch tavr segment management raise full year earning outlook analyst forecast share be shallow consolidation march high related big picture be bull market finally facebook twitter boee paypal visa earning action planboee lift earning cash flow view crush estimate twitter stock jump beating earning revenue forecast northrop grumman general dynamic top earning view
39,EW,index dow jone industrial average nasdaq tumble week alphabet googl caterpillar cat mmm earning treasury yield spook investor stock market average pare loss strong earning amazon amzn facebook fb boee ba visa other index dow jone nasdaq find support day move average rebound close week fractional loss year treasury hit first time year hit week pull back short term yield continue rise faster long term rate squeeze yield spread alphabet googl expense ongoing chip weakness also hit stock amazon amzn facebook fb boee ba visa rally strong result intel intc microsoft msft initially hit buy point friday pull back amazon first quarter earning sky-rocket more double ep estimate revenue rise fifth straight quarter accelerate sale growth revenue amazon web service rise aw account most amazon overall operate profit amazon share shot record high friday pare gain advance ebay ebay stock drop report result fall short consensus estimate end quarter global active buyer facebook fb stock surge post first quarter result blow past expectation dash fear exodus user advertiser social medium giant twitter twtr report strong earning guidance share fall ceo make cautious comment slow growth get free access ibd digital april
40,EW,get premium stock list pass fail stock rating more start hereboee ba easily beat forecast raise full year guidance aerospace giant say aircraft completion center china be nearly finished downplay china trade war fear fellow dow jone stock unite technology utx report stronger expect earning sale industrial giant also raise full year adjust ep sale forecast lockheed martin lmt top first quarter estimate defense contractor raise ep revenue target maker didn raise cash flow expectation northrop grumman noc also report earning estimate northrop say didn submit bid air force gps iii contract leave lockheed likely lone bidder raytheon rtn raise full year earning forecast consensus earning revenue top estimate general dynamic gd beat earning meet revenue view share defense contractor sell sharply week software kingpin earn cent share year year sale fiscal third quarter analyst expect cent microsoft msft have be shift business desktop pc software cloud compute infrastructure application such office azure microsoft commercial cloud revenue rise fiscal software giant initially reclaim recent buy point friday pare gain intel intc earning rise sale grow well analyst view chip giant guide higher current quarter sale indicate third straight quarter top line growth share initially jump year high friday reversed close slightly lower texas instrument txn advanced micro device amd stm xilinx xlnx get boost upbeat earning report chip gear maker teradyne ter tumble warning weak demand equipment test mobile device western digital wdc make disk drife memory chip tumble friday beating fiscal view philadelphia semiconductor index fought support day move average google parent alphabet googl report earning revenue top view sharp rise capital spending margin pressure higher traffic acquisition cost spark sell internet search giant capex jump year period include real estate purchase manhattan traffic cost google pay partner website generate advertising revenue jump google have hike spending youtube video content cloud compute smart home consumer appliance artificial intelligence project paypal pypl top earning revenue expectation total payment volume rise year year vs estimate company raise revenue adjust ep guidance management point momentum partnership visa international bank technology platform such baidu bidu exxon mobil xom miss earning view output slip recent surge oil price chevron cvx fall short revenue conocophillip cop crushed estimate hess hes report shallower expect loss royal dutch shell rdsa report highest profit oil price crash energy information administration say crude inventory rise barrel vs drop analyst expect domestic production rise barrel day barrel increase crude oil future briefly top barrel highest level late trade little change week general motor gm ford motor fiat chrysler fcau beat quarterly estimate ford not invest traditional sedan north america go forward almost phase passenger car consumer migrate suvs light truck gm still see small car opportunity home abroad even too shift focus larger more profitable vehicle casino operator la vegas sand lvs top first quarter result estimate help strong demand global gaming hub macau singapore macau also help result wynn resort wynn overall macau sale disappoint analyst wynn resort also approve dividend increase earning report wynn be first steve wynn resign ceo sell stake follow allegation sexual misconduct mgm resort mgm narrowly beat stock tumble decline traffic location mgm be more focuse sand wynn amgen amgn alexion pharmaceutical alxn broadly top view amgen sale adjust profit outlook be bit soft midpoint sale alexion blockbuster soliris miss estimate share pop promising study new drug alxn biogen biib sale lag sluggish spinraza multiple sclerosis drug revenue prothena prta tank monday scrap rare disease drug fail phase study eli lilly lly broadly beat consensus diabetes drug chemotherapy help offset short sale psoriasis drug taltz glaxosmithkline gsk sale adjust profit lag abbvie abbv bristol myer squibb bmy top profit view raise full year guidance bristol sale miss estimate shire shpg say consider raise takeover bid japan takeda vertex pharmaceutical vrtx top view sale decline vs last year vertex say ll move triple pill regimen phase study domino dpz deliver ep gain revenue leap blow view share rise thursday chipotle grill cmg stock vault month high ep unexpectedly jump same store sale also top starbucks sbux be par earning ep rise cent rise sale outdo analyst prediction new oriental education edu earn cent share revenue grow total student enrollment rise year year ibd stock tal education tal ep jump cent share revenue soar student enrollment balloon vs year earlier new oriental tal share pop respective earning day be slightly lower week intraday friday pultegroup phm tuesday crushed view ep jump cent home sale revenue leap homebuilder stock be generally muted due rise interest rate horton dhi biggest builder thursday best view ep surge revenue swell homebuilder stock rally solid gain help cool treasury yield new home sale rise march annualize sale pace unit month high meanwhile exist home price rise february vs year earlier china search engine leader baidu bidu report profit blow past estimate lift share baidu still own majority iqiyi iq hold ipo march video stream iqiyi account roughly parent revenue share iqiyi fall release earning tandem baidu visa report ep gain revenue rise beating fiscal view credit debit card giant raise full year revenue outlook share leap thursday mmm meet ep view revenue rise just consensus dow jone giant slash full year ep target stock plunge caterpillar cat report strong earning sale share heavy construction equipment maker reversed sharply lower tuesday warning operate margin hit high watermark year servicenow now report profit revenue estimate customer now spend annually metric be year year edward lifescience ew top sale adjust profit view share tank sale transcatheter heart valve replacement lag illumina ilmn beat consensus adjust profit rise share sale swell align technology algn report adjust earning share revenue handily beating view cent respectively td ameritrade amtd deliver impressive ep revenue growth fall short lofty expectation share fall week trade financial etfc continue rise last week strong result first solar fslr hit year high earning top expectation due sale several solar project expand production proofpoint pfpt cybersecurity firm top adjust first quarter earning revenue view guide low profit share fall friday advanced protection solution nearly double make new add booking prior quarter
41,EW,here investing action plan tuesday need know investor come day industry giant caterpillar cat lockheed martin lmt wynn resort wynn edward lifescience ew freeport mcmoran fcx report be truly bumper day earning front meanwhile illumina ilmn new oriental education
42,EW,keep watch list date be key make money stock market ibd help do regularly update stock screen ibd sector leader ibd big cap ipo leader table see stock have just be add remove list ibd display video id
43,EW,tableau software datum break base friday company beat fourth quarter expectation stock gap clear buy point cup handle base heavy volume trade buy range volume be many time greater average relative strength line be new high chart
44,EW,ibd stock screen be regularly update add new stock watch well weed have start show weakness table ll see stock have be add remove list ibd sector leader ibd big cap screen be
45,EW,here weekly investing action plan need know investor come week lead tech company facebook fb amazon amzn alphabet googl microsoft msft report earning aerospace defense giant boee ba oil major exxon mobil xom stock watch hot software stock
46,EW,edward lifescience ew rocket late thursday beating fourth quarter sale estimate better expect demand transcatheter heart valve replacement hour trading stock market today edward share pop close regular session fourth quarter edward report adjust income cent share beating estimate cent sale grow crushed consensus revenue transcatheter heart valve therapy advanced beating consensus evercore analyst vijay kumar write note growth be drive robust adoption more center edward say press release transcatheter heart valve replacement tavr be method replace diseased heart valve resort open heart surgery arena edward compete closely medtronic mdt do not experience much slowdown typically see last week year chief executive michael mussallem say written statement ibd take edward ibd composite rating rise twice last week be now best possible meaning outpace stock term key growth metric head ibd datum story more go edward rating increase surgical heart valve therapy sale advanced drive strong sale aortic valf region share gain new product edward say critical care sale rise company now see sale line midpoint analyst view revenue adjust profit be expect come share crush consensus model march quarter edward expect report sale current foreign exchange rate adjust earning share consensus have see adjust profit share sale related boston scientific top fourth quarter sale view earning linebiotech roundup pop drug merger earning news crispr small biotech company cure disease
47,EW,earning tap apr ibd sector leader member align technology algn be currently buy point current formation be third stage cup handle mean more prone failure first second stage formation keep mind risky buy stock just report reduce risk wait see company report market react see ibd help make more money stocksin term top bottom line number company have post rise ep growth last report revenue growth have also rise same period analyst expect earning share growth quarter growth full year earning estimate full year be recently revise upward align technology have composite rating hold rank peer medical product industry group align technology algn edward lifescience ew be also group highest rate stock note date earning report be subject change check company update get newsletter deliver inbox more info product service privacy policy term also earning calendar analyst estimate stock watchnew option strategy limit risk earning
48,EW,repligen rgen see ibd smartselect composite rating jump wednesday day upgrade mean stock currently top other stock term key performance metric technical strength top perform stock tend have better grade kick significant move so be sure keep mind look best stock buy watch repligen be not currently proper buy zone see stock go form new base offer new buy opportunity look winning stock try simple stock sport ep rating meaning recent quarterly longer term annual earning growth top stock accumulation distribution rating show moderate buy institutional investor last week get newsletter deliver inbox more info product service privacy policy term usein company report ep growth have now post accelerate ep growth consecutive quarters revenue growth increase prior quarter company have now post accelerate growth last report repligen hold rank peer medical product industry group abiom abmd align technology algn edward lifescience ew be top highly rate stock group related company be now outperform stock see stock just come ibd top stock list
49,EW,next earning report schedule apr merit medical system mmsi be trading approximately buy point chart pattern be first stage flat base keep mind risky buy stock just report reduce exposure wait see company report market react way minimize risk post earning sell be use option strategy look best stock buy watch start hereearning growth decrease last quarter revenue gain moved higher consensus analyst estimate call earning share growth quarter growth full year annual growth estimate be recently revise upward company have composite rating earn rank peer medical product industry group abiom abmd align technology algn edward lifescience ew be top highly rate stock group note date earning report be subject change check company update get newsletter deliver inbox more info product service privacy policy term also earning calendar analyst estimate stock watchnew option strategy limit risk earning
50,EW,keep watch list date be key make money stock market ibd help do regularly update stock screen ibd sector leader ibd big cap ipo leader table see stock have just be add remove list ibd display video id
51,EW,boston scientific bsx have relative strength rs rating upgrade friday welcome improvement still short higher score prefer see look best stock buy watch factor watch closely be relative price strength exclusive rating investor business daily track price performance worst best score rating show stock price movement trail week hold other stock database year market history reveal stock go make biggest gain often have higher rs rating launch biggest price move see boston scientific continue rebound hit benchmark see ibd help make more money stocksboston scientific be work consolidation entry see clear price heavy volume ep growth decline company most recent report sale rise look next report apr company earn rank peer medical product industry group abiom abmd align technology algn edward lifescience ew be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
52,EW,keep copy ibd weekly track change ibd kudo investor re likely quite keen spot moment stock market vanguard quickly shift consider swift intermediate level correction stock investor see past week have fact be
53,EW,ibd stock list be regularly update add new stock watch well weed have start show weakness table ll see stock have be add remove list ibd sector leader ibd big cap screen be
54,EW,ibd stock screen be regularly update add new stock watch well weed have start show weakness table ll see stock have be add remove list ibd sector leader ibd big cap stock watch
55,EW,ab large cap growth apgax be elite group top mutual fund be ibd best mutual fund award winner top mutual fund beat benchmark past year dec take extraordinary consistency large cap growth other stock mutual fund bogey ve beaten be category only eligible fund manage time feat more impressively ab large cap growth outperformed time period category diversify equity fund growth fund large cap fund hard be gain entry winner circle only eligible diversify stock fund make best mutual fund award list become top mutual fund lead manager frank caruso co manager john fogarty senior research analyst vinay thapar have assemble diversify portfolio include lead stock auto part health care financial technology such copart cprt edward lifescience ew zoetis zts global spgi nvidia nvda hold period vary stock past month have rise edward global zoetis copart nvidia get newsletter deliver inbox more info product service privacy policy term usestill caruso team have be trimming lead stock grow competitive threat caruso describe stock have reservation meanwhile overall find stock persistently outperform market depend caruso say find idiosyncratic opportunity invest year old caruso colleague fogarty thapar discuss other aspect team investment approach ibd office manhattan ibd portfolio be ibd best mutual fund award winner do take outperform so consistently period short month year frank caruso focus look business not stock be attract business differentiate competitive position company produce higher average level profitability profitability exceed fair cost capital here secret sauce start look good business then obsess company idiosyncratic opportunity invest earn high return capital ibd exactly do mean idiosyncratic opportunity invest caruso be investment opportunity be company specific occur company take action put upward pressure profitability take nike nke ve be chasing low cost labor noticed patent filing look new manufacturing technology build shoe robotize machine build plant closer consumer save tariff duty shipping ibd fund be fairly concentrated just stock jan do prefer concentrated approach caruso first think re good research company want get paid research second have name allow get exposure larger cap company also seed portfolio sometimes younger more exciting company be small end portfolio size range have be low mid sixty first take portfolio be still shape portfolio vision ibd auto auctioneer copart be smaller name market cap have post straight quarters earning share growth acceleration driver caruso re probably not type business lot growth portfolio have high profitability be high versus cost capital yet surprisingly stable secular trend give confidence sustainability performance be auto become more complex lead more attractive salvage rate more more car too expensive repair one get damage so copart supply inventory get bigger ibd begin current stake august then caruso multiyear period copart infrastructure do not perform efficiently exploit new inventory arise due hurricane so company invest money upgrade capability august hurricane season investor question copart have do enough lower copart share price buy uncertainty ibd most part ve be build stake edward lifescience vinay thapar pioneer development transcatheter aortic valf patient have do open heart surgery go bypass machine have valf repair edward get engineering product be insert snake catheter artery leg be far more minimally invasive result faster discharge hospital average patient cost be less open heart procedure yet product have higher average gross margin operate margin expect uplift return company invest capital roic have occur roic be close upper echelon other company company forecast market be only now re look used same procedure different valve mitral valve be new market ibd zoetis be name ve be build stake fuel interest thapar re leader pharmaceutical animal health thesis be pfizer have opportunity improve operate performance right size number skus item sale close manufacturing facility improve gross margin commit investing higher return project single digit top line growth market growth rate cost improvement have lead higher return go forward pipeline product be yet be reflect stock price ve commit reduce inventory balance improve return invest capital ibd global be hold ep growth have accelerate have happened caruso re modele annual revenue growth area next year low single digit earning growth index business have be big part success rating business be best class franchise low rate environment good level volatility expectation be increase world rating business benefit maybe part index business ibd ve be nvidia long time do story have much runway left front caruso be portfolio graphical chip have find new application think ai artificial intelligence think hyperscale datum center think vr virtual reality think auto vision nvidia gpus be general purpose chip think be application specific chip early stage company become competitive market share next month so ve be trimming position ibd book holding bkng be priceline new name do particular online travel agency john fogarty change name reflect primary asset online travel portfolio appeal be dominant position europe hotel market be far more fragmented industry be dominate chain book take advantage europe fragmentation so enjoy higher commission rate result ibd paypal pypl be relative newcomer portfolio do introduce fogarty begin buy fourth quarter growth paypal be essentially ride increase adoption online payment particular mobile payment re attract rise return asset trajectory not just growth increase profitability ibd anyone want add comment caruso john summarize thought paypal take market share expect grow high teen next year complement visa exposure ibd take paypal be former stock ibd swingtrader exclusive ibd feature help take advantage short term trend apply rule ibd slim investing system swing trading environment detail past trade be accessible swingtrader subscriber trialist free trial be available also nike facebook frank caruso project long term earning need much retirement saving age incomebond mutual fund help steadier long term interest rate
56,EW,ibd stock list be regularly update add new stock watch well weed have start show weakness table ll see stock have be add remove list ibd sector leader ibd big cap stock list
57,EW,relative strength rs rating merit medical system mmsi enter new percentile friday rise re research best stock buy watch be sure pay attention relative price strength exclusive rating investor business daily measure share price performance worst best score rating show stock price behavior trail week hold other stock database decade market research show best stock tend have rs rating north begin biggest run look best stock buy watch start herenow be not ideal time jump isn proper buy zone see stock be able form consolidation break earning growth decline company most recently report quarter revenue grow prior report company earn rank peer medical product industry group abiom abmd align technology algn edward lifescience ew be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also ibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
58,EW,nephew snn see positive improvement relative strength rs rating friday rise look best stock buy watch factor watch closely be relative price strength exclusive rating investor business daily measure share price performance worst best score score show stock price behavior last week compare other stock database year market history show stock go make biggest gain typically have rs rating least launch largest price move see nephew continue show renew price strength hit benchmark see ibd help make more money nephew be build consolidation entry see stock clear price heavy trading nephew report ep growth most recent report revenue rise company earn rank peer medical product industry group abiom abmd align technology algn edward lifescience ew be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also ibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
59,EW,friday baxter international bax get positive adjustment relative strength rs rating re research best stock buy watch be sure pay attention relative price strength proprietary rating identify technical performance used worst best score identify stock price performance last week stack other stock database year market history show best perform stock tend have better rs rating early stage move see baxter international continue show renew price strength clear threshold look best stock buy watch start herebaxter international be try complete flat base buy point see clear price heavy trading baxter international show earning growth last quarter revenue increase baxter international hold rank peer medical product industry group abiom abmd align technology algn edward lifescience ew be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
60,EW,build watch list focus stock higher rs rating neogen neog now meet criterium jump wednesday look best stock buy watch keep close eye relative price strength ibd proprietary rating identify market leadership worst best score score show stock price movement last week hold other stock database year market history reveal top perform stock typically have rs rating north launch biggest climb look winning stock try simple routineneogen break earlier have fall back prior entry consolidation stock re tracking break past buy point then fall more original entry price consider fail base best stock form new consolidation also keep mind latest consolidation be later stage base such basis be more prone failure earning growth picked last quarter sale fall look next report mar neogen earn rank peer medical product industry group abiom abmd align technology algn edward lifescience ew be top highly rate stock group related ibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
61,EW,neogen neog be expect report earning mar stock be now trading buy point second stage consolidation clear earlier buy stock just ahead earning be risky typically don have enough time build profit cushion latest quarterly number come be sure follow sound buy sell rule minimize exposure look winning stock try simple routineearning growth increase last quarter sale fall analyst expect ep growth quarter growth full year ep estimate full year be recently revise upward neogen have composite rating earn rank peer medical product industry group abiom abmd align technology algn edward lifescience ew be top highly rate stock group note date earning report be subject change check company update related earning calendar analyst estimate stock watchnew option strategy limit risk earning
62,EW,top rate growth stock new high weren easy find stock market tuesday medical product firm make cut neogen neog maker diagnostic test kit other product food animal safety reversed slightly lower touch new high share be little change try clear shallow consolidation buy point neogen be speculative side average daily dollar volume just composite rating be solid help consistent track record earning sale growth integra lifescience iart meanwhile specialize product orthopedic neurosurgery reconstructive general surgery latest report quarter earning share jump year quarter cent sale growth accelerate sharply rise get newsletter deliver inbox more info product service privacy policy term company acquisition last year johnson johnson codman neurosurgery business just be big factor integra strong sale growth share reach high clear week pattern reversed lower afternoon trading volume be average drawback attempt stock have already top buy point handle pattern company trade nasdaq other top rate health care name score new high include edward lifescience ew radnet rdnt orthofix ofix addus homecare adus be extend past proper buy point related top biotech stock celgene consider go private best stock buy invest stock market used simple routine
63,EW,merit medical system mmsi see ibd smartselect composite rating jump wednesday day new rating show stock be outpace stock come most important stock pick criterium market biggest winner often have higher grade early stage new price run so good start point look best stock buy watch merit medical system break earlier have fall back prior entry flat base stock re tracking clear buy point then decline more original entry price consider fail base stock set new chart pattern buy point look winning stock try simple stock earn ep rating meaning recent quarterly annual earning growth be outpace stock accumulation distribution rating show moderate buy institutional investor last week company report increase earning top line growth rise prior report mark quarter rise revenue growth merit medical system earn rank peer medical product industry group abiom abmd align technology algn edward lifescience ew be top highly rate stock group related company be now outperform stock
64,EW,relative strength rs rating teleflex tfx enter new percentile monday increase look best stock buy watch factor watch closely be relative price strength ibd proprietary rs rating track market leadership used worst best score indicate stock price action last week match other stock year market history reveal stock go make biggest gain often have rs rating north launch biggest climb look winning stock try simple routineteleflex be work consolidation buy point see stock break heavy trade teleflex report ep growth last quarter sale growth come teleflex earn rank peer medical product industry group abiom abmd align technology algn edward lifescience ew be top highly rate stock group related stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
65,EW,cooper company coo see ibd smartselect composite rating rise monday day upgrade mean stock be now outpace other stock term key performance metric technical strength history show top market performer tend have higher score launch major climb cooper company break earlier have fall back prior entry flat base case stock break then fall more entry price consider fail happen best new base form see ibd help make more money stock have ep rating meaning recent quarterly annual earning growth top stock accumulation distribution rating show moderate buy institutional investor last week company post ep growth have now post accelerate ep gain consecutive quarters sale growth increase prior report mark quarter rise revenue increase cooper company earn rank peer medical product industry group abiom abmd align technology algn edward lifescience ew be top highly rate stock group related company be now outperform stock
66,EW,account usaa aggressive growth fund usaux tidy gain so far year term holding credit go amazon amzn mastercard salesforce com crm book holding bkng formerly priceline re fund best perform stock year have help propel gain go thursday vs large cap growth peer track morningstar stock not have have meaningful position portfolio be not new fund manager john jare craig behnke take rein fund august last year board usaa aggressive growth fund be straw break camel back year consistently trail benchmark russell growth index fund post return year russell growth rise index gain fund parent company know drastic action need be take fire subadvisor manage fund capital wellington capital give house portfolio manager john jare craig behnke august track top stock market trend free ibd then manager have look stock fund do own fundamental research ve sell many stock narrowing fund smaller lighter more concentrated portfolio stock goal hit don know be go virtue have subadvisor be diversify have little chance outperform say jare want differentiate base security selection keep beta line benchmark add alpha stock selection re nearly do process have name go fund keep top holding apple aapl microsoft msft alphabet goog be parent google visa amazon also keep facebook fb paypal pypl name sell be alibaba baba expedia expe citrix system ctxs amdocs dox teradyne ter cirrus logic crus re not just selling ve also be add new stock boost concentration one take fund stock make portfolio jare say time do stock make total asset tale different time period say behnke dec be process turn lot portfolio performance relative russell growth trail basis point even so fund end vs russell now fund be closer manager ideal portfolio jan march beat benchmark basis point jare say fund have perform well holding technology consumer discretionary sector manager have reduce fund technology weighting increase consumer discretionary weighting overall ve broaden fund sector exposure diversify number sector concentrate number stock new stock vulcan material vmc so much become top hold base birmingham ala company supply crushed stone know aggregate concrete asphalt make road bridge aggregate have see nice pricing power say jare improve economy have infrastructure program come pike volume outlook be excellent company have grow earning annual clip past year stock be week high trading day day move average bearish sign edward lifescience ew make catheter treat heart disease have grow earning annual pace past year original estimate market be next year say behnke lower death rate lower complication compare surgery number be so strong total addressable market increase current estimate be research industry contact next month estimate market push range jare also like hp hpq expect become growth company again best know make computer printer hp jare note be launch new line copier printing kick company become leader again say jare say expect hp see growth return mid single digit range fund charge average expense ratio related look hot stock be drive market beating mutual funddow retake day apple peg new close high bitcoin dife
67,EW,penumbra pen have relative strength rs rating upgrade thursday try find best stock buy watch be sure pay attention relative price strength ibd proprietary rating measure market leadership worst best score score show stock price performance trail week hold other stock database decade market research reveal best stock typically have higher rs rating launch biggest climb look best stock buy watch start stock be theipo leader list be try complete cup handle buy point see stock clear price heavy trading take look revenue profit performance penumbra have post rise ep growth last report revenue gain have also rise same period company earn rank peer medical product industry group abiom abmd align technology algn edward lifescience ew be top highly rate stock group related stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
68,EW,penumbra pen see positive improvement relative strength rs rating monday rise proprietary rating measure technical performance used worst best score identify stock price performance trail week match other stock history show best stock tend have rs rating north launch largest climb see penumbra continue show renew price strength hit benchmark look best stock buy watch start herepenumbra be work cup handle entry see clear price heavy volume earning growth decrease most recent quarter revenue gain moved higher next quarterly result be expect feb company earn rank peer medical product industry group abiom abmd align technology algn edward lifescience ew be top highly rate stock group related ibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
69,EW,merit medical system mmsi be form base entry next quarterly ep report set feb current formation be first stage flat base understand buy stock just ahead earning be risky typically don have enough time establish profit cushion latest quarterly number come be sure follow sound buy sell rule minimize exposure look best stock buy watch start heremerit medical system post earning share growth last quarter sale growth come consensus analyst estimate call earning share growth quarter growth full year annual earning share estimate be recently revise upward merit medical system have composite rating earn rank peer medical product industry group abiom abmd align technology algn edward lifescience ew be top highly rate stock group note date earning report be subject change check company update related earning calendar analyst estimate stock watchnew option strategy limit risk earning
70,EW,lemaitre vascular lmat see ibd smartselect composite rating rise friday day new score tell company be now outperform stock term most important fundamental technical stock pick criterium lemaitre vascular be currently form consolidation entry see stock break heavy trade least higher normal keep mind later stage base such basis be more prone failure be aware be thinly trade stock average daily dollar volume such stock show wider daily weekly fluctuation stock greater liquidity look winning stock try simple stock earn ep rating mean recent quarterly longer term annual earning growth top stock accumulation distribution rating show roughly equal amount buy selling institutional investor last week company post earning growth sale growth increase prior report mark quarter accelerate revenue increase lemaitre vascular earn rank peer medical product industry group abiom abmd align technology algn edward lifescience ew be top highly rate stock group related company be now outperform stock
71,EW,integra lifescience iart see positive improvement relative strength rs rating friday increase exclusive rating investor business daily measure market leadership worst best score grade show stock price performance trail week compare other stock database year market history reveal market biggest winner tend have rs rating begin largest climb see integra lifescience continue show renew price strength hit benchmark see ibd help make more money stocksintegra lifescience be work consolidation entry see stock break volume least average integra lifescience post earning growth last quarter sale growth come look next report feb integra lifescience earn rank peer medical product industry group abiom abmd align technology algn edward lifescience ew be top highly rate stock group related stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
72,EW,friday quidel qdel get upgrade ibd smartselect composite rating upgrade mean stock currently top other stock term key performance metric technical strength best stock tend have better grade kick significant move quidel break earlier be now prior entry consolidation stock re tracking clear buy point then retreat more original entry price consider fail base best stock form new base also keep mind most recent consolidation be later stage base make riskier establish new position add share exist see ibd help make more money stocksone weak spot be company ep rating track quarterly annual earning share growth look improve better show top stock accumulation distribution rating show moderate buy institutional investor last week company post earning gain have now post accelerate ep gain consecutive quarters revenue growth increase prior report mark consecutive report increase revenue gain quidel hold rank peer medical product industry group abiom abmd align technology algn edward lifescience ew be top highly rate stock group related company be now outperform stock
73,EW,relative strength rs rating neogen neog jump higher percentile thursday get lift proprietary rating measure technical performance show stock price movement last week compare other stock database year market history reveal best perform stock typically have rs rating north early stage move see neogen continue show renew price strength hit benchmark look winning stock try simple routineneogen be try complete consolidation buy point see stock break heavy trade company top line growth fall last quarter bottom line grow previous report next quarterly result be expect mar company earn rank peer medical product industry group abiom abmd align technology algn edward lifescience ew be top highly rate stock group related stock be show improve price performance use ibd relative strength rating relative strength line help judge stock
74,EW,thursday edward lifescience ew get upgrade relative strength rs rating ibd unique rating identify market leadership worst best score rating show stock price behavior last week hold other stock database decade market research reveal best stock typically have rs rating north early stage move see edward lifescience continue show renew price strength hit benchmark look winning stock try simple routineedward lifescience be work cup handle entry see stock clear price volume least higher normal edward lifescience post earning growth latest quarterly report sale growth come company hold rank peer medical product industry group align technology algn abiom abmd inogen ingn be top highly rate stock group related stock be show improve technical action use ibd relative strength rating relative strength line help judge stock
75,EW,year ibd showcased just company gigantic medical sector look back copy remember be do well memory be photographic be unite therapeutic uthr ibd biotech group patient datum monitoring gear expert masimo masi medical
76,EW,relative strength rs rating neogen neog enter higher percentile friday get lift exclusive rating investor business daily identify share price action worst best score grade show stock price behavior last week compare other stock database year market history reveal market biggest winner tend have higher rs rating early stage move see neogen continue show renew price strength clear threshold see ibd help make more money stocksneogen be work consolidation entry see clear price heavy volume earning growth rise last quarter revenue gain fall company earn rank peer medical product industry group abiom abmd align technology algn edward lifescience ew be top highly rate stock group related stock be show improve technical action use ibd relative strength rating relative strength line help judge stock
77,EW,friday globus medical gmed get upgrade ibd smartselect composite rating revise score mean stock currently top other stock term key performance metric technical strength globus medical have now climb proper buy zone breaking entry consolidation look best stock buy watch start hereone weak spot be company ep rating track quarterly annual earning growth look improve better show top stock accumulation distribution rating show heavy buy institutional investor such mutual fund pension fund last week company report earning growth sale growth climb prior quarter mark quarter increase revenue gain company next quarterly report be expect feb globus medical earn rank peer medical product industry group abiom abmd align technology algn edward lifescience ew be top highly rate stock group related company be now outperform stock
78,EW,resm rmd see ibd smartselect composite rating jump friday day new rating show stock be outpace stock come most important stock pick criterium resm be now buy range clear entry flat base look best stock buy watch start stock earn ep rating mean recent quarterly annual earning growth top stock accumulation distribution rating show moderate buy institutional investor last week company report ep growth mark straight report rise ep gain sale be flat match prior report resm earn rank peer medical product industry group abiom abmd align technology algn edward lifescience ew be top highly rate stock group related company be now outperform stock
79,EW,teleflex tfx be expect report earning feb teleflex now trading buy point second stage cup handle clear earlier understand risky buy stock just report minimize exposure wait see company report market react see ibd help make more money stocksearning grow last quarter prior report revenue also increase analyst expect earning growth quarter growth full year annual ep estimate be recently revise upward company have composite rating hold rank peer medical product industry group align technology algn abiom abmd edward lifescience ew be top highly rate stock group note date earning report be subject change check company update related earning calendar analyst estimate stock watchnew option strategy limit risk earning
80,EW,wednesday cambrex cbm earn upgrade relative strength rs rating exclusive rating investor business daily identify market leadership worst best score grade show stock price behavior last week compare other stock database year market history reveal stock go make biggest gain often have higher rs rating early stage move see cambrex continue show renew price strength hit benchmark look winning stock try simple routinecambrex be work consolidation buy point see break heavy volume cambrex post ep growth latest quarterly report sale growth come company hold rank peer medical product industry group align technology algn abiom abmd edward lifescience ew be top highly rate stock group related stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
81,EW,relative strength rs rating baxter international bax enter new percentile monday get lift ibd proprietary rating identify share price performance worst best score rating show stock price movement trail week stack other stock database decade market research show best stock often have better rs rating early stage move see baxter international continue rebound clear threshold look best stock buy watch start herewhile not currently ideal time jump see stock be able offer clear appropriate buy point company show earning growth latest quarterly report revenue gain come baxter international earn rank peer medical product industry group align technology algn abiom abmd edward lifescience ew be top highly rate stock group related stock be show improve technical action use ibd relative strength rating relative strength line help judge stock
82,EW,monday integra lifescience iart earn upgrade relative strength rs rating ibd unique rating track share price movement worst best score grade show stock price behavior last week hold other stock database decade market research reveal best stock typically have better rs rating early stage move see integra lifescience continue rebound clear threshold see ibd help make more money stocksintegra lifescience be try complete consolidation entry see break heavy trading integra lifescience post ep growth most recent report sale growth come look next report feb integra lifescience hold rank peer medical product industry group abiom abmd align technology algn edward lifescience ew be top highly rate stock group related stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
83,EW,stock arrive proper buy point investor buy same stock bring different expectation investor be gun gain intention take profit move next second regard gain something
84,EW,here investing action plan thursday need know investor come day day earning start chinese tech giant alibaba baba end tech leader apple aapl amazon amzn alphabet googl also be frantic day quarterly report visa ticker
85,EW,here weekly investing action plan need know investor come week tech sector heavyweight facebook fb apple aapl amazon amzn alphabet googl microsoft msft dominate come week earning news oil major exxon mobil xom chevron cvx also report
86,EW,earning tap jan ibd sector leader member align technology algn be trading approximately shy buy point pattern be third stage cup handle mean more prone failure first second stage formation understand buy just stock report be risky don know stock report market react don have enough time build profit cushion minimize exposure wait see actual number market reaction way minimize risk post earning sell be use option strategy look best stock buy watch start herein term top bottom line number company have post rise ep growth last report sale growth have also moved higher same period analyst be look ep growth quarter growth full year earning share estimate full year be recently revise upward company have composite rating earn rank peer medical product industry group abiom abmd edward lifescience ew be also group highest rate stock note date earning report be subject change check company update related earning calendar analyst estimate stock watchnew option strategy limit risk earning
87,EW,relative strength rs rating accelerate diagnostic axdx jump new percentile friday increase exclusive rating investor business daily track share price performance worst best score rating show stock price performance trail week hold other stock database year market history reveal market biggest winner often have better rs rating early stage move see ibd help make more money diagnostic be build cup handle buy point see stock break volume least higher normal company see earning sale growth rise last quarter earning share increase revenue rise company earn rank peer medical product industry group align technology algn abiom abmd edward lifescience ew be top highly rate stock group related stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
88,EW,monday lead drugmaker abbvie abbv announce positive phase trial result psoriasis treatment risankizumab tuesday ibd big cap be fractionally potential new buy zone result ongoing study show nearly half risankizumab patient achieve complete skin clearance pasi vs
89,EW,here weekly investing action plan need know investor come week earning season be here again give top company chance provide more detail tax cut recently sign law change guidance profit come year delta air line dal
90,EW,edward lifescience ew plunge late tuesday firm report third quarter sale profit lag expectation reaffirm sale guidance xin hour trading stock market today edward topple close fraction share have be form flat base late july buy point third quarter sale grow miss consensus view adjust income cent share lag cent grow edward say adjust earning have be cent share base excess tax benefit estimate prior guidance period transcatheter heart valve therapy sale grow edward rival make heart valve replacement allow physician fix narrow heart valve resort open heart surgery sale grow edward say statement expect transcatheter heart valve therapy unit be opportunity base continue strength outside ibd take edward have ibd composite rating best possible meaning outperform more stock term key growth metric head ibd stock checkup look other strong performer medical product industry group meanwhile surgical heart valve therapy sale grow just critical care revenue increase year year unit include catheter sensor monitor other equipment monitor patient firm see metric come high end prior guidance adjust earning view share midpoint edward guidance lag consensus revenue adjust earning share fourth quarter guidance sale adjust ep cent bracket consensus view cent sale guidance be just ahead consensus midpoint adjust earning guidance miss midpoint related top medical stock try pump new breakoutedward lifescience try close key technical benchmarkibd rating upgrade resm show improve technical strength
91,EW,medtronic mdt surge month high tuesday medical device maker top fiscal second quarter earning view report revenue heart valve replacement grow more third xby close bell stock market today medtronic surge close meanwhile share edward lifescience ew medtronic key rival know transcatheter aortic heart valve replacement lift finish regular trading day fiscal second quarter medtronic report adjust income share sale revenue be line medtronic pre announcement beat view earning crushed consensus cent year year basis metric decline medtronic say release adjust foreign exchange rate divestiture impact hurricane marium revenue earning have climb respectively firm cardiac vascular group post sale be help sale transcatheter aortic heart valf tavr grow high thirty percentage tavr be method repair damage heart valve resort open heart surgery ibd take biotech sector large cap struggle quarter smaller firm lead way outperform expectation head industry snapshot breakdown quarter edward rival medtronic tavr boston scientific bsx doesn have product approve be expect re enter european market early recall product due problem locking mechanism minimally invasive restorative therapy group split impact hurricane marium bash puerto rico quarter comparable basis sale group grow apiece firm reiterate guidance constant currency sale growth fiscal adjust profit share growth related rival take chunk medtronic heart unit electricity replace opioid treat chronic painedward lifescience crash heart valve sale miss lofty view
92,EW,edward lifescience ew crash lowest point month lag overly aggressive expectation flagship heart valve replacement business analyst say wednesday xby close bell stock market today edward have plunge finish earlier fall much lowest point april share begin form flat base july buy point quarter edward domestic transcatheter aortic valve replacement also know tavr sale grow line market fall short street lofty expectation canaccord analyst jason mill call otherwise rock star business tavr be method fix narrow harden heart valve resort open heart surgery quarter edward transcatheter heart valve therapy unit bring sale consensus have modeled domestic sale think management commentary insinuate market remain strong market be begin incur inevitability law larger number mill say note client ibd take keep earning season bookmarking weekly review quick rundown company report stock be move attempt rein expectation be prudent move say analyst become overly aggressive tavr prediction boston scientific bsx look enter market soon medtronic mdt be increase access more patient create headwind edward edward retain guidance imply tavr growth fourth quarter mill say expect street recalibrate expectation say remain bullish market potential total addressable market relative potential edward growth reacceleration low risk approval write rbc analyst glenn novarro say conversation investor suggest street have be happier domestic tavr sale growth third quarter slow again first quarter second quarter write note client edward be target opportunity segment novarro expect more clarity guidance be give edward investor day december midteen sale compound annual growth rate be sufficient achieve edward transcatheter heart valve therapy sale forecast more believe higher growth rate be necessary edward share maintain healthy premium large cap medtech peer say related edward topple third quarter miss soft glaxosmithkline scoop pfizer counter unit biogen dife top view lilly novartis beat
93,EW,major index pare loss afternoon trading still close lower wednesday second decline day tech rich nasdaq composite skid lower end well early lows facebook fb netflix nflx fall roughly drop weigh heavy earning related loss chipotle grill cmg edward lifescience ew dow jone industrial average slough boee ba post deepest loss dow name drop more preliminary datum show volume be higher nyse nasdaq vs tuesday trade investor focuse wednesday mixed earning report concern tax reform washington largely ignore positive durable good order datum spike new home sale september nike nke soar lead dow ceo mark parker plot course high single digit revenue growth ep growth midteen next year gain punch nike share back week move average right side month consolidation boee be dow sinker nearly report forecast third quarter earning guidance revenue be lighter hope charge kc aerial refueling tanker program slim tax margin move pull share back tuesday high set stock track first decline week china base name come heavy selling pressure jupai holding jp diving weibo wb tal education tal fall almost retail giant jd com jd shed diversify internet play alibaba group baba fall search engine leader baidu bidu hold decline positive earning result report late tuesday send specialty plastic maker rally kraton kra vault put share penny april record thinly trade kraton be now october extend buy point ohio base peer polyone pol bag gain top analyst forecast lift stock buy range flat base buy point polyone have receive ibd rating upgrade september ibd stock grubhub grub deliver gain earning revenue guidance top expectation third quarter gain heft share back week move average just fraction buy point week flat base related pressure tesla grow daimler unveil heavy duty electric truckleaner meaner coke fend pepsi market big pictureibd investor research tool get start ibd
94,EW,here investing action plan tuesday need know investor come day xan earning tsunami hit lead big name such mcdonald mcd general motor gm caterpillar cat unite technology utx lockheed martin lmt just begin here be other company report tuesday
95,EW,here weekly investing action plan need know investor come week upcoming week earning give investor much broader look corporate america economy stalwart tech industrial energy medical consumer sector weigh quarterly result such amazon com amzn alphabet ticker
96,EW,welcome move edward lifescience ew see relative strength rating improve tuesday ibd unique rating identify share price movement worst best score rating show stock price behavior trail week stack other stock database history reveal market biggest winner tend have rs rating least early stage move see edward lifescience continue rebound clear threshold edward lifescience be build flat base entry see stock clear price heavy trade earning growth rise last quarter revenue gain fall edward lifescience hold rank peer medical product industry group align technology algn inogen ingn lemaitre vascular lmat be top highly rate stock group related stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
97,EW,welcome move edward lifescience ew see relative strength rating improve tuesday ibd unique rs rating identify market leadership show stock price action last week compare other stock database history show best perform stock tend have better rs rating launch largest climb see edward lifescience continue show renew price strength hit benchmark stock be build flat base entry be trading week move average see stock retake benchmark line break heavy volume earning growth picked last quarter sale fall company hold rank peer medical product industry group align technology algn be top rank stock group related stock be show improve technical action use ibd relative strength rating relative strength line help judge stock
98,EW,stock index step backward midday friday gdp result match street expectation consumer datum show bright spot nasdaq lose blue chip dow jone industrial average be flat volume stock market today be run lower previous session lower volume decline be bull prefer see stock retreat gdp come best growth third quarter line estimate consumer spending also match view gain bright spot be revision consumer spending initial read be revise university michigan consumer sentiment gauge july confirm upward trend come vs expectation stock ibd list best stock fundamental technical be mixed advance strong volume include invisible brace maker align technology algn software provider logmein logm chip equipment maker ichor holding ichr facebook fb nice follow thursday gain day loser ibd include contract manufacturer ttm technology ttmi dave buster entertainment play head sixth day row medical device maker edward lifescience ew edward lifescience have be hurt defeat republican skinny repeal obamacare bill ve suspend year tax medical device manufacturer excise tax be suspend be schedule resume action be take meanwhile blue chip dow jone industrial average be track outperform major index fourth session row chevron cvx american express axp lead component dow gain respectively related mastercard visa join ibd big cap tobacco company face new regulation
99,EW,edward lifescience ew overcome nervous petrified street view late wednesday top second quarter revenue adjust income expectation analyst say follow announcement investor be somewhere nervous petrified edward transcatheter aortic valve replacement print think sequential growth meet beat expectation evercore analyst vijay kumar say note client share jump hour trading stock market today close june edward break cup handle begin october hit buy point share have close straight day second quarter end june edward report adjust income share revenue respective vs year earlier period metric top view analyst poll zack investment research cent sale be shift surgical heart valve replacement transcatheter heart valve replacement tavr edward say latter don require open heart surgery be see safer strong demand tavr therapy result total sale growth underlie basis chief executive michael mussallem say prepared statement ibd take edward have ibd composite rating best possible meaning perform top stock term key growth metric company medical product industry group be now rank group ibd track other top performer group head ibd stock checkup edward also boost adjust income guidance share low point easily top consensus edward now see full year sale come high end prior view third quarter end september edward guide underlie sale adjust earning share cent analyst have call revenue adjust profit cent share related earning trade name look most actionable
100,EW,resm rmd have relative strength rs rating upgrade thursday welcome improvement still better score look ibd proprietary rating track market leadership worst best score score show stock price behavior trail week hold other stock database decade market research show top perform stock tend have higher rs rating early stage move see resm continue show renew price strength clear threshold resm be not proper buy point right now see be able form break proper chart pattern earning growth increase last quarter sale fall resm hold rank peer medical product industry group abiom abmd align technology algn edward lifescience ew be top highly rate stock group related stock be show improve price performance use ibd relative strength rating relative strength line help judge stock
101,EW,medical wmgi have relative strength rs rating upgrade tuesday welcome improvement still better score prefer see unique rating identify technical performance used worst best score identify stock price action trail week stack other stock database decade market research reveal best stock often have rs rating least early stage move see medical continue show renew price strength hit benchmark medical be build consolidation entry see stock clear price heavy volume company report ep growth most recent report sale growth come medical hold rank peer medical product industry group abiom abmd align technology algn edward lifescience ew be top highly rate stock group related stock be show improve price performance use ibd relative strength rating relative strength line help judge stock
102,EW,resm rmd see positive improvement relative strength rs rating tuesday increase ibd proprietary rs rating measure technical performance used worst best score indicate stock price performance trail week compare other publicly trade company decade market research reveal stock go make biggest gain tend have rs rating north launch largest price move see resm continue rebound clear threshold now be not ideal time jump isn proper buy zone see stock manage form base break earning growth moved last quarter revenue fall resm earn rank peer medical product industry group abiom abmd align technology algn edward lifescience ew be top highly rate stock group related ibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
103,EW,future index nasdaq dow jone industrial average edge higher early wednesday ahead new wave big earning federal reserve latest policy announcement strong result late tuesday texas instrument txn be good news apple aapl iphone ecosystem ahead apple own earning meanwhile facebook fb paypal pypl be ibd stock earning due wednesday facebook provide further evidence be beating back snapchat operator snap snap dow industrial rise tuesday regular session lead earning caterpillar cat mcdonald mcd well strength financial nasdaq composite weigh google parent alphabet googl close just break even do hit new time high index rise fresh record meanwhile cboe volatility index vix hit yet record intraday low tuesday vix lows be sign investor complacency often associate least short term market top still dow future rise vs fair value nasdaq future equity generally advanced globe crude oil price continue climb big gain tuesday fed be not expect make policy change wednesday afternoon policymaker surprise announce plan let central bank balance sheet start decline most analyst see shift happen september meeting president trump tell wall street journal apple build plant trump have make similar statement apple have comment tuesday operation ease political pressure likely be more expensive possible foxconn key assembler iphone set plant america ibd take buy hold stock be risky head earning report here earning option strategy help cash post earning stock gain minimize risk weak quarter option strategy be highlighted ibd weekly earning preview column meanwhile texas instrument report better expect earning late tuesday give bullish guidance texas instrument be big automotive chip many other segment well mobile device apple iphone ti follow beat raise last week skywork solution swks apple iphone chipmaker ibd member report better expect wireless subscriber figure churn hit record low good sign apple iphone sale be spring lull ahead iphone later year relatively strong iphone demand be key give likelihood next generation iphone be delay apple share edge higher premarket trading apple close tuesday stock market trading apple be approach flat base buy point facebook paypal lam research lrcx edward lifescience ew be ibd stock report earning wednesday also facebook paypal lam research boast best possible composite rating mean outperform other stock base proprietary fundamental technical rating big stock winner often have composite rating least start big price run facebook be third fang facebook amazon com amzn netflix nflx google parent alphabet stock report result follow alphabet late monday netflix last week amazon be set close fang earning thursday facebook presumably provide new figure grow popularity instagram story other offering clone snapchat feature here stat already snap march ipo facebook market capitalization have increase snap market value have retreat just so facebook have add equivalent nearly snapchat snap brief history public firm facebook dip tuesday stock market trading hit fresh record high monday facebook be extend possible entry snap fall hit new record low paypal dip just chase zone flat base buy point clear earlier month mobile payment firm expand reach deal month apple jpmorgan chase jpm chip equipment maker lam research be cup base just possible buy point edward lifescience have fall back buy point big cup handle base undercut day line tuesday vertex pharmaceutical vrtx horton dhi servicenow now fortinet ftnt be many other top rate stock set report earning wednesday related texas instrument amd beat target guide higherat adjust profit beat pay tv video subscriber fallwill facebook earning support strong stock growth big picture nasdaq lag alphabet loss industrial financial growth stock netflix nvidia earning
104,EW,lantheus holding lnth end week new high extend perform nearly textbook perfect rebound week move average lantheus produce definity liquid design improve result ultrasound diagnostic procedure also manufacture technelite type generator contain radioactive isotope used radiopharmacy
105,EW,here weekly investing action plan need know investor come week biggest name tech defense energy automotive telecom restaurant industry report include fang stock facebook fb amazon amzn alphabet googl federal reserve hold policy meeting opec
106,EW,larger pile growth stock high many more solid basis other buy range recent breakout perfect storm growth investor right yes hand good see market serve increase supply bullish technical setup typically sign healthy market stock be build
107,EW,medical device supply maker have outperformed recently stock industry group make stock spotlight screen tuesday issue heart valve maker edward lifescience ew part ibd leaderboard feb medical supply developer becton dickinson bdx be extend respective buy point boston scientific bsx remain well buy range ahead
108,EW,base monday rise relative strength rs rating edward lifescience ew climb new percentile jump stock be tuesday give back morning gain ibd unique rating measure share price action worst best score rating show stock price performance last week compare other stock database history show stock go make biggest gain typically have rs rating early stage move edward lifescience be just buy zone clear buy point cup handle proper buy range be initial entry once stock hit benchmark best hold investing set buy opportunity company post accelerate gain top bottom line earning grow prior report revenue increase edward lifescience earn rank peer medical product industry group inogen ingn be also group highest rate stock related stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
109,EW,tuesday hour session be busy earning report apple aapl twitter twtr ebay ebay chipotle grill cmg buffalo wild wing bwld panera bread pnra apple earn share fiscal year earlier cent wall street estimate revenue fall vs view first quarterly sale drop apple ship iphone quarter first ever year year decline estimate apple also give weak revenue guidance apple cfo say macro environment be very weak apple raise capital return program include extra buyback share fall late trading short form social platform adjust ep pop cent surpass estimate cent revenue jump miss expectation twitter expect revenue range well analyst estimate share dive late trade ebay gaap ep fall cent top view cent revenue grow edge view ebay see revenue ep cent analyst have modeled ep cent revenue share rise initially be little change chipotle lose cent share little better expect sale plunge vs view same store sale fall vs year earlier chipotle say april same store sale be so far surprising analyst have expect more improvement chipotle fall late buffalo wild wing ep rise miss estimate cent revenue increase mil well forecast same store sale fall company own store franchised restaurant company see ep short wall st estimate buffalo share tumble late panera bread ep grow beating view cent revenue rise top estimate company own bakery comparable sale increase panera raise full year ep guidance vs view share rise extend trading edward lifescience ew crushed first quarter estimate earning share time item climb cent revenue grow analyst consensus be cent ep medical device maker say sale transcatheter heart valve jump company project ep cent midpoint top wall street cent target edward lifescience stock rise fractionally close
110,EW,nasdaq look poise ninth straight gain afternoon trading wednesday help strength fiber optic networking chip equipment stock nasdaq composite rise add oil gas stock outperformed dow jone industrial average gain weigh weak earning ibm ibm small cap do well russell volume nyse nasdaq be tracking tad higher tuesday level new york mercantile exchange august west texas intermediate crude oil rally cent barrel week high weekly supply datum show sharp drop stockpile last week meanwhile production climb highest level july accord energy information administration stock market today fiber optic stock outperformed again leader group be apply optoelectronic aaoi too late buy stock be extend price gain last week share be additional week earlier today crown castle international cci announce plan buy lightower deal nearly double mile fiber crown castle control allow expand cellular service key market include boston new york philadelphia chip equipment firm get lift dutch firm asml hold asml jump strong earning industry group peer mks instrument mksi be featured tuesday sector leader column ibd chip equipment firm ichor ichr nova measure instrument nvmi lam research lrcx outperformed gain ibd index lead growth stock look poise day outperformance name more also ibd edward lifescience ew pop make good case support day move average trade just alternate handle entry elsewhere spice maker mccormick mkc slump news acquire reckitt benckiser north american food business reckitt more popular brand include french mustard frank redhot sauce meanwhile discovery communication disca gap be session report company be talk acquire scripps network sni scripps network include food network hgtv wall street like sound potential deal send share discovery higher scripps surge morgan stanley ms reclaim buy point early session strong earning give back early gain hit intraday high share be recently trading related stock be buy zone ahead earning tonightchip gear maker asml jump record high beatthese tech firm be corporate america biggest cash hoarder
111,EW,stock stage mostly mild decline monday drowsy action masked excellent upside action few name largest most important sector market namely medical fall give back half friday advance nasdaq also be miserly mood follow solid start new
112,EW,stock drift moderate loss close monday small cap stock take biggest hit nasdaq finished lower dow jone industrial average drop small cap russell fall volume track lower exchange accord preliminary datum west texas intermediate delivery tumble barrel decline further skepticism probability opec production cut virgin america va soar news have enter agreement be acquire alaska air alk alaska descend gunmaker wesson swhc sturm ruger rgr be take shot analyst downgrade report gun sale be slow analyst cowen say national instant criminal background check system show sequential decline march datum handgun long gun be biggest decade wesson recoil heavy volume plunge cup buy point day move average sturm ruger misfire decline also fall day line edward lifescience ew gap gain weekend company reveal positive result clinical trial involve patient intermediate risk open heart surgery image provide shutterstock
113,EW,due considerable market volatility past several week investor focus stock pullback be quiet calm orderly longtime ibd sector leader abiom abmd be exemplify trait consolidate recent gain cup handle late april massachusett base medical device maker have stranglehold artificial heart market impella heart
114,EW,neogen neog see ibd smartselect composite rating rise monday friday new rating be sign stock be outpace stock come most important stock pick criterium neogen be currently form flat base entry look stock break volume least average be aware be thinly trade stock average daily dollar volume such stock show wider daily weekly fluctuation stock greater trading volume stock have ep rating meaning recent quarterly annual earning growth top stock accumulation distribution rating show moderate buy institutional investor last week company report ep gain mean now post straight quarters rise ep gain revenue growth climb prior quarter mark quarters increase revenue gain neogen earn rank peer medical product industry group abiom abmd edward lifescience ew inogen ingn be top highly rate stock group related company be now outperform stock
115,EW,stock market open quietly lower monday nasdaq dow jone industrial average lose small cap outperformed early go russell only economic release expect stock market today be february factory order commerce department service sector datum march be expect tuesday high point quiet week economic news be likely be minute federal open market committee march meeting be due wednesday be closely watch boston federal reserve bank president eric rosengren speak morning earning report have slow trickle gpu technology conference san jose calif grab attention week oil be little change west texas intermediate brent slip fraction oil price post first decline week last week commodity biggest rally april gold dip less hold ounce europe benchmark index paris frankfurt trade more midday london ftse trail gain market china end session narrowly mixed japan nikkei inched apple aapl home depot hd pfizer pfe be early leader dow nasdaq facebook fb be early decliner nearly stock capped week advance friday end just buy point cup base share be recently trading virgin america va soar alaska airline alk slump alaska agree acquire virgin deal value share virgin rise week friday speculation deal alaska end friday buy point cup handle base edward lifescience ew bolt higher announce positive result clinical trial sapien aortic valve replacement medical device leader end last week extend cup base buy point tesla motor tsla rise tweet chief executive elon musk announce order new tesla model rise end day saturday tesla briefly clear cup handle buy point friday then trim gain end just buy point
116,EW,mfs mid cap growth fund otcix be rev engine improve performance relative peer fund top midcap growth rival track morningstar inc month go wednesday improve outperformance year date past month year vs peer group big cap bogey manager paul gordon pin improvement market rotate back type growth stock favore fellow manager eric fischman matthew sabel last year person start gain additional confidence economy lot more cyclical lower valuation company start rally gordon say have extreme rally trump election typically not area invest look long term not short term valuation opportunity year have be reversal trend back secular growth company holding have notch nice gain year include graphic chip maker nvidia nvda be so far year chipmaker monolithic power system mpwr be design automation software maker cadence design system cdns be nvidia be member ibd list stock strong relative price strength fundamental gain have left nvidia monolithic cadence share price extend outside buy range investor look optimal entry point other holding have post good gain be still buy range edward lifescience ew maker heart valf other vascular disease product be stock gordon fund have raise share count recent disclosure have best possible composite rating ibd medical device company have product be better way do traditional aortic valve replacement surgery gordon say tend provide better medical result safety think runway be long continue increase number procedure be do way go forward ibd take addition edward lifescience sterling composite rating have consecutive year annual earning share growth see easy understand fundamental technical datum stack rival ibd stock checkup logmein logm be stock fund have be build stake earning share maker business software rise past quarters analyst poll thomson reuter expect second quarter profit rise very good cent share have nice market share niche market gordon say recently purchase asset call getgo product include gotomeeting related offering citrix system ctxs think have opportunity improve business citrix be not part core business so do not get maximum attention bigger company now be very complementary logmein know do software maker ss technology ssnc be so far year gordon say provide back office software financial company re take share house other third party company sell last year height investor fear decline hedge fund growth stock have re-cover offer trendy high quality brand sell less store plan open more be be bit combination dollar store price store so sell low price item change seasonally be attractive customer require bit treasure hunt re fun place shop fairly cheap consumable item total store opportunity company be fairly large return new store be very high so be able get great footage growth high rate cash flow think continue share be year ibd reader recognize wednesday afternoon be trading shade entry point gordon summarize fund strategy focuse secular growth company have high confidence long duration average earning growth market be perform trump dump rotate away lower value cyclical stock benefit trump policy provide fund only small additional tailwind gordon say provide opportunity only margin find additional name add portfolio past year fund average annual return top only direct rival manager fischman gordon sabel joined fund respectively related top mutual fund portfolio trump era stock play stock matter presidentmfs align management team growth fund mid cap growth
117,EW,stock market turn lower monday decent gain early session nasdaq fall lose dow jone industrial average give volume be tracking close friday level stock market today economic news order place factory slip february commerce department report reverse downwardly revise increase january february result be largely line economist consensus have forecast slip dow stock be evenly split loss be deeper gain general electric ge goldman sachs gs intel intc drop more home depot hd lead upside gain virgin america va ruckus wireless rkus grab headline spiking respectively start trade virgin announce takeover alaska airline alk ruckus say be fold brocade communication brcd stock related natural gas packed top natural gas price pop edward lifescience ew lead ibd list spiking start gate irvine cal base medical device maker announce positive trial sapien sapien xrt aortic valve replacement share be now extend almost cup base buy point mortgage lend service provider lendingtree tree climb moderate trade rise bring stock back buy point first stage cup handle base stock remain buy range wesson swhc dive apparently trip analyst downgrade bb capital market trim rating hold buy cowen co downgrade stock market perform outperform stock have be fight hold buy point cup base monday heavy volume move send share mark support week move average possible factor be firearm background check march be rough gauge industrywide sale march number be lowest month peer sturm ruger rgr feel suction diving powerful trade also cut week move average
118,EW,stock strengthen be session high late afternoon trading tuesday help comment federal reserve chair janet yellen be perceive dovish once again wall street chip equipment stock help lift nasdaq gain small cap also do well russell add dow jone industrial average gain volume nyse nasdaq be tracking higher tuesday level money flow bond year treasury yield tumble basis point speech economic club new york fed chair janet yellen say be appropriate central banker proceed cautiously raise interest rate big gainer nasdaq include chip equipment firm lam research lrcx surge past cup handle buy point rise stock be well buy range economic news consumer confidence come better expect accord latest datum conference board index rise prior read economist expect smaller increase meanwhile case shiller city composite index january show home price rise year earlier mostly line expectation ibd homebuilding group outperformed rise lennar len pop report solid earning open horton dhi nvr nvr extend gain more recent breakout stock market today buyer be dave buster play ahead earning report due close share rise pullback stock be only week high consensus estimate call profit cent share year sale be see rise ibd outperformed nicely name more tal education xrs broadsoft bsft prestige brand pbh leaderboard name edward lifescience ew show gain more new york mercantile exchange west texas intermediate crude oil delivery slump nearly barrel
119,EW,most stock big cap be extend mean shareholder probably be look profit take opportunity yet several stock find screen past week be buy zone just buy point be too late buy analog device adi break cup base tuesday
120,EW,week row recent base just week april past buy point week lose mere respectively see such action stock chart time sit pay attention have just find
121,EW,xenterprise software firm oracle orcl used car dealer carmax kmx restaurant chain texas roadhouse txrh receive stock rating upgrade thursday wall street analyst also fiber optic communication stock lumentum holding lite viavi solution viav earn price target hike redwood city calif base oracle receive flurry price target increase stock thursday deliver fiscal fourth quarter result late wednesday soundly beat estimate wedbush securty upgrade oracle outperform least other investment bank raise price target stock other firm include bmo capital market cowen drexel hamilton jeffery rbc capital market drexel be most bullish reiterate buy rating hike price target oracle share spiked stock market today hit ew time high intraday oracle vault flat base form past week buy point oracle be clearly demonstrate market company have establish formidable force cloud naysayer past few year be be proven wrong drexel analyst brian white say report year oracle begin push aggressively cloud negatively impact sale ep way however believe worst transition be rbc capital market upgrade share carmax outperform sector perform raise price target richmond va base carmax jump retake day day move average wednesday rise trade carmax wednesday report fiscal first quarter result beat expectation sale earning be drive strong truck suv sale well surplus attractively price lease vehicle carmax sale growth be impressive tough environment rbc analyst scot ciccarelli say report carmax result continue outpace expectation say believe be due fall used vehicle value make used more attractive vs new significant improvement search engine optimization believe trend continue ciccarelli say bmo capital market upgrade texas roadhouse stock outperform market perform also up price target louisville ky base company see stock break week consolidation period buy point have struggle stay point then wednesday fall end day day move average texas roadhouse climb stifel give price target hike thursday lumentum holding viavi solution stifel reiterate buy rating lumentum up price target stock lumentum be currently rank ibd list top perform growth stock lumentum initially rise close stifel maintain hold rating viavi raise price target viavi advanced
122,EW,big cap have lose luster even have gain biotech stock such celgene celg regeneron pharmaceutical regn vertex pharmaceutical vrtx xso far year big cap still lead advantage have fluctuated recent session low percentage point
123,EW,be upside intuitive surgical isrg guidance analyst suggest tuesday investor be already pay downgrade stock likelihood subdue demand asia canaccord analyst jason mill also see medtronic mdt know make heart valve replacement rival edward lifescience ew stout competitor surgery robotic year date intuitive surgical stock be phenomenal year canaccord analyst jason mill write note client intuitive end year sale growth earning growth cash health care sector have be top performer so far intuitive surgical have be lead charge mill say however investor exuberance company strong performance past few year have drive stock unprecedented valuation level mill downgrade intuitive surgical stock hold rating buy year keep price target close stock market today intuitive surgical be expect intuitive surgical deliver solid result believe risk reward setup tilt too much former present say stock hasn trade valuation be now premium own year average ibd take intuitive surgical stock have ibd composite rating best possible rank fourth ibd company medical system equipment industry group idexx laboratory idxx stock lead group cr look group setup head ibd stock checkup guidance have play big role intuitive surgical stock mill say company typically offer conservative guidance easily outperform thus investor expect positive guidance revision balance not be case easter weekend tailwind first quarter become headwind second quarter outside business be slow mill write procedure growth be expect be subdue japan moderate china think be upside current guidance think re already pay write meantime competition be loom say intuitive surgical make robotic assist perform surgery medtronic reiterate earning call last week plan launch surgical robotic outside april fiscal medtronic competitive approach seem be center ability target customer myriad surgical spectrum also deduce conversation management target cost side equation well mill say medtronic not become much competitor late early domestic launch creep closer intuitive surgical investor begin account upcoming competition multiple afford share say related robot surgeon maker launch record high strong
124,EW,stock open higher thursday once again quickly turn mixed busy session stir late season earning news heavy economic calendar dow jone industrial average russell dip narrow loss tick nasdaq power ahead apple aapl rise netflix nflx advanced early action turbulent session drive largely datum news release wednesday thursday start even busier earning economic schedule researcher markit rolled country country manufacturing index today begin weak overnight read small midsize business china report show slow output new order quicker staff reduction pressure sector contraction first time nearly year markit release manufacturing index et monthly job cut report challenger gray christmas show layoff number be skewer restructure plan ford account announce layoff report say private nonfarm employer add new worker adp estimate national employment report be april disappointing tally country mile expectation decline new hire service sector employer account new job construction provide largest number new job good produce industry first time unemployment claim rise week end labor department say economist have project uptick new claim commerce department april construction spending estimate institute supply management manufacturing index be due oil price trade higher west texas intermediate barrel week ahead energy information administration supply datum due et weekly datum american petroleum institute wednesday reportedly show sharp decline inventory automaker be release sale figure session banking stock show early strength rebound sharp sell wednesday goldman sachs gs jpmorgan jpm bank america bac well fargo wfc trade respectively general electric ge microsoft msft surge lead dow industrial early trade ibd stock lumentum holding lite cirrus logic crus swung more gain moved lumentum top buy range buy point cirrus exit buy range cup base entry cloud base software integrator box box open outfit report first quarter loss be narrower forecast jump revenue top expectation gain lift share buy range cup base buy point palo alto network panw bolt higher open trade retake week move average powerful trade security software developer report late wednesday jump fiscal third quarter earning revenue gain easily clear analyst estimate advance lift share well right side month consolidation fiber optic gear maker ciena corp cien flash higher brake buy point cup base hanover md base company report big beat revenue earning line fiscal second quarter deere co climb announce pay acquire german road equipment maker wirtgen group company expect cash deal close early next year deere have be trading high extend clear flat base buy point april hewlett packard enterprise hpe shed more ahead open month old ipo report late wednesday fiscal second quarter earning meet analyst target revenue fall less expect management earning guidance be consensus view loss send share week move average heavy trade trigger sell signal related tech leader high earning tap investing action plantop software firm have flip loss ep gain see thursday
125,EW,medtech player medtronic mdt tack growth heart valve replacement sale outgrow broader market fiscal fourth quarter revenue earning top wall street expectation medtronic share rise stock market today market open thursday medtronic release fiscal result evercore analyst vijay kumar call well round performance dublin base medical device maker earn share exclude item sale also fiscal fourth quarter end april analyst have modeled respectively fourth quarter result be strong finish fiscal year balanced diversify growth group region medtronic ceo omar ishrak say statement fiscal year be solid year overall medtronic robust sale minimally invasive therapy group include electrosurgical tool advanced vessel sealing device help medtronic total sale beat view globally unit pull rbc analyst glenn novarro call novarro keep outperform rating medtronic stock note restorative therapy group top view strong growth brain specialty therapy respectively spine revenue grow miss novarro forecast meanwhile cardiac vascular group just meet expectation revenue sale pacemaker implantable cardioverter defibrillator decline low single digit range group also see growth sale transcatheter aortic valve replacement tavr top broader market growth tavr be method insert heart valve replacement catheter be less invasive safer open heart surgery sector medtronic corevalve product rival sapien device edward lifescience ew boston scientific bsx also have compete device call lotus isn approve medtronic also guide growth fiscal sale growth earning share certain item be generally line previous communication evercore kumar say note client ibd take medtronic stock hit buy point tuesday else be report thursday take look investing action plan related boston heart valve win face trial rival medtronicedward rocket month high strong heart valve salescardinal health plunge big deal medtronic
126,EW,good week market be very good week ibd stock nearly third pressed further new high hold close high post past several week fact many be extend buy point be good sign be produce profit shareholder buy proper buy point still
127,EW,american century ultra fund twcux be roll outperform peer year date past month large cap growth fund be benefit strong showing stock fund fast grow large cap company fund manager have be busy refresh portfolio recent month highly rate stock have advanced new high year ultra be year go thursday vs fund large cap growth peer track morningstar inc past month ultra be vs fund peer fund be outperform newcomer portfolio fund past disclosure include edward lifescience ew idexx laboratory idxx paypal holding pypl happen be member ibd list stock strong relative price strength fundamental additional newcomer include abiom abmd adobe system adbe analog device adi have composite rating ibd composite rating start run combine ibd performance rating stock poise move higher often have comp rating higher think see pattern re right information technology health care be fund first third biggest sector march weighting respectively consumer discretionary stock such amazon com amzn time warner twx fund third ninth biggest position feb constitute fund second biggest sector bet reflect fund overall strategy be long term capital growth investing mainly large company fund manager lee michael li jeff bourke seek high growth investing industry lead firm show sustainable accelerate earning growth positive price momentum edward be leader make replacement heart valf also make cardiac monitoring unit earning grow rate past year sale growth earning share grow past quarters ibd allison gatlin recently report edward sapien valve have relatively low rate deadly paravalvular leak result insufficient sealing site replace valve ibd reader recognize edward be trading buy point large cup handle base pattern often form prior big advance lead stock abiom make device design improve blood flow stock ibd medical product industry group abiom outrank edward abiom ep grow past quarters earning grow rate past year sale growth company be not carry debt ibd take see abiom additional easy understand fundamental technical datum stack rival ibd stock checkup trading share price be extend entry point be buy range alternate entry chipmaker analog device share price be past week way stock also provide income forward annual dividend be share yielding payout have growth rate analog be lead designer maker high performance analog mixed signal digital signal process integrate circuit used signal process application company be slate report second quarter result earning share be expect rise year accord ibd stock checkup paypal show fund latest disclosure stock rank ibd finance credit card payment process industry group share price be year trading share be extend be not currently proper buy point company fundamental continue heat ep grow past quarters american century ultra have expense ratio average large cap growth fund turnover rate be mild related american century ultra fund be poise tech stock reboundtop mutual fund manager have several stock buy zonemarket tailwind be already lift top fidelity mutual fund manager portfolio
128,EW,xmajor stock index end tuesday session decent gain light volume be disappointing particularly straight decline nasdaq average trading dow jone industrial average hit record high rise add nasdaq composite lead way rise russell small cap index perform line
129,EW,boston scientific bsx see positive improvement relative strength rs rating friday upgrade ibd proprietary rating measure market leadership worst best score grade show stock price behavior trail week stack other stock database decade market research show best stock tend have rs rating launch largest climb see boston scientific continue show renew price strength hit benchmark boston scientific be still buy range clear buy point flat base once stock move higher initial entry consider extend buy range company show growth last quarter sale growth come boston scientific hold rank peer medical product industry group abiom abmd mimedx mdxg edward lifescience ew be top highly rate stock group related stock be show improve technical action use ibd relative strength rating relative strength line help judge stock
130,EW,boston scientific bsx lotus heart valve prove superior rival medtronic mdt corevalve yearlong trial boston scientific medtech player say tuesday prompt share jump early lotus corevalve be transcatheter aortic valve replacement tavr patient harden artery be not eligible surgery process be less invasive open heart surgery allow new valve be insert catheter year boston scientific study pair lotus valf show superiority medtronic corevalf primary effectiveness lotus valf be not fda approve also prove inferior safety risk death disable stroke paravalvular leak result insufficient sealing site replace valve be lower boston lotus medtronic corevalve boston say boston lotus also prove safer have lower rate moderate severe paravalvular leak medtronic corevalve most leak follow heart valve replacement be minor large leak have be link heart failure ibd take edward lifescience be leader medtech ibd composite rating landing third spot top company medical product industry group head ibd stock checkup list other leader separately rate disable stroke lotus patient be just compare corevalve patient overall stroke rate be closer lotus patient vs corevalve patient larger percentage corevalve patient die result cardiac death corevalve patient lotus patient evercore analyst vijay kumar say fact lotus achieve overall superiority study be link lower rate paravalvular leak note shouldn be surprise lotus have lower paravalvular leak rate be key distinguish feature valve separate study edward lifescience ew sapien valve have comparably low rate leak close stock market today boston stock be lift much earlier day share top buy point flat base april have linger buy zone medtronic stock be fraction share edward be related edward rocket month high strong heart valve salesdid baxter hoodwink fda inspector be probe just extraordinary medtech stock buy ahead
131,EW,share eli lilly lly dow component pfizer pfe topple month lows tuesday sustain pair downgrade lilly grab buy rating pfizer sank sell rating close stock market today lilly stock be pfizer stock lose share hit lows last see mid february goldman sachs analyst jami rubin remove lilly conviction list replace ibd member edward lifescience ew product story see potential more upside lilly stock be still rate buy price target lilly stock be year date vs have rise long term fundamental look strong lilly be face term risk patent battle regard chemotherapy alimta decision be expect june be unique situation lilly have already win district court appeal same patent rubin say usually district court process follow patent review likelihood lilly lose patent review process be low result earlier expect generic competition vs alimta second half rubin write note client meanwhile food drug administration decision regard rheumatoid arthritis drug olumiant be weigh lilly stock write earlier year fda ask more dose safety datum drug just month european official sign ibd take lilly have middling ibd composite rating best possible meaning outperform nearly stock term key growth metric still lag leader zoetis cr head ibd stock checkup list top perform drugmaker longer term rubin see upside diabetes drug trulicity breast cancer drug abemaciclib migraine drug galcanezumab take time lilly get credit wall street rubin say pfizer other hand be cut sell rating neutral citi price target cut accord streetinsider citi say medicare part coverage pfizer oncology drug be risk pfizer count prostate cancer drug xtandi breast cancer drug ibrance lung cancer drug xalkori citi analyst andrew baum say pfizer member dow jone industrial average need deal hit consensus view profit consensus expect pfizer report adjust earning share respectively related teva hold own bring migraine drug market drug stock rally relief gop health care bill win roche cancer failure tank bristol pfizer not merck
132,EW,stock open positive momentum tuesday quarterly report weibo wb sina sina home depot hd help counter weak housing market datum dow jone industrial average pop start bell nasdaq add apiece just enough lift nasdaq fresh high china base tech name claw market best early move weibo bolt higher open china most popular microblogging video sharing site report rise earning revenue gain analyst target management heft second quarter revenue guidance well consensus projection stock be nail new high extend cup handle buy point sina vault higher web portal majority owner weibo turn cent share profit first quarter swing loss cent share year well expectation revenue gain also top view gain moved share buy range flat base buy point vipshop holding vip perked report late monday revenue earning growth top forecast first quarter stock be top buy range slightly flat base buy point retailer be mixed start home depot pressed higher first quarter report other take hard early hit gain send home depot new high buy range flat base buy point tjx company tjx shed release first quarter result staple spls give report mixed first quarter performance dick sporting good dks dump open bell retailer report earning revenue line estimate first quarter comparable store sale rise vs company guidance gain dick share have be consolidate december vodafone group vod open higher lead nasdaq base wireless service provider report strong fiscal fourth quarter result raise dividend lift full year profit guidance share be now november low back key level support year decline ibd stock edward lifescience ew jumpoed start trade goldman sachs initiate coverage stock buy rating price target stock remain buy range buy point cup handle base oil price pressed higher gain put west texas intermediate barrel gold be trading ounce dollar trade lower bond flattened leave year yield new housing start slow april annualize rate commerce department say department also revise march estimate downward economist have project increase pace start april build permit activity slow annualize basis rate permit march disappointing expectation increase rate permit industrial activity improve april federal reserve report production rise vs march gain better double advance expect economist utilization production capacity improve march best expectation increase europe market remain mixed gain strength afternoon trade london ftse climb paris cac be frankfurt dax turn positive add related nasdaq mark new high be growth stock outperform cisco buy point analyst tout new effort earning
133,EW,medical related exchange trade fund have rac healthy gain year ongoing quest longer healthier life outperformer be ishare medical device ihi gain year date well ahead gain period fund boast year average annual return vs benchmark index accord morningstar inc ihi launch track dow jone select medical equipment index top holding etf include medtronic mdt abbott laboratory thermo fisher scientific tmo abbott developer generic drug disease screening system other product be buy range clear flat base entry thursday xihi be etf pick featured ibd last month oscar pursche chief executive bruderman brother bruderman asset management opposed take broad view health care sector do overall see great opportunity medical device space investor get exposure ishare medical device etf say also note fund top holding account nearly portfolio increase risk profile ihi be extend past buy point clear april ibd take find biotechs stand benefit most president trump propose tax reform recent tech column spdr health care equipment xhe return ytd year average year old fund track health care equipment select industry index have gather asset top holding include align technology algn intuitive surgical isrg edward lifescience ew account portfolio xhe be trading record high be extend recent bounce day line spdr biotech xbi year have average annual gain past year fund launch january be form flat base buy point entry still july peak vertex pharmaceutical vrtx regeneron pharmaceutical regn abbvie abbv be top name hold xbi top holding make asset related be best health care etf gop move replace etf ride industry recovery
134,EW,do lead player long run bull market today have be spanking new issue not necessarily scan date stock ibd go public find just name make debut past year baby group floor decor fnd april ipo
135,EW,stock big cap be situation require patience sound judgment october edward lifescience ew have be form cup handle pattern cup decline william neil book make money stock point usual correction absolute peak vary
136,EW,edward lifescience ew stock rocket month high wednesday medical tech player report particular strength heart valve replacement sale follow several quarters up down stock market today edward soar earlier rise much high last achieve october sale transcatheter aortic heart valf tavr grow edward say tuesday first quarter earning conference call beat consensus rbc analyst glenn novarro say note client unexpectedly strong quarter tavr sale couple upward revision revenue earning guidance send edward share market trading novarro say edward late tuesday report tavr be method replace diseased heart valve catheter process have become more popular recent year less risky require shorter recovery period surgery medtronic mdt boston science bsx be also work realm quarter end march edward report sale grow top consensus canaccord analyst jason mill write research report edward report cent adjust earning share beating cent mill be pound drum again primary reason own edward include total addressable market tavr edward outgrow market quarter increase tavr sale vs other company edward have share tavr market mill estimate ibd take boston scientific make acquisition december rattle edward lifescience medtronic pay head sector leader deep dive first quarter validate bullish view tavr market estimate target population penetration model estimate market edward hold share write also note edward strong earning leverage grow opportunity transcatheter mitral valve repair portfolio positively surprise investor earlier acquisition cardiaq be expect drive material profit loss contribution also tuesday edward boost low end yearly sale guidance now see revenue company also raise adjust ep guidance second quarter edward model sale exclude germany stocking sale adjust earning cent cent share mill keep price target buy rating edward stock novarro boost price target maintain outperform rating edward related medtech stock buy ahead boston scientific make acquisition battle medtronic do heart valve study rival reap benefit
137,EW,xlate session decline whittle wednesday moderate gain weak finish earning disappointment be lead culprit gnawing away week early momentum grind dow jone industrial average early gain decline nasdaq also shred gain nasdaq end flat less index remain firmly positive week compare busy session monday tuesday wednesday action be comparatively quiet preliminary datum show trade slightly higher nyse slightly lower nasdaq end dow industrial unite technology utx rise nearly procter gamble pg drop quarterly result unite tech remain buy range flat base buy point more half dow stock trade higher verizon vz home depot hd traveler trv also post gain edward lifescience ew easily lead pulse more higher report strength heart valve replacement help power first quart earning gain rise sale number clobber analyst expectation move hoist share back week move average edward work right side month consolidation gain be more modest nasdaq lead advance norwegian cruise line nclh gain put share narrowly buy point month long flat base low end nasdaq be different story seagate technology stx gouge loss maker computer hard drife post ep gain analyst target revenue advance stop short expectation loss send share week move average heavy trade trigger sell signal hard drive peer western digital wdc slip strong trade report earning market close thursday leisure lodging group post strongest gain industry wyndham worldwide wyn spiked record higher turn powerful first quarter performance raise full year guidance share end session buy point flat base heavy hour report session wednesday be schedule include report la vegas sand lvs citrix system ctxs xylinx xlnx amgen amgn equinix eqix other related trump unveil sweeping tax cut plan jpmorgan say be impossible la vegas sand report late casino stock hot streak
138,EW,stock open flat wednesday logging day powerful gain dow jone industrial average nasdaq be less dow jone industrial average rolled wednesday session monday morning trading less march high be ahead so far week just half percent high nasdaq have take new high past day combine session week heavy slate earning report continue trigger move early wednesday number report company see breakout twitter twtr fly higher strong first quarter beat cree cree macom technology solution mtsi drop respectively follow quarterly report macom sank much ass buy point dow industrial boee ba groan lower mixed result unite technology utx climb report solid performance unite tech remain buy range buy point edward lifescience ew clock early gain report late tuesday result easily outpaced analyst expectation stock be form base base have form almost entirely day move average health insurer anthem antm climb sale earning top expectation wide margin management also raise full year ep revenue guidance consensus view anthem be buy range buy point flat base computer accessory maker logitech logi open switzerland base manufacturer post better expect profit sale announce share buyback initiative share rebound test support week move average fiber optic telecom network component maker te connectivity tel ring gain fiscal result trounce analyst projection share break past buy point flat base wynn resort wynn book advance report earning revenue gain company also announce start construction new resort la vegas early december stock close monday just april high extend clear flat base mid march downside steel tank report surprise loss cent share vs expectation cent share profit revenue rise less expect company lower full year guidance half consensus expectation stock gap day move average lowest level november seagate technology stx drop start regular trade hard disk drive maker report mixed result revenue come just analyst target management say demand remain stable oil price dip leave west texas intermediate hover barrel ahead energy information administration release weekly stockpile report et gold dip fraction ounce dollar tick higher bond slip lift year yield basis point market china post moderate gain japan tokyo nikkei power third straight day better gain market europe remain mixed afternoon trade ftse london frankfurt dax show narrow decline cac paris defend fractional gain related near high fang stock be buy rangeearning put stock buy zone investing action plan
139,EW,baxter bax stock fall monday worry related department justice investigation potential price fix intravenous fluid allegation analyst deem extraordinary stock market today baxter stock fall justice department send grand jury subpoena baxter employee subpoena be receive friday relate criminal investigation justice department antitrust arm ask document testimony related manufacturing pricing selling shortage intravenous solution baxter communication rival evercore analyst vijay kumar note price fix allegation isn new stem year old investigation begin new york ongoing class action suit northern district illinois related supply shortage shortage be trigger flu season benefit manufacturer hospira third quarter see growth unit produce intravenous fluid kumar say hospira be acquire pfizer pfe class action lawsuit allege manufacturer intravenous fluid falsely create shortage justify spiking price baxter have file motion dismiss suit call allegation extraordinary idea public company voluntarily create supply shortage hope competitor similarly restrict output order raise price seem stretch kumar tell client note ibd take baxter stock trade ibd company medical product industry group be lead medtronic mdt stryker syk boston scientific bsx term market cap medtronic boston edward lifescience ew compete heart valve replacement market check edition sector leader see stack fda regulator regularly inspect manufacturing facility note class action lawsuit seem imply baxter other intravenous fluid manufacturer be able hoodwink inspector post shortage notice say baxter say incur cost comply increase fda regulatory requirement meet supply constraint meanwhile price increase only contribute growth kumar say intravenous fluid solution contribute third segment growth imply pricing be average kumar say assume bag intravenous fluid cost equate increase cent bag apart price collusion prosecutor have argue baxter earning increase intravenous fluid price be reasonable kumar estimate hike price intravenous fluid baxter have margin earning interest taxe related boston scientific make acquisition battle medtronic edward best stock own analyst
140,EW,scripps ssp see ibd smartselect composite rating jump thursday day revise score mean stock currently top other stock term key performance metric technical strength market biggest winner often have higher grade early stage new price run scripps be currently form flat base entry try retake week move average line see stock break volume least higher normal weak spot be company ep rating track quarterly annual earning growth look improve better show top stock accumulation distribution rating show moderate buy institutional investor last week company report earning growth sale growth increase prior quarter mark consecutive report increase revenue gain company next quarterly report be expect scripps earn rank peer medium diversify industry group gray television gtn be rank stock group related company be now outperform stock
141,EW,johnson johnson jnj zimmer biomet zbh be medtech stock own go earning season several other be put buy list pullback analyst say rbc analyst glenn novarro say wednesday large cap medtech stock johnson zimmer offer best risk reward first quarter earning season zimmer be cheapest arena johnson have lag group investor sentiment have turn more favorable johnson recent week anticipate further multiple expansion back strong first quarter result consensus estimate move higher year write research report consensus analyst poll yahoo yhoo broadly expect johnson report sale year year share adjust earning dip johnson be also cusp close acquisition actelion pharmaceutical second quarter sanofi sny be lock battle late last year take swiss biotech johnson bid win company zimmer company just have hit consensus estimate stock move higher novarro say consensus model year year sale growth adjust earning share novarro however say abbott laboratory boston scientific bsx edward lifescience ew stryker syk be attractive pullback see deliver solid result reaffirm guidance investor likely track ongoing litigation abbott alere alr heart valve replacement sale edward boston likely comment voluntary recall lotus heart valve replacement company recall lotus device discover malfunction result premature release pin implantation medtronic mdt onyx stent launch represent term challenge boston still want own boston novarro say small midsize cap world novarro recommend nuvasive nuva medical group wmgi group potential takeout be likely baked stock price nuvasive say ibd take isn first time edward have be list best stock own head ibd technology page deeper dive edward be hold strong remain top pick small midsize medtech group expect play catch group investor focus shift company impressive new product lineup improve international sale growth company experience distributor issue write novarro needham analyst mike matson also prefer zimmer also have strong buy rating share inogen ingn mimedx mdxg see cardiovascular orthopedic market slow diagnostic market improve quarter matson model cardiovascular market growth decelerate fourth quarter orthopedic market advance vs growth prior quarter diagnostic sale likely grow say be standout matson say model transcatheter aortic valve replacement market boston edward medtronic operate have grow orthopedic matson model growth extremity market related medtronic do heart valve study rival reap benefitsboston scientific make acquisition battle medtronic edward
142,EW,major stock exchange trade fund pause wednesday strong recent gain wall street focuse more corporate earning await detail president trump tax plan tax plan trump administration be set unveil wednesday afternoon be widely expect call corporate rate spdr spy spdr dow jone industrial average dium powershare qqq qqq eke gain shortly open stock market today major stock index track etfs be record high risk appetite sharpen investor trader health sector lead gain morning trade health care select sector spdr xlv add morning trade share edward lifescience ew jolted much higher maker cardiac product trump first quarter view spdr health care etf have be rally day so far week sector have lag peer month date gain xlv sit march high health insurer anthem antm advanced early trading report easily top estimate ishare nasdaq biotechnology ibb rise wednesday day surge more impressive earning beat biogen biib ibd take trump agenda emerge read ibd leaderboard big picture day learn actionable stock potential big upward move related be go etf market
143,EW,boston scientific bsx say thursday plan acquire swiss firm symetis deal deepen heart valve rivalry medtronic mdt edward lifescience ew symetis offer several transcatheter aortic valve replacement product europe internationally add boston lotus heart valve device late february be recall due mechanical issue deal be expect close second quarter be earning accretive hit return interest third year boston say presentation boston also reiterate plan launch lotus heart valve device device be expect return european market later year believe be offensive rather defensive move needham analyst mike matson say do not believe be stopgap address lotus recall shortcoming lotus ip intellectual property issue matson keep buy rating price target boston scientific stock boston share finished regular trading stock market today follow announcement boston have be pressure recently patent battle edward share fall feb boston voluntarily recall lotus heart valve device company discover mechanical issue lead premature release pin doctor implant device patient die attempt replace lotus heart valve ibd take not first time boston scientific have make acquisition help battle medtronic edward lifescience already have transcatheter aortic heart valve device head sector leader see rivalry be shape boston see symetis complementary lotus have do deal even lotus be not have be recall evercore analyst vijay kumar write note client investor concern symetis acquisition imply lotus be further delay provide reassurance say symetis be also unlikely trigger more patent issue edward kumar say patent doesn appear symetis work support beam locking mechanism heart valve replacement be be contest edward related medtronic edward best stock own analystboston topple heart valve bug wo boost edward do heart valve study rival reap benefit
144,EW,medtronic mdt edward lifescience ew stock dip monday series bullish report include call heart valve replacement rival stock own term midday trading share medtronic end virtually flat stock market today edward close rbc analyst glenn novarro expect have strong catalyst term note client sunday novarro say see edward medtronic stryker syk zimmer biomet zbh group stock own term call edward medtronic best idea cardiovascular work heart valve replacement recent study medtronic show new method insert heart valve be superior open heart surgery be encourage novarro say result help stoke growth transcatheter aortic valve replacement market say check ibd best mutual fund awardsfollow novarro report evercore analyst vijay kumar upgrade edward stock buy rating raise price target needham analyst mike matson reiterate buy rating price target medtronic stock matson expect medtronic maintain mid single digit sale growth double digit earning growth overcome temporary product cycle competitive issue fiscal third quarter believe medtronic product cycle remain very strong effectively fend competitive product launch investor concern matson write note client medtronic compete edward lifescience smaller outfit heart valve replacement boston scientific bsx also be look break transcatheter aortic valve replacement market doesn yet have fda approval ibd take boston scientific be work catch medtronic edward lifescience strategic acquisition read sector leader next month medtronic have number launch help boost growth company see strong growth emerge market segment make total sale have see double digit growth recent quarters believe medtronic sustain double digit growth market drive market development channel optimization public private partnership matson say saudi arabia see return growth soon rbc novarro expect medtronic continue gain share implantable cardioverter defibrillator market device be used manage tachycardia expect transcatheter aortic valve replacement drug coat balloon perform well novarro call line slightly better first second quarter metric edward expect medtronic launch corevalve evolut drive growth also edward sapien xt device be transcatheter aortic valve implant patient harden heart valf unable undergo open heart surgery novarro recommend own edward stock go second half expectation market growth evercore kumar note edward stock be growth stock therefore volatile nature lower investor expectation believe edward share be poise catch trade offer asymmetric risk reward current level write research report see upside current stock level kumar be previously sideline edward stock competition boston scientific international market boston pull lotus valve market late february give edward first break month still company be likely patent standoff first half related medtronic do heart valve study rival reap benefitsboston scientific win patent battle vs edward german courtboston topple heart valve bug wo boost edward medtronic
145,EW,edward lifescience ew boston scientific bsx stock get boost friday medtronic mdt publish study show new method insert heart valve be better alternative open heart surgery close bell stock market today edward stock pop boston stock follow medtronic conduct study exposure transcatheter aortic valve replacement tavr market be smaller share lift fraction company play market boston be still testing product realm patient harden valf condition call aortic stenosis procedure allow new heart valve be insert catheter new device push diseased aortic valve aside trial monitored patient receive heart valve replacement year year mark patient undergo transcatheter aortic valve replacement have die suffer disable stroke vs patient undergo surgery analyst have generally expect rate death disable stroke patient undergo new method heart valve replacement evercore analyst vijay kumar write research report ibd take boston scientific be look take medtronic edward lifescience acquisition december be successful head sector leader look upcoming battle medical technology surgery be much riskier involve longer recovery period medtronic meet goal prove tavr be not inferior surgical method replace diseased heart valve help push more doctor used newer method rbc analyst glenn novarro say believe positive edward stock reaction be due fact larger body clinical evidence show tavr safe effective convince more surgeon consider tavr viable option aortic stenosis patient lower surgical risk write note novarro forecast tavr market exceed grow compound annual growth rate next year see medtronic get fda approval corevalve tavr platform intermediate risk patient next month related boston scientific win patent battle vs edward german courtboston topple heart valve bug wo boost medtronic edwardsedward restart cardiaq heart valve set europe launch rbc
146,EW,integra lifescience hld iart see positive improvement relative strength rs rating monday rise ibd proprietary rs rating measure technical performance used worst best score identify stock price performance last week match other stock history reveal best perform stock often have higher rs rating early stage move integra lifescience hld be now consider extend buy range clear buy point first stage cup handle see stock form new pattern follow buy opportunity week tight pullback day week move average top bottom line growth moved higher last quarter earning be compare prior report revenue increase integra lifescience hld earn rank peer medical product industry group abiom abmd align technology algn edward lifescience ew be top highly rate stock group related stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
147,EW,welcome move nephew snn see relative strength rating improve thursday ibd proprietary rating track market leadership worst best score score show stock price performance trail week hold other stock database decade market research show market biggest winner typically have rs rating north launch biggest climb see nephew continue rebound clear threshold nephew break earlier have fall back prior entry flat base stock re tracking clear buy point then fall more original entry price consider fail base stock set new base buy point also understand most recent consolidation be later stage base make riskier establish new position add share exist nephew report earning growth last quarter sale growth come company hold rank peer medical product industry group abiom abmd align technology algn edward lifescience ew be top highly rate stock group related stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
148,EW,welcome move globus medical gmed see relative strength rating improve thursday exclusive rating investor business daily identify price movement worst best score rating show stock price performance trail week hold other stock database history reveal market biggest winner typically have rs rating north begin largest climb see globus medical continue show renew price strength clear threshold globus medical be build flat base buy point see clear price volume least average earning growth increase last quarter revenue gain fall company hold rank peer medical product industry group abiom abmd align technology algn edward lifescience ew be top highly rate stock group related stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
149,EW,thursday livanova livn earn upgrade relative strength rs rating ibd unique rating track market leadership worst best score grade show stock price behavior last week stack other stock database year market history show market biggest winner typically have better rs rating early stage move livanova be now consider extend buy range clear buy point first stage cup handle see stock form new pattern follow buy opportunity week tight pullback day week move average ep growth decline company most recent report revenue rise company earn rank peer medical product industry group abiom abmd align technology algn edward lifescience ew be top highly rate stock group related ibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
150,EW,thursday penumbra pen earn positive adjustment relative strength rs rating unique rating identify market leadership used worst best score show stock price performance last week match other publicly trade company year market history reveal stock go make biggest gain typically have higher rs rating early stage move stock be try complete flat base entry see stock clear price heavy trade company show earning growth most recent report sale growth come penumbra earn rank peer medical product industry group abiom abmd align technology algn edward lifescience ew be top highly rate stock group related stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
151,EW,medical wmgi have relative strength rs rating upgrade tuesday welcome improvement still shy better score prefer see unique rating identify market leadership used worst best score show stock price action trail week compare other publicly trade company year market history reveal best stock typically have rs rating least early stage move see medical continue rebound hit benchmark stock be build consolidation entry see stock clear price volume least higher normal medical post ep growth latest quarterly report sale growth come medical earn rank peer medical product industry group abiom abmd align technology algn edward lifescience ew be top highly rate stock group related ibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
152,EW,integra lifescience hld iart see welcome improvement relative strength rs rating tuesday rise exclusive rating investor business daily identify price action worst best score score show stock price behavior trail week compare other stock database history show stock go make biggest gain often have better rs rating launch biggest price move integra lifescience hld be now consider extend buy range clear buy point first stage cup handle see stock form new pattern follow buy opportunity week tight pullback day week move average top bottom line growth moved higher last quarter earning be compare prior report revenue increase integra lifescience hld earn rank peer medical product industry group abiom abmd align technology algn edward lifescience ew be top highly rate stock group related stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
153,EW,penumbra pen see positive improvement relative strength rs rating tuesday rise ibd unique rating identify market leadership worst best score rating show stock price movement trail week stack other stock database history reveal stock go make biggest gain typically have rs rating early stage move see penumbra continue show renew price strength hit benchmark penumbra be try complete flat base buy point see break volume least average penumbra show ep growth most recent report sale rise keep eye company next round number aug penumbra earn rank peer medical product industry group abiom abmd align technology algn edward lifescience ew be top highly rate stock group related ibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
154,EW,monday teleflex tfx get upgrade ibd smartselect composite rating new score tell company be now outperform stock term most important fundamental technical stock pick criterium teleflex be trading buy range entry cup handle keep mind later stage base such basis be more prone failure stock earn ep rating meaning recent quarterly annual earning growth top stock accumulation distribution rating show moderate selling institutional investor last week look rating improve least better company post earning share growth top line growth fall prior quarter teleflex earn rank peer medical product industry group abiom abmd align technology algn edward lifescience ew be top highly rate stock group related company be now outperform stock
155,EW,boston scientific bsx edward lifescience ew reach cross licensing agreement design heart valf evercore analyst vijay kumar suggest thursday boston triumph german court patent issue court rule edward infringe boston patent skirt sac reduce leak transcatheter aortic valve replacement court also rule boston infringe edward patent structure heart valve know support beam tossed second edward patent german decision put boston command position ip litigation edward kumar write research report expect boston file court action prevent edward selling heart valve germany injunction be unlikely edward appeal be ongoing write thursday ruling follow decision last week court rule edward patent sac outside anchor provide seal valid infringe second patent fabric seal sapien valve be rule invalid edward say thursday plan appeal german decision company expect court proceedings continue various location extend period time med tech giant also be battle france canada boston scientific stock close stock market today edward jump ibd take boston scientific edward lifescience medtronic be battle heart valve market lead head sector leader deep dive edward be also appeal portion uk court decision precedence doesn look good company kumar write earlier patent battle medtronic mdt regard heart valve tech higher court upheld decision germany uk medtronic edward ultimately settle medtronic pay edward royalty less annually edward have transcatheter aortic valve replacement type heart valve replacement market kumar write medtronic trail used earlier settlement model edward end pay boston less year say duo agree license tech scenario analysis have note event boston scientific win edward lifescience come poorer hand potentially force player arrive cross licensing agreement write related edward stock dip patent loss lawsuit rival bostonmedtronic downgrade increase boston st jude rivalriesboston topple heart valve bug wo boost medtronic edward
156,EW,share edward lifescience ew crumble friday judge rule heart valve patent be invalid suit bring rival boston scientific bsx stock market today edward stock fall continue be test day line earlier lose much announce court decision boston scientific stock slip cent judge rule edward patent protect sapien transcatheter aortic heart valve be invalid second patent be valid have be infringe patent deal outer seal valve boston scientific rival heart valve lotus be credit lower rate leak side heart valve evercore analyst ross muken write research report company used skirt minimize leak court edward patent sac outside anchor provide seal be rule valid second patent deal fabric seal be rule invalid ibd take boston scientific edward lifescience medtronic be pit heart valve market boston decision buy neovasc advanced tissue business december give leg see sector leader be battle edward be appeal decision keep guidance believe company ultimately prevail decision doesn affect commercial availability sapien valve court proceedings be ongoing germany france canada decision be expect german lawsuit first quarter court date march french case be still build muken write court decision come week boston scientific say delay lotus heart valve mechanical issue involve excess tension pin boston stock fall feb day announce issue topple much related boston topple heart valve bug wo boost edward medtronicedward restart cardiaq heart valve set europe launch rbcmedtronic downgrade increase boston st jude rivalry
157,EW,boston scientific bsx stock topple week low thursday medtech maker say delay lotus heart valve mechanical issue give rival medtronic mdt edward lifescience ew boost stock market today boston scientific stock fall plunge much edward lifescience stock jump medtronic climb needham analyst mike matson argue investor overreact accord file boston scientific early thursday removal be voluntary enable company deal premature release pin connect lotus delivery system company note excess tension pin mechanism introduce manufacturing process boston be expect relaunch lotus ibd take boston scientific be take edward lifescience medtronic key acquisition read sector leader detail recent buy new business help boston take rival matson estimate boston be take cent hit earning boston earlier guide structural heart sale matson see risk have modeled structural heart sale lotus watchman still expect lotus be differentiate share taker think today sell reduce boston market cap be overdo write be buyer weakness evercore analyst vijay kumar expect boston scientific wo be unexpected boon medtronic edward lifescience medtronic increase confidence organic top line growth see fiscal be sustainable say edward boost sale percentage point still kumar see boston third player transcatheter aortal valve replacement tavr market have buy rating price target boston stock matson keep buy rating price target share delay lotus be doubt disappointing continue believe lotus be meaningful opportunity boston scientific medium term kumar write report success europe adoption give confidence be room third player fast grow tavr market related edward restart cardiaq heart valve set europe launch rbcmedtronic post quickest comeback heart valve brain boost ep potential divestiture
158,EW,edward lifescience ew cardiaq heart valve resume clinical testing company say late friday putt track european launch launch rbc estimate stock market today edward stock jump earlier rise much nearly week high retake day line edward stock plunge feb valve related issue cause company halt enrollment feasibility study have receive requisite regulatory approval begin key trial europe edward opted delay enrollment work issue edward expect resume clinical activity transcatheter mitral valve ibd take boston scientific be make play beat edward medtronic heart valve market read sector leader restart be occur sooner expect rbc analyst glenn novarro write research report see valve launch next year europe novarro keep outperform rating price target edward stock concern tavr transcatheter aortic valve replacement linger acc american college cardiology annual meeting believe cardiaq overhand have now be remove write edward compete boston scientific bsx medtronic mdt heart valve market competitor be larger market cap novarro see edward best growth story large cap medtech related medtronic post quickest comeback heart valve brain therapiesedward heart valve guidance lag medtronic boston downgrade increase boston st jude rivalry
159,EW,president trump harp drug price tweet early tuesday prompt generic drugmaker teva pharmaceutical teva mylan myl dip even house proposal replace obamacare doesn touch drug price be work new system be competition drug industry trump write tweet open tuesday pricing american person come way drug biotech stock broadly dip response close stock market today ibd company generic drug industry group be fall much earlier touch week low share biotech specialty drug company fall nearly biggest stock loser be specialty drug firm supernus pharmaceutical supn be supernus however also settle patent dispute zydus pharmaceutical marketing generic version supernus seizure treatment trokendi zydus be only company allow market drug certain circumstance start also fall be share endo international endp valeant pharmaceutical vrx plunge trump specific method target drug price competition wasn immediately clear tuesday house release early version bill replace obama linchpin legislation affordable care act ibd take biotech leader celgene major breakthrough head ibd stock analysis deeper dive dub american healthcare act republican proposal end individual mandate bring penalty not have health insurance proposal also repeal medical device tax evercore analyst vijay kumar note latter point be positive general majority device company have be reinvest benefit current temporary repeal device tax be potential boon med tech maker medtronic mdt boston scientific bsx edward lifescience ew make heart valf bill still have long way go make way trump desk evercore analyst terry haine write research report need unanimous support house senate republican democrat likely be opposition be only begin legislative process part aca reform write continue think end june be realistic target document release late monday be merely tax revenue portion aca repeal congress use budget reconciliation process require only majority house portion haine write broader aca reform probably not be finalize year need bipartisanship succeed write today none be apparent be early day related quickly find top rate stock buy point
160,EW,medtronic mdt stock pop tuesday medical product maker top fiscal expectation board evercore analyst vijay kumar call quickest comeback large cap land fiscal end jan medtronic report earning share ex item sale respectively vs year earlier quarter consensus see kumar write research report beat help medtronic stock lift stock market today touch highest point disappointing sale guidance month send share fall ibd take boston scientific make key acquisition late last year help battle edward lifescience medtronic read sector leader boston chance overtake medtronic edward key market highlight include growth cardiac rhythm heart failure brain therapy unit medtronic diabetes group grow vs year earlier quarter lead growth patient monitoring recovery medtronic reaffirm guidance mid single digit sale growth constant currency basis fiscal company see sale grow lower half mid single digit range constant currency basis medtronic compete closely edward lifescience ew boston scientific bsx heart disease market medtronic lead term market cap nearly compare boston edward related medtronic boost ep potential downgrade increase boston st jude rivalriesedward heart valve guidance lag medtronic boston rivalry
161,EW,thursday see tooth session left stock lower second time week facebook fb reversed early gain investor look amazon com amzn quarterly report close january payroll report come friday morning preliminary datum show volume tracking well wednesday level stock market today early datum show jump january layoff lower expect weekly unemployment claim slowdown fourth quarter worker productivity contribute session wobbly start bond be steady ahead friday job report oil close west texas intermediate barrel facebook backed modest early gain end lower follow fiscal first quarter earning beat late wednesday stock close cup handle buy point amazon manage gain regular trade quickly drop close commerce giant result be mixed better forecast jump earning revenue gain miss analyst expectation hour decline put share back buy point cup handle base extend session gain loss often do not carry next session regular trade amgen amgn athenahealth athn decker outdoor deck visa be other name expect report close infant formula maker mead johnson mjn spiked confirm be discussion base reckitt benckiser acquire mead outstanding share value deal mead enfamil be second largest infant formula brand world reckitt benckiser share end higher london stock exchange merck mrk be dow big winner mixed fourth quarter result be affected launch resource plan system patent expiration several key drug merck close december low climb right side month base pattern ibd stock cadence system cdns scream higher design automation software developer report late wednesday fourth quarter result narrowly top analyst projection management first quarter earning guidance be line consensus view revenue come expectation gain left stock new high flat base buy point prestige brand holding pbh also ibd stock belt gain maker chloraseptic clear eye efferdent beano stomp analyst fourth quarter expectation tighten full year guidance low volume move clear buy point imperfect cup handle base edward lifescience ew drop heavy trade report better forecast fourth quarter result late wednesday full year guidance be line analyst view btig downgrade stock neutral buy edward have be uptrend early december work recover deep month sell related online broker fall schwab slash stock etf trading feesamazon mixed visa amgen beat chipotle profit miss late
162,EW,medtronic mdt prep dredge edward lifescience ew share heart valve replacement market johnson johnson jnj boston scientific bsx st jude medical stj be line gouge various piece medtronic business medtronic edward lifescience stock rift tuesday differ analyst view stock market today medtronic stock fall morgan stanley analyst downgrade stock edward stock rise month high david lewis morgan stanley downgrade medtronic stock equal weight overweight also cut price target share close vastly day move average likely be muted growth perspective year lewis say medtronic complete acquisition covidien irish medical product device maker january margin disappear aftermath acquisition expect organic growth serve nice bridge lewis write research report organic growth have decelerate last quarters write be not convince see path outperformance light topline headwind management demonstrate more durable cost opportunity fiscal ibd take late last year boston scientific acquire neovasc tissue business deal hurt rival medtronic edward lifescience check sector leader be battle medical product field medtronic growth hinge part traction minime hybrid close loop diabetes management system food drug administration approval large valve indication intermediate risk patient expect mid lewis project organic growth medtronic launch gain traction meanwhile medtronic see increase competition mri safe launch boston boston st jude be emerge rival deep brain stimulation parkinson patient spectranetic soon compete drug coat balloon dcb treatment be get minimally invasive procedure arena edward stock other hand pull upgrade tuesday guggenheim analyst chris pasquale upgrade edward stock buy neutral establish price target say transcatheter aortic valve replacement tavr expectation have come back earth lackluster still room growth tavr market pasquale write report estimate global tavr sale come edward bring consensus estimate be lower january note have be hard imagine be consider disappointing outcome year yet investor sentiment edward tavr opportunity have soured somewhat wake result fail show kind positive inflection many street model forecast write analyst be exceptionally bullish edward get intermediate risk indication tavr patient august pasquale note temporary capacity constraint center natural ebb flow market likely lead major disappointment pasquale estimate procedure still grow year year last quarter expect worldwide tavr sale double next year trend edward be primary beneficiary even competition increase say related edward heart valve guidance lag medtronic boston rivalryedward guidance likely hinge rivalry medtronic boston
163,EW,edward lifescience ew fiscal guidance lag wall street heart valve replacement tech fierce competition medtronic mdt boston scientific bsx sale view be line share near month high thursday stock market today edward lifescience stock lift share be year date remain sharply follow edward earning report oct then share topple sale fall short fiscal edward guide sale earning share ex item sale guidance meet consensus growth ep be line analyst expectation evercore analyst vijay kumar write research report transcatheter aortic valve replacement tavr guidance lag consensus kumar write firm guide sale midpoint edward guidance lag analyst view growth kumar note however edward typically guide conservatively end beating raise tavr guidance miss come mount pressure rival medtronic boston scientific food drug administration look likely approve medtronic large valve indication intermediate risk patient mid boston scientific potentially enter tavr market end kumar write report wednesday ibd take boston scientific acquire neovasc tissue business earlier year asset help take medtronic edward lifescience see sector leader be deal ongoing rivalry meanwhile edward peer be see surgical aortic valve replacement savr sale lag try get handle transcatheter mitral valve replacement repair market edward enter replacement side acquisition cardiac recently acquire valtech cardioband repair follow edward disappointing thursday analyst day be clear event kumar say couple factor investor need consider be assumption tavr growth eu likely impact competition be write be important give market growth be trend boston scientific be unchanged thursday medtronic stock fall related medtronic dife month low sluggish diabetes valve salesedward medtronic rebound negative report medtech spiraling
164,EW,relative strength rs rating globus medical gmed enter new percentile monday get lift ibd proprietary rs rating identify technical performance used worst best score indicate stock price action last week compare rest market year market history show market biggest winner often have rs rating begin biggest climb see globus medical continue show renew price strength clear threshold globus medical be work flat base entry see break volume least higher normal earning growth picked last quarter revenue gain fall company hold rank peer medical product industry group abiom abmd align technology algn edward lifescience ew be top highly rate stock group related ibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
165,EW,resm rmd see positive improvement relative strength rs rating monday rise proprietary rating measure market leadership used worst best score indicate stock price performance trail week match other stock year market history show market biggest winner tend have rs rating least launch biggest price move see resm continue rebound hit benchmark resm be not currently potential buy zone see stock go form promising consolidation ignite new run sale growth fall last quarter bottom line grow prior report resm hold rank peer medical product industry group abiom abmd align technology algn edward lifescience ew be top highly rate stock group related stock be show improve technical action use ibd relative strength rating relative strength line help judge stock
166,EW,welcome move edward lifescience ew see relative strength rating improve friday ibd unique rs rating track technical performance show stock price action last week measure other stock database decade market research show market biggest winner tend have rs rating north early stage move see edward lifescience continue show renew price strength clear threshold edward lifescience be not currently show potential buy point see stock go form sound pattern kick new climb earning growth increase last quarter top line fall company earn rank peer medical product industry group align technology algn cambrex cbm be also group highest rate stock related stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
167,EW,edward lifescience ew have relative strength rs rating upgrade friday welcome improvement still shy higher score look exclusive rating investor business daily measure market leadership worst best score rating show stock price performance last week hold other stock database year market history show best stock often have higher rs rating early stage move see edward lifescience continue rebound clear threshold not currently ideal time invest see stock be able form base break revenue growth fall last quarter bottom line grow prior report edward lifescience hold rank peer medical product industry group abiom abmd be rank stock group related ibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
168,EW,here investing action plan wednesday need know investor come day xa range industrial tech consumer medical company report wednesday lead boee ba facebook fb paypal pypl edward lifescience ew federal reserve also wrapped policy meeting market await more clue
169,EW,high profile earning report loom large horizon name position call option trade xibd option strategy earning help investor maximize gain minimize risk buy stock just ahead earning re not protected stock gap price call put option downside risk be
170,EW,thursday be shape be solid show technology stock share facebook fb jump early strong earning wave selling hit nasdaq composite early afternoon trading growth stock take chin more half name ibd more nasdaq be reverse intraday gain ease dow jone industrial rise slightly thank bullish gain boee ba walt disney merck mrk verizon vz stall session nasdaq wednesday basically be heavy volume price progress tech index be poise distribution day thursday volume nyse nasdaq be tracking higher wednesday level selling pressure be intense nasdaq leader nvidia nvda netflix nflx show loss stock market today big seller be amazon com amzn earning report close intraday gain turn loss afternoon trading be surprised see strong quarter amazon stock have make big run already recently clear later stage base earning news edward lifescience ew gap try clear cup handle buy point gain fade share be recently trading enterprise software name servicenow now meet similar fate solid quarter poke entry couldn hold ibd evercore partner evr be bright spot work right side cup shape base close watch report proofpoint pfpt logmein logm benchmark crude oil rise year treasury yield add basis point related facebook surge blowout earning get price target hike best stock buy reason southwest spirit air be plunge
171,EW,stock rattle solid gain wednesday open market haul large dose positive early earning news oil price continue recent rebound dow jone industrial average jump future climb nasdaq composite scale enough knock new high investor attention be spread thin wednesday powerhouse session big name earning report ahead federal reserve policy announcement hour session quarterly result be due facebook fb paypal pypl edward lifescience ew other federal open market committee wrapped day meeting today washington policy announcement afternoon et expectation be low sort material change policy follow last month rate hike release be closely scan hint future hike particularly clue fed action begin reduce bond debt amassed quantitative ease period other economic news day be light release june new home sale figure set et commerce department et energy information administration deliver weekly oil inventory report oil price climb look add third day recent bounce lift west texas intermediate back barrel premarket session be buzz earning news open higher steel vault akamai technology akam drop ford fall follow quarterly report advanced micro device amd gap gain earning accelerate triple digit growth jump revenue top expectation strong volume move left share extend buy point cup handle base wynn resort wynn take stumble start bell report second quarter result late tuesday earning gain surge revenue top analyst estimate loss send share week move average heavy trade sell signal boee ba haul dow higher surge report earning share cent share loss year stock be extend clear flat base early june dow peer verizon vz swung more ahead second quarter report schedule early thursday apple aapl fang stock trade higher early action amazon com amzn netflix nflx rise more facebook open gain head second quarter report close electronic component manufacturer amphenol aph pop powerful trade mark past buy point week flat base wallingford conn base operation turn strong second quarter earning revenue also top expectation management ratchete third quarter revenue earning guidance consensus view share remain buy range triumph group tgi dive open second quarter revenue earning miss forecast stock have be advance attempt climb month correction related future ibd stock report earning apple near big picture new breakout emergemcdonald ti amd get price target hike electronic art be buy
172,EW,medical device maker edward lifescience ew be more wednesday morning analyst raise estimate wake strong earning report late tuesday edward profit rise year earlier quarter share beating analyst consensus cent accord thomson reuter sale increase more
173,EW,big cap stock step new high wednesday late sell major index dow component walt disney surge huge volume share gap higher open response fiscal earning revenue easily top consensus view stock be now past buy point clear late october
174,EW,stock remain mixed mostly little change late thursday surge prior session nasdaq rise putt back level dow jone industrial average be respectively volume be tracking lower major exchange stock market today microsemi mscc rally new high now past buy point flat base putt profit take territory most case investor book gain once amount wednesday microsemi agree buy vitesse semiconductor vtss cash deal be expect add cent share earning first full fiscal year close cerner cern stretched gain nearly putt further record high territory earlier robert baird upgrade stock outperform neutral raise price target stock be extend rebound week line nike nke seesaw fractional gain ahead fiscal report set be release close analyst poll thomson reuter see athletic apparel footwear giant earn cent share year sale be expect nike be trading long flat base buy point ctrip com international ctrp fall nearly ahead fourth quarter result company report close chinese provider online travel service be expect post loss cent share sale be expect year
175,EW,stock reversed higher close bell monday end session skid rout china stock market further drop oil price
176,EW,dow jone industrial average rise edge nasdaq dip volume stock market today rise nasdaq nyse compare friday accord preliminary datum
177,EW,energy mining biotech stock lag department store hospital tobacco stock lead upside
178,EW,aluminum producer alcoa aa rise hour follow earning report stock end regular session nearly decline eighth straight session
179,EW,macy lead rise strong volume investment advisory firm starboard value reportedly say monday support department store recent joint venture mall base real estate property other department store stock also rally kohl kss rise dd
180,EW,sour note ibd stock celgene celg drop nearly lowest level month biotech offer guidance name coo mark alle new ceo start march current chief bob hugin become executive chairman
181,EW,company due report quarterly result tuesday include csx csx ihs ihs
182,EW,labor department be due release closely watch job opening labor turnover survey jolt tuesday stock reversed higher close bell monday end session skid rout china stock market further drop oil price dow jone industrial average rise edge nasdaq dip volume stock market today rise nasdaq nyse compare friday accord preliminary datum energy mining biotech stock lag department store hospital tobacco stock lead upside aluminum producer alcoa aa rise hour follow earning report stock end regular session nearly decline eighth straight session macy lead rise strong volume investment advisory firm starboard value reportedly say monday support department store recent joint venture mall base real estate property other department store stock also rally kohl kss rise dd sour note ibd stock celgene celg drop nearly lowest level month biotech offer guidance name coo mark alle new ceo start march current chief bob hugin become executive chairman company due report quarterly result tuesday include csx csx ihs ihs labor department be due release closely watch job opening labor turnover survey jolt tuesday
183,EW,stock finished flourish tuesday cap afternoon rally close day high
184,EW,nasdaq rise gain dow jone industrial average be volume be higher monday board accord preliminary datum
185,EW,dow stock be higher caterpillar cat chevron cvx exxon mobil xom lead way higher caterpillar rise oil giant gain
186,EW,energy stock be best performer oil rise more barrel close just
187,EW,chipotle grill cmg fall sharply hour report earning beat estimate earning meet revenue same store sale guidance be light
188,EW,edward lifescience ew rise hour report earning share vs estimate cent revenue come compare estimate
189,EW,gilead science gild also rise hour report earning share vs estimate revenue be vs estimate
190,EW,disney be close report ep compare consensus estimate
191,EW,ism service index be report eastern time wednesday economist forecast january vs december
192,EW,later day crude oil inventory be report stock finished flourish tuesday cap afternoon rally close day high nasdaq rise gain dow jone industrial average be volume be higher monday board accord preliminary datum dow stock be higher caterpillar cat chevron cvx exxon mobil xom lead way higher caterpillar rise oil giant gain energy stock be best performer oil rise more barrel close just chipotle grill cmg fall sharply hour report earning beat estimate earning meet revenue same store sale guidance be light edward lifescience ew rise hour report earning share vs estimate cent revenue come compare estimate gilead science gild also rise hour report earning share vs estimate revenue be vs estimate disney be close report ep compare consensus estimate ism service index be report eastern time wednesday economist forecast january vs december later day crude oil inventory be report
193,EW,ibd company kind be expect report solid quarterly result come week potentially indication gear drive tech retail auto medical defense sector be move more freely here look analyst expect nxp semiconductor nxpi security chipmaker help keep apple pay transaction safe report fourth quarter result close wednesday netherlands base company recently introduce technology allow driver lock unlock car phone owe much success immense popularity apple aapl iphone nxp be supplier analyst expect nxp ep springboard strongest gain ibd stock review here revenue be see increase nxp share emerge first stage flat base month have rattle day line investor often buy share have faith company stock have ascend share slip stock market friday be still hold buy point be buy range medical device maker edward lifescience ew report tuesday company artificial heart valve sapien have help keep gain aloft recent quarters analyst expect earning share rise year earlier cent revenue be expect rise edward result october indicated analyst growth global transcatheter aortic valve replacement market continue exceed expectation stock be last year recent week have converge day line share fall friday key level support more business adapt so call omnichannel retail customer use combination online store outlet buy product manhattan associate manh supply chain management software help keep track order company report result tuesday analyst expect see ep rise cent revenue elevate july last time stock spend extend time day line manhattan share have rise more share trip last november try clear cup handle base begin march ricochete day line early january have remain car dealer operator asbury auto abg have thrive recent year auto industry rebound analyst expect company report result wednesday grow ep mark slowest growth sale be see increase share enter sixth stage consolidation july november have be seek support day line most january later stage greater stock chance top ibd research find still share be reilly auto part orly also report result wednesday more car last longer company have benefit part replacement month get colder reilly also see sale pick repair winter ravage car spirit aerosystem spr company propulsion fuselage wing system go military aircraft passenger jet report result tuesday analyst see ep increase cent revenue be expect rise spirit serve such company defense contractor general dynamic gd aerospace giant boee ba week report estimate top result spirit share clear flat base have find support day line apparel retailer armour ua athleisure wear continue attract athletic leisure alike report result wednesday close analyst see ep escalate cent revenue rise continue slight deceleration sale gain past quarters citigroup month upgrade armour buy cite company domestic international prospect upgrade come day jeffery downgrade stock cite few term catalyst valuation accurately reflect company long term growth prospect armour stock clear fourth stage cup handle base thursday struggle momentum friday slip
194,EW,share cyberonic cybx gap record high thursday company report better expect earning growth say be merge italy sorin move headquarters europe new treasury rule intend curb tax inversion deal stock transaction create global contender start annual revenue
195,EW,stock remain higher late trade fed stand pat interest rate do not give many hint ll start rise central bank give more positive view labor market
196,EW,dow jone industrial average rise climb due weakness biotechs software internet issue nasdaq lag gain volume be again run lower major exchange stock market today
197,EW,buffalo wild wing bwld gap bolt post disappointing result late tuesday stock be near buy point long consolidation
198,EW,fellow restaurant issue panera bread pnra be session high still nearly stock gap surge much news strong sale current quarter offset weaker expect earning sale panera stage breakaway gap past flat base buy point
199,EW,downside vasco datum security international gap day line plunge weak outlook trump better expect quarterly result stock fall lowest level more month
200,EW,other security software stock be also have tough day cheetah mobile cmcm fall more cyberark software cybr palo alto network panw lose more apiece
201,EW,facebook fb mckesson mck nxp semiconductor nxpi skecher skx whole food market wfm be few notable company report earning close stock remain higher late trade fed stand pat interest rate do not give many hint ll start rise central bank give more positive view labor market dow jone industrial average rise climb due weakness biotechs software internet issue nasdaq lag gain volume be again run lower major exchange stock market today buffalo wild wing bwld gap bolt post disappointing result late tuesday stock be near buy point long consolidation fellow restaurant issue panera bread pnra be session high still nearly stock gap surge much news strong sale current quarter offset weaker expect earning sale panera stage breakaway gap past flat base buy point downside vasco datum security international gap day line plunge weak outlook trump better expect quarterly result stock fall lowest level more month other security software stock be also have tough day cheetah mobile cmcm fall more cyberark software cybr palo alto network panw lose more apiece facebook fb mckesson mck nxp semiconductor nxpi skecher skx whole food market wfm be few notable company report earning close
202,EW,stock slump second straight session monday putt blemish new market uptrend nasdaq shed close back day move average chip solar stock be area weakness tech heavy index biotechs buck weakness also end selling energy stock day
203,EW,share nuvasive nuva moved higher early trading stock market today maker spinal product receive analyst upgrade cite potential grab more market share particularly internationally
204,EW,morning research note rbc capital market analyst glenn novarro upgrade nuvasive outperform sector perform also raise price target stock cite san diego base company superior sale outlook improve profitability attractive valuation
205,EW,nuvasive share rise more year high early thursday
206,EW,be confident nuva management continue take share worldwide spine market novarro note
207,EW,not only be nuvasive well position roughly mis minimally invasive spine market say also have plenty runway left expand internationally
208,EW,particularly true china novarro say nuvasive do not have much infrastructure country currently believe potential chinese announcement occur
209,EW,meanwhile expect nuvasive continue improve margin so move closer margin rival such globus medical gmed ldr hold ldrh
210,EW,nuvasive have ibd composite rating belong ibd medical product group rank industry track
211,EW,top rate stock group be edward lifescience ew composite rating biggest stock market cap be medtronic mdt covidien cov baxter international bax share nuvasive nuva moved higher early trading stock market today maker spinal product receive analyst upgrade cite potential grab more market share particularly internationally morning research note rbc capital market analyst glenn novarro upgrade nuvasive outperform sector perform also raise price target stock cite san diego base company superior sale outlook improve profitability attractive valuation nuvasive share rise more year high early thursday be confident nuva management continue take share worldwide spine market novarro note not only be nuvasive well position roughly mis minimally invasive spine market say also have plenty runway left expand internationally particularly true china novarro say nuvasive do not have much infrastructure country currently believe potential chinese announcement occur meanwhile expect nuvasive continue improve margin so move closer margin rival such globus medical gmed ldr hold ldrh nuvasive have ibd composite rating belong ibd medical product group rank industry track top rate stock group be edward lifescience ew composite rating biggest stock market cap be medtronic mdt covidien cov baxter international bax
212,EW,stock market make bullish reversal monday again find support recent lows
213,EW,climb lead market thank part rebound energy stock strength financial index find support level have do so several week
214,EW,nasdaq close higher composite defend floor dow jone industrial average rise
215,EW,volume fall sharply board accord unconfirmed figure increase trading have make monday gain look better market breadth be decidedly bullish stock market today winner top loser nearly nyse nasdaq
216,EW,tuesday automaker report january sale earning report announcement be expect chipotle grill cmg gilead science gild edward lifescience ew unite parcel service up stock market make bullish reversal monday again find support recent lows climb lead market thank part rebound energy stock strength financial index find support level have do so several week nasdaq close higher composite defend floor dow jone industrial average rise volume fall sharply board accord unconfirmed figure increase trading have make monday gain look better market breadth be decidedly bullish stock market today winner top loser nearly nyse nasdaq tuesday automaker report january sale earning report announcement be expect chipotle grill cmg gilead science gild edward lifescience ew unite parcel service up
217,EW,medical stock have be mainstay new high screen recent session more score fresh milestone tuesday alexion pharmaceutical alxn bolt time high heavy trading share close best gain more month still buy range week tight buy point alexion be
218,EW,december be usually quiet month medical tech news year bring few potentially stock move event worth keep eye digest thanksgiving turkey here be top chronological order dec biotech incyte incy be look get important expansion label sole market drug jakafi explain recent incyte profile new america incyte partner novartis nvs have be pull respectable income jakafi treatment rare bone marrow cancer call myelofibrosis fda be ponder add indication polycythemia vera milder more common condition uptake condition be expect be fairly slow expect help push incyte more consistently profitable territory next year day later hot medical device company edward lifescience ew hold annual investor day be expect give guidance first time company impressed street last month strong report guidance strong launch latest sapien artificial heart valve currently analyst be forecasting sale year estimate earning share be expect rise then sometime dec likely mean dec fda be due issue verdict abbvie abbv hepatitis combo viekirax exviera clinical trial datum be so good street probably be less surprised meteor hit manhattan fda reject drug have analyst pin needle be price be price significantly lower gilead science gild recently launch harvoni cost week treatment help abbvie gain market share certainly please pharmacy benefit manager express script esrx have be hope start price war drive suddenly high cost hepatitis treatment however most analyst be expect abbvie price only little bit lower also affected be enanta pharmaceutical enta license component viekirax abbvie speaking hepatitis sometime end year street be expect hear phase clinical trial datum achillion pharmaceutical achn drug belong coveted nucleoside inhibitor class gilead mega blockbuster sovaldi also component harvoni belong have otherwise show enough safety issue be few left development especially merck mrk acquire idenix pharmaceutical nuc speculation achillion be next target have drive stock price street have see little real datum safety effectiveness datum help analyst determine just much company be worth speculation exist abort takeover attempt earlier year be re up street seem have mostly give possibility pfizer pfe make bid astrazeneca azn month cool period mandate takeover rule expire wednesday astra ceo pascal soriot throw more cold water appear cnbc thursday say deal have fall apart even have be make propose restriction tax inversion deal however rbc capital market analyst glenn novarro be still hold hope union orthopedic firm stryker syk nephew snn stryker didn bid company news report leak be work get slap month cool period anyway expire nov believe syk snn deal provide more recon reconstructive surgery scale particularly international market expand syk presence trauma sport medicine bring cost synergy novarro write note friday
219,EW,medical device maker edward lifescience ew jump time high stock market today beat earning estimate late thursday get barrage price target increase analyst
220,EW,edward earning rise year earlier quarter cent share beating analyst consensus cent sale increase more street average estimate
221,EW,fourth quarter firm expect sale year set ep range cent be level figure be line consensus
222,EW,rbc capital market analyst glenn novarro raise price target stock note sale artificial heart valve sapien rise year earlier quarter top estimate even have be face new competition year medtronic mdt corevalve keep sector perform rating edward stock friday trading be already target
223,EW,leerink analyst danielle antalffy affirm outperform rating price target
224,EW,quarterly sale beat be affirmation global tavr transcatheter aortic valve replacement market growth continue dramatically exceed expectation write research note friday tavr just cusp penetrating much larger intermediate risk patient population europe still probably month away see sustainably strong double digit market growth ahead
225,EW,security raise price target maintain outperform rating stifel nicolaus raise maintain buy rating piper jaffray lift target
226,EW,edward sale profit growth drop single digit last year have be accelerate then stock hold stellar ibd composite rating
227,EW,follow amy reeve twitter ibd_areeve medical device maker edward lifescience ew jump time high stock market today beat earning estimate late thursday get barrage price target increase analyst edward earning rise year earlier quarter cent share beating analyst consensus cent sale increase more street average estimate fourth quarter firm expect sale year set ep range cent be level figure be line consensus rbc capital market analyst glenn novarro raise price target stock note sale artificial heart valve sapien rise year earlier quarter top estimate even have be face new competition year medtronic mdt corevalve keep sector perform rating edward stock friday trading be already target leerink analyst danielle antalffy affirm outperform rating price target quarterly sale beat be affirmation global tavr transcatheter aortic valve replacement market growth continue dramatically exceed expectation write research note friday tavr just cusp penetrating much larger intermediate risk patient population europe still probably month away see sustainably strong double digit market growth ahead security raise price target maintain outperform rating stifel nicolaus raise maintain buy rating piper jaffray lift target edward sale profit growth drop single digit last year have be accelerate then stock hold stellar ibd composite rating follow amy reeve twitter ibd_areeve
228,EW,major average end week solid foot friday extend gain nasdaq confirm new uptrend oct health care name dominate new high list again common theme recent day edward lifescience ew gap time high rise strong earning late thursday be catalyst third quarter profit
229,EW,stock look poise end week positive note friday
230,EW,dow jone industrial average add rise nasdaq picked nyse be tracking lower thursday level nasdaq volume be tracking close thursday gauge
231,EW,nasdaq still have day move average conquer nasdaq be point line same
232,EW,stock market today procter gamble pg be standout performer dow rise earning share meet expectation sale slightly miss company also say prefer split duracell battery business separate company hasn reach decision yet
233,EW,constant contact ctct gap rise online marketing company report earning late thursday be consolidate gain week be now week high growth prospect be solid profit see rise earning be expect rise
234,EW,edward lifescience ew gap time high rise strong earning late thursday be catalyst third quarter profit rise cent share nicely consensus estimate sale rise year nice acceleration growth second quarter strong sale heart valf fuel result also prompt company raise prior full year earning sale guidance
235,EW,drugmaker ibd outperformed friday gilead science gild salix slxp jazz jazz alexion alxn celgene celg score gain
236,EW,thinly trade mineral technology mtx jump nearly break week consolidation report bullish third quarter result maker synthetic mineral product earn share year earlier sale soar
237,EW,downside peripheral maker synaptic syna plummet amazon com amzn slump disappointing earning
238,EW,economic news september new home sale come unit little better expect expect august datum be revise lower initially report homebuilder shrug news ibd build residential commercial group be stock look poise end week positive note friday dow jone industrial average add rise nasdaq picked nyse be tracking lower thursday level nasdaq volume be tracking close thursday gauge nasdaq still have day move average conquer nasdaq be point line same stock market today procter gamble pg be standout performer dow rise earning share meet expectation sale slightly miss company also say prefer split duracell battery business separate company hasn reach decision yet constant contact ctct gap rise online marketing company report earning late thursday be consolidate gain week be now week high growth prospect be solid profit see rise earning be expect rise edward lifescience ew gap time high rise strong earning late thursday be catalyst third quarter profit rise cent share nicely consensus estimate sale rise year nice acceleration growth second quarter strong sale heart valf fuel result also prompt company raise prior full year earning sale guidance drugmaker ibd outperformed friday gilead science gild salix slxp jazz jazz alexion alxn celgene celg score gain thinly trade mineral technology mtx jump nearly break week consolidation report bullish third quarter result maker synthetic mineral product earn share year earlier sale soar downside peripheral maker synaptic syna plummet amazon com amzn slump disappointing earning economic news september new home sale come unit little better expect expect august datum be revise lower initially report homebuilder shrug news ibd build residential commercial group be
239,EW,broad market advance outperformance leader instill confidence rally ibd name do not disappoint tuesday broadsoft bsft lead way buy point volume average stock surge nearly close remain buy range
240,EW,stock index post only modest gain friday afternoon strong pop volume nasdaq ride higher dow jone industrial average trot ahead respectively small cap trail russell retreat volume stock market today be run sharply higher vs previous session blue chip be mostly visa lead dow gain average volume dow rival mastercard add average turnover financial service dfs higher visa mastercard be high respectively be high visa have best ibd composite rating composite rating combine ibd rating single number rating mean stock be top percentile top rate stock head completion bullish pattern friday close domino pizza dpz edward lifescience ew have meet minimum length flat base base pattern ibd industry group biomed lead upside oil driller lead downside neither biom group oil driller represent market lead performer crude oil decline saudi official say freeze oil production only other nation include iran participate west texas intermediate crude oil fall more barrel image provide shutterstock
241,EW,stock market show tiny loss early afternoon trading monday major index trade tight range nasdaq dow jone industrial average fall volume nyse nasdaq be tracking slightly lower friday level stock market today generic drugmaker biotechs outperformed gold miner homebuilder lag new york mercantile exchange wte crude oil delivery fall nearly barrel apple aapl merck mrk pfizer pfe outperformed dow gain trio ibd name make nice move edward lifescience ew soar company announce positive trial sapien sapien xrt aortic valve replacement share be now extend cup base buy point mortgage lend service provider lendingtree tree climb nearly rise bring stock back buy point first stage cup handle base michael kor kor give back early gain still rise close recent high share be recently trading hit intraday high elsewhere tesla motor tsla jump ceo elon musk say pre order model electric car reach saturday night virgin america va meanwhile surge alaska air alk agree buy deal value image provide shutterstock
242,EW,stock open sharply lower tuesday follow lead overseas market slip nasdaq lose dow jone industrial average give stock market today appear pull premarket cue europe stock be pressure raft unexpectedly soft economic datum cac paris frankfurt dax trade more ftse london show loss afternoon trading market receive dose service sector datum later morning london base researcher markit release march service purchasing manager index et institute supply management deliver march index labor department report job opening labor turnover survey february early report show trade gap widen slightly february upwardly revise january commerce department report economist consensus have forecast milder uptick oil price dip slightly left west texas intermediate bob barrel natural gas jump more gain last week monday gold future climb more ounce dollar be mixed bond blipped higher send year yield basis point dow stock slide almost unanimously lower cisco system csco lead downside fall early outperformer include pfizer pfe procter gamble pg johnson johnson jnj pfizer report positive result psoriatic arthritis treatment phase clinical trial federal regulator announce pending rule change affect potential inversion merger rule directly affect pfizer allergan deal set close later year share ireland base allergan agn crumble tesla motor tsla lag nasdaq fall late monday company give delivery count mentioned model part shortage nearly ibd stock be flat start regular trade edward lifescience ew backed suggest well earn pause monday price spike wesson swhc show sign life sell monday japan tokyo nikkei dive week low yen continue gain strength disappointing industry forecast send iron steel issue tumble china market end mixed shanghai composite hong kong hang seng index stock india skid lower reserve bank india cut interest rate basis point line consensus expectation market have already price react cue global market bloomberg report send mumbai benchmark sensex index image provide shutterstock
243,EW,early gain reversed late morning loss monday several key market name take heavy hit nasdaq drop slip dow maintain decline volume be soft stock market today nyse just lower nasdaq compare relatively heavy trade friday natural gas producer muscle many best gain stock southwest energy swn spiked range resource rrc jump consol energy cnx miner coal rally automotive drivetrain component maker borgwarner bwa drop citi downgrade stock neutral buy national homebuilder pulte group phm swoon powerful trade chairman chief executive richard dugas announce retire reportedly pressure company founder board member accord bloomberg zelman assoc downgrade stock hold buy facebook fb sag heavy trade social networking leader climb straight week friday be buy point cup base be build handle edward lifescience ew build early gain now more cardiovascular technology firm issue positive result trial compare sapien sapien xrt aortic replacement valf outcome open heart surgical replacement leerink swann maintain outperform rating boost price target stock bmo capital also keep outperform rating lift price target edward be trading cup base buy point also ibd list stamp com stmp lendingtree tree rise more wesson holding swhc drop more bottom list possibly hurt weak firearm background check datum march analyst downgrade cowen co loss send share well day move average heavy trade
244,EW,even market have score solid gain major index stage follow feb most lead stock haven follow suit nasdaq composite have advanced more plenty ibd stock have break yet only handful have rise buy zone other have turn south
245,EW,re dominant player rapidly grow market wall street tend take shine stock case edward lifescience ew maker product treat cardiovascular disorder much company growth come market transcatheter aortic valve replacement product edward chief rival medtronic mdt be
246,EW,load player stock make sustain climb need large infusion capital mutual fund other institutional investor have be sign recently fund manager continue pump more money edward lifescience ew lead maker heart valf other product treat cardiovascular disorder make ibd most recent list
247,EW,stock market didn do much anything monday end mixed mostly unchanged ahead start day fed meeting lose nasdaq rise less dow jone industrial average logged highest close year rise volume nyse nasdaq fall friday level decline stock
248,EW,most actively trade etfs have something common certain presidential candidate not donald trump ve recently rally lows be various stage trend higher spdr spy be week high powershare qqq qqq be next gap small cap ishare russell iwm be shy mark spy have be make lower high lower lows past year investor exchange trade fund have time run patience wait spy return winning way yanked just first month however asset etf have grow march investor seem feel more optimistic job growth manufacturing home less bother picture disarray abroad spy set high friday nice turnaround largest exchange trade fund last month be week high now trading level here look top ibd stock have contribute comeback paypal pypl stock seem ready bolt new high positive sign company be lead player electronic payment industry have grow earning annually past year sale company official be doubt look rearview mirror wall street bank be get more aggressive make inroad mobile payment field ross store rost biggest discount apparel retailer have be describe retail pick hold even recession stock be trading highest level december ross have straight quarters earning sale growth belt company latest full year guidance lag expectation plan hike wage retail uncertainty edward lifescience ew make treatment cardiovascular disease include heart valve disorder global sale aortic valve product exceed accord company medical company have quarters double digit earning growth stock be trading multiyear high well touch week high friday telecom stock defensive play have hold young market uptrend yield make coveted stock income investor growth have be accelerate recent quarters thank part takeover directv reynold american rai be also trading new week high cigarette maker brandish consecutive quarters accelerate sale growth earning grow average past year stock yield make nice dividend play acquisition lorillard maker newport cigarette be consider key strategic move spy have portfolio stake less other top hold be apple aapl weighting etf be year date gain stock market friday
249,EW,wednesday follow day launch new stock market uptrend gain traction launch new run lead stock stock be set used apple aapl amazon amzn alphabet googl facebook fb example see spot chart signal show former big winner be get ready launch new run also available itune video audiowatch individual show segmentsrelated resource event be wealth summit amy larry elder pasadena feb
250,EW,join amy investing workshop houston txrelated link hot stock consider market firm
251,EW,ibd stock analysis paypal find mobile mojo millennial venmo app
252,EW,ibd stock analysis mutual fund keep pump money edward lifescience
253,EW,stock spotlight top stock ellie mae blast higher near buy point
254,EW,energy just ugly shale producer earning guidance be week line cross back week line show renew strength be stock find support hit resistance
255,EW,read stock chartstake free trial leaderboard
256,EW,ibd print eibd digital editionattend ibd investing workshop find level topic right send feedback questionsemail email protected
257,EW,nasdaq take step bottom tuesday robust gain mixed volume heel friday gain lower volume nasdaq add higher volume rise dow industrial picked volume nyse fall friday average volume level higher volume wasn
258,EW,few lead stock have show stellar action give market be correction ibd stock be look better most take hold recent buy point ross store rost rise much intraday settle gain average volume stock be back buy
259,EW,new high list expand nicely stock market wednesday help follow big percentage gain higher volume index confirm new stock market uptrend edward lifescience ew rise still buy range buy point reclaim entry tuesday average trade edward compete medtronic mdt
260,EW,stock shot higher wednesday major index post hefty gain third straight session deliver follow process stock market paled area outstanding breakout number highly rate stock run new high reason appear caution patience be still very good card
261,EW,nasdaq stay strong go noon hour wednesday rest market be surrender early gain boost fed chief janet yellen dovish comment nasdaq be gain dow jone industrial average be slightly small cap russell be volume be tracking lower
262,EW,medical sector be area have have many stock hit new high recent session wednesday continue trend amgen amgn gap rally more triple average trade stock score record high close nearly past buy point first stage cup handle base
263,EW,many recent breakout lead stock have faltered market action remain choppy facebook fb instance clear buy point jan heavy trade advanced much turn south market now entry hold better other stock be find support
264,EW,stock settle small gain thursday wobble back forth much conviction nasdaq draft gain take almost trip direction dow jone industrial average rise respectively ibd slide volume fall nasdaq rise nyse so far best
265,EW,most stock continue struggle few big name be continue make new high mattel mat make strong move new high territory thursday follow gain company earning beat estimate late monday toy maker announce turnaround earning growth increase quarters decline profit strong growth
266,EW,stock slice lower market approach midday point nasdaq lose respectively dow jone industrial average keep gain volume be run higher board technical action be bad nasdaq undercut intraday low jan blue chip exxon mobil xom chevron ticker
267,EW,market volatility rev high gear january make investor queasy up down stock end bust first month year back oil slump weak corporate earning nasdaq plunge january sank manager nation best perform fund past month have step brake slow stock buy just select few top rate stock have defy gravity household tech name such facebook fb alphabet googl verizon communication vz equinix eqix have see buy action lead fund latest report period click here see list new buy top mutual fundsa handful property reit such stor capital stor mid america apartment community maa sovran self storage sss be solid performer recent month also favore top perform fund finance property reit group be rank industry wednesday top fund also add defensive utility stock atmos energy ato pnm resource pnm itc hold itc american water work awk black hill bkh ibd spot lead fund buy edward lifescience ew investing estimate latest report period fidelity contrafund fcntx add share portfolio irvine calif base firm make market medical device treat heart disease edward report fourth quarter earning result cent share year earlier beating analyst estimate cent revenue rise fourth quarter earning growth be drive high demand sapien sapien xt heart valf be deliver procedure call transcatheter aortic valve replacement therapy tavr critical care product group include hemodynamic monitoring device also perform well globally fourth quarter edward stock hold steady most stock market sell january stock clear flat month base wednesday upbeat fourth quarter earning nation lead fund have be unload lilly eli co lly latest report period be net selling fund position other drugmaker zoetis zts baxalta bxlt be also slash click here top fund latest sell
268,EW,stock advanced wednesday open then drop back moderate loss weak reading service sector nasdaq tumble drop dow clock drop volume slip stock market today nyse nasdaq relative trade
269,EW,stock future tick minor gain ahead wednesday open dow future blipped fair market value nasdaq future be also russell future inched stock market today jump hump day nasdaq lower friday blue chip loss be line general mood dow small cap be little weaker send russell tuesday employment picture weaken january adp national employment report show employer hire worker month be upwardly revise hiring december comfortably consensus estimate addition once again service sector hire run far ahead good producer institute supply management serve january service sector index et oil price bob back barrel west texas intermediate brent american petroleum institute datum release late tuesday show barrel build inventory week end jan energy information administration report weekly inventory datum dow stock be generally positive mmm have gain miner be also active vale vale pop rio rio climb ferrari race surge weaker forecast earning report late tuesday illumina ilmn dump india infosys infy drop deliver quarterly result big drugmaker be motion glaxosmithkline gsk jump merck mrk pull back report large insurer prudential puk spiked metlife meet be flat ahead earning report today close herbicide pesticide seed strain developer syngenta syt spark confirm agree be acquire state own china national chemical corp deal value more switzerland base syngenta share gap tuesday news report detailed possible tie company chipotle grill cmg fall report mixed result firm also announce center disease control prevention conclude investigation coli outbreak link chain receive subpoena attorney office central district california broaden scope previously announce criminal investigation chain ibd list edward lifescience ew skip trouncing analyst earning revenue estimate raise ep guidance well consensus view edward have be loll week move average week shallow base buy point
270,EW,here quick rundown tuesday hour action yahoo yhoo report fourth quarter earning drop be line estimate revenue edge beat view company say explore strategic option include reverse spin alibaba stake sale core asset yahoo plan cut workforce share fall late edward lifescience ew say fourth quarter revenue increase earning jump surpass estimate medical device maker also raise guidance forecast share jump nearly extend trade gilead science gild handily top fourth quarter earning revenue estimate ep pop revenue rise product sale forecast be roughly line analyst estimate hepatitis hiv drugmaker also announce share buyback program share rise fractionally late illumina ilmn fourth quarter earning fall revenue rise bottom line miss penny top line beat view maker gene sequence system issue full year revenue guidance be line view earning guidance be light share fall late close chipotle grill cmg issue first quarterly report be hit coli outbreak chipotle earning plunge be not bad wall street fear revenue decline miss expectation cdc declare monday outbreak be criminal investigation be ongoing chipotle warn be very difficult year predict first quarter ep be breakeven wall street have expect share chipotle tumble late trading
271,EW,medical device maker edward lifescience ew be rise heavy trading thursday receive upgrade base bullish outlook sapien transcatheter aortic valve replacement tavr suntrust robinson humphrey analyst bruce nudell upgrade edward stock buy neutral raise price target base last friday announcement fda have approve new study sapien elderly patient have severe aortic stenosis have low risk death traditional surgical valve replacement edward launch sapien last year high risk patient study potentially expand market base somewhat more lenient standard expect nudell write follow fda approval initiate sapien low risk ide investigational device exemption study year primary endpoint vs anticipate year follow ve update tavr market model reflect expedite timeline label expansion substantial patient pool nudell write research note estimate tavr market increase line company projection currently tavr market be split edward sapien medtronic mdt corevalve leerink analyst danielle antalffy also raise estimate same reason maintain outperform rating edward stock update model assume conservatively so believe just modest uptake low risk patient reach penetration europe year approval antalffy write research note thursday low risk approval believe global tavr market growth be sustainable foreseeable future ramp volume help offset model be mid single digit annual price decline new competitor enter market predominantly edward be lead stock medical product group strong ibd composite rating early afternoon stock market today edward stock be medtronic stock be nearly follow amy reeve twitter ibd_areeve facebook
272,EW,edward lifescience ew guidance slate release analyst day event thursday be somewhat strangle likelihood rival medtronic mdt boston scientific bsx pressure heart valve replacement market evercore analyst vijay kumar say tuesday kumar expect edward issue conservative transcatheter aortic valve replacement tavr view tough comp continue competitive pressure fda be expect grant medtronic large valve indication intermediate risk patient mid boston compete year end follow international pressure begin edward tavr sale begin decelerate follow entry medtronic boston kumar write wall street model growth factset polling growth internationally ibd take boston scientific acquisition neovasc rattle medtronic edward lifescience hit sector leader deep dive edward likely issue tavr guidance growth midpoint just miss broader analyst view kumar write edward have historically issue conservative outlook then raise course year say give move part wouldn be surprised see range widen write research report investor be likely key thursday edward plan deal competitive pressure kumar say still edward have strong track record outlasting rival sale grow half thus far additional pressure meanwhile tavr sale be cannibalize savr surgical aortic valve replacement sale kumar say also identify tmvr transcatheter mitral valve replacement repair single largest pipeline opportunity edward lifescience other cardio player next year tmvr be especially important be method treatment replacement repair edward have traditionally play replacement arena acquisition cardiac acquisition valtech cardioband open repair side kumar say kumar see edward touch tmvr market analyst day commentary thought be complementary acquisition investor have wonder be sign edward lifescience be hedge bet crucial pipeline opportunity write keep hold rating price target edward stock close stock market today edward stock be close tuesday more record high touch late september plunge october weak sale share medtronic lift boston add finshed day related medtronic dife month low sluggish diabetes valve salesedward medtronic rebound negative report medtech spiraling
273,EW,lead index end higher back forth session thursday stock climb open bell half day then begin trim gain nasdaq rise early afternoon peak then settle close higher pitch hour open close higher dow industrial add small cap have good day smallcap jump index st gain past session left comfortably record high investor have mixed opinion european central bank decision extend quantitative ease stimulus december say trim monthly bond buy effort begin april eurozone market rally lead gain dax frankfurt stock also receive mixed input weekly jobless claim datum be positive not much economist have expect goldman sachs gs lead dow broad stride end heavy volume stock be extend clear month consolidation rebound edward lifescience ew outpaced other stock gain wynn resort wynn take index hardest hit regulator china moved limit atm withdrawal country gamble haven macau consumer lender be day clear winner outpace other industry group china base yirendai yrd pop more lift ibd global leader stock back day line month base build effort same group michigan credit acceptance cacc rumble clear buy point stock be thinly trade fiber optic stock also figured thursday upside ciena cien storm mixed fiscal fourth quarter result include order backlog management claim be company highest ever gain left stock extend past couple alternative buy point standard buy point be double bottom base also fiber optic group lumentum holding lite bolt higher clear buy point cup deep handle finisar fnsr charge ahead heavy trade putt buy point flat base close share rally company report quarterly adjust profit cent share increase related finisar earning outlook top view optical party continue lateciena surge order backlog
274,EW,boston scientific bsx be prep take edward lifescience ew medtronic mdt acquisition neovasc nvcn advanced tissue business equity stake smaller firm infusion cash also act lifeline neovasc be order pay edward lifescience subsidiary cardiac valve technology
275,EW,medtronic mdt stock plunge month low tuesday medical device maker report fiscal sale miss wall street view earning top penny lower guidance medtronic stock close heart valve rival edward lifescience ew see share tumble month low fiscal end oct medtronic report sale miss analyst view vs year earlier quarter medtronic earning share ex item be revenue be disappointing do not meet expectation medtronic ceo omar ishrak say earning release face issue affected growth include slower expect revenue await new product introduction particularly cvg diabetes ibd take medtronic stock have ibd composite rating meaning perform middle stock term key growth metric better bet dig ibd stock checkup more revenue medtronic cardiac vascular group cvg rise mainly growth follow acquisition heartware growth aortic peripheral vascular apv division sale coronary structural heart csh division be flat minimally invasive therapy group mitg grow largely due growth surgical solution growth be partially offset competitive pressure reprocess advanced energy tool timing issue middle east medtronic slash guidance mid single digit revenue growth vs earlier view higher single digit growth company now expect sale hit assume exchange rate remain same evercore analyst vijay kumar note medtronic stock have pull back recently customer await new product large valf have be approve transcatheter aortic valve replacement tavr help second half write research note diabetes sale slow growth customer await minime be set launch early minime be first hybrid close loop system get food drug administration approval automatically adjust delivery basal insulin be disappointing quarter medtronic kumar write say think recent pullback underperform vs bake kumar keep buy rating price target medtronic stock related edward medtronic rebound negative report medtech spiraling
276,EW,edward lifescience ew medtronic mdt stock rebound tuesday report suggest key heart procedure be deadlier surgery medical tech sector remain poise historically bad quarter say evercore ishare medical device etf be year dip monday german study patient treat aortic stenosis show higher death rate treat transcatheter aortic valve replacement tavr vs surgical aortic valve replacement savr year mortality rate tavr patient be vs savr patient adjust sickness level age patient mortality rate be respectively monday share edward lifescience medtronic topple respectively news be alone tavr market edward lifescience rally tuesday close medtronic rise stock market today ibd company medical product industry group fall monday add tuesday ishare medtech etf climb ibd take etfs be good proxy broader sector make sure keep tab ibd etfs fund page hot cold sector evercore analyst vijay kumar say tavr patient be higher risk doesn put much stock report present american heart association conference tavr be important grow area represent opportunity say expect reach look slide believe tavr patient be high risk pool relative savr comparison be apple orange write research report such do not expect german registry datum have impact tavr adoption say medtech industry be downturn relative basis ishare medical device etf be quarter date vs evercore say be second worst quarter financial crisis share duck worst quarter kumar blame uncertainty surround affordable care act follow election donald trump trump campaign premise repeal obamacare have waffle say like piece law provision deny coverage base pre exist condition prior correction medtech be pre empt period soft volume peak pricing pressure not case time kumar say pricing be currently stable utilization have be strong new product be open number greenfield opportunity rather correction be imply aca go away write believe medtech stock be currently pricing scaling back aca lead volume weakness write long be new incremental negative fundamentally think stock be compelling here relatedzimmer plunge lower full year forecast weak salesedward lifescience revenue miss jolt investor
277,EW,heart valve maker edward lifescience ew plunge month low early wednesday post revenue miss wall street expectation least investment bank lower price target edward lifescience stock result same outfit rbc capital market also maintain outperform rating stock be buyer weakness write rbc analyst glenn navarro research note company earning release edward ceo michael mussallem say revenue be consistent increase expectation company top product sapien valve platform remain track generate more sale originally expect year sale year earlier quarter miss analyst consensus estimate poll thomson reuter rare miss ep ex item cent be merely line view edward lifescience stock plunge stock market today lowest price june ibd take ibd leaderboard be place find top stock be breakout fall leader leaderboard stock don just disappear longer qualify instead move leaderboard cut list ll find edward lifescience number other company earning season shuffle company last month win european approval expand use sapien heart valve certain intermediate risk patient intermediate risk
278,EW,opportunity be real navarro write ew miss revenue do not perceive structural change tavr market ew ability capitalize very
279,EW,large market opportunity estimate tavr stand transcatheter aortic valve replacement minimally invasive alternative open heart surgery only edward medtronic mdt be market boston scientific bsx be work get be related market navarro say tavr sale outside miss estimate cite france weaker market also write be already assume more gradual ramp
280,EW,ous outside sale next year believe mdt bsx capture share also writing expect ew outperform medtech peer
281,EW,next several year give superior growth profile medtronic stock fall wednesday do boston scientific post ep ex item meet view sale edge wall street estimate company also hike sale outlook year midpoint guidancerelated edward lifescience get expand use sapien europeedward revenue miss stock late
282,EW,edward lifescience ew report third quarter earning market close tuesday maker sapien transcatheter heart valf other product be expect maintain solid growth have make longtime member ibd leaderboard ibd list top perform stock wall street estimate analyst poll thomson reuter expect earning share item jump year earlier quarter cent revenue be see rise result ep ex item cent line sale miss estimate company maintain sale guidance up ep outlook prior quarter ep ex item rise cent sale rise transcatheter heart valve therapy sale jump company guidance ep ex item cent cent july exchange rate revenue stock edward lifescience stock plunge hour trading revenue miss expectation share fall fairly steadily stock market today then plunge end regular session end day fall solidly key day move average share touch follow entry point oct hit time high oct
283,EW,zimmer biomet holding zbh monday plunge monday month low medical supplier lower full year forecast weak third quarter earning report warsaw ind base maker orthopedic device say now see diluted earning share previous forecast adjust earning estimate be cut range share bring upper end spread share end day tumble zimmer violent stock reaction parallel other medical supplier have report recent day edward lifescience ew plunge more wednesday earning disappoint abiom abmd stumble more day last week boston scientific bsx slip few point report earning stryker syk see healthy uptick report gain more zimmer expect revenue growth be well exclude company acquisition ldr hold growth be expect run instead previous forecast company say net income quarter be adjust earning be share line analyst estimate revenue fall short forecast analyst survey thomson reuter expect zimmer expect full year earning range share revenue range analyst be predict earning share sale
284,EW,market pressure even top rate stock essent esnt feel heat index hold rebound private mortgage insurer put payment new subsidiary include essent guaranty essent reinsurance company offer private mortgage insurance single family mortgage loan provide private capital lender
285,EW,general market pressure even top rate stock essent esnt feel heat index hold rebound private mortgage insurer put payment new subsidiary include essent guaranty essent reinsurance bermuda base company offer private mortgage insurance single family mortgage loan subsidiary
286,EW,apple aapl edge past earning view close share fall modest addition iphone maker fast casual restaurant chipotle grill cmg panera bread pnra highly rate edward lifescience ew have report panera earning sale top chipotle do even expect edward life fall sharply sale miss weak guidance here be detail estimate fiscal ep revenue analyst expect apple sell iphone mac computer ipad prior quarter ep fall revenue sank result ep revenue apple ship iphone macs ipad service revenue climb outlook apple se fiscal vs estimate be modest gain vs year earlier stock apple share fall nearly hour action signale move alternate buy point share close stock market today best close early december share have rally recent month anticipation worst be apple iphone launch do better expect samsung cancellation galaxy note phone report explosion help iphone apple clear buy point continue move higher apple then top alternate buy point earlier month thursday apple unveil latest mac notebook desktop computer related apple earning close expectibd take buy stock current choppy market environment be risky especially so earning season ibd swing trader now offer option earning estimate ep cent revenue rise result ep cent sale outlook ep cent vs view cent sale vs estimate prior quarter ep climb cent second straight quarter accelerate growth sale expand gain accelerate third straight quarter stock edward lifescience fall hour action tumble more edward close sinkng just day line monday stock have be extend buy point edward lifescience break july then shot almost next day earning result edward continue rise fda european regulator give approval expand use sapien heart valve top product estimate ep revenue nearly result chipotle earn cent share revenue fall nearly same store sale fall outlook chipotle see same store sale low single digit help easier year earlier comparison see comp high single digit ep analyst expect ep prior quarter ep tumble cent sale skid stock chipotle initially jump hour reversed trade more share close stock have be struggle recover wave food bear illness outbreak hit many location country late last year stock actually begin selling year chipotle report slow growth share have moved sideway recent month haven be day line year chipotle have take longer many expect regain lose customer summer reward program chiptopia be criticize be too complex too generous chipotle be try bounce back time restaurant generally be struggle menu price have rise much faster cost cook own food rise labor cost further squeeze chain related apple chipotle edward life earning due expectrobot push fight backer workestimate ep revenue climb be smallest gain quarters result panera bread earn share sale rise company own same store sale rise outlook panera see full year ep line view prior quarter ep rise sale climb stock panera bread rise hour action share close tuesday breaking early march panera share moved sideway series fail breakout way share fall sharply day move average then undercut day line related restaurant brand dife burger king comp fallmcnugget mcpick breakfast help mcdonald beat restaurant slump
287,EW,stock remain stick red early wednesday earning report continue dominate market apple aapl result late tuesday weigh nasdaq fall dow jone industrial average shed volume be tracking slightly higher nyse lower nasdaq vs same time tuesday dow be sea red today stock market action lead apple drop share gap alternate entry remain prior buy point day move average stock fall back buy range purchase be riskier market uptrend pressure close tuesday iphone maker report mixed fiscal result slight earning beat revenue miss analyst be mixed stifel cut apple rating price target piper jaffray raise price target also blue chip boee ba slide report better expect result lift full year earning commercial aircraft delivery outlook stock be shape right side flat base buy point northrop grumman noc gap soar clear flat base entry fast turnover defense contractor announce earning sale beat view raise full year guidance top bottom line back downside edward lifescience ew plunge gapping day line massive trade late tuesday medical product maker earning meet revenue miss view chipotle grill cmg gap sank hefty volume more year low close tuesday embattled burrito chain deliver disappointing result include drop same store sale related apple stock sink mixed report guidanceapple mixed divide analyst armour gm downgradedboee raise earning commercial delivery guidance topsnorthrop stock enter buy zone strong outlook beat
288,EW,stock index battle overcome turbulence midday wednesday slew issue suffer bearish gap move open nasdaq gap much then backfill gap loss early dunk take composite back day line find support bounce be flat dow jone industrial average advanced volume stock market today be run modestly higher major exchange compare previous session unusually high number blue chip stock suffer gap down open gap occur stock open stay lowest price previous day range be comprise biggest blue chip dozen stock gap be unusual conservative stock gap down include simon property group spg apple aapl home improvement chain lowe low early gap down reversed fill part gap session continue ibd take gap down make individual investor think twice buy stock northrop grumman gap buy zone wednesday case negative reaction seem bit excessive dow transport member southwest airline luv gap torrid volume earning top consensus estimate revenue fall shy expectation guidance be weak company say expect unit revenue decline strong market have shrug negative focuse earning beat least contain damage market be clearly pressure growth stock also suffer gap down medical device maker edward lifescience ew be online food delivery service provider grubhub grub pizza chain papa john pzza surgical product firm zimmer biomet zbh internet content company line ln chipotle grill cmg relatedchange focus help coca cola beat earning estimateswhy do wall street clinton
289,EW,stock open lower wednesday investor wade thick earning season dow industrial nasdaq fall dip cap russell future drop earning report be center stage stock market today fraction chipotle grill cmg report result late tuesday panera bread pnra jump comcast cmcsa fall nearly deliver target result apple aapl open lower report mixed fiscal fourth quarter result late tuesday apple be now buy point edward lifescience ew tank open medical product heavyweight turn weaker expect third quarter result late tuesday earning meet view revenue didn company gross margin drop sharply boee ba reversed early gain drop fraction top third quarter view raise earning delivery guidance premarket gain imply stock open just buy point week flat base akamai technology akam surge network performance specialist report earning gain rise revenue analyst view akamai end tuesday session just buy range buy point cup handle base logitech international logi spiked meeting fiscal second expectation late tuesday brean murray launch coverage stock buy rating price target logitech briefly clear flat base buy point early month then pull back just buy point week move average trade deficit narrow september commerce department report be august well expectation increase preliminary september service purchasing manger index estimate researcher markit be expect et september new home sale be tap et energy information administration report weekly oil inventory massive hour report schedule include tesla motor tsla nxp semiconductor nxpi barrick gold abx buffalo wild wing bwld oil price slump nearly send west texas intermediate barrel price have act floor recent trading level gold ease fraction ounce dollar be mixed dollar index etch month high tuesday bond ease lift year yield basis point market be generally pressure overseas china market close lower tokyo nikkei add yen slip month low dollar european index be post new session lows afternoon trade ftse london drop frankfurt dax slip cac paris be related edward lifescience revenue miss stock plunge late
290,EW,load player here investing action plan need know investor come day apple aapl be expect report third straight quarter year year earning revenue decline tuesday general motor gm fiat chrysler automobile fcau lockheed martin lmt merck mrk edward lifescience ew also be tap
291,EW,lead tech stock tumble last week mutual fund sell share like facebook apple amazon google manager franklin dynatech fund ibd best mutual fund award winner isn panic judge dynatech fkdnx lowly portfolio turnover rate comment lead manager matthew moberg power drive growth several key holding fund remain hitch big way market lead stock dynatech have outsized bet technology weighting june accord franklin templeton sort megabet single sector make fund volatile fund performance be consistent well strong fund be so far year oct be dynatech return top peer track morningstar inc averaged gain fund generate average annual return past year fund be ibd best mutual fund award winner have outperformed year period end dec only diversify stock fund meet standard be top category equity large cap growth fund click here see list ibd mutual fund month leadersmoberg year old have be shepherd dynatech talk ibd investment approach office san mateo calif ibd matthew do fund have such large technology weighting moberg fund focus innovation growth name dynatech stand dynamic technology define dynamic force stimulate change progress innovation be bulk wealth creation occur view broad mandate re able look innovation anywhere believe need active management invest innovation part market be often misunderstand person believe be too expensive too unknown so area look mean opportunity get overlooked click here see list mutual fund category performance leadersibd be current tech weighting typical fund moberg be high sector classification change amazon amzn be now classify consumer discretionary stock early be tech visa mastercard be holding re still consider information technology company argue be financial look innovation be find lot place ibd health care be second largest sector weighting hotbed innovation right moberg not great year health care election candidate talk price control yes lot innovation see possibly emerge treatment disease hepatitis cystic fibrosis even cancer ibd be name space moberg celgene celg incyte incy click here see list biggest mutual fund rank performanceibd be fund performance consistent be diversify expose other sector not just tech health care else moberg yes be diversify consistency be also due fundamental research sometimes find stock market doesn appreciate quickly come market best example be facebook fb launch mobile ad first quarter only do revenue be total revenue year month later mobile be do more advertising revenue cbs similar quarter technology adoption be accelerate world be more global investor often don appreciate fast new technology rise so try think long term short term performance be just byproduct think long term ibd take see facebook other highly rate stock be proper buy point visit ibd leaderboard ibd part facebook story do most now moberg first mobile usage mobile ad be more effective other ad argue facebook probably have best set mobile application runway growth second re start monetize instagram person share picture next step be monetize messenger whatsapp usage have be explosive good chance go commerce rather remain solely social activity finally re think monetize year oculus make virtual reality headset be interesting acquisition facebook didn pay much probably monetize year have long runway messenger whatsapp ibd edward lifescience ew seem be benefit new management fiscal discipline key new product transcatheter aortic value replacement tavr moberg yes right now re go very nice product cycle tavr have rough start now tavr be example sensational innovation enable patient avoid need open heart surgery crack open rib cage make giant incision instead put tavr artery small incision patient spend less time hospital go less pain iteration valve get smaller easier insert product cycle last year re also work something mitral valf be harder reach hope expect be leader field well do double addressable market ibd edward have disappointing sale stock plummet have change outlook company stock moberg remain positive edward lifescience edward be still early stage capture transcatheter aortic valve replacement opportunity share so market be only third penetrate stock also fail account potential transcatheter mitral valve replacement opportunity mitral valve disease be twice prevalent aortic valve disease have face misstep new product again world doesn work linearly believe be excellent business ibd ll make wild guess be not investor find amazon product experiment wasteful moberg re incredibly innovative re continually investing new thing ve have big success first be prime get money upfront consumer drive usage amazon significantly second be let third party sell fulfillment amazon require investment inventory generate higher margin addition have amazon web service be increasingly important fastest grow software service company ever amazon continue invest find new idea ve have quite few failure way understand need take risk succeed attitude give confidence continue growth ibd concern amazon miss result sign more weakness come moberg have go many investment cycle past step up investment don always fact rarely work quarterly report cycle understand long term amazon have have very good return invest capital prefer grow organically have culture innovation didn see anything quarter suggest be longer case ibd pioneer natural resource pxd be somewhat new portfolio have straight quarters slow earning thesis moberg invest small position see do try hold long term anything fundamental change right add pioneer be best position oil service be lowest price producer think oil stabilize barrel range ibd do chinese online gaming company netease nte moberg believe gaming space be secular winner netease have game have do well secular trend gaming be better china be very strong see more virtual reality different kind game way person spend leisure time play game ibd do still broadcom avgo much used moberg don believe be innovative used be most accelerate earning share be due consolidation prefer company innovation be first still be do great job buy company rationalize cost raise price ceo be incredibly well thought chipmake industry execute strategy extremely well re pleased someone be take lead start consolidation industry ibd nvidia nvda be relative newcomer portfolio do chipmake moberg be view provider graphic chip pcs then expand make chip game console now re break free prison make central process unit virtual reality re also need car autonomous drive also hyperscale server re used co processor cad cam artificial intelligence total addressable market be explode think lot sustainability company long trajectory earning growth ibd have exposure pet care industry do moberg shocking well treat animal now vs year cancer treatment ct scan be unavailable year so secular trend company most have own longer have largest position be idexx lab idxx idexx be particularly well position business competitively give unique ability single handedly bundle outsourced diagnostic practice diagnostic instrument idexx also offer superior information management capability regard animal diagnostic report record keep relative competitor ibd special aspen technology azpn software firm moberg do supply chain management process industry software be so important even company go bankrupt pay aspen bill be backbone many company have tremendous operate margin profitability competition be serious large company need technology customer be incredibly sticky ibd tell co manager moberg be lead manager fund be founder rupert johnson co manager be fund first manager know be also vice chairman franklin resource ibd matthew person often wonder portfolio manager do hour moberg used run mile week used have hobby now have year old re hobby forget mention avid reader history be history major college find useful look micro trend adoption rate period major minor innovation pattern recognition new technology well macro trend low interest rate federal reserve action period government response related top mutual fund manager capture solid return messy top mutual fund manager win flavor growth hartford growth opportunity fund target stock fidelity contrafund manager play downturn
292,EW,ve hear old wall street see countless time rise tide lift boat so mutual fund helmsman do hard tell tide be rise challenge face john wilson peter deininger tchintcia barro manager columbia large cap growth fund gegtx economic growth be slow earning growth be scarce point most recent commentary make harder execute investment game plan find stock earning growth forecast conviction be lot stronger most investor expect only doesn re not find more difficult find buy today say lead manager wilson actually be easier make buy growth oriented stock be beaten earlier year add fund add health care name biogen biib edward lifescience ew well consumer cyclical alibaba group baba recent portfolio report biogen be transition new phase growth wilson say happen maturation market company multiple sclerosis ms drug company be look more pipeline new treatment wilson like company newfound fiscal discipline impose new manager company be go management transition re constructive wilson say be try spend research development dollar more focuse fashion focus make pipeline new product interesting say include possible treatment alzheimer disease wilson colleague also development edward be very innovative have lead position new market product allow minimally invasive heart valve replacement surgery edward transcatheter aortic valve replacement tavr have be approve only high risk patient wilson say last year tavr be approve use intermediate risk patient be larger market tavr be alternative more expensive less effective treatment wilson add tavr treatment be still early stage adoption physician patient say alibaba wilson say be not faze stock sell recent day pullback reflect investor concern weak economic datum china overall not alibaba particular have long term view say company be well position term market presence ability monetize emerge chinese online consumer company have several online sale platform well cloud service arm also wilson like alibaba development new service offer live online demonstration product columbia large cap growth biggest sector weighting be technology have shareholder money work aug accord morningstar inc be overweight vs fund russell growth index benchmark look drive lot innovation lot driver be technology wilson say fund holding be spread name related internet semiconductor cloud compute software service saas add holding include facebook fb amazon com amzn classify consumer cyclical many investor facebook be fund top holding overall june accounting nearly fund asset be also ibd leaderboard ibd take see facebook amazon other highly rate stock be proper buy point visit ibd leaderboard wilson like prospect facebook messenger app whatsapp messaging app day feature advertising also like facebook new live basically used facebook platform broadcast live event service have monetization potential boost facebook bottom line wilson say facebook earning share growth have sped quarters row most recently be amazon have rac straight quarters triple digit earning share growth reversed stanzas slow growth company have business wilson say biggest be retail operation second be web service be provide backbone lot information technology system cloud revenue be grow more annually amazon be leader space wide margin portfolio position today determine successful manager be resume long term outperformance fund average annual gain rank top peer track morningstar past year go thursday beating year span end dec feat achieve just diversify stock mutual fund fund be ibd best mutual fund award winner year date fund gain trail direct rival well advance related ibd best mutual fund bet amazon broadcom pricelineellie mae red hat servicenow flex muscle lead software hartford growth opportunity fund target stock giddyap
293,EW,several ibd stock be work basis ahead quarterly earning report edward lifescience ew make heart valf have retake day move average work flat base buy point relative strength line be rise give stock better chance breaking successfully now market
294,EW,stock track worst january least breakout have be few far stock break have form base first here look ibd stock be build basis facebook fb starbucks sbux ulta beauty ulta foot locker fl edward lifescience ew facebook earn highest possible ibd composite rating social networking giant report quarterly earning close wednesday share be trading consolidation buy point last week share be able find support key day line facebook rise tuesday starbucks have composite rating also find support day line last week share be trading buy point starbucks rise tuesday last thursday coffee giant beat quarterly earning expectation miss revenue view issue weak guidance still starbucks say bullish expansion china ulta beauty report better expect quarterly result early december beauty product retailer have composite rating ulta stock be build flat base buy point be trading pivot share be look retake day line tuesday session ulta rise day foot locker be try retake day line look be hit resistance share be trading consolidation buy point re today shoe retailer have composite rating edward lifescience have composite rating heart valve maker issue quarterly result next week earning be project have rise share be able retake day move average just few session find support day line stock be now just flat base buy point stock fall cent reilly automotive orly ross store rost campbell soup cpb be other ibd member work basis breakout provide buy opportunity current market environment warrant cautious outlook
295,EW,stock attempt feeble comeback wednesday only key index hold gain nasdaq composite gain nearly halter day sell lift disappoint hopeful greedy tech rich index have squander early gain much volume edge end less point
296,EW,stock shake early setback wednesday techs lead market higher soft trade nasdaq jump gain dow industrial add early action volume run sharply lower nyse lower nasdaq compare action same time tuesday
297,EW,stock exit back forth premarket session mixed open thursday quickly settle positive trade dow jone industrial average hold tight gain tick nasdaq add stock see heavy trade early overall volume be week nasdaq lower nyse relative wednesday early action stock market today feel mixed early influence overseas market asia market post broad loss second straight session shanghai composite hong kong hang seng index end lower tokyo nikkei take hit stock europe extend early gain solid rebound european central bank president mario draghi follow bank vote hold eurozone interest rate steady say bank be prepare increase monetary stimulus effort march dax frankfurt cac paris be apiece afternoon trade london ftse gain oil price decline ease less putt west texas intermediate just brent crude just barrel market await energy information administration weekly oil inventory datum due et economic be negative open trade weekly unemployment claim rise more expect manufacturing mid atlantic region continue decline slower rate accord philly fed index dow be third positive open home depot hd lead more top natural gas producer southwest energy swn soar energy related stock take index best open gain chip developer xilinx xlnx run close second surge more start gate report better expect fiscal result late wednesday bottom list railroad union pacific unp slump omaha neb outfit report earning dime analyst forecast larger expect revenue decline carload decline volume decrease transporter business group save automotive ibd list edward lifescience ew gap gain heavy trade maker heart valf monitoring device announce report fourth quarter result market close feb gain extend stock rebound test support day move average edward be week deep consolidation nike nke jump more better double average trade share be work third gain find support day move average week deep consolidation
298,EW,frank caruso helm mid february almost exactly year ab large cap growth fund apgax have top peer track morningstar inc jan fund notch average annual gain time vs direct rival garner month performance rating ibd meaning performance be top mutual fund time lately mutual fund have show outperform ugly market well beautiful one lose less peer broad market turbulent past month fund rank top category fall last month little better average diversify stock fund decline caruso be year old be member ab fund complex last year change name caruso lead manager fund discuss ibd manhattan office team invest ibd have achieve outperformance bad market well good caruso focus great business obsession fundamental integrity holding way manage risk look datum march dec month time be rd percentile peer month be percentile beating peer risk adjust performance portfolio be extremely good ibd business cycle be not focus right caruso don want person associate overarch concern business cycle look consistent performance particularly important growth stock investing company want need have kind business have long runway invest high return earn return excess cost capital so combination persistence duration create unleash power compound rather say look high grow company look return look really good business ibd be look company meet requirement several year right caruso window be year company russell ve get high teen number earning forecast year next then fall cliff get fewer estimate year variability forecast increase lot longer time horizon lead inefficiency growth stock investing ibd other word have longer time horizon most other investor easier find company be price inefficiently caruso be absolutely ibd recent example please caruso most investor look nike nke see most efficiently price stock market change longer term provocative be ve be experiment new manufacturing technology weave technology most person say nike biggest cost be labor not shipping tariff duty eliminate lot localize manufacturing weave technology let do instead need lot low paid worker cut bang stitching glue coloring pack product have smaller factory world decrease shipping tariff duty cost so model nike push profitability hundred basis point give confidence long term inform want behave short term volatility ibd manager pay little attention short term re do well short term luck design caruso fact stock go doesn impact way manage portfolio have say year have have good consistent performance last year start see lot risk exposure momentum stock spend entire year manage more conservative level have see reversion mean ibd recent month volatility have trim have add caruso part ve do well be market continue be concern earning portfolio be deliver ve reduce size excess winner last year redeploy more not defensive more edgy controversial company have not be leadership stock intuitive surgical isrg be name ibd fang do own have trim caruso don own amazon com amzn netflix nflx have facebook fb google alphabet googl haven trim ve be more incline trim discretionary stock take profit reduce position starbucks sbux nike thought moment be pretty fully value welcome opportunity build back volatility disney be trim monster mnst staple spls have be phenomenal performer be trim ve add last summer be basically market weight health care little overweight be put grinder late summer early fall emerge correction start increase exposure add intuitive surgical last summer rebalance biogen biib introduce position edward lifescience ew do number thing tech introduce adobe adbe cognizant ctsh do add longer term position such servicenow now ibd do intuitive surgical caruso company have unbelievable return have enterprise cash debt re see utilization robotic ever increase number procedure company long term see more surgeon adoption robotic re see stock suffer fair amount past couple year stick knit add stake re start see contribution fund performance stock ibd weren facebook ipo buy many other be flee thesis caruso be controversial buyer rest street be puke re proud go back ipo summer banker buy have year forecast model be terminal year now current forecast be higher be back then point be fundamental overachievement be really hard model facebook have potential drive tremendous excess performance ibd go back monster beverage do trim caruso be verge deploy lot capital be able sell overseas then coke ko take strategic position company shareholder appreciate many other monster not have spend become global company be able leverage coke best planet global distribution platform get profit thought see year growth opportunity be increase exponentially so sizing decision be really starbucks type decision have be unbelievably successful stock valuation get little uncomfortable short term so reduce exposure diminution long term conviction ibd boost current stake cognizant september november attraction caruso bring level expertise software service mobility solution company be try figure get architecture next level position key technology interest cognizant be stock talk end step away more recently start build back ibd adobe post earning share gain quarters suffering ep decline prior stanzas crux thing be work caruso used put product shrink wrapped box sell ve switch subscription model allow be consistent upgrade be manage deploy customer don have upgrade model be destine compress up down business lower volatility result be good valuation point view model let manage risk piracy more head fashion so long term value subscription model be more attractive old model ibd be investor start alphabet more company bring ruth porat cfo caruso yes become excited bring porat morgan stanley ms google have great business focuse search used cash flow fund variety initiative many case didn appear make lot sense appearance strong cfo hope be finally adult room bring financial discipline way thought allocate capital so far do now ve get company basically be focuse advertising youtube be grow economically handsome property search then ve get essentially call option driverless car robotic ve be deploy capital build telecom network city so portfolio early stage company acquire nurtured ready prime time need more incubation split company let investor have more transparency properly value business
299,EW,stock be still red early afternoon trading wednesday big jump crude oil price weaker expect economic datum weigh nasdaq lead decline loss shed dow jone industrial average slip volume be tracking higher board stock market today vs same time tuesday automaker internet content provider car part maker lead loser tesla tsla skid lower fast turnover extend monday drop share be now year low berenberg initiate coverage electric car maker sell rating price target pacific crest security tuesday cut earning estimate cite evidence lag model order yahoo yhoo plunge heavy trade hit lowest level intraday august internet company late tuesday announce result confirm slash workforce explore sale noncore division asset yahoo earning fall last year line view total revenue climb thomson reuter consensus estimate other internet content provider big volume linkedin lnkd give alphabet googl facebook fb alphabet reversed lower breach day move average have regain friday still slightly extend past buy point facebook also reversed lower ibd stock remain buy range entry internet retail side amazon com amzn lose slice day line fast trade first time year share be high be buy point trigger sell signal few ibd stock score big gain edward lifescience ew gap leap robust trade near top flat base buy point webmd wbmd rise strong volume gold mining oil steel stock outperformed chevron cvx exxon mobil xom be dow top gainer more west texas intermediate price rebound back barrel
300,EW,flagship stock etfs stage smart recovery wednesday close session high snap day lose streak oil drive narrative again commodity surge dollar plummet weak service datum marquee name struggle however first trust dow jone internet fdn drop top holding facebook fb amazon amzn
301,EW,be economy move snail peacock turtle matter animal analogy prefer everyone agree re slow growth mode do not mean have put hard earn money slowpoke company even kingdom big cap stock america gdp rise just
302,EW,load player mutual fund manager other large investor take interest medical product maker zimmer biomet zbh have earn spot ibd list top growth stock industry peer align technology algn edward lifescience ew tuesday stock fall day move average heavy volume
303,EW,be huge week earning apple aapl amazon amzn alphabet googl be list headliner slew industrial medical restaurant more also report tesla motor tsla report surprise profit qualcomm qcom buy nxp semiconductor nxpi nasdaq fall week amazon miss apple modest beat fail impress tech heavy index drop day line retake level last week sank dow rise bond continue fall world push year treasury yield multimonth high september quarter apple earn share year year sale analyst expect apple earn share sale holiday quarter apple guide wall street higher revenue profit margin outlook come short apple also unveil new macbook pro notebook computer feature touch screen strip application command shortcut replace function key apple fall week remain day line amazon report earning cent share big gain well short estimate cent commerce giant plow money amazon web service cloud compute unit big expansion fulfillment center head holiday season revenue rise meeting view aw be bright spot earning report revenue rise year year beating consensus revenue guidance also lag amazon share fall friday close day line first time month earning share item rise total revenue climb vs consensus estimate google parent alphabet signale higher investment cloud compute business higher marketing cost tie september launch pixel brand smartphone smart home speaker compete amazon echo google net revenue higher traffic acquisition cost tac cost be top view alphabet share nearly hit record high friday morning close day fractionally higher week fractionally lower still buy range tesla motor earn cent share exclude item soundly beating consensus estimate cent loss revenue climb top estimate elon musk have push tesla boost delivery turn profit analyst be skeptical effort be sustainable tesla maintain guidance vehicle delivery second half plan just tesla solarcity scty late friday be expect unveil integrate product offer solar panel battery storage charger tesla be process buy solarcity elon musk be top shareholder company well spacex tesla find resistance day line reversed end week cent solarcity climb gigamon gimo report third quarter profit revenue blow past estimate raise current quarter guidance santa clara calif base gigamon say ep item rise cent revenue jump analyst have project cent current quarter gigamon forecast ep cent revenue midpoint guidance vs consensus estimate cent profit revenue growth analyst say be new customer join mobile tmus gigamon shot friday hit record high intraday share have fall thursday day line lumentum lite say ep rise cent revenue climb top expectation current quarter revenue guidance be light telecom component shortage unnamed supplier ep guidance cent midpoint be consensus estimate cent lumentum fall late thursday report follow fall thursday acacia communication acia crash day week chinese telecom gear giant zte key acacia customer report weak revenue qualcomm announce deal buy nxp semiconductor create chipmaker revenue intel intc include debt deal be worth mobile communication chipmaker qualcomm say acquisition expand footprint key growth market include automotive internet thing security networking qualcomm nxp transaction mark biggest semiconductor deal ever surpass technology purchase broadcom avgo new oriental education technology edu meet fiscal ep view gain cent revenue climb analyst expectation enrollment boom ibd stock see revenue analyst guidance fellow chinese profit school stock tal education xrs result top estimate total student enrollment jump guide revenue wall street view new oriental stock rise more week blast base new high tal education climb also high related new oriental education break strong revenue guidancetal education stock enter profit take sell territory beatchipotle grill cmg earn cent share revenue fall nearly expect same store sale tumble fast casual burrito chain still struggle recover late food bear illness outbreak share fall wednesday hit year low panera bread pnra beat view send stock higher intraday wednesday reversed lower fall month low thursday buffalo wild wing bwld meet ep view miss sale share rise thursday recent lows food delivery service provider grubhub grub report ep rise revenue top grubhub active diner rise miss estimate slightly share have be month high fall nearly wednesday tumble day line biogen biib post sale ep ex item top view prod share nearly thursday bristol myer squibb bmy rise celgene celg alexion alxn beating earning amgen amgn late thursday beat share tumble nearly friday concern key drug enbrel go forward also friday nordisk nvo dive sanofi sny rise european drugmaker have different view outlook insulin treatment meanwhile drug distributor mckesson mck crash friday big miss blame rival abc heavy competition further pressure political attention drug price fall cardinal health cah nearly report earning next week related bristol myer celgene stock rocket sweeping top alzheimer datum vs eli lilly positivealexion crush expectation stock bound drug trial plansabiom abmd fall short earning send share tumble thursday edward lifescience ew revenue come light sale guidance also light send share plunge boston scientific bsx stock fall modestly ep meet sale top stryker syk narrowly top ep sale view late thursday send share friday third quarter gdp growth top forecast fastest growth year consumer spending growth slow significantly business investment remain weak real final sale exclude inventory gain next export slow separately durable good order edge lower core capital good demand fall most february boee ba say realistic possibility launch new midsize plane longer version max seek counter gain airbus eadsy boee result top analyst view revenue commercial airplane division fall defense revenue fall boee share rise week breaking base high related boee realistic possibility midsize jet stretch stock buy zonelockheed martin lmt top view defense giant raise full year outlook next production batch be split separate contract northrop grumman noc raise full year guidance report result analyst view send stock buy territory raytheon ep top estimate revenue be light patriot missile system maker improve guidance still fall short wall street view related lockheed soar outlook payout next contract see splitnorthrop stock enter buy range strong outlook beatbomb lift raytheon outlook be dud stock divesexxon mobil xom top ep estimate revenue fall well short capital spending fall oil production dip chevron cvx crushed ep view revenue miss slightly downstream profit be oil major refine margin weaken conocophillip cop loss wasn bad expect company raise full year production outlook lower capital spending guidance general electric ge be talk oil service firm baker hughe bhi partnership not purchase baker hughe break buy zone tuesday report better expect earning add friday industrial giant unite technology utx caterpillar cat mmm issue weak financial forecast global economic uncertainty hurt sector broadly general electric ge several other notable industrial firm already have cut guidance general motor gm meanwhile warn impact brexit plateau auto market strong full year ep guidance overall athletic apparel maker earning rise sale top view gross margin dip negative impact timing liquidation increase promotion foreign exchange rate armour ua see revenue growth consensus armour vow invest aggressively share fall more wee hit year low related armour dife growth target exec vow invest aggressively
304,EW,weak earning apple aapl fuel selling nasdaq wednesday weakness wasn pronounce close nasdaq composite lose seek support day move average again drop small cap lag russell dow jone industrial average add help strength boee ba nike nke preliminary datum show volume nyse nasdaq come slightly higher tuesday level wednesday hour session serve plenty earning winner include tesla motor tsla servicenow now vmware vmw oil price reversed lower government report show crude stockpile unexpectedly decrease last week december west texas intermediate crude fall cent settle barrel weakness nasdaq bellwether apple weigh sentiment share gap lose ibd take give apple credit still hold day move average mixed analyst commentary result boee ba lead rally aerospace defense stock other big gainer group include flir system flir transdigm group tdg earning report be catalyst boee flir system boee jump nearly clear base buy point flir surge transdigm add wall street also didn report edward lifescience ew chipotle cmg grubhub grub loss range edward report second straight quarter earning sale growth sale miss expectation earning sale come short chipotle grubhub beat handily earning sale rise active customer disappoint trucking stock outperformed strong earning small cap saia saia give group lift share jump stock clear flat base buy point akamai akam also buck trend soar nearly network performance specialist report earning gain rise revenue analyst view akamai end tuesday session just buy range buy point cup handle base vantiv vntv provider payment process service extend gain recent cup handle base share jump heavy volume strong result related takeaway apple mixed earning reporttesla profit shock servicenow beat texas instrument reportboee realistic possibility midsize jet stretch stock buy zone
305,EW,earning season kick high gear tuesday heavy report schedule culminate close quarterly result apple aapl edward lifescence ew other dow industrial nasdaq be open dow issue be busy stock market today procter gamble pg jump consumer product giant report fiscal first quarter earning rise more revenue fall less expect analyst company core operate profit margin expand basis point unite technology utx climb report stronger forecast third quarter result caterpillar cat rise mmm be report armour ua buckled diving report forecast third quarter sale earning guide full year revenue just consensus estimate burger joint sonic sonc drop more report fiscal fourth quarter earning narrowly beat expectation revenue fall well short projection stock correction have deepen april baker hughe bhi leap mixed third quarter result share end monday january low keycorp key rolled gain third quarter result top analyst target stock clear cup handle buy point early month end monday penny high year set ibd stock new oriental education technology edu jump more china base network learn center report first quarter earning line revenue analyst expectation stock be breaking past buy point later stage flat base home price continue improve steady rate august rise year year monthly basis accord case shiller city home price index increase meet analyst expectation federal housing finance agency housing price index increase august vs gain july better economist expectaion increase conference board october consumer confidence index drop atlanta federal reserve bank president dennis lockhart be schedule speak opportunity finance network conference atlanta et crude price hold flat west texas intermediate sticking recent range barrel gold inched just ounce dollar firm bond flattened leave year yield china market end tuesday session narrowly mixed tokyo nikkei jump second straight advance europe stock stick close start point afternoon trade cac paris frankfurt dax ahead london ftse steady related be alphabet activision new oriental ripe pick gm unite tech caterpillar beat earning view
306,EW,here weekly investing action plan need know investor come week tech darling apple aapl tesla motor tsla amazon amzn alphabet googl report earning well aerospace defense leader boee ba lockheed martin lmt industrial giant big biotechs medical device maker weigh too oil
307,EW,load player main index bounce tuesday provide glimmer hope market week have have little cheer add remain stick sideway trend nasdaq rise close few point day move average line have be barrier more
308,EW,quiet low volume session stock friday see modest gain close small yet compelling crop new high semiconductor bellwether intel intc score new high friday complete week tight pattern way stock reversed early gain share lose penny still intel have be renew accumulation
309,EW,stock future be mildly lower steady ahead tuesday open dow future trade point fair market value nasdaq future be point future backed point
310,EW,stock market today set nasdaq begin high nasdaq open year high marked july be high index be sit top week rally strongest run up october november rally last year
311,EW,light day economic news include october car sale number release automaker day commerce department report september factory order datum et
312,EW,oil trade less west texas intermediate hold barrel gold slip fraction just ounce
313,EW,stock king digital entertainment king maker addictive candy crush online game zoom premarket action video game heavyweight activision blizzard atvi agree buy ireland base king cash activision share monday close just oct high slip
314,EW,big name motion follow earning report include daniel adm sprint tech name fitbit fit taser international tasr be also sharply lower quarterly result
315,EW,discovery communication disca skip report mixed result earning top revenue miss analyst consensus estimate management also announce share buyback program stock have be weaken consolidation month
316,EW,zoetis zts report healthy beat jump florida park company top estimate sale earning line hoist full year ep guidance expectation stock have scoop deep consolidation begin june
317,EW,leader atlanta base payment processor global payment gpn jump bell stock end monday just last week high well extend buy point
318,EW,ryanair holding ryaay picked premarket gain ireland base economy airline be flat base buy point
319,EW,overseas market be mixed japan morning standout tokyo nikkei drop drag iron steel stock tumble weak manufacturing datum china stock future be mildly lower steady ahead tuesday open dow future trade point fair market value nasdaq future be point future backed point stock market today set nasdaq begin high nasdaq open year high marked july be high index be sit top week rally strongest run up october november rally last year light day economic news include october car sale number release automaker day commerce department report september factory order datum et oil trade less west texas intermediate hold barrel gold slip fraction just ounce stock king digital entertainment king maker addictive candy crush online game zoom premarket action video game heavyweight activision blizzard atvi agree buy ireland base king cash activision share monday close just oct high slip big name motion follow earning report include daniel adm sprint tech name fitbit fit taser international tasr be also sharply lower quarterly result discovery communication disca skip report mixed result earning top revenue miss analyst consensus estimate management also announce share buyback program stock have be weaken consolidation month zoetis zts report healthy beat jump florida park company top estimate sale earning line hoist full year ep guidance expectation stock have scoop deep consolidation begin june leader atlanta base payment processor global payment gpn jump bell stock end monday just last week high well extend buy point ryanair holding ryaay picked premarket gain ireland base economy airline be flat base buy point overseas market be mixed japan morning standout tokyo nikkei drop drag iron steel stock tumble weak manufacturing datum china
320,EW,edward lifescience stock jump midday trading stock market today follow fda approval late monday latest artificial heart valve sapien xt edward ew sapien xt be transcatheter aortic valve update version original sapien launch fda approve patient be inoperable high risk death
321,EW,medical device giant medtronic mdt early tuesday report soft quarter announce settlement long run patent dispute send share morning trading stock market today medtronic sale fiscal fourth quarter end april rise year earlier quarter miss analyst consensus share profit
322,EW,stock future veer sharply lower ahead friday open wild session drag oil price international market deep loss dow future swoon lower third loss come past hour
323,EW,nasdaq future point lower future be russell future show decline
324,EW,premarket stance stock market today be negative first time week head friday session effectively flat week nasdaq start loss test recent lows rebound thursday premarket momentum appear set retest support keep mind nyse nasdaq exchange be close monday martin luther king jr holiday
325,EW,china shanghai composite tumble putt week more dec high decline typically denote bear market hong kong hang seng index drop friday give loss week hang seng be october
326,EW,european market feel drag china tumble oil price mining stock suck lower bhp billiton bhp announcement impairment charge value onshore oil gas asset bhp billiton share dive premarket trade
327,EW,london ftse dump morning trade cac paris frankfurt dax be more stock exchange europe china be open regular trade monday
328,EW,oil price pitch lower west texas intermediate diving brent crude nearly barrel gold silver rise fraction copper fall more dollar bond shift lower
329,EW,economic news open commerce department report retail sale dip december upwardly revise increase november not good read holiday sale season auto sale be also vs gain november economist have project gain auto december
330,EW,price paid producer december slip labor department report reversed increase november be shade decline forecast economist food energy price eke line expectation
331,EW,new york region manufacturing unexpectedly tumble month new york federal reserve empire state manufacturing survey drop tally december deep figure expect consensus estimate
332,EW,federal reserve be next release december industrial production capacity datum et university michigan deliver preliminary read january consumer sentiment commerce department report november business inventory baker hughe bhi report weekly rig count triad federal reserve bank president william dudley john william rob kaplan have speech schedule trading hour
333,EW,dow chevron cvx walt disney exxon mobil xom be more
334,EW,intel intc fall furthest plummet meeting beating most performance measure report late thursday management offer revenue guidance just expectation cite uncertainty chinese market stock have be consolidate dec high
335,EW,oil mining issue cram low end william wmb take hardest hit more
336,EW,upside microchip technology mchp pop germany dialog semiconductor say late thursday be back away bidding war acquire atmel atml microchip bid share cash stock deal atmel say week be superior dialog offer atmel share be flat premarket trade
337,EW,most ibd stock remain flat ahead open huntington ingall hii flash higher earlier premarket action then fall back flat trade shipbuilder end thursday almost cup handle buy point edward lifescience ew dive stock future veer sharply lower ahead friday open wild session drag oil price international market deep loss dow future swoon lower third loss come past hour nasdaq future point lower future be russell future show decline premarket stance stock market today be negative first time week head friday session effectively flat week nasdaq start loss test recent lows rebound thursday premarket momentum appear set retest support keep mind nyse nasdaq exchange be close monday martin luther king jr holiday china shanghai composite tumble putt week more dec high decline typically denote bear market hong kong hang seng index drop friday give loss week hang seng be october european market feel drag china tumble oil price mining stock suck lower bhp billiton bhp announcement impairment charge value onshore oil gas asset bhp billiton share dive premarket trade london ftse dump morning trade cac paris frankfurt dax be more stock exchange europe china be open regular trade monday oil price pitch lower west texas intermediate diving brent crude nearly barrel gold silver rise fraction copper fall more dollar bond shift lower economic news open commerce department report retail sale dip december upwardly revise increase november not good read holiday sale season auto sale be also vs gain november economist have project gain auto december price paid producer december slip labor department report reversed increase november be shade decline forecast economist food energy price eke line expectation new york region manufacturing unexpectedly tumble month new york federal reserve empire state manufacturing survey drop tally december deep figure expect consensus estimate federal reserve be next release december industrial production capacity datum et university michigan deliver preliminary read january consumer sentiment commerce department report november business inventory baker hughe bhi report weekly rig count triad federal reserve bank president william dudley john william rob kaplan have speech schedule trading hour dow chevron cvx walt disney exxon mobil xom be more intel intc fall furthest plummet meeting beating most performance measure report late thursday management offer revenue guidance just expectation cite uncertainty chinese market stock have be consolidate dec high oil mining issue cram low end william wmb take hardest hit more upside microchip technology mchp pop germany dialog semiconductor say late thursday be back away bidding war acquire atmel atml microchip bid share cash stock deal atmel say week be superior dialog offer atmel share be flat premarket trade most ibd stock remain flat ahead open huntington ingall hii flash higher earlier premarket action then fall back flat trade shipbuilder end thursday almost cup handle buy point edward lifescience ew dive
338,EW,cardiac device giant edward lifescience ew issue guidance low side estimate wednesday raise long term market estimate key product line kick annual investor day edward affirm previous guidance forecast next year sale represent growth
339,EW,stock market make feeble attempt rebound tuesday remain woozy prior day beating nasdaq fall climb day market have trouble find direction index go gain loss dozen time volume fall board institutional
340,EW,stock blink start level monday market look wednesday federal reserve decision lead index nasdaq dow jone industrial average be shortly start trade
341,EW,week big news arrive wednesday afternoon policy announcement follow federal open market committee day meeting washington
342,EW,fed chairwoman janet yellen have prime expectation body first change federal fund rate june
343,EW,monday otherwise quiet economic calendar quiet trade nasdaq nyse vs friday activity left stock market today hang company news effect unravele oil price
344,EW,benchmark west texas intermediate trim early loss back europe brent crude maintain decline trading lowest level
345,EW,energy related issue take worst loss stock newell rubbermaid nwl drop index worst decline newell say pay cash stock acquire boca raton fla base jarden jah jarden share rise
346,EW,dow chemical dow dupont dd drop more dow announce board director unanimously approve merger agreement reach last week chemical giant
347,EW,gain loss leader be generally mild ibd group post gain dycom dy imax imax lead nearly apiece
348,EW,dycom friday have slip buy point investor have cushion stock opt not sell point keep careful eye stock share add definitely be sell stock dife pivot
349,EW,imax be attempt regain support week move average hold most part steady cup handle buy point
350,EW,edward lifescience ew rise stock split take effect move confused automate datum gatherer hadn be adjust split show gain more monday gain put share back buy range just barely bit less split adjust buy point
351,EW,bottom ibd grupo financiero galicia ggal drop start trade loss put hold company argentina largest bank week move average stock last week trip sell signal turn gain buy point loss stock blink start level monday market look wednesday federal reserve decision lead index nasdaq dow jone industrial average be shortly start trade week big news arrive wednesday afternoon policy announcement follow federal open market committee day meeting washington fed chairwoman janet yellen have prime expectation body first change federal fund rate june monday otherwise quiet economic calendar quiet trade nasdaq nyse vs friday activity left stock market today hang company news effect unravele oil price benchmark west texas intermediate trim early loss back europe brent crude maintain decline trading lowest level energy related issue take worst loss stock newell rubbermaid nwl drop index worst decline newell say pay cash stock acquire boca raton fla base jarden jah jarden share rise dow chemical dow dupont dd drop more dow announce board director unanimously approve merger agreement reach last week chemical giant gain loss leader be generally mild ibd group post gain dycom dy imax imax lead nearly apiece dycom friday have slip buy point investor have cushion stock opt not sell point keep careful eye stock share add definitely be sell stock dife pivot imax be attempt regain support week move average hold most part steady cup handle buy point edward lifescience ew rise stock split take effect move confused automate datum gatherer hadn be adjust split show gain more monday gain put share back buy range just barely bit less split adjust buy point bottom ibd grupo financiero galicia ggal drop start trade loss put hold company argentina largest bank week move average stock last week trip sell signal turn gain buy point loss
352,EW,medical device giant medtronic mdt be early trading thursday beat fiscal earning estimate raise low end full year profit guidance quarter end oct medtronic make share exclude time item year earlier quarter cent analyst consensus accord thomson reuter sale totale line consensus pro basis adjust acquisition covidien last spring foreign currency headwind medtronic guide full year ep raise low end previous range cent affirm previous guidance sale growth come fact medtronic be expect stronger foreign currency headwind do take cent full year ep medtronic stock be nearly morning trading stock market today trading time high hit march ep upside be drive slightly better expect expense control lower tax rate lower net interest expense write rbc capital market analyst glenn novarro research note lower tax rate contribute ep lower net interest expense contribute expect ep growth accelerate fiscal second half cost saving covidien kick forecast operate margin second half vs first half leerink analyst danielle antalffy also see potential upside covidien integration underlie operational sale growth guidance fall basically line believe be growth trajectory cardio more broadly notably medtronic primary competitor boston scientific bsx st jude medical stj do believe guidance prove conservative medtronic continue integrate recently acquire covidien potentially recognize sale synergy be too early potentially more come fiscal antalffy add strong sale medtronic coronary structural heart division indicated market transcatheter aortic valve replacement be grow faster expect bode well edward lifescience ew medtronic lone competitor field edward stock be nearly morning trading thursday follow amy reeve twitter ibd_areeve facebook
353,EW,ibd big cap member constellation brand stz lose steam touch new high end stock clear buy point flat base friday morning intraday stock rise nearly touch time high recent week area have be tough crack
354,EW,marked follow day wednesday fed raise interest rate quarter point first increase june nasdaq rally dow rise ibd add market breadth be solid advance stock beating decliner nyse nasdaq
355,EW,nation best perform stock mutual fund past month have be slowly add top rate fabless chip stock such nvidia nvda inphi iphi maxlinear mxl silicon motion simo computer software firm such netease nte ebix ebix veeva system veev paycom payc qualys qlys also make top fund buy list computer networking firm arista network anet netgear ntgr be also favore lead fund wednesday ibd computer software subgroup education medium enterprise gaming be rank top industry click here new buy top perform stock fund past monthsmanager lead stock mutual fund have continue graze medical product firm edward lifescience ew align technology algn inogen ingn vascular solution vasc build stock thor industry thor patrick industry patk aos lgi home lgih central garden pet centa be defensive name top fund be buy latest report period other industrial material stock be look good include metal fabricator gibraltar industry rock worthington industry wor top fund hold big stake chinese internet retail giant alibaba group baba lead fund buy stock investing estimate latest report period clear consolidation mid august alibaba have continue trek north notch new week high ibd take ibd best mutual fund award winning manager michael carman hartford growth opportunity fund explain have be build stake alibaba ibd report ibd see top perform fund snap gibraltar industry investing estimate goldman sachs small cap value fund gssmx add share portfolio latest report period buffalo base firm make distribute build product processed metal industrial infrastructure residential market product include postal approve single unit steel mailbox well centralize mailbox parcel locker industrial area gibraltar fabricate metal bar grating engineer bearing joint be used bridge road airport runway gibraltar have benefit construction boom well diversify material firm have display healthy earning growth recent year ep growth range past quarters firm also raise full year ep guidance range hit week high aug gibraltar have be work fourth stage flat base trading buy range country lead fund have be get rid big household name latest report period include internet search giant alphabet googl online retailer amazon com amzn credit card processor mastercard banking stock such bank america bac suntrust bank sti morgan stanley ms be also cut list related top fund latest sell
356,EW,edward lifescience ew touch new high second day company early week announce approval europe expand use sapien heart valve certain intermediate risk patient edward lifescience stock be stock market today share have jump more company share be extend july cup handle base buy point ibd take company make ibd ranking top perform stock past week ibd leaderboard very top stock breakout company watch currently only company make list edward facebook monday edward say have receive ce mark expand use sapien transcatheter heart valve treat patient suffering severe symptomatic aortic stenosis be intermediate risk open heart surgery ibd company medical product group meanwhile be fraction thursday rise group nearly stock market overall dive early february touch record high rank group month week other group glaukos gkos be thursday extend buy point touch last thursday cup base company make procedure treat glaucoma group maker spine product rise possible buy point flat base other group stock include novocure nvcr nephew snn related glaukos win fight glaucoma putt stick eyeedward be take surgery heart surgery
357,EW,here investing action plan thursday need know investor come day share domino pizza dpz edward lifescience ew present trading opportunity goldman sachs communacopia conference also wrapped executive verizon communication vz discovery communication disca mobile tmus set take stage stock watch ibdchart
358,EW,medtronic mdt stock retreat medical device titan early thursday deliver mixed quarter affirm guidance meanwhile st jude medical stj tumble claim product be hack medtronic fiscal profit share beat consensus cent be slightly year earlier quarter revenue be bit expectation prior year leerink analyst danielle antalffy write market open probably wouldn help stock expectation be high go peer boston scientific bsx st jude medical edward lifescience ew report strong quarters operate margin key metric medtronic have underperform past again miss street expectation come basis point consensus basis point antalffy write research note ibd take medtronic be strong group medical product currently industry group rank group medtronic rank just smaller upstart abiom take top spot rbc capital market analyst glenn novarro write cardiac vascular group thought outperform be show sign competitive pressure medtronic cardiac therapy device continue outperform market new entrant implantable cardioverter defibrillator evera mri pacemaker micra tps segment appear share gain be slow give recent launch boston scientific novarro write research note medtronic corevalve evolut be benefit strong procedure growth medtronic performance quarter suggest lose share edward antalffy add however medtronic longer term record be solid now consecutive quarters mid high single digit sale growth constant currency basis medtronic continue build consistent track record market growth write medtronic stock fall close stock market today be head sell zone drop flat base have form hit lifetime high july separately st jude medical fall short seller muddy water say st jude icds crt cardiac therapy device be risk cyberattack st jude share fall low intraday lowest nearly month related edward lifescience be take surgery heart round heart failure offering heartware buy
359,EW,medical device giant medtronic mdt be due report fiscal earning early thursday report peer indicated solid growth sector analyst expect single digit revenue earning growth constant currency basis foreign exchange headwind have see overall sale decline ep dip penny rbc capital market analyst glenn novarro write monday recent report cardiac device company boston scientific bsx edward lifescience ew st jude medical stj signale strength market drive upside surprise medtronic cardiac vascular group see ibd coverage edward earning boston scientific earning margin concern likely prove overblown novarro add preview note gross margin adjust foreign exchange rate be tracking level sg sale general administrative expense similarly adjust be lower year year fiscal benefit ongoing integration medtronic covidien medtronic acquire surgical product leader covidien last year medtronic close acquisition tuesday pay heartware maker ventricular assist device heart failure patient medtronic stock also get buy rating tuesday citi initiate coverage stock have be form flat base hit lifetime high july medtronic stock rise fraction tuesday look set open trading stock market today time high touch last month buy point flat base medtronic stock be so far ibd take medtronic be biggest player field leaderboard stock edward lifescience have be consistently higher stock rating learn edward be ahead medtronic key technology related drife spinal stock ldr nuvasive globus medicalboston scientific stock year high margin boost plan
360,EW,share medical device maker edward lifescience ew pop thursday afternoon fda grant expand indication lead product boost market agency approve sapien sapien xt transcatheter aortic valve replacement tavr patient intermediate risk death complication open heart surgery valf be implanted catheter small incision patient groin be previously approve only patient high risk approval have be expect early april result large clinical trial intermediate risk population drive stock day result show significantly lower rate death stroke patient receive valve tavr method compare surgical method tavr line already account more half edward revenue have be fuel growth well rise stock market june initiation report edward guggenheim analyst chris pasquale write intermediate risk approval increase addressable market half also give edward edge rival medtronic mdt corevalve tavr intermediate risk datum isn due next year edward stock close higher stock market today record close high edward stock hit record high late last month medtronic stock be fraction ibd take highest possible composite rating edward lifescience be longtime resident ibd list lead growth stock also regular ibd big cap growth stock select add stability
361,EW,be time life medical device company single food drug administration ruling have pivotal impact future edward lifescience recently get such decision ruling come thursday regard sapien edward ew transcatheter aortic valve replacement tavr artificial valve implanted patient aortic stenosis disease bring real valve start malfunction due calcification fda decision mean instantly increase potential market lead product half make sapien different other valf be transcatheter part traditionally aortic valf have be replace medical vernacular crack chest not surprisingly pretty traumatic patient especially risky re talk elderly population suffering heart disease tavr be deliver catheter small hole groin make much less shock less decade first commercial tavr case be perform europe technology have prove not only be invaluable option patient too sick frail undergo open heart surgery also superior treatment strategy large swath traditional surgical population write guggenheim analyst chris pasquale june initiation report edward however fda heart surgeon be naturally cautious new technology give don mess vital organ lightly so first generation sapien be approve be only patient highest risk death surgery expand other patient edward have have conduct large clinical trial segment population prove sapien benefit outweigh risk april edward demonstrated exactly person study patient intermediate risk complication surgery day procedure patient treat tavr die compare patient receive surgical valve replacement year death rate be tavr group surgery group similar contrast appear prevalence stroke investor know meant edward stock leap almost day news hit clinical datum presentation represent best case scenario sapien broader tavr market write rbc capital market analyst glenn novarro research note time key debate be fda accelerate approval timeline intermediate risk label turn fda approve indication past thursday line management recent guidance come sometime third quarter statement edward call major milestone share rise thursday early friday trading timing be significant not only help edward term financial also competitive position only other tavr player market be medtronic mdt acquisition corevalve corevalve sapien hit european market medtronic have lag bit edward timeline get corevalve approve january be more year sapien medtronic also be conduct trial intermediate risk patient result aren due next year expect label use corevalve intermediate risk patient once sapien label be expand penetration population be likely accrue edward medtronic surtavi trial read analyst pasquale write report stake be big be aortic stenosis sufferer alone sapien corevalve have grow analyst have be see not just displace surgery increase demand aortic replacement general quarterly report estimate overall tavr market size go ibd take edward lifescience be top rate stock ibd leaderboard check here find buy range better expect growth now quarters row ramp competition europe signify tavr market be clearly grow seemingly sustainably faster expect now expect exceed time frame edward sapien be best class particularly now datum demonstrate overwhelming superiority vs surgery intermediate risk patient leerink analyst danielle antalffy write research note edward second quarter report july quarterly report push stock new high revenue earning growth accelerate last quarters earning rise year earlier quarter cent share sale be strong financial stock performance have keep edward constant presence ibd big cap last few month tavr line be growth driver now account more half revenue edward be continue work other heart related device aug rolled new intuity elite valve system number product make traditional surgical valve replacement believe surgery continue have vital role patient even tavr expand edward spokeswoman heather chamber tell investor business daily email be patient include younger patient patient complex need continue be well serve surgery chamber add be lot other structural heart defect surgery be best option other defect be also ripe minimally invasive approach transcatheter mitral valve replacement tmvr have lately become hot area cardiac device field medtronic boston scientific bsx abbott laboratory work device edward have be develop house tmvr call fortis last year add program acquire privately hold cardiaq valve technology tmvr turn be even bigger opportunity tavr give higher prevalence mitral regurgitation population challenge treat many patient surgically pasquale write report add many question remain unanswered however include treatment strategy be optimal repair replacement disease morphology benefit most transcatheter approach degenerative functional prospective clinical study be design evaluate new technology
362,EW,today ibd show many stock have be winner year real question be one be screen rally start top perform leader didn get ibd make big advance more impressive be stock be list market bottom late
363,EW,cardiac implant maker ibd stock edward lifescience ew beat earning estimate raise guidance late tuesday send stock hour trading edward sale grow year earlier quarter more analyst consensus earning jump cent share also beating estimate edward say now expect full year sale be high end previous guidance raise earning guidance consensus represent growth last year highlight be tavr tran aortic valve replacement grow year year vs international tavr growth accelerate vs evercore isi analyst vijay kumar write research note shv surgical valf decline raise question potential cannibalization tavr management highlighted temporary suspension mitral valve production culprit kumar note continue high expectation tavr lead edward sapien line valf drive guidance increase edward be ibd list top growth stock rise regular trade tuesday close
364,EW,quiet morning stock start edge red afternoon trading friday downward trend gain momentum nasdaq composite have inched positive ground be recent action dow industrial be nearly dollar rally most other currency year treasury yield add basis point ross store rost be big gainer nasdaq gapping more report strong earning late thursday early leader dow include nike nke nearly beneficiary strong earning foot locker fl share foot locker soar stock break downtrend aug have extend gain then option expire today skewer volume bit nyse nasdaq volume exchange be tracking higher thursday level more so nyse stock market today apply material amat gap strong earning bullish guidance share gain don chase well extend prior flat base entry new issue twilio twlo reversed higher try halt session slide share picked more enterprise software name try form new base here entry big mover ibd include edward lifescience ew positive fda news fuel gain stock thursday edward extend gain friday rise ibd take edward be several top rate name medical product group see other leader be ibd stock checkup buyer also come grubhub grub friday share rise more level be key resistance area watch grubhub soar week end july help strong result earning sale growth accelerate nicely first quarter rise respectively
365,EW,share device maker edward lifescience ew jump early trading stock market today word get late friday company have win court injunction limit sale medtronic mdt corevalve artificial heart valve
366,EW,medtronic stock be
367,EW,corevalve have be sell europe several year be approve fda january edward rival sapien product have be sell america have long fought corevalve entry patent litigation jury trial find medtronic have infringe edward patent friday federal judge grant injunction limit corevalve sale patient extreme risk start april medtronic say appeal
368,EW,judge do say corevalve seem be safer product better outcome order company agree way allow physician trained corevalve implantation currently hospital continue use product accord own clinical judgment
369,EW,give rare injunction be be surprised court decision write rbc capital market analyst glenn novarro research note monday
370,EW,novarro see possible outcome point scenario mdt gain stay april be change estimate mdt then move forward appeal injunction play court year
371,EW,scenario mdt do not stay ew enforce injunction note ew have petition patent trademark office extend anderson patent early thus worst case scenario mdt likely be market early
372,EW,scenario mdt do not gain stay ew allow mdt sell hospital be currently trained corevalve
373,EW,novarro maintain sector perform rating stock crt capital upgrade edward buy fairly value jpmorgan upgrade neutral underweight deutsche bank maintain hold rating edward lift price target edward stock be trading monday morning
374,EW,follow amy reeve twitter ibd_areeve
375,EW,related medtronic price target raise already beat share device maker edward lifescience ew jump early trading stock market today word get late friday company have win court injunction limit sale medtronic mdt corevalve artificial heart valve medtronic stock be corevalve have be sell europe several year be approve fda january edward rival sapien product have be sell america have long fought corevalve entry patent litigation jury trial find medtronic have infringe edward patent friday federal judge grant injunction limit corevalve sale patient extreme risk start april medtronic say appeal judge do say corevalve seem be safer product better outcome order company agree way allow physician trained corevalve implantation currently hospital continue use product accord own clinical judgment give rare injunction be be surprised court decision write rbc capital market analyst glenn novarro research note monday novarro see possible outcome point scenario mdt gain stay april be change estimate mdt then move forward appeal injunction play court year scenario mdt do not stay ew enforce injunction note ew have petition patent trademark office extend anderson patent early thus worst case scenario mdt likely be market early scenario mdt do not gain stay ew allow mdt sell hospital be currently trained corevalve novarro maintain sector perform rating stock crt capital upgrade edward buy fairly value jpmorgan upgrade neutral underweight deutsche bank maintain hold rating edward lift price target edward stock be trading monday morning follow amy reeve twitter ibd_areeve related medtronic price target raise already beat
376,EW,new high be even shorter supply thursday market again end red mostly lackluster name be one muster new high unilever ul gap rise heavy trading share british maker food personal care product hit record high early session close
377,EW,artificial heart valve battle remain bit draw
378,EW,medtronic mdt edward lifescience ew offer compete set datum artificial heart valf american college cardiology meeting washington last weekend
379,EW,wednesday rbc capital market analyst glenn novarro hike price target medtronic stock share already trade new price
380,EW,medtronic be nearly midday trading stock market today edward stock be fraction
381,EW,company present datum heart valf meeting sunday analyst leane medtronic provide better number edward also be upbeat stock rise ibd report
382,EW,edward stock climb monday fraction tuesday be midday wednesday medtronic stock rise monday fraction tuesday
383,EW,novarro have favorite
384,EW,mdt emerge clear winner clinician enthusiasm company high risk datum set excitement future tavr market overall write research note tavr stand transcatheter aortic valve replacement target high risk patient not candidate traditional open chest surgery
385,EW,additionally management disclose expand label not have face panel push approval few month say
386,EW,also say expect company release positive trial result medical conference saturday london pact drug eluting balloon product heart patient result say support fda approval artificial heart valve battle remain bit draw medtronic mdt edward lifescience ew offer compete set datum artificial heart valf american college cardiology meeting washington last weekend wednesday rbc capital market analyst glenn novarro hike price target medtronic stock share already trade new price medtronic be nearly midday trading stock market today edward stock be fraction company present datum heart valf meeting sunday analyst leane medtronic provide better number edward also be upbeat stock rise ibd report edward stock climb monday fraction tuesday be midday wednesday medtronic stock rise monday fraction tuesday novarro have favorite mdt emerge clear winner clinician enthusiasm company high risk datum set excitement future tavr market overall write research note tavr stand transcatheter aortic valve replacement target high risk patient not candidate traditional open chest surgery additionally management disclose expand label not have face panel push approval few month say also say expect company release positive trial result medical conference saturday london pact drug eluting balloon product heart patient result say support fda approval
387,EW,stock future hold steady healthy gain ahead monday open market look short week preholiday trade dow future be level trading point fair market value
388,EW,nasdaq future future be also steady point respectively
389,EW,stock market today have work cut christmas week trade generally tend be light young uptrend run heavy distribution friday raise question long last
390,EW,economic news isn likely have much impact chicago federal reserve national activity index most prominent piece economic news prior open show slip november accelerate october contraction be not economist consensus have expect increase
391,EW,international market also appear have negligible effect stock europe trade modestly higher midday china market rise include jump shanghai composite tokyo nikkei japan slip
392,EW,dollar rise bond edge oil price slip west texas intermediate bob barrel brent crude just most metal trade higher big gain
393,EW,be star war effect early trade walt disney be stock lead dow better gain premarket trade goldman sachs gs apple aapl also gain more
394,EW,disney star war force awaken gross estimate canada weekend be expectation beating prior record holder jurassic world gross premier june avenger pull premier
395,EW,disney share briefly clear buy point cup handle base november then drop undercut buy point more trigger sell rule
396,EW,huge screen savvy imax imax jump new star war film reportedly premier imax screen weekend pull set imax record top open weekend take jurassic world accord box office figure deadline hollywood imax ibd stock end friday buy point cup handle base
397,EW,also ibd list arm armh perked ahead open share cambridge england base chip designer tumble last week end stock converge week line support stock future hold steady healthy gain ahead monday open market look short week preholiday trade dow future be level trading point fair market value nasdaq future future be also steady point respectively stock market today have work cut christmas week trade generally tend be light young uptrend run heavy distribution friday raise question long last economic news isn likely have much impact chicago federal reserve national activity index most prominent piece economic news prior open show slip november accelerate october contraction be not economist consensus have expect increase international market also appear have negligible effect stock europe trade modestly higher midday china market rise include jump shanghai composite tokyo nikkei japan slip dollar rise bond edge oil price slip west texas intermediate bob barrel brent crude just most metal trade higher big gain be star war effect early trade walt disney be stock lead dow better gain premarket trade goldman sachs gs apple aapl also gain more disney star war force awaken gross estimate canada weekend be expectation beating prior record holder jurassic world gross premier june avenger pull premier disney share briefly clear buy point cup handle base november then drop undercut buy point more trigger sell rule huge screen savvy imax imax jump new star war film reportedly premier imax screen weekend pull set imax record top open weekend take jurassic world accord box office figure deadline hollywood imax ibd stock end friday buy point cup handle base also ibd list arm armh perked ahead open share cambridge england base chip designer tumble last week end stock converge week line support
398,EW,stock be still higher tuesday midday gain have fade
399,EW,trim gain nasdaq pare advance just dow jone industrial average stay session high gain caterpillar cat chevron cvx exxon mobil xom be biggest winner blue chip index volume be run higher board stock market today
400,EW,lead stock linkedin lnkd rise goldman sachs put share conviction buy list raise price target professional networking operator report earning thursday analyst poll thomson reuter see profit rise cent share linkedin be base buy point
401,EW,lithia motor lad tack fast trade stock stage upside reversal find support day line monday car dealer report earning feb lithia be expect earn share year
402,EW,rival asbury automotive group abg be also flat base entry
403,EW,downside stratasys ssys be still whopping reaction late monday disappointing preliminary fiscal result outlook piper jaffray brean capital downgrade share tuesday stock be still higher tuesday midday gain have fade trim gain nasdaq pare advance just dow jone industrial average stay session high gain caterpillar cat chevron cvx exxon mobil xom be biggest winner blue chip index volume be run higher board stock market today lead stock linkedin lnkd rise goldman sachs put share conviction buy list raise price target professional networking operator report earning thursday analyst poll thomson reuter see profit rise cent share linkedin be base buy point lithia motor lad tack fast trade stock stage upside reversal find support day line monday car dealer report earning feb lithia be expect earn share year rival asbury automotive group abg be also flat base entry downside stratasys ssys be still whopping reaction late monday disappointing preliminary fiscal result outlook piper jaffray brean capital downgrade share tuesday
404,EW,stock future trade lower steady ahead monday open oil price federal reserve test investor confidence dow future trade point fair market value future hung point line nasdaq future be mild point small cap be pressure russell future fall point stock market today open clear caution flag ahead wednesday policy decision federal reserve nasdaq drop last week slice support day day move average crumple also violate level support mean bet be market direction next day uncertainty oil price continue diving early monday west texas intermediate more barrel lowest mark more decade brent crude drop nearly weakest level benchmark have logged steady loss dec organization petroleum export country meeting group fail agree production quota permit member country continue current production level oil price slump be dupont dd apple aapl drag dow open dupont dip more apple trim premarket loss dive morgan stanley cut price target cite pressure international iphone price due oversupply outside china apple end friday well august low struggle retake week move average month consolidation jarden jah jump newell rubbermaid nwl slip more newell say pay cash stock deal acquire boca raton fla base maker sunbeam iron marmot outdoor gear crock pot cookware newell management say combination be target annualize cost saving be immediately positive earning close jarden rise last week merger speculation move stock right side month consolidation china base maker solar electrical component trina solar tsl spiked news report company have receive offer be take private share shanghai xingsheng equity investment management offer be friday close price edward lifescience ew be confuse brokerage datum collection system premarket trade prepared go live stock split today open be company first stock split overseas europe stock come lows midday london ftse reversed early loss wrestle narrowly positive territory frankfurt dax be loss cac paris ease loss asia market be widely mixed hong kong hang seng index dip shanghai composite jump nikkei tokyo stumble loss
405,EW,ahead thanksgiving day stock inched higher wednesday quiet volume dow jone industrial average nasdaq rise tick fraction volume nyse nasdaq be tracking well tuesday level stock market today pfizer pfe be best performer dow rise recently announce plan buy allergan agn economic news personal income rise october line estimate spending come bit short rise commerce department also say durable good order jump october double expectation exclude transportation order rise tad better expect earning news pc printer manufacturer hp hpq tumble report sluggish earning issue weak guidance hewlett packard enterprise hpe spun hp earlier month rise nearly report solid result late tuesday ibd euronet worldwide eeft be get support week move average recent share rise edward lifescience ew garner more strength buy point share rise nearly new york mercantile exchange wti crude oil future fall cent barrel stock market be close thursday thanksgiving be open half session friday close et follow ken shreve twitter ibd_kshreve facebook
406,EW,championship boxer mutual fund manager outperform extend period know roll market punch attack open portfolio manager mainstay large cap growth fund have demonstrated skill recently cope market summer volatility add portfolio strategically upgrade portfolio great growth company price correct say co manager justin kelly subadvisor capital management fund have generate average annual return past year vs large cap growth peer track morningstar year go tuesday fund gain vs peer fund carry ibd month performance rating third quarter stock market nose dive pull regeneron regn mainstay manager see attractive entry point fund invest type growth stock long term sustainable earning growth quality cyclical earning growth industry rapid growth fund buy share regeneron have lead treatment retinal eye disease compelling pipeline include new cholesterol drug kelly say investor follow ibd slim method stock show entry point regeneron have ibd composite rating powerful scale more health stocksin fund start stake edward lifescience ew product treat advanced cardiovascular disorder kelly cite edward leadership transcatheter heart valf end market be bigger most investor believe propel earning growth street expect say stock have composite rating be trading little cup handle entry bristol myer squibb bmy be health care name fund begin position kelly like company new lung cancer drug opdivo company blood thinner plavix be world second best selling drug also active other sector mainstay fund boost overweight consumer discretionary sector fund start position armour ua kelly say company continue take market share grow athletic leisurewear market stock advanced have trend lower then slip week move average dick sporting good dks weak hurt armour accord piper jaffray dick also issue weak outlook tuesday stock market news help send armour day mainstay manager kelly clark patrick burton add stake amazon amzn home depot hd kelly like amazon web service business be mushrooming say amazon have comp rating be extend past buy point quarters earning share decline amazon ep rise past stanzas home depot comp rating be entry point benefit demand home improvement company report jump ep tuesday
407,EW,stock give further ground early afternoon trading earning continue take center stage fall nasdaq slide dow jone industrial average give volume be tracking higher board vs same time monday manage care chipmaker biotechs be biggest gainer stock market today transport energy consumer electronic retailer lag reynold american rai gap fall brisk trade stock be still time high extend past buy point clear late last month camel cigarette maker report adjust ep rise cent meet view sale rise forecast alibaba baba more halved early gain hold highest level month chinese commerce giant report profit sale beat view mobile transaction revenue surge last year yahoo yhoo own stake alibaba be search giant plan spin stake shareholder end year apple aapl early pare gain iphone maker be slate give quarterly report close analyst expect fiscal earning rise share higher sale walgreen boot alliance wba report earning wednesday open jump heavy volume drugstore chain be close striking deal buy rival rite aid rad announcement expect wednesday accord wall street journal rite aid share soar ibd cal maine food calm lgi home lgih be biggest loser respectively edward lifescience ew cavium cavm more lead upside follow nancy gondo twitter ibd_ngondo
408,EW,stock be trading slightly lower go noon hour tuesday third quarter earning report come hot heavy nasdaq fall slightly drop dow jone industrial average be stock market today volume track higher nyse nasdaq
409,EW,jetblue airway jblu fall give day move average destroy double bottom base make company report earning cent share vs estimate cent revenue come vs estimate company say have benefit lower fuel price
410,EW,integrate device technology idti break cup base big volume report earning gap be trading higher have be early session
411,EW,medical drug biotech stock be best perform industry group manage care be top gain lead magellan health mgln solid volume better expect earning report
412,EW,ibd stock best performer be edward lifescience ew also produce cheery earning report be nearly attempt ragged cup handle base
413,EW,cadence design system cdns ibd name gain report earning breaking base have be morning
414,EW,worst performer ibd be egg producer cal maine food calm back drop monday stock have break cup handle base stock be trading slightly lower go noon hour tuesday third quarter earning report come hot heavy nasdaq fall slightly drop dow jone industrial average be stock market today volume track higher nyse nasdaq jetblue airway jblu fall give day move average destroy double bottom base make company report earning cent share vs estimate cent revenue come vs estimate company say have benefit lower fuel price integrate device technology idti break cup base big volume report earning gap be trading higher have be early session medical drug biotech stock be best perform industry group manage care be top gain lead magellan health mgln solid volume better expect earning report ibd stock best performer be edward lifescience ew also produce cheery earning report be nearly attempt ragged cup handle base cadence design system cdns ibd name gain report earning breaking base have be morning worst performer ibd be egg producer cal maine food calm back drop monday stock have break cup handle base
415,EW,pandora medium hold own likely boost user base too even face competition apple aapl music accord report macquarie capital monday bid confidence send pandora stock rise macquarie analyst amy yong say research note monday impact apple
416,EW,stock be modestly lower late monday even nasdaq turn red stay green much day dow jone industrial average be respectively tech heavy nasdaq slip turnover be run sharply lower major exchange stock market today
417,EW,lead stock cirrus logic crus widen loss nearly stock breach day day move average medium report peg cirrus weakness disappointing quarterly result fellow apple aapl supplier dialog semiconductor cirrus report fiscal earning wednesday close other apple supplier be weak monday
418,EW,cal maine food calm drop fast trade putt close day move average intraday cal maine fall nearly buy point handle go bad investor cut loss maximum
419,EW,luxoft lxft slump almost fast trade erase gain prior session intraday stock fall buy point flat base clear friday
420,EW,lendingtree tree ease session high be still follow morning solid result open online lender post earning cent share year earlier revenue jump fourth straight period acceleration
421,EW,broadcom brcm cadence design system cdns edward lifescience ew be few notable company report earning close
422,EW,follow vincent mao twitter ibd_vmao stock be modestly lower late monday even nasdaq turn red stay green much day dow jone industrial average be respectively tech heavy nasdaq slip turnover be run sharply lower major exchange stock market today lead stock cirrus logic crus widen loss nearly stock breach day day move average medium report peg cirrus weakness disappointing quarterly result fellow apple aapl supplier dialog semiconductor cirrus report fiscal earning wednesday close other apple supplier be weak monday cal maine food calm drop fast trade putt close day move average intraday cal maine fall nearly buy point handle go bad investor cut loss maximum luxoft lxft slump almost fast trade erase gain prior session intraday stock fall buy point flat base clear friday lendingtree tree ease session high be still follow morning solid result open online lender post earning cent share year earlier revenue jump fourth straight period acceleration broadcom brcm cadence design system cdns edward lifescience ew be few notable company report earning close follow vincent mao twitter ibd_vmao
423,EW,new stock market uptrend underway edward lifescience ew be try complete early stage base global leader heart valve technology remain relatively immune recent maul top medical stock hillary clinton send tweet last month accuse big pharma price gouge biotech drug maker stock gilead science gild biogen biib
424,EW,stock close slightly higher thursday gain energy stock outweighed decline tech bellwether such cisco system csco nasdaq rise dow jone industrial average be more small cap be outperform russell rebound dip wednesday volume nyse nasdaq be run wednesday level stock market today oil driller producer lead gain front month west texas intermediate crude oil future jump barrel oil be rise ahead meeting top petroleum producer next month result output cut oil producer denbury resource dnr lead jump wpx energy wpx rise clear buy point heavy volume hit new week high other hand cisco fall give cautious earning guidance latewednesday computer networking giant also say cut job total effort boost competitiveness cisco receive composite rating maximum ibd stock checkup stock relative price strength rating be drag overall composite rating however buy point long consolidation remain intact cisco share be also appear gain support once be prior level upside price resistance ibd acacia communication acia rally new high heavy volume maker high speed interconnect module cloud infrastructure have soar nearly past week wake blowout earning report ibd take heavy volume be important stock clear buy point sign institutional investor be move click here investor corner column learn more importance stock price volume movement also acacia communication news include strong gain earning sale ibd first cover company detail industry theme column accessible research section investor com
425,EW,medical stock particularly drugmaker play key role buoy challenged market first half year year date tuesday ibd medical sector industry group show average loss biotechs ethical drugmaker be hardest respectively have left medical group rank
426,EW,here investing action plan need know investor come week federal reserve annual symposium feature remark fed chairwoman janet yellen well other central banker ulta beauty ulta medtronic mdt lead group lower profile highly rate company report earning share facebook fb nike nke
427,EW,country best perform fund past month have be build portfolio market lead stock variety sector include build metal medical retail build stock include aos fortune brand home security fbhs lennox international lii draw industry dw martin marietta material mlm masco mas latest report period other industrial stock perform well include metal fabricator insteel industry iiin gibraltar industry rock handful medical issue also see heavy buy best perform fund include vascular solution vasc edward lifescience ew align technology algn ligand pharmaceutical lgnd market outlook have be confirm uptrend june click here see list new buy top mutual fundsretailer ulta beauty ulta contour way top fund portfolio top fund have add cosmetic fragrance store investing estimate american fund growth fund america recently add share latest report period manager lead fund also shop share discount retailer ollie bargain outlet olli other retailer worth shopping include burlington store burl pool pool ibd find top perform fund add ollie bargain outlet investing estimate pioneer select midcap growth add share newly issue company run chain bargain warehouse style store buy good stuff cheap harrisburg base firm have store selling closeout excess inventory salvage merchandise everything buy ollie have day hard time guarantee customer aren happy purchase return day purchase full refund sale receipt ollie stock clear buy point double bottom base aug have straddle level then bargain store have be grow steadily rac solid double digit earning growth past quarters same period revenue growth be more subdue slightly range other notable stock new buy list act well include gun maker wesson swhc hawaiian holding edward lifescience ew stock be currently etching handle part cup handle base pattern make sure put stock watch list nation lead fund have be take profit online retailer giant amazon com amzn computer software firm symantec symc electronic art ea aspen technology azpn be also sell top perform fund latest report period top fund also unload beverage company monster mnst constellation brand stz monster report second quarter earning result cent miss view cent revenue beat expectation click here see list latest sell top mutual fund
428,EW,better expect earning apple aapl result strong show nasdaq wednesday action nyse index be quieter new high list once again show nice breadth leaderboard name edward lifescience ew jump late tuesday heart valve maker report strong second quarter beat raise third quarter full year guidance edward be
429,EW,major stock index be mixed late trading wednesday apple aapl federal reserve meeting dominate headline flow nasdaq outperformed rise help strong earning apple earning beat lower expectation even total revenue slip result be help part better expect iphone sale share apple be lose less dow jone industrial average turn positive add volume nyse nasdaq be tracking higher tuesday level stock market today fed statement et didn move market much policymaker keep interest rate unchanged left door open rate hike september meeting mining stock outperformed again barrick gold abx anglogold ashanti buenaventura bvn show gain apiece other market outperformer include drive assistance technology firm mobileye mbly share rebound crash tuesday earning well news dissolve relationship tesla tsla citigroup defend mobileye tuesday say tesla business be not material mobilieye financial result big gainer ibd include edward lifescience ew share jump late tuesday heart valve maker report strong second quarter beat raise third quarter full year guidance edward be now extend handle entry double bottom base ibd take top fundamental bullish chart edward be also member leaderboard investor com first joined list elite growth stock feb then rejoin list july leaderboard name facebook fb add ahead second quarter earning report close volume have dry facebook recent day trade buy point consensus estimate call profit cent share year earlier sale economic news order durable good fall june biggest drop almost year consensus estimate decline ex transportation order fall expectation gain oil price fall energy information administration report unexpected build crude inventory barrel west texas intermediate crude oil september delivery be nearly barrel
430,EW,techs lead market open bell wednesday heavyweight earning report stir trading nasdaq rise dow industrial climb add action start bell feel strong impact apple aapl follow fiscal third quarter earning report wednesday morning earning roster include report boee ba coca cola ko glaxosmithkline gsk other market recent uptrend slow crawl trading wednesday afternoon policy announcement federal open market committee be key watch change policy be expect fed view economy potential rate hike september influence market order durable good fall june commerce department estimate deeper consensus forecast dip department also revise estimate lower decline order transportation order slip vs economist target increase national association realtor report pending home sale datum june et weekly oil inventory stat be due energy information administration et fed policy announcement be set et apple climb fiscal third quarter earning report show iphone sale decline less expect edward lifescience ew rumble nearly higher tuesday close heart device maker report strong second quarter beat raise third quarter full year guidance edward end tuesday session buy range buy point double bottom base boee climb earning decline revenue rise more analyst expect malaysia airline also announce order max jet list price value remote connectivity software brand logmein logm sprung higher report strong second quarter result announce deal merge citrix system ctxs virtual meeting unit goto company value deal citrix system share slip switzerland base garmin grmn rise top analyst expectation raise full year guidance coca cola drop report healthy second quarter result early wednesday lower full year earning guidance consensus view akamai technology akam veer lower second quarter earning meet expectation revenue stop short consensus target akamai management warn margin narrow due pricing pressure strategy shift networking client such apple facebook fb microblogging site operator twitter twtr tumble twitter report mixed second quarter result offer weak third quarter guidance close trade tuesday crude oil future be unevenly lower west texas intermediate fraction barrel brent crude drop gold edge less ounce dollar be mixed vs pound yen outpaced rise euro year treasury yield ease basis point china market book sharply mixed session japan tokyo nikkei rebound report pending stimulus package european market gain ground cac paris lead region afternoon trade
431,EW,medical device giant medtronic mdt edward lifescience ew offer compete set datum artificial heart valf weekend stock be morning trading stock market today american college cardiology meeting washington medtronic report patient high risk death open heart surgery have significantly higher survival
432,EW,stock jump start gate monday accord sort eurozone greece brushed global market bit optimism
433,EW,nasdaq pull early action dow jone industrial average climb rise volume be mixed early reading show trade nasdaq nyse compare action same time friday
434,EW,stock market today open note eurozone creditor strike deal greece not open door bailout fund deal require greece government put place wednesday pension reform tax increase be refuse greek voter july referendum deal also make available immediately shore greece falter bank require government privatize portfolio asset most proceed go repay debt recapitalize weaken bank greece bank stock market remain close prime minister alexis tsipra go home attempt convince government go plan order hang euro currency bloc greece face debt deadline european central bank july
435,EW,europe top index have ease slightly early high cac paris frankfurt dax hold gain dollar climb vs euro
436,EW,stock airline early lead industry possibly owing dive oil price american airline group aal leap delta air line dal unite continental holding ual southwest airline luv gain apiece
437,EW,gps device leader garmin grmn wynn resort wynn climb run head nasdaq
438,EW,head marathon petroleum mpc turn gain start trade marathon pipeline master limit partnership mplx mplx announce acquire mlp markwest energy partner mwe deal value mplx share dive markwest jump
439,EW,newlink genetic nlnk pop lead ibd list stock be low april high climb right side month consolidation
440,EW,very few ibd stock post early decline ambarella amba taser international tasr be stock jump start gate monday accord sort eurozone greece brushed global market bit optimism nasdaq pull early action dow jone industrial average climb rise volume be mixed early reading show trade nasdaq nyse compare action same time friday stock market today open note eurozone creditor strike deal greece not open door bailout fund deal require greece government put place wednesday pension reform tax increase be refuse greek voter july referendum deal also make available immediately shore greece falter bank require government privatize portfolio asset most proceed go repay debt recapitalize weaken bank greece bank stock market remain close prime minister alexis tsipra go home attempt convince government go plan order hang euro currency bloc greece face debt deadline european central bank july europe top index have ease slightly early high cac paris frankfurt dax hold gain dollar climb vs euro stock airline early lead industry possibly owing dive oil price american airline group aal leap delta air line dal unite continental holding ual southwest airline luv gain apiece gps device leader garmin grmn wynn resort wynn climb run head nasdaq head marathon petroleum mpc turn gain start trade marathon pipeline master limit partnership mplx mplx announce acquire mlp markwest energy partner mwe deal value mplx share dive markwest jump newlink genetic nlnk pop lead ibd list stock be low april high climb right side month consolidation very few ibd stock post early decline ambarella amba taser international tasr be
441,EW,fda approve medtronic mdt corevalve artificial heart valve friday well ahead april deadline send share competitor edward lifescience ew tumble stock market today
442,EW,corevalve be transcatheter aortic valve approve treat aortic stenosis patient too frail open heart surgery similar edward sapien have market be approve share market europe edward have sue medtronic patent infringement result jury award earlier week win stop launch compete product edward win permanent injunction
443,EW,approval earlier expect share loss ew likely occur sooner expect write analyst glenn novarro rbc capital market research note also write corevalve be smaller current sapien model give competitive advantage edward own smaller model sapien xt be approve say be few month
444,EW,late morning announcement medtronic stock be fraction be trading hit year high jan edward stock be recover year low hit dec be afternoon trading friday
445,EW,follow amy reeve twitter ibd_areeve fda approve medtronic mdt corevalve artificial heart valve friday well ahead april deadline send share competitor edward lifescience ew tumble stock market today corevalve be transcatheter aortic valve approve treat aortic stenosis patient too frail open heart surgery similar edward sapien have market be approve share market europe edward have sue medtronic patent infringement result jury award earlier week win stop launch compete product edward win permanent injunction approval earlier expect share loss ew likely occur sooner expect write analyst glenn novarro rbc capital market research note also write corevalve be smaller current sapien model give competitive advantage edward own smaller model sapien xt be approve say be few month late morning announcement medtronic stock be fraction be trading hit year high jan edward stock be recover year low hit dec be afternoon trading friday follow amy reeve twitter ibd_areeve
446,EW,stock trim loss open lower weak economic datum china nasdaq be have be much respectively dow jone industrial average slip just volume be run mixed stock market today nyse trading be tracking higher nasdaq volume be run lower
447,EW,lead stock zoe kitchen zoe fall putt back day move average regain monday cup handle base buy point be still place zoe accumulation distribution rating have sharply improve hit late august
448,EW,noah holding noah drop more rise straight session stock be build right side deep base be biggest percentage decliner ibd
449,EW,elsewhere edward lifescience ew cognizant technology solution ctsh netease nte be
450,EW,toll bro tol rise fraction seesaw trading morgan stanley upgrade stock overweight equal weight hike price target
451,EW,follow vincent mao twitter ibd_vmao stock trim loss open lower weak economic datum china nasdaq be have be much respectively dow jone industrial average slip just volume be run mixed stock market today nyse trading be tracking higher nasdaq volume be run lower lead stock zoe kitchen zoe fall putt back day move average regain monday cup handle base buy point be still place zoe accumulation distribution rating have sharply improve hit late august noah holding noah drop more rise straight session stock be build right side deep base be biggest percentage decliner ibd elsewhere edward lifescience ew cognizant technology solution ctsh netease nte be toll bro tol rise fraction seesaw trading morgan stanley upgrade stock overweight equal weight hike price target follow vincent mao twitter ibd_vmao
452,EW,maybe tell best perform stock week ibd list be maker device prevent heart attack edward lifescience ew bolt higher past week rise straight session decisively regain week move average first time early august gain put upper half
453,EW,stock bounce back big loss end big gain friday also capped wild week gain nasdaq jump rally weak september job report have nasdaq well excess friday worst level turnover end higher major exchange stock market today accord preliminary datum
454,EW,week rally nasdaq rise
455,EW,top rate stock thinly trade autobytel abtl bolt regain day line more twice average trade company announce thursday buy autoweb automotive search firm stock warrant transaction raise guidance stock be build double bottom base buy point
456,EW,dave buster entertainment play rally reverse higher stock have already gain thursday pricing share offer dave buster be recently featured stock spotlight
457,EW,edward lifescience ew jump nearly be biggest percentage gainer ibd build right side consolidation buy point stock relative strength line have hit new high ahead price
458,EW,google googl rise oppenheimer upgrade share outperform market perform boost price target close company reorganization alphabet hold company take effect start monday class share continue trade goog ticker class share retain googl symbol
459,EW,report service side economy institute supply ism markit be monday morning
460,EW,follow vincent mao twitter ibd_vmao stock bounce back big loss end big gain friday also capped wild week gain nasdaq jump rally weak september job report have nasdaq well excess friday worst level turnover end higher major exchange stock market today accord preliminary datum week rally nasdaq rise top rate stock thinly trade autobytel abtl bolt regain day line more twice average trade company announce thursday buy autoweb automotive search firm stock warrant transaction raise guidance stock be build double bottom base buy point dave buster entertainment play rally reverse higher stock have already gain thursday pricing share offer dave buster be recently featured stock spotlight edward lifescience ew jump nearly be biggest percentage gainer ibd build right side consolidation buy point stock relative strength line have hit new high ahead price google googl rise oppenheimer upgrade share outperform market perform boost price target close company reorganization alphabet hold company take effect start monday class share continue trade goog ticker class share retain googl symbol report service side economy institute supply ism markit be monday morning follow vincent mao twitter ibd_vmao
461,EW,sector rotation be pretty much do deal big cap be guide last spring summer medical sector be provide third half name big cap summer leader chart now look sad biogen biib be high illumina ilmn be high plunge hour preannounce revenue full year guidance miss view regeneron regn be high tuesday big cap only medical stock make list heart valve maker edward lifescience ew be list couple breakout offer meager gain march yielded gain session then stock consolidated july yielded gain week stock consolidated small gain do not give individual investor much chance make money edward be now form new consolidation be good news monday ibd medical sector be sector be top most year september medical sector be finished leader have replace medical stock investor just well ask hasn replace medical stock big cap leadership be now more diverse have be year stock be many sector include retail software tobacco leisure many be early stage pattern thank reset breakout didn advance more reset occur stock low undercut low previous base reset count first second stage base have better shot success later stage base follow big cap stock feature first stage basis software sector play salesforce com crm be work first stage consolidation stock have regain day day line be only new high breakout year lead gain stock hasn post gain august november retail sector stock chipotle grill cmg be work first stage pattern stock be high be battle retake day line breakout year lead gain most recently tobacco sector stock reynold american rai clear buy point monday strong volume be miss valid usually deliver volume spike least average strong volume be mark institutional activity food meat stock hormel hrl rushed past buy point monday volume be average stock be defensive seldom deliver big gain breakout hormel last big gain be pop november
462,EW,merit medical system break past buy point cup handle pattern monday share surge volume be average disappointing however sometimes heavy volume come stock day
463,EW,stock base pattern run week correct show net accumulation share be still buy range
464,EW,merit medical mmsi develop manufacture disposable medical device interventional diagnostic procedure cardiology radiology endoscopy south jordan utah base company be founder distribute product worldwide
465,EW,earning growth have accelerate straight quarters most recent period sale growth have decelerate modestly same period sale rise just
466,EW,third quarter result be schedule be report oct market close analyst be forecasting dip earning share gain sale
467,EW,fund sponsorship merit have rise past quarters well regard oppenheimer discovery fund own share most recent report period
468,EW,fundamental concern stock include sluggish annual growth rate return equity just most big winning stock past have roe greater
469,EW,merit be part highly rank medical product group be well represent monday ibd edward lifescience ew inogen ingn cambrex cbm make list elite growth stock abiom abmd be highly rate stock group
470,EW,merit medical be first stock break market follow friday confirm new uptrend investor look start slowly ease back market carefully watch progress early breakout merit medical system break past buy point cup handle pattern monday share surge volume be average disappointing however sometimes heavy volume come stock day stock base pattern run week correct show net accumulation share be still buy range merit medical mmsi develop manufacture disposable medical device interventional diagnostic procedure cardiology radiology endoscopy south jordan utah base company be founder distribute product worldwide earning growth have accelerate straight quarters most recent period sale growth have decelerate modestly same period sale rise just third quarter result be schedule be report oct market close analyst be forecasting dip earning share gain sale fund sponsorship merit have rise past quarters well regard oppenheimer discovery fund own share most recent report period fundamental concern stock include sluggish annual growth rate return equity just most big winning stock past have roe greater merit be part highly rank medical product group be well represent monday ibd edward lifescience ew inogen ingn cambrex cbm make list elite growth stock abiom abmd be highly rate stock group merit medical be first stock break market follow friday confirm new uptrend investor look start slowly ease back market carefully watch progress early breakout
471,EW,health care etfs pump big gain tuesday slew solid drugmaker earning technology focuse peer lag get boost tomorrow apple aapl stock advanced close better expect earning revenue sluggish day stock health etfs rise strong report pfizer pfe merck mrk bristol myer squibb bmy new york base pfizer gap earning beat new jersey peer merck rise more report profit jump latest quarter boost annual outlook medical equipment company edward lifescience ew grab gain beat top bottom line spdr health care xlv etf tracking sector rise stock market today spdr etf peer carve sector post loss tuesday energy stock lead decline xlv largest broad base health care etf allocate roughly asset combination stock pfizer merck bristol myer etf hold stock gilead science gild xlv third largest stock hold fall hour report robust profit raise full year outlook biotech giant have be rally straight week powershare dynamic pharmaceutical pjp pop drugmaker advanced etf hold stock allocate asset bristol myer pfizer merck pjp be top perform pharmaceutical etf year date rise vs xlv meanwhile alibaba baba leap china internet giant easily clear analyst expectation fiscal earning revenue mobile revenue surge gain fail give much boost etfs big stake stock kraneshare csi china internet kweb renaissance ipo ipo eke fractional gain tuesday alibaba be hold kweb asset hold ipo asset etfs hold safe haven asset such bond gold climb marginally tuesday listless stock market here look benchmark exchange trade fund tracking various asset class perform today follow daily etf market action be key successful investing bellwether etfs spdr spy rs powershare qqq qqq rs spdr dow jone industrial average dium rs ishare core mid cap ijh rs ishare russell iwm rs ishare msci eafe efa rs vanguard ftse emerge market vwo rs spdr gold share gld rs ishare core aggregate bond agg rs powershare db dollar bullish uup rs follow aparna narayanan twitter ibd_anarayanan
472,EW,stock take moderate loss early action tuesday wave mixed earning report weak economic news drop dow jone industrial average nasdaq backed apiece
473,EW,volume be sharply mixed rise nyse fall nasdaq relative trade same time monday
474,EW,stock market today feel early drag commerce department weaker expect september durable good report
475,EW,case shiller city composite home price index be bit more positive rise august be slip july line expectation
476,EW,preliminary read october service sector activity researcher markit put purchasing manager index september disappointing forecast
477,EW,consumer sentiment also pull back october conference board consumer confidence index read vs revise tally september far estimate
478,EW,stock alibaba group baba broad jump join rank big tech name post solid earning beat china base diversify internet play report ep gain rise revenue fiscal easily top consensus forecast mobile revenue rise cloud compute internet infrastructure revenue rise
479,EW,company also announce security exchange commission give notice conclude inquiry enforcement action be recommend issue revolve interaction regulator china
480,EW,alibaba heavy volume gain send share back day move average month consolidation
481,EW,yahoo yhoo pop pull stake alibaba
482,EW,coach coh bag gain sneak past analyst consensus earning expectation meeting revenue forecast
483,EW,edward lifescience ew jump more top revenue earning expectation third quarter stock remain just buy point cup handle base
484,EW,pfizer pfe grab gain lead dow new york base drugmaker report earning gain vs expectation loss revenue fall less expect strong volume gain send share past buy point cup handle base pfizer peer merck mrk rank second dow gain nearly strong third quarter report
485,EW,coal miner consol energy cnx tank report adjust loss cent share vs expectation cent loss
486,EW,leader cadence design system cdns rise step early lead ibd stock developer automate circuit design software report earning revenue forecast give full year guidance consensus view gain massive trade trigger break past buy point cup handle base
487,EW,cal maine food calm take group largest loss almost send stock week move average heavy trade buy point trigger sell signal stock take moderate loss early action tuesday wave mixed earning report weak economic news drop dow jone industrial average nasdaq backed apiece volume be sharply mixed rise nyse fall nasdaq relative trade same time monday stock market today feel early drag commerce department weaker expect september durable good report case shiller city composite home price index be bit more positive rise august be slip july line expectation preliminary read october service sector activity researcher markit put purchasing manager index september disappointing forecast consumer sentiment also pull back october conference board consumer confidence index read vs revise tally september far estimate stock alibaba group baba broad jump join rank big tech name post solid earning beat china base diversify internet play report ep gain rise revenue fiscal easily top consensus forecast mobile revenue rise cloud compute internet infrastructure revenue rise company also announce security exchange commission give notice conclude inquiry enforcement action be recommend issue revolve interaction regulator china alibaba heavy volume gain send share back day move average month consolidation yahoo yhoo pop pull stake alibaba coach coh bag gain sneak past analyst consensus earning expectation meeting revenue forecast edward lifescience ew jump more top revenue earning expectation third quarter stock remain just buy point cup handle base pfizer pfe grab gain lead dow new york base drugmaker report earning gain vs expectation loss revenue fall less expect strong volume gain send share past buy point cup handle base pfizer peer merck mrk rank second dow gain nearly strong third quarter report coal miner consol energy cnx tank report adjust loss cent share vs expectation cent loss leader cadence design system cdns rise step early lead ibd stock developer automate circuit design software report earning revenue forecast give full year guidance consensus view gain massive trade trigger break past buy point cup handle base cal maine food calm take group largest loss almost send stock week move average heavy trade buy point trigger sell signal
488,EW,cardiac device maker edward lifescience ew beat analyst estimate raise guidance late monday send stock more hour trading edward earning totale share year earlier quarter beating analyst consensus cent accord thomson reuter revenue rise consensus
489,EW,apple aapl twitter twtr edward lifescience ew panera bread pnra report quarterly earning close tuesday estimate analyst expect apple report drop earning share time item most recent quarter be second decline row revenue fiscal third quarter be forecast fall year year lower iphone sale result apple earn share revenue fall apple sell iphone handset revenue apple give relatively upbeat fiscal guidance vs view apple usually offer conservative outlook apple share jump early hour action stock close stock market today fall back day move average estimate analyst consensus be short messaging service twitter report hike ep cent increase revenue result twitter report adjust ep be cent revenue be twitter add monthly user little higher expect twitter see revenue vs view twitter stock crash early hour action retreat close bell estimate medical device maker edward lifescience be see record rise ep cent jump sale result edward lifescience earn cent adjust revenue edward see ep cent vs analyst view cent analyst see edward report positive study latest transcatheter heart valve thv product favorable jury verdict be award damage edward lifescience jump nearly late trading close estimate operator nearly fresh bakery sandwich restaurant be forecast report increase diluted ep revenue be expect edge result panera earn share ex item revenue be company own same store sale rise panera bread see full year adjust ep analyst have expect panera stock rise initial hour action close ibd take panera bread have form flat base buy point earlier form cup handle shape base fail break report earning late tuesday more information panera check ibd stock checkup panera earning come heel report tuesday stifel nicolaus cut rating restaurant group bearish bullish stifel cut rating panera chipotle grill cmg other sell say economy likely fall recession next month buffalo wild wing bwld be also slate report earning late tuesday be upscale pizza beer chain bj restaurant bjri buffalo wild wing earn share cent view sale rise buffalo wild see ep roughly line view bj earn cent share vs estimate cent revenue be also estimate comp fall buffalo wild wing rise initial hour action close bj stock be indicated lower close
490,EW,key stock index make mild move en route dull finish tuesday stock swung sharply follow quarterly result armour be case point go high reverse sharp loss sport apparel firm report first net loss more year nasdaq composite inched nearly edge fractionally higher dow jone industrial average finished lower volume grow sharply exchange stock market today accord preliminary datum armour ua say lose cent share second quarter adjust profit penny share meet wall street consensus view sale jump continue firm record solid double digit top line growth prior quarters sale grow respective strong footwear sale help rise back hot demand company stephen curry endorse basketball shoe note earlier ibd story armour want bolster prestige new flagship store space formerly occupied fao schwarz fame manhattan toy store close year be however armour become stock market leader have be digest long term gain top september last year tuesday drop send stock back day move average useful gauge long term price trend line have be slope lower armour get middling composite rating ibd stock checkup investor likely have more success growth stock be breaking show composite rating maximum higher meanwhile edward lifescience ew jump hour report bullish result ibd leaderboard member earn cent share adjust basis well ahead consensus view cent revenue rise sharply beating consensus view jump stretched edward trend accelerate top line growth third straight quarter gain prior period respectively edward end tuesday regular session nearly just past double bottom handle entry small medium size business expert ultimate software ulti report gaap profit cent meeting consensus estimate revenue rise stock fall regular session extend recent pivot point earlier session jetblue jblu gain triple average volume airline post jump earning cent share wall street view revenue gain stock reclaim day move average be still fly downward slant day line stock have lot lose ground recover get proper buy range dow jone transport average climb more tuesday ibd name lgi home lgih continue roll higher rise heavy trade now advanced nearly past new handle entry point homebuilder rally back better expect new home sale june annualize rate sharply past econoday forecast lgi have increase earning share respective vs year level past quarters wall street see earning cent share slowdown prior quarters increase still meet minimum gain require ibd slim investment paradigm see monday big picture column market pulse table market be currently confirm uptrend mean investor have higher probability make money buy breakout high quality growth stock proper buy point market follow june be stock be best class industry group term profit growth margin sale return equity institutional fund sponsorship relative price strength check investor com exclusive tool ibd stock checkup
491,EW,many big cap leader be extend well past buy range name today list be set potential move remain striking distance recent edward lifescience ew be work handle double bottom base buy point stock july clear earlier entry
492,EW,ishare medical device etf ihi be year top etf leader ride best part mixed health care sector year medical sector have diverged industry fare much better other biotechs other drugmaker be roughly ibd medical product equipment industry group be only diversify medical company be do quite well health care much outperformance medical device owe superior result top manufacturer innovation have play key role ignite industry leader stock etf medtronic mdt be largest hold more portfolio share have climb much buy point april stock have perform decently fact earning have be basically flat quarters outlook be improve analyst expect profit rise fiscal year end april next year investor day june medtronic forecast mid single digit revenue growth develop product pipeline draw diversify market edward lifescience ew be stock have shoulder etf advance share be time high main move year be april company announce sapien transcatheter aortic valve replacement be show reduce death heart attack patient moderate risk open heart surgery share soar news medtronic corevalve compete edward heart valve replacement patient not able have open heart surgery analyst canaccord genuity remain bullish stock follow earning report say dominate market transcatheter aortic valve replacement show potential market expansion share stryker syk have broadest range orthopedic product peer have climb much year fall sharply july earning report be clear explanation slide other softness emerge market other key contributor ishare medical device be thermo fisher scientific tmo make equipment medical research zimmer biomet zbh just post strongest quarter sale growth nearly decade becton dickinson bdx have be trend higher fall sharply thursday cut full year sale forecast cite currency headwind etf be extend april pullback day move average june remain buy point week tight pattern form july ibd etf leader index show performance model portfolio exchange trade fund be lead overall market computer algorithm select etfs base relative strength other objective performance rating periodic adjustment market trend condition universe etfs be select include fund list
493,EW,many top rate stock have rise buy range market uptrend number ibd name be still buy range shape basis concrete uscr have retake day move average work base base pattern potential buy point maker ready mix concrete other product
494,EW,be huge week earning apple aapl facebook fb alphabet googl amazon amzn beat forecast mcdonald mcd ford motor indicated weakness demand tech step include verizon vz deal buy yahoo yhoo core asset economy be grow lot slower expect oil price be near barrel nasdaq composite rise best level early december fuel strong earning apple facebook alphabet amazon hit new record high friday close week fractionally dow jone industrial average fall also snap week uptrend weaker oil price earning report hit energy sector federal reserve statement term economic risk have diminish seem have little impact investor iphone maker earn share year year sale be apple second straight decline earning revenue iphone sale be still better expect apple current quarter revenue target be midpoint wall street consensus iphone be expect be release mid september apple stock rise week just retake day line amazon ep shatter estimate revenue rise amazon web service continue boom revenue guidance also be strong operate income be light amazon stock rise week hit record intraday friday ibd take amazon be leaderboard stock hit new high growth boom only rate ibd retail internet group see go ibd stock checkup facebook report revenue maintain streak double digit growth go back more year ep jump cent shatter consensus cent be fourth straight quarter accelerate earning growth facebook stock rise hit record high still range buy point twitter twtr report ep top view revenue fall short revenue guidance also miss estimate twitter stock fall close week day line bounce back miss alphabet report ep revenue blow past expectation google parent earning item rise share total revenue climb google size still deliver growth say mark mahaney analyst rbc capital be now straight quarter ish year year revenue growth do mention acceleration say report alphabet stock rise close just entry point rise high ford motor send signal long auto industry bull market be auto sale stall higher incentive hit profit margin automaker earning share revenue rise ep growth be weakest quarters sale growth be slimmest quarters ford cite downside risk global growth offer further evidence slow auto part maker lear lea miss sale warn revenue gentherm thrm earning miss volkswagen vlkay sale edge net profit plunge vs year early struggle recover emission test cheating scandal involve diesel engine model ford stock fall federal reserve left interest rate unchanged day policy meeting expect policymaker say term economic risk have diminish suggest baby step raise rate analyst say open door slightly september rate increase fed meeting weak gdp datum investor push back expectation next hike next month economy rise annual rate less half wall street expect downwardly revise pace consumer spending be very strong climb residential investment fall even separate report show new exist home sale hit multiyear high business investment contract third straight quarter oil price fall back barrel corporate spending remain weak go forward crude oil future tumble barrel hit month lows crude tumble july crude gasoline supply rise again accord energy information administration also report higher production number oil rig operation rise fifth straight week suggest further production gain glut gasoline refine product suggest less refinery demand crude ahead meanwhile exxon mobil xom chevron cvx conocophillip cop report weaker expect result mobileye mbly report ep jump cent revenue grow top view maker driver assistance system say relationship tesla motor tsla be end news send mobileye tuesday stock pare loss week tesla rise boee ba report first quarterly loss year due various charge wasn deep fear free cash flow be better expect big jet delivery northrop grumman noc report modest earning sale growth top view weaker tech service revenue hurt margin raytheon rtn beat view raise profit guidance general dynamic gd top earning raise ep guidance revenue miss mcdonald earn share beating analyst expectation total revenue fall vs year earlier analyst have expect global same store sale exclude currency effect rise vs estimate same store sale rise just management say be not immune consumer unease be finance election general unsettled world have hurt other restaurant quarter share fall week tumble day day move average buy point stifel nicolaus downgrade large number restaurant stock jeffery predict recession hit sector top rate texas roadhouse txrh report earning come week fall wednesday steakhouse chain find support day line close week unite technology utx maker pratt whitney brand aircraft engine otis elevator other product report second quarter earning share revenue beat estimate raise ep estimate stock hit year high buy point caterpillar cat ep revenue fall mining construction equipment giant deal energy mining downturn stock hit roughly year high rise entry point chemical giant dupont dd be merge dow chemical dow crushed earning estimate be light revenue share rise highest point mid december trigger buy point meanwhile mmm make tape adhesive medical supply other product also report higher ep lower revenue beating estimate share fall analog device adi agree buy linear technology lltc cash stock deal worth create microchip industry giant deal be expect close first half meanwhile oracle orcl say buy cloud service provider netsuite deal oracle larry ellison be lead shareholder netsuite meanwhile citrix system ctxs merge go meeting unit logmein logm citrix be already plan spin go meeting verizon communication acquire struggle core asset yahoo nearly include stock compensation cost massive execution challenge ahead yahoo acquisition demonstrate verizon recognize own limitation consumer brand say research firm diffusion group verizon report revenue miss view line ep add fewer wireless postpaid phone subscriber expect mobile tmus add postpaid phone subscriber top sprint verizon lose postpaid phone subscriber mobile earning fall still beat expectation revenue rise nearly tmus revenue growth continue significantly outpace peer say matthew niknam deutsche bank analyst report armour ua meet top line bottom line expectation report share earning penny prior year revenue growth nike nke rival announce several assertive plan include takeover fao schwarz space manhattan well partnership kohl kss share tumble week amgen amgn beat raise stock slip growth continue be drive price increase rather volume celgene celg meanwhile jump only third growth be price drive make hit earlier week drug revlimid fail lymphoma trial abbvie abbv merck mrk alexion pharmaceutical alxn also rise solid report astrazeneca azn be biggest winner stock wise jump thursday rumor swiss pharma novartis nvs be think acquire biggest loser be gilead science gild trim guidance hepatitis franchise continue decline meanwhile top rate medical device company edward lifescience ew orthopedic giant zimmer biomet zbh hit new high beating estimate raise guidance big cap stalwart boston scientific bsx hit year high report strongest quarter sale growth nearly decade
495,EW,nation best perform stock mutual fund past month have be slowly add financial reit issue such coresite realty cor store capital stor equity lifestyle property el latest report period ibd financial reit group rank ibd industry subsector handful computer software firm be also favore fund industry most successful manager pick include netease nte veeva system veev paycom software payc click here see list new buy top mutual fundsseveral retailer be likewise spot new buy list include burlington store burl pool pool dave buster entertainment play medical product stock such vascular solution vasc teleflex tfx align technology algn ibd leaderboard member edward lifescience ew have be heavily buy lead fund veterinarian medical service firm vca woof be also keeper ibd see lead fund add netease investing estimate john hancock discipline value mid cap fund jvmax add share latest report period netease be chinese provider online gaming software high quality mobile pc game year electronic entertainment expo los angele netease premier several new game include tianxia evercraft fly dagger netease stock break month cup handle base june zip high next day ease back buy range earning growth have be robust ramp past quarters respectively revenue growth have be mostly triple digit same period lead fund have be selling utility such nisource ni exelon exc xcel energy xel cms energy cms spire sr latest report period big manage health care firm be also be offed include unitedhealth group unh centene cnc be top fund selling unitedhealth group buyer leave net total selling fund large insurer be pull state exchange market loss affordable care act plan click here see list latest sell top mutual fund
496,EW,major average kick week quiet loss monday pretty good performance light last week solid gain ease dow jone industrial average lose nasdaq rise close stock market today
497,EW,decline stock outnumber advancer nyse nearly margin ratio be nasdaq
498,EW,dow share apple aapl slump soar last week apple report earning tuesday close consensus estimate call profit share year sale be expect rise microsoft msft be best percentage gainer dow rise nearly heel strong earning last week
499,EW,economic news september new home sale plunge annual pace unit well consensus estimate news left homebuilder generally unfazed
500,EW,ibd homebuilding group fall early end loss housing datum come ahead start day fed meeting tomorrow accord cme group fedwatch fed fund future trader have odd rate hike week
501,EW,day big mover lendingtree tree gap day move average rise strong earning bullish guidance be catalyst
502,EW,meanwhile china base baidu bidu soar news solid interest qunar qunr top online travel firm china ctrip com ctrp china base online travel firm baidu now have stake ctrip share ctrip jump qunar add priceline pcln benefit news share jump nearly
503,EW,new york mercantile exchange december crude oil lose cent barrel roughly month low
504,EW,close watch earning edward lifescience ew integrate device technology idti monolithic power system mpwr
505,EW,follow ken shreve twitter ibd_kshreve facebookmajor average kick week quiet loss monday pretty good performance light last week solid gain ease dow jone industrial average lose nasdaq rise close stock market today decline stock outnumber advancer nyse nearly margin ratio be nasdaq dow share apple aapl slump soar last week apple report earning tuesday close consensus estimate call profit share year sale be expect rise microsoft msft be best percentage gainer dow rise nearly heel strong earning last week economic news september new home sale plunge annual pace unit well consensus estimate news left homebuilder generally unfazed ibd homebuilding group fall early end loss housing datum come ahead start day fed meeting tomorrow accord cme group fedwatch fed fund future trader have odd rate hike week day big mover lendingtree tree gap day move average rise strong earning bullish guidance be catalyst meanwhile china base baidu bidu soar news solid interest qunar qunr top online travel firm china ctrip com ctrp china base online travel firm baidu now have stake ctrip share ctrip jump qunar add priceline pcln benefit news share jump nearly new york mercantile exchange december crude oil lose cent barrel roughly month low close watch earning edward lifescience ew integrate device technology idti monolithic power system mpwr follow ken shreve twitter ibd_kshreve facebook
506,EW,stock market today get wobbly start weak trade nasdaq backed early monday dow jone industrial average show decline
507,EW,volume dip sharply friday strong trading level nasdaq lower nyse
508,EW,commerce department report new home sale slip september annualize pace be home sell august also undercut consensus estimate milder downtick sale
509,EW,dalla federal reserve bank report regional manufacturing survey october et
510,EW,stock apple aapl weigh heavily dow sag nearly ahead earning report due tuesday close
511,EW,laboratory corp america lh rolled ahead top score win earning revenue line stock have be settle deepen consolidation april
512,EW,china base online travel broker ctrip com international ctrp spiked gapping past buy point double bottom base search engine operator baidu bidu agree share swap deal leave ctrip voting interest qunar cayman island qunr baidu voting interest ctrip baidu share jump qunar seize gain
513,EW,leader lgi home lgih lead ibd list rise more gain put share last wednesday high stock remain extend oct rebound week support
514,EW,low end list cirrus logic crus swoon surrender most gain post last week loss send share back day move average left day line stock be august lows try build right side month long deep consolidation
515,EW,busy hour earning report session show result due edward lifescience ew allison transmission alsn iac interactive iaci other stock market today get wobbly start weak trade nasdaq backed early monday dow jone industrial average show decline volume dip sharply friday strong trading level nasdaq lower nyse commerce department report new home sale slip september annualize pace be home sell august also undercut consensus estimate milder downtick sale dalla federal reserve bank report regional manufacturing survey october et stock apple aapl weigh heavily dow sag nearly ahead earning report due tuesday close laboratory corp america lh rolled ahead top score win earning revenue line stock have be settle deepen consolidation april china base online travel broker ctrip com international ctrp spiked gapping past buy point double bottom base search engine operator baidu bidu agree share swap deal leave ctrip voting interest qunar cayman island qunr baidu voting interest ctrip baidu share jump qunar seize gain leader lgi home lgih lead ibd list rise more gain put share last wednesday high stock remain extend oct rebound week support low end list cirrus logic crus swoon surrender most gain post last week loss send share back day move average left day line stock be august lows try build right side month long deep consolidation busy hour earning report session show result due edward lifescience ew allison transmission alsn iac interactive iaci other
516,EW,stock try claw way back even go lunch hour friday weak open result disappointing september job report nasdaq narrow loss dow jone industrial average trim early dife stock market today volume run slightly higher thursday pace exchange labor department report nonfarm payroll rise job well short economist expect employment number be announce et gold abruptly rise dollar treasury yield abruptly fall gold miner be stock market best perform group rise financial stock be punish prospect continue low interest rate bank be worst perform industry group super regional bank drop dow component goldman sachs gs jpmorgan jpm be nearly worst performer widely watch index edward life science ew be ibd best performer nearly rise fifth straight day fashion right side base relative strength line have hit new high autobytel abtl rise company announce be buy autoweb stock warrant transaction company raise guidance move put stock back day move average build right side double bottom base cal maine food calm rise less volume be well average fourth straight day have re-cover most loss monday be result disappointing earning report
517,EW,major index flirted negative territory morning biotech rally run steam nasdaq be dow jone industrial average give hold fractional gain volume be tracking slightly higher nyse lighter nasdaq vs same time monday
518,EW,more half dow component be lower apple aapl goldman sachs gs nike nke provide biggest drag
519,EW,apple reversed downward fall third straight decline slide start downward reversal friday iphone retail launch kick sterne agee crt begin cover ipad maker buy rating price target monday apple say sell more iphone model first day retail sale last year previous record unit
520,EW,life insurer medical stock oil driller be biggest gainer stock market today latter group get boost higher crude oil price coal dairy product maker homebuilder lag
521,EW,ibd stock cal maine food calm lead gainer rebound fast trade stock be still day move average monday slump disappointing fiscal result
522,EW,amsurg amsg edward lifescience ew climb respectively average volume amsurg operate ambulatory surgery center be still day line buy point heart valve maker edward be work new base day day line
523,EW,follow nancy gondo twitter ibd_ngondo major index flirted negative territory morning biotech rally run steam nasdaq be dow jone industrial average give hold fractional gain volume be tracking slightly higher nyse lighter nasdaq vs same time monday more half dow component be lower apple aapl goldman sachs gs nike nke provide biggest drag apple reversed downward fall third straight decline slide start downward reversal friday iphone retail launch kick sterne agee crt begin cover ipad maker buy rating price target monday apple say sell more iphone model first day retail sale last year previous record unit life insurer medical stock oil driller be biggest gainer stock market today latter group get boost higher crude oil price coal dairy product maker homebuilder lag ibd stock cal maine food calm lead gainer rebound fast trade stock be still day move average monday slump disappointing fiscal result amsurg amsg edward lifescience ew climb respectively average volume amsurg operate ambulatory surgery center be still day line buy point heart valve maker edward be work new base day day line follow nancy gondo twitter ibd_ngondo
524,EW,growth stock tend be smaller capitalization quite few big cap ibd be make case bigger be better least just good median market capitalization last week ibd be squarely midcap range stock have market cap be term small cap
525,EW,more dozen component top market cap big cap be perform just well case better minnow
526,EW,starbucks sbux be try rise buy point fundamental reflect company still spry leg already record history best stock run ep growth accelerate past couple quarters revenue gain also have accelerate coffeehouse chain
527,EW,measure performance breakout nike nke be better perform ibd stock share be buy point
528,EW,athletic apparel maker earning report beat expectation spark stock latest rally
529,EW,public storage psa be buy range oct share self storage real estate investment trust stall get lift past week
530,EW,visa chipotle cmg netease nte edward lifescience ew cognizant technology solution ctsh ando reilly automotive orly be form basis
531,EW,friday facebook fb edge past buy point cup handle base volume be normal however
532,EW,most company post earning gain lower most recent quarters weaker typical number winning stock produce ahead big price move
533,EW,yet profit gain haven stop ibd leader such reilly make big run
534,EW,big cap be elephantine growth best one draw considerable demand mutual fund pension fund other institution
535,EW,example regeneron pharmaceutical regn see ep slip second quarter be still nearly institutional investor own share more start year
536,EW,week ibd climb line major index gain growth stock tend be smaller capitalization quite few big cap ibd be make case bigger be better least just good median market capitalization last week ibd be squarely midcap range stock have market cap be term small cap more dozen component top market cap big cap be perform just well case better minnow starbucks sbux be try rise buy point fundamental reflect company still spry leg already record history best stock run ep growth accelerate past couple quarters revenue gain also have accelerate coffeehouse chain measure performance breakout nike nke be better perform ibd stock share be buy point athletic apparel maker earning report beat expectation spark stock latest rally public storage psa be buy range oct share self storage real estate investment trust stall get lift past week visa chipotle cmg netease nte edward lifescience ew cognizant technology solution ctsh ando reilly automotive orly be form basis friday facebook fb edge past buy point cup handle base volume be normal however most company post earning gain lower most recent quarters weaker typical number winning stock produce ahead big price move yet profit gain haven stop ibd leader such reilly make big run big cap be elephantine growth best one draw considerable demand mutual fund pension fund other institution example regeneron pharmaceutical regn see ep slip second quarter be still nearly institutional investor own share more start year week ibd climb line major index gain
537,EW,stock future be narrowly higher early high ahead wednesday open comparatively quiet premarket session dow future show point gain point hour earlier nasdaq future trade point fair market value future struggle hold point gain
538,EW,pope be washington chinese president xi jinp be west coast work way washington yom kippur begin sundown stock market today be midway interesting week nasdaq dow start today session minor loss drag lower sharp bout selling tuesday
539,EW,wednesday volume be lower usual related rosh hashana holiday stock feel early drag related disappointing manufacturing datum china
540,EW,preliminary purchasing manager manufacturing index estimate markit caixin fall september august vs expectation mild uptick september estimate be year low markit deliver early september pmi estimate et
541,EW,oil trade bit less early wednesday almost week ahead energy information administration weekly oil inventory datum due
542,EW,stock mmm lead dow premarket action slip tuesday nike nke post index biggest loss nearly
543,EW,redwood city calif base biotech heron therapeutic hrtx jetted higher ahead open company say late tuesday receive positive result inflammatory drug htx midstage clinical trial assess pain reduction follow bunion removal
544,EW,number lead stock be pressure premarket trade
545,EW,edward lifescience ew fall stock have be build possible base still week move average fail july attempt
546,EW,technology avgo slip almost singapore base chip developer be feel impact china manufacturing number morning stock end tuesday just move average battle build right side month consolidation
547,EW,overseas asia market fall echo european loss tuesday hong kong hang seng drop tokyo nikkei drop second straight day europe market leane modest bounce top index london frankfurt paris trading midday stock future be narrowly higher early high ahead wednesday open comparatively quiet premarket session dow future show point gain point hour earlier nasdaq future trade point fair market value future struggle hold point gain pope be washington chinese president xi jinp be west coast work way washington yom kippur begin sundown stock market today be midway interesting week nasdaq dow start today session minor loss drag lower sharp bout selling tuesday wednesday volume be lower usual related rosh hashana holiday stock feel early drag related disappointing manufacturing datum china preliminary purchasing manager manufacturing index estimate markit caixin fall september august vs expectation mild uptick september estimate be year low markit deliver early september pmi estimate et oil trade bit less early wednesday almost week ahead energy information administration weekly oil inventory datum due stock mmm lead dow premarket action slip tuesday nike nke post index biggest loss nearly redwood city calif base biotech heron therapeutic hrtx jetted higher ahead open company say late tuesday receive positive result inflammatory drug htx midstage clinical trial assess pain reduction follow bunion removal number lead stock be pressure premarket trade edward lifescience ew fall stock have be build possible base still week move average fail july attempt technology avgo slip almost singapore base chip developer be feel impact china manufacturing number morning stock end tuesday just move average battle build right side month consolidation overseas asia market fall echo european loss tuesday hong kong hang seng drop tokyo nikkei drop second straight day europe market leane modest bounce top index london frankfurt paris trading midday
548,EW,stock sank deeper red final hour trading friday give midday attempt pare loss dow jone industrial average plunge nasdaq volume be sharply higher board due partly quadruple witching option future contract expire energy steel financial stock be biggest loser stock market today utility drugmaker reit make few group advanced loser overwhelmed winner margin nyse nasdaq dow component fall chevron cvx exxon mobil xom crude oil price tumble more goldman sachs gs jpmorgan chase jpm fall ibd stock advanced decline upside ibd stock edward lifescience ew climb brisk trade too work new base pattern share heart valve maker be still day average appear be shape cup base penumbra pen make medical device treat stroke other vascular condition soar first day trading share price last night adobe system adbe spiked much intraday settle gain close day line first time aug digital medium software company late thursday report fiscal result top view guidance fall short follow nancy gondo twitter ibd_ngondo
549,EW,medical device giant medtronic mdt be trading year high monday company prepared report fiscal result open tuesday analyst poll thomson reuter estimate medtronic make cent share quarter end oct year earlier quarter sale be also estimate have rise
550,EW,largest biotechnology etfs be poise critical juncture trouble growth story be too early call reversal fortune re certainly stock investment idea once again spdr biotech xbi thursday break first stage base climb highest level early june industry giant biogen biib trounce analyst estimate profit sale growth stock jump heavy trading volume report global growth multiple sclerosis hemophilia business largest biotech fund ishare nasdaq biotechnology ibb follow xbi footstep week retake day move average do so etfs manage hold critical line strength suggest investor be rekindle love affair biotech earning week play part success failure attempt industry heavyweight gilead science gild report monday edward lifescience ew tuesday amgen amgn wednesday celgene celg step friday spdr biotech exchange trade fund be mired price investor be willing pay year have rebound past month outpace virtually other segment stock market jeffrey loo equity analyst global market intelligence consider biotechnology subindustry attractively price sharp sell couple biogen solid report be recent rally suggest ibd take biotech exchange trade fund offer diversify exposure high risk high reward industry lower single stock risk fund investor get know individual company own learn stock be top rate biotechnology group check ibd leaderboard march report loo write biotech industry sustain healthy growth next several year breakthrough drug gilead sovaldi harvoni hepatitis be help drive sale loo also have positive outlook issue key interest investor industry pipeline be also solid several drug have blockbuster sale potential write potential headwind come month november election email ibd loo note scrutiny high drug price fall have weigh heavily biotechnology company now hillary clinton tweet price gouge trigger scrutiny be poise become official democratic candidate next president unite state ibb have see asset shrink year net inflow first month fund hold stock skews large cap such amgen celgene well gilead biogen xbi have also see asset diminish have take new investor money first half year offer more exposure smaller cap name ibb well lower expense ratio performance be neck neck longer period time have produce annual average gain past year comparison spdr proxy broad market averaged gain same period
551,EW,quarterly earning once again take center stage stock hold solid gain close friday extend major market index streak fourth straight week eye be dow component apple aapl caterpillar cat mcdonald mcd report tuesday nasdaq rise dow jone industrial average add volume dip slightly board vs thursday accord preliminary datum week nasdaq be winner gain dow climb respectively alcoholic beverage transportation software maker lead upside today stock market action shoe apparel maker homebuilder oil stock lag west texas intermediate crude oil future slide barrel boston beer sam score biggest gain alcoholic beverage group spike massive trade stock reclaim day move average first time nearly month maker samuel adam twisted tea issue strong report starbucks sbux fall late thursday fiscal revenue miss view re-cover gain friday robust trade goldman sachs lower price target coffee giant chipotle grill cmg jump fast turnover close well day line close thursday embattled fast casual burrito chain report lower expect earning sale note progress effort customer back ibd gigamon gimo take lead jump ahead earning report thursday close stock be extend more handle buy point profit take range other ibd stock centene cnc paycom software payc add gain more silicon motion technology simo shed fast trade third straight decline report result close thursday top view share be week high company report earning early next week include gilead science gild monday edward lifescience ew mobileye mbly armour ua tuesday light economic datum schedule include dalla federal reserve manufacturing survey july
552,EW,here investing action plan need know investor come week more tech giant apple aapl facebook fb amazon amzn alphabet googl report earning do biggest name oil such exxon mobil xom chevron cvx fast food leader mcdonald mcd aerospace giant boee ba federal reserve policymaker
553,EW,here investing action plan need know investor come week facebook fb stock make bullish move earning season kick high gear report heavy hitter netflix nflx microsoft msft general electric ge starbucks sbux general motor gm defense giant lockheed martin lmt also come
554,EW,gamer descend church shopping mall national landmark nab pokemon investor exchange trade fund be single mind hunt last month safe haven fortunately labor deliver more little virtual monster matter freaky cute zubat sandshrew squirtle investor see mega portfolio return etfs hold gold gold stock dividend low volatility stock long government well high grade corporate bond month end july rocky market iffy growth outlook haven asset vaneck vector gold miner gdx remain ensconce best perform etfs so far stock dive late june briton defy expectation thumb nose european union bureaucrat vote leave regional bloc then stock snap right back follow bullish report job growth hope more global stimulus brexit debacle june stock market be back confirm uptrend benchmark blue chip dow jone industrial average small cap index be now time high beloved name facebook fb amazon amzn apple aapl have more claw back heavy brexit loss market lead stock edward lifescience ew netease nte be clamber back buy zone have climb sector be black year financial volatile month end july spdr spy hold large cap pull gain comparison ishare msci eafe efa climb period reflect greater challenge vanguard ftse emerge market vwo jump find favor yield hungry investor brexit dim rate hike outlook click here see list best perform etfs investor overarch question be current earning season buttress next move stock beat top bottom line alcoa aa tuesday augur well aluminum producer dow alum be see less less barometer corporate america strength smart money pro find way tap most promising pocket market load risk remain issue etf investing expert tell ibd intend play favore pokestop month ahead emerge market value stock high yield duncan rolph be manage partner miracle mile advisor los angele independent advisory firm fiduciary approximately asset management expect positive equity growth next month due low interest rate improve earning growth benefit weaker dollar higher energy price ishare edge msci minimum volatility emerge market eemv struggle emerge market be come back life back recover commodity price softening dollar emerge market have attractive valuation compare equity reap benefit fed hold raise interest rate low volatility emerge market etfs provide exposure less volatile emerge market stock relative market cap weight index eemv be also underweight china relative msci emerge market index be benefit give question surround chinese economy have relatively low expense ratio yield ishare value ive value stock be favor underperform growth stock last year large cap value etfs continue perform well second half investor favor high quality low volatility company ive be outperform growth etf counterpart ishare growth ivw year july ive have yield expense ratio only first trust prefer security income fpe global market still deal consequence british exit european union don expect fed raise interest rate least december therefore expect high yield fix income continue outperform corporate government fix income area high yield be preferred hybrid security characteristic stock bond fpe have solid yield be july even interest rate rise faster expect fpe holding be fix float rate security mute interest rate sensitivity michael krause be chief analyst altavista research florida base firm offer fundamentally drive forward look etf analysis financial advisor sophisticated individual investor brexit wobbly european bank lackluster corporate profit give fed excuse need stay lower longer think lead reflation commodity price money flow back beaten emerge market search higher return alp emerge sector dividend dog edog dismal few year emerge market rally first month certain commodity drive market roar much higher edog be base dog dow theory classic investment strategy invest dow stock highest dividend yield end year hold stock exactly year however edog select company highest dividend yield equity sector emerge market weight sector equally avoid outsized exposure financial chinese bank come more popular fund ishare msci emerge market eem also provide tilt commodity drive market like china south korea taiwan dominate eem edog offer yield base consensus dividend share estimate fund constituent vs eem ishare msci usa value factor vlue growth stock have far outpaced value last decade mean reversion finally be take hold make sense give anemic economic growth value benefit more multiple expansion induced lower interest rate vlue sector allocation mirror rather tilt heavily financial utility many value fund ultra low interest rate flat yield curve be help financial utility valuation be stretched roar higher first half year spdr barclay high yield bond jnk not high see winter correction credit spread remain elevated vs last few year suggest be still value lower quality bond calculate yield maturity jnk even assume loss base historical default bond similar quality maturity result realize yield compare favorably most investment grade corporate lastly credit quality also improve oil price back roughly february lows
555,EW,major average reversed higher soft start wednesday release minute mid june federal reserve meeting come go much fanfare biotechs celgene celg incyte incy buoy nasdaq facebook fb also outperformed facebook rise close day line first time june fall early nasdaq end gain add dow jone industrial average rise preliminary datum show nyse nasdaq volume come slightly higher tuesday level advance stock outnumber decliner exchange less dow leader include merck mrk home depot hd cisco system csco merck rise home depot cisco touch intraday low barrel benchmark west texas intermediate crude oil add nearly barrel year treasury yield be mostly unchanged minute june fed meeting be release et brexit vote fed have signale couple rate hike end year change decide exit european union currently future trader see little chance rate hike year year treasury yield be recently basis point hit time low tuesday stock market today edward lifescience ew be strong performer ibd screen lead growth stock edward lifescience reclaim day move average rise nearly average volume homebuilder horton dhi also do well rise strong turnover still buy range early flat base entry horton be select group leader ibd home build group see other be ibd stock checkup
556,EW,stock index turn higher afternoon trading wednesday be sign strength riskier play nasdaq stage positive reversal late morning be now be much dow jone industrial average also turn higher afternoon dow small cap russell lead advance volume be run lower nyse modestly higher nasdaq compare previous session conservative stock struggle dow jone utility average retreat ibd big cap currently feature many conservative dividend stock growth play be beating income stock day top gainer big cap edward lifescience ew ulta beauty ulta boston scientific bsx intuitive surgical isrg none pay dividend edward lifescience rise ulta beauty boston scientific intuitive surgical climb meanwhile worst performer be dividend payer such verizon communication vz real estate investment trust venta vtr feature annualize dividend yield more verizon venta have hit record high recent day post brexit defensive play bull welcome shift more growth oriented stock be way know represent change be merely day minor adjustment year treasury yield edge hit record lows earlier west texas intermediate crude oil rise more barrel tumble tuesday spdr gold share gld exchange trade fund gap nearly more highest level march gold etf be so far year
557,EW,ibd stock be choose largely strong fundamental market leader often start break sale profit growth fade important monitor chart action other indicator sign time sell coresite cor operate datum center be handful ibd stock have climb more
558,EW,energy stock impose heavy drag early trade friday help haul stock uneven loss sizable volume dow jone industrial average drop slip nasdaq hold loss
559,EW,stock market today see expiration quarterly monthly stock option future know quadruple witching session significantly drive volume friday early trade run more higher nasdaq higher nyse action same time thursday
560,EW,economic news have essentially effect conference board announce lead indicator index have inched august be less increase expect economist consensus better group upwardly revise change estimate july
561,EW,stock exxon mobil xom chevron cvx lead decline dow apiece west texas intermediate dive nearly brent crude slip bit less oil mining issue post worst early decline
562,EW,philly chip index micron technology mu asml hold asml sandisk sndk drop more
563,EW,adobe system adbe reversed premarket loss bag gain early trade developer desktop publish imaging software report better expect fiscal result late thursday management trim ep guidance consensus view huge volume gain punch adobe share back week move average further right side tight week consolidation
564,EW,more ibd stock fall start gate few advanced didn go far lead edward lifescience ew rise edward have climb aug low remain sandwich week move average
565,EW,decline weren so bad biggest drop come technology avgo brook loss pressure share back test support week line stock have be climb aug low retake support build right side month consolidation
566,EW,cognizant technology ctsh slip less fall further week move average sixth week consolidation energy stock impose heavy drag early trade friday help haul stock uneven loss sizable volume dow jone industrial average drop slip nasdaq hold loss stock market today see expiration quarterly monthly stock option future know quadruple witching session significantly drive volume friday early trade run more higher nasdaq higher nyse action same time thursday economic news have essentially effect conference board announce lead indicator index have inched august be less increase expect economist consensus better group upwardly revise change estimate july stock exxon mobil xom chevron cvx lead decline dow apiece west texas intermediate dive nearly brent crude slip bit less oil mining issue post worst early decline philly chip index micron technology mu asml hold asml sandisk sndk drop more adobe system adbe reversed premarket loss bag gain early trade developer desktop publish imaging software report better expect fiscal result late thursday management trim ep guidance consensus view huge volume gain punch adobe share back week move average further right side tight week consolidation more ibd stock fall start gate few advanced didn go far lead edward lifescience ew rise edward have climb aug low remain sandwich week move average decline weren so bad biggest drop come technology avgo brook loss pressure share back test support week line stock have be climb aug low retake support build right side month consolidation cognizant technology ctsh slip less fall further week move average sixth week consolidation
567,EW,recent sell left lot newly public company gasp air share portable oxygen concentrator maker inogen ingn be float even higher
568,EW,share goleta calif base company have more triple go public share valentine day perhaps fitting day start trading be love compassion inogen be conceive
569,EW,year cfo alison bauerlein grandmother be diagnosed progressive respiratory condition know chronic obstructive pulmonary disease copd result oxygen therapy hampered mobility greatly
570,EW,mae bauerlein describe active lady love travel meet friend be suddenly anchor heavy tank dictate movement
571,EW,get put oxygen therapy really limit much get house do want do bauerlein tell ibd even make plan go shopping see movie revolve many oxygen tank be available long last concern traffic way home do need save tank doctor appointment tomorrow have be take consideration
572,EW,bauerlein then only sophomore university california santa barbara mulled problem few classmate formulate business plan build smaller lighter medical oxygen source enter college annual entrepreneurial competition undergraduate graduate student
573,EW,plan win first place judge kathy dell steve cooper like idea so much become first head inogen
574,EW,hour supply
575,EW,company go develop portable oxygen concentrator pocs use chemical process separate oxygen nitrogen surround air meaning user do not have rely finite supply tank traditional oxygen cylinder doesn last long normal size tank provide air hour say bauerlein inogen current model last hour double battery be recharge plug typical outlet
576,EW,technology have be long time say optimized miniaturize
577,EW,october grandmother receive first product line weigh nearly pound
578,EW,be exactly be hope say bauerlein mae used newfound freedom take cruise mexico family
579,EW,inogen bring revenue last year sale poc rental company sell unit almost year end year patient rent equipment more say
580,EW,stock now have best possible ibd composite rating be member ibd medical product industry group include such leader edward lifescience ew abiom abmd cambrex cbm group be rank industry group track ibd
581,EW,inogen share break flat base buy point aug day company beat analyst forecast earning leap cent share revenue jump
582,EW,firm also boost full year sale guidance better expect business business revenue worldwide wall street current expectation run higher year
583,EW,follow release inogen result leerink jpmorgan stifel raise price target stock
584,EW,analyst appear bullish company growth opportunity
585,EW,home oxygen therapy be say be market annum growth rate mere oxygen be deliver pocs right now stifel analyst thomas carroll tell ibd leerink estimate poc penetration now be
586,EW,see significant runway growth still here line better project compound annual growth rate timeframe even ingn put growth year note leerink analyst danielle antalffy
587,EW,european sale grow too
588,EW,report inogen say domestic business business sale climb drive grow reseller private label demand pocs international sale rise european strength company increase sale staff late last year first half year prompt direct consumer sale grow
589,EW,inogen focus remain pocs singularity doesn seem be terribly big concern
590,EW,be risk be get saturate market re not say carroll
591,EW,inogen newest product be view favorably
592,EW,stationary concentrator be go compete very effectively competitor stifel analyst thomas carroll tell ibd
593,EW,look alone stationary concentrator sell look something buy brookstone vs competition size chair look something see hallway hospital
594,EW,new poc be expect launch commercially first half be see significant growth driver next year note needham analyst mike matson june
595,EW,road bauerlein say company plan increase sale rep staff boost distribution worldwide
596,EW,inogen product have presence country have very little penetration outside europe say expansion be limit reimbursement market
597,EW,analyst have also set sight overseas
598,EW,reimbursement pocs be substantially higher europe time higher many health care system allow patient choose tank pocs write matson give expect pocs continue sustain rapid growth europe
599,EW,headwind include expect reimbursement cut medicare domestically demographic be play favor say carroll especially younger ambulatory group become medicare eligible
600,EW,bauerlein know next generation patient have higher expectation say inogen be ready meet
601,EW,redefine mobility
602,EW,definition mobility be different standard oxygen therapy patient say bauerlein define mobility go grocery store own be able attend wedding be birth grandchild not be homebound
603,EW,see especially more baby boomer come age bracket want tech savvy solution say win just guess rest life now ll be more homebound recent sell left lot newly public company gasp air share portable oxygen concentrator maker inogen ingn be float even higher share goleta calif base company have more triple go public share valentine day perhaps fitting day start trading be love compassion inogen be conceive year cfo alison bauerlein grandmother be diagnosed progressive respiratory condition know chronic obstructive pulmonary disease copd result oxygen therapy hampered mobility greatly mae bauerlein describe active lady love travel meet friend be suddenly anchor heavy tank dictate movement get put oxygen therapy really limit much get house do want do bauerlein tell ibd even make plan go shopping see movie revolve many oxygen tank be available long last concern traffic way home do need save tank doctor appointment tomorrow have be take consideration bauerlein then only sophomore university california santa barbara mulled problem few classmate formulate business plan build smaller lighter medical oxygen source enter college annual entrepreneurial competition undergraduate graduate student plan win first place judge kathy dell steve cooper like idea so much become first head inogen hour company go develop portable oxygen concentrator pocs use chemical process separate oxygen nitrogen surround air meaning user do not have rely finite supply tank traditional oxygen cylinder doesn last long normal size tank provide air hour say bauerlein inogen current model last hour double battery be recharge plug typical outlet technology have be long time say optimized miniaturize october grandmother receive first product line weigh nearly pound be exactly be hope say bauerlein mae used newfound freedom take cruise mexico family inogen bring revenue last year sale poc rental company sell unit almost year end year patient rent equipment more say stock now have best possible ibd composite rating be member ibd medical product industry group include such leader edward lifescience ew abiom abmd cambrex cbm group be rank industry group track ibd inogen share break flat base buy point aug day company beat analyst forecast earning leap cent share revenue jump firm also boost full year sale guidance better expect business business revenue worldwide wall street current expectation run higher year follow release inogen result leerink jpmorgan stifel raise price target stock analyst appear bullish company growth opportunity home oxygen therapy be say be market annum growth rate mere oxygen be deliver pocs right now stifel analyst thomas carroll tell ibd leerink estimate poc penetration now be see significant runway growth still here line better project compound annual growth rate timeframe even ingn put growth year note leerink analyst danielle antalffy european sale grow tooin report inogen say domestic business business sale climb drive grow reseller private label demand pocs international sale rise european strength company increase sale staff late last year first half year prompt direct consumer sale grow inogen focus remain pocs singularity doesn seem be terribly big concern be risk be get saturate market re not say carroll inogen newest product be view favorably stationary concentrator be go compete very effectively competitor stifel analyst thomas carroll tell ibd look alone stationary concentrator sell look something buy brookstone vs competition size chair look something see hallway hospital new poc be expect launch commercially first half be see significant growth driver next year note needham analyst mike matson june road bauerlein say company plan increase sale rep staff boost distribution worldwide inogen product have presence country have very little penetration outside europe say expansion be limit reimbursement market analyst have also set sight overseas reimbursement pocs be substantially higher europe time higher many health care system allow patient choose tank pocs write matson give expect pocs continue sustain rapid growth europe headwind include expect reimbursement cut medicare domestically demographic be play favor say carroll especially younger ambulatory group become medicare eligible bauerlein know next generation patient have higher expectation say inogen be ready meet redefine mobility definition mobility be different standard oxygen therapy patient say bauerlein define mobility go grocery store own be able attend wedding be birth grandchild not be homebound see especially more baby boomer come age bracket want tech savvy solution say win just guess rest life now ll be more homebound
604,EW,stock reversed higher early afternoon trading start steep loss heel disappointing september job report nasdaq lead gain dow jone industrial average be volume be tracking slightly higher stock market today vs same time thursday gold miner casino operator biotechs be session top gainer casino stock gain year year drop macau gamble revenue september bloomberg report chinese government take step support once hot gamble enclave economy wynn resort wynn lead jump melco crown entertainment mpel soar la vegas sand lvs mgm resort international mgm stock be still well week high bank stock sag disappointing september job report fuel uncertainty federal reserve hike interest rate goldman sachs gs jpmorgan chase jpm continue weigh dow job report likely rule increase fed fund rate fomc next meet late october mid december rate increase now look less likely pnc senior economist gus faucher say note financial market be now pricing first increase fund rate march pfizer pfe reversed upward gain heavy volume track fourth straight advance drugmaker wednesday say expect recently complete buy hospira boost ep cent share revenue guide profit share revenue ibd stock netease nte lead gain nearly reclaim day move average find resistance mid august cambrex cbm dave buster play edward lifescience ew be follow nancy gondo twitter ibd_ngondo
605,EW,edward lifescience ew late tuesday beat second quarter earning estimate keep alive streak have last more year heart valve maker say second quarter earning share item rise year earlier quarter
606,EW,edward have beaten estimate analyst poll thomson reuter quarter go back least second quarter analyst average have forecast earning just share
607,EW,revenue irvine calif base company also come ahead projection rise analyst have expect
608,EW,edward be develop array transcatheter heart valf consider be less invasive other treatment more suit patient be ineligible open heart surgery device be implanted catheter tube
609,EW,company say transcatheter business grow year year meaning now represent nearly half sale gross profit margin quarter rise
610,EW,edward stock break cup handle base july rise tuesday edward lifescience ew late tuesday beat second quarter earning estimate keep alive streak have last more year heart valve maker say second quarter earning share item rise year earlier quarter edward have beaten estimate analyst poll thomson reuter quarter go back least second quarter analyst average have forecast earning just share revenue irvine calif base company also come ahead projection rise analyst have expect edward be develop array transcatheter heart valf consider be less invasive other treatment more suit patient be ineligible open heart surgery device be implanted catheter tube company say transcatheter business grow year year meaning now represent nearly half sale gross profit margin quarter rise edward stock break cup handle base july rise tuesday
611,EW,stock be struggle direction tuesday higher open quickly lose steam nasdaq be flat dow jone industrial average slip
612,EW,volume be run mixed stock market today nyse trade be run higher compare same time monday nasdaq volume be tracking touch lower
613,EW,economic news industrial production fall october vs view gain
614,EW,nahb well fargo housing market index fall november vs consensus estimate econoday october read be revise
615,EW,stock nuance communication nuan gap day line bolt post fiscal earning beat view late monday stock clear buy point consolidation deutsche bank canaccord genuity raise price target stock
616,EW,netease nte rally bounce back loss prior session be biggest gainer ibd monday stock fall more buy point consolidation mark sell signal
617,EW,downside urban outfitter urbn gap plunge reaction late monday disappointing sale comment cfo frank conforti business fourth quarter stock hit lowest level july
618,EW,urban outfitter also announce monday be acquire vetri family group restaurant chain location move baffle market watcher
619,EW,follow vincent mao twitter ibd_vmao stock be struggle direction tuesday higher open quickly lose steam nasdaq be flat dow jone industrial average slip volume be run mixed stock market today nyse trade be run higher compare same time monday nasdaq volume be tracking touch lower economic news industrial production fall october vs view gain nahb well fargo housing market index fall november vs consensus estimate econoday october read be revise stock nuance communication nuan gap day line bolt post fiscal earning beat view late monday stock clear buy point consolidation deutsche bank canaccord genuity raise price target stock netease nte rally bounce back loss prior session be biggest gainer ibd monday stock fall more buy point consolidation mark sell signal downside urban outfitter urbn gap plunge reaction late monday disappointing sale comment cfo frank conforti business fourth quarter stock hit lowest level july urban outfitter also announce monday be acquire vetri family group restaurant chain location move baffle market watcher follow vincent mao twitter ibd_vmao
620,EW,stock sell broadly tuesday index start swerve monthlong uptrend nasdaq gap loss fall be second decline more past session index trim loss afternoon price chart be left distinct
621,EW,ukrainian hacker security trader netted illegal profit snatch corporate press announcement then trading information go public federal prosecutor say federal authority say scheme largest yet know government result ill get gain company such caterpillar cat vmware vmw panera bread ticker
622,EW,study ibd see best stock isn necessarily biggest gain rise stock offer glide wild rodeo ride difficult stock be hold matter edward lifescience ew be recent example hard case feb stock clear buy
623,EW,top ibd stock be work new basis be look better other boast strong fundamental such strong sale profit growth robust return equity technical indicator be mixed several fall support day move average market uptrend pressure investor
624,EW,international stock etfs post gain tuesday lead part oil semiconductor stock however health care etfs wilted key drugmaker nurse gape wound spdr spy set new high oil settle barrel first time july prop investor sentiment energy technology help lead advance sector energy select sector spdr xle jump stock market today spdr semiconductor xsd add break extend cup handle base buy point volume be average suggest lack institutional move follow week gain propel xsd day move averagexsd be close week high stock portfolio skews smaller company also include heavyweight such broadcom avgo ibd leaderboard stock be trading time high earning beat last week meanwhile health care select sector spdr xlv give tuesday health sector trail decline sector pharmaceutical stock take hard blow xlv hold stock include alexion biogen etf sit july high other fund sector ishare nasdaq biotechnology ibb give here look major exchange trade fund tracking various asset class perform today follow daily etf market action be key successful investing spdr spy rs powershare qqq qqq rs spdr dow jone industrial average dium rs ishare core mid cap ijh rs ishare russell iwm rs ishare msci eafe efa rs vanguard ftse emerge market vwo rs spdr gold share gld rs unite state oil uso rs ishare core aggregate bond agg rs powershare db bullish uup rs ipath vix short term future vxx rs
625,EW,money manager vladimir val vassal hold same kind lead stock probably try buy say portfolio have outperformed peer vassal glenmede investment management aim remove messy emotion buy sell decision add performance long run say colleague include co manager paul sullivan have steer glenmede large cap growth fund gtllx average annual gain top large cap growth rival track morningstar inc past year vassal take rein early mutual fund have score average annual gain averaged fund star performance long short term make ibd best mutual fund award winner shine category equity fund growth fund large cap click here see list mutual fund month leadersin interview ibd philadelphia office vassal share investing secret here have say technique allow investing team beat time again ibd have quantitative investment approach do mean do mix fundamental research vassal look process quantitative discipline base fundamental insight work fundamental manager year be value oriented growth oriented small cap large cap even international basically responsibility be objectively assess criterium select stock particular sector universe assess work didn ve try remove emotion subjectivity process so ve build library factor work didn re different different sector talk tech analyst versus utility analyst talk very different metric company be effective not so ve build model be unique sector factor be similar look stock look relative peer sector term attractiveness be continual process year add year datum analysis ll test new idea have dialogue internal portfolio manager analyst also have dialogue lead street research firm empirical research partner bernstein jpmorgan jpm citi ibd type market do approach work best vassal process work valuation earning matter look create portfolio be cheap high cash flow versus benchmark have strong consistent profitability stock own be likely have positive earning revenue surprise fewer negative earning revenue surprise benchmark strategy struggle be investor be distract macro issue financial crisis great recession earning didn matter investor fled equity didn care price situation investor be not focuse specific company fundamental be drive macro behavioral issue model have less efficacy ibd more recently vassal other period strategy underperform be risk rally ve have pretty strong risk rally start march year lot riskiest name be outperform last couple month risk rally be lot price dislocation look stock sector lot gap high low price stock measure say price book so year risk rally be good environment active equity manager seem be large arbitrage opportunity cheap expensive stock maybe be take advantage create opportunity future price appreciation ibd so current market vassal indicator still suggest re positive growth environment economy have weak quarters model suggest expect rebound most economist expect annualize growth gdp quarter next couple quarters click here see list mutual fund category performancewe favor more cyclical sector right now technology consumer discretionary re underweight interest rate sensitive sector utility reit ibd let talk put strategy work do edward lifescience ew fit question be latest disclosure vassal own jan have good return equity more sell side analyst be raise lower estimate year next year valuation be not cheap fact more analyst be raise estimate have strong profitability momentum historically strong earning growth offset rich valuation include stock ibd other holding be attract similar reason vassal other name buy january be oracle orcl masco mas schwab schw again be attractive base criterium combination earning growth analyst estimate stock sell january be block hrb be bottom quintile sector fortunately sell something hit downside screen force portfolio question ask take time fundamental analyst portfolio manager fall love stock once put portfolio hard let go try remove emotion process long term add performance ibd do approach differ fundamental only fund manager vassal look stock be cheap have positive growth metric coverage analyst be raise estimate just look criterium work best differentiate stock sector health care company don look pipeline example stock ranking model health care emphasize high free cash flow yield low relative price book strong reinvestment rate positive earning revenue estimate revision ibd facebook fb have quarters accelerate earning share growth do look hold vassal attractive model valuation be not cheap fundamental growth story be positive so be fact analyst be raise estimate have be period sell facebook be get too rich last year fang stock facebook amazon amzn netflix nflx google be now alphabet googl be just fly valuation get too rich wouldn hold point facebook still be consider buy model ibd open stake lowe low just last year be thesis
626,EW,vassal start stake june rank top third stock ranking model have positive revenue earning estimate revision sell side analyst valuation be not too extreme price earning ratio year earning be stock ranking model be base month period look turn portfolio month maintain attractiveness month look refresh harvest loss offset short term gain particular ibd cadence design cdns earning share growth have accelerate quarters quant view vassal have have very positive earning revision run january analyst raise estimate company be not expensive be january have do well be now little ibd thinly trade mettler toledo mtd be uptrend ep growth be slow slightly view vassal be still attractively rank model estimate revision be more neutral show positive look forward analyst estimate have very strong profitability very high roe january roe be be contingent book value decelerate historically growth have be look forward still look double digit growth even low double digit ibd ve be boost stake accenture acn vassal have very attractive rank tech sector analyst margin be raise estimate have high roe good track record dividend growth ibd make different other quant oriented fund manager vassal difference be principle first believe active management stock get misprice issue benchmark index be stock be overpriced effectively be overweight address ignore weight individual stock want avoid idiosyncratic risk overexposure single name everything else be equal midcap mega cap name wouldn invest instead overweighting just have larger weight benchmark second treat sector differently don believe model be used stock stock different sector have different attribute business model third downside risk screen include quality earning avoid company poor stock quality debt high idiosyncratic risk fourth differentiate stock be more likely have positive versus negative surprise base sell side analyst behavior company fundamental technical datum ibd idea quantitative approach be home factor identify stock outperform enable avoid be sidetrack subjective factor be basically irrelevant outperformance right vassal yes build extensive back test go back year identify combination criterium create portfolio stock outperform average stock sector roll month basis be top most attractive stock ibd risk vassal re look most consistent excess return roll month period so re look highest return unit shortfall risk shortfall risk be stock didn outperform average stock least basis point want have upside don want have much downside performance relative average stock ibd manager portray person eat sleep fund management do nothing else ve get least interesting hobby tell please vassal well hobby be genealogy last name be french old french name have family tree go back more year apparently family member do year reunion learn fact have lot documentation interesting history family go france ukraine early actually past saturday see relative didn know be third cousin get touch frenchman be do genealogical research family end connect first time
627,EW,market have challenged investor recent year short rally make tough build meaningful profit stock position shallow correction make easy get shake
628,EW,investor find success take smaller gain cut loss quicker lead introduction column new product swingtrader let start basic swing trading strategy goal be not hit home run just get first base rather target profit most stock profit goal be more modest even just tougher market type gain not seem be life change reward typically seek stock market ever expect score huge winning stock buy be bunt be time factor come swing trader focus isn gain develop week month average length trade be more day put string base hit together score just advance runner be happy gain month more gain week add significant profit course still have factor loss progress smaller gain only be achieve loss be keep small rather normal stop loss take loss quicker maximum keep profit loss ratio sound portfolio management rule success critical component whole system outsized loss away lot progress make smaller gain swing trading still deliver larger gain individual trade stock exhibit enough initial strength be hold bigger gain partial profit be take give remain position room run edward lifescience ew score outsized gain swingtrader beta performance stock break short consolidation april volume be average highest nearly month positive clinical trial lead move next day stop be immediately raise buy price protect profit strategy have be book partial profit point stock be remove april close day move average gain
629,EW,week insider trade include sale executive tesla motor tsla schlumberger slb apple aapl supplier skywork solution swks edward lifescience ew continental resource clr vice president engineering dougla field disclose thursday sell share share field be recruit tesla apple serve vice president mac hardware engineering head electric vehicle maker new car development program tech giant have engage have call poach war hire other executive tesla ceo elon musk have even dismiss apple tesla graveyard say iphone maker hire person tesla fire electrek april report apple have hire former tesla vp vehicle engineering chris porritt special project further fuel speculation apple be develop own vehicle tesla motor share close week erase solid gain report safety regulator be probe tesla suspension company nondisclosure agreement oilfield service giant ceo paal kibsgaaard monday disclose sale schlumberger share rally oil price energy industry have be hit hard oil gas price plunge last couple year prompt schlumberger rival halliburton hal baker hughe bhi cut ten thousand job uptrend oil have bring drill back life oil rig count rise recent week schlumberger share be week chairman david aldrich report thursday sale share apple chip supplier transaction value prior be name chairman aldrich have serve company chief executive skywork be form merger alpha industry be president ceo conexant system citigroup downgrade skywork thursday say rival qorvo qrvo be better position grow citi cut fiscal earning share view skywork consensus be skywork share be week apple be chairman ceo michael mussallem thursday report selling share medical device maker ibd stock guggenheim security wednesday initiate coverage edward neutral rating last month edward report jump quarterly ep rise sale edward share edge cent week chief risk officer general counsel eric eissenstat filing monday disclose sell share continental resource total thursday continental ceo harold hamm tell bloomberg company have start complete drilled uncompleted well oil price rally share reversed oil price general market close insider transaction don typically have major impact stock indicate major pending news rapid liquidation most insider holding however affect stock
630,EW,wedbush initiate coverage fitbit fit top rating citigroup upgrade apple aapl chipmaker qorvo qrvo rbc capital upgrade linkedin lnkd raise price target proofpoint pfpt wedbush start coverage outperform rating pt cite expand install base program corporate wellness initiative share fitbit close have swoon more company have ibd composite rating possible citigroup upgrade apple chip supplier qorvo neutral sell downgrading skywork solution swks sell neutral believe qorvo sustain dollar content gain momentum samsung galaxy iphone gain year say citigroup report qorvo share edge skywork fall rbc capital upgrade business social network outperform neutral pt linkedin stock plunge feb mountain view calif company forecast full year revenue consensus estimate owing advertising slowdown rbc mark mahaney say survey human resource professional show linkedin be reasonably well position very large recruitment advertising tam total addressable market linkedin share climb raise pt proofpoint security software firm host analyst day thursday san francisco introduce financial target include reach revenue proofpoint have ibd composite rating possible fall guggenheim security initiate coverage medical product maker boston scientific bsx stryker syk buy rating boston scientific have ibd composite rating possible climb thursday stryker have cr add guggenheim start coverage spectranetic spnc buy rating edward lifescience ew medtronic mdt have neutral rating raymond james longbow research deutsche bank ub downgrade restoration hardware rh neutral home furnishing retailer late wednesday unexpectedly report fiscal loss slash full year profit outlook share plunge other analyst move brean capital downgrade qualcomm qcom hold rw baird upgrade solarcity scty outperform
631,EW,share heart valve maker edward lifescience ew be more hour trading monday company warn expect report revenue year earlier quarter july guidance analyst poll thomson reuter expect sale
632,EW,whew week fall much nasdaq notch weekly gain upside reversal see nasdaq have look capitulation be often see market bottom market remain correction proven otherwise drop much ibd add
633,EW,heart pump maker abiom have add handle latest base carve buy point share have hold well recent market turmoil be time high abiom abmd be part highly rate medical product group also home edward lifescience ew break similar pattern
634,EW,stock future be have pull back early high ahead thursday open surprise jump mid atlantic region manufacturing
635,EW,dow future trade point fair market value point gain hour earlier nasdaq future hold point gain sticking close earlier high future pull back point gain
636,EW,stock market today carry bit less weight shoulder decisively punch past day move average nasdaq gain more altitude important line support wednesday
637,EW,investor draw confidence minute fed oct meeting show majority federal open market committee favor rate hike december apple aapl also factor day gain gapping better gain upgrade goldman sachs
638,EW,current uptrend still bear heavy load distribution day nasdaq be good cause keep cautious stance new purchase stock flash sell signal
639,EW,relatively light economic calendar open labor department report weekly jobless claim ease week end nov prior week economist consensus have forecast pullback claim week move average continue higher mark third straight advance
640,EW,philadelphia federal reserve regional manufacturing survey firm november rise beat consensus expectation flat outcome index fall read october follow tally september
641,EW,conference board be set release lead economic indicator index october et
642,EW,dow unitedhealth unh drop premarket action minnetonka minn base manage care provider trim full year ep guidance consensus view company say claim activity deteriorate individual participation insurance exchange lag
643,EW,seller keep pressure retail apparel maker send best buy bby perry ellis pery loss mixed quarterly report buckle bke ton store bont report earning miss stock remain unchanged premarket trade
644,EW,keurig green mountain gmcr ahead top premarket action owner cup coffee franchise trounce analyst earning expectation revenue fall less forecast management boost quarterly dividend cent keurig share end wednesday november high
645,EW,salesforce com crm jab bell ep leap gain revenue narrowly clear analyst consensus projection revenue earning projection be line analyst view management hoist full year ep guidance just consensus software service leader end wednesday buy range bit more cup base buy point
646,EW,china base play chalk strong premarket move
647,EW,ctrip com international ctrp soar higher deliver result online travel site end wednesday buy point double bottom base
648,EW,china base micro blog site weibo wb shot premarket trade report ep cent cent share loss year view cent revenue surge better forecast stock finished wednesday deep cup base stock future be have pull back early high ahead thursday open surprise jump mid atlantic region manufacturing dow future trade point fair market value point gain hour earlier nasdaq future hold point gain sticking close earlier high future pull back point gain stock market today carry bit less weight shoulder decisively punch past day move average nasdaq gain more altitude important line support wednesday investor draw confidence minute fed oct meeting show majority federal open market committee favor rate hike december apple aapl also factor day gain gapping better gain upgrade goldman sachs current uptrend still bear heavy load distribution day nasdaq be good cause keep cautious stance new purchase stock flash sell signal relatively light economic calendar open labor department report weekly jobless claim ease week end nov prior week economist consensus have forecast pullback claim week move average continue higher mark third straight advance philadelphia federal reserve regional manufacturing survey firm november rise beat consensus expectation flat outcome index fall read october follow tally september conference board be set release lead economic indicator index october et dow unitedhealth unh drop premarket action minnetonka minn base manage care provider trim full year ep guidance consensus view company say claim activity deteriorate individual participation insurance exchange lag seller keep pressure retail apparel maker send best buy bby perry ellis pery loss mixed quarterly report buckle bke ton store bont report earning miss stock remain unchanged premarket trade keurig green mountain gmcr ahead top premarket action owner cup coffee franchise trounce analyst earning expectation revenue fall less forecast management boost quarterly dividend cent keurig share end wednesday november high salesforce com crm jab bell ep leap gain revenue narrowly clear analyst consensus projection revenue earning projection be line analyst view management hoist full year ep guidance just consensus software service leader end wednesday buy range bit more cup base buy point china base play chalk strong premarket move ctrip com international ctrp soar higher deliver result online travel site end wednesday buy point double bottom base china base micro blog site weibo wb shot premarket trade report ep cent cent share loss year view cent revenue surge better forecast stock finished wednesday deep cup base
649,EW,heart surgery giant edward lifescience ew rise more time high monday morning analyst upgrade wake acquisition rbc capital market glenn novarro raise rating outperform sector perform set price target novarro write edward acquisition cardiaq announce close friday
650,EW,earning season have kick high gear number top rate stock such vasco datum security vdsi facebook fb be due report earning come week computer generate ibd list premier stock be base combination company recent profit growth record ibd composite rating price performance
651,EW,hot new technology widespread deadly disease whole lot money change hand be story last wednesday st jude medical stj agree pay cash thoratec thor developer implant call left ventricular assist device lvad help heart failure patient keep blood move lately be
652,EW,heart pump maker abiom abmd be close buy point get ready report earning aug mission recover heart save life abiom develop impella bill world smallest heart pump june justice department say end investigation company marketing
653,EW,stock show reluctance move much direction monday afternoon stock breakout remain razor thin gold stock meanwhile appear poise further decline underlie commodity be face headwind headwind get stronger investor consensus build federal reserve show more willingness raise short term interest rate more quickly originally thought hike fed fund rate central bank june meeting indicate belief belt tighten be order follow stronger expect increase consumer level price worker wage lately be virtually flat mid afternoon trade dow jone industrial average nasdaq composite lift help strong monday start apple aapl still largest company market apple gain nearly news indicate tech giant see robust sale future iphone model stock market today lead gold stock weren make much move be clearly lose momentum term gold commodity future more end april spot price gold be ounce gold maintain strong year date gain nearly jan however largest gold miner market cap take beating last week be not show much strength today goldcorp gg be vie third straight gain have recoup only small fraction last wednesday drubbing heavy trade try stay rise day move average wall street have recently shave full year profit estimate earning be still see rebound cent share goldcorp earn share goldcorp currently show solid relative strength rating do other gold miner fare compare ibd proprietary research tool stock checkup south african miner anglogold ashanti be show similar action slightly monday still struggle claw back day line healthy lead stock often trade so strong don touch day move average many week follow good anglogold have post nice run clear bottom base heavy trade feb randgold gold lackluster volume so far have be subdue day line gap follow result same day randgold post rise earning share revenue boost net margin fall newmont mining nem continue outperform bunch rise nearly global gold producer have relatively light debt load long term debt equity ratio end compare favorably anglogold ashanti goldcorp boast ltd equity ratio just follow mini rebound biotech share last week see gain last week ishare nasdaq biotech ibb etf medical sector continue gain headway monday edward lifescience ew member ibd leaderboard year date reclaim day move average gain nearly flat trading wellcare health plan wcg burst higher volume run higher usual manage health insurer have average daily volume share stock have retake buy point long cup handle earlier breakout march april fail stick reflect challenge environment trader stock have have trouble crack price level march however good sign wellcare be recent movement have quiet show less willingness institution dump share rs line be also move sharply higher wellcare recently report jump profit follow gain prior quarters revenue increase composite rating be not hot street see profit rise share
654,EW,re novice experience investor everyone make mistake time time easy get discourage loss pile faster win contrary conventional wisdom possible still achieve outstanding gain ask whole secret winning big stock market be not be right time lose least amount possible re wrong ibd founder chairman william neil write investment classic make money stock cut loss short locking gain be key investing success follow neil approach used loss ratio take profit re winner cut loss re purchase price do often stay ahead so stay discipline be key let say ve invest stock portfolio be edward lifescience ew stock initially faltered clear buy point feb re crossed entry feb average volume rise much stock gap soar april past buy point now trading more past entry investor lock gain here haven already supreme conviction let stock ride bit further investment edward earlier buy point be worth gain offset other position sell loss totale loss cut loss more quickly even better loss cut discipline be good rule thumb be prudent cut loss even less depend broader market be act market be correction pressure more stock be likely fall then rise so re see lot red flag used smaller number make sense even market be rally never take more loss study stock year neil find most lead stock tend advance base pause correct consolidate be good take profit most stock also find best institutional quality stock rarely fall proper buy point sound chart pattern speculator be correct half time be hit good average fame wall street trader bernard baruch have say even be right time yield person fortune have sense cut loss quickly venture have be wrong
655,EW,medical device maker ibd stock edward lifescience ew beat analyst estimate raise guidance late tuesday send stock fraction hour trading share touch new high regular session edward make cent share quarter exclude time item year earlier quarter top analyst consensus cent accord thomson reuter sale rise vs consensus edward lift full year earning guidance dime guidance issue report add sale range now company also add guidance specifically transcatheter heart valve therapy thvt sapien line valve replacement have drive much edward recent growth now guide sale represent underlie growth edward say market expansion sapien be main driver guidance increase month company sapien transcatheter aortic valve replacement tavr be show reduce death stroke treat aortic stenosis patient intermediate risk open heart surgery boost stock april sapien be only approve patient high risk so add moderate risk patient significantly broaden market company earning conference call analyst tuesday ceo michael mussallem say edward submit datum fda few week be modele approval new indication early come earlier be enthusiastic continue expansion transcatheter base therapy many structural heart patient still need mussallem say statement be confident outlook strong sale growth remain passionate develop impactful therapy help more patient world edward also guide expectation ep cent sale analyst expect earning cent share sale apart thvt business critical care division grow surgical heart valve therapy group decline edward have be exit strategic product line latter group say number surgical procedure be grow edward stock have be roll year hit record high tuesday close fraction ibd composite rating ibd list top perform stock past month strong recent performance explain small move stock make hour tuesday expectation head be elevated edward do not disappoint investor write evercore isi analyst vijay kumar research note be thing have pick be underlie tavr growth international market underlie tavr sale be total tavr growth imply international growth further deceleration conference call mussallem say international thvt sale have actually grow admit have be lose market share abroad sapien line have face competition europe longer have medtronic mdt corevalve be approve year earlier approval january say market share have increase slightly however overall kumar say quarter be very solid expense be say spending come well expectation gross margin decline be already model
656,EW,huge medical sector be low rate show pocket strength sector include drugmaker manage care many other health related stock be rank friday normally lead stock top few sector have best chance success doesn mean weak sector lack potential winner
657,EW,group medical product company have be trading sideway month perhaps base long advance stock group look ready assume leadership market find way sustain rally group be rank monday week
658,EW,load player zimmer biomet zbh be close new buy zone medical product industry group rise ranking week today maker orthopedic reconstructive product have composite rating earn spot industry leader such align technology algn cambrex cbm edward
659,EW,be lot hand wring lately iconic have go more year mark new time high don despair re smart etf investor spot opportunity even other agonize stock be stick rut geniuse indexing shop don just offer product track broad basket asset such large cap russell small cap also slice dice index finer segment aim boost return reduce risk sometimes aim do achieve aim screen stock factor characteristic such low volatility high quality several exchange trade fund tracking index base have score time high recently re not only outperform bellwether spdr spy also attract gob new investor money powershare high dividend low volatility sphd proshare dividend aristocrat nobl powershare quality sphq make time high april powershare low volatility splv do same powershare ex rate sensitive low volatility xrlv follow suit sphd cherry pick market rather deliver whole basket accord industry research firm etf com invest least risky highest yielding stock indexing method skews defensive sector such utility centerpoint energy cnp be top stock hold stock be trading week high investor have favore defensive cast income potential utility sector choppy year etf have outperformed spy year date past year vs gain better know peer sphd also see net inflow first month year comparison spy leak proshare dividend aristocrat hold stock parent index have hike dividend payment least consecutive year then equal weight holding account big midcap stake irish medical device maker medtronic mdt be dividend aristocrat portfolio company make heart valve product just ibd leaderboard aristocrat edward lifescience ew do nobl have advanced year date absorb net january april dividend name nobl yield relatively modest less spy sphd
660,EW,well trained open water swimmer learn technique order deal rough condition mean other thing sacrifice symmetry efficiency order flow punch chop stock attempt build basis difficult market show similar adaptation common result base base pattern investor standpoint base base be exercise frustration stock form base break then immediately fall back second consolidation ideal base base see low second consolidation just touch high point prior base reality stack pattern seem messy disorderly generally be indicator strong stock struggle advance stubborn market be reason slim stand market condition stock fight weak market be clearly try swim upstream rather show typical gain separate distinct basis lead stock choppy market rise only few percentage point pull back often form flat base cup use platform advance base dip well prior base be generally call base beside base pattern be still valid structure doesn normally carry firepower base base facebook fb have stage awkward base beside base pattern november yet be still advance price universal display oled prestige brand holding pbh offer somewhat more tidy example case particularly consolidate market new base dive back low prior base decline reset stock base count new base be consider first stage formation suggest stock have additional room advance priceline group pcln citrix system ctxs demonstrate recent base reset constellation brand stz have trade tightly fourth straight week recent price movement rest just high prior base hold week pattern become flat base base maybe best recent example come edward lifescience ew lead maker heart valve replacement edward have stack series base base base next base pattern begin early last year first cup handle base july rise less week turn cup handle investor not have want hold deep consolidation trick be keep stock watch list jump second late october take little longer ride rise less week then consolidation share correct clear handle buy point heavy trade feb then drop pivot stopping just short sell rule please see daily chart investor com edward retook buy point day run mid february stock rise week stall flat consolidation prior consolidation pattern dip only hold comfortably week move average time be killer powerful trade april positive trial result sapien heart valve true character share rise next week then pull back well become consolidation stay tune
661,EW,many lead stock have give most not post gain broader market continue week slide name be buck downtrend retain big gain hold buy point red flag ulta beauty ulta be extend buy point initially clear march share gap
662,EW,edward lifescience ew share be more early trading thursday company wednesday announce favorable action food drug administration advisory panel
663,EW,company say panel unanimously vote favor recommend approval edward sapien transcatheter heart valve transfemoral transapical delivery treatment high risk patient severe symptomatic aortic stenosis
664,EW,such approval fda open product bigger pool potential patient nonsurgical implant be now approve only patient unable risk open heart procedure
665,EW,panel vote abstention benefit heart valve outweighed risk patient edward say
666,EW,canaccord genuity analyst jason mill reiterate buy recommendation stock thursday maintain price target share now trade mill write full fda approval be likely late early earlier expect approval be possible
667,EW,edward ceo michael mussallem company news release say company be very encourage advisory panel strong recommendation approval expand current indication edward sapien valve patient high risk surgery broader indication high risk patient enable multus disciplinary heart team choose approach best suit patient need edward lifescience ew share be more early trading thursday company wednesday announce favorable action food drug administration advisory panel company say panel unanimously vote favor recommend approval edward sapien transcatheter heart valve transfemoral transapical delivery treatment high risk patient severe symptomatic aortic stenosis such approval fda open product bigger pool potential patient nonsurgical implant be now approve only patient unable risk open heart procedure panel vote abstention benefit heart valve outweighed risk patient edward say canaccord genuity analyst jason mill reiterate buy recommendation stock thursday maintain price target share now trade mill write full fda approval be likely late early earlier expect approval be possible edward ceo michael mussallem company news release say company be very encourage advisory panel strong recommendation approval expand current indication edward sapien valve patient high risk surgery broader indication high risk patient enable multus disciplinary heart team choose approach best suit patient need
668,EW,edward lifescience ew share be more early trading thursday company wednesday announce favorable action food drug administration advisory panel
669,EW,company say panel unanimously vote favor recommend approval edward sapien transcatheter heart valve transfemoral transapical delivery treatment high risk patient severe symptomatic aortic stenosis
670,EW,such approval fda open product bigger pool potential patient nonsurgical implant be now approve only patient unable risk open heart procedure
671,EW,panel vote abstention benefit heart valve outweighed risk patient edward say
672,EW,canaccord genuity analyst jason mill reiterate buy recommendation stock thursday maintain price target share now trade mill write full fda approval be likely late early earlier expect approval be possible
673,EW,edward ceo michael mussallem company news release say company be very encourage advisory panel strong recommendation approval expand current indication edward sapien valve patient high risk surgery broader indication high risk patient enable multus disciplinary heart team choose approach best suit patient need edward lifescience ew share be more early trading thursday company wednesday announce favorable action food drug administration advisory panel company say panel unanimously vote favor recommend approval edward sapien transcatheter heart valve transfemoral transapical delivery treatment high risk patient severe symptomatic aortic stenosis such approval fda open product bigger pool potential patient nonsurgical implant be now approve only patient unable risk open heart procedure panel vote abstention benefit heart valve outweighed risk patient edward say canaccord genuity analyst jason mill reiterate buy recommendation stock thursday maintain price target share now trade mill write full fda approval be likely late early earlier expect approval be possible edward ceo michael mussallem company news release say company be very encourage advisory panel strong recommendation approval expand current indication edward sapien valve patient high risk surgery broader indication high risk patient enable multus disciplinary heart team choose approach best suit patient need
674,EW,new lows have mostly have strong hand week now go tuesday session combine new lows nasdaq nyse averaged previous session astounding number particularly ibd screen be abbreviated quality
675,EW,new high
676,EW,same period new high averaged
677,EW,now number deserve qualifier last week new high recapture dominant position be last week monday new lows be back control
678,EW,get stranger many day triple digit new high coexist triple digit new lows have happened half session
679,EW,be peculiar action market uptrend peculiar be seldom word associate healthy bull market
680,EW,context lessen worry tuesday oil mining steel utility stock laggard populate new lows tally group provide day new lows accord preliminary datum
681,EW,laggard have be do quite bit lately be good thing market laggard be selling activity rotate money stronger group
682,EW,still bull see situation change normal uptrend new high hold upper hand new low tally fade digit peculiar have place table
683,EW,niche normalcy be find top rate stock continue make new high
684,EW,tuesday google googl bound new intraday high strong volume reversed modest gain
685,EW,facebook fb add score new high sixth time session volume be heavy
686,EW,celgene celg pop new high volume be only moderately higher
687,EW,edward lifescience ew also poke new high volume be fifth slower usual
688,EW,total system service tss thrust more new high strong volume midcap company be payment system provider
689,EW,tally new high lows engender concern be secondary gauge more certain guidance stay focuse market
690,EW,click here view full list week new high lows new lows have mostly have strong hand week now go tuesday session combine new lows nasdaq nyse averaged previous session astounding number particularly ibd screen be abbreviated quality new high same period new high averaged now number deserve qualifier last week new high recapture dominant position be last week monday new lows be back control get stranger many day triple digit new high coexist triple digit new lows have happened half session be peculiar action market uptrend peculiar be seldom word associate healthy bull market context lessen worry tuesday oil mining steel utility stock laggard populate new lows tally group provide day new lows accord preliminary datum laggard have be do quite bit lately be good thing market laggard be selling activity rotate money stronger group still bull see situation change normal uptrend new high hold upper hand new low tally fade digit peculiar have place table niche normalcy be find top rate stock continue make new high tuesday google googl bound new intraday high strong volume reversed modest gain facebook fb add score new high sixth time session volume be heavy celgene celg pop new high volume be only moderately higher edward lifescience ew also poke new high volume be fifth slower usual total system service tss thrust more new high strong volume midcap company be payment system provider tally new high lows engender concern be secondary gauge more certain guidance stay focuse market click here view full list week new high lows
691,EW,artificial heart valve pioneer edward lifescience still make valf be implanted traditional way open heart surgery smaller profile transcatheter valf implanted catheter be make edward ew pulse beat faster day fast first month year sale transcatheter heart valf thv jump year earlier
692,EW,stock remain black early afternoon trade wednesday be still well early morning high
693,EW,be dow jone industrial rally nasdaq be volume grow nyse be mildly nasdaq exchange compare same time tuesday
694,EW,stock market today heavily batter industry group pace advance ibd oil gas equipment agricultural operation oil gas royalty trust coal datum storage industry group gain more stock gain strong increase durable good order july follow bounce june
695,EW,few stock laggard group however be furnishing potential new market leader high growth investor buy
696,EW,datum storage group rank industry group month relative price performance wednesday ibd not single stock be trading least share show composite rating higher emc emc giant industry market cap have lowly composite grade stock have slump day move average early january fail hold key support level
697,EW,rise nearly wednesday fast turnover emc be year full year earning share be expect fall
698,EW,point stock index have not reach bear market territory re close
699,EW,monday intraday low nasdaq composite fall time high post july
700,EW,google googl grab headline thank strong upgrade goldman sachs company long term prospect stock more halter massive day slide institutional investor shore stock fast rise day move average
701,EW,july google clear early buy point long consolidation powerful volume breakout turnover rise more day average volume have higher rate success certainly case google day later stock gap time high
702,EW,investment bank note world premier search engine be early stage multus year cycle expand margin drive earning outperformance multiple expansion
703,EW,google post rise ep last month biggest jump quarters new cfo ruth porat help company control expense slow revenue increase revenue be just gain prior quarters net margin rise basis point vs year
704,EW,ibd_chung stock remain black early afternoon trade wednesday be still well early morning high be dow jone industrial rally nasdaq be volume grow nyse be mildly nasdaq exchange compare same time tuesday stock market today heavily batter industry group pace advance ibd oil gas equipment agricultural operation oil gas royalty trust coal datum storage industry group gain more stock gain strong increase durable good order july follow bounce june few stock laggard group however be furnishing potential new market leader high growth investor buy datum storage group rank industry group month relative price performance wednesday ibd not single stock be trading least share show composite rating higher emc emc giant industry market cap have lowly composite grade stock have slump day move average early january fail hold key support level rise nearly wednesday fast turnover emc be year full year earning share be expect fall point stock index have not reach bear market territory re close monday intraday low nasdaq composite fall time high post july google googl grab headline thank strong upgrade goldman sachs company long term prospect stock more halter massive day slide institutional investor shore stock fast rise day move average july google clear early buy point long consolidation powerful volume breakout turnover rise more day average volume have higher rate success certainly case google day later stock gap time investment bank note world premier search engine be early stage multus year cycle expand margin drive earning outperformance multiple expansion google post rise ep last month biggest jump quarters new cfo ruth porat help company control expense slow revenue increase revenue be just gain prior quarters net margin rise basis point vs year ibd_chung
705,EW,biotechs continue rebound medical related stock remain center stage week big cap accounting half list edward lifescience ew gap past cup handle buy point initially clear tuesday rbc capital market upgrade heart valve maker outperform sector outperform lift price target friday
706,EW,stock build early gain go lunch hour monday be trading day high europe crisis greece appear wane greek parliament have wednesday pass reform demand european union
707,EW,nasdaq gap open rise gain dow jone industrial average be higher volume be tracking lower vs same time friday nyse higher nasdaq exchange
708,EW,euro be sharply treasury yield rise third straight day investor take more risk
709,EW,edward lifescience ew rise nearly breaking cup handle base buy point rbc capital market upgrade stock sector perform outperform raise price target analyst glenn novarro say market transcatheter aortic valf grow estimate other analyst have grow bullish heart value market
710,EW,domino pizza dpz rise nearly solid volume have break flat base buy point be still buy zone company report earning thursday morning analyst be expect ep cent increase year
711,EW,solaredge technology sedg rise third straight day company announce be sunrun prefer supplier optimized inverter share rise
712,EW,walgreen boot alliance wba rise complete cup base buy point report better expect earning thursday
713,EW,phillip partner psxp fall well fargo initiate coverage stock outperform rating stock build early gain go lunch hour monday be trading day high europe crisis greece appear wane greek parliament have wednesday pass reform demand european union nasdaq gap open rise gain dow jone industrial average be higher volume be tracking lower vs same time friday nyse higher nasdaq exchange euro be sharply treasury yield rise third straight day investor take more risk edward lifescience ew rise nearly breaking cup handle base buy point rbc capital market upgrade stock sector perform outperform raise price target analyst glenn novarro say market transcatheter aortic valf grow estimate other analyst have grow bullish heart value market domino pizza dpz rise nearly solid volume have break flat base buy point be still buy zone company report earning thursday morning analyst be expect ep cent increase year solaredge technology sedg rise third straight day company announce be sunrun prefer supplier optimized inverter share rise walgreen boot alliance wba rise complete cup base buy point report better expect earning thursday phillip partner psxp fall well fargo initiate coverage stock outperform rating
714,EW,trouble europe asia stock claw way back morning worst level go lunch hour monday
715,EW,major index fall volume be run higher thursday pace nyse nasdaq exchange stock market today
716,EW,greece overwhelmingly vote sunday reject european austerity demand analyst say chance greece leave euro be now high morgan stanley peg odd european leader meet tuesday
717,EW,eye be europe chinese stock overnight struggle volatile session government attempt shore rapidly fall stock market chinese adrs be generally lower
718,EW,netease nte ibd name fall slice day move average
719,EW,treasury be higher flight safety dollar be moderately higher euro be moderately lower
720,EW,west texas intermediate crude oil fall more reach lowest level april hit energy stock
721,EW,santander consumer usa sc fall nearly slash day line company say jason kula have be name ceo replace thomas dundon accordance board approve succession plan morgan stanley analyst cheryl pate maintain overweight rating say buy dip
722,EW,santander be worst performer ibd soon open ibd stock be lower noon be higher be lower
723,EW,best performer elite list be edward lifescience ew morgan stanley upgrade stock overweight raise price target analyst say market transcatheter aortic valve replacement quintuple trouble europe asia stock claw way back morning worst level go lunch hour monday major index fall volume be run higher thursday pace nyse nasdaq exchange stock market today greece overwhelmingly vote sunday reject european austerity demand analyst say chance greece leave euro be now high morgan stanley peg odd european leader meet tuesday eye be europe chinese stock overnight struggle volatile session government attempt shore rapidly fall stock market chinese adrs be generally lower netease nte ibd name fall slice day move average treasury be higher flight safety dollar be moderately higher euro be moderately lower west texas intermediate crude oil fall more reach lowest level april hit energy stock santander consumer usa sc fall nearly slash day line company say jason kula have be name ceo replace thomas dundon accordance board approve succession plan morgan stanley analyst cheryl pate maintain overweight rating say buy dip santander be worst performer ibd soon open ibd stock be lower noon be higher be lower best performer elite list be edward lifescience ew morgan stanley upgrade stock overweight raise price target analyst say market transcatheter aortic valve replacement quintuple
724,EW,stock continue hold session high late monday hope greece nasdaq climb gain meanwhile dow jone industrial average rally issue higher microsoft msft dupont dd be biggest percentage mover turnover be tracking higher major exchange trade be only hair nyse
725,EW,lead stock netflix nflx rally time high goldman sachs jacked price target analyst heath terry be bullish netflix international expansion
726,EW,edward lifescience ew trim gain stock open buy point cup handle base poke july earlier stock market today rbc capital market upgrade stock sector perform outperform raise price target netflix be well extend gapping cup handle base april
727,EW,armour ua add new high be follow clear buy point cup handle base friday roughly average volume trade be tracking much higher monday jordan spieth armour sponsored athlete win john deere classic sunday
728,EW,facebook fb rise new high now past buy point flat base initially clear june facebook be finally gain traction period sideway trading stock continue hold session high late monday hope greece nasdaq climb gain meanwhile dow jone industrial average rally issue higher microsoft msft dupont dd be biggest percentage mover turnover be tracking higher major exchange trade be only hair nyse lead stock netflix nflx rally time high goldman sachs jacked price target analyst heath terry be bullish netflix international expansion edward lifescience ew trim gain stock open buy point cup handle base poke july earlier stock market today rbc capital market upgrade stock sector perform outperform raise price target netflix be well extend gapping cup handle base april armour ua add new high be follow clear buy point cup handle base friday roughly average volume trade be tracking much higher monday jordan spieth armour sponsored athlete win john deere classic sunday facebook fb rise new high now past buy point flat base initially clear june facebook be finally gain traction period sideway trading
729,EW,market be pace third straight weekly decline only few sell signal have be trigger weekly review santander consumer usa sc set round trip sell signal erase gain flat base april sell start monday santander slice day move average news ceo thomas dundon be step
730,EW,chinese video game firm netease nte be bounce back huge swoon early week stock briefly erased gain past cup buy point remember sound portfolio management rule be take least profit amount
731,EW,positive side number lead stock be still shape basis market pull back stock columbia sportswear colm fleetmatic group fltx edward lifescience ew allergan agn be shape fresh cup handle pattern
732,EW,fleetmatic be testing support day move average strong advance recent lows stock handle be show buy point flaw base be volume be mostly light stock climb right side pattern
733,EW,columbia sportswear be week shallow pattern buy point similar fleetmatic upside volume pattern have be lackluster
734,EW,edward lifescience show better accumulation base share surge week end june heaviest weekly volume nearly year june edward lifescience announce fda approval latest heart valve sapien treatment high risk patient stock rs line be new high be also bullish
735,EW,allergan be sit just buy point find support day move average trading base have be tight late stage pattern add risk market be pace third straight weekly decline only few sell signal have be trigger weekly review santander consumer usa sc set round trip sell signal erase gain flat base april sell start monday santander slice day move average news ceo thomas dundon be step chinese video game firm netease nte be bounce back huge swoon early week stock briefly erased gain past cup buy point remember sound portfolio management rule be take least profit amount positive side number lead stock be still shape basis market pull back stock columbia sportswear colm fleetmatic group fltx edward lifescience ew allergan agn be shape fresh cup handle pattern fleetmatic be testing support day move average strong advance recent lows stock handle be show buy point flaw base be volume be mostly light stock climb right side pattern columbia sportswear be week shallow pattern buy point similar fleetmatic upside volume pattern have be lackluster edward lifescience show better accumulation base share surge week end june heaviest weekly volume nearly year june edward lifescience announce fda approval latest heart valve sapien treatment high risk patient stock rs line be new high be also bullish allergan be sit just buy point find support day move average trading base have be tight late stage pattern add risk
736,EW,earning report have hammer lead stock hasn be case most big cap member most quarterly report way big capitalization leader have sail past earning announcement
737,EW,most beat wall street expectation also most have climb earning press release come past couple week medical sector have largest share big cap account several earning winner gilead science gild gap report sale profit exceed expectation also raise full year guidance share beat analyst consensus cent largest margin victory earning race stock have rise almost day july report be form right side base better expect sale earning also help valeant pharmaceutical vrx break base july illumina ilmn however be medical leader tumble gene sequence company july beat earning estimate miss revenue expectation share sell day report sink back prior buy point illumina drop big cap alexion pharmaceutical alxn beat estimate thursday guidance fall short expectation cost stock have fall modestly report remain entry market also have cool reception edward lifescience ew result even sale earning be higher analyst expect stock have be day number be release week outside health care ebay ebay top profit estimate july charge new high follow news share have recede bit have hold high chipotle grill cmg barely beat second quarter view ep rise share sale climb estimate yet chipotle have best post earning performance big cap share soar day earning report investor turn optimistic third quarter sale traffic trend chipotle remain new high reynold american rai also have do well quarterly report tobacco company be second quarter earning top expectation company raise full year outlook stock be extend buy point few big cap company have not report result yet include monster beverage mnst hca holding hca
738,EW,heart valve maker edward lifescience ew see share plummet open friday company late thursday issue forecast far short analyst expectation company expect revenue quarter lower expect wall street see earning share item cent
739,EW,big percentage gain european stock index spil nasdaq friday major average end week positive note nasdaq jump chip stock beaten biotechs outperformed nasdaq add dow jone industrial average rise philadelphia semiconductor index outperformed rise just preliminary datum show volume nasdaq come slightly higher thursday level nyse volume fall bit stock market today week dow lose nasdaq gain picked dupont dd american express axp intel intc outperformed dow gain nasdaq leader include apply material amat micron mu lam research lrcx apply material soar late thursday chip equipment firm report earning nearly sixfold jump display order etf space ishare nasdaq biotechnology ibb rise few biotechs be buy point recent sell off exchange ice add try clear long consolidation conventional entry entry daily chart show earlier handle entry mobile tmus gain close just early entry cent april intraday high edward lifescience ew add just seek support day move average first time edward be part leaderboard portfolio investor com see other stock make cut here new york mercantile exchange wti crude oil june delivery fall cent barrel week rise just
740,EW,spot leadership trend stock market study leader make ibd screen week be sound strategy look cluster company particular industry group such grouping indicate rotation industry leadership more build related medical stock have crop lately build sector be pressure
741,EW,allianzgi focuse growth fund pgwax performance rank top peer group track morningstar inc past year year certainly do not entitle fund manager scott migliori karen hiatt raphael edelman free pass market challenge include market volatility manager expect continue be more clarity global growth prospect especially china europe other challenge be disappointing growth ongoing geopolitical tension recession europe slower expect growth china so be do focuse growth manager think large cap growth stock be ll find most opportunity have long term track record visible cash flow flexibility consistent payout re multinational exposure hiatt say re enter period be much less rise tide lift boat so only good stock picker outperform be time active manager shine vs ve see recent year hiatt say fund largest holding march have composite rating ibd top new buy have very strong comp rating composite rating combine ibd performance rating include ep relative strength rating facebook fb be fund top hold march comp rating be earning share grow past quarters latest result first quarter come wednesday thursday share gap buy point briefly dip entry friday hold weak broad market negative stock have weak accumulation distribution rating indicate deep pocket institutional investor mutual fund aren participate wholeheartedly buy share change stock volume day start outnumber volume day
742,EW,number daily active facebook user have top facebook grow mobile platform be bring bulk company total ad revenue shift digital advertising continue hiatt say company have not only facebook also instagram early stage company monetize
743,EW,edward lifescience ew be new top buy comp rating be medical device maker be member ibd beat analyst first quarter estimate earning revenue raise guidance late tuesday developer treatment cardiovascular disorder gap april report positive clinical datum newest heart valve heart valve replacement be clean new option intermediate risk patient hiatt say clinical trial allow analyst bring expectation quickly valve be launch total market be
744,EW,trading share be extend entry constellation brand stz be top new buy comp rating be hiatt colleague see unusual consumer staple sell modest premium staple overall grow twice rate hiatt say short run earning have be hurt company construction brewing plant bring bottle molding house see significant increase free cash flow get next year hiatt say also see lot room increase market share go friday fund carry month performance rating ibd be year be past month outperform peer mutual fund modest gain
745,EW,stock market myth abound unfortunately many keep investor reap big profit market big say avoid stock high price earning ratio re too expensive many ask buy stock trading high buy low think high stock car pay used car mile ante pay high quality new car have better chance give more bang buck latter course work same way stock market many low stock be damage good re bargain rack good reason conversely high stock be premium merchandise stock market many case big earning sale growth be fuel big market share gain so stock command premium valuation so contrary conventional wisdom stock high ratio deliver explosive gain be risky slight earning sale miss lukewarm guidance result sharp sell so loss stock investment be cut less stock trail ratio be base past earning forward be base earning estimate current next full year average trail stock be recently compare average trail recent ibd screen faster grow firm be find ibd so make sense average ratio be higher be better time other own high stock scenario have good chance work be meaningful market correction big enough pullback be often enough shake last seller market pave way new institutional money come sideline growth fund manager aren afraid pay stock especially growth story market team ibd doesn let high ratio get way decision add stock leaderboard accessible investor com leader list have yielded big winner recent year market pundit be call expensive edward lifescience ew add ibd leaderboard february just gap buy point have be standout performer ratio time be expensive sure market be optimistic sapien heart valve be still early stage growth palo alto network panw get nod leaderboard soar base late time have trail ratio pricey sure more double price less year thank huge earning sale growth expand market share network security software space facebook fb joined leaderboard break powerfully july time be selling time trail earning be major growth story go time optimism future growth facebook more double price next year growth story be still very much intact
746,EW,market outlook shift uptrend pressure alphabet googl microsoft msft sink armour ua other leader jump see handle stock gap heavy volume report strong earning take look recent gap up stock ulta beauty ulta citrix system ctxs be fare current market also available itune video audiosee current leader buy point free trial action plan apple facebook amazon boee oil giantsrelated link week market segment top medical stock be buy point
747,EW,ibd stock analysis touch put paypal step ahead visa amazon alphabet
748,EW,earning season armour see sale top quarter skecher soar
749,EW,earning season facebook linkedin twitter put light social networksget latest ibd market analysis big picture
750,EW,stock market today intraday update
751,EW,stock market today handle stock gap earning don be afraid buy stock gap price
752,EW,gap gain be best time buytake free trial leaderboard
753,EW,ibd print eibd digital editionattend ibd investing workshop find level topic right send feedback questionsemail email protected
754,EW,pocket health care sector be ailing other have perked right ishare medical device ihi bound week high thursday eye fourth straight weekly gain relative strength line gauge performance vs be bolt higher defiance overall stock market mood market uptrend have come pressure week ihi be target bet health care niche invest company manufacture distribute medical device edward lifescience ew be top rate ibd stock industry group base measure technical fundamental health such earning sale growth ihi count edward top holding give portfolio weighting edward stock have jump past month california base company be battle top spot heart valve market sapien receive fda approval treatment high risk patient suffering severe symptomatic aortic stenosis chief rival be medtronic mdt hold ihi portfolio edward report quarterly result april close wall street stock analyst track thomson reuter expect gain earning quarter year
755,EW,major stock hold ihi report week late tuesday surgical robot maker intuitive surgical isrg beat earning estimate stock hit new high wednesday receive series price target hike wednesday orthopedic giant stryker syk also beat expectation raise guidance stryker intuitive stock have fall then volatile trade ihi also have smaller weighting cantel medical cmn steris ste cynosure cyno device specialist top notch ibd composite rating respectively steris provide product prevent infection control contamination report jump sale latest report quarter help buyout base synergy health small cap cantel medical be also infection control prevention business cynosure develop treatment system hair removal skin rejuvenation ihi have relative strength rating mean outperformed other stock etfs ibd database last month accumulation distribution rating point healthy institutional demand share etf see net inflow first quarter asset have grow year year date april ihi have advanced vs broadly diversify health care select sector spdr xlv xlv largest health care etf have be hurt year hefty combine stake underperform pharmaceutical biotech industry past year xlv produce annual average gain vs ihi
756,EW,medical stock have be increase presence ibd majority aren company make drug rather most be more scene player provide drug development service make medical equipment pra health science prah provide outsourced clinical development service biotech pharmaceutical industry raleigh base company have work pharmaceutical company more
757,EW,several mutual fund firm hitch etf bandwagon smart beta strategy new large cap product beat bellwether large cap exchange trade fund spdr spy first quarter smart beta fund follow index stray traditional market cap weighting stock weight stock accord dividend sale momentum other factor goal typically be boost portfolio return adjust portfolio risk new fund follow rule active management work say todd rosenbluth director etf research global market intelligence describe goldman sachs gs jpmorgan jpm legg mason lm john hancock well establish asset manager stock pick skill be now package etf wrapper big mutual fund company be look make inroad etf industry more more investor dollar flow passive index base investment writing be wall active manager rosenbluth be intrigue mutual fund firm launch similar sound strategy almost same time last year so decide look more closely new etfs performance be surprised find virtually beat spy only large cap actively manage mutual fund manage beat same period accord morningstar inc rosenbluth believe low cost etf structure likely give new fund edge actively manage mutual fund tend have much higher expense ratio be drag return course single quarter performance only mean so much however rosenbluth believe new etfs be solid choice successful investing investor concept screening stock base multiple fundamental factor product offer say re well structure relatively cheap backed firm likely be etf space long haul rare etf achieve asset haul just month etf issuer strong ty institutional investor help rosenbluth say gslc be also competitively price smart beta etf expense ratio stock holding include heavyweight such apple aapl less well know name such edward lifescience ew heart valve maker top rate ibd leaderboard stock gslc gain vs spy jpus have expense ratio gain pull well ahead spy well new peer jhml hold asset have expense ratio also launch september rise line spy udbi have asset expense ratio debut december add image provide shutterstock
758,EW,unsettled market make sense err side caution sometimes mean focuse less aggressive growth small cap name more liquid large cap name find week big cap big cap component be generally less volatile small cap name partly due heavy mutual fund sponsorship name
759,EW,stock further perked late tuesday be track end session slide major index have already re-cover monday loss then
760,EW,help mining energy stock surge dow jone industrial average rally nasdaq gain volume be run higher board stock market today
761,EW,masco mas gap day line surge company top view earlier stock market today share clear buy point flat base masco make behr paint delta faucet showerhead well denova countertop
762,EW,jazz pharmaceutical jazz rally nearly new high stock take buy point flat base jazz have clear several basis september have not produce big gain
763,EW,becton dickinson bdx rise fast trade month high share pass buy point cup handle base maker medical supply device report fiscal earning aug analyst poll thomson reuter see profit rise share snap quarters single digit growth march becton dickinson complete buyout carefusion
764,EW,leader volume be few ellie mae elli have trim loss stock find support day line nearly return buy point flat base intraday
765,EW,akamai technology akam buffalo wild wing bwld citrix system ctxs edward lifescience ew gilead science gild macom mtsi panera bread pnra sturm ruger rgr sunpower spwr twitter twtr yelp yelp be notable company report earning close stock further perked late tuesday be track end session slide major index have already re-cover monday loss then help mining energy stock surge dow jone industrial average rally nasdaq gain volume be run higher board stock market today masco mas gap day line surge company top view earlier stock market today share clear buy point flat base masco make behr paint delta faucet showerhead well denova countertop jazz pharmaceutical jazz rally nearly new high stock take buy point flat base jazz have clear several basis september have not produce big gain becton dickinson bdx rise fast trade month high share pass buy point cup handle base maker medical supply device report fiscal earning aug analyst poll thomson reuter see profit rise share snap quarters single digit growth march becton dickinson complete buyout carefusion leader volume be few ellie mae elli have trim loss stock find support day line nearly return buy point flat base intraday akamai technology akam buffalo wild wing bwld citrix system ctxs edward lifescience ew gilead science gild macom mtsi panera bread pnra sturm ruger rgr sunpower spwr twitter twtr yelp yelp be notable company report earning close
766,EW,stock further weaken be back session lows late monday worry greece again weigh market
767,EW,nasdaq be dow jone industrial average fall turnover be tracking higher major exchange compare same time thursday
768,EW,lead stock santander consumer usa sc stretched loss nearly putt further day line breach earlier session late thursday company say jason kula have be name ceo replace thomas dundon accordance board approve succession plan gain past buy point be almost go
769,EW,centene cnc tumble slice day line share health care provider have already tumble thursday news bidding rival health net hnt health net drop late monday
770,EW,earlier stock market today aetna aet announce friday buy rival humana hum be
771,EW,upside edward lifescience ew be session high still share be nearly be upgrade overweight equal weight morgan stanley also raise price target stock be cup handle base buy point stock further weaken be back session lows late monday worry greece again weigh market nasdaq be dow jone industrial average fall turnover be tracking higher major exchange compare same time thursday lead stock santander consumer usa sc stretched loss nearly putt further day line breach earlier session late thursday company say jason kula have be name ceo replace thomas dundon accordance board approve succession plan gain past buy point be almost go centene cnc tumble slice day line share health care provider have already tumble thursday news bidding rival health net hnt health net drop late monday earlier stock market today aetna aet announce friday buy rival humana hum be upside edward lifescience ew be session high still share be nearly be upgrade overweight equal weight morgan stanley also raise price target stock be cup handle base buy point
772,EW,health care hospital stock community health system cyh hca holding hca team health holding tmh get boost thursday supreme court decision uphold federal obamacare subsidy other medical sector stock have also be show strength be edward lifescience ew develop product treat advanced cardiovascular disorder june investor pump stock
773,EW,leadership be broad ibd medical product group tuesday close stock have composite rating higher much leadership have come small cap name such cambrex cbm vascular solution vasc inogen ingn several large cap name cardiovascular focus be act well trading high
774,EW,edward lifescience ew composite rating be set cup shape base show buy point now try add handle area yield earlier entry
775,EW,technical health improve quite bit share surge heavy volume week end june move come fda approve thinner version company artificial heart valve dub sapien valve approve europe last year be insert open heart surgery
776,EW,st jude medical stj large cap name be hold week move work flat base buy point
777,EW,big player cardiovascular medical device market earlier month company get go ahead fda resume evaluation portico transcatheter aortic valve implantation system
778,EW,firm well medtronic mdt boston scientfic bsx be expect benefit bright growth prospect asia pacific region come year
779,EW,meanwhile small cap merit medical system mmsi be trading close point company make disposable device used primarily cardiology radiology endoscopy share surge april firm smash earning estimate rise quarterly profit leadership be broad ibd medical product group tuesday close stock have composite rating higher much leadership have come small cap name such cambrex cbm vascular solution vasc inogen ingn several large cap name cardiovascular focus be act well trading high edward lifescience ew composite rating be set cup shape base show buy point now try add handle area yield earlier entry technical health improve quite bit share surge heavy volume week end june move come fda approve thinner version company artificial heart valve dub sapien valve approve europe last year be insert open heart surgery st jude medical stj large cap name be hold week move work flat base buy point big player cardiovascular medical device market earlier month company get go ahead fda resume evaluation portico transcatheter aortic valve implantation system firm well medtronic mdt boston scientfic bsx be expect benefit bright growth prospect asia pacific region come year meanwhile small cap merit medical system mmsi be trading close point company make disposable device used primarily cardiology radiology endoscopy share surge april firm smash earning estimate rise quarterly profit
780,EW,handful ibd stock get boost last week buck overall market weakness thank better expect quarterly result illumina ilmn make genetic testing equipment be few disappointment plunge wednesday sale trail analyst forecast stock slice day move average line erased gain past buy point trigger sell signal
781,EW,illumina have rebound have find support day line be nearly past entry just buy range
782,EW,valeant pharmaceutical vrx clear buy point flat base thursday strong volume better expect earning report valeant reversed time high friday be still buy range
783,EW,base be late stage have form stock have already enjoy long advance make risky stock relative strength line be hit new high indicate outperform demand share remain strong
784,EW,manhattan associate manh develop supply chain management software wide range industry jump new high wednesday profit rise easily beating view manhattan associate pull back lower volume remain more past buy point cup base buy range
785,EW,cirrus logic crus report late wednesday profit fiscal first quarter jump cent share easily beating wall street estimate apple aapl supplier stock jump next day clear day line come close buy point
786,EW,cirrus logic fall back day friday heavy volume
787,EW,starbucks sbux get nice bounce better expect earning report late thursday coffee retailer jump much new high friday pare much gain starbucks be nearly flat base buy point clear january also extend multiple rebound day line
788,EW,ibd company report quarterly earning week include taser international tasr edward lifescience ew unite therapeutic uthr vasco datum security vdsi reilly automotive orly facebook fb universal health service uhs ellie mae elli
789,EW,week ibd fall much less decline handful ibd stock get boost last week buck overall market weakness thank better expect quarterly result illumina ilmn make genetic testing equipment be few disappointment plunge wednesday sale trail analyst forecast stock slice day move average line erased gain past buy point trigger sell signal illumina have rebound have find support day line be nearly past entry just buy range valeant pharmaceutical vrx clear buy point flat base thursday strong volume better expect earning report valeant reversed time high friday be still buy range base be late stage have form stock have already enjoy long advance make risky stock relative strength line be hit new high indicate outperform demand share remain strong manhattan associate manh develop supply chain management software wide range industry jump new high wednesday profit rise easily beating view manhattan associate pull back lower volume remain more past buy point cup base buy range cirrus logic crus report late wednesday profit fiscal first quarter jump cent share easily beating wall street estimate apple aapl supplier stock jump next day clear day line come close buy point cirrus logic fall back day friday heavy volume starbucks sbux get nice bounce better expect earning report late thursday coffee retailer jump much new high friday pare much gain starbucks be nearly flat base buy point clear january also extend multiple rebound day line ibd company report quarterly earning week include taser international tasr edward lifescience ew unite therapeutic uthr vasco datum security vdsi reilly automotive orly facebook fb universal health service uhs ellie mae elli week ibd fall much less decline
790,EW,stock climb tuesday extend rebound remove more gloom market nasdaq lead advance biotechs be source strength composite index third straight day climb aid largely energy sector rally international agreement eventually let iran put
791,EW,stock future signale higher open wednesday wall street assessed probability impasse congressional budget battle possibility interest rate hike europe dow future climb point bell nasdaq future gain point future rise point gold price continue trade higher oil hold steady barrel dollar slip vs euro european central bank commissioner be schedule meet thursday discuss interest rate increase number application new mortgage rise week end april accord mortgage banker association be busiest level year statement association credit gain sharp increase application government loan ahead schedule increase fha insurance premium become effective last friday refinance activity slip edward lifescience ew rebound pre market trade maker synthetic heart valf other medical device suffer day heavy selling drive support week move average edward be fifth week possible flat base accumulation be weak company weekend release mixed result study sapien invasive heart valve replacement study show slightly higher survival rate sapeint recipient vs patient undergo open heart surgery post surgical complication be higher sapient population monday jeffery raise rating edward stock buy hold jeffry citigroup increase price target stock market china rise first session central bank raise interest rate attempt slow economy hong kong hang seng index add shanghai composite rise tokyo nikkei slip europe london ftse gain frankfurt dax be market moved afternoon trading
792,EW,stock future knock healthy gain ahead monday open probationary deal eurozone open door possible bailout fund greece
793,EW,dow future be point fair market value tick higher nasdaq future be solid point future jump point small cap be less impressed russell future edge point
794,EW,greece be again lead early influence stock market today accord fashion eurozone creditor greece leader follow night session clear path struggle country receive much be release prime minister alexis tsipra prove government able implement so call austerity measure
795,EW,plan be enough keep greece now euro currency bloc tsipra enact tax hike pension change wednesday step be refuse greek voter referendum just week
796,EW,global market be positive china top index block solid gain shanghai composite hong kong hang seng europe cac paris surge frankfurt dax climb london ftse add
797,EW,market open day nasdaq stare underside day move average move line be positive still leave market range have contain trade march nasdaq start monday session june high start high
798,EW,treasury department serve june budget number et earning calendar get slow start monday ibd stock bank ozark ozrk report close pace pick tuesday report due jpmorgan jpm well fargo wfc johnson johnson jnj
799,EW,stock unite continental ual climb wynn resort wynn tack gain
800,EW,medical sector stock small large be hammer big premarket move
801,EW,anacor pharmaceutical anac spiked announce eczema skin rash lotion crisaborole meet endpoint late stage clinical trial palo alto calif base biotech say submit new drug application food drug administration early anacor end friday new high july gain year
802,EW,conformis cfms leap market surgical knee implant july new issue end friday high ipo price
803,EW,edward lifescience ew notch rbc capital upgrade stock outperform sector perform irvine calif base company announce friday pay acquire privately hold heart device maker cardiaq valve technology edward end friday just buy point cup handle base
804,EW,other trading dollar gain vs euro yen yen rise vs euro oil price slip bit less gold be fraction stock future knock healthy gain ahead monday open probationary deal eurozone open door possible bailout fund greece dow future be point fair market value tick higher nasdaq future be solid point future jump point small cap be less impressed russell future edge point greece be again lead early influence stock market today accord fashion eurozone creditor greece leader follow night session clear path struggle country receive much be release prime minister alexis tsipra prove government able implement so call austerity measure plan be enough keep greece now euro currency bloc tsipra enact tax hike pension change wednesday step be refuse greek voter referendum just week global market be positive china top index block solid gain shanghai composite hong kong hang seng europe cac paris surge frankfurt dax climb london ftse add market open day nasdaq stare underside day move average move line be positive still leave market range have contain trade march nasdaq start monday session june high start high treasury department serve june budget number et earning calendar get slow start monday ibd stock bank ozark ozrk report close pace pick tuesday report due jpmorgan jpm well fargo wfc johnson johnson jnj stock unite continental ual climb wynn resort wynn tack gain medical sector stock small large be hammer big premarket move anacor pharmaceutical anac spiked announce eczema skin rash lotion crisaborole meet endpoint late stage clinical trial palo alto calif base biotech say submit new drug application food drug administration early anacor end friday new high july gain year conformis cfms leap market surgical knee implant july new issue end friday high ipo price edward lifescience ew notch rbc capital upgrade stock outperform sector perform irvine calif base company announce friday pay acquire privately hold heart device maker cardiaq valve technology edward end friday just buy point cup handle base other trading dollar gain vs euro yen yen rise vs euro oil price slip bit less gold be fraction
805,EW,stock market get rough start tuesday fall hard morning major average re-cover nicely close perhaps help news eurozone be consider proposal interim funding greece fall early nasdaq show gain close loss morphed
806,EW,appeal big capitalization stock be resilience market sell off account big cap stock have do better job loss list range much monday broad market tumble most decline be
807,EW,volume stock be not excessive most have trading total be well normal other have increase
808,EW,consider massive selling market be significant not massive
809,EW,medical leader such unitedhealth group unh edward lifescience ew continue form basis hold new high
810,EW,facebook fb have modest decline close buy point most recent pattern volume be norm
811,EW,loss wasn alarm
812,EW,illumina ilmn also dip back buy point close just buy point clear couple week
813,EW,big cap stock be health care speak strength sector be pattern present not just big cap leader other area market ibd sector leader also have fair share medical stock
814,EW,gilead science gild fall buy point sell signal biotech so far
815,EW,volume be average not exactly avalanche seller more share nonetheless
816,EW,few big cap leader slide day move average institutional investor step buy dip watch rebound line evidence
817,EW,skywork solution swks be watch regard
818,EW,chipmaker come day line nearly double average volume not exactly gentle pullback chart reader look skywork find back favor rebound quickly strong volume
819,EW,walt disney share have be make new high streak come stop monday
820,EW,stock erased have be small gain buy point be back entry
821,EW,compare stumble other leader take entertainment colossus come day proceedings relatively minor damage
822,EW,starbucks sbux give shareholder best hope
823,EW,share fall volume average more important stock hold solid uptrend remain well extend january couple normal pullback week move average
824,EW,starbucks have notch week streak look firm lead stock appeal big capitalization stock be resilience market sell off account big cap stock have do better job loss list range much monday broad market tumble most decline be volume stock be not excessive most have trading total be well normal other have increase consider massive selling market be significant not massive medical leader such unitedhealth group unh edward lifescience ew continue form basis hold new high facebook fb have modest decline close buy point most recent pattern volume be norm loss wasn alarm illumina ilmn also dip back buy point close just buy point clear couple week big cap stock be health care speak strength sector be pattern present not just big cap leader other area market ibd sector leader also have fair share medical stock gilead science gild fall buy point sell signal biotech so far volume be average not exactly avalanche seller more share nonetheless few big cap leader slide day move average institutional investor step buy dip watch rebound line evidence skywork solution swks be watch regard chipmaker come day line nearly double average volume not exactly gentle pullback chart reader look skywork find back favor rebound quickly strong volume walt disney share have be make new high streak come stop monday stock erased have be small gain buy point be back entry compare stumble other leader take entertainment colossus come day proceedings relatively minor damage starbucks sbux give shareholder best hope share fall volume average more important stock hold solid uptrend remain well extend january couple normal pullback week move average starbucks have notch week streak look firm lead stock
825,EW,edward lifescience ew be early tuesday jpmorgan upgrade stock overweight neutral say fundamental be strong recent market slowdown increase competition medtronic mdt
826,EW,analyst michael weinstein write research note edward stock have fall back march high concern slowdown transcatheter aortic valve replacement tavr market
827,EW,last year market grow robustly due launch edward sapien xt valve entry medtronic corevalve market so year year comparison be tough weinstein admit however say field research suggest market have picked american college cardiology acc meeting mid march
828,EW,field check suggest tavr market have accelerate post acc meaning edward market be likely surprise upside balance weinstein write reinforce view be survey conduct last week tavr implanter point volume sequentially vs current consensus expectation
829,EW,weinstein theorize datum support survival benefit tavr acc meeting drive increase
830,EW,recent pullback edward be lead stock ibd medical product industry group composite rating morning trading stock market today stock be edward stock touch month low
831,EW,follow amy reeve twitter ibd_areeve edward lifescience ew be early tuesday jpmorgan upgrade stock overweight neutral say fundamental be strong recent market slowdown increase competition medtronic mdt analyst michael weinstein write research note edward stock have fall back march high concern slowdown transcatheter aortic valve replacement tavr market last year market grow robustly due launch edward sapien xt valve entry medtronic corevalve market so year year comparison be tough weinstein admit however say field research suggest market have picked american college cardiology acc meeting mid march field check suggest tavr market have accelerate post acc meaning edward market be likely surprise upside balance weinstein write reinforce view be survey conduct last week tavr implanter point volume sequentially vs current consensus expectation weinstein theorize datum support survival benefit tavr acc meeting drive increase recent pullback edward be lead stock ibd medical product industry group composite rating morning trading stock market today stock be edward stock touch month low follow amy reeve twitter ibd_areeve
832,EW,medical device giant medtronic mdt release preliminary fiscal earning tuesday be expectation warn outlook be batter foreign exchange headwind medtronic be more early trading stock market today medtronic stock touch time high march medtronic say sale quarter end
833,EW,stock pare early loss early afternoon trading tuesday bond yield ease follow initial move higher nasdaq dow jone industrial average lose volume nyse nasdaq be run higher compare same time monday
834,EW,major average be much early session yield year european bond rise highest level month higher bond yield suggest higher borrow cost individual corporation year treasury yield be recently trading basis point
835,EW,hospital stock be biggest decliner stock market today universal health service uhs operate acute care hospital behavioral health center slide nearly past cup buy point high end buy range
836,EW,oil gas stock be best performer oil climb barrel weaker dollar expectation datum due wednesday show decline crude stockpile chesapeake energy chk transocean rig rise
837,EW,edward lifescience ew be nearly heavy volume jpmorgan upgrade stock overweight neutral say fundamental be strong recent market slowdown increase competition medtronic mdt edward be still day move average recently trigger sell signal fall more flat base buy point stock pare early loss early afternoon trading tuesday bond yield ease follow initial move higher nasdaq dow jone industrial average lose volume nyse nasdaq be run higher compare same time monday major average be much early session yield year european bond rise highest level month higher bond yield suggest higher borrow cost individual corporation year treasury yield be recently trading basis point hospital stock be biggest decliner stock market today universal health service uhs operate acute care hospital behavioral health center slide nearly past cup buy point high end buy range oil gas stock be best performer oil climb barrel weaker dollar expectation datum due wednesday show decline crude stockpile chesapeake energy chk transocean rig rise edward lifescience ew be nearly heavy volume jpmorgan upgrade stock overweight neutral say fundamental be strong recent market slowdown increase competition medtronic mdt edward be still day move average recently trigger sell signal fall more flat base buy point
838,EW,kind big cap stock be worth look tentative uptrend first kind stock consider be have good fundamental sport chart look result medically induced coma stock move sideway month never seem wake dr market put
839,EW,big cap easily outperformed overall market finished fractionally higher volatile trading list large capitalization growth leader hammer gain week list have healthy dose stock buy point history steady earning growth calm price performance many be trading close
840,EW,last week space several big cap stock show healthy earning sale increase be discuss week column ask question big cap name be make most sale growth other word much profit be generate dollar sale profit margin tell well
841,EW,growth stock have blowout week fifth ibd list rise more top list akorn akrx rebound week take back prior week loss end comfortably week move average biogen idec biib spiked end far new high edward lifescience ew
842,EW,stock turn mixed midday monday round similarly mixed earning report well economic report foreign domestic
843,EW,nasdaq turn loss gain biotechs software issue outperformed pare deficit dow jone industrial average fall volume be tracking sharply lower board stock market today compare same time friday
844,EW,highly rate stock globant glob rally nearly time high clear buy point heavy trading hour session thin stock already match day average volume
845,EW,nike nke climb more new high be upgrade buy hold bb now past buy point athletic apparel footwear giant be recently mentioned new high column
846,EW,downside microsemi mscc drop news offer buy pmc sierra pmcs bid top buyout offer apple aapl supplier skywork solution swks microsemi fall buy point consolidation clear friday pmc share jump
847,EW,valeant vrx slump beating view raise guidance open canadian drugmaker post adjust earning share year sale grow third straight period acceleration almost lift full year sale forecast
848,EW,profit be now expect share prior outlook last week valeant say receive subpoena federal prosecutor massachusett new york request information patient assistance program drug pricing decision
849,EW,follow vincent mao twitter ibd_vmao stock turn mixed midday monday round similarly mixed earning report well economic report foreign domestic nasdaq turn loss gain biotechs software issue outperformed pare deficit dow jone industrial average fall volume be tracking sharply lower board stock market today compare same time friday highly rate stock globant glob rally nearly time high clear buy point heavy trading hour session thin stock already match day average volume nike nke climb more new high be upgrade buy hold bb now past buy point athletic apparel footwear giant be recently mentioned new high column downside microsemi mscc drop news offer buy pmc sierra pmcs bid top buyout offer apple aapl supplier skywork solution swks microsemi fall buy point consolidation clear friday pmc share jump valeant vrx slump beating view raise guidance open canadian drugmaker post adjust earning share year sale grow third straight period acceleration almost lift full year sale forecast profit be now expect share prior outlook last week valeant say receive subpoena federal prosecutor massachusett new york request information patient assistance program drug pricing decision follow vincent mao twitter ibd_vmao
850,EW,day medical stock perform admirably be surprise also make noteworthy new high edward lifescience ew break flat base rise triple average volume stock close buy point weekend edward announce encourage trial sapien heart
851,EW,stock score big gain monday mark positive action week loss jump close back day move average also recoup last week loss then nasdaq run higher too wipe loss past week nasdaq
852,EW,stock open broad gain rise trade monday dollar oil price decline
853,EW,dow jone industrial average jump leap nasdaq grab gain right start gate
854,EW,volume edge higher open quietly mixed stock market today nasdaq volume turn positive be trade nyse be compare action same time friday
855,EW,economic front industrial production eke february federal reserve report be improvement january decline less gain project analyst consensus utilization factory capacity decline vs january economist have forecast increase
856,EW,homebuilder sentiment also tick lower national association homebuilder report march housing market index drop february read analyst have project uptick
857,EW,drug stock be stir valeant pharmaceutical vrx raise bid salix pharmaceutical slxp share endo pharmaceutical endp subsequently withdraw compete offer stock rise
858,EW,nearly ibd list stock open higher monday
859,EW,largest gain edward lifescience ew leap report result year trial show positive result patient used sapien aortic valf trial find outcome implant similar open heart surgery find deterioration valf gain drive share flat base buy point heavy trade
860,EW,manhattan associate manh knock gain move send developer supply chain software new high leave extend rebound week support stock open broad gain rise trade monday dollar oil price decline dow jone industrial average jump leap nasdaq grab gain right start gate volume edge higher open quietly mixed stock market today nasdaq volume turn positive be trade nyse be compare action same time friday economic front industrial production eke february federal reserve report be improvement january decline less gain project analyst consensus utilization factory capacity decline vs january economist have forecast increase homebuilder sentiment also tick lower national association homebuilder report march housing market index drop february read analyst have project uptick drug stock be stir valeant pharmaceutical vrx raise bid salix pharmaceutical slxp share endo pharmaceutical endp subsequently withdraw compete offer stock rise nearly ibd list stock open higher monday largest gain edward lifescience ew leap report result year trial show positive result patient used sapien aortic valf trial find outcome implant similar open heart surgery find deterioration valf gain drive share flat base buy point heavy trade manhattan associate manh knock gain move send developer supply chain software new high leave extend rebound week support
861,EW,health etfs perked tuesday follow better expect report nation largest health insurer gold price surge boost gold stock material sector help cross keenly watch level first time early december spdr spy post fresh high stock market today highest level dec stock gain follow steadying oil price key earning hearten investor health care select sector spdr xlv jab higher unitedhealth unh earning revenue beat forecast health insurer raise full year forecast strong organic growth good customer retention level xlv slice day move average monday first time health care sector be laggard year trail only financial unitedhealth first health insurer report first quarter be now have report scrutinize clue health care industry be fare company announce remain only handful obamacare public exchange next year state exchange currently unitedhealth stock jump more strong volume johnson johnson jnj also beat earning estimate tuesday revenue match forecast medical product maker add nearly raise full year forecast johnson johnson be hold xlv stock portfolio unitedhealth be medical peer ibd leaderboard stock edward lifescience ew report april meanwhile robotic surgery specialist intuitive surgical isrg report close beat earning estimate stock rise hour orthopedic giant stryker syk be report close wednesday material select sector spdr xlb carved gain tuesday hit fresh high etf have rise session xlb gain come soar gold price boost gold stock include portfolio member newmont mining nem market vector gold miner gdx gap add nearly gdx have soar year date hand profit etf investor buy day global silver miner sil streak ahead highest level more year ishare silver trust slv commodity etf flash more higher highest level june key outside market be bullish posture precious metal tuesday dollar index be weaker crude oil price be higher kitco senior technical analyst jim write tuesday weaker expect housing report give more price upside gold market say here look major exchange trade fund tracking various asset class perform today follow daily etf market action be key successful investing spdr spy rs powershare qqq qqq rs spdr dow jone industrial average dium rs ishare core mid cap ijh rs ishare russell iwm rs ishare msci eafe efa rs vanguard ftse emerge market vwo rs spdr gold share gld rs ishare core aggregate bond agg rs powershare db bullish uup rs ipath vix short term future vxx rs
862,EW,stock market lose mojo second half april grow concern global recession market outlook turn uptrend pressure april tech biotech heavy nasdaq slump spring month be mostly unchanged country lead mutual fund have amp build stock recent month fund have make new additional share purchase such stock concrete uscr mueller water product mwa toro ttc trex trex thor industry tho latest report period medical issue have also be top fund buy list include edward lifescience ew inogen ingn therapeutic anik cambrex cbm utility firm itc holding itc educational course provider new oriental education tech edu stand group heavy buy lead fund click here see list new buy top mutual fundsibd spot top perform fund beef china lodging group htht investing estimate oppenheimer develop market fund odvyx add stock latest report period china base company run several group hotel china typically locate prime location select city such beij shanghai china lodging employ business strategy used lease operate model also utilize manage franchised manachised model model company manage franchised hotel collect fee franchisee china lodging have brand hotel operate hotel city april original hotel brand include joya ji starway hanting strategic alliance accorhotel bring more brand include novotel grand mercure biggest opportunity growth be manachised hotel plan hotel opening mainly focus economy hotel future growth driver come shanghai disney resort first disney park mainland china slate open june stock break cup shape base mid march then currently trading flat base sit just high earning have grow steadily double digit past quarters country lead fund have be take profit member ibd finance property reit group such prologis pld cubesmart cube terreno realty trno dougla emmett dei latest report period wednesday industry group be rank week top fund also sell toy maker mattel mat oil giant exxon mobil xom click here see list latest sell top mutual fund
863,EW,load player clinical trial fda approval process make break biotech pharmaceutical medical device maker stock just ask edward lifescience ew rise nearly april positive trial result sapien family heart valf so much ride success trial surprise clinical
864,EW,week end april diversify stock mutual fund lose average reversed course prior week gain investor be shy take risk weigh stock market news concern prospect interest rate increase central bank apparent inability boost growth globally oil direction china economic slowdown uncertainty cloud decision make portfolio retirement plan latest week top performer diversify stock mutual fund more asset be columbia select large cap growth fund urlgx gain large cap growth fund have shareholder money work stock balance foreign stock feb manager thomas galvin richard carter todd herget have make health care fund largest sector weighting ve bet technology consumer cyclical weighting be year date fund be average annual gain trail year be acuity brand ayi help latest week maker light product rise wednesday stock break conviction breakaway gap past alternate entry remain buy range be trading have be toy buy point earlier week current action remain solid thursday reversal heavy trade acuity lead ware be see strong demand earning share rise past quarters respectively thursday canaccord genuity raise price target clsa downgrade acuity rating outperform buy edward lifescience ew soar week slip thursday developer treatment cardiovascular disorder gap april report positive clinical datum newest heart valve stock be profit take zone past buy point buy mid february however new buyer get now stock gap past buy point monday important buy close open price possible company say february expect global sale aortic valve product exceed entire industry sherwin william shw gain nearly latest week
865,EW,paint maker year average annual earning growth rate be dividend yield be have year streak yearly dividend increase operate margin be double industry average thestreet say brand sherwin william sell include dutch boy hgtv home minwax thompson water seal well namesake label march company say acquire competitor valspar latest week broad market measure lose large cap growth fund lead diversify stock fund lose least week dedicate short bias fund gain health biotechnology fund lead sector tack week global stock fund trail stock fund lose average week china region fund lead global fund category narrowest loss taxable bond fund inched week investor flee risk oriented security treasury fund lead taxable category advance tax exempt bond fund gain average
866,EW,lead medical device maker edward lifescience ew jump monday day artificial heart valve pass hurdle greatly expand market edward conduct large clinical trial compare transcatheter aortic valve replacement tavr sapien traditional open heart surgical valve replacement patient aortic stenosis shrink aortic valve heart be characterize intermediate risk open heart surgery study follow patient day surgery again year later find death stroke be significantly lower sapien group sapien be deliver catheter small incision patient thigh be approve june patient be high risk have open heart surgery add intermediate risk population patient pool lead several analyst hike sale estimate product estimate patient population increase include intermediate risk patient write canaccord genuity analyst jason mill research note raise price target edward lifescience stock increase edward sale estimate pro ep forecast top line projection increase pro ep edward stock rise stock market today close hit new lifetime high stock be already do well ranking ibd also rating spot ibd leaderboard buy point thus profit take zone news also lead analyst lift estimate entire tavr market be currently split edward sapien medtronic mdt corevalve leerink danielle antalffy raise estimate global market edward sapien likely only valve available intermediate risk patient population least next month assume majority incremental market opportunity benefit fall edward antalffy write research note raise price target stock btig analyst sean lavin upgrade stock buy neutral price target medtronic stock rise monday
867,EW,modest loss stock market monday didn get way burgeon new high list screen run late session yielded more name top rate growth stock edward lifescience ew soar company release positive clinical datum new sapien heart valve greatly expand market
868,EW,stock continue hold session high monday afternoon pullback dollar round weaker expect economic datum drop oil price dow jone industrial average lead gain broader rally nasdaq climb volume be run lower major exchange stock market today crude oil be barrel hit year low barrel earlier host medical stock show strength monday edward lifescience ew stretched gain medical device maker release positive study result weekend sunday company say positive result patient treat sapien transcatheter aortic valve point early fda approval edward clear flat base buy point salix pharmaceutical slxp rise valeant pharmaceutical vrx raise buyout offer company rival suitor endo international endp have now drop bid salix share valeant endo be actavis act rise more time high news european regulator clear buyout botox maker allergan agn share actavis be now past buy point flat base downside madison square garden msg be session low still more follow ceo tad departure year job still stock fall back buy point flat base clear early february
869,EW,last monday afternoon entertainment weekly post story book section ominous headline hugo award nomination fall victim misogynistic racist voting campaign few hour headline change correction hugo award voting campaign spark controversy correction so happened version ew story be annual hugo award give science fiction fantasy writer original version ew isabella biedenharn claim misogynist group lobby nominate only white male science fiction book award urge follower cast vote female writer writer color turn slate author recommend group least do include woman minority several fact group campaign fact have nothing do woman minority effort get talented worthy deserving author normally never have chance be nominated supposedly prestigious hugo award accord larry correia brad torgersen start sad puppy campaign bring more ideological diversity hugo nomination start campaign few year correia write blog believe award be politically bias dominate few insider clique author didn group fail appease politically be shun ew reporter didn reach correia anyone else involved check fact apparently didn know story now completely discredit roll stone campus rape article show danger increasingly bias mainstream news medium story fit reporter editor ideological predisposition get rushed print little skepticism careful review apparently actual fact check always vigilant instapundit highlight story follow john merline twitter ibd_jmerline
870,EW,stock be hold session high go noon hour monday volume be tracking lower stock market today
871,EW,crude oil drop nearly bring west texas intermediate lowest level late january
872,EW,tesla motor tsla rise nearly ceo elon musk take twitter announce hold press conference thursday address concern battery range model
873,EW,edward lifescience ew bolt more huge volume company say positive result patient treat sapien transcatheter aortic valve point early fda approval edward clear flat base buy point
874,EW,netflix nflx tumble nearly evercore downgrade share hold sell lower price target trading stock gap be struggle support day move average
875,EW,specialty drugmaker endo international endp withdraw offer salix pharmaceutical slxp valeant vrx sweeten offer
876,EW,valeant raise bid share cash share company have agree last month
877,EW,endo rise salix valeant rise
878,EW,share actavis act allergan agn hit fresh time high european commission approve merger stock be hold session high go noon hour monday volume be tracking lower stock market today crude oil drop nearly bring west texas intermediate lowest level late january tesla motor tsla rise nearly ceo elon musk take twitter announce hold press conference thursday address concern battery range model edward lifescience ew bolt more huge volume company say positive result patient treat sapien transcatheter aortic valve point early fda approval edward clear flat base buy point netflix nflx tumble nearly evercore downgrade share hold sell lower price target trading stock gap be struggle support day move average specialty drugmaker endo international endp withdraw offer salix pharmaceutical slxp valeant vrx sweeten offer valeant raise bid share cash share company have agree last month endo rise salix valeant rise share actavis act allergan agn hit fresh time high european commission approve merger
879,EW,stock finished lower monday volume be lighter investor watch development greece ukraine
880,EW,nasdaq drop dow jone industrial average fall stock market today accord preliminary datum
881,EW,ibd stock be higher be lower best performer be generic drug maker lannett lci report last wednesday earning revenue be better expect stock continue shape right side late stage base
882,EW,worst performer be edward lifescience ew dip back day move average fall more monday be now nearly flat base buy point
883,EW,paycom software payc be nearly buy point double bottom base company report earning close tuesday analyst be forecasting quarterly result cent share vs cent loss year quarter
884,EW,crude oil finished higher make energy stock top performer oil gas driller rise more
885,EW,toy maker be also strong thank well receive quarterly report hasbro have jump more break base new time high
886,EW,airline be worst performer more stock finished lower monday volume be lighter investor watch development greece ukraine nasdaq drop dow jone industrial average fall stock market today accord preliminary datum ibd stock be higher be lower best performer be generic drug maker lannett lci report last wednesday earning revenue be better expect stock continue shape right side late stage base worst performer be edward lifescience ew dip back day move average fall more monday be now nearly flat base buy point paycom software payc be nearly buy point double bottom base company report earning close tuesday analyst be forecasting quarterly result cent share vs cent loss year quarter crude oil finished higher make energy stock top performer oil gas driller rise more toy maker be also strong thank well receive quarterly report hasbro have jump more break base new time high airline be worst performer more
887,EW,abiom abmd cambrex cbm have be standout performer ibd medical product industry group stock be extend now good news be several other name group be set potential move higher head thursday medical product group rank group rank ibd base month price performance
888,EW,stock market bounce session lows tuesday new sign last week bottom hold nasdaq rise erase morning loss apple aapl composite largest component climb nearly news be plan tv subscription service also pare loss still close lower russell
889,EW,edward lifescience corporation ew free report first quarter adjust earning share ep come report ep be cent adjust ep figure beat zack consensus estimate moreover adjust earning improve year year primarily drive strong sale growth transcatheter heart valf business sale detailsfirst quarter sale improve fall short zack consensus estimate underlie sale increase include impact germany stocking sale customer nation choose purchase additional inventory sapien valve anticipation potential supply interruption result recent intellectual property litigation revenue be primarily drive considerable growth transcatheter heart valve sale well strong performance critical care product line segmental detailsin first quarter company report transcatheter heart valve therapy thvt sale reflect growth prior year quarter unite state thvt procedure grow mid teen year year growth be drive excellent clinical performance sapien well continue strong therapy implementation region surgical heart valve therapy sale quarter totale prior year quarter include sale return reserve conversion consignment inventory model however edward lifescience continue witness solid uptake edward intuity elite valve system strong demand latest inspiris resilium aortic valve unite state further company latest product drive underlie sale growth rate surpass total procedure growth rate edward lifescience corporation price consensus ep surprise edward lifescience corporation price consensus ep surprise edward lifescience corporation quotecritical care sale be report quarter represent increase first quarter upside be attribute solid growth product category largely lead hemosphere advanced monitoring platform solid growth unite state asia pacific marginsin first quarter gross margin contract basis point bps owing adverse currency movement continue operational investment however be partially offset more profitable product mix lead grow sale transcatheter valf sg expense rise year year account sale personnel related expense well strengthen euro comparison dollar expenditure increase year year owing continue investment transcatheter aortic valve mitral valve program expenditure clinical trial accordingly adjust operate margin quarter contract bps cash positionedward lifescience exit first quarter cash cash equivalent short term investment compare end long term debt report quarter totale versus end cash flow operate activity be first quarter exclude capital spending free cash flow be quarter average diluted share outstanding totale guidance raisededward lifescience raise adjust ep expectation previous zack consensus estimate full year adjust ep stand low end company guide range however company continue maintain sale expectation high end previously project range zack consensus estimate full year revenue be guide range second quarter company project sale zack consensus estimate revenue be company estimate range company forecast adjust ep meanwhile zack consensus estimate adjust ep be be company forecast range takeedward lifescience exit first quarter mixed note strong transcatheter valve sale domestic market well overseas be major positive raise ep guidance buoy optimism management expect gain traction ever expand tavr market base increase preference transcatheter aortic valve replacement well compelling clinical evidence lead strong adoption thv therapy however tough competition cardiac device market reimbursement issue continue raise concern zack rank key picksedward lifescience have zack rank hold few better rank stock broader medical sector be abaxis inc abax free report bio rad laboratory inc bio free report resm inc rmd free report abaxis bio rad sport zack rank strong buy resm carry zack rank buy see complete list today zack rank stock here abaxis be expect release fourth quarter fiscal result apr zack consensus estimate adjust ep be cent revenue be bio rad be expect report first quarter result zack consensus estimate adjust ep be cent revenue be resm be slate release third quarter fiscal result apr zack consensus estimate adjust ep be cent revenue be investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
890,EW,investor be always look stock be poise beat earning season edward lifescience corporation ew free report be such company firm have earning come pretty soon event be shape quite nicely report be edward lifescience be see favorable earning estimate revision activity late be generally precursor earning beat analyst raise estimate right earning most date information possible be pretty good indicator favorable trend surface ew report fact most accurate estimate current quarter be currently share ew compare broader zack consensus estimate share suggest analyst have very recently bump estimate ew give stock zack earning esp head earning season edward lifescience corporation price ep surprise edward lifescience corporation price ep surprise edward lifescience corporation quotewhy be important positive read zack earning esp have proven be very powerful produce positive surprise outperform market recent year backtest show stock have positive earning esp zack rank hold better show positive surprise nearly time have return average annual return see more top earning esp stock here give ew have zack rank esp positive territory investor want consider stock ahead earning see complete list today zack rank strong buy stock here clearly recent earning estimate revision suggest good thing be ahead edward lifescience beat be card upcoming report today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
891,EW,cardiovascular system inc csii free report expect fiscal first quarter revenue be affected devastate harvey irma hurricane earlier company have estimate revenue range quarter however take effect hurricane account company anticipate drop first quarter revenue previously guide range accord cardiovascular system more company revenue be generate houston florida hurricane have dent procedure volume greater houston area florida moreover fiscal first quarter revenue be more heavily weight september procedure volume start pick summer level thus company be not confident meeting previously guide range first quarter revenue management expect short term performance be affected long term prospect be likely be untarnished majority last year cardiovascular system have be trading broader industry currently stock have gain higher gain broader industry however stock lose announcement sep estimate revision estimate revision trend have be unfavorable company current quarter estimate moved north compare movement opposite direction last month result zack consensus estimate full year have fall cent loss cent share same period zack rank key systemscarry zack rank hold few better rank medical stock be edward lifescience corporation ew free report amedisys inc am free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy amedisys idexx carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month amedisys have long term expect earning growth rate stock have gain last year idexx have long term expect earning growth rate stock have gain last year promising stock pick keep eye news story computer hacking identity theft become increasingly commonplace cybersecurity industry look promising investment opportunity stock buy zack just release cybersecurity investor guide locking profit help answer question new special report give information need make well inform investment choice space more importantly also highlight cybersecurity pick strong profit potential get new investing guide now
892,EW,transcatheter aortic valve replacement tavr market be project witness cagr report analytic publish reportsnreport have be constantly radar market expert courtesy stir cause forerunner space boston scientific corporation bsx free report last february company voluntarily recall core lotus valve device include lotus depth guard drag share pre market trading session article medical device diagnostic industry sadly again november boston scientific announce further delay re launch lotus edge aortic valve system fail meet commit timeline hurt shareholder sentiment even more article medical device diagnostic industry company have opted piper jaffray healthcare conference new york same day pull stock be follow decline market cap meanwhile rejoice situation be edward lifescience corporation ew free report lead player tavr market encouragingly company share have soar lotus valve device recall last february let take sneak peek brewing market investor be keen effectively put money healthcare space backdropboston scientific have be consistently dominate headline development lotus valve device unpleasant reason last february company have call back lotus valve device due issue related premature release pin connect lotus valve delivery system however be not first time company have face such situation earlier company have retract lotus edge valve system similar ground even have face brunt fda order withdraw unit lotus valve circulation europe due lotus valve get unlock delivery system release company have also be disappointing investor continuously delay filing premarket approval pma fda lotus edge valve system currently company expect lotus edge be back european market not also intend roll same unite state same year nevertheless major market analyst believe such numerous product misstep have always end tarnishing brand image deviate customer clinician interest edward lifescience seize boston scientific hit rough patch issue surround lotus valve device edward lifescience reap maximum benefit solid transcatheter heart valve therapy thvt platform company annual investor conference chairman ceo michael mussallem note come end performance accomplishment year significantly exceed expectation expect be strong year edward lifescience primary factor drive company global growth be prosper transcatheter aortic valve therapy business further assert regard management currently project sale transcatheter heart valve therapy moreover edward lifescience expect global tavr opportunity be more make most company have be fire cylinder lately line edward lifescience have term product pipeline track expect new sapien ultra system feature balloon delivery system next generation sheath technology be launch unite state europe later year also company anticipate begin pivotal trial ce marked centera valve system furthermore edward lifescience expect result partner trial sapien valve be present acc follow fda approval later year note market speculator believe edward lifescience solid global presence particularly high potential region europe japan delay comeback key competitive product boston scientific lotus valve help company further cement hold highly potential tavr space other major player ride gain medtronic plc mdt free report corevalve evolut tavr platform comprise corevalve corevalve evolut corevalve evolut pro system have well maintain company position formidable player tavr space article reuter share medtronic have inched boston scientific announcement withdrawal lotus valve device last february notably company record tavr growth mid unite state low international market last report quarter furthermore post acquisition st jude medical abbott laboratory free report integrate popular ce marked portico tavr former structural heart portfolio be expect gain momentum space boston scientific rebound card winston have rightly say man make mistake only wise man learn mistake unwilling let go bountiful opportunity tavr market boston scientific acquire symetis sa structural heart company focuse minimally invasive tavr device company have start selling acurate neo aortic valve europe be also work design acurate neo aortic valve system equip enhance outer sealing skirtfeature moreover boston scientific be look forward leverage exist lotus infrastructure enhance acurate neo valve system better field support geographic expansion next generation product company plan invest unite state japan trial well acurate replace lotus however several opinion have be make round tavr space late market expert believe company eventually replace lotus valve device symetis portfolio other speculate deal have be clinch cushion jitter stem lotus valve device withdrawal few analyst be also opinion boston scientific expend huge amount symetis buyout deal use contingency plan case lotus valve device issue remain unresolved nonetheless dismiss such speculation boston scientific have be consistently emphasize symetis acquisition move broaden tavr suite not replacement lotus valve device end speculation let watch find not boston scientific lotus valve find right weather bloom again zack editor chief go stockfull disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
893,EW,bid strengthen position predictive analytic edward lifescience corporation ew free report have recently announce approval request fda acumen hypotension prediction index hpi software notably company plan target launch product unite state ce marked adjunctive predictive cardiovascular indicator designate fda come minimally invasive flotrac iq sensor advantage acumen hpi software be assist improve decision make high risk surgical patient used software algorithms predict future cardiovascular event evaluation cardiovascular vital sign furthermore acumen hpi feature go well edward minimally invasive hemodynamic monitoring solution glimpse critical care critical care portfolio include pulmonary artery catheter disposable pressure transducer advanced monitoring system aside have line balloon catheter base product surgical clip insert critical care product group sale totale fourth quarter rise underlie basis solid improvement product category be drive strong growth company core product mainly unite state china also company aim tighten hold critical care technology ongoing rollout hemosphere monitoring platform further expansion enhance surgical recovery program market potentialper report market research global predictive analytic market be expect witness cagr approximately thus latest development have come opportune time company cash bountiful opportunity high potential niche market price performanceover past month edward share have outperformed industry belong stock have rally compare industry rise zack rank other key picksedward carry zack rank buy other top rank stock broader medical sector be bio rad laboratory bio free report athenahealth inc athn free report varian medical system inc var free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate athenahealth be zack rank player company have long term expect earning growth rate varian medical have long term expect earning growth rate stock carry zack rank today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
894,EW,edward lifescience corporation ew free report announce receipt ce mark self expand centera valve valve be used severe symptomatic aortic stenosis patient high risk open heart surgery however centera valve be not approve commercial sale unite state company edward centera valve be repositionable retrievable be deliver low profile french motorize delivery system ce mark be base centera eu trial result be present europcr study enrolled high risk patient center europe australia new outcome trial demonstrated high survival rate low rate disable stroke new permanent pacemaker day regulatory approval be likely boost company transcatheter heart valf thv segment precisely thv focusthv segment include technology design treat heart valve disease used catheter base approach opposed open surgical technique fourth quarter company report thv sale growth prior year quarter double digit procedure growth europe latest development be likely further enhance company prospect europe outside unite state underlie growth rate be contribution region late edward lifescience have witness multiple development thv segment edward lifescience announce receipt fda approval aortic mitral valve valve procedure used sapien transcatheter heart valve june management release positive patient outcome sapien valve include high survival rate low rate stroke paravalvular leak market potentialtaking consideration huge growth potential thv market recent ce mark centera valveis strategic persistence market research report global heart valve repair replacement market be project reach worth cagr share price estimate revision trendedward lifescience have be gain investor confidence consistently positive result last year company share price have outperformed industry stock have gain compare industry current estimate revision trend be favorable current year estimate moved north compare movement opposite direction last month result zack consensus estimate full year have rise share zack rank other key picksedward lifescience carry zack rank buy few other top rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report becton dickinson company bdx free report bio rad laboratory have zack rank see complete list today zack rank strong buy stock here company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank becton dickinson company have zack rank company have long term expect earning growth rate wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
895,EW,sep issue update research report lead manufacturer proprietary life science material research system bruker corporation brkr free report last month billerica base company have gain compare industry company impressive second quarter earning revenue growth have bolster market confidence lead further rally share price late company have be witness growth nano surface business restructure cost reduction action portfolio also get boost acquisition hysitron nano indent product begin improve result axs business moreover be upbeat thecompany recent launch venture biotool laboratory macromolecular crystallography be part axs segment bruker nano additionally company gain traction semiconductor metrology market certain industrial apply end market segment zack rank hold company have be consistently introduce product portfolio company recently unveil ray diffraction xrd system japan analytical scientific instrument show jasis be also encourage launch eiger latest generation hybrid photon count hpc pixel detector bruker dectris notably build dectris eiger detector have be integrate bruker advance instrument platform enhance several ray diffraction xrd application be also impressed bruker latest product developmental activity nuclear magnetic resonance nmr spectroscopy business company line launch include neo platform next generation nmr console tiger series spectrometer management also claim have make technical quality progress high temperature superconduct ht tape management expect ht boost ultra high field gigahertz nmr business be also upbeat company receipt fda approval add new species maldi biotyper system efficient microbial identification notably maldi biotyper be company latest revolutionary approach analysis microorganism late bruker have be work chalk strategy improve financial performance initiative include divestiture certain core business outsource various manufacturing activity transfer cease operation certain facility meanwhile company raise revenue guidance raise optimism flip side bruker conduct business international market result adverse currency fluctuation continue result loss company moreover headwind such unfavorable economic condition intense competition continue threat key picksa few better rank medical stock be edward lifescience corporation ew free report amedisys inc am free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy amedisys idexx carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month amedisys have long term expect earning growth rate stock have gain last month idexx have long term expect earning growth rate stock have gain last year promising stock pick keep eye news story computer hacking identity theft become increasingly commonplace cybersecurity industry look promising investment opportunity stock buy zack just release cybersecurity investor guide locking profit help answer question new special report give information need make well inform investment choice space more importantly also highlight cybersecurity pick strong profit potential get new investing guide now
896,EW,aug issue update research report pleasanton base cooper company coo free report company currently carry zack rank buy share cooper have outperformed industry year date share company have increase compare industry gain additionally company earning estimate have moved north current year reflect analyst optimism past month current next earning estimate have increase respectively moreover cooper report earning have beaten zack consensus estimate trail quarters average surprise company lead position market specialty lense be also support highly exclusive product biofinity clariti fact flagship silicone hydrogel lense be expect deliver strong sale come quarters company have also initiate process introduce myday lense domestic market be already available europe have gain significant traction short span time clariti lense also hold significant growth prospect company outlook contact lens industry be favorable fall dropout rate contact lens wearer further market penetration especially develop nation be expect continuous improvisation technology growth international market be something contact lens manufacturer be banking furthermore user preference be shift low feature commodity lense more expensive single use specialty lense such lense aspherical optical property higher oxygen permeable lense silicone hydrogel believe cooper be well position address shift customer preference base expansive product portfolio company recently introduce biofinity energys contact lense be target group user frequently complain discomfort arise prolong usage smartphone tablet laptop car display other device company be leader high margin toric lens market offer multiple design toric lense wide range parameter competitor offer same lense limit design be expect further boost top line growth go forward flip side macroeconomic concern several international market spell trouble company additionally slowdown chinese economy continue dent discretionary spending also give significant international presence cooper remain highly vulnerable fluctuation exchange rate other key picksother top rank medical stock include idexx laboratory inc idxx free report lantheus holding inc lnth free report edward lifescience corporation ew free report edward lifescience sport zack rank strong buy lantheus holding idexx laboratory carry zack rank see complete list today zack rank stock here idexx laboratory have long term expect earning growth rate stock have gain last month lantheus holding have long term expect earning growth rate stock have surge last month edward lifescience have long term expect earning growth rate stock have rally roughly last month simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
897,EW,investor be always look stock be poise beat earning season edward lifescience corporation ew free report be such company firm have earning come pretty soon event be shape quite nicely report be edward lifescience be see favorable earning estimate revision activity late be generally precursor earning beat analyst raise estimate right earning most date information possible be pretty good indicator favorable trend surface ew report analyst have very recently bump estimate ew give stock zack earning esp head earning season edward lifescience corporation price ep surprise edward lifescience corporation price ep surprise edward lifescience corporation quotewhy be important positive read zack earning esp have proven be very powerful produce positive surprise outperform market recent year backtest show stock have positive earning esp zack rank hold better show positive surprise nearly time have return average annual return see more top earning esp stock here give ew have zack rank esp positive territory investor want consider stock ahead earning see complete list today zack rank strong buy stock here clearly recent earning estimate revision suggest good thing be ahead edward lifescience beat be card upcoming report hottest tech mega trend last year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
898,EW,boston scientific corporation bsx free report have recently announce major investment santa rosa base millipede inc augment position field mitral regurgitation mr millipede be developer iris transcatheter annuloplasty ring system treatment severe mr term agreement boston scientific have purchase portion millipede company have also keep option acquire remain share millipede point time prior completion first human clinical study meet certain parameter also millipede have option compel boston scientific purchase remain share closure clinical study full buyout millipede need additional payment boston scientific further be paid achievement commercial milestone regard management note mr occur leak mitral valve cause blood regurgitate left ventricle left atrium heart condition gradually lead heart failure heart rhythm problem patient severe mr often complain compromise heart function tolerate open heart surgery repair replacement leak valve management be optimistic large patient population space be unfortunately underserved moment hence area represent lucrative market be tap patient population benefit fully percutaneous transcatheter procedure fix dilate mitral reduce regurgitation undergo surgery encouragingly millipede iris annuloplasty ring claim be highly customizable specific patient anatomy disease state device be supply transcatheter transseptal delivery system follow standard surgical approach mend decrease size dilate mitral positive note global transcatheter mitral valve replacement market be grow stupendously cagr approximately datum provide technavio apart boston scientific other major player field be edward lifescience corporation ew free report medtronic plc mdt free report abbott free report wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
899,EW,nov issue update research report edward lifescience corporation ew free report stock carry zack rank hold edward lifescience third quarter performance be disappointing revenue earning lag respective zack consensus estimate natural disaster impact third quarter sale tune also higher operate expense continue be drag stock valuation remain stretched huge investment related continuous launch promotion product stiff competition currency headwind reimbursement issue be other challenge last month lead molecular diagnostic company have be trading broader industry stock have lose broader industry gain period positive note third quarter company report transcatheter heart valve therapy thvt sale growth prior year quarter upside be lead strong continue adoption therapy geographical region management thvt adoption quarter grow consistently robust performance sapien valve edward lifescience corporation price edward lifescience corporation price edward lifescience corporation quotewe be also encourage company long term growth strategy recent progress technology pipeline far transcatheter heart valve thv be concern edward lifescience expect maintain leadership position global transcatheter aortic valve replacement tavr market also company focus build pipeline strengthen foothold operate business bode well edward lifescience have also witness growth emerge portfolio mitral tricuspid repair therapy key picksa few better rank stock broader medical sector be petm express inc pet free report myriad genetic inc mygn free report luminex corporation lmnx free report petm myriad sport zack rank strong buy luminex carry zack rank buy see complete list today zack rank stock here petm have long term expect earning growth rate stock have soar roughly year myriad genetic have long term expect earning growth rate stock have gain last month luminexha long term expect earning growth rate stock have rally last month today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
900,EW,company be expect report week include bunch prominent large cap company many dow industrial company have take investor have fall love large cap name company be report week be most watch name street chart aren too shabby not only have beaten nearly quarter past year several be trading year even time high be price perfection win be able match be hot global economy give multinational stock new boost company have spectacular earning chart mcdonald mcd free report hasn miss earning big story be hot stock have be past year now trading forward keep expectation lockheed martin lmt free report have best chart street look beauty have only miss once last year share just keep hit new year high edward lifescience ew free report have see big pullback share last year even keep beating earning be back track break year high visa free report be beast hasn miss year have be nearly ride year high be best chart wall street be too good be true heating global economy give share even more fuel boee ba free report have miss just time last year be also global growth story share have break beat boost share even higher want learn trade option have always want trade stock option be unsure begin look week zack dave bartosiak bring detailed explanation trade live youtube watch go trade answer question real time become dave minion join zack live trader community today free click here join dave more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
901,EW,aug issue update research report sunnyvale base accuray inc aray free report lead developer designer radiosurgery radiation therapy system treatment tumor company currently carry zack rank sell accuray have have unimpressive run bourse late glimpse recent price performance reveal share decline past month compare unfavorably industry increase company have dismal track record characterize consecutive earning miss trail quarters accuray witness low product margin fourth quarter fiscal end jul basis point bps fact dismal performance product segment cause adjust loss cent share wider zack consensus estimate loss penny additionally unsatisfactory performance cyberknife tomotherapy system japan asia pacific be headwind unfavorable product mix more replacement sale cyberknife exist customer base cause drag moreover time employee severance related expense other time part cost dent service margin recent time accuray top line be highly dependent cyberknife tomotherapy system sale however system require high capital expenditure act deterrent healthcare provider positive note be particularly upbeat company extensive product portfolio grow customer base especially eimea region international expansion initiative be poise drive growth moreover receipt fda approval radixact treatment delivery platform be likely boost product revenue long haul key pickssome better rank medical stock be edward lifescience corp ew free report lantheus holding inc lnth free report stryker corporation syk free report edward lifescience sport zack rank strong buy lantheus holding stryker carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have climb last month lantheus holding have long term expect earning growth rate stock have surge last month stryker corporation have long term expect earning growth rate stock have rally roughly last month simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
902,EW,earning season have kick start last week result participant total market cap have be report so far observed index have make pretty good open respect earning revenue growth latest earning preview oct total earning member go higher revenue member line release quarterly result week be decidedly bullish equity market scenario gradually demonstrate improvement sequentially last quarter look medtech space medical overall growth have be steadily accelerate precede few quarters performance investor be concern medical sector zack sector have see lot struggle past half year thank political power change ongoing policy restructure related battle lack visibility befuddle favorable trend sector be maintain past few quarters third quarter expect earning growth rate be standing revenue growth projection comparison report earning growth rate second quarter be quite impressive revenue growth needless say current crisis medtech industry integral part broader medical sector show sign abate medtech space be earlier hopeful change power white house however be currently fuss total failure republican obamacare repeal replacement consider prevailing uncertainty implementation health policy respite term seem unlikely political turmoil health policy related battle apart majority stock bottom line space be likely be hurt third quarter escalate cost induced consecutive hurricane mexico earthquake give gloomy backdrop investor interested medtech space keenly await earning report key medtech company namely edward lifescience corporation ew free report bard inc oct quantitative model stock solid zack rank strong buy buy hold be combine positive earning esp then chance beating estimate be always high uncover best stock buy sell re report earning esp filter sneak peek stockssimilar sequentially last quarter edward lifescience seem be gain strong transcatheter heart valve therapy thvt segment banking continue therapy adoption geographical region notable strength unite state company be expect maintain bullish trend third quarter well growth thvt be drive excellent clinical performance result sapien well continue strong therapy implementation region last quarter also receipt expand fda approval sapien valve early june top line thvt segment be expect get further boost yet be report quarter read edward lifescience gain thvt earning zack consensus estimate thvt net sale reflect increase year quarter zack consensus estimate transcatheter heart valf thv sale unite state show increase year quarter overall third quarter revenue be project also zack consensus estimate net sale unite state reflect increase year quarter notably company earning have outpaced zack consensus estimate average trail quarters edward lifescience have earning esp carry zack rank see complete list today zack rank stock here further stock have see zack consensus estimate third quarter earning cent share be revise penny downward last day however have show rally year report figure zack consensus estimate company revenue be peg yet be report quarter improvement year report number regard also anticipate company arch rival transcatheter heart valf space boston scientific corporation bsx free report fare well business third quarter boston scientific be slate report third quarter number oct market open edward lifescience corporation price ep surprise edward lifescience corporation price ep surprise edward lifescience corporation quote look bard recent performance trend believe grow adoption company flagship lutonix drug coat balloon dcb continue be key growth catalyst soon be report quarter endovascular business peripheral pta line sale be solely drive accelerate demand lutonix dcb unite state expect product significantly contribute company top line quarter read cr bard spring surprise earning season notably company earning have outpaced zack consensus estimate average trail quarters bard have earning esp carry zack rank stock have see zack consensus estimate third quarter earning share be revise penny downward last day however have show improvement year report figure zack consensus estimate company revenue be peg yet be report quarter compare year report figure reflect gain regard note bard be slate be acquire becton dickinson company bdx free report fourth quarter acquisition be expect strengthen company footprint home healthcare market unite state bard inc price ep surprise bard inc price ep surprise bard inc quote comparative analysisanalyze revenue driver other fundamental factor edward lifescience bard respective zack consensus estimate conclude edward lifescience be expect perform better bard yet be report quarter make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
903,EW,edward lifescience corporation ew free report be schedule report third quarter earning oct market close last quarter company have post positive earning surprise be worth note edward lifescience have outperformed zack consensus estimate precede quarters average positive earning surprise let take look thing be shape prior announcement key catalystsimilar prior quarter edward lifescience be expect gain strength transcatheter heart valve therapy segment thvt banking continue therapy adoption geography notable strength unite state company be expect maintain bullish trend third quarter well growth thvt be drive excellent clinical performance result sapien well continue strong therapy implementation region last report quarter moreover receipt expand fda approval sapien valve early june be expect further boost top line thvt segment be report quarter also zack consensus estimate thvt net sale reflect increase year quarter zack consensus estimate transcatheter heart valf thv sale unite state show increase year quarter overall third quarter revenue be project edward lifescience corporation price ep surprise edward lifescience corporation price ep surprise edward lifescience corporation quotehere be other factor influence edward lifescience third quarter result domestic market edward lifescience be expect continue strong performance base strength thvt other segment surgical heart valve therapy critical care company witness strength surgical heart valve therapy back strong uptake edward intuity elite valve system progress surgical heart valve therapy company receive fda approval inspiris resilium aortic valf july other hand growth critical care group be lead double digit growth enhance surgical recovery program especially unite state also zack consensus estimate net sale unite state reflect increase year quarter edward lifescience earlier raise full year sale expectation high end previously provide range moreover note company project total sale adjust earning share cent cent third quarter flip side tough competition cardiac device market reimbursement issue continue challenge company also believe unfavorable foreign currency affect company gross margin be report quarter also management expect third quarter be seasonally lowest quarter add concern here be quantitative model predict edward lifesciencesdoe not have right combination main ingredient positive earning esp zack rank hold higher increase odd earning beat zack esp earning esp foredward lifescience be uncover best stock buy sell re report earning esp filter zack rank edward lifescience carry zack rank increase predictive power esp however also need have positive esp be confident positive earning surprise nonetheless zack consensus estimate earning cent reflect improvement year year basis stock worth lookhere be few medical stock worth consider have right combination element post earning beat quarter abbott free report have earning esp zack rank buy see complete list today zack rank strong buy stock here align technology inc algn free report have earning esp zack rank henry schein inc hsic free report have earning esp zack rank hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
904,EW,sep issue update research report edward lifescience corporation ew free report stock currently carry zack rank hold last month lead molecular diagnostic company have be trading broader industry stock have gain period higher broader industry gain recent fda approval several product include sapien thv valve valve procedure inspiris resilium aortic valve seem be bolster investor confidence stock also raise guidance hint brighter prospect fact outlook raise be backed strong performance company product line be encourage company long term growth strategy recent progress technology pipeline far transcatheter heart valve thv be concern edward lifescience expect maintain leadership position global transcatheter aortic valve replacement tavr market also company focus build pipeline strengthen foothold operate business bode well edward lifescience have also witness growth emerge portfolio mitral tricuspid repair therapy flip side foreign exchange headwind continue mar company international business also competitive landscape overseas market weigh company prospect key picksa few better rank medical stock medical sector be orthofix international ofix free report owen minor inc omi free report orasure technology inc osur free report orthofix international owen minor sport zack rank strong buy orasure technology carry zack rank buy see complete list today zack rank stock here orthofix international have long term expect earning growth rate stock have rally roughly last month owen minor have long term expect earning growth rate stock have gain last month orasure technology have long term expect earning growth rate stock have gain last month today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
905,EW,abbott free report ellipse implantable cardioverter defibrillator icd recently gain fda approval magnetic resonance mr conditional labele solidify company footprint rhythm management space post approval patient implanted ellipse device durata optisure lead be able undergo mri scan moreover ellipse now be available patient suffering severely high heart rhythm need icd mri scan thus believe latest regulatory approval expand company customer base drive top line moreover ellipse be embed feature know abbott tailoredtherapy be capable directly securely wirelessly forwarding therapy related datum patient physician merlin net patient care network continue effort expand mr conditional labele enabled device company receive fda approval mr conditional labele assurity mri pacemaker tendril mri pace lead also company have receive certain prior mr conditional labele approval europe meanwhile abbott have apply fda approval mri conditional labele quadra assura cardiac therapy defibrillator crt product quartet family left ventricular lead interestingly company witness softness rhythm management segment majorly due tough competition mri conditional category product market be dominate well establish player medtronic plc mdt free report boston scientific corporation bsx free report edward lifescience corporation ew free report other abbott strategy gain traction rhythm management sub segment seem be align datum provide ally market research report global cardiac monitoring cardiac rhythm management market be expect see cagr reach value believe unhealthy lifestyle rise agee population continue result high incidence cardiovascular disease be further support datum provide gbi research report global cardiovascular disease market see cagr space market be expect witness highest momentum cagr make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
906,EW,boston scientific bsx free report recently launch advanced resonate family implantable cardioverter defibrillator icd cardiac therapy defibrillator crt system feature heartlogic heart failure diagnostic notably device be fda approve conditional use magnetic resonance imaging mri environment help physician improve heart failure hf management personalize care device combine company smartcrt technology enduralife battery technology allow physician customize device setting accord individual patient need drain battery have go unnecessary replacement procedure heartlogic diagnostic alarm doctor worsening hf condition combine datum sensor assess heart sound respiration rate volume thoracic impedance heart rate activity crt ds resonate family device be enabled smartcrt technology help physician modify pace lower chamber heart used multisite pace capability multus electrode pace company recently initiate enrolment patient manage hf study further assess heartlogic diagnostic boston scientific recently announce positive clinical trial datum multisensor chronic evaluation ambulatory heart failure patient multisense study study base patient be conduct examine performance heartlogic diagnostic prediction possibility study demonstrated heartlogic diagnostic increase ability classify patient high low risk experience hf event last report second quarter boston scientific cardiac rhythm management crm segment reflect year year increase sale meanwhile company have be consistently focuse product development strengthen position niche accord report globaldata heart failure market be estimate reach value cagr consider huge potential market believe latest development be strategically place however company be face tough competition global cardiac monitoring device market establish player abbott free report medtronic plc mdt free report edward lifescience corporation ew free report make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
907,EW,laboratory corporation america holding lh free report labcorp recently announce successful closure acquisition chiltern international group limit specialty cro contract research organization earlier company have enter definitive agreement chiltern shareholder purchase company cash transaction value roughly labcorp expect chiltern generate revenue roughly adjust earning interest taxe depreciation amortization exclude transaction related time cost cost synergy labcorp expect deal boost adjust earning free cash flow first year help earn cost capital third year post acquisition chiltern form part labcorp covance drug development segment management chiltern be major partner serve top biopharma segment help labcorp focus high growth emerge mid market biopharma segment labcorp buyout be expect strengthen position innovative diagnostic drug development solution encouragingly note new combine entity have approximately employee americas europe middle east africa asia pacific labcorp have be consistently headline owing chiltern buyout deal earlier company have announce federal trade commission ftc have grant request early termination wait period chiltern buyout hart scott rodino antitrust improvement act hsr act moreover apart substantial buyout covance labcorp have be consistently enhance add capability strategic merger regard company recently announce plan acquire analytical testing service business chromadex corporation cdxc free report company also announce renewal extension agreement interpace diagnostic group inc idxg free report aim boost cancer portfolio moreover last month labcorp have be trading broader industry period stock have rally industry decline believe chiltern buyout help stock scale higher zack rank key picklabcorp carry zack rank hold better rank medical stock be edward lifescience corporation ew free report sporting zack rank strong buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
908,EW,sep issue update research report gnc holding inc gnc free report lead global specialty retailer product health wellness include vitamin mineral herbal supplement sport nutrition diet company currently carry zack rank hold past year gnc holding have be underperform broader industry company have lose compare decline broader industry period weak margin significant decline revenue year year basis raise concern tough competition change consumer preference federal trade commission ftc regulation continue challenge moreover pittsburgh pa base company exit second quarter disappointing note revenue miss zack consensus estimate earning exceed consensus estimate year year decline front be dampening decline be attribute lower sale company canada manufacturing wholesale segment positive note second quarter management witness positive response new gnc plan company have start incorporating change operation also management be currently work product pricing innovation moreover new consumer enrollment mygnc reward program launch gnc storefront amazon buoy optimism gnc holding be develop product formula address unmet customer need be also expand customer brand raw mega man woman ultra mega gnc probiotic also company prospect international business strong cash position be encourage management expect continue capitalize international revenue opportunity addition franchise store exist market expansion new high growth market growth product distribution exist new market second quarter company international business drive increase revenue rise operate income apart strong commerce business china company witness improvement trend mexico south korea hong kong meanwhile nutritional supplement industry be characterize rapid frequent change demand product new product introduction apart gnc holding international competitor include large pharmacy chain major supermarket chain other big base company global operation management fear face stiff competition company fail function effectively attempt do so require price reduction turn hurt margin key picksa few better rank medical stock be edward lifescience corporation ew free report lantheus holding inc lnth free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy lantheus holding idexx laboratory carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month idexx laboratory have long term expect earning growth rate stock have gain last year zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
909,EW,community health system inc cyh free report subsidiary have close sale washington hospital associate asset regional health divestiture be part company plan selling hospital generate fund minimize debt level hospital divest be yakima regional medical cardiac center yakima toppenish community hospital toppenish long term softening admission have hit hospital company community health system be burden high level long term debt naturally company be take resort divesture pay debt focus more sustainable portfolio hospital network community health system aim reduce debt jul company long term debt stand second quarter community health system receive sale hospital company utilize sale proceed pay term loan earlier community health system have show interest divest hospital have incur comparatively lower bad debt expense divestiture be estimate generate proceed fact company announce expand divestiture program be plan divest hospital account least net revenue mid single digit ebitda margin community health system want focus hospital generate volume growth higher ebitda margin better cash flow company have be aggressively divest asset quest reduce long term debt july company enter agreement hca healthcare inc hca free report sell weatherford regional medical center texas expect divestiture help company lower debt burden zack rank share price movement currently community health system carry zack rank strong sell share community health have gain year date outperform industry gain expect company portfolio restructure drive share stock consider few better rank stock hospital industry be edward lifescience corporation ew free report enteromedic inc sporting zack rank strong buy see complete list today zack rank stock here edward lifescience corporation provide product technology treat structural heart disease critically ill patient worldwide company deliver positive earning surprise last quarters average beat enteromedic develop device treat obesity metabolic disease other disorder company deliver positive earning surprise last quarters average beat be more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
910,EW,sep issue update research report model modn free report provider cloud base revenue management software model be benefit grow customer base transition cloud base application synergy revita acquisition be evident third quarter result adjust loss cent share be narrower year quarter loss dent figure be also better zack consensus estimate loss cent share revenue increase year year model expect fourth quarter gaap revenue come range fiscal gaap revenue defer revenue adjustment be expect be range management continue expect annualize recur revenue arr be represent year year growth share model have gain year date significantly outperform rally industry key growth driverswe believe model be significantly benefit acquisition revita third quarter revita contribute approximately saas maintenance revenue approximately company license implementation revenue follow revita acquisition company have be able expand product suite turn customer base also frequent contract win exist new customer have boost company top line model inc revenue ttm model inc revenue ttm model inc quotedure last report quarter customer base witness addition icu medical medtech company high tech company call ampleon radio frequency rf power provider moreover significant number system become operational third quarter include nephew edward lifescience ew free report japan stryker syk free report shire notably company have eliminate duplicate general administrative sale marketing cost well redundant product outside life science vertical post acquisition initiative be well reflect cost structure drive bottom line zack rank key pickmodel currently have zack rank buy better rank stock broader technology sector be apply material inc amat free report sporting zack rank strong buy see complete list today zack rank stock here long term earning growth rate apply material be project be hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
911,EW,edward lifescience corporation ew free report transcatheter heart valve therapy segment thvt business have be strong growth trajectory late company have be witness continue therapy adoption geography notable strength unite state past few quarters expect strength get reflect first quarter result be schedule release market close apr click here know company overall performance be expect be spotlight thvt thvt business include technology design treat heart valve disease used catheter base approach opposed open surgical technique past few quarters thvt business have be major contributor top line further management continue be bullish business accordingly zack consensus estimate thvt net sale reflect increase year quarter recent time thvt be strong growth trajectory unite state company have be gain receipt fda approval aortic mitral valve valve procedure used sapien transcatheter heart valve be expect boost top line thvt segment be report quarter well edward lifescience corporation price ep surprise edward lifescience corporation price ep surprise edward lifescience corporation quotefurther company be expect continue gain strong sapien clinical performance unite state well strong therapy implementation region accordingly zack consensus estimate transcatheter heart valf thv sale unite state show increase year quarter outside unite state underlie growth rate be impressive contribution region edward lifescience continue see strong tavr therapy adoption japan drive sapien company have be fortify thvt business europe well regard company maintain double digit procedure growth europe last report quarter further edward lifescience announce receipt ce mark self expand centera valve february latest development be likely enhance company prospect europe however zack consensus estimate thv sale outside unite state reflect drop year quarter believe recent development thv space help company deliver superior performance compare last quarter zack consensus estimate thv sale outside unite state reflect sequential rise zack rank stock consideredward lifescience carry zack rank hold few better rank stock broader medical sector be bio rad laboratory bio free report laboratory corporation america holding lh free report labcorp abiom inc abmd free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here have long term expect earning growth rate labcorp have long term expect earning growth rate stock carry zack rank buy abiom have long term expect earning growth rate stock carry zack rank wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
912,EW,pacific bioscience california inc pacb free report first quarter result expect release apr be assume show steady growth product revenue wing core business majorly drive growth decline revenue other segment mar company prospect first quarter last report quarter company report loss cent share year year miss zack consensus estimate penny revenue come beating zack consensus estimate year year basis notably first quarter zack consensus estimate be peg loss cent share reflect year year growth other hand zack consensus estimate revenue be pin indicate decline pacific bioscience report average negative earning surprise trail quarters let delve deeper number pacific bioscience california inc price ep surprise pacific bioscience california inc price ep surprise pacific bioscience california inc quoteproduct revenue focuspacific bioscience flagship platform sequel system have be fortify company footprint worldwide fiscal product revenue account whopping company net revenue fourth quarter fiscal segment post revenue worth year year be encourage note current quarter zack consensus estimate segment revenue be fix year year basis consumable revenue fourth quarter be year year basis mark metric eighth consecutive quarter growth continue consumable sale momentum upside be drive increase utilization company grow install base sequel system also know pacbio sequel system however instrument revenue dip year year basis other factor playpacbio sequel system drife growthper management sequel generate revenue grow more fold fourth quarter represent whopping fourth quarter revenue additionally bgi china order sequel system make primary growth driver pacific bioscience past year number study have be used plan use pacbio whole genome sequence goal increase cure rate genetic disease study include stanford university school medicine european solve rd consortium perform individual rare disease study novogene have announce plan sequence chinese genome platform have also witness series development lately flagship pacbio sequel be currently be used alabama base hudsonalpha institute biotechnology support goal dramatically increase diagnostic success rate challenge pediatric clinical case moreover beij base annoroad gene technology have recently place purchase order pacbio sequel system be expect increase annoroad large scale genomic service capability various field view first quarter revenue be expect be slightly lower report count fourth quarter fiscal due seasonality banking better expect fourth quarter show pacific bioscience expect revenue grow year figure translate approximately total revenue shrink service revenue marginsin last report quarter revenue service other segment fall year year basis almost full year fiscal revenue segment deteriorate compare full year zack consensus estimate segment revenue first quarter be fix year year other hand gross margin quarter be basis point year year company incur operate loss wider loss year quarter here be quantitative model predict pacific bioscience carry zack rank buy do not have positive earning esp need increase odd earning beat zack esp earning esp pacific bioscience be uncover best stock buy sell re report earning esp filter zack rank pacifc bioscience carry zack rank increase predictive power esp however also need positive esp be confident earning beat stock worth lookhere be few medical stock worth consider have right combination element post earning beat quarter stryker corp syk free report have earning esp zack rank see complete list today zack rank strong buy stock here hologic inc holx free report have earning esp zack rank hold edward lifescience ew free report have earning esp zack rank hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
913,EW,myriad genetic inc mygn free report present encourage medical tool riskscore test datum also announce favorable study result myrisk hereditary cancer suite result be present annual conference national society genetic counselor nsgc columbus company have introduce riskscore myrisk hereditary cancer testing portfolio solidify footprint rapidly grow hereditary cancer testing market base salt lake city ut lead molecular diagnostic personalize medicine provider proprietary riskscore be precision medical tool use myrisk get test do notably highly advanced prediction tool help determine woman risk develop breast cancer combine genetic marker genome patient family clinical history management riskscore also assist patient negative result pertain heredity cancer gene derive proper conclusion june company present favorable datum patient clinical study myrisk hereditary cancer test american society clinical oncology asco result highlighted importance multus gene panel testing advancement hereditary cancer risk evaluation platform myriad have be ride high strength heriditary cancer testing space last report quarter company witness year year rise heriditary cancer testing volume mark third consecutive quarter sequential growth report dpi research medium breast cancer screening market unite state be expect reach value roughly moreover article breastcancer org approximately new case invasive breast cancer woman be likely be diagnosed unite state also project new case invasive breast cancer year well believe agee population rise awareness expenditure healthcare continue drive growth breast cancer screening market however market be dominate many well establish player quest diagnostic dgx free report be most prominent space quest diagnostic quest vantage service help discovery genetic variant related hereditary risk type cancer include breast colorectal pancreatic renal moreover myriad have be gain investor confidence consistently positive result past month company share price have outperformed broader industry stock have gain higher broader industry company have also outperformed gain market same time frame zack rank key picksmyriad carry zack rank hold couple better rank medical stock be edward lifescience corporation ew free report lantheus holding inc lnth free report edward lifescience sport zack rank strong buy lantheus holding carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month new report investor guide have become more frequent destructive ever fact re expect cause year damage cybersecurity industry be expand quickly response threat fact project year be spend protect consumer corporate asset zack have just release cybersecurity investor guide locking profit reveal promising investment candidate download new report now
914,EW,initiative boost customer base algerium lead medical device software manufacturer varian medical system inc var free report recently announce conduction day workshop radiotherapy practitioner country varian have system operate algerium moment latest development signify company long term goal serve cancer patient year workshop demonstrate advanced prostate head neck treatment technique be attend clinical team regional hospital latest development be collaboration algerian ministry health help clinician use varian technology deliver advanced radiotherapy cancer patient algerium fact first varian linear accelerator be install year country varian also inked deal algerian ministry equip country cancer treatment center company technology radiotherapy radio surgery meanwhile varian solid performance radiotherapy business improve margin launch halcyon radiotherapy treatment system be key highlight furthermore strong revenue opportunity several oncology imaging component product grow adoption proton therapy strong overseas presence particularly emerge country new partnership be key positive varian have be consistently expand internationally long fact company have receive order australia belgium india morocco romania russia turkey unite kingdom last quarter regard varian proton therapy unit have seal deal bangkok base king chulalongkorn memorial hospital earlier year march brazil base moinhos hospital initiate cancer treatment country used varian technology precisely moinhos used company flagship product calypso tumor tracking system cancer treatment varian have zack rank hold past month varian medical have outperformed broader industry term price company have return compare sub industry also current return be higher gain same time frame key picksa few better rank stock broader medical sector be edward lifescience corp ew free report idexx laboratory inc idxx free report cogentix medical inc notably edward lifescience sport zack rank strong buy idexx laboratory cogentix medical have zack rank buy see complete list today zack rank stock here edward lifescience deliver average earning beat last quarters company have long term expect earning growth rate idexx laboratory deliver average earning beat trail quarters have long term expect earning growth rate cogentix medical come positive earning surprise last quarter stock represent stellar return last year new report investor guide have become more frequent destructive ever fact re expect cause year damage cybersecurity industry be expand quickly response threat fact project year be spend protect consumer corporate asset zack have just release cybersecurity investor guide locking profit reveal promising investment candidate download new report now
915,EW,sep issue update research report latham ny base angiodynamic inc ango free report company be expect maintain focus exclusive technology offer superior outcome economic value healthcare system company currently have zack rank hold strong demand company bioflo platform continue drive sale angiodynamic angiodynamic expand product portfolio international market expansion cost save initiative represent considerable growth opportunity company design manufacture sell wide range medical surgical diagnostic device exclusive endexo technology bioflo be expect enhance company growth trajectory fact new bioflo midline catheter feature have gain significant traction short span time owing easy insertion procedure ability effectively draw blood apart bioflo angiodynamic be lead player thrombolytic catheter space catheter direct thrombolysis well company boast unique catheter uni fuse speedlyser pulse spray thrombus portfolio flipside angiodynamic have high debt level be likely impose certain operate financial restriction impede company core business initiative company end fourth quarter fiscal debt notably company operate result capital resource prove inadequate face substantial liquidity problem be force dispose material asset operation meet debt obligation additionally company also be require reduce delay plan expansion capital expenditure sell asset restructure refinance debt seek additional equity capital sluggish capital spending environment third party risk pricing headwind due aggressive competition regulatory setback be also expect dent top line growth company yielded return almost last year current level be significantly same time frame furthermore current level be lower broader industry gain notably angiodynamic be expose pricing headwind stem lower selling price peripheral vascular product due aggressive price competition key picksa few better rank stock broader medical sector be edward lifescience corp ew free report idexx laboratory inc idxx free report cogentix medical inc notably edward lifescience sport zack rank strong buy idexx laboratory cogentix medical have zack rank buy see complete list today zack rank stock here edward lifescience deliver average earning beat last quarters company have long term expect earning growth rate idexx laboratory deliver average earning beat trail quarters have long term expect earning growth rate cogentix medical come positive earning surprise last quarter stock represent stellar return last year new report investor guide have become more frequent destructive ever fact re expect cause year damage cybersecurity industry be expand quickly response threat fact project year be spend protect consumer corporate asset zack have just release cybersecurity investor guide locking profit reveal promising investment candidate download new report now
916,EW,sep issue update research report omnicell inc omcl free report stock currently have zack rank hold market be upbeat company recently launch xt series automate supply dispense cabinet next generation supply solution have feature provide additional flexibility modular design increase storage capacity advanced technology omnicell have also launch software xt hardware allow aesynt customer fully benefit xt further omnicell recent partnership completerx provide comprehensive medication distribution management solution commonwealth massachusett state office pharmacy service sop be encourage omnicell inc price omnicell inc price omnicell inc quotemoreover company be expand footprint globally omnicell have establish footprint sweden germany singapore middle east south africa china also company witness strong business trend europe healthy acceptance medication adherence product flip side omnicell face intense competition medication management supply chain solution market further company have adopt several strategy drive top line include portfolio expansion acquisition further penetration medication adherence market thus company continue battle escalate cost also stretched valuation add concern last month omnicell have be trading industry latest share price movement stock have gain significantly industry addition key picksa few top rank medical stock be edward lifescience corporation ew free report idexx laboratory inc idxx free report amedisys inc am free report edward lifescience sport zack rank strong buy idexx laboratory amedisys carry zack rank see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month idexx laboratory have long term expect earning growth rate stock have gain last year amedisys have long term expect earning growth rate stock have gain last year look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
917,EW,sep issue update research report align technology inc algn free report stock currently have zack rank hold align technology manufacture market system clear aligner therapy intra oral scanner cad cam computer aid design manufacturing digital service used dentistry orthodontic dental record storage have be trading industry past month stock have gain period compare growth industry company strong invisalign technology prospect growth north america international region look encourage align technology witness balanced sale growth channel recent past primarily drive continue strong invisalign technology case volume customer channel geography align technology inc price align technology inc price align technology inc quotemoreover align technology have be ride high back strong growth internationally reflect continue strong performance emea apac region company also reach new benchmark patient have adopt invisalign treatment encourage development company recently sign distribution agreement patterson dental exclusive agreement effective september align technology itero element intraoral scanning system be available part patterson dental cad cam portfolio unite state canada be also upbeat company sopening new invisalign technology treatment plan facility china company receipt patent smarttrack aligner material also buoy optimism contrary foreign exchange headwind continue raise concern align technology international operation also escalate cost expense be weigh margin moreover tough competitive landscape other macroeconomic headwind pose concern key picksa few top rank medical stock be edward lifescience corporation ew free report idexx laboratory inc idxx free report amedisys inc am free report edward lifescience sport zack rank strong buy idexx laboratory amedisys carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month idexx laboratory have long term expect earning growth rate stock have gain last year amedisys have long term expect earning growth rate stock have gain last year look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
918,EW,sep issue update research report phibro animal health corporation pahc free report nj base company be lead global diversify animal health mineral nutrition company last month phibro have be trading broader industry currently stock have gain compare broader industry be encourage note outside unite state phibro have extend reach brazil other country south america china india asia pacific russia africa feel help company counter competition company continue invest far east asia poultry dairy industry be expect grow exponentially currently company be expand dairy business market australia brazil mexico believe turmoil economy russia greece brazil china phibro have perform quite well have potential maintain performance meanwhile phibro end fiscal fourth quarter solid note net sale adjust earning beating zack consensus estimate also year year increase count be encourage further company witness year year improvement segment be also encourage expansion gross operate margin report quarter moreover full year basis adjust earning net sale surpass zack consensus estimate well year year increase meanwhile company have provide fiscal guidance net sale adjust earning flip side phibro operate highly competitive industry respect major product face threat substantial number global regional player phibro competitive position be principally base product registration customer service support breadth product line product quality manufacturing technology facility location product price furthermore withdrawal approval mecadox carbadox fda continue be concern additionally phibro conduct operation globally entail transaction variety currency result currency fluctuation be major issue company zack rank key picksphibro carry zack rank hold few better rank medical stock medical sector be edward lifescience corporation ew free report lantheus holding inc lnth free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy lantheus holding idexx carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month idexx have long term expect earning growth rate stock have gain last year look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
919,EW,thermo fisher scientific inc tmo free report recently complete buyout patheon notably patheon be lead contract development manufacturing organization cdmo serve pharmaceutical biotechnology sector close deal patheon be part thermo fisher laboratory product service segment thermo fisher initial tender offer patheon expire close deal share cash patheon generate approximately revenue fiscal thermo fisher collaboration significantly strengthen unique value proposition pharmaceutical biotech customer add highly complementary service thermo fisher revenue laboratory product service segment account total revenue grow second quarter company be make consistent effort drive revenue growth segment management expect realize total synergy approximately year follow close acquisition consist approximately cost synergy adjust operate income benefit revenue related synergy accord report market market global laboratory equipment service market be estimate reach cagr look bountiful opportunity niche space believe development be strategic fit be upbeat other takeover thermo fisher recent time regard note thermo fisher buyout fei company close late have help thermo fisher access fei industry lead high performance electron microscopy platform used protein study facilitate life science research company latest takeover affymetrix also deserve mention here genetic analysis affymetrix technology perfectly complement thermo fisher product target clinical apply market also take consideration other strategic purchase thermo fisher finesse solution alfa aesar advanced scientific lambda doe ingall past month thermo fisher have be trading broader industry last trading price stock have gain better broader market decline period zack rank key picksthermo fisher carry zack rank hold few better rank medical stock be edward lifescience corporation ew free report lantheus holding inc lnth free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy lantheus holding idexx laboratory carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month idexx laboratory have long term expect earning growth rate stock have gain last month surprising tech stock keep eye tech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
920,EW,sep issue update research report haemonetic corporation hae free report base lead provider blood management solution customer encompass blood plasma collector hospital health care provider globally stock currently carry zack rank hold haemonetic have be trading broader industry last month stock have now gain broader industry fall year year increase report sale gross margin buoy optimism haemonetic corporation price consensus haemonetic corporation price consensus haemonetic corporation quotemarket be upbeat haemonetic encourage growth plasma haemonetic management franchise company swung operate income first quarter fiscal loss year quarter haemonetic have be witness strong flourish plasma franchise quite time now management have also maintain high confidence continue growth commercial plasma collection business quarter north america plasma disposable revenue increase growth continue be lead strong end market demand plasma derive company hospital business be also progress well teg line product gain popularity worldwide teg be sanction broad set indication top market teg teg manager approval be same set indication europe australia japan flip side company have be witness sluggish revenue growth blood center franchise significantly affect result past few quarters management also doesn expect early recovery blood center outcome macroeconomic uncertainty continue challenge haemonetic management also anticipate slower expect product adoption customer reduce revenue profit also currency fluctuation stiff competition continue hamper stock other key picksa few better rank medical stock be edward lifescience corporation ew free report lantheus holding inc lnth free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy lantheus holding idexx laboratory carry zack rank buy cansee complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have surge last month idexx laboratory have long term expect earning growth rate stock have gain last month more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
921,EW,major breakthrough diabetic business abbott free report recently announce receipt national reimbursement freestyle libre glucose monitoring system japan development have widen illinois base medical device major customer base diabetes management management population diagnosed diabetes japan be consider nation highest rate person suffering condition company state grant reimbursement also make freestyle libre system widely available more japanese person diagnosed type type diabetes insulin therapy vary age also reimbursement approval japan mark milestone abbott freestyle libre system stand partially fully cover country include france germany notably freestyle libre system be presently review fda await approval unite state abbott have be move steadily development diabetic segment july company partner bigfoot biomedical solidify footprint rapidly grow diabetes therapeutic market moreover company recently announce receipt health canada license freestyle libre flash glucose monitoring system further stimulate growth diabetes care sale segment be second quarter continue consumer acceptance freestyle libre internationally expect freestyle libre further contribute abbott top line canadian development french health ministry recently approve national reimbursement device report mordor intelligence global market diabetes care device be project reach value cagr consider market potential abbott current development diabetes care segment recent national reimbursement grant japan accelerate top line believe agee population unhealthy lifestyle rise awareness expenditure healthcare continue drive growth diabetes market however market be dominate many well establish player johnson johnson jnj be most prominent space johnson johnson also have tie base corporation successfully develop innovate insulin delivery system moreover abbott have be gain investor confidence consistently positive result last month company share price have outperformed broader industry stock have gain contrast broader industry decline company have also outperformed fall market same time frame zack rank key picksabbott carry zack rank hold few better rank medical stock be edward lifescience corporation ew free report lantheus holding inc lnth free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy lantheus holding idexx laboratory carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month idexx laboratory have long term expect earning growth rate stock have gain last month more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
922,EW,cooper company inc coo free report report adjust earning third quarter fiscal surpass zack consensus estimate cent improve year quarter believe upside be drive robust revenue growth stock carry zack rank buy revenue increase record prior year quarter figure also beat zack consensus estimate solid top line performance be drive innovative product biofinity daily silicone hydrogel lense revenue cooper company have business segment coopervision cvi coopersurgical csi coopervision segment cvi revenue increase constant currency cc year year basis revenue continue gain company silicone hydrogel lense lead solid prospect myday clariti biofinity platform come major catalyst cvi segment robust performance toric cvi revenue multifocal cvi revenue single use sphere lense cvi revenue single use sphere lense propel solid growth multifocal revenue rise cc toric revenue increase cc year year basis single use sphere lense sale climb cc sale single use sphere lense inched cc year year geographically cvi revenue increase americas revenue asia pacific emea rise year year cc coopersurgical segment csi revenue jump cc year year basis come csi segment fertility category witness rise cc sale report quarter year year basis totale however office surgical product category csi segment inched cc cooper company inc price consensus cooper company inc price consensus cooper company inc quotemargin detailsadjust gross margin report quarter be revenue compare register year quarter gross margin improvement be fuel favorable product mix coopervision segment improve margin coopersurgical segment favorable foreign exchange adjust operate margin percentage revenue be fiscal third quarter flat year year basis guidancefiscal fiscal total revenue be expect band previously issue range revenue cvi segment be estimate previously guide range csi revenue be project range little lower previously guide range meanwhile adjust earning be anticipate band previously provide range share fourth quarter cooper company expect revenue range cvi revenue be expect csi revenue be anticipate company expect adjust earning share cooper company end third quarter fiscal solid note beating zack consensus estimate line company have always see impressive result coopervision business segment coopersurgical segment also deliver strong sale third quarter buoy robust toric performance company provide strong guidance fiscal however dampening outlook coopersurgical segment indicate loom concern furthermore intensify competition contact lens space continue increase pricing pressure company also note cooper company have complete acquisition small specialty contact lens company name procornea earlier month add lead ortho technology company lens portfolio acquisition marked company foray emerge myopia controlled market consider outstanding performance stock expect cooper company scale higher come quarters regard positive long term growth hold promise key picksa few better rank stock broader medical sector be edward lifescience corp ew free report idexx laboratory inc idxx free report cogentix medical inc notably edward lifescience sport zack rank strong buy idexx laboratory cogentix medical have zack rank buy see complete list today zack rank stock here edward lifescience deliver average earning beat trail quarters company have long term expect earning growth rate cogentix medical register positive earning surprise last report quarter stock represent stellar return last year idexx laboratory deliver average earning beat trail quarters have long term expect earning growth rate more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
923,EW,solid prospect lantheus holding inc lnth free report be attractive pick present stock have rally last month ahead gain also better broader industry stock have market cap diagnostic medical imaging agent product provider estimate revision trend current year have also be positive past day analyst moved north be movement opposite direction magnitude estimate revision increase share cent same time frame company report stellar quarter positive average earning surprise earning surprise last report second quarter let find recent positive trend be sustainable headquarter north billerica lantheus holding post solid second quarter result year year increase earning revenue earning share increase year year revenue improve globally back approximately growth definity growth technelite sale globally also raise revenue guidance full year indicate possibility continuation bullish trend full year worldwide revenue guidance have be raise worldwide revenue third quarter be project gross margin exclude impact ge healthcare payment be approximately reflect increase basis point last year improvement be drive increase contribution higher margin product impact xenon cost saving generate addition process finishing capability billerica facility market be also upbeat zack rank buy company consistent effort expand globally company be also look forward receipt chinese regulatory approval necessary start confirmatory study partner double crane definity china program notably first patient cardiac study have already enrolled company have also receive regulatory approval taiwan other key picksa few other better rank medical stock be edward lifescience corporation ew free report petm express inc pet free report idexx laboratory inc idxx free report edward lifescience petm express sport zack rank strong buy idexx laboratory carry zack rank cansee complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month petm express have long term expect earning growth rate stock have gain last month idexx laboratory have long term expect earning growth rate stock have gain last month surprising tech stock keep eye tech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
924,EW,associate home care subsidiary amedisys inc am free report recently enter agreement acquire intercity home care agreement be schedule close oct intercity home care entire asset base be take associate home care post successful acquisition renown home health hospice service provider have more wide spread presence massachusettsas intercity home care have location greater boston north shore merrimack valley community moreover amedisys also gain access extend customer base expect serve client massachusett company have be make encourage move respect recently integrate personal care business last report quarter net service revenue personal care witness increase year year segment generate operate income quarter also amedisys be look forward huge growth prospect personal care segment moreover management segment be perform expectation integrate recent tuck acquisition earlier march company decide buy personal care provider east tennessee personal care service company believe acquisition expand personal care footprint outside massachusett notably management expect company have enough cash balance left make plenty such acquisition future moreover amedisys be currently explore opportunity home health hospice segment too company favorable demographic trend strategic acquisition encourage well moreover amedisys have be gain investor confidence consistent positive result past month company share price have outperformed broader industry stock have gain comparison broader industry gain company have also outperformed fall market same time frame zack rank other key picksamedisys carry zack rank buy other top rank medical stock be edward lifescience corporation ew free report lantheus holding inc lnth free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy lantheus holding idexx laboratory carry zack rank see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month idexx laboratory have long term expect earning growth rate stock have gain last month more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
925,EW,perkinelmer inc pki free report first quarter result expect release apr market close be likely show steady growth core diagnostic business prove be major driver decline revenue other segment mar overall result fourth quarter fiscal company report adjust earning cent share beating zack consensus estimate cent meanwhile revenue be approximately beat zack consensus estimate revenue also surpass year quarter notably first quarter zack consensus estimate earning be peg cent reflect year year growth same revenue be pin indicate growth perkinelmer deliver average positive earning surprise trail quarters perkinelmer inc price ep surprise perkinelmer inc price ep surprise perkinelmer inc quotelet dig deeper diagnostic revenue focusdiagnostic revenue account total revenue last quarter revenue segment rise year also reflect improvement organically segment have be fortify company market position term exclusiveness service respective market diagnostic market company offer product be used detect genetic disorder perkinelmer also provide digital ray flat panel detector infectious disease testing solution diagnostic portfolio first quarter result be likely indicate strong growth diagnostic revenue last report quarter operate profit margin segment percentage revenue be basis point bps year year be also encourage note zack consensus estimate diagnostic segment be sequentially other factor playeuroimmun buyout divestment medical imaging business acquisition euroimmun medical laboratory diagnostic ag have be major driver segment perkinelmer announce completion euroimmun buyout approximately cash december euroimmun be autoimmune testing company emerge player infectious disease allergy testing space management euroimmun buyout have expand perkinelmer capability help gain considerable traction have lead increase diagnostic employee more strengthen company platform company be optimistic increase spending be likely account product revenue fourth quarter euroimmun contribute revenue approximately represent growth be also likely add bps perkinelmer organic growth discovery analytical solution da revenue da totale fourth quarter year quarter perkinelmer have be focuse finalize organizational change associate life science business da lately company have collaborate helix develop commercialize sequence base test help consumer take proactive health management decision however zack consensus estimate revenue be sequentially guidance company issue adjust earning guidance adjust earning be expect share further expect report revenue range include approximately foreign exchange tailwind euroimmun perkinelmer project organic revenue growth thus perkinelmer be confident improve growth trajectory first quarter quantitative model show earning beat perkinelmer quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate zack esp earning esp perkinelmer be uncover best stock buy sell re report earning esp filter zack rank perkinelmer carry zack rank favorable zack rank increase predictive power esp stock worth lookhere be few medical stock worth consider have right combination element post earning beat quarter stryker corporation syk free report have earning esp zack rank see complete list today zack rank stock here hologic inc holx free report have earning esp zack rank edward lifescience ew free report have earning esp zack rank hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
926,EW,align technology inc algn free report be set report first quarter earning result apr market close last quarter company post positive earning surprise align technology have outperformed zack consensus estimate precede quarters average positive earning surprise be let take look thing be shape prior announcement invisalign system major growth driversimilar prior quarters align technology be expect gain continue adoption invisalign technology first quarter well accordingly company project invisalign case shipment band be report quarter year notably november align technology announce achievement milestone patient undergo treatment invisalign system interestingly consider fast expand market clear aligner therapy align technology have undertake several strategy drive adoption core invisalign product line include product technology development extend clinical effectiveness promote invisalign brand name boost international growth company have also be focuse increase invisalign utilization orthodontist particularly target teenager align technology have adopt marketing strategy accelerate consumer demand allow gp dentist treat increase number case invisalign system align technology inc price ep surprise align technology inc price ep surprise align technology inc quotestrength scanner service businessalign technology have also be witness strong revenue growth scanner service business past few quarters moreover company have be witness increase adoption itero scanner invisalign case submission instead pvs impression especially north america thereby drive invisalign utilization management expect bullish trend reflect company first quarter result well same time align technology have be focuse expand option itero scanner context last november company sign agreement glidewell dental distribute itero element intraoral scanning system latest glidewell io office solution north america align technology have also sign distribution agreement patterson dental make available itero element intraoral scanning system part patterson dental cad cam portfolio unite state canada solid global prospect align technology have introduce clear aligner solution class ii correction invisalign technology mandibular advancement certain market canada emea apac be indicative grow popularity dental product international market further recent past align technology report strong international invisalign technology volume continue strong performance emea apac region last report quarter emea volume be continue adoption invisalign technology core market spain france well rapid growth smaller market eastern europe central europe middle east africa asia pacific region company witness impressive volume growth lead china japan australia expect see similar trend yet be report quarter result well overall align technology project ep cent revenue first quarter zack consensus estimate total revenue first quarter indicate rise year quarter quantitative model suggestsper proven zack model company favorable zack rank strong buy buy hold have good chance beating estimate also have positive earning esp align technology have earning esp zack rank combination suggest company likely beat earning quarter uncover best stock buy sell re report earning esp filter zack consensus estimate earning cent reflect rise year year basis other stock considerhere be few other medical stock worth consider have right combination element beat estimate time laboratory corporation america holding lh free report have earning esp zack rank see complete list today zack rank stock here henry schein inc hsic free report have earning esp zack rank edward lifescience corporation ew free report have zack rank earning esp hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
927,EW,be company report earning week focus really be hot big cap stock include dow component fang stock amazon facebook take lot oxygen investor shouldn overlook dozen big cap stock be also everyone radar many company have beat zack consensus estimate consistently past year not easy do several be also trading new multus year high be too hot handle hottest earning chart week edward lifescience ew free report have only miss time last year impressive track record share have bust new year high head report keep momentum boee ba free report have miss only once year share be go nowhere soar share have pull back hit new high january get mojo back return new high visa free report have best chart street period hasn miss year share continue trade time high beat put new level paypal pypl free report hasn miss ipo be spun ebay worry revenue now agreement ebay have change have keep share narrow trading range appease investor fear quarter chipotle cmg free report beat last quarter share still trade year lows really same store sale restaurant chain last quarter first time several year post strong sss number build momentum quarter be chipotle back make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
928,EW,cerner corporation cern free report first quarter result be schedule release market close system sale be likely be growth driver improvement other segment also lead better result fourth quarter cerner report adjust earning share cent cent year figure also miss zack consensus estimate cent cerner have average negative earning surprise trail quarters meanwhile revenue rise year year marginally miss zack consensus estimate first quarter zack consensus estimate earning be peg cent same revenue be reflect year year growth cerner corporation price ep surprise cerner corporation price ep surprise cerner corporation quotelet dig deeper system sale focusin last report quarter segment account total revenue revenue segment totale year year management upside be attribute growth license software moreover full year system sale revenue grow margin increase first quarter zack consensus estimate segment revenue be pin year year other factor playehr prospectscerner electronic health record ehr platform have majorly trigger growth lately company witness slew development ehr platform cerner millenium ehr have be choose be implement new cerner health deployment model texas base menninger clinic cerner be also select illinois rural community care organization ircco implement cerner healtheintent accountable care organization notably healtheintent play significant role drive cerner earning last report quarter company end year healtheintent client resultantly population health booking grow revenue rise furthermore last report quarter company witness record booking growth more be attribute latest ehr deal booking come outside core millennium install base support maintenance servicein last report quarter segment account whopping total revenue revenue segment come year year basis line management expectation first quarter zack consensus estimate revenue segment be peg reflect rise year year guidance solidcerner expect first quarter revenue adjust earning share be project range cent revenue be forecast band full year adjust earning share be estimate range new business booking first quarter be expect range decline margin high debtin last report quarter operate margin come contract basis point bps year year basis downside be cause year year surge operate expense rise be drive personnel expense related revenue generate associate cash item additionally long term debt amount end quarter quantitative model do not conclusively show beat cerner earning season be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate zack esp earning esp cerner be uncover best stock buy sell re report earning esp filter earning esp filter zack rank cerner carry zack rank increase predictive power esp stock worth lookhere be few medical stock worth consider have right combination element post beat earning season stryker corporation syk free report have earning esp zack rank see complete list today zack rank stock here hologic inc holx free report have earning esp zack rank edward lifescience ew free report have earning esp zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
929,EW,athenahealth inc athn free report be schedule report first quarter result apr market close company strong product portfolio solid network expansion strategy unique business model be key tailwind moment last quarter athenahealth post adjust earning share beat zack consensus estimate cent further earning increase whopping year year basis company post revenue beating zack consensus estimate revenue increase year year current quarter zack consensus estimate revenue be peg reflect rise year year zack consensus estimate earning be peg cent indicate increase year year athenahealth inc price ep surprise athenahealth inc price ep surprise athenahealth inc quotewe expect athenahealth witness steady growth business service sale major revenue component be project drive first quarter earning expect improvement implementation other segment also help company generate impressive result consider question linger investor mind be athenahealth be able deliver positive earning surprise be report quarter let delve other factor be likely impact company first quarter result business service focusbusiness service contribute net revenue last quarter upcoming quarterly result zack consensus estimate business service be peg reflect rise year year application athenaclinical athenaclinical streamline athenainsight athenaone athenacollector hospital health system brand promise unbreak healthcare come athenahealth business service segment segment have be fortify company market position term exclusiveness service respective market athenahealth unique business model make strong niche provider revenue cycle management rcm service small physician practice meanwhile research report market market global revenue cycle management market be project reach cagr upcoming result be likely indicate strong growth business service unit other factor other contribute net revenue last quarter zack consensus estimate implementation other be peg reflect rise year year segment include electronic health record ehr electronic medical record implementation late athenahealth have be hog limelight cloud base big datum network athenanet recently company launch machine learn model automate faxe development implementation other be likely drive athenahealth be likely be reflect first quarter result strong product portfolio comprise wide array product include electronic health record revenue cycle management medical bill patient engagement care coordination population health management epocrate end fourth quarter athenahealth launch first machine learn model automate faxe company pilot service authorization management have be plan expand company client base athenainsight online news hub report healthcare activity trend healthcare provider identify patient have also be major contributor athenahealth rapidly expand patient record sharing capability commonwell carequality upcoming quarterly result reflect benefit company strong product portfolio aggressive rivalryon flipside athenahealth ehr solution face significant competition like allscript healthcare solution other competitor such cerner offer long standing seamless product integrate inpatient ambulatory care system dampen company prospect reflect first quarter result model predictsour quantitative model do not conclusively predict earning beat athenahealth quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate be illustrated zack esp earning esp athenahealth be uncover best stock buy sell re report earning esp filter zack rank athenahealth carry zack rank stock worth lookhere be few medical stock worth consider have right combination element post earning beat quarter edward lifescience corporation ew free report have earning esp zack rank see complete list today zack rank stock here hologic inc holx free report have earning esp zack rank teleflex incorporate tfx free report have earning esp zack rank hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
930,EW,only handful player have release number so far earning season expect first quarter see strong revenue reflect solid upward trend estimate revision meanwhile back back event quarter have rattle global economy first be china trade war chaos then come tech backlash stem facebook fb datum fiasco finally chemical attack syrium pave way fresh trouble america russia furthermore apprehension related further rate hike fed continue do round be medical device safe haven be say stock market run sentiment unforeseen event particular sector have ripple effect other go notion medical device sector broader medical universe have proven be refuge investor shrug ongoing tension sector have return year date significantly higher return be medical device company have be ride high innovation increase consolidation focus emerge market tax abolition fact latest earning preview give encourage picture broader medical space expect register year year earning growth revenue growth so rather be interesting see medical device company be place ahead report cycle be major factor shape release growth driversgo cision report unite state be largest medical device market world rake more revenue have be very profitable investment space late consider agee population change market dynamic artificial intelligence ai big datum application upbeat consumer sentiment increase business investment medical device sector appear be pink health here be latest headline space taxe abolish bipartisan year suspension medical device tax impose excise tax medtech manufacturer have be temporary relief be again put effect jan repeal be expect boost hire investment america base medical device manufacturer instilling investor optimism ratification tax repeal amendment have encourage massive investment sector digital revolution take medtech latest trend robotic surgery big datum analytic bio printing printing electronic health record ehr predictive analytic real time alert revenue cycle management service medtech space have be gain prominence various report suggest strategic application ai sphere healthcare provide impetus productivity evidently company adopt ai technology have witness reduction healthcare cost have also experience improve patient outcome more rise minimally invasive surgery higher demand liquid biopsy test use quick improve patient care shift payment system value base model have be drive profit medical device company late buyout rushlately health insurer have be look collaborate pharmacy benefit manager medtech space streamline cost drug supply chain buoy continue capital inflow strategic policy key medical device player have expand customer base moderate leverage enhance cash flow have also alleviate pricing pressure competition medtech space regard latest buyout announcement express script esrx cigna follow just month drug chain pharmacy giant cvs health corp cvs announcement plan acquire nation third largest health insurer aetna be important becton dickinson company bdx takeover bard be also worth mention zack methodology rescuegiven existence number player medical device industry find right stock have potential beat earning banking factor quite intimidate task proprietary zack methodology however make fairly simple narrow choice focuse specifically medical instrument medical product stock specialize chunk medical device subcategory sport desirable combination positive earning esp favorable zack rank strong buy buy hold earning esp be proprietary methodology determine stock have best chance surprise next earning announcement provide percentage difference most accurate estimate zack consensus estimate research show stock combination chance positive earning surprise be high go criterion hereby present stock be poise beat estimate quarter picksedward lifescience corporation ew free report headquarter irvine edward lifescience deal product technology aim treat advanced cardiovascular disease especially structural heart disease critically ill patient company strong pipeline product solid performance deliver tavr market bolster confidence stock edward lifescience higher operate expense have make investor apprehensive be respite fund be used adopt advanced initiative drive overall sale edward lifescience report first quarter result apr market close believe company be set beat zack consensus estimate have zack rank earning esp hologic inc holx free report headquarter bedford hologic develop manufacture supply diagnostic medical imaging system surgical product cater healthcare need woman company be focuse mammography system breast examination osteoporosis assessment company release result second quarter fiscal market close hologic zack rank earning esp raise possibility beat quarter meanwhile see complete list today zack rank stock here stryker corporation syk free report headquarter kalamazoo mi stryker be world largest medical device company operate orthopedic market mako be stryker robotic arm assist surgery platform provide predictable surgical experience perform joint replacement surgery recently stryker launch robotic arm assist total knee arthroplasty application use mako system notably be first only robotic technology be used total knee hip partial knee replacement procedure notably mako total knee utilize stryker robotic platform triathlon total knee system guide ct base modele bone anatomy system also allow intra operative plan assist bone resection procedure stryker report first quarter result apr market close believe stryker be poise trump zack consensus estimate have encourage combination zack rank earning esp teleflex incorporate tfx free report headquarter wayne pa teleflex develop manufacture supply single use medical device common diagnostic therapeutic procedure critical care surgical application worldwide company strong focus high flow nasal cannula therapy hfnct be likely lend competitive edge niche space solid growth preload microbial thrombogenic vps piccs platform be likely strengthen vascular platform surgical segment new product efx ae fortify company foothold finally company flagship lma unique product strengthen anasthesia product line company be expect report first quarter result expect earning beat stock have zack rank earning esp hacker put money portfolio earlier year credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
931,EW,ve written large cap gold miner barrick gold abx free report many time year bear day feature steadily erode earning outlook company be surprise even price gold rally summer peak yellow metal have fall support rally back meanwhile barrick gold share have fall market vector gold miner etf gdx free report fall look earning picture abx zack proprietary price consensus chart explain see be ep left hand scale colored line represent change annual estimate time right hand scale be stock price show steady decline earning growth never really show past year top line isn much better year expect revenue haul post decline last year average price gold be hold higher look technically robust monetary myth barbarous cost produce ounce gold be majority miner element high cost production always hurt miner be past hedge miner have obligation future option otc forward contract sell gold say even then rise spot price don have direct margin leverage think remain bearish gold believe nothing monetary policy inflation outlook much help get back october write special report zack confidential title monetary myth gold explain barbarous relic be soon doom high tech age fiat currency digital finance artificial intelligence instead recommend investor put money real economic growth story nvidia nvda free report alibaba baba free report edward lifescience ew free report report have detailed thesis dynamic gold include dollar inflation relativity currency fluctuation global economy even suggest cryptocurrency bitcoin be prove digital era offer more important economic innovation extract anything dig ground barrick gold indeed be worth something wouldn pay now cash flow be head wrong direction be disclosure own share nvda baba zack tazr trader share ew zack healthcare innovator breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
932,EW,corporation abc free report have underperform industry year time company share grow compare industry rally also sluggishness consult service abcs segment be concern continue witness headwind thank slowdown hepatitis revenue conversion brand drug lower price generic further temporary slowdown pharmedium growth be expect mar bottom line consequently zack consensus estimate adjust earning slip share past month company have zack rank sell indicate expectation term thus here take detailed analysis factor have be plague plague recently receive grand jury subpoena attorney office western district tennessee document lab testing certain type syringe make pharmedium lab base lab be company largest highly automate production facility result subpoena suspend operation recall product facility have yet expire fact official fda also visit facility same reason recently sluggishness unit be likely hamper company specialty distribution segment long haul first quarter fiscal segment result be mar pharmedium company reporty lower expect revenue profit contribution management pharmedium contribution adjust ebit ep fiscal be lower expect due certain ongoing incremental expense operate highly competitive pharmaceutical distribution related health care service market company primary competitor include cardinal health mckesson national generic distributor regional distributor time offload consider headwind investor find be right time dump regard vgm style score model turn be helpful be comprehensive tool help investor screen winning stock broader sector further score highlight determine element stock drive higher unfortunately have vgm style score indicate worst perform stock medtech space least now fact research show stock vgm score combine zack rank strong buy buy offer best upside potential key picksa few better rank player broader medical sector be bio rad laboratory bio free report abaxis inc abax free report edward lifescience corporation ew free report bio rad laboratory sport zack rank see complete list today zack rank stock here company have long term expect earning growth rate abaxis zack rank stock have long term earning growth rate edward lifescience have long term expect earning growth rate stock have zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
933,EW,cardinal health inc cah free report third quarter fiscal result be schedule release market open result be likely show decline core pharmaceutical segment growth other segment be likely make partially second quarter fiscal company report adjust earning share prior year quarter also zack consensus estimate revenue come year year basis outpace consensus estimate notably cardinal health have negative average earning surprise trail quarters zack consensus estimate third quarter earning be peg reflect decline year year same revenue be pin indicate growth cardinal health inc price ep surprise cardinal health inc price ep surprise cardinal health inc quotelet delve deeper pharmaceutical segment focusin last report quarter segment account enormous company revenue revenue segment come year year basis segment witness strong growth specialty business also gain huge number pharmaceutical distribution customer however see drop profit thank generic pharmaceutical pricing recent investment pharmaceutical platform lackluster generic program performance management growth segment be further impede expiration large mail order prime therapeutic current quarter zack consensus estimate revenue sequentially other factor playguidance liftedconsider benefit slash federal tax rate cardinal health raise fiscal outlook company expect adjust earning share continue operation compare previous range medical segmentin fiscal second quarter segment account company revenue revenue segment grow primarily drive patient recovery acquisition medical segment profit increase courtesy higher contribution new exist customer acquisition patient recovery business current quarter zack consensus estimate revenue segment be peg sequentially medical glove unitcardinal health offer robust portfolio medical glove include surgical glove exam glove clean room glove company have be lately face challenge exam glove sub segment last report quarter commodity pricing supply disruption be major draghunt section fiscal lower expectation medical segment due trouble exam glove segment raise concern quantitative model do not conclusively predict earning beat cardinal health earning season be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate zack esp earning esp cardinal health be uncover best stock buy sell re report earning esp filter zack rank cardinal health carry zack rank sell stock worth lookhere be few medical stock worth consider have right combination element post beat earning season stryker corporation syk free report have earning esp zack rank see complete list today zack rank stock here hologic inc holx free report have earning esp zack rank edward lifescience ew free report have earning esp zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
934,EW,boston scientific bsx free report announce positive clinical trial datum multisensor chronic evaluation ambulatory heart failure patient multisense study study base patient be conduct examine performance heartlogic heart failure diagnostic predict impending heart failure hf decompensation study demonstrated heartlogic diagnostic iincrease ability classify patient high low risk experience future hf event presently physician recommend blood test diagnose hf determine disease severity however method be less reliable assessment lose relevance patient condition change multisense trial datum show heartlogic diagnostic expand ability baseline blood test identify patient high risk hf event notably heartlogic diagnostic be already ce marked fda approve be available commercially later year rhythm management segment last report second quarter rhythm management be second largest contributor boston scientific top line include cardiac rhythm management crm crm reflect year year increase sale report quarter accord report globaldata heart failure market be estimate reach value cagr consider huge potential market believe latest development be strategic fit past year boston scientific have be trading broader industry stock have rise period gain broader industry estimate revision estimate revision trend have be favorable company current year estimate moved north compare movement opposite direction last month result zack consensus estimate full year have increase share same period zack rank key picksboston scientificcarry zack rank hold few better rank medical stock be edward lifescience corporation ew free report amedisys inc am free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy amedisys idexx carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month amedisys have long term expect earning growth rate stock have gain last month idexx have long term expect earning growth rate stock have gain last month more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
935,EW,becton dickinson company bdx free report commonly know bd recently launch bd ultra fine micro pen needle mm use pen injection device needle offer comfortable injection experience enhance customer satisfaction notably device be slate distribution month bd have widen needle length option diabetic person interestingly most insurance plan include medicare part cover bd ultra fine micro mm pen needle person diabetes require inject insulin subcutaneous fat abdomen thigh upper arm buttock bd latest needle diabetic person be less likely inject insulin dose muscle accidently accord company needle be rigorously test ensure performance maintain high quality standard medical technology company be consistently try improve performance diabetes care unit bd medical segment bd see diabetes care revenue growth last report third quarter expect bd see higher growth segment day ahead accord report bccresearch global diabetes market reach worth cagr also report market market global human insulin market be expect value grow cagr consider huge potential market believe latest development be strategic fit last year bd have outperformed broader industry term share price company have return compare favorably broader industry gain estimate revision estimate revision trend have be favorable company current year estimate moved north compare movement opposite direction last month result zack consensus estimate full year have increase share zack rank key picksbd carry zack rank hold few better rank medical stock be edward lifescience corporation ew free report amedisys inc am free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy amedisys idexx carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month amedisys have long term expect earning growth rate stock have gain last month idexx have long term expect earning growth rate stock have gain last month more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
936,EW,halyard health inc lead medical technology company recently announce positive clinical datum support use coolief treatment chronic osteoarthritis knee pain coolief be invasive patient treatment used cool radiofrequency technology safely treat chronic pain be also know cool radiofrequency therapy lead dr timothy davis founder medical director orthopedic pain specialist santa monica california randomize multus center study include examination patient month primary effectiveness month month study coolief provide significantly greater longer last pain relief improve physical function higher patient satisfaction intra articular steroid injection positive datum be present last week european society regional anaesthesia pain therapy annual congress lugano switzerland april halyard health receive clearance food drug administration fda marketing coolief relief chronic moderate severe knee pain cause osteoarthritis halyard health share have outperformed industry past month stock have gain period industry decline current level be also better return zack consensus estimate halyard health fiscal increase couple cent share last day similarly fiscal estimate increase cent share same time frame halyard health be alpharetta ga base medical technology company advance health healthcare deliver clinically superior solution prevent infection eliminate pain expedite recovery company offer surgical infection prevention product operate room portfolio innovative medical device focuse pain management respiratory digestive health zack rank other stock considerhalyard health carry zack rank buy few well rank medical stock medical sector be edward lifescience corporation ew free report lantheus holding inc lnth free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy lantheus holding idexx carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month idexx have long term expect earning growth rate stock have gain last year more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
937,EW,transenterix inc trxc free report global medical technology company recently announce have file response fda related senhance surgical robotic system submission company expect receive fda approval system fiscal transenterix share have outperformed industry past month stock have skyrockect compare industry gain same period current level be better return estimate revision trend stock have be dismal estimate move south last month estimate move north notably current year estimate stock decrease cent loss cent share same time frame come back news be bullish company progress fda approval senhance robotic surgery system senhance be multiport surgical robotic system help perform minimally invasive surgery patient recently system get install imperial college london notably senhance be ce marked use general surgery gynecology urology thoracic surgery be not available sale unite state company acquire senhance italy sofar be upbeat global market trend show minimally invasive surgical instrument market be forecast reach total cagr market market follow submission clearance senhance system fda company be able tap bountiful prospect domestic market zack rank key carry zack rank hold few better rank medical stock medical sector be edward lifescience corporation ew free report lantheus holding inc lnth free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy lantheus holding idexx carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month idexx have long term expect earning growth rate stock have gain last year more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
938,EW,abbott free report recently have initiate pivotal clinical study evaluate safety effectiveness modify version amplatzer device device be design correct common congenital heart defect pre term infant device be same larger size amplatzer duct occluder ii product clinical study be conduct patient center unite state accord abbott patent ductus arteriosus pda be life threaten vascular pathway duct heart remain open due failure fetal duct close birth case pda fail close spontaneously premature baby lead difficulty breathe fee pharmaceutical be used time close duct be less effective pre term infant current treatment option pre term infant be not responsive pharmaceutical be limit surgery however surgery be not always possible leave duct open lead fatal outcome infant breaking conventional treatment abbott be develop amplatzer duct occluder ii additional size ado ii device provide physician nonsurgical treatment option address pda defect newborn pre term infant ado ii be already approve use europe study be successful trial result support abbott application fda approval pediatric use country note abbott have be consistently try expand vascular business medical device segment be solid growth trajectory late last report second quarter medical device business sale spiked report basis also recent development include receipt fda approval full maglev heartmate left ventricular assist system also know lvad heartmate system enable physician manage advanced heart failure patient need short term hemodynamic support abbott also announce ce mark first use new confirm rx insertable cardiac monitor icm be world first smartphone compatible icm help physician identify difficult detect cardiac arrhythmia include atrial fibrillation af accord report market market global pediatric interventional cardiology market be estimate see cagr look bountiful opportunity niche space believe company latest development be strategical fit last month abbott have be trading broader industry stock have now gain industry decline zack rank key picksabbott carry zack rank hold few better rank medical stock be edward lifescience corporation ew free report lantheus holding inc lnth free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy lantheus holding idexx laboratory carry zack rank buy cansee complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month idexx laboratory have long term expect earning growth rate stock have gain last month more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
939,EW,phibro animal health corporation pahc free report report adjust earning share ep cent fourth quarter fiscal year year adjust ep also surpass zack consensus estimate cent accord company year year improvement be primarily drive higher gross profit ratio reduce interest expense lower effective income tax rate include time item company report ep cent line year quarter full year adjust earning come increase year period also figure surpass zack consensus estimate net salesin report quarter phibro net sale be year year improvement be drive sale growth animal health mineral nutrition segment performance product fiscal register net sale year also revenue beat zack consensus estimate phibro animal health corporation price consensus ep surprise phibro animal health corporation price consensus ep surprise phibro animal health corporation quotesale segmentsnet sale animal health segment increase report quarter back volume increase nutritional specialty vaccine product group segment nutritional specialty product grow sale vaccine increase principally volume growth product poultry swine industry however sale medicated feed additive mfa other fall primarily due volume decline domestic net sale mfa other decline due reduce volume medically important antimicrobial international net sale increase drive growth asia pacific region be partially offset decline brazil due economic condition net sale mineral nutrition segment increase increase volume higher average selling price result underlie raw material commodity price increase net sale performance product segment increase be drive higher volume copper base product personal care ingredient increase average selling price copper base product however increase be partially offset lower average selling price personal care ingredient operational updatephibro fiscal fourth quarter gross profit increase year year gross margin expand basis point bps selling general administrative expense rise operate margin expand bps year year quarter financial update year date phibro generate cash flow operation compare year period capital expenditure amount period reflect reduction fiscal fy outlookphibro provide fiscal guidance company currently expect generate net sale current zack consensus estimate fall guide range phibro provide adjust ep guidance range current zack consensus estimate be lower end company guide range takephibro end fiscal fourth quarter solid note net sale adjust earning beating zack consensus estimate also year year increase front be encourage further company witness year year improvement segment be also encourage expansion gross operate margin report quarter moreover full year basis adjust earning net sale have surpass zack consensus estimate well year year increase company have provide fiscal guidance net sale adjust earning zack rank peer currently have zack rank hold few better rank medical stock be edward lifescience corp ew free report petm express inc pet free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy petm idexx carry zack rank buy see complete list today zack rank stock here edward lifescience second quarter adjust earning improve year year primarily drive strong sale growth company transcatheter heart valf business stock have gain last month idexx laboratory record second quarter ep cent cer year year report basis moreover revenue rise year year organic basis petm report earning share cent first quarter fiscal year quarter cent moreover net sale report quarter rise year year simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
940,EW,aug issue update research report radnor pa base vwr corporation offer laboratory product service solution company currently carry zack rank buy be eagerly wait close vwr acquisition avantor global supplier ultra high purity material life science advanced technology industry post close expect fourth quarter consolidated entity create major consumable focuse solution service provider high growth life science advanced technology industry buyout build avantor strength include cgmp current good manufacturing practice process significant exposure emerge market vwr vital position americas well europe combine company therefore be serve global customer base area activity research production thus reflect unique advantage fast grow marketplace shareholder point view potential merger avantor seem beneficial move moment consolidation deal have be fix share cash vwr common stock represent enterprise value approximately purchase price represent approximate premium unaffected close stock price day market speculation potential sale vwr start vwr corporation price consensus vwr corporation price consensus vwr corporation quotenotably stock price have already inched closer avantor offer price investor merger closure hence short term upside potential vwr be limit now other key picksa few other top rank medical stock be edward lifescience corporation ew free report lantheus holding inc lnth free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy lantheus holding idexx laboratory carry zack rank cansee complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have surge last month idexx laboratory have long term expect earning growth rate stock have gain last month simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
941,EW,initiative eradicate ambiguity determine medicinal cost discount allscript healthcare solution inc mdrx free report recently launch allscript real time health system exclusive work flow solution optimize clinical financial impact medical prescription enhance prescription price transparency latest launch allscript aim provide clinician patient complete information include medication price cost alternative therapy competitive price prescribe therapy different pharmacy notably allscript be first major healthcare information technology player come such solution undoubtedly allscript real time health system boost consumer knowledge satisfaction management company emb prescription pricing information work flow system help lead pharmacy benefit manager technology partner nation regard management allscript be hopeful company partnership drfirst goodrx surescript deliver real time benefit price information earlier month allscript announce dbmotion solution platform have be select south western sydney phn swsphn deliver integrate care notably dbmotion solution be allscript proprietary community platform dbmotion solution support swsphn goal improve clinical excellence promote quality care also help swsphn collaborate internationally recognize dbmotion site unite state canada israel stock performance lack lusterallscript have zack rank hold company have have discourage run bourse last year stock represent return just compare unfavorably gain further current level be lower broader industry return same time frame notably allscript expect modest increase operate expense second half support business growth company product have long sale cycle involve decision make different managerial level increase company operate expense even result cancellation order takeallscript management be focuse various restructure initiative research development plan launch exclusive product management have also be try streamline operational efficiency cater client need introduction product believe favorable demographic trend reinforce supportive regulatory environment be expect sustain growth demand company higher client demand company population health management solution drive long term growth long term expect earning growth rate instill confidence investor regard key picksa few better rank stock broader medical sector be edward lifescience corp ew free report idexx laboratory inc idxx free report cogentix medical inc notably edward lifescience sport zack rank strong buy idexx laboratory cogentix medical have zack rank buy see complete list today zack rank stock here edward lifescience deliver average earning beat last quarters company have long term expect earning growth rate idexx laboratory deliver average earning beat trail quarters have long term expect earning growth rate cogentix medical come positive earning surprise last quarter stock represent stellar return last year look stock skyrocket upside zack have just release special report boom investment opportunity legal new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
942,EW,sep issue update research report thermo fisher scientific inc tmo free report lead scientific instrument maker stock currently carry zack rank buy past month thermo fisher have be trading broader industry last trading price stock have gain higher broader market gain time frame company continue see strong growth pharma biotech backed solid market fundamental plan growth strategy raise guidance be also encourage company acquisition activity drive growth inorganically also raise hope be particularly upbeat company foray high potential contract development manufacturing organization cdmo space recent acquisition patheon moreover takeover fei company have start contribute thermo fisher analytical instrument portfolio few company other strategic purchase be finesse solution alfa aesar meanwhile waltham base company plan continue strengthen foothold emerge market such china india translate success other high priority opportunity region such south korea russia brazil second quarter company record solid contribution china india middle east be also upbeat company recent open center excellence electron microscopy saudi arabia additionally thermo fisher have strong cash balance enable adopt attractive share repurchase program turn provide solid return investor flip side thermo fisher derive majority revenue international market expose fluctuation foreign currency management currently estimate unfavorable foreign exchange have negative impact top line landscape have become intensely competitive thank change technology customer demand require continual research development other key picksa few other top rank medical stock be edward lifescience corporation ew free report lantheus holding inc lnth free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy lantheus holding idexx carry zack rank see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month idexx have long term expect earning growth rate stock have gain last year look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
943,EW,effort strengthen global presence nuvasive inc nuva free report be plan renovate extend san diego global headquarters lead medical device company also aim add highly sophisticated innovation center excellence facility nuvasive further plan add world class surgeon education lab apart expand work space company intend introduce educate surgeon globe company highly sophisticated spine technology procedure innovation center excellence nuvasive pioneer apply procedurally integrate solution minimally disruptive spine surgery have be steadily strengthen global position company open center excellence amsterdam be follow build new sq ft medical device facility west carrollton moreover company own sq ft facility be used central distribution hub tn nuvasive have be ride strength international business interestingly company witness year year improvement top line front second quarter account robust growth international business encouragingly note quarter marked third consecutive quarter more growth international business thus company effort solidify global footprint seem be strategically align report becker spine review global minimally invasive spine surgery market be expect witness cagr give current market potential believe company be right track gain traction believe agee population unhealthy lifestyle rise awareness expenditure healthcare continue drive growth minimally invasive spine surgery market however market be dominate many well establish player stryker corporation syk free report zimmer biomet holding inc zbh free report notably stryker provide range product es spinal system mantis implant lite decompression tube many more minimally invasive spine surgical solution portfolio moreover zimmer biomet range thoracolumbar product form comprehensive portfolio minimally invasive spine surgery however past month nuvasive share price have underperform industry stock have decline contrast broader industry gain company have also underperform gain market same time frame zack rank key picknuvasive carry zack rank hold better rank medical stock be edward lifescience corporation ew free report zack rank strong buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month surprising tech stock keep eye tech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
944,EW,follow strong revenue performance second quarter luminex corporation lmnx free report announce plan collaborate sutter health bolster molecular diagnostic testing portfolio collaboration be expect enhance company patient care technique especially case cystic fibrosis illness respiratory tract infection meanwhile share luminex have inched follow news release however last month stock have lose almost much wider broader industry decline only term deal sutter health be leverage luminex molecular diagnostic system include xtag cystic fibrosis ary hsv verigene respiratory pathogen flex panel panel reduce diagnosis time patient help eliminate unnecessary procedure molecular testing portfolio get latest development be significant addition luminex molecular testing diagnostic portfolio company have broad product portfolio comprise advanced ary system verigene xmap xtag multicode technology more molecular diagnostic group revenue jump year year basis second quarter solid performance be drive growth automate solution verigene ary platform furthermore segment get additional momentum recently negotiate group purchasing organization agreement be add ary platform exist verigene agreement be establish new agreement company also have large install instrument base luminex lx luminex lx flexmap system magpix technology company have accelerate market acceptance xmap technology development marketing distribution partnership lead company life science market favorable global trendsreport suggest molecular diagnostic market be expect witness stellar growth long haul frost sullivan niche space be currently see cagr compound annual growth rate be estimate reach worth believe collaborative agreement expand luminex customer base bolster foothold niche space meanwhile thermo fisher scientific inc tmo free report be lead player molecular diagnostic space initiative strengthen company laboratory product service revenue segment thermo fisher recently acquire patheon lead contract development manufacturing organization favorable estimate revision company recent earning estimate have be robust current year have see estimate go higher past day next year estimate have see same time period have have significant impact consensus estimate current year consensus have rise past month next year estimate have increase owing favorable estimate revision luminex sport zack rank strong buy signify probability outperformance term other collaborative agreement glanceapart latest deal sutter health luminex have collaborative agreement several company help expand use product technology regard note luminex have earlier announce signing new supply distribution agreement bio techne corp tech luminex also enter similar deal affymetrix affx term agreement ebioscience business division affymetrix commercialize magpix luminex flexmap multiplexed assay platform select country americas asia europe key pickanother top rank stock broader medical sector be edward lifescience corp ew free report notably company sport zack rank see complete list today zack rank stock here edward lifescience have long term expect earning growth rate represent impressive year date return surprising tech stock keep eye tech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
945,EW,becton dickinson company bdx free report popularly know bd second quarter fiscal result be schedule release market open result be likely show steady growth core bd medical segment rise revenue other segment also act driver first quarter bd report earning share beat zack consensus estimate adjust earning increase constant currency cc year year basis revenue come beating consensus estimate show rise year quarter second quarter zack consensus estimate earning be peg reflect year year growth same revenue be pin indicate growth bd deliver average positive earning surprise trail quarters becton dickinson company price ep surprise becton dickinson company price ep surprise becton dickinson company quotelet delve deeper bd medical key growth driverin last report quarter bd medical account whopping company total revenue revenue segment rise cc year year basis management include headwind approximately basis point bps dispense change furthermore add legacy bard have lead accelerate growth segment be also encourage note second quarter zack consensus estimate segment be sequentially medication procedural solution mps revenue grow first quarter second quarter zack consensus estimate be peg sequentially growth be likely be drive continue strength pre filled flush device infection prevention surgical product diabetes care revenue grow growth pen needle yet zack consensus estimate quarter be pin sequentially pharmaceutical system revenue grow first quarter zack consensus estimate second quarter be show rise sequentially revenue medication management solution mms decline zack consensus estimate be sequentially other factor playview solidbd expect fiscal revenue growth range report basis however revenue be expect grow band company expect adjust earning share range previous range current range indicate growth approximately report basis cc management expect bd medical grow life science segment be expect rise growth new bd interventional segment be anticipate acquisition divestituresbd acquisition drive strategy have be instrumental drive growth recently bd acquire bard management bd be way become biggest medical technology device company world approximately annualize revenue closure takeover lead third new business segment bd interventional bd collaborative move fresenius medical care provide sodium chloride saline customer be also worth mention last year bd announce merit medical system have sign agreement acquire certain asset company bd life sciencesrevenue bd life science totale fiscal first quarter cc year segment performance be backed strong number bioscience diagnostic system preanalytical system unit segment also see solid growth outside unite state recently bd announce pre market approval fda bd onclarity hpv assay management be likely boost bd diagnostic system segment zack consensus estimate second quarter be pin sequentially quantitative model predict earning beat bd quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate zack esp earning esp bd be uncover best stock buy sell re report earning esp filter zack rank bd carry zack rank favorable zack rank increase predictive power esp other stock worth lookhere be few other medical stock worth consider have right combination element post beat earning season stryker corp syk free report have earning esp zack rank see complete list today zack rank stock here hologic inc holx free report have earning esp zack rank edward lifescience ew free report have earning esp zack rank today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
946,EW,have be month last earning report edward lifescience corporation ew free report share have lose time frame underperform market recent negative trend continue lead stock next earning release be due dive investor analyst have react late let take quick look most recent earning report order get better handle important catalyst recent earningsedward lifescience report second quarter adjust earning share ep surpass zack consensus estimate wide margin adjust earning also improve stupendous year year primarily drive strong sale growth company transcatheter heart valf business exclude time item net income second quarter come share year year respectively sale detailsedward lifescience second quarter sale improve figure also beat zack consensus estimate underlie sale increase include impact germany stocking sale customer germany elect purchase additional inventory sapien valve anticipation potential supply interruption result recent intellectual property litigation revenue be primarily drive considerable growth transcatheter heart valve sale well strong performance other product line region segment second quarter company report transcatheter heart valve therapy thvt sale reflect growth prior year quarter thvt sale quarter be year year growth be drive excellent clinical performance result be deliver sapien well continue strong therapy implementation region surgical heart valve therapy sale quarter be prior year quarter be lead strong demand edward intuity elite valve system supply recovery mitral valve sale partially offset continue shift surgical aortic valf sapien valve critical care sale be report quarter represent increase second quarter solid growth product category be drive double digit growth company enhance surgical recovery program mainly asia pacific marginsin second quarter gross margin expand basis point bps owing more profitable product mix lead grow sale transcatheter valf be however partially offset adverse foreign exchange sg expense rise year year account sale personnel related expense primarily transcatheter valve thv segment other hand expenditure increase year year owing continue investment company transcatheter mitral valve mitral valve program include expenditure clinical trial adjust operate margin quarter expand bps rise revenue outweighed increase operate expense cash positionedward lifescience exit second quarter cash cash equivalent short term investment compare end first quarter long term debt quarter totale compare report previously cash flow operate activity be second quarter compare previous quarter exclude capital spending free cash flow be quarter management repurchase share offset dilution associate valtech cardio acquisition stock base incentive compensation update guidancebanking solid second quarter performance edward lifescience have raise full year sale expectation high end previously project range zack consensus estimate full year revenue be high end guide range adjust ep expectation have also be raise zack consensus estimate full year adjust ep stand company guide range third quarter company project sale adjust effect germany stocking sale zack consensus estimate revenue be project range company estimate adjust ep meanwhile zack consensus estimate adjust ep be be also company forecast range have estimate be move then follow release investor have witness upward trend fresh estimate have be revision higher current quarter edward lifescience corporation price consensus edward lifescience corporation price consensus edward lifescience corporation quotevgm scoresat time edward lifescience stock have subpar growth score however momentum be do bit better however stock be allocate grade value side putt bottom investment strategy overall stock have aggregate vgm score aren focuse strategy score be be interested company stock be suitable solely momentum base style score outlookestimate have be trend upward stock magnitude revision also look promising stock have zack rank strong buy be expect average return stock next few month
947,EW,aug issue update research report sunnyvale base intuitive surgical inc isrg free report manufacturer da vinci surgical system advanced robot assist surgical system related instrument accessory company currently carry zack rank hold major positive intuitive surgical have have impressive run bourse late glimpse recent price performance reveal favorable return past year compare favorably industry increase company have solid track characterize consecutive earning beat trail quarters recent time intuitive surgical report stellar performance mainly due grow adoption da vinci system physician overall growth global procedure da vinci surgical system enable minimally invasive surgery help avoid trauma associate open surgery performance be also aid grow volume courtesy general surgery oncology urology gynecology procedure intuitive surgical continuously introduce technology surgical system company also plan launch upgrade da vinci flagship vinci xi technology regard management confirm submission document ce mark approval vinci furthermore company expect availability device europe end long haul extensive expenditure product pipeline expansion international market europe drive growth company flipside company expect procedure growth rate slow bit outside unite state come quarters long sale purchase order cycle da vinci system have add wo also expense research development increase significantly first half reflect high spending advanced imaging advanced instrumentation next generation robotic key picksa few better rank medical stock be idexx laboratory inc idxx free report lantheus holding inc lnth free report edward lifescience corporation ew free report edward lifescience sport zack rank strong buy lantheus holding idexx laboratory carry zack rank buy see complete list today zack rank stock here idexx laboratory have long term expect earning growth rate stock have gain last month lantheus holding have long term expect earning growth rate stock have surge last month edward lifescience have long term expect earning growth rate stock have rally roughly last month surprising tech stock keep eye ontech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
948,EW,nxstage medical inc nxtm free report recently announce regulatory approval system platform fda solo home hemodialysis treatment company have also announce provide patient training new indication later year system have be flagship platform nxstage contribute significantly company top line latest development system platform be exclusively formulate new exist system patient reduce transportation cost re hospitalization rate provide dialysis care site fact solo home hemodialysis eradicate need care partner treatment procedure notably company get first only home nocturnal hemodialysis clearance way back management globally number patient fail opt home hemodialysis date due absence care partner help process latest regulatory go ahead be likely lend nxstage competitive edge expand patient base solid access clinical benefit associate home hemodialysis nxstage partner dialyze direct site latest regulatory progress closely follow solid development nxstage dialysis platform earlier month company announce subsidiary nxstage kidney care be partner dialyze direct support need patient need site skilled nursing facility snf dialysis treatment ohio nxstage now leverage system platform dialyze direct unique model treat geriatric snf patient end stage renal disease esrd nxstage be acquiredearlier month german dialysis provider fresenius medical care fms sign agreement acquire outstanding share nxstage share transaction have be value be subject close approval nxstage stockholder other customary condition note nxstage have be gain prominence market late product nxstage pureflow dialysis preparation system nx connect health nxstage system market trend buoy optimismdata market market reveal global hemodialysis peritoneal dialysis market be expect reach worth cagr nxstage continuous effort bolster dialysis unit be likely be benefit bountiful prospect niche space furthermore increase rate esrd case enhance probability nxstage outperformance niche space term share price move upover past year nxstage have add compare favorably same time frame furthermore current level be way higher broader industry gain just same time frame nxstage carry zack rank hold key picksa few better rank stock broader medical sector be edward lifescience corp ew free report idexx laboratory inc idxx free report cogentix medical inc notably edward lifescience sport zack rank strong buy idexx laboratory cogentix medical have zack rank buy see complete list today zack rank stock here edward lifescience deliver average earning beat trail quarters company have long term expect earning growth rate cogentix medical register positive earning surprise last report quarter stock represent stellar return last year idexx laboratory deliver average earning beat trail quarters have long term expect earning growth rate zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
949,EW,strengthen breast health portfolio hologic inc holx free report recently announce receipt pma approval fda clarity hd high resolution imaging intelligent imaging technology follow approval product be now available dimension breast tomosynthesis system notably conjunction enhance image quality radiologist system provide improve technologist moreover aim provide more comfortable mammography experience low dose option encouragingly note hologic have already place mammography system unite state company be optimistic recent addition suite breast cancer screening diagnostic interventional solution breast health business clarity hd high resolution imaging intelligent imaging technologiesper company clarity hd high resolution imaging technology have be develop design articulately subtle lesion fine calcification help diagnose cancer early moreover clarity hd technology combination innovative detector advanced imaging algorithm aid produce superior image regardless breast density size furthermore intelligent imaging technology combination clarity hd technology deliver exceptional overall image quality lower dose breast health unit focuswe be upbeat hologic consistent effort gain traction breast health business have contribute company overall top line growth first quarter fiscal segment record growth constant currency quarter company unique direct consumer initiative segment provide competitive edge niche space bid enhance breast health portfolio hologic recently announce worldwide collaboration deal royal philips phg lead health technology company global partnership agreement provide integrate imaging solution woman health november company announce development distribution agreement clarius mobile health portable ultrasound scanner system also announce receipt clearance fda quantra breast density assessment software later month notably software be used hologic mammography system segment company have redesign strategy continue innovation leadership position mammography also november announce plan make mammography system available dutch breast cancer screening program collaboration tromp medical hologic distributor netherlands line start hologic latest dimension mammography system be install mobile stationary screening facility netherlands market trend buoy optimismper report dpi research medium breast cancer screening market unite state be expect reach value roughly also report gbi research global breast cancer treatment market reach value cagr thus company clearly have solid prospect market share price performanceover past month hologic decline underperform industry gain believe latest fda nod help stock rebound zack rank key pickshologic carry zack rank hold better rank stock broader medical sector be bio rad laboratory bio free report athenahealth inc athn free report edward lifescience corporation ew free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here have long term expect earning growth rate athenahealth be zack rank player have long term expect earning growth rate edward lifescience have long term expect earning growth rate stock carry zack rank buy make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
950,EW,mar issue update research report thermo fisher scientific inc tmo free report company boast strong international operation have witness consistent growth asia pacific emerge market however company earning have be affected unfavorable foreign exchange last few quarters stock carry zack rank hold lead scientific instrument maker have be outperform industry past year stock have rally compare gain industry meanwhile thermo fisher have be witness solid growth globally strong expansion company plan continue strengthen foothold emerge market such china india other region such south korea russia brazil fourth quarter standout contributor be china india south korea china lead way growth high teen company open customer demo center region reflect company lead position electron microscopy precision medicine space company have also invest significantly digital capability india company be currently work tap growth opportunity biopharma healthcare food safety market part strategy effectively deploy capital thermo fisher have undertake several acquisition recent past apart boost revenue deal have drive operate margin also result tax synergy regard thermo fisher acquisition fei company have start boost analytical instrument portfolio also company spend acquisition add lead biopharma contract development manufacturing service patheon buyout significantly enhance company value proposition biopharma customer patheon have start contribute thermo fisher laboratory product service segment flip side thermo fisher derive huge portion revenue international market expose fluctuation foreign currency past several year company earning be affected adverse currency movement great extent apart competitive headwind rise operate cost threat zack rank key pickssome better rank stock broader medical sector be bio rad laboratory bio free report athenahealth inc athn free report edward lifescience corporation ew free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate athenahealth be zack rank player company have long term expect earning growth rate edward lifescience have long term expect earning growth rate stock have zack rank buy make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
951,EW,walgreen boot alliance inc wba free report report adjust earning share ep second quarter fiscal year year constant exchange rate cer figure surpass zack consensus estimate report basis net earning come reflect increase prior year quarter report ep come year year basis total saleswalgreen boot record total sale fiscal second quarter year year cer top line outpaced zack consensus estimate walgreen boot alliance inc price consensus ep surprise walgreen boot alliance inc price consensus ep surprise walgreen boot alliance inc quote segment detailwalgreen boot report operate segment retail pharmacy usa retail pharmacy international pharmaceutical wholesale retail pharmacy segment record sale second quarter highlight improvement year year segment total sale comparable drugstore rise prescription filled comparable store grow account medicare part growth volume growth strategic pharmacy collaboration comparable retail sale drop pharmacy sale account retail pharmacy usa division sale quarter increase year quarter pharmacy sale comparable store rise higher volume retail pharmacy retail pharmacy international division rise year year basis cer owing currency fluctuation cer comparable store sale second quarter decline year year uptick comparable pharmacy sale pharmaceutical pharmaceutical wholesale division record quarterly sale year year cer marginsgross profit report quarter increase year year however gross margin contract basis point bps selling general administrative sg expense be year year however adjust operate income increase adjust operate margin contract bps financial boot exit second quarter cash cash equivalent compare end first quarter long term debt be compare end precede quarter year date company have generate operate cash flow compare year resultant free cash flow be guidance raisedwalgreen boot have raise low high end outlook fiscal ep zack consensus estimate earning be peg company guide range company now expect cash tax benefit tax law change excess fiscal compare previously announce estimate more takewalgreen boot report impressive second quarter fiscal year year increase earning revenue be encourage well also bid ensure availability specialty brand drug express walgreen boot recently announce plan expand exist group purchasing effort be encourage note report quarter company witness highest sale growth last quarters company be also upbeat recent acquisition store rite aid also solid guidance buoy optimism zack rank key pickswalgreen boot carry zack rank hold better rank stock broader medical sector be bio rad laboratory bio free report athenahealth inc athn free report edward lifescience corporation ew free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate athenahealth be zack rank player company have long term expect earning growth rate edward lifescience have long term expect earning growth rate stock have zack rank buy make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
952,EW,medical instrument bigshot abiom inc abmd free report steris plc ste free report be pit other prospective medtech space be estimate reach cagr lucintel notably company benefit innovation increase consolidation recent tax abatement have similar business model often become difficult decide investment option be better further thing stand now scale apparently look evenly balanced company carry zack rank buy thus here take detailed look fundamental company determine stock be currently position better medical instrument space detailed market cap abiom be engage develop manufacturing marketing medical product design assist replace pump function heart failure steris develop manufacture market infection prevention decontamination microbial reduction well surgical support product service company have market cap see complete list today zack rank stock here price performance company have outperformed industry past year abiom share have fared better fact abiom price performance be expect improve latest development signify probability company penetration prophylactic high risk pci cardiogenic shock patient market abiom share surge last month higher rally steris consequently abiom win steris price performance be be consider earning growth projection abiom zack consensus estimate be peg share represent year year growth stock have long term expect earning growth rate steris zack consensus estimate be peg fiscal reflect year year increase abiom win round sale growth projection abiom zack consensus estimate sale be peg next quarter reflect rise prior year steris consensus estimate sale be project next quarter indicate rise almost year year abiom have edge here well drive abiom abiom extensive product portfolio robust demand impella line product continue serve key growth catalyst next several year impella abiom flagship product line have consistently be growth driver impella be world smallest heart pump be support system percutaneous catheter base device offer hemodynamic support heart platform reflect stellar performance third quarter unite state pci cardiogenic shock indication establish new quarterly record company impella adoption increase total high risk pci emergency patient be drive company clinical benefit previous fda approval outside unite state revenue impella heart pump totale be year year predominantly germany record additionally company record revenue japan third quarter fiscal company deliver breakthrough term record earning revenue growth management operational excellence discipline help company achieve highest gross operate margin date abiom inc price consensus abiom inc price consensus abiom inc quote steris solid bulk steris revenue be obtain healthcare pharmaceutical industry growth industry be primarily drive age global population increase number individual be enter prime healthcare consumption year further industry be dependent advancement healthcare delivery acceptance new technology government policy general economic condition increase global life expectancy larger age population increase demand medical procedure turn translate higher consumption single use medical device surgical kit processed steris consider consistent success achieve company offer varied medical equipment customer believe steris hold huge potential expand foothold industry current macroeconomic environment globe have affected steris financial operation government insurance company continue look way contain rise cost healthcare put pressure player healthcare industry steris be exception increase price lesser availability raw material well oil gas impair steris procurement necessary material product manufacture company compete pharmaceutical research industrial customer several player have robust product portfolio global reach well number small company limit product offering operation few country steris plc price consensus steris plc price consensus steris plc quote concludeour comparative analysis indicate abiom be position better steris consider price performance earning growth expectation sale expectation key picksa few other top rank player broader medical sector be abaxis inc abax free report edward lifescience corp ew free report abaxis zack rank stock have long term earning growth rate edward lifescience have long term expect earning growth rate stock have zack rank today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
953,EW,edward lifescience corporation ew free report be slate report first quarter result market close apr last quarter company earning share beat zack consensus estimate moreover edward lifescience have deliver positive earning surprise trail quarters average beat be let see thing be shape prior announcement key catalystsimilar prior quarter edward lifescience be expect gain strength transcatheter heart valve therapy segment thvt banking continue therapy adoption geography notable strength unite state company be expect maintain bullish trend first quarter well company be expect continue gain strong clinical performance sapien unite state well strong therapy implementation region zack consensus estimate transcatheter heart valf thv sale unite state show increase year quarter outside unite state underlie growth rate be solid double digit procedure growth europe be maintain last quarter company also continue see strong tavr therapy adoption japan drive sapien overall first quarter total revenue be project prior year quarter edward lifescience corporation price ep surprise edward lifescience corporation price ep surprise edward lifescience corporation quote here be other factor influence edward lifescience first quarter result edward lifescience be expect continue strong performance base strength other segment surgical heart valve therapy critical care surgical heart valve therapy product group deliver strong performance last quarter drive encourage performance new product strong uptake aortic valf geography moreover buoy continue strong adoption intuity elite valve system management expect intuity elite valve system sale remain track account global aortic sale fiscal management january company have rolled inspiris resilium aortic valf unite state edward lifescience also inform plan launch inspiris resilium japan be track progress well thezack consensus estimate surgical heart valve therapy product sale reflect rise year quarter be also upbeat critical care product group sale witness solid growth product category drive strong growth company core product mainly unite state china also edward lifescience aim strengthen hold critical care technology ongoing rollout hemosphere monitoring platform expansion enhance surgical recovery program accordingly zack consensus estimate critical care product group sale show increase year quarter first quarter company project sale adjust ep model zack model company zack rank strong buy buy hold have good chance beating estimate also have positive earning esp uncover best stock buy sell re report earning esp filter edward lifescience have zack rank earning esp combination suggest company be likely beat estimate zack consensus estimate earning reflect rise year year basis other stock worth lookhere be few other medical stock worth consider also have right combination element post earning beat quarter myriad genetic inc mygn free report have earning esp zack rank see complete list today zack rank stock here henry schein inc hsic free report have earning esp zack rank quest diagnostic incorporate dgx free report have earning esp zack rank medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
954,EW,varian medical system inc var free report recently launch velocity new version flagship velocity cancer imaging platform system enhance patient specific imaging radiation dosimetry target cancer therapy velocity be design patient liver malignancy include rapidsphere module selective internal radiation therapy sirt dosimetry analysis believe varian medical strategy target radiation dosimetry market be timely consider higher profit niche space report business wire global market radiation dosimeter be project witness cagr notably velocity rapidsphere module have receive clearance fda earlier share upvarian medical share have rally follow announcement close fact zack rank hold company outperformed industry year time precisely stock have return compare favorably industry rally also current return be higher index gain varian medical velocity unit drive growthvarian medical velocity platform be major contributor revenue grow strong double digit first quarter fiscal velocity oncology imaging informatic system be vendor neutral software solution collect integrate oncology datum pertain medical imaging treatment metadata help patient ready datum access system allow clinician measure change time enable tumor delineation evaluate cancer treatment used medical imaging datum inclusion rapidsphere software velocity now provide ability cancer care team study tumor response normal tissue toxicity individual patient receive sirt market prospect brightwhile latest development focuss specifically liver cancer space varian medical have be global leader develop deliver cancer care solution type research report mordor intelligence project global liver cancer therapeutic market be expect register cagr however aggressive rivalry niche market be headwind varian medical compete large electronic company such siemens philips well smaller more specialize radiation therapy equipment manufacturer accuray key picksa few better rank player broader medical sector be bio rad laboratory bio free report abaxis inc abax free report edward lifescience corporation ew free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate abaxis zack rank buy stock have long term earning growth rate edward lifescience have long term expect earning growth rate stock have zack rank medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
955,EW,dexcom inc dxcm free report recently announce fda have grant approval marketing new dexcom cgm monitoring system check blood sugar level child adult prick finger diabetes management be first glucose monitoring system permit fda be used standalone continuous glucose monitoring cgm integration automate insulin dose aid system be fda classification particular product platform establish new device type classification necessary control product code further device have approval be eligible approval submission large expand diabetes market strong product portfolio positive tiding regulatory front be likely provide dexcom competitive edge medtech sector cgm prominent space medtechcgm provide continuous insight glucose level day night cision global cgm market be estimate reach report unite state be leader global cgm market dexcom be lead player global cgm market other cgm dexcom fda clear platinum platform be significantly boost company top line inbuilt feature platinum make most innovative system market dexcom announce receipt fda approval dexcom mobile app android device end fourth quarter company confirm development fully disposable real time cgm system verily be expect be complete end company be confident sensor lacklustre price performance dexcom price movement past year have be unimpressive company report negative return compare unfavorably industry rally current level be also lower index gain zack rank key picksdexcom carry zack rank hold few better rank stock broader medical sector be bio rad laboratory bio free report athenahealth inc athn free report edward lifescience corporation ew free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate athenahealth be zack rank player company have long term expect earning growth rate edward lifescience have long term expect earning growth rate stock carry zack rank buy make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
956,EW,mar issue update research report accuray inc aray free report zack rank hold be focuse acquisition partnership stiff competition be major concern buyout tomotherapy morphormic past have help accuray expand product offering capability meanwhile collaboration christie innome help product gain better visibility canada accuray recently announce agreement neuro spinal hospital dubai uae agreement neuro spinal hospital acquire company proprietary medical system consist cyberknife system radixact system tie up premier amerinet be expect help company gain significant traction hospital oncology center flip side accuray be expose intense competition radiation oncology market be characterize rapid technological change company compete like varian medical elekta ab mitsubishi heavy industry viewray brainlab ag market accuray top line be highly dependent cyberknife tomotherapy system sale however system require high capital expenditure be deterrent healthcare provider price performance lack lusterthe company have have unimpressive run bourse late glimpse recent price performance reveal share have lose past month compare unfavorably industry decline believe cutthroat competition weak international sale have lead downside key pickssome better rank stock broader medical sector be bio rad laboratory bio free report athenahealth inc athn free report edward lifescience corporation ew free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate athenahealth be zack rank player company have long term expect earning growth rate edward lifescience have long term expect earning growth rate stock have zack rank buy make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
957,EW,aug issue update research report pleasanton base veeva system inc veev free report global provider cloud software datum solution life science industry company currently carry zack rank hold veeva have impressive run bourse year date trading industry term price performance glimpse price movement reveal veeva share have gain compare favorably industry decline company have solid track characterize consecutive earning beat trail quarters company have strengthen recur part revenue mix significant growth subscription revenue recent time moreover launch veeva vault veeva commercial cloud platform be encourage company be also support considerable strength crm platform veeva industry specific focus give significant leverage view be aptly demonstrated strong sale growth aid new business gain better pricing product innovation company knowledge different component life science industry be help build target product notably product veeva opendata provide customer datum healthcare professional hcp healthcare organization hco affiliation life science major market look ahead veeva be optimistic product pipeline include exclusive range product flagship vault commercial cloud platform product include vault ctms vault promomat dam crm engage meeting crm engage webinar glimpse last report fiscal second quarter result reveal strong revenue adjust earning top bottom line beat zack consensus estimate additionally solid year year subscription revenue growth have enhance recur part company revenue mix however flip side unfavorable foreign currency be expect hurt earning term also escalate cost expense be weigh margin last month comparative study veeva forward forward month basis multiple reflect stock have be quite overvalue key picksa few better rank medical stock be idexx laboratory inc idxx free report lantheus holding inc lnth free report edward lifescience corporation ew free report edward lifescience sport zack rank strong buy lantheus holding idexx laboratory carry zack rank buy see complete list today zack rank stock here idexx laboratory have long term expect earning growth rate stock have gain last month lantheus holding have long term expect earning growth rate stock have surge last month edward lifescience have long term expect earning growth rate stock have rally roughly last month zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
958,EW,aug issue update research report hill holding inc hrc free report stock currently have zack rank sell hill exit last report third quarter mixed note earning ahead estimate revenue miss same company disappoint decline patient support system revenue due impact watchchild architectural product divestiture lower rental revenue hill have underperform broader industry last month stock have now lose versus industry gain foreign exchange stiff competition remain headwind company lower full year revenue earning guidance be indicative persistent sluggish trend go ahead positive note hill see solid year year increase revenue strong international growth hill currently aim gain traction untapped international market successful execution company be focuse product innovation research development also product launch slate fourth quarter be pump investor confidence commercial launch centrella med surg platform regard be worth mention additionally hill merger acquisition pipeline remain robust company aggressively pursue acquisition accelerate growth key clinical focus area namely advance patient mobility wound care prevention surgical safety efficiency clinical solution respiratory help key pick few better rank medical stock be idexx laboratory inc idxx free report lantheus holding inc lnth free report edward lifescience corporation ew free report edward lifescience sport zack rank strong buy lantheus holding idexx laboratory carry zack rank buy cansee complete list today zack rank stock here idexx laboratory have long term expect earning growth rate stock have gain last month lantheus holding have long term expect earning growth rate stock have surge last month edward lifescience have long term expect earning growth rate stock have rally roughly last month more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
959,EW,healthcare diagnostic company laboratory corporation america holding lh free report labcorp continue expand inorganic mean apart huge buyout covance company be steady spree add complementary capability strategic merger follow company announcement acquire analytical testing service business chromadex corp cdxc free report last week labcorp be again headline earlier announce impending acquisition chiltern international group limit specialty cro contract research organization company source federal trade commission ftc have grant request early termination wait period chiltern buyout hart scott rodino antitrust improvement act hsr act close acquisition be expect sep be still subject other customary close condition notably last month labcorp have enter definitive agreement chiltern shareholder purchase company cash transaction value approximate labcorp consolidation strengthen position innovative diagnostic drug development solution buyout covance have already demonstrated value combine diagnostic cro capability labcorp cro business have grow nearly annual revenue chiltern addition be expect further promote development also provide labcorp enhance capability broader client base combine entity have approximately employee americas europe middle east africa asia pacific closure transaction chiltern become part labcorp covance segment former integration enhance latter offering chiltern be major partner serve top biopharma segment assist labcorp focus high growth emerge mid market biopharma segment last month labcorp have be trading broader industry period stock have rally industry loss zack rank key pick labcorp carry zack rank hold better rank medical stock be idexx laboratory inc idxx free report edward lifescience corporation ew free report edward lifescience sport zack rank strong buy idexx laboratory carry zack rank buy cansee complete list today zack rank stock here idexx laboratory have long term expect earning growth rate stock have gain last month lantheus holding have long term expect earning growth rate stock have surge last month edward lifescience have long term expect earning growth rate stock have rally roughly last month more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
960,EW,edward lifescience corporation ew free report have be gain investor confidence consistently positive result past month stock have gain industry decline also company have outperformed increase manufacturer tissue heart valf repair product used replace repair patient diseased defective heart valve have market cap company historical year growth rate be favorable compare industry solid prospect zack rank buy stock be attractive pick investor moment style score edward lifescience have growth score be reflective company strong prospect research show stock growth style score combine zack rank strong buy offer best upside potential let find recent positive trend be sustainable impressive long term growth strategy last december edward lifescience announce outlook focuse long term growth technology pipeline thv edward lifescience expect maintain leadership position global tavr market enhance focus expand patient access actively leverage current valve platform additional indication develop next generation valve platform maintain trust relationship clinician payer regulator long term edward lifescience expect generate organic underlie sale growth meaningfully higher rate industry average margin front company anticipate moderate expansion gross margin improve mix partially offset capacity investment solid global prospectswe believe huge untapped potential emerge market be likely act positive catalyst edward lifescience management be strive strengthen foothold market asia especially japan management continue believe japan hold immense prospect business expansion major emerge nation launch sapien valve japan edward lifescience gas see strong adoption device nation company be look forward launch inspiris resilium aortic valve japan product pipeline development trackwe be encourage edward lifescience focus build pipeline strengthen foothold operate business company also witness growth emerge portfolio mitral tricuspid repair therapy latest development edward lifescience recently announce clinical trial sapien ultra system management expect receive ce mark ultra system second half moreover edward lifescience new ultra system include balloon delivery system next generation sheath technology be expect be available unite state late other key pickssome other top rank stock broader medical space be genomic health ghdx free report align technology inc algn free report stryker corporation syk free report genomic health have expect earning growth rate current quarter stock sport zack rank see complete list today zack rank stock here align technology have project long term earning growth rate zack rank stryker have project long term earning growth rate stock carry zack rank medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
961,EW,ve written large cap gold miner barrick gold abx free report many time year bear day feature most recently april right company report earning fall line analyst estimate here write april steadily erode earning outlook company be surprise even price gold rally summer peak yellow metal have fall support rally back meanwhile barrick gold share have fall market vector gold miner etf gdx fall end april bear day excerpt then abx have actually hold ground yellow metal have drop interest rate rise dollar have rally analyst ep estimate barrick have fall cent cent full year continuation longer term trend be full view zack proprietary price consensus chart see be ep left hand scale colored line represent change annual estimate time right hand scale be stock price show steady decline earning growth never really show past year top line isn much better year expect revenue haul post decline last year be april sale projection current consensus estimate next year show least drop top bottom line be expect monetary myth barbarous relic cost produce ounce gold be majority miner element high cost production always hurt miner be past hedge miner have obligation future option otc forward contract sell gold say even then rise spot price don have direct margin leverage think remain bearish gold believe nothing monetary policy inflation outlook much help get back october write special report zack confidential title monetary myth gold explain barbarous relic be soon doom high tech age fiat currency digital finance artificial intelligence instead recommend investor put money real economic growth story nvidia nvda free report alibaba baba free report edward lifescience ew free report report have detailed thesis dynamic gold include dollar inflation relativity currency fluctuation global economy email ultimate zack com request copy even suggest cryptocurrency bitcoin be prove digital era offer more important economic innovation extract anything dig ground barrick gold indeed be worth something wouldn pay now cash flow be head wrong direction be disclosure own share nvda baba zack tazr trader share ew zack healthcare innovator today stock zack hottest strategy hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
962,EW,varian medical system inc var free report be prospective name global medtech space stock have return compare favorably industry gain year time also current return be higher index rally market capitalization approximately stock have meet earning expectation past trail quarters however company have be grapple few issue moment cutthroat competition persistent softness market freestand clinic be likely hamper company prospect thank somewhat mixed trend stock have zack rank hold here take detailed look company performance operation analyze investor hold stock favore varian medical varian medical impressive performance oncology business improve margin launch halcyon radiotherapy treatment system be key highlight moment favorable revenue opportunity various oncology imaging component product grow adoption proton therapy strong overseas presence particularly emerge country well new partnership deal be positive company have be strong player latin america varian medical announce open new facility jundia brazil extend global manufacturing training footprint region partnership brazilian ministry health varian medical aim bring greater access advanced radiotherapy treatment country greater latin america believe brazil base facility provide access advanced radiotherapy treatment latin america regard research report market datum forecast show radiotherapy market latin america be worth be estimate witness cagr reach consider bountiful prospect varian medical be likely grow manifold leverage oncology segment estimate international agency research cancer world health organization annual cancer rate world be project increase believe higher demand varian medical product china india brazil continue drive international revenue long run company expect revenue range adjust earning share be expect band cash flow operation be project range be probable headwind varian medical compete large electronic company such siemens philips well smaller more specialize radiation therapy equipment manufacturer elekta accuray emerge proton therapy market company face competition hitachi ion beam application mevion medical system sumitomo intense competition be anticipate increase expenditure nascent proton therapy market keep margin pressure moreover pricing pressure traditional radiotherapy be major concern further lackluster performance particle therapy segment have be concern revenue segment decline year year basis first quarter fiscal still hold unhindered persistent issue analyst be optimistic varian medical zack consensus estimate be peg share show increase last month current quarter zack consensus estimate be reflect rise varian medical system inc price consensus varian medical system inc price consensus varian medical system inc uptick be attribute varian medical product solution have be experience rapid adoption be evident company impressive top line performance first quarter revenue totale increase year year varian medical have vgm style score here stand value growth momentum notably vgm score be comprehensive tool help investor screen winning stock broader sector further score highlight determine element stock drive higher research show stock vgm score offer best upside potential varian medical system inc revenue ttm varian medical system inc revenue ttm varian medical system inc quotein investor want hold stock courtesy prospect outperform peer future temporary sluggishness company have be successful front be evident year year expansion top line believe varian medical innovative product pipeline continue drive overall growth long term key picksa few better rank player broader medical sector be bio rad laboratory bio free report abaxis inc abax free report edward lifescience corporation ew free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate abaxis inc abax free report zack rank buy stock have long term earning growth rate edward lifescience have long term expect earning growth rate stock have zack rank look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
963,EW,surmodic inc srdx free report recently announce promising clinical trial presentation datum preveil early feasibility study ef company surveil drug coat balloon dcb vascular interventional advance conference accord company preveil be multus center single arm trial design evaluate safety feasibility paclitaxel dcb surveil be used treat subject symptomatic peripheral artery disease pad due lesion femoral popliteal artery surmodic share have outperformed broader industry past month stock have gain period compare industry current level be also better return positive surveil result closely follow regulatory approval same platform reflect surmodic solid surface technology muscular device particularly drug delivery space come back news month datum be base patient be treat clinical site study show subject secure positive outcome demonstrate trial acute success measure safety company aim use lower drug dosage enhance drug transfer impact arterial wall reduce amount drug reach tissue outside area treatment surveil dcb meanwhile company anticipate increase expense second half fiscal be increase investment related surveil dcbtrial other proprietary product estimate revision latest estimate revision trend have be favorable company current year estimate moved north compare movement opposite direction last month result zack consensus estimate full year earning have increase cent share takeaccording report market research future global peripheral artery disease market be expect reach worth cagr period consider huge potential market believe latest development be strategic fit zack rank key zack rank hold few better rank medical stock medical sector be edward lifescience corporation ew free report lantheus holding inc lnth free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy lantheus holding idexx carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month idexx have long term expect earning growth rate stock have gain last year look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
964,EW,lead provider advanced cloud base datum analytic datum drive intervention platform healthcare industry inovalon holding inc inov free report recently announce have enter year agreement unitedhealth group unh free report agreement inovalon holding proprietary platform be utilize unitedhealth enable unitedhealth enable ultra high speed analytic better clinical quality outcome insight real time datum visualization medicare advantage commercial membership nationwide engagement help drive population health program more member unite state use platform bolster unitedhealth health management business include aggregation patient datum multiple health information technology resource analysis datum single actionable patient record synthesize datum then be used improve clinical financial outcome past month inovalon holding have outperformed industry stock have increase compare only gain industry belong inovalon holding aim make big market population health management be anticipate grow significantly come year need population health management be become imperative healthcare payment system be shift base fee service volume patient serve base value improvement patient health associate decrease healthcare cost go forward be optimistic continue advancement inovalon holding technology platform client base expand platform applicability sale pipeline also long term expect earning growth rate project sale growth instill confidence investor inovalon holding be technology company provide cloud base datum analytic datum drive intervention platform healthcare sector company operate service group zack rank key picksinovalon holding carry zack rank hold few better rank medical stock medical sector be edward lifescience corporation ew free report amedisys inc am free report edward lifescience sport zack rank strong buy amedisys carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month amedisys have long term expect earning growth rate stock have gain last month trade profit big league trump policy stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
965,EW,nuvasive inc nuva free report successfully continue make way company strategy strengthen footprint fast grow spine market follow last week announcement vertera spine buyout company be once again news courtesy commercial launch lessray software technology system nuvasive lessray system be base propriety software algorithm hardware component particularly work help address overexposure radiation hospital operate room mostly case minimally invasive spine surgery mis study result provide company spine orthopedic surgeon receive lifetime occupational radiation limit first year career statistic reveal cancer rate contraction cataract associate radiation exposure be nearly double compare other surgery practice nuvasive claim lessray system proprietary image enhancement technology improve low dose low radiation fluoroscopy image derive similar diagnostic capability conventional full dose fluoroscopy accordingly reduce radiation emission exposure retain high resolution full radiation dose shot nuvasive consider breakthrough important milestone healthcare facility begin sell capital equipment bring technology advancement hospital apart curb radiation exposure lessray system enhance imaging capability improve spine surgery productivity eventually predictability take consideration healthy pipeline interest customer nuvasive expect huge customer adoption rate follow launch lessray system notably nuvasive be leave stone unturned capture rapidly evolve spine market recently report second quarter company core spinal hardware business maintain bullish trend report growth upside be drive strong consistent adoption reline posterior fixation system company iga platform company also witness steady uptake recently launch expandable interbody cage base ti interfixated alif procedure latest acquisition vertera spine nuvasive aim market distribute vetera spine fda approve cohere cervical coalescetm lumbar interbody fusion device unite state deal also lend company dimensional porous interbody technology peek titanium material past month nuvasive have underperform broader industry stock have sunk contrast gain broader industry period expect company bounce back slew latest development spine space zack rank key picksnuvasive currently carry zack rank hold better rank medical stock be edward lifescience corporation ew free report lantheus holding inc lnth free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy lantheus holding idexx carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have surge last month idexx have long term expect earning growth rate stock have soar last year trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
966,EW,ishare morningstar mid cap growth etf jkh free report be launch be passively manage exchange trade fund design offer broad exposure mid cap growth segment equity market fund be sponsored blackrock have amassed asset make average size etfs attempt match mid cap growth segment equity market mid cap growthmid cap company have market capitalization usually have higher growth prospect large cap company be less volatile small cap company thus have nice balance growth potential stability quality growth stock include faster growth rate compare broader market well higher valuation higher average sale earning growth rate also growth stock be type equity carry more risk compare other consider growth versus value growth stock be usually clear winner strong bull market tend fall flat nearly other environment costssince cheaper fund tend produce better result more expensive fund assume other factor remain equal be important investor pay attention etf expense ratio annual operate expense etf be putt par most peer product space have month trail dividend yield sector exposure top holdingsetfs offer diversify exposure thus minimize single stock risk be still important delve fund holding investing most etfs be very transparent product many disclose holding daily basis etf have heaviest allocation information technology sector portfolio healthcare industrial round top look individual holding servicenow inc now free report account total asset follow edward lifescience corp ew free report red hat inc rht free report top holding account total asset management performance riskjkh seek match performance morningstar mid growth index fee expense morningstar mid growth index measure performance stock issue mid capitalization company morningstar index methodology define mid capitalization stock stock form market capitalization percentile market capitalization stock eligible be include morningstar market index etf return be roughly so far year be last year past week period have trade etf have beta standard deviation trail year period make medium risk choice space holding effectively diversify company specific risk morningstar mid cap growth etf hold zack etf rank strong buy be base expect asset class return expense ratio momentum other factor jkh be outstanding option investor seek exposure mid cap etfs segment market be other additional etfs space investor consider well ishare mid cap growth etf ijk free report ishare russell mid cap growth etf iwp free report track similar index ishare mid cap growth etf have asset ishare russell mid cap growth etf have ijk have expense ratio iwp charge bottom linepassively manage etfs be become increasingly popular institutional well retail investor due low cost transparency flexibility tax efficiency be excellent vehicle long term investor learn more product other etfs screen product match investment objective read article latest development etf investing universe please visit zack etf center
967,EW,global medical device industry have demonstrated strong sustainable growth recent past banking age population increase incidence chronic lifestyle disease increase adoption artificial intelligence ai big datum application upbeat consumer sentiment increase business investment sector appear be pink health go kpmg datum medical device industry global annual sale be forecast rise more year reach nearly cision report say unite state be largest medical device market world present rake more revenue several socio political hazard economic dip medical device company have be ride high innovation increase consolidation emerge market expansion tax cut undoubtedly have be very profitable investment space late here be few major development abolition medtech tax bipartisan year suspension medical device tax impose excise tax medtech manufacturer mark temporary relief be again put effect jan repeal be expect boost hire investment america base medical device manufacturer thus instilling investor optimism ratification tax repeal amendment have encourage massive investment sector uptrend continuesapart tax relief medtech fraternity have also be ride high ongoing merger acquisition trend space fact various report suggest have be key catalyst drive healthcare space late datum provide biospectrum asia activity medtech space surge increase value aggregate more major acquisition recent past include becton dickinson company bdx free report acquisition bard johnson johnson jnj free report buyout actelion pbm health insurer health insurer have be look collaborate pharmacy benefit manager medtech space streamline cost drug supply chain buoy continue capital inflow strategic policy key medical device player have expand customer basis moderate leverage enhance cash flow have also alleviate pricing pressure competition medtech space regard latest buyout announcement express script cigna ci free report come just month drug chain pharmacy giant cvs health corp cvs free report announcement acquire nation third largest health insurer aetna be important digital revolution medtechlatest trend robotic surgery big datum analytic bio printing printing electronic health record ehr predictive analytic real time alert revenue cycle management service medtech space be gain prominence various report suggest strategic application ai sphere healthcare provide impetus productivity company adopt ai technology have witness reduction healthcare cost have also experience improve patient outcome more rise minimally invasive surgery higher demand liquid biopsy test use quick improve patient care shift payment system value base model have be drive profit medical device company late trade war fear grip medtechthe sector have be identify trump imposition higher tariff be now investor radar healthcare include medical equipment be sector likely bear brunt trade dispute go datum provide article christian jone mondaq medtech firm unite state currently sell annually china nation import china total medical device export medical device last year totale create worldwide trade surplus needless say medical device lobby be extremely apprehensive propose tariff chinese product significantly affect international trade zack industry rankwithin zack industry classification medical device be broadly group medical sector zack sector further sub divide industry expand level medical instrument medical product medical dental supply medical info system rank industry zack sector base earning outlook fundamental strength constituent company zack industry rank be top zack classify industry medical info system top medical dental supply top medical instrument bottom medical product backtesting show top zack rank industry outperform bottom factor more analyze zack industry rank different medical device segment be say apart certain medical product stock term outlook aforementioned medical device subsector be overall positive price price performance major zack categorize sub industry be follow past day have gain med instrument space have rise stock space have be trading be varian medical system inc var free report steris plc ste free report edward lifescience corp ew free report medical product subsector industry rank indicated bearish tone sector have increase period player space be haemonetic corp hae free report baxter international inc bax free report boston scientific bsx free report zack ipo watch listbefore look stock mentioned want get head start potential tech ipos be pop zack radar imagine be first wave investor jump company almost unlimited growth potential special report give current scoop go public time have drive valuation year other be little less obvious already show jaw drop growth download ipo watch list today free
968,EW,fomc be poise raise fed fund target rate quarter point hour be certainty morning ppi inflation datum come hotter expect market player be most focuse be dot plot pace future hike show more rate increase be more likely year show committee member think economic growth inflation datum warrant more hike video accompany article go market psychology large investor fear drive stock market sell fed view be seize buy opportunity addition explain thing investor be worry flatten yield curve rise inflation datum give probability weight scenario stock market reaction also share wisdom favorite economist brian wesbury first trust have be astute fed watcher couple decade lean brian here help navigate level interest rate economy handle still support expansion investor optimism come away completely confident conclusion buy sell unfold come day week favorite stock target be alibaba baba free report lam research lrcx free report centene cnc free report edward lifescience ew free report latter have be make great new time high month even add more crispr therapeutic crsp free report fear gene editing go wrong get do disclosure own baba lrcx share zack tazr trader portfolio cnc ew crsp zack healthcare innovator portfolio kevin cook be senior stock strategist zack investment research run tazr trader healthcare innovator service click follow author receive latest stock research macro analysis hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
969,EW,share boston scientific corporation bsx free report gain close jun follow speculation company rival stryker corporation syk free report consider bid acquire former news be wall street journal report trading stock be temporarily pause monday session nyse yesterday close boston scientific market cap be compare stryker follow reuter report state be still unclear boston scientific be open potential buyout proposal stryker prospective acquirer too decline comment report meanwhile benzinga report write bid have surpass share accord stifel nicolaus well fargo predict share be value base becton dickinson cr bard deal accord bloomberg previous bsx stryker be not first time stryker boston scientific have come strategic collaboration back orthopaedic device giant buy boston scientific neurovascular unit time rationale divestment decision boston scientific come part company aggressive restructure initiative more specifically neurovascular division company core business be struggle depress sale rationale latest rumore boston scientific position prospect possible sell rumor be still unknown analyst believe reason company contemplation probable sell lie interest gain further competitive edge medical device space be important note post colossal merger medtronic mdt free report covidien abbott free report st jude medical last couple year boston scientific also need make mammoth move maintain foothold highly competitive medical technology space merger get materialize finally consider boston scientific stryker present market cap then consolidated entity have combine market cap more accord well fargo security be position only medtronic johnson johnson term total device revenue react widely speculate buyout bid retire twin city med tech stock analyst thom gunderson say make perfect sense go big go home be rule day analyst seem optimistic allege deal believe finally work boston scientific score vantage point fast grow competitive heart valve replacement market be currently trail edward lifescience ew free report medtronic also merger be expect reduce cost combine company time healthcare industry be already battle severe pricing pressure share price comparisonover past year share boston scientific have rally ahead stryker increase broader sector remain much rise boston scientific stryker currently carry zack rank buy see complete list today zack rank stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
970,EW,edward lifescience corporation ew free report have be healthy growth trajectory late positive tiding regulatory front have be lend company competitive edge medtech solid prospect zack rank buy stock be attractive pick moment edward lifescience have outperformed broader industry last month stock have gain ahead decline industry stock have market cap company year historical growth rate be also favorable compare increase industry gain company have positive earning surprise last quarters also have long term expect earning growth rate headquarter irvine company estimate revision trend current year have be positive past couple month analyst moved north movement opposite direction earning estimate rise share same time frame let find recent positive trend be sustainable favorable regulatory tidingsin bid strengthen position predictive analytic edward lifescience recently announce approval request fda acumen hypotension prediction index software notably company plan target launch product unite state market be also upbeat edward lifescience recent ce mark self expand centera valve regulatory approval be likely boost company transcatheter heart valf segment management continue anticipate ce mark enrollment cardiaq valve regard company have already begin treat patient ce mark trial call clasp pascal transcatheter mitral repair program solid guidanceedward lifescience have raise sale expectation high end previously project range adjust ep expectation have also be lift earlier product pipeline developmentwe be encourage edward lifescience focus build pipeline further strengthen foothold operate business company also witness growth emerge portfolio mitral tricuspid repair therapy edward lifescience new ultra system include balloon delivery system next generation sheath technology be expect be available unite state europe late other key picksa few other top rank stock broader medicalsector be bio rad laboratory bio free report athenahealth inc athn free report varian medical system inc var free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate athenahealth be zack rank player company have long term expect earning growth rate varian medical have long term expect earning growth rate stock carry zack rank medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
971,EW,walgreen boot alliance inc wba free report be slate release second quarter fiscal result market open mar last quarter company have deliver positive earning surprise be noteworthy walgreen boot have outperformed zack consensus estimate precede quarters average positive earning surprise let take look thing be shape prior announcement key catalystsover recent past have observed walgreen boot retail pharmacy usa division witness comparable prescription growth benefit strength retail prescription market several plan development early benefit new pharmacy contract well increase volume owing previously announce pharmacy partnership have be drive growth space past few quarters moreover rise expenditure prescription drug grow demand specialty drug have be strengthen retail pharmacy market meanwhile first quarter fiscal company exceed script day adjust roll annual basis first time touch new milestone furthermore company effort boost digital capability have start pay regard more company retail refill script be initiate digital channel walgreen mobile app have be download excess time launch be also encourage increase sale retail pharmacy international segment furthermore company have be gain account company strategic tie up bring more patient pharmacy walgreen boot alliance inc price ep surprise walgreen boot alliance inc price ep surprise walgreen boot alliance inc quote meanwhile strong market growth certain emerge market drive company pharmaceutical wholesale division solid performance first quarter fiscal expect trend get reflect fiscal second quarter result well zack consensus estimate total revenue reflect rise year year basis also be upbeat company expand global footprint decision acquire stake sinopharm hold guoda drugstore co ltd guoda subsidiary china national accord medicine corporation ltd completion investment provide strong impetus walgreen boot worldwide retail pharmacy business notably shanghai base guoda be large national pharmacy chain china be retail pharmacy platform china national pharmaceutical group corporation cnpgc moreover company acceptance proposal sell part investment chinese wholesale partner guangzhou pharmaceutical corporation huge cash return buoy optimism be also upbeat walgreen boot plan expand exist group purchasing effort express script hold company ensure availability specialty brand drug biosimilar have potential lower production cost move be consider be prudent timely flip side walgreen boot gross margin figure continue contract last report quarter well lower pharmacy margin reflect reduction funding lead downside however company be work tirelessly increase efficiency provide high quality cost effective pharmacy service order reduce overall pharmacy cost here be quantitative model predict walgreen boot have right combination main ingredient positive earning esp zack rank hold higher need increase odd earning beat zack esp earning esp walgreen boot be uncover best stock buy sell re report earning esp filter zack rank walgreen boot carry zack rank buy zack consensus estimate earning reflect rise year year basis other stock worth lookhere be few other medical stock worth consider have right combination element post earning beat quarter edward lifescience corporation ew free report have earning esp zack rank see complete list today zack rank strong buy stock here align technology inc algn free report have earning esp zack rank henry schein hsic free report have earning esp zack rank medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
972,EW,genomic health inc ghdx free report biocartis group nv bcart sign agreement develop diagnostic ivd version oncotype dx breast recurrence scoretest biocartis proprietary idylla platform be perform locally laboratory partner well hospital globally biocartis be innovative molecular diagnostic company provide next generation diagnostic solution accord genomic health oncotype dx breast recurrence score test evaluate activity gene patient breast tumor tissue provide customize treatment option base biology patient individual disease company claim be only proven test predict chemotherapy benefit consequently be include major cancer guideline worldwide further test be consider standard care early stage breast cancer biocartis idylla platform provide unique solution be unparalleled localization complex molecular diagnostic base advanced feature idylla platform genomic health expect local pathology lab generate oncotype dx breast recurrence score result minimal labor efficient turnaround time company also look forward maintain high quality clinical utility physician patient expect oncotype dx agreement provide genomic health right develop commercialize oncotype dx breast recurrence score test idylla platform development oncotype dx ivd test be expect initiate late genomic health be anticipate pay biocartis third quarter rest payment be make biocartis achieve few commercial milestone exclude transaction cost partnership genomic health continue anticipate earn profit full year agreement company make royalty payment base net sale ivd test develop biocartis idylla platform post september genomic health announce new datum show additional evidence unmatched value oncotype dx breast recurrence scoretest predict outcome early stage breast cancer patient accurately july majority panelist st gallen international breast cancer conference expert panel support oncotype dx be only test provide information aid physician take decision omit chemotherapy patient positive node panel also publish update guideline endorse oncotype dx guide chemotherapy treatment decision node negative node positive breast cancer patient june study breast cancer be present american society clinical oncology asco annual meeting include new analysis tie up surveillance epidemiology end result seer registry program study focuse outcome more woman have receive oncotype dx breast recurrence score test analysis examine risk breast cancer specific mortality full range recurrence score result be consistent previous validation study accord report gbi research global breast cancer therapeutic market be estimate reach cagr consider huge potential market believe latest agreement be strategical fit past year genomic health have be trading broader industry stock have gain comparison broader industry gain zack rank key picksgenomic health carry zack rank hold few better rank medical stock medical sector be edward lifescience corporation ew free report lantheus holding inc lnth free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy lantheus holding idexx carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month idexx have long term expect earning growth rate stock have gain last year trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
973,EW,aug issue update research report burlington nc base laboratory corporation america holding lh free report popularly know labcorp company be major player healthcare diagnostic space provide comprehensive clinical laboratory service end end drug development support last month labcorp have be trading broader industry stock have surge industry loss period continue dull performance company covance drug development business market be upbeat diagnostic business have successfully demonstrated solid show recent past covance drug development financial performance be year year recently report second quarter company be currently track achieve target cost synergy year period end have also complete remain consolidation central lab facility europe unite state notably company strategic focus woman health reproductive genetic acquisition sequenom leader invasive prenatal testing have reenergize larger genetic testing portfolio diagnostic also market be look forward long standing strategic collaboration andme have already demonstrated impressive growth trajectory provide further strategic collaboration opportunity flip side unfavorable foreign exchange remain drag late reduce guidance also fail indicate chance respite soon be also apprehension tough reimbursement scenario company be already face degree zack rank key pickslabcorp carry zack rank hold few better rank medical stock be idexx laboratory inc idxx free report lantheus holding inc lnth free report edward lifescience corporation ew free report edward lifescience sport zack rank strong buy lantheus holding idexx laboratory carry zack rank buy cansee complete list today zack rank stock here idexx laboratory have long term expect earning growth rate stock have gain last month lantheus holding have long term expect earning growth rate stock have surge last month edward lifescience have long term expect earning growth rate stock have rally roughly last month zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
974,EW,aug issue update research report medtronic plc mdt free report medtronic exit fiscal first quarter mixed note earning exceed zack consensus estimate revenue miss same last month medtronic have underperform broader industry company have witness decline share price release quarterly result last share price movement company have lose broader industry gain last month moreover escalate cost expense be weigh margin also unfavorable foreign exchange continue remain drag positive note apart display successful integration achievement synergy target medtronic major business group continue contribute top line growth highlighted sustainability segment geography recently company announce receipt ce mark attain stability quad mri active fixation heart lead be also encourage solid growth trend continue unite state well healthy global acceptance advanced therapy moreover consistent gradually stabilize movement global cardiac rhythm heart failure crhf market be observed improve further come quarters be also look forward medtronic receive cash patient monitoring recovery pmr division divestment strengthen company position make further developmental investment meanwhile post covidien acquisition consolidated company have so far successfully demonstrated strong segmental performance reflect successful integration achievement synergy target apart note face severe macroeconomic pressure medtronic see growth emerge market last report quarter contribute nearly company overall revenue strong growth figure be line company double digit growth projection long term company be currently resort possible mean boost growth include penetrating emerge market expansion portfolio restructure initiative benefit medtronic long term be also encourage foray rapidly grow transcatheter mitral valve replacement market acquisition california base medical device start inc present medtronic carry zack rank sell key picksa few better rank medical stock be edward lifescience corporation ew free report idexx laboratory inc idxx free report lantheus holding inc lnth free report edward lifescience sport zack rank strong buy lantheus holding idexx laboratory carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month idexx laboratory have long term expect earning growth rate stock have gain last month zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
975,EW,aug issue update research report petm express inc pet free report operate petmed company be lead nationwide pet pharmacy petm currently sport zack rank strong buy last month petm have be trading broader industry last trading price company have gain stupendous compare gain broader industry petm post better expect result first quarter mark solid start fiscal be encourage significant increase reorder sale new order sale quarter well expect company impressive first quarter performance maintain momentum petm be strive implement several strategy revitalize top line include focuse advertising efficiency boost new order sale shift sale higher margin item also expand product offering however be apprehensive escalate advertising expense incur quarter company market product primarily well know brand medication such frontline advantix advantage heartgard sentinel interceptor other flip side petm operate highly competitive fragmented pet medication market competitor include veterinarian traditional retailer other mail order online retailer pet medication other health product also acquisition novartis animal health division eli lilly company have give rise more challenge petm other key picksa few other top rank medical stock be idexx laboratory inc idxx free report lantheus holding inc lnth free report edward lifescience corporation ew free report edward lifescience sport zack rank lantheus holding idexx laboratory carry zack rank buy cansee complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month idexx laboratory have long term expect earning growth rate stock have gain last month zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
976,EW,edward lifescience corporation ew free report have announce compute tomography imaging partner trial sapien valve sub study have recently complete enrollment notably sub study be evaluate leaflet mobility sapien surgical heart valf patient be low risk experience valve replacement treat severe aortic stenosis datum main partner study be present acc notably company expect fda approval indication late management edward lifescience be study sapien ultra system feature balloon delivery system next generation sheath technology part single arm multus center trial intermediate risk patient company now anticipate system launch late europe unite state also announce update timing european launch system do not change sale guidance peg high end project range market potentialper report market research global heart valve device market be estimate be worth end cagr very noteworthy player niche be abbott free report thv focusbasically sapien be artificial valve fall edward lifescience transcatheter heart valf thv segment thv segment include technology design treat heart valve disease used catheter base approach opposed open surgical technique fourth quarter company report thv sale growth prior year quarter tally unite state thv increase year year attributable excellent clinical performance sapien well continue strong therapy implementation region outside unite state underlie growth rate be contribution region company continue see strong tavr therapy adoption japan drive sapien buoy previous quarter strong performance edward lifescience now predict full year thv sale growth rate high end guide range also management thv boast highest margin business late edward lifescience have witness multiple development thv segment good news be company have recently receive ce mark self expand centera also management release positive patient outcome sapien valve include high survival rate low rate stroke paravalvular leak share price estimate revision trendedward have be gain investor confidence consistently positive result year time company share price have outperformed industry stock have soar compare industry rally headquarter irvine company estimate revision trend have be positive past couple month analyst moved north revision opposite direction earning estimate rise share zack rank other key picksedward lifescience carry zack rank buy other top rank stock broader medical sector be bio rad laboratory bio free report varian medical system inc var free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate varian medical have long term expect earning growth rate stock carry zack rank look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
977,EW,ministry health labour welfare mhlw japan grant national reimbursement abbott free report mitraclip therapy move be likely improve company structural heart business mitraclip be fda approve ce marked system also nearly country more person have be treat mitraclip mhlw approve mitraclip system japan november be mitraclip mitraclip therapy be used treat patient mitral regurgitation reimbursement be effective april japan reimbursement entitle patient access therapy country health insurance plan company mitral regurgitation be serious progressive heart disease mitral valve do not close properly allow blood flow backward heart mitraclip system be approve japan treatment severe degenerative mitral regurgitation dmr functional mitral regurgitation fmr heart disease glimpse structural heart businessabbott medical device segment presently comprise new cardiovascular neuromodulation heart failure structural heart rhythm management vascular business diabetes care business sale improvement segment be drive double digit growth heart failure structural heart neuromodulation diabetes care last quarter notably structural heart business account total revenue medical device segment upside be lead continue double digit growth mitraclip believe latest development boost company top line recently company announce receipt fda approval world smallest rotatable bileaflet mechanical heart valve master hp mm approval company have expand master series portfolio structural heart business market prospectsper report ally market research tanscatheter mitral valve repair replacement market be estimate worth repair replacement valf cagr noteworthy company space be edward lifescience corporation ew free report share price estimate revision trendabbott have be gain investor confidence consistent positive result last month stock have outperformed industry stock have moved comparison broader industry gain current estimate revision trend be favorable current year estimate moved north compare movement opposite direction last month result zack consensus estimate full year have rise share zack rank key picksabbott carry zack rank hold couple better rank stock broader medical sector be bio rad laboratory bio free report varian medical system inc var free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate varian medical have long term expect earning growth rate stock carry zack rank buy today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
978,EW,medical device industry have be ride high optimism courtesy senate latest decision postpone industry wide excise tax year know medical device tax notably tax be effective jan bill also delay so call cadillac tax tax employer insurance repeal tax paradigm be expect boost hire investment america base medical device manufacturer instilling investor optimism medical device tax be tax innovation tax job tax health well be million american patient scott whitaker president ceo advanced medical technology association medical device taxe be originally implement part obamacare taxe impose excise tax medtech manufacturer reduce research development prospect consider headwind senate place temporary suspension taxe january december datum provide medical device trade group ken blackwell article publish daily caller partial year repeal medtech tax result rise investment medtech player however taxe be again bring back jan jan fed come new law respite bill tax cut be medtech fraternity happy revamp staturemedtech company now be able reinvest profit tax saving enhance stature launch new product reduce capital depreciation invest early stage med tech company execute clinical trial fuel next generation life change technology patient report association advancement medical instrumentation suggest big shot boston scientific bsx free report expressed concern email statement regard lesser investment innovative project lead medical facility taxe be back tax repeal be likely reinforce domestic production increase hire skilled professional lower nation overdependence offshore production report suggest complete repeal generate more job very soon increase wage report modern healthcare report suggest job be lose nationally year tax be effect taxe be reestablish nation have suffer cumulative loss job let take quick look major medtech company be go make best recent tax repeal upheaval stock ride high trendsthere be hardly evidence medtech company witness strong growth margin expansion tax repeal however market expect recent tax repeal have favorable impact margin upcoming quarters happen follow company be lead one have take help zack stock screener select favorable stock shortlist stock vast universe medical device have picked one carry zack rank strong buy zack rank buy see complete list today zack rank stock here surmodic inc srdx free report stock sport zack rank past year stock have return higher industry return surmodic effort improve research development stature have be key growth driver company whole product solution pipeline sirolimus base knee dcb drug coat balloon program deserve mention surmodic have be make progress used internally develop dcb balloon platformin drug delivery pipeline surmodic receive fda clearance telemark support microcatheter telemark support microcatheter offer superior crossability complex coronary peripheral lesion microcatheter combine surmodic extreme composite shaft technology high performance pristine hydrophilic coating together provide exceptional deliverability kink resistance complex lesion cross first quarter fiscal expense be net sale net sale year quarter edward lifescience corp ew free report stock have zack rank past year stock have return higher industry return december edward lifescience announce strategic framework outlook indicate company long term growth strategy recent progress technology pipeline thv transcatheter heart valf edward lifescience expect maintain leadership global tavr market increase focus expand patient access margin front company anticipate moderate expansion gross margin improve mix partially offset capacity investment more specifically term capacity investment heavy investment be go facility expand capacity unite state outside edward lifescience also expect global tavr opportunity exceed haemonetic corporation hae free report stock sport zack rank past year stock have return higher industry return continue momentum new business generation geographical expansion have help company deliver strong result quarter company strong cash position boost investor confidence expansion gross operate margin buoy optimism raise fiscal adjust earning guidance be also impressive paradoxnot forget brunt tax relief be huge report publish congressional budget office cbo project year suspension cost federal government period federal budget deficit next decade notably federal budget deficit reach first month current fiscal more deficit first quarter fiscal however republican spurn concern belief tax cut drive faster growth national prosperity don even think buy bitcoin read most popular cryptocurrency sky-rocket last year give investor chance bank return even more gain however come serious volatility risk bitcoin sank more time zack have just release new special report help reader capitalize explosive profit potential bitcoin other cryptocurrency significantly less volatility buy directly see crypto related stock now
979,EW,share edward lifescience corporation ew free report scale new week high mar close session lower company have outperformed industry last month stock have gain compare gain industry stock have market cap company have positive earning surprise last quarters also have long term expect earning growth rate further company estimate revision trend current year be favorable past couple month analyst moved north movement opposite direction earning estimate rise share company year historical growth rate be also favorable compare industry edward lifescience carry zack rank buy company have impressive growth style score well growth style score highlight vital metric company financial obtain clearer picture quality sustainability growth research show stock style score combine zack rank strong buy hold offer best investment opportunity take stable stock performance consideration expect edward lifescience scale higher come quarters base several growth driver strong fourth quarter performance edward lifescience fourth quarter performance be quite promising revenue earning beating zack consensus estimate be also encourage strong performance company product line company also perform well respect gross adjust operate margin company be focuse product innovation research development solid guidance edward lifescience have raise sale expectation high end previously project range zack consensus estimate full year revenue be well guide range adjust earning share expectation have also be raise previous zack consensus estimate full year adjust earning stand low end company guide range ce mark centera valve market be upbeat edward lifescience recent ce mark self expand centera valve regulatory approval be likely boost company transcatheter heart valf segment acquisition harpoon medical edward lifescience recently acquire harpoon medical inc privately hold medical technology company focuse beating heart repair degenerative mitral regurgitation agreement harpoon medical flagship beating heart repair procedure mitral valve patient harpoon system be add edward lifescience surgical heart valve therapy portfolio treat structural heart disease other key picksother top rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report athenahealth inc athn free report perkinelmer have long term expect earning growth rate stock carry zack rank bio rad laboratory sport zack rank see complete list today zack rank stock here company have long term expect earning growth rate athenahealth be zack rank player company have long term expect earning growth rate don even think buy bitcoin read most popular cryptocurrency sky-rocket last year give investor chance bank return even more gain however come serious volatility risk bitcoin sank more time zack have just release new special report help reader capitalize explosive profit potential bitcoin other cryptocurrency significantly less volatility buy directly see crypto related stock now
980,EW,growth stock be most exciting pick market high flyer captivate investor attention produce big gain well however also lead downside growth story be so be important find company be still see strong growth prospect business such company be well position future earning growth be edward lifescience corporation ew free report firm be medical instrument industry see ep growth last year be look great year too fact current growth estimate year call earning share growth furthermore long term growth rate be currently impressive suggest pretty good prospect long haul edward lifescience corporation price consensus edward lifescience corporation price consensus edward lifescience corporation wasn enough stock have actually see estimate rise past month current fiscal year thank rise earning estimate ew have zack rank buy further underscore potential outperformance company see complete list today zack rank strong buy stock here so be look fast grow stock be still see plenty opportunity horizon make sure consider ew not only do have double digit earning growth prospect impressive zack rank suggest analyst believe better day be ahead ew well hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
981,EW,edward lifescience corporation ew free report have be healthy growth trajectory late positive tiding regulatory front strategic acquisition have be provide company competitive edge medtech solid prospect zack rank buy stock be attractive pick moment edward lifescience have outperformed broader industry last month stock have gain ahead gain broader industry stock have market cap company year historical growth rate be also favorable compare increase industry gain company have positive earning surprise last quarters also have long term expect earning growth rate headquarter irvine company estimate revision trend current year have be positive past couple month analyst moved north movement opposite direction earning estimate rise share same time frame let find recent positive trend be sustainable edward lifescience fourth quarter performance be quite promising company beating zack consensus estimate revenue earning also raise guidance hint brighter prospect fact raise outlook be backed strong performance company product line market be also upbeat edward lifescience recent ce mark self expand centera valve regulatory approval be likely boost company transcatheter heart valf thv segment edward lifescience recently acquire harpoon medical inc privately hold medical technology company focuse beating heart repair degenerative mitral regurgitation agreement harpoon medical flagship beating heart repair procedure mitral valve patient harpoon system be add edward lifescience surgical heart valve therapy portfolio treat structural heart disease other key picksother top rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report becton dickinson company bdx free report bio rad laboratory have zack rank see complete list today zack rank strong buy stock here company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank becton dickinson company have zack rank company have long term expect earning growth rate more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
982,EW,aug issue update research report austin tx base luminex corp lmnx free report manufacturer marketer proprietary biological testing technology application life science diagnostic industry company currently sport zack rank strong buy luminex second quarter see strong top line performance solid cash flow soar profit company assay business be likely be key growth driver long term luminex report earning cent share second quarter revenue quarter increase almost year year company reiterate annual revenue guidance have project third quarter revenue range previously issue band luminex expect revenue segment be impact funding challenge related multus year bulk bead contract life science customer company also witness favorable tiding regulatory front second quarter regard recent ce ivd mark ary norovirus assay fda approval ary assay reimbursement approval verigene assay japan be noteworthy luminex be verge complete clinical study group strep be close submit same fda review company have broad product portfolio comprise advanced xmap xtag multicode technology moreover luminex have collaborative agreement several company help expand use product technology regard note luminex have earlier announce signing new supply distribution agreement bio techne corp tech luminex also enter similar deal affymetrix affx term agreement ebioscience business division affymetrix commercialize magpix luminex flexmap multiplexed assay platform select country americas asia europe flipside reimbursement landscape cutthroat competition continue be major challenge also share price movement luminex have be unfavorable last year notably stock lose broader industry gain roughly further luminex stock look little overvalue moment comparative analysis company ttm basis multiple reflect relatively gloomy picture be cause investor concern zack rank key picksluminex sport zack rank strong buy few other top rank medical stock be idexx laboratory inc idxx free report lantheus holding inc lnth free report edward lifescience corporation ew free report edward lifescience sport zack rank lantheus holding idexx laboratory carry zack rank buy cansee complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month idexx laboratory have long term expect earning growth rate stock have gain last month surprising tech stock keep eye tech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
983,EW,apr issue update research report medtronic plc mdt free report be encourage global acceptance company advanced therapy escalate cost expense raise concern company have zack rank hold positive note be upbeat medtronic recently launch restructure initiative call enterprise excellence plan aim annual growth run rate saving end fiscal company new program have be design increase effectiveness growth related reinvestment ability consistent boost margin expansion drive ep leverage also gradually stabilize movement witness global cardiac rhythm heart failure crhf market bode well further improvement come quarters medtronic plc price medtronic plc price medtronic plc quote meanwhile end third quarter fiscal medtronic note have successfully meet covidien synergy commitment time significantly come company priority be optimize commitment medtronic have start deliver cost synergy annual saving end fiscal flip side share medtronic have underperform broader industry past month stock have lose versus broader industry gain company have be expose escalate cost expense weigh heavily margin reiteration guidance favorable foreign currency translation forecast dampen investor confidence stock key picksa few better rank stock broader medical sector be bio rad laboratory bio free report athenahealth inc athn free report edward lifescience corporation ew free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here have long term expect earning growth rate athenahealth be zack rank player have long term expect earning growth rate edward lifescience have long term expect earning growth rate zack rank buy today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
984,EW,align technology inc algn free report have make extension invisalign clear aligner range latest launch vivera retainer precision bite ramp be claim be first retainer market be customize provide additional support deep bite correction notably vivera retainer be make same state art technology invisalign aligner employ digital imaging proprietary clear thermoplastic material advanced fabrication technology stronger retention precise comfortable fit align precision bite ramp be first introduce be design disocclude posterior tooth open bite improve efficiency deep bite invisalign treatment precision bite ramp be part invisalign integration vivera retainer be expect bring greater clinical success align orthodontic space deep bite malocclusion gradually become very common orthodontic occurrence worldwide consider development major breakthrough align respect customer adoption rate deep bite malocclusion case be mostly high north america emea register patient region accord statistic provide align date more moderate severe deep bite patient include teenager have be treat invisalign clear aligner patient datum also show doctor be increasingly fix severe deep bite invisalign precision bite ramp be important note align have recently undertake several strategy improve adoption invisalign technology globally include product technology development extend clinical effectiveness expansion invisalign technology brand drive international growth parallel press release today company have introduce expand invisalign product portfolio offer new option greater flexibility wider range patient earlier company have introduce clear aligner solution class ii correction invisalign technology mandibular advancement certain market canada emea apac be indicative grow popularity align dental product international market long term expect similar innovation act major catalyst align new well exist market past month share align have outperformed industry stock have surge compare increase industry zack rank key picksalign carry zack rank buy few better rank stock broader medical sector be bio rad laboratory bio free report athenahealth inc athn free report edward lifescience corporation ew free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here have long term expect earning growth rate athenahealth be zack rank player have long term expect earning growth rate edward lifescience have long term expect earning growth rate stock carry zack rank today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
985,EW,abiom inc abmd free report recently announce receipt fda pre market approval pma impella cpheart pump smartassist feature optical sensor broaden portfolio flagship impella heart pump company plan controlled roll technologically advanced heart pump hospital site develop heart recovery protocol next fiscal year be pma fda special medical device class iii tag require pma nod availability market notably class iii device have extremely high level risk associate usage consequently general regulatory approval alone assure safety effectiveness device abiom impella cp heart pump be class iii medical device datum submit fda support pma include engineering report comprehensive technical specification company clinical datum informatic have be verify patient abiom impella controller hospital unite state notably impella impella cp be only percutaneous temporary ventricular support device fda have approve safe effective high risk pci furthermore impella cp smartassist also boast ce mark approval have already be used treat patient site impella product line major growth driverabiom main product line impella comprise impella impella impella ld impella cp impella rp flagship product line continue be growth catalyst reflect stellar performance last report quarter well expand impella portfolio company recently announce impella impella cp heart pump have receive pma fda expand use product now be used elective urgent high risk percutaneous coronary intervention pci procedure notably be second pma row device be earlier grant fda treat heart failure associate cardiomyopathy lead cardiogenic shock encouragingly note last report quarter install customer base impella cp heart pump grow new hospital take total number impella cp site thus latest fda approval technologically advanced impella cp help company gain momentum accelerate top line contribution product cardiac disease trend cardiovascular marketper research conduct american college cardiology cardiovascular disease account approximately death unite state more american carry diagnosis disease accord research market global cardiovascular implant market be poise grow cagr next decade promising datum indicate timely strategic role latest fda approval be go play favor abiom price performanceover past year abiom gain whopping surpass industry gain zack rank key picksabiom carry zack rank strong buy other top rank stock broader medical sector be bio rad laboratory bio free report athenahealth inc athn free report edward lifescience corp ew free report bio rad laboratory sport zack rank see complete list today zack rank stock here have long term expect earning growth rate athenahealth be zack rank player have long term expect earning growth rate edward lifescience have long term expect earning growth rate stock carry zack rank buy hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
986,EW,mar issue update research report walgreen boot alliance inc wba free report be currently look forward company modify rite aid contract expect benefit company long run stock carry zack rank hold past month share walgreen boot have outperformed industry stock have lose narrower industry decline note company report better expect second quarter fiscal result have gross highest sale last quarters be encourage company consistent sale increase retail pharmacy international business moreover walgreen boot have be gain traction slew strategic tie up bring more patient pharmacy walgreen boot alliance inc price walgreen boot alliance inc price walgreen boot alliance inc quote be also upbeat company alliance express script company aim expand respective exist group purchasing effort latest pact be expect improve express script supply chain make medicine include biosimilar affordable accessible patient positive apart walgreen boot decision buy stake china sinopharm hold guoda drugstore look promising provide strong impetus company worldwide retail pharmacy business limit number rite aid store acquisition also impress company have recently secure regulatory approval however walgreen boot face headwind form fierce competition tough industry condition even company continue reap growth initiative major mass merchant be already advance boost pharmacy business fair market share notably slowdown generic introduction last few year have be affect walgreen boot margin also escalate reimbursement pressure generic drug cost inflation have be hamper walgreen boot margin significantly key pickssome better rank stock broader medical sector be bio rad laboratory bio free report athenahealth inc athn free report edward lifescience corporation ew free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate athenahealth be zack rank player have long term expect earning growth rate edward lifescience have long term expect earning growth rate stock carry zack rank buy hacker put money portfolio earlier year credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
987,EW,aug issue update research report cincinnatus base cheme corporation che free report company currently operate wholly own subsidiary vita healthcare roto rooter last month cheme have be trading broader industry term price stock have gain higher industry loss improvement average net medicare reimbursement rate increase average daily census recently report second quarter be encourage raise outlook roto rooter segment earning share be indicative company anticipate improve operate result upcoming quarters boost investor optimism stock notably cheme vita business have be trouble past few quarters due certain admission coding change initiate center medicare medicaid service cms however management note recent admission trend be positive continue come quarters well cheme corp price consensus cheme corp price consensus cheme corp quotedure second quarter vita perform well financially operationally surpass company expectation business experience net revenue growth compare prior year quarter vita also generate admission growth quarter term roto rooter business display robust performance core plumbing drain clean service segment second quarter well prompt solid rise water restoration management increase expectation achieve roto rooter full year revenue growth higher earlier expect range revenue estimate be base increase job pricing approximately continue growth water restoration service however headwind reimbursement related issue seasonality business competitive landscape dependence government mandate challenge cheme also tweak guidance medicare cap bill limitation be matter concern zack rank key pickscheme currently have zack rank buy few other top rank medical stock be edward lifescience corporation ew free report lantheus holding inc lnth free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy lantheus holding idexx laboratory carry zack rank see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally last month lantheus holding have long term expect earning growth rate stock have surge last month idexx laboratory have long term expect earning growth rate stock have gain roughly last month surprising tech stock keep eye tech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
988,EW,headquarter pleasanton veeva system inc veev free report report second quarter fiscal adjust earning cent share end jul company earning beat zack consensus estimate cent year figure cent total revenue report quarter be year quarter project increase year year be well ahead zack consensus estimate quarter service revenue be year quarter increase year year professional service revenue increase almost primarily owing strong adoption vault platform second quarter company witness number registration veeva commercial cloud platform world veeva system have many core crm project track large pharma company globe report quarter veeva system make significant progress various field geography courtesy product veeva network veeva align veeva opendata veeva crm approve email come vault platform company booking account more half total quarter cloud platform veeva system gain significant market traction zinc ahead adoption vault qualitydocs vault qms be also rise company gain considerable traction market top pharmaceutical company be standardized vault etmf platform veeva system announce entry clinical datum management space solution veeva vault edc veeva vault esource veeva system inc price consensus ep surprise veeva system inc price consensus ep surprise veeva system inc quotemargin margin veeva system expand basis point bps report quarter owing favorable revenue mix higher percentage subscription revenue company report surge bps subscription gross margin totale almost balance sheetveeva system end report quarter nearly cash short term investment versus end sequential quarter calculate billing totale quarter be ahead management guidance courtesy impressive sale performance strong service revenue fiscal end jan total revenue be anticipate band adjust operate income be likely be adjust earning be forecast cent cent third quarter fiscal end oct veeva expect total revenue range meanwhile adjust operate income be expect adjust earning be forecast cent cent takewe be upbeat veeva system product launch industry focuse approach grow global demand cloud base vault application also boost opportunity company veeva system have strengthen recur part revenue mix mark significant growth subscription revenue be well ahead service revenue moreover new launch be highly encourage view be likely fortify company position enhance growth prospect long haul zack rank key pickscurrently veeva system have zack rank hold few better rank stock broader medical sector be edward lifescience corp ew free report idexx laboratory inc idxx free report cogentix medical inc edward lifescience sport zack rank strong buy idexx laboratory cogentix medical carry zack rank buy see complete list today zack rank stock here edward lifescience deliver average earning beat trail quarters cogentix medical deliver positive earning surprise last report quarter idexx laboratory deliver average earning beat trail quarters surprising tech stock keep eye ontech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
989,EW,underlie strength earning growth prospect make thermo fisher scientific inc tmo free report solid bet now factor drive stock higher include impressive organic growth well growth acquisition solid balance sheet position company have impressive earning surprise history have surpass zack consensus estimate trail quarters average have also be successful gain analyst confidence analyst revise current year earning estimate upward past day estimate rise share justify stock zack rank buy share thermo fisher have gain past month compare industry gain act favor stock revenue strength company have be witness consistent improvement revenue last year total revenue see cagr project revenue growth rate be peg compare industry average steady addition capacity company have be steadily add capacity enhance exist one acquisition regard acquisition fei have already start generate synergy contribute largely company analytical instrument portfolio have turn boost market optimism stock moreover be look forward company latest patheon buyout thermo fisher forayed high potential contract development manufacturing organization cdmo space solid prospect high potential emerge market massachusett base medical instrument manufacturer plan continue strengthen foothold emerge market such china india translate success other high priority opportunity region such south korea russia brazil second quarter company record solid contribution china india middle east be also upbeat company recently open center excellence electron microscopy saudi arabia earning share growth thermo fisher have record earning growth rate last year compare index further earning momentum be likely continue long term year reflect company project earning share growth rate compare index superior return equity thermo fisher have return equity compare industry average indicate company be efficient utilize shareholder fund strong cash position thermo fisher exit last report second quarter cash cash equivalent moreover company record year date net cash operate activity believe company strong cash balance enable carry strategy inorganic expansion effective capital deployment company have be actively return capital shareholder regard last report second quarter company complete worth share buyback paid dividend aug company have available future repurchase exist share repurchase policy raise guidance buoy optimism backed solid second quarter performance less adverse foreign exchange environment forecast thermo fisher raise full year guidance raise guidance be suggestive brighter prospect other key picksa few other top rank medical stock be edward lifescience corporation ew free report lantheus holding inc lnth free report cheme corporation che free report edward lifescience sport zack rank strong buy lantheus holding cheme carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month cheme have long term expect earning growth rate stock have gain last month simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
990,EW,sep issue update research report pleasanton base cooper company coo free report share cooper have outperformed industry year date share company have increase compare industry gain additionally company earning estimate have moved north current year reflect analyst optimism past month current next quarter earning estimate have increase respectively moreover cooper report earning have surpass zack consensus estimate trail quarters average surprise company lead position market specialty lense be also support highly exclusive product biofinity clariti fact flagship silicone hydrogel lense be expect deliver strong sale come quarters company have also initiate process introduce myday lense domestic market be already available europe have gain significant traction short span time clariti lense hold significant growth prospect company outlook contact lens industry be favorable fall dropout rate contact lens user further market penetration especially develop nation be expect continuous improvisation technology growth international market be something contact lens manufacturer be banking furthermore user preference be shift low feature commodity lense expensive single use specialty lense such lense aspherical optical property higher oxygen permeable lense silicone hydrogel believe cooper be well position address shift customer preference base expansive product portfolio company recently introduce biofinity energys contact lense be target group user frequently complain discomfort arise prolong usage smartphone tablet laptop car display other device company be leader high margin toric lens market offer multiple design toric lense wide range parameter competitor offer same lense limit design be expect further boost company top line growth go forward flip side macroeconomic concern several international market spell trouble company additionally slowdown chinese economy continue dent discretionary spending also give significant international presence cooper remain highly vulnerable fluctuation exchange rate zack rank key pickscooper carry zack rank hold few better rank medical stock be edward lifescience corporation ew free report lantheus holding inc lnth free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy lantheus holding idexx laboratory carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have surge roughly last month lantheus holding have long term expect earning growth rate stock have rally last month idexx laboratory have long term expect earning growth rate stock have gain last month simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
991,EW,share price align technology inc algn free report scale new week high sep eventually close nominally lower company have gain year much higher gain same frame align technology have also beat broader industry gain respect share price movement year stock have market cap further align technology estimate revision trend current year be favorable past day estimate moved moved estimate be share same time frame company also have trail quarter average positive earning surprise positive long term growth hold promise align technology inc price consensus align technology inc price consensus align technology inc company year historical growth rate be also favorable compare broader industry align technology carry zack rank hold company have impressive growth style score growth style score highlight vital metric company financial obtain clearer picture quality sustainability growth research show stock style score combine zack rank strong buy buy offer best investment opportunity growth market be upbeat exclusive distribution agreement sign patterson dental september agreement align technology itero element intraoral scanning system be available patterson dental cad cam portfolio unite state canada boost itero scanner customer base considerable extent further june align technology have announce inclusion esteem index boost investor confidence stock considerably be also encourage align technology solid second quarter performance year year increase earning revenue company encourage invisalign technology prospect growth north america international region also raise hope company recently open new invisalign technology treatment plan facility china meanwhile company multus dollar marketing campaign invisalign technology brand be encourage factor be expect boost company share price day ahead key picksa few better rank medical stock be edward lifescience corporation ew free report lantheus holding inc lnth free report idexx laboratory inc idxx free report edward lifescience sport zack rank lantheus holding idexx laboratory carry zack rank cansee complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month idexx laboratory have long term expect earning growth rate stock have gain last month surprising tech stock keep eye tech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
992,EW,sep issue update research report lead medical device company boston scientific corporation bsx free report past month boston scientific have be trading broader industry several issue stock have improve compare broader industry gain period adverse foreign exchange continue challenge be concern company recall prime product lotus range heart device be important note last quarter foreign exchange headwind affected company top line adjust gross margin basis point also dull defibrillator sale core cardiac rhythm management crm continue remain drag overall growth wo challenge economy competitive landscape persistently burden stock boston scientific corporation price consensus boston scientific corporation price consensus boston scientific corporation quotehowever give company bullish second quarter result several recent development find quite few positive factor rely company be leave stone unturned strengthen core business invest more global market recent upside worth mention be company acquisition symetis bid fortify european structural heart business be also encourage company secure multiple product approval domestic overseas market notably company receive fda approval resonate family icd crt system additionally market hold optimism stock follow company recent release outline sustain growth strategy focuse plan expansion new market consolidate product line business segment company particularly plan launch product high growth adjacent market strong potential reap incremental market opportunity zack rank key picksboston scientific carry zack rank hold few better rank medical stock be edward lifescience corporation ew free report lantheus holding inc lnth free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy lantheus holding idexx laboratory carry zack rank buy cansee complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have surge roughly last month lantheus holding have long term expect earning growth rate stock have rally last month idexx laboratory have long term expect earning growth rate stock have gain last month surprising tech stock keep eye tech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
993,EW,myriad genetic inc mygn free report introduce riskscore myrisk hereditary cancer testing portfolio launch be aim solidify company footprint rapidly grow hereditary cancer testing market base salt lake city ut lead molecular diagnostic personalize medicine provider intend make riskscore precision medical tool patient use myrisk get test do notably riskscore help determine woman risk develop breast cancer combine genetic marker genome patient family clinical history management highly advanced prediction tool also aid patient negative result heredity cancer gene derive proper conclusion june company have present encourage datum patient clinical study myrisk hereditary cancer testsat american society clinical oncology asco result highlighted importance multus gene panel testing advancement hereditary cancer risk evaluation platform management identify mutation be find patient do not comply testing guideline study also find identify mutation unexpected gene myriad genetic have be ride high strength heriditary cancer testing space last report quarter company see year year rise heriditary cancer testing volume mark third consecutive quarter sequential growth report dpi research medium breast cancer screening market unite state be expect reach value roughly moreover article brestcancer org approximately new case invasive breast cancer woman be likely be diagnosed unite state also project new case invasive breast cancer year well believe agee population rise awareness expenditure healthcare continue drive growth breast cancer screening market however market be dominate many well establish player quest diagnostic dgx free report be most prominent space quest diagnostic quest vantage service help discovery genetic variant related hereditary risk type cancer include breast colorectal pancreatic renal moreover myriad genetic have be gain investor confidence consistently positive result past month company share price have outperformed broader industry stock have gain higher broader industry company have also outperformed gain market same time frame zack rank key picksmyriad genetic carry zack rank hold couple better rank medical stock be edward lifescience corporation ew free report lantheus holding inc lnth free report edward lifescience sport zack rank strong buy lantheus holding carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month surprising tech stock keep eye tech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
994,EW,mar issue update research report resm inc rmd free report stock carry zack rank hold company achieve strong global revenue growth past few quarters back robust sale sleep device respiratory care device mask system software solution also synergy draw acquisition have act significant contributor resm operate result expect company product launch strategy gain traction sleep disordered breathe market further boost term performance recent development resm have already inform first self brand portable oxygen concentrator mobi schedule launch third quarter fiscal further have introduce airmini world smallest pap positive airway pressure device significantly lead medical device company continue invest resource expand footprint high growth market china south korea india brazil many country eastern europe interestingly region company implement long term plan improve quality patient life deliver better patient outcome reduce overall system healthcare cost second quarter fiscal revenue unite state canada latin american country grow year year europe asia other market improve year year cer constant exchange rate past month share resm have outperformed broader industry stock have rally higher broader industry rise however challenge competitive bidding reimbursement issue continue plague stock company also remain expose foreign exchange fluctuation additionally rise operate expense be other major headwind key pickssome better rank stock broader medical sector be bio rad laboratory bio free report athenahealth inc athn free report edward lifescience corporation ew free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here have long term expect earning growth rate athenahealth be zack rank player have long term expect earning growth rate edward lifescience have long term expect earning growth rate stock carry zack rank buy investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
995,EW,luminex corporation lmnx free report have be healthy growth trajectory late have rally month time ahead gain stock have market cap solid prospect zack rank buy stock be attractive pick now company estimate revision trend current year have also be positive past day estimate have go upward luminex none move downward same time period zack consensus estimate moved cent cent same time frame let find recent positive trend be sustainable luminex second quarter witness strong top line performance solid cash flow soar profit company assay business be likely be key growth driver long term notably revenue quarter increase high year year further luminex reiterate annual revenue guidance band depict year year growth follow strong revenue performance second quarter luminex recently announce plan collaborate sutter health bid bolster molecular diagnostic testing portfolio collaboration be anticipate enhance company patient care technique especially case cystic fibrosis illness respiratory tract infection also late july luminex receive fda clearance ary assay be moderate complexity sample answer test rapid detection however stiff competition life science industry stretched valuation reimbursement issue be challenge stock other key picksother top rank stock medical sector be edward lifescience corporation ew free report lantheus holding inc lnth free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy lantheus holding idexx carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain month time idexx have long term expect earning growth rate stock have gain last year trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
996,EW,abbott free report recently announce receipt national reimbursement freestylelibre glucose monitoring system national health service nhs business service authority notably be major breakthrough diabetic business development have widen illinois base medical device major customer base diabetes management begin nov abbott flagship glucose monitoring system be available reimbursement nhs england wale nhs scotland health social care northern ireland abbott grant reimbursement also make freestylelibre system widely available person be diagnosed diabetes also management expect be roughly person have diabetes be yet be diagnosed reimbursement approval mark milestone abbott freestyle libre system stand partially fully cover country include france germany japan notably freestyle libre system be presently review fda await approval unite state meanwhile abbott have be move steadily development diabetic segment recently company announce receipt national reimbursement freestyle libre japan moreover company recently announce receipt health canada license freestyle libre flash glucose monitoring system further stimulate growth diabetes care sale segment be second quarter continue consumer acceptance freestyle libre internationally expect freestyle libre further contribute abbott top line japanese canadian development french health ministry recently approve national reimbursement device apart july company partner bigfoot biomedical solidify footprint rapidly grow diabetes therapeutic market report mordor intelligence global market diabetes care device be project reach value cagr consider market potential abbott slew latest development diabetes care segment recent national reimbursement grant accelerate top line however diabetes market be dominate many well establish player johnson johnson jnj free report be most prominent space johnson johnson also have tie base corporation successfully develop innovate insulin delivery system share price have be gain investor confidence consistently positive result last month abbott share price have outperformed broader industry stock have gain comparison broader industry gain company have also outperformed gain market same time frame zack rank key picksabbott carry zack rank hold few better rank medical stock medical sector be edward lifescience corporation ew free report lantheus holding inc lnth free report edward lifescience sport zack rank strong buy lantheus holding carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
997,EW,davita inc dva free report subsidiary davita medical group recently announce receipt leadership energy environmental design leed gold certification green build council usgbc award have be confer davita base facility also know casa pacifica build notably leed gold certification be exclusively grant building situate sustainable site strong water energy atmosphere material resource efficiency additionally building operate superior indoor environment show innovation design regional priority credit undoubtedly davita casa pacifica build be solid choice base aforementioned criterium initiative bolster davita environmental goal company operation be conduct healthy environment davita be solely commit improve health care unite state violate basic environmental norm regard casa pacifica construction waste be divert landfill share lack lusterdavita have have unfavorable run bourse last month stock have lose almost much wider broader industry decline just current level also substantially underperform gain roughly deterioration be largely due ongoing political conundrum medical world have initiate presidential election high debt level adverse effect healthcare reform escalate expense be other major stock dampener favorable estimate revision estimate revision trend have be favorable company current quarter estimate moved north compare movement opposite direction last month result zack consensus estimate ongoing quarter have inched cent share same time frame davita carry zack rank hold full year estimate moved upward compare downward movement result zack consensus estimate full year have increase share same period takedavita environment friendly operation be likely enhance company sustainable growth long haul fact davita base headquarters be award leed platinum certification usgbc operation maintenance efficiency only last year davita significant growth recent time be reflect back strong patient service last quarter company see solid improvement kidney care davita also make crucial effort control expense company strength basically lie enhance service offering compelling inorganic growth story support strong financial position be key development catalyst moment key picksa few better rank stock broader medical sector be edward lifescience corp ew free report idexx laboratory inc idxx free report cogentix medical inc notably edward lifescience sport zack rank strong buy idexx laboratory cogentix medical have zack rank buy see complete list today zack rank stock here edward lifescience deliver average earning beat trail quarters company have long term expect earning growth rate idexx laboratory deliver average earning beat trail quarters have long term expect earning growth rate cogentix medical come positive earning surprise last quarter stock represent stellar return last year trade profit big league trump policy stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
998,EW,fresenius medical care fms free report recently announce open regional manufacturing plant bandar enstek malaysia plant be state art facility be fresenius medical regional manufacturing hub southeast asia addition supply high quality haemodialysis concentrate disinfectant plant also produce peritoneal dialysis pd product necessary advanced continuous ambulatory pd capd treatment pd be form dialysis used natural line patient abdomen filter waste blood feel plant expand presence fast grow market dialysis patient malaysia market have ample scope growth plant bandar enstek be second plant fresenius medical malaysia ipoh company produce water treatment system ensure high quality water essential dialysis anticipate latest development help company counter pressure margin management latest development be significant step boost company long term goal fresenius medical have set strong long term objective growth strategy formulate few initiative attain solid market traction postulate growth strategy fresenius aim boost revenue corresponding average annual growth rate enhance core business care coordination unit full year fresenius medical estimate revenue growth cc net income attributable shareholder company be likely increase meanwhile stock represent solid return compare favorably industry gain just last month furthermore fresenius medical promise long term expect earning growth rate almost indicate chance outperformance long haul takefresenius medical provide wide range dialysis product own dialysis clinic third party clinic company offer wide array hemodyalisis peritoneal dialysis acute dialysis product well however latest development be expect fortify company foothold home dialysis market particularly renal care space report news long island global renal dialysis market be expect see cagr reach worth zack rank key picksfresenius medical carry zack rank hold few better rank medical stock medical sector be edward lifescience corporation ew free report lantheus holding inc lnth free report amedisys inc am free report edward lifescience currently sport zack rank strong buy lantheus holding amedisys carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month amedisys have long term expect earning growth rate stock have gain last month trade profit big league trump policy stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
999,EW,share price deerfield il base baxter international inc bax free report scale new week high share sep then close bit lower company have gain past month much better rise past month zack rank hold stock have steadily outshined broader industry stock price have climb substantially higher broader industry gain stock have market cap almost also company estimate revision trend current quarter be favorable past month estimate have moved downward revision magnitude estimate revision same time period increase cent share company also have quarter average positive earning surprise baxter international inc price consensus baxter international inc price consensus baxter international inc quotegrowth catalystslong term outlook upbeat buoy stellar growth earning sale second quarter company raise long term outlook baxter estimate sale growth approximately compound annual basis notably adjust operate margin full year be expect be approximately revenue much previously issue guidance baxter expect full year adjust diluted earning band share fact baxter raise full year expectation sale growth approximately cc constant currency adjust earning share continue operation be forecast range third quarter baxter estimate sale rise cc adjust earning share be project cent bracket broad product spectrum latest week high come back company impressive product line baxter have exciting product portfolio improve exist product new product development namely more convenient kidney dialysis solution regenerative tissue product next generation sigma spectrum infusion pump last quarter baxter launch new version ak hd system platform offer way connectivity capability meet need potential patient favorable tiding regulatory front be well regulatory front baxter last quarter company receive clearance regulatory authority regard propose acquisition claris injectable additionally fda approval new premixed injectable be key catalyst company new product home pd technology also get fda nod second quarter platform leverage baxter flagship amia automate peritoneal dialysis apd system sharesource telehealth platform recently baxter achieve regulatory milestone advanced dialysis technology good news be company receive significant guidance fda clarify regulatory pathway home peritoneal dialysis pd solution system improve patient access same key picksa few better rank stock broader medical sector be edward lifescience corp ew free report idexx laboratory inc idxx free report cogentix medical inc notably edward lifescience sport zack rank strong buy idexx laboratory cogentix medical have zack rank buy see complete list today zack rank stock here edward lifescience deliver average earning beat trail quarters company have long term expect earning growth rate idexx laboratory deliver average earning beat trail quarters have long term expect earning growth rate cogentix medical register positive earning surprise last quarter stock represent stellar return last year trade profit big league trump policy stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
1000,EW,sep issue update research report idexx laboratory inc idxx free report lead molecular diagnostic company stock currently have zack rank buy be encourage note idexx continue demonstrate solid global growth potent international expansion international revenue last report second quarter grow high single digit drive organic rise cag diagnostic recur revenue gain water business indicated continue consumable revenue gain support strong catalyst instrument customer base average testing utilization idexx derive lion share revenue companion animal group segment cag second quarter cag organic revenue rise low double digit year year basis support cag diagnostic recur organic well cag instrument revenue growth believe management innovation base global strategy be lead growth cag diagnostic also idexx recently announce addition rvetlink portfolio technological application notably rvetlink be advanced inclusive referral management solution design specialty care hospital simplify referral procedure primary care specialty care veterinarian additionally company have strong cash balance enable carry share repurchase program turn provide solid return investor flipside last month idexx have be trading broader industry respect share price movement stock have rally period comparison gain broader industry idexx high dependence third party distributor intense competition continue threat moreover grow international expansion company companion animal diagnostic business be likely suffer adverse currency fluctuation competitive landscape overseas market weigh company well other key picksa few other top rank medical stock be edward lifescience corporation ew free report lantheus holding inc lnth free report amedisys inc am free report edward lifescience sport zack rank strong buy lantheus holding amedisys carry zack rank see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month amedisys have long term expect earning growth rate stock have gain last month more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1001,EW,major development ear nose throat ent product business medtronic plc mdt free report recently launch stealthstation ent fda approve ce marked surgical navigation system allow surgeon treat condition ent anatomy technology used proprietary electromagnetic tracking technology similar gps system used car company generate electromagnetic field target patient anatomy surgery so instrument position be dynamically track procedure stealthstation ent system enable surgeon gain better visualization accord company system offer edge traditional endoscope sense former include software hardware innovation virtual endoscopy help surgeon gain simulate view sinus cavity latter accord report market market global surgical navigation system market be expect reach worth cagr period consider huge potential market believe latest development be strategical fit last month medtronic have underperform broader industry latest share price movement company lose compare gain broader industry period however expect slew new development business help make comeback zack rank key picksmedtronic currently carry zack rank sell few better rank medical stock medical sector be edward lifescience corporation ew free report lantheus holding inc lnth free report amedisys inc am free report edward lifescience sport zack rank strong buy lantheus holding amedisys carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month amedisys have long term expect earning growth rate stock have gain last month more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1002,EW,month have go last earning report edward lifescience corporation ew free report share have add time frame recent positive trend continue lead next earning release be ew due pullback dive investor analyst have react late let take quick look most recent earning report order get better handle important driver recent earningsedward lifescience first quarter adjust earning share ep come report ep be cent adjust ep figure beat zack consensus estimate moreover adjust earning improve year year primarily drive strong sale growth transcatheter heart valf business sale detailsfirst quarter sale improve fall short zack consensus estimate underlie sale increase include impact germany stocking sale customer nation choose purchase additional inventory sapien valve anticipation potential supply interruption result recent intellectual property litigation revenue be primarily drive considerable growth transcatheter heart valve sale well strong performance critical care product line segmental detailsin first quarter company report transcatheter heart valve therapy thvt sale reflect growth prior year quarter unite state thvt procedure grow mid teen year year growth be drive excellent clinical performance sapien well continue strong therapy implementation region surgical heart valve therapy sale quarter totale prior year quarter include sale return reserve conversion consignment inventory model however edward lifescience continue witness solid uptake edward intuity elite valve system strong demand latest inspiris resilium aortic valve unite state further company latest product drive underlie sale growth rate surpass total procedure growth rate critical care sale be report quarter represent increase first quarter upside be attribute solid growth product category largely lead hemosphere advanced monitoring platform solid growth unite state asia pacific marginsin first quarter gross margin contract basis point bps owing adverse currency movement continue operational investment however be partially offset more profitable product mix lead grow sale transcatheter valf sg expense rise year year account sale personnel related expense well strengthen euro comparison dollar expenditure increase year year owing continue investment transcatheter aortic valve mitral valve program expenditure clinical trial accordingly adjust operate margin quarter contract bps cash positionedward lifescience exit first quarter cash cash equivalent short term investment compare end long term debt report quarter totale versus end cash flow operate activity be first quarter exclude capital spending free cash flow be quarter average diluted share outstanding totale guidance raisededward lifescience raise adjust ep expectation previous zack consensus estimate full year adjust ep stand low end company guide range however company continue maintain sale expectation high end previously project range zack consensus estimate full year revenue be guide range second quarter company project sale zack consensus estimate revenue be company estimate range company forecast adjust ep meanwhile zack consensus estimate adjust ep be be company forecast range have estimate be move then past month investor have witness downward trend fresh estimate have be revision higher current quarter compare lower edward lifescience corporation price consensus edward lifescience corporation price consensus edward lifescience corporation quotevgm scoresat time ew have nice growth score however momentum be do bit better however stock be allocate grade value side putt bottom investment strategy overall stock have aggregate vgm score aren focuse strategy score be be interested style score indicate stock be more suitable momentum investor growth investor outlookestimate have be broadly trend downward stock magnitude revision indicate downward shift notably ew have zack rank hold expect line return stock next few month
1003,EW,launch ishare morningstar mid cap growth etf jkh free report be passively manage exchange trade fund design provide broad exposure mid cap growth segment equity market fund be sponsored blackrock have amassed asset make average size etfs attempt match mid cap growth segment equity market mid cap growthwith market capitalization mid cap company usually contain higher growth prospect large cap company be consider less risky small cap counterpart thus company fall category provide stable growth heavy investment quality growth stock include faster growth rate compare broader market well higher valuation higher average sale earning growth rate something keep mind be higher level volatility be affiliated growth stock compare value stock growth stock be safer bet strong bull market don perform strongly almost other financial environment costscost be important factor select right etf cheaper fund significantly outperform more expensive counterpart other fundamental be same annual operate expense etf be putt par most peer product space have month trail dividend yield sector exposure top holdingsetfs offer diversify exposure thus minimize single stock risk be still important delve fund holding investing most etfs be very transparent product many disclose holding daily basis etf have heaviest allocation information technology sector portfolio industrial healthcare round top look individual holding red hat inc rht free report account total asset follow servicenow inc now free report edward lifescience corp ew free report top holding account total asset management performance riskjkh seek match performance morningstar mid growth index fee expense morningstar mid growth index measure performance stock issue mid capitalization company morningstar index methodology define mid capitalization stock stock form market capitalization percentile market capitalization stock eligible be include morningstar market index etf return be roughly so far year be last year past week period have trade etf have beta standard deviation trail year period make medium risk choice space holding effectively diversify company specific risk morningstar mid cap growth etf carry zack etf rank hold be base expect asset class return expense ratio momentum other factor thus jkh be sufficient option seek exposure mid cap etfs area market investor also want consider other etf option space ishare mid cap growth etf ijk free report ishare russell mid cap growth etf iwp free report track similar index ishare mid cap growth etf have asset ishare russell mid cap growth etf have ijk have expense ratio iwp charge bottom linepassively manage etfs be become increasingly popular institutional well retail investor due low cost transparency flexibility tax efficiency be excellent vehicle long term investor learn more product other etfs screen product match investment objective read article latest development etf investing universe please visit zack etf center
1004,EW,sep issue update research report lead molecular diagnostic company amedisys inc am free report stock currently carry zack rank buy last month amedisys have gain industry decline company impressive result second quarter earning revenue significantly improve year year have bolster market confidence lead further rally share price be encourage company long term strategy evolve traditional home health hospice care company focuse bring home continuum care serve patient better diversify source payment become less reliant medicare moreover company have be witness growth personal care segment synergy acquisition company recently make number strategic acquisition recent be intercity home carein massachusett be slate close oct home health industry be poise substantial growth long term drive positive demographic trend unite state company be expect continue benefit age demographic population higher acuity patient home nursing environment notably company be track fortify footprint market place recently announce completion national readmission prevention collaborative nrpc certification program clinical program team handle home healthcare program additionally company strong cash balance position bolster confidence stock flip side expect synergy tenet healthcare acquisition escalate cost operate expense weigh company margin also intense competitive landscape regulatory concern continue challenge home health hospice industry other key picksa few other top rank medical stock be edward lifescience corporation ew free report lantheus holding inc lnth free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy lantheus holding idexx carry zack rank see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month idexx have long term expect earning growth rate stock have gain last year trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
1005,EW,medtronic plc mdt free report have make encourage move respect aortic peripheral vascular apv business company recently announce receipt regulatory approval pact admiral drug coat balloon dcb japanese ministry health labour welfare mhlw medtronic pact admiral dcb gain approval treat peripheral artery disease pad upper leg particularly thigh superficial femoral artery knee popliteal artery however commercial launch product medtronic have collaborate japanese mhlw attain reimbursement approval company believe reimbursement approval widen global customer base pact admiral dcb japanese regulatory approval be grant pact admiral dcb ground successful result pact sfa japan trial development be line company strategy focus research development high end medical device product core business line note pact admiral dcb receive fda approval december treat superficial femoral popliteal artery moreover be commercially available europe receipt ce mark approval so far pad patient europe have be treat device interestingly medtronic revenue apv division improve year year constant exchange rate first quarter fiscal moreover peripheral vascular business grow low double digit atherectomy drug coat balloon latest development boost company performance segment medtronic strategy gain traction peripheral vascular sub segment seem be align datum provide report interventional cardiology peripheral vascular device market be expect see cagr reach value believe high incidence peripheral artery disease due unhealthy lifestyle age population penetration company untapped market rise need minimally invasive angioplasty procedure technological advancement increase awareness person continue drive global acceptance technology view encourage factor believe company japanese development pact admiral dcb be strategic broaden customer base however last month medtronic have be underperform broader industry stock have decline contrast industry gain also underperform gain same time frame nevertheless believe latest japanese regulatory approval boost investor confidence stock zack rank stock currently carry zack rank sell few better rank medical stock medical sector be edward lifescience corporation ew free report lantheus holding inc lnth free report amedisys inc am free report edward lifescience sport zack rank strong buy lantheus holding amedisys carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month amedisys have long term expect earning growth rate stock have gain last month more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1006,EW,lead veterinary product distributor henry schein inc hsic free report continue expand global footprint successfully several partnership acquisition latest list be company agreement buy merritt veterinary supply inc independent family own supplier animal health product financial term deal have be keep wrapped company declare expect transaction get complete third quarter headquarter columbia south carolina merritt have veterinary clinic eastern unite state strong presence southeastern part nation company offer comprehensive line product include pharmaceutical diagnostic equipment lead independent regional veterinary supplier have total sale approximately post close transaction merritt become part henry schein animal health company acquisition meaningfully strengthen exist animal health business also benefit animal health diagnostic equipment surgical instrument business include scil kruuse veterinary instrumentation henry schein henry schein inc price henry schein inc price henry schein inc quotenotably henry schein revenue growth animal health business have be consistently support niche acquisition robust buyout strategy help pursue target provide access additional product line begin henry schein enter brazilian animal health market investment tecnew privately hold distributor animal health product prior company acquire rxwork lead provider veterinary practice management software primarily customer australia new uk netherlands other world wide country business impending merritt buyout be set fortify global animal health operation go forward henry schein have outperformed broader industry year stock have gain compare broader industry rise zack rank key pickshenry schein currently carry zack rank hold few better rank medical stock be idexx laboratory inc idxx free report lantheus holding inc lnth free report edward lifescience corporation ew free report edward lifescience sport zack rank strong buy lantheus holding idexx laboratory carry zack rank buy see complete list today zack rank stock here idexx laboratory have long term expect earning growth rate stock have gain last month lantheus holding have long term expect earning growth rate stock have surge last month edward lifescience have long term expect earning growth rate stock have rally roughly last month zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
1007,EW,abbott laboratory free report have make encourage move respect medical device business company recently announce fda approval full maglev heartmate left ventricular assist device lvad build sophisticated full maglev fully magnetically levitated flow technology heartmate system provide advanced short term hemodynamic support advanced heart failure patient full maglev technology enable heartmate system lower trauma blood pass pump optimize blood flow interestingly heartmate be upgrade version exist heartmate ii system be used longer duration much await fda approval be award abbott post successful result momentum clinical study also encouragingly note heartmate receive ce mark management person unite state suffer heart failure roughly new patient be diagnosed condition year support datum statista report heart failure market state market be project value witness cagr moreover see encourage growth user penetration rate share ailing person thus consider datum base believe latest fda nod accelerate top line growth report culrav org global lvad market be project value witness cagr moreover transperency market research north american market ventricular assist device be expect see cagr period thus consider market potential abbott latest development help gain traction lvad space interestingly abbott medical device operate segment total revenue stand highest revenue gross business second quarter moreover company cardiovascular neuromodulation sub segment be highest contributor make total medical device revenue sale unite state alone thus company latest development help boost performance segment believe agee population unhealthy lifestyle rise awareness expenditure healthcare continue drive growth heart failure market however market be dominate many well establish player medtronic plc mdt free report boston scientiific corporation bsx free report be most prominent one moreover abbott have be gain investor confidence consistently positive result past month company share price have outperformed industry stock have gain higher broader industry gain company have also outperformed gain market same time frame zack rank key pickabbott carry zack rank hold better rank medical stock be edward lifescience corporation ew free report zack rank strong buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
1008,EW,medtronic plc mdt free report lead global player medical technology service solution have make encourage move respect cardiac rhythm heart failure crhf business companyrecently announce ce mark approval attain stability quad mri active fixation heart lead be line company strategy focus research development high end medical device product core business line notably company be engage clinic trial evaluate attain stability quad mri active fixation heart lead unite state canada other region medtronic latest offer feature active fixation technology assist precise lead placement stability pair company quadripolar cardiac therapy defibrillator crt pacemaker crt company also initiate multicenter clinical study target enroll roughly patient site unite state canada europe hong kong malaysia global study be aim evaluate safety efficacy lead heart failure patient interestingly medtronic cardiac vascular group cvg segment account total revenue first quarter fiscal moreover company crhf sub segment be highest contributor make total cvg revenue be largely backed strong growth arrhythmia management well heartware international acquisition thus company latest development help boost performance segment medtronic strategy gain traction crhfsub segment seem be align datum provide ally market research report global cardiac monitoring cardiac rhythm management market be expect see cagr reach value believe high incidence cardiac disease due unhealthy lifestyle penetration concern company untapped market technological advancement increase awareness person continue drive global acceptance technology view encourage factor believe company european development attain stability quad mri active fixation heart lead be strategic broaden customer base however last month medtronic have be underperform broader industry stock have decline compare industry fall also underperform decline same time frame nevertheless believe latest ce mark approval boost investor confidence stock zack rank key picksmedtronic currently have zack rank hold few better rank medical stock be edward lifescience corporation ew free report lantheus holding inc lnth free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy lantheus holding idexx laboratory carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have gain last month idexx laboratoriesha long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month surprising tech stock keep eye tech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
1009,EW,aug issue update research report waltham base perkinelmer inc pki free report company provide scientific instrument consumable service pharmaceutical biomedical environmental testing chemical general industrial market worldwide company currently have zack rank hold perkinelmer expand product portfolio be help company market share worldwide short span time new product have gain significant traction consumer believe product continue boost company market share area diagnostic research environment moreover perkinelmer be well position benefit investment area cancer immunotherapy well rise trend outsource instrument maintenance scientific service long term acquisition strategic partnership have be key catalyst perkinelmer year earlier year company announce plan acquire euroimmun medical laboratory diagnostic ag approximately cash deal be expect close fourth quarter acquisition euroimmun medical laboratory diagnostic expand perkinelmer reach autoimmune allergy diagnostic market acquisition also reinforce company capability pertain new infectious disease chinese market management acquisition be expect add cent cent adjust earning perkinelmer continue acquire large number company improve revenue opportunity add integration risk frequent acquisition also negatively impact balance sheet form high level goodwill intangible asset frequent acquisition be also distraction management impact organic growth stock performance share price movement past year have be unsatisfactory company represent return almost bit lower broader industry return almost company have be witness weakness academic market outside unite state furthermore lackluster performance europe impact company third party logistic second quarter estimate revision trend have be favorable perkinelmer last month current quarter estimate moved north compare movement opposite direction full year estimate moved north same time frame have have significant impact magnitude estimate current quarter estimate increase full year estimate inched same time frame key picksa few better rank stock broader medical sector be edward lifescience corp ew free report idexx laboratory inc idxx free report cogentix medical inc notably edward lifescience sport zack rank strong buy idexx laboratory cogentix medical have zack rank buy see complete list today zack rank stock here edward lifescience deliver average earning beat trail quarters company have long term expect earning growth rate cogentix medical register positive earning surprise last report quarter stock represent stellar return last year idexx laboratory deliver average earning beat trail quarters have long term expect earning growth rate surprising tech stock keep eye ontech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
1010,EW,aug issue update research report st paul mn base ecolab inc ecl free report company be lead provider water hygiene energy technology service stock currently carry zack rank hold ecolab have impressive run bourse last month trading industry term price performance glimpse price movement reveal ecolab share have gain compare favorably industry decline ecolab report stellar second quarter fiscal result beating zack consensus estimate count upside come new business gain better pricing product innovation cost efficiency overall adjust quarterly net sale be year period more offset higher deliver product cost third quarter ecolab project adjust diluted earning share range compare year ecolab considerable earning growth challenge business environment instill confidence additionally company large base recur revenue industry lead technology excellent field service be significant propeller long term growth company prospect global industrial global institutional business segment be also bright last report quarter sale segment scale year year basis furthermore ecolab boast compelling fundamental revenue adjust earning multiply rate last year however flip side unfavorable foreign currency impact venezuelan deconsolidation be expect hurt earning term also escalate cost expense be weigh margin last month comparative study ecolab forward forward month basis multiple reflect stock have be quite overvalue key pickssome better rank medical stock be edward lifescience corp ew free report lantheus holding inc lnth free report stryker corporation syk free report edward lifescience sport zack rank strong buy lantheus holding stryker carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have climb last month lantheus holding have long term expect earning growth rate stock have surge last month stryker corporation have long term expect earning growth rate stock have rally roughly last month surprising tech stock keep eye ontech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
1011,EW,medtronic plc mdt free report report financial result first quarter fiscal adjust earning share ep report quarter come surpass zack consensus estimate year year adjustment quarter primarily include certain impact restructure charge intangible asset amortization acquisition related item adjust unfavorable foreign exchange impact cent adjust ep come year year adjustment company report net income cent share year year total revenue report quarter gross constant exchange rate cer basis report basis top line miss zack consensus estimate foreign currency fluctuation affected medtronic fiscal first quarter revenue quarter review sale total revenue increase year year develop market revenue totale total revenue reflect increase cer report emerge market total revenue amount cer report medtronic plc price consensus ep surprise medtronic plc price consensus ep surprise medtronic plc quotesegment company currently generate revenue major group viz cardiac vascular group cvg minimally invasive therapy group mitg restorative therapy group rtg diabetes group cvg comprise cardiac rhythm heart failure crhf coronary structural heart csh aortic peripheral vascular division apv mitg include surgical solution patient monitoring recovery pmr division rtg include spine brain therapy specialty therapy pain therapy segment diabetes group incorporate intensive insulin management iim intensive diabetes therapy ndt diabetes service solution dss division revenue cvg improve cer report drive strong balanced growth division crhf sale be year year cer report come back growth arrhythmia management lead high teen growth atrial fibrillation solution cer amplify penetration micra transcatheter pace system strong uptake tyrx absorbable antibacterial envelope continue worldwide customer demand reveal linq insertable cardiac monitor apart heartware international acquisition drive growth heart failure division csh revenue be cer report back high constant currency growth transcatheter aortic valf result strong customer uptake corevalve evolut pro platform unite state continue demand corevalve evolut mm valve unite state well europe apv revenue register growth cer report drive continue adoption endurant iis aortic stent graft remarkable strength heli fx endoanchor system peripheral be drive low double digit growth atherectomy drug coat balloon mitg worldwide sale reach mark year year increase cer same report mid single digit growth surgical solution low single digit growth pmr rtg worldwide revenue be year year cer same report high single digit growth brain therapy mid single digit growth specialty therapy low single digit growth spine thus mitigate decline pain therapy however revenue diabetes group decrease cer same report marginsgross margin report quarter contract basis point bps increase gross profit adjust operate margin remain flat year year be owing decline research development expense be offset rise selling general administrative expense other expense report quarter be compare year period reiterate fiscal constant currency revenue ep guidance company still expect full year revenue growth range cer however company revise foreign currency fluctuation estimation be now project have positive impact fiscal year compare expect positive impact state previously zack consensus estimate revenue remain fiscal fiscal adjust earning share growth be still expect range cer currency translation be now expect have adverse impact cent positive impact cent compare earlier expectation negative impact approximately cent zack consensus estimate fiscal earning be peg moreover second quarter fiscal medtronic expect currency translation have favorable impact revenue currency translation be expect have favorable impact cent second quarter earning share takemedtronic exit fiscal fourth quarter mixed note earning ahead zack consensus estimate report revenue fail meet estimate company demonstrated improve segmental performance cer escalate cost expense continue weigh bottom line unfavorable currency translation act dampener company quarterly performance however fiscal guidance represent chance respite positive note major business group contribute solid top line growth cer highlighted sustainability group region addition display successful integration achievement synergy target be also encourage solid growth trend successfully continue well healthy global acceptance advanced therapy apart product innovation company be currently focuse geographical diversification business zack rank peer currently have zack rank hold few better rank medical stock be edward lifescience corp ew free report haemonetic corp hae free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy haemonetic idexx carry zack rank buy see complete list today zack rank stock here edward lifescience second quarter adjust earning improve stupendous year year primarily drive strong sale growth company transcatheter heart valf business stock have gain last month idexx laboratory record second quarter ep cent cer year year report basis moreover revenue rise year year organic basis haemonetic report adjust ep cent first quarter fiscal year year moreover revenue inched year year cer quarter zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
1012,EW,headquarter billerica bruker corporation brkr free report be focuse strengthen position grow scientific instrument market line company recently announce venture biotool laboratory macromolecular crystallography be part bruker axs segment bruker nano venture biotool have few latest feature term source detector sample handle technology company feature new im diamond is diamond brightest microfocus ray source also is diamond run continuously routine maintenance bruker also offer uptime guarantee new technology further latest version excillum metaljet be powerful alternative compact microfocus is diamond accord bruker venture biotool feature new photon iii largest photon count pixel array detector home laboratory company new automate cryo cool crystal handle system feature ceiling mount robot sampling handle state art cryogenic technology incorporate new agh automate goniometer head agh allow sample be align automatically ray management believe venture biotool have enabled company set new standard crystallography system home laboratory accord report market market protein crystallization market be estimate see cagr reach worldwide market recent development bruker nano segment be launch next generation wavelength dispersive ray fluorescence wdxrf spectrometer tiger series be versatile wdxrf tool available advanced quantitative elemental analysis industrial academic material research industrial quality control qc material last report quarters bruker nano business see profit prior restructure cost action last report second quarter solid growth be drive contribution hysitron nanoindenting product acquisition late january improve result axs business bruker have be trading broader industry last month period stock have generate positive return higher gain broader industry zack rank key picksbruker currently carry zack rank hold few better rank medical stock be edward lifescience corp ew free report lantheus holding inc lnth free report stryker corporation syk free report edward lifescience sport zack rank strong buy lantheus holding stryker carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have gain last month stryker have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
1013,EW,lead diagnostic testing company laboratory corporation america holding lh free report agreement interpace diagnostic group inc idxg have be renew extend extend deal agreement be deem valid january successful initial phase press release interpace diagnostic be fully integrate commercial company provide clinically useful molecular diagnostic test pathology service evaluate risk cancer leverage latest technology personalize medicine better patient diagnosis management labcorp have originally enter agreement january offer interpace diagnostic molecular test thygenx thyramir thygenx thyramir reflex testing yield high predictive value determine presence absence cancer thyroid nodule simpler word test provide latest technology diagnosis thyroid cancer indeterminate thyroid nodule patient accord report market datum forecast thyroid cancer market be estimate reach worth cagr consider bountiful opportunity niche space believe be strategic move company late labcorp have be take strategic initiative specialize test recently start offer new proprietary adamts test distinguish disease characterize life threaten acute thrombotic microangiopathy tma notably tma be relatively rare serious syndrome tma small blood vessel develop blood clot result mechanical destruction red blood cell company also announce availability pretrm test unite state pretrm test be develop sera prognostic inc be only validate blood test offer early individualized prediction preterm birth risk pregnant woman further labcorp announce significant enhancement proprietary vistaseq hereditary cancer portfolio new test panel focuse risk specific hereditary cancer syndrome majority last month labcorp have be trading broader industry period stock have gain industry decline zack rank key pickslabcorp carry zack rank hold few better rank medical stock be idexx laboratory inc idxx free report lantheus holding inc lnth free report edward lifescience corporation ew free report edward lifescience sport zack rank strong buy lantheus holding idexx laboratory carry zack rank buy cansee complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month idexx laboratory have long term expect earning growth rate stock have gain last month zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
1014,EW,murray hill nj base bard inc recently announce premarket approval lutonix drug coat balloon pta catheter dcb fda platform have be declare safe effective end stage renal disease esrd patient stenotic lesion dialysis arteriovenous fistulae av av fistula be abnormal connection passageway artery vein surgically create hemodialysis treatment lutonix be available market now fda go ahead lutonix platform be backed favorable outcome clinical trial name lutonix av be investigational device exemption ide trial used drug coat balloon treat patient stenotic lesion av fistulae lutonix dcb platform lutonix drug coat balloon dcb be flagship product company angioplasty balloon be coat therapeutic dose drug paclitaxel used treat patient peripheral arterial disease pad recent past lutonix platform catheter get favorable response regulatory front treatment superficial femoral artery sfa popliteal artery disease early market acceptance device have be impressive company be likely witness expand adoption technology market continue mature also center medicare medicaid service cms approve pass payment lutonix dcb believe latest regulatory development ease stiff pricing environment boost adoption device regard major competitor bard hemodialysis space include fresenius medical care fms free report davita healthcare partner inc dva free report favorable global trendsmore patient undergo hemodialysis treatment treatment process last almost hour occur thrice week buoy factor increase number esrd patient rapid growth age population preference dialysis treatment kidney transplant global hemodialysis peritoneal dialysis market have be grow manifold research report market market show market be expect reach worth cagr share price move upover past year bard have add compare favorably same time frame furthermore current level be way higher broader industry gain just same time frame meanwhile estimate revision trend current quarter be unfavorable estimate move last month compare movement opposite direction notably current quarter estimate stock fall last month bard carry zack rank hold key picka better rank stock broader medical sector be edward lifescience corp ew free report notably company sport zack rank strong buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate represent impressive year date return zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
1015,EW,friday have be rough day wall street several major index include dow nasdaq hover deep red early afternoon trading hour be nasdaq composite be lower meanwhile dow jone industrial average be more point roughly putt popular indicator track worst week year friday slump come back bureau labor statistic first job report accord latest datum add job january outpace estimate call growth job report also note wage rise annualize basis new job info send interest rate higher friday morning benchmark year yield moved year high year yield touch highest level march have not be bad news today accord barchart com least stock surge new time high several positive move stem strong earning result company be amazon com inc amzn free report share commerce king gain much touch new intraday peak morning trading company post robust earning revenue growth thursday amazon surpass analyst estimate top bottom line jeff bezos lead company notch revenue growth operate income soar amazon say sale bud web service division reach quarter company witness strong post earning move be edward lifescience corporation ew free report edward post fourth quarter report thursday afternoon report adjust earning share revenue result beat respective zack consensus estimate edward say adjust earning grow total revenue expand back strong sale growth company transcatheter heart valf business management also acknowledge strong performance surgical heart valve therapy critical care product line share edward lifescience moved much higher touch new time high morning trading hour finally investor note popular recent ipo canada goose holding inc goos free report surge new peak share early afternoon trading not see canada goose latest result next week wall street be clearly get excited trendy winter apparel maker base current consensus estimate expect canada goose report earning share revenue company say yesterday release latest result bell open feb want more analysis author make sure follow ryan_mcqueeney twitter breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth click here access stock
1016,EW,edward lifescience corporation ew free report fourth quarter adjust earning share ep come cent exclude net expense share impact tax reform report ep come cent adjust ep figure beat zack consensus estimate cent however adjust earning improve year year primarily drive strong sale growth company transcatheter heart valf business full year adjust ep come beating zack consensus estimate moreover figure beat year number sale detailsfourth quarter sale improve moreover figure beat zack consensus estimate underlie sale increase include impact germany stocking sale customer nation choose purchase additional inventory sapien valve anticipation potential supply interruption result recent intellectual property litigation net revenue totale outpace zack consensus estimate figure also improve year number revenue be primarily drive considerable growth transcatheter heart valve sale well strong performance surgical heart valve therapy critical care product line too edward lifescience corporation price consensus ep surprise edward lifescience corporation price consensus ep surprise edward lifescience corporation quote segment detailsin fourth quarter company report transcatheter heart valve therapy thvt sale reflect growth prior year quarter unite state thvt sale totale year year growth be drive excellent clinical performance sapien well continue strong therapy implementation region surgical heart valve therapy sale quarter be prior year quarter be lead strong demand edward intuity elite valve system solid uptake core product outside unite state critical care sale be report quarter represent increase fourth quarter solid growth product category be drive strong growth company core product mainly unite state china marginsin fourth quarter gross margin expand basis point bps owing more profitable product mix lead grow sale transcatheter valf be however partially offset shutdown company manufacturing plant switzerland sg expense rise year year account sale personnel related expense primarily transcatheter valve thv segment expenditure increase year year owing continue investment transcatheter aortic valve mitral valve program adjust operate margin quarter expand bps rise revenue outweighed increase operate expense cash positionedward lifescience exit cash cash equivalent short term investment compare end long term debt totale compare report previous year cash flow operate activity be exclude capital spending free cash flow be quarter average diluted share outstanding be guidance raisededward lifescience have raise sale expectation high end previously project range zack consensus estimate full year revenue be well guide range adjust ep expectation have also be raise previous range zack consensus estimate full year adjust ep stand low end company guide range first quarter company project sale zack consensus estimate revenue be company project range company estimate adjust ep meanwhile zack consensus estimate adjust ep be be also company forecast range takeedward lifescience exit fourth quarter solid note strong transcatheter valve sale domestic market well overseas be major positive company also perform well gross margin front management expect gain traction ever expand tavr market base increase preference favor transcatheter aortic valve replacement well compelling clinical evidence lead strong adoption thv therapy however tough competition cardiac device market reimbursement issue continue challenge zack rank key picksedward lifescience have zack rank hold few better rank stock report solid result earning season be petm express pet free report perkinelmer pki free report resm rmd free report petm sport zack rank strong buy perkinelmer resm carry zack rank buy see complete list today zack rank strong buy stock here petm recently report third quarter fiscal result adjust earning share be cent prior year quarter revenue report quarter rise year year basis perkinelmer report fourth quarter adjust earning share cent adjust revenue be approximately year quarter resm post second quarter fiscal adjust earning share prior year quarter revenue report quarter increase year year constant exchange rate cer breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
1017,EW,fourth quarter earning season be gain momentum participant have already release financial number jan latest earning preview report cycle be encourage start average proportion company edge past top bottom line expectation total earning member have improve increase revenue result roughly member slate be announce week zack datum estimate period be gradually trend upward board zack sector medical bracket be expect witness earning rise fourth quarter revenue growth projection store medical device industry medical device space broader medical sector somewhat display mixed bag sort part tax overhaul corporate tax rate have be slash previous thus lend huge relief medtech mammoth however ahead industry fourth quarter earning release section analyst expect new tax law negatively impact industry due possible cut overall medicare spending certain criterium be not fulfilled specific date congressional budget office apprehend absence alternative meet fiscal deficit huge tax reduction automatic cut back worth include medicare cut mandatory budget spending be trigger tax reform related concern news congress delay medical device tax year come huge boost industry player investor tax be earlier delay congress couple year deferral once again largely propel activity space let take sneak peek performance major medical device company wait report earning feb boston scientific corporation bsx free report be optimistic company gradually improve performance interventional cardiology lead innovative portfolio robust commercial team globally more specifically watchman platform be expect experience excellent quarter consistent global momentum boston scientific multiple market development effort continue push growth company have positive earning esp zack rank hold favorable zack esp indicate likely positive surprise bullish zack rank strong buy buy increase predictive power esp conversely sell rate stock never be consider go earning announcement especially company be see negative estimate revision read more watchman boost boston scientific earning boston scientific corporation price ep surprise boston scientific corporation price ep surprise boston scientific corporation quotebaxter international inc bax free report fourth quarter baxter international be anticipate gain strong hospital product drive solid sale fluid system business well robust demand injectable pharmaceutical hospital product segment expect fluid system maintain momentum evident zack consensus estimate be report quarter reflect improvement year period banking solid prospect quantitative model also show beat company give combination zack rank earning esp uncover best stock buy sell re report earning esp filter read more baxter beat earning hospital product baxter international inc price ep surprise baxter international inc price ep surprise baxter international inc quotemckesson corporation mck free report major player pharmaceutical medical supply distribution market expect witness solid performance canadian business third quarter fiscal also mckesson specialty health unit be likely drive company top line same time frame unit be likely benefit close intrafusion acquisition recent bdi pharma buyout be unable conclude mckesson be likely beat earning quarter stock carry zack rank increase predictive power esp earning esp however need have positive esp be confident earning surprise see complete list today zack rank stock here read more mckesson report earning beat card mckesson corporation price ep surprise mckesson corporation price ep surprise mckesson corporation quoteedward lifescience corporation ew free report lead cardiovascular product maker be expect grow robust transcatheter heart valve therapy segment fourth quarter back continue therapy adoption geography notable strength unite state company be likely retain bullish run period be report edward lifescience be zack rank player have earning esp positive zack esp denote likely earning surprise favorable zack rank company raise predictive power esp read more edward lifescience thvt likely drive earning edward lifescience corporation price ep surprise edward lifescience corporation price ep surprise edward lifescience corporation quoteidexx laboratory inc idxx free report repeating precede quarter success idexx be estimate gain strong global footprint companion animal group diagnostic recur revenue fourth quarter be also upbeat idexx enhance commercial capability unite state maintain recur revenue growth cag diagnostic company be rank player have earning esp therefore be unable conclude idexx be likely beat earning quarter however idexx trail month average beat be read more idexx post beat earning cag strength idexx laboratory inc price ep surprise idexx laboratory inc price ep surprise idexx laboratory inc hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1018,EW,edward lifescience corporation ew free report be schedule report fourth quarter earning feb market close edward lifescience have outperformed zack consensus estimate precede quarters average positive earning surprise let take look thing be shape prior announcement key prior quarter edward lifescience be expect gain strength transcatheter heart valve therapy segment thvt banking continue therapy adoption geography notable strength unite state company be expect maintain bullish trend fourth quarter well unite state transcatheter heart valve sale grow year year third quarter outside unite state underlie growth rate be strong contribution japan edward lifescience corporation price ep surprise edward lifescience corporation price ep surprise edward lifescience corporation quote last report quarter growth thvt be drive excellent clinical performance result sapien well continue strong therapy implementation region also zack consensus estimate thvt net sale reflect increase year quarter overall fourth quarter revenue be project here be other factor influence edward lifescience fourth quarter result investor be bullish harpoon medical acquisition be complete dec intention enhance surgical heart valve therapy portfolio however buyout be not expect contribute significantly fourth quarter revenue meanwhile intuity elite valve system be approve medicare new tech add payment effective oct recognize intuity latest technology provide substantial clinical improvement conventional valf company believe many hospital be help add payment next year simplify adoption rapid deployment valve shorten minimally invasive complex procedure edward lifescience expect sale meet high end range moreover note company project total sale adjust earning share cent cent fourth quarter however company expect change fourth quarter gross margin earning be expect be impact foreign currency fluctuation also tough competition cardiac device market reimbursement issue continue raise caution here be quantitative model predict edward lifescience have right combination main ingredient positive earning esp zack rank hold higher increase odd earning beat zack esp earning esp edward lifescience be uncover best stock buy sell re report earning esp filter zack rank edward lifescience carry zack rank increase predictive power esp meanwhile zack consensus estimate earning cent reflect improvement year year basis other stock worth lookhere be few other medical stock worth consider have right combination element post earning beat quarter bio rad laboratory bio free report have earning esp zack rank buy see complete list today zack rank strong buy stock here myriad genetic mygn free report have earning esp zack rank henry schein hsic free report have earning esp zack rank hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1019,EW,initiative enhance clinical development japan parexel international corporation global service company provider clinical research logistic have form alliance osaka international cancer institute bolster patient enrollment clinical trial oncology hematology management osaka leverage parexel expertise provide wide range potential treatment option cancer patient believe solid advancement clinical trial scientific expertise oncology segment fortify parexel foothold niche market oncology regard oncology be largest fastest grow therapeutic area parexel fact segment grow average past year however believe initiative help parexel drive top bottom line solid long term expect earning growth rate hold promise regard furthermore service market be healthy parexel enjoy competitive edge space solid prospect asia pacificparexel growth story asia pacific have be compelling japan company have lead position company be well position advantage outsource market be relatively underpenetrated parexel have operation tokyo kobe osaka japan report third quarter fiscal paraxel business asia have more double last year cagr almost apart japan company see solid prospect china world second largest pharmaceutical market witness double digit growth share shine brightparexel have have impressive run bourse last month company have gain compare favorably broader industry addition stock have also outperformed return same time frame estimate revision trend current quarter full year have be stable last month notably zack consensus estimate current quarter full year stand cent respectively same time frame parexel have zack rank hold bottom lineapart fortify hold oncology space parexel be focuse expedite activity area protocol design study start trial execution regulatory submission product company provide broad range clinical research consult medical communication technology solution service pharmaceutical biotechnology medical deviceindustry worldwide fact global market trend seem favorable moment market be anticipate reach worth cagr persistence market research expect parexel gain significant traction related ancillary market courtesy favorable trend latest partnership key picksa few better rank stock broader medical sector be edward lifescience corp ew free report idexx laboratory inc idxx free report stryker corporation syk free report notably edward lifescience sport zack rank strong buy idexx laboratory stryker corporation have zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate notably stock represent impressive year date return idexx laboratory have long term expect earning growth rate notably stock represent stellar year date return stryker represent impressive year date return stock have long term expect earning growth rate zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
1020,EW,sep issue update research report north kansa city mo base cerner corporation cern free report lead global provider healthcare information technology solution hcit stock currently carry zack rank hold believe cerner have solid growth opportunity revenue cycle management rcm suite solution fact segment have be strong contributor recent time revwork service deliver solid performance fact booking second quarter be time high year year basis secondary growth driver cerner be population health ph management platform notably company clinch high number large contract ph platform last report quarter cerner offer exposure worldwide healthcare automation international operation provide more diversify revenue stream past company win contract well middle east furthermore cerner constantly pursue complementary business acquisition enable expand solution device offering service flipside company operate hcit space be intensely competitive fast evolve subject rapid technological change share price estimate revisioncerner have impressive run bourse last month trading industry term price performance glimpse price movement reveal cerner share have gain compare favorably rise industry belong cerner corporation price cerner corporation price cerner corporation quoteon flip side estimate revision trend current year remain unfavorable estimate move south last month compare only movement opposite direction company current estimate slip past month key picksa few better rank medical stock be edward lifescience corp ew free report idexx laboratory inc idxx free report cogentix medical inc edward lifescience sport zack rank strong buy idexx laboratory cogentix medical hold zack rank buy see complete list today zack rank stock here edward lifescience deliver average earning beat last quarters company have long term expect earning growth rate idexx laboratory have average earning beat trail quarters have long term expect earning growth rate cogentix medical come positive earning surprise last quarter stock represent stellar return last year look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1021,EW,sep issue update research report petm express inc pet free report petm currently carry zack rank hold last month petm have be trading broader industry last trading price company have gain stupendous compare growth broader industry fiscal first quarter petm post better expect result mark solid start fiscal be encourage significant increase reorder sale new order sale quarter expect same continue year petm be strive implement several strategy revitalize top line include focuse advertising efficiency boost new order sale shift sale higher margin item expand product offering however be apprehensive escalate advertising expense incur quarter company market product primarily well know brand medication such frontline advantix advantage heartgard sentinel interceptor other flip side petm operate highly competitive fragmented pet medication market competitor include veterinarian traditional retailer other mail order online retailer pet medication other health product also acquisition novartis animal health division eli lilly company have give rise more challenge petm key pickssome better rank medical stock be edward lifescience corporation ew free report idexx laboratory inc idxx free report amedisys inc am free report edward lifescience sport zack rank strong buy idexx amedisys carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month amedisys have long term expect earning growth rate stock have gain last month idexx have long term expect earning growth rate last month stock have return look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1022,EW,medtronic plc mdt free report continue broaden portfolio pain therapeutic solution follow fda approval company have recently make significant breakthrough launch intelli platform management certain type chronic intractable pain medtronic intelli platform be able overcome certain limitation related current spinal cord stimulation scs system battery performance platform power evolve standardize guidance balance high dose hd low dose ld therapy setting other advancement platform be worth mention be manage samsung galaxy tab tablet interface provide physician faster delivery evolve workflow software upgrade intelli platform include medtronic proprietary mri technology broadest access available mri diagnostic imaging simple eligibility determination well adaptivestim technology automatic adjustment deliver right therapy dose right location pain target shift accord body position transparency market research report global pain management therapeutic market be expect ascend medtronic back problem be top most expensive medical condition estimate patient annually undergo lumbosacral spine procedure develop chronic intractable pain keep problem mind be look forward solid customer adoption intelli platform consider huge grow market chronic pain management medtronic plc price medtronic plc price medtronic plc quote last month medtronic have underperform broader industry stock have lose versus gain broader industry period zack rank key picksmedtronic carry zack rank sell better rank medical stock be edward lifescience corporation ew free report cheme corporation che free report amedisys inc am free report edward lifescience sport zack rank strong buy cheme amedisys carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month cheme have long term expect earning growth rate stock have gain last month amedisys have long term expect earning growth rate stock have gain last month trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
1023,EW,angiodynamic inc ango free report be set report second quarter fiscal result jan market open last quarter company report adjust earning cent share miss zack consensus estimate cent average angiodynamic deliver positive earning surprise trail quarters however lackluster price performance last year high debt level continue hinder company angiodynamic share have return mere compare industry rally let see thing be shape prior announcement factor playstrong product portfolio angiodynamic wide array product angiovac bioflo nanoknife enhance market opportunity notably pv business peripheral vascular sale have also build strong momentum angiodynamic have be experience growth other product family food management thrombus management bioflo product nanoknife disposable oncology section solero mta system drive growth company ride market solid response solero microwave tissue ablation mta system especially microwave ablation space platform be intend be used ablation soft tissue open procedure management solero be primary driver whopping year year increase oncology surgery sale last quarter robust fundamental growth story last year company sale witness cagr earning share see cagr company expect benefit ongoing market transition less invasive interventional procedure upcoming year unfavorable estimate revision trend estimate revision trend current quarter have be unfavorable angiodynamic current quarter zack consensus estimate revenue fall year year further zack consensus estimate earning decline cent share year year basis angiodynamic inc price ep surprise angiodynamic inc price ep surprise angiodynamic inc quoteearning quantitative model do not conclusively show earning beat angiodynamic quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate be not case here see zack esp angiodynamic currently have earning esp be most accurate estimate zack consensus estimate be peg cent uncover best stock buy sell re report earning esp filter zack rank angiodynamic currently carry zack rank increase predictive power esp however esp make surprise prediction difficult caution stock zack rank sell rate stock go earning announcement especially company be see negative estimate revision momentum stock considerhere be company want consider model show have right combination element post earning beat quarter edward lifescience corp ew free report have earning esp zack rank thermo fisher scientific inc tmo free report have earning esp zack rank medtronic plc mdt free report have earning esp zack rank investor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
1024,EW,sep issue update research report chesterbrook pa base corporation abc free report world largest pharmaceutical service company company focus provide drug distribution related service reduce health care cost improve patient outcome company currently have zack rank hold have unimpressive run bourse last month trading industry term price performance glimpse price movement reveal share have lose compare unfavorably gain broader industry unfavorable performance be lead pricing pressure generic drug space lackluster guidance full year expect fiscal revenue growth range significantly lower previous band company expect brand drug inflation range take pharmedium healthcare holding back believe temporary slowdown pharmedium growth mar bottom line come quarters notably company aim boost investment enhance pharmedium quality assurance qa quality control qc system term product quality patient safety lend competitive advantage long haul result bottom line headwind business fiscal lackluster performance hepatitis revenue segment be concern witness negative revenue impact decline sale segment last report second quarter revenue improve only quarter have be adverse impact hepatitis segment cutthroat competition niche space be additional concern operate highly competitive pharmaceutical distribution related health care service market company primary competitor be national generic regional distributor generic industry be witness consolidation customer manufacturer globalization increase quality regulatory challenge company also face competition manufacturer chain drugstore specialty distributor packaging health care technology company key picksa few better rank medical stock be edward lifescience corporation ew free report lantheus holding inc lnth free report cheme corporation che free report edward lifescience sport zack rank strong buy lantheus holding cheme carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month cheme have long term expect earning growth rate stock have gain last month more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1025,EW,sep issue update research report cvs health corp cvs free report provider integrate offering entire spectrum pharmacy care company currently carry zack rank hold post better expect performance second quarter cvs health be observed trading significantly ahead industry last month stock have inched contrast industry decline same period positive note strong pharmacy service number benefit upside specialty pharmacy encourage fact be year year decline hepatitis script volume recently report second quarter lower new patient enrolment cvs health specialty business growth outperformed market company be currently work integration omnicare specialty operation company exist specialty business profile cvs health specialty connect offer continue experience strong surge prescription volume high satisfaction score patient payer provider be also impressed company robust pbm pharmacy benefit management selling season incidentally cvs health have already confirm very successful selling season year base expect revenue be increase last quarter regard pbm selling season have already begin start current year company have successful second quarter magnitude bidding opportunity be flat year year gross new business be net new business commendably reach new business number include loss fep federal employee program specialty contract lack impact individual med pdp company have already complete client renewal however highly competitive retail pharmacy business pose severe threat company have deliver sluggish number retail long term care business recent past company decision restrict participate tricare network many fully insure prime network be due negative impact pharmacy sale script comp also dull economic condition unite state hamper company profit margin other key pickssome better rank medical stock be edward lifescience corporation ew free report lantheus holding inc lnth free report cheme corporation che free report edward lifescience sport zack rank strong buy lantheus holding cheme carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have surge last month cheme have long term expect earning growth rate stock have gain last month more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1026,EW,abbott free report be healthy growth trajectory late stock have gain last month ahead gain broader industry decline stock have market cap company current year growth rate be also favorable compare increase broader industry solid prospect zack rank buy stock emerge attractive pick illinois base medical device major estimate revision trend current year have also be positive past couple month analyst moved north just movement opposite direction estimate be marginally revise upward share same time frame company also have trail quarter average positive earning surprise let find recent positive trend be sustainable market be upbeat abbott gain national reimbursement freestylelibre glucose monitoring system national health service nhs business service authority unite kingdom have be major breakthrough diabetic business reimbursement grant make freestylelibre system widely available person unite kingdom also other development include abbott srecent fda approval full maglev heartmate left ventricular assist device lvad be encourage addition company announce receipt national reimbursement freestyle libre glucose monitoring system japan breakthrough have widen medical device major customer base diabetes management company also recently sign manage equipment service contract north west london pathology nwlp host imperial college healthcare nhs trust abbott expect alliance solidify footprint rapidly grow diagnostic market abbott second quarter performance have be promising sale adjust earning continue operation increase year year several strategic progress make expect growth stream continue day ahead other key picksother top rank medical stock be edward lifescience corporation ew free report cheme corporation che free report amedisys inc am free report edward lifescience sport zack rank strong buy cheme amedisys carry zack rank see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month cheme have long term expect earning growth rate stock have gain last month amedisys have long term expect earning growth rate stock have gain last month trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
1027,EW,healthequity inc hqy free report report earning cent share second quarter fiscal surpass zack consensus estimate cent figure be higher year earning cent revenue margin expansion share healthequity have gain only value year date compare unfavorably industry gain belong quarter detailsrevenue say quarter amount reflect increase year year surpass zack consensus estimate service total revenue custodial interchange revenue be year year respectively growth service revenue be drive year year increase average health saving account hsa be offset decrease service revenue average hsa decline be lead company strategy offer lower service fee hsa more volume network partner particularly higher balance healthequity state profitability hsa business model increase balance grow growth custodial revenue be support higher average daily cash aum strong year year growth interchange revenue be drive increase card spending more favorable interchange term higher spend volume jul total number hsa member company serve bank custodian increase year year total asset management aum surge year year healthequity inc price consensus ep surprise healthequity inc price consensus ep surprise healthequity inc quotefinancial conditiona jul company have cash cash equivalent marketable security outstanding debt compare favorably cash cash equivalent marketable security outstanding debt jan fiscal end jan healthequity forecast revenue range net income be forecast range result net income diluted share range cent cent adjust ebitda outlook be estimate band business outlook fiscal end jan assume project effective income tax rate approximately zack rank key pickscurrently healthequity have zack rank hold few better rank medical stock be edward lifescience corporation ew free report lantheus holding inc lnth free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy lantheus holding idexx laboratory carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month idexx laboratory have long term expect earning growth rate stock have gain last month surprising tech stock keep eye ontech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
1028,EW,renown information technology service provider healthcare organization allscript healthcare solution inc mdrx free report recently announce dbmotion solution platform have be select south western sydney phn swsphn deliver integrate care notably dbmotion solution be allscript proprietary community platform come back news allscript dbmotion integrate discrete real time patient datum diverse care setting health information technology system single patient record provider such synchronize information entire system enable provider easily access manage information familiar workflow facilitate better care disease management swsphn be not profit health organization focuse support general practitioner practice nurse other primary health provider aim improve access quality local health care whole community be first asia pacific organization select dbmotion solution platform dbmotion solution support swsphn overall goal improve clinical excellence advancement lead quality care also help swsphn collaborate internationally recognize dbmotion site locate unite state canada israel past month allscript have outperformed broader industry stock have increase compare only gain industry belong allscript be lead provider healthcare information technology solution management be focuse various restructure initiative such streamline operational efficiency increase cater client need go forward believe favorable demographic trend reinforce supportive regulatory environment be expect sustain growth demand service zack rank key picksallscript carry zack rank hold few better rank medical stock be edward lifescience corporation ew free report lantheus holding inc lnth free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy lantheus holding idexx laboratory carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month idexx laboratory have long term expect earning growth rate stock have gain last month surprising tech stock keep eye ontech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
1029,EW,integra lifescience holding corporation iart free report recently sign definitive agreement sell company certain neurosurgery asset healthcare product service provider natus medical incorporate baby free report total deal value form part company effort fulfill certain close condition propose acquisition johnson johnson jnj free report codman neurosurgery business integra have decide sell global camino icp monitoring product line include san diego manufacturing facility natus medical natus also get hold right related integra fix pressure shunt well right codman duraform dural graft implant standard evd catheter csf collection system announce entire set divestiture integra have also discuss imminent financial impact company approximately revenue be earn neurosurgery product line associate divestiture take net divestiture codman acquisition account company preliminary basis estimate fourth quarter revenue contribution approximately full year integra expect codman neurosurgery contribute revenue net divestiture overall codman neurosurgery business be expect remain accretive integra adjust earning share contribute least cent however full year integra expect minimal contribution codman neurosurgery adjust earning share notably integra propose acquisition codman declare february provide company global reach neurosurgery connote core expertise integra specialty surgical solution integra codman neurosurgery exist portfolio new product pipeline advanced hydrocephalus neuro critical care be go complement acquirer lead product pipeline tissue ablation dural repair cranial stabilization post completion acquisition consolidated portfolio offer complete solution neurosurgery scale invest bring new technology table patient worldwide notably report radiant insight global neurosurgery market be expect witness estimate cagr take consideration huge growth prospect believe integra initiative strengthen foothold particular niche be well time overall integra lifescience have be consistently trading broader industry last month stock have rally year date substantially outperform gain industry zack rank key pickintegra currently carry zack rank hold better rank medical stock be edward lifescience corporation ew free report sporting zack rank strong buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have gain roughly last month more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1030,EW,california base align technology inc algn free report recently sign distribution agreement patterson dental business unit patterson company inc pdco free report exclusive agreement effective september align technology itero element intraoral scanning system be available part patterson dental cad cam portfolio unite state canada thus believe align technology slatest deal boost itero scanner customer base considerable extent be also optimistic company expand work flow option lead itero scanner context align technology recently launch software upgrade itero element intraoral scanner be capable compare patient scan time latest timelapse technology also align technology collaborate exocad gmbh march integrate portfolio result high tech solution efficient scanning design manufacturing house dental prosthesis february company announce addition digital nobel biocare implant itero intraoral scanner portfolio interestingly revenue scanner service improve substantial last report second quarter moreover company see increase adoption itero scanner invisalign case submission instead pvs impression especially north america thereby drive invisalign utilization line latest development itero scanner space align technology latest deal buoy optimism report medgadget global market dental scanner be project see cagr period consider market potential align technology current development scanner service space collaboration seem be strategic believe unhealthy lifestyle rise awareness expenditure healthcare continue drive growth dental scanner market however market be dominate many well establish player dentsply sirona be prominent align technology have be gain investor confidence consistent positive result past month company share price have outperformed broader industry stock have gain broader industry fall company have also outperformed gain market same time frame zack rank key picksalign technology currently have zack rank hold few better rank medical stock be edward lifescience corporation ew free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy idexx laboratory carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have gain last month idexx laboratory have long term expect earning growth rate stock have rally roughly last month simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
1031,EW,henry schein inc hsic free report have recently team integrate medical foundation imf lugpa association independent urology group practice raise awareness prostate cancer more specifically henry schein global corporate social responsibility program henry schein care work matter henry schein support imf lugpa series communication effort increase awareness practitioner public importance early detection prostate cancer accord have be widely accept early detection prostate cancer greatly enhance patient chance recover disease believe company move be well time take consideration frequency rate prostate cancer be grow national cancer institute estimate approximately man be diagnosed disease lifetime american cancer society more man be expect be diagnosed prostate cancer more man succumb disease henry schein be yet make foray world cancer research have already come several awareness drife late only last month company announce offer dental animal health medical customer opportunity join fight cancer proposal be open september december purchasing range pink product customer support company practice pink program initiative design increase awareness back cure breast cancer well other cancer therapy past month henry schein have underperform broader industry stock have lose compare broader industry decline zack rank key pickshenry schein carry zack rank hold few better rank medical stock be edward lifescience corporation ew free report lantheus holding inc lnth free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy lantheus holding idexx laboratory carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have surge last month idexx laboratory have long term expect earning growth rate stock have gain last month be reissue article correct mistake original article issue september longer be rely zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
1032,EW,sep issue update research report quest diagnostic inc dgx free report major commercial laboratory service provider stock currently carry zack rank hold last month quest diagnostic have be trading broader industry last share price movement stock have gain contrast decline broader industry same time frame company earning last report second quarter exceed estimate revenue lag same company have witness significant growth infectious disease testing prescription drug monitoring wellness business be currently refocusing core diagnostic information service business discipline capital deployment finally raise guidance indicate chance continuation bullish trend addition alliance hospital integrate delivery network be other growth driver company be particularly positive peacehealth acquisition pacific northwest be expect bolster growth rest be also encourage launch qherit quest diagnostic july qherit pan ethnic expand carrier screen be panel test heritable disease mentioned new screening guideline issue march american college gynecology acog further company have complete previously announce acquisition laboratory business med fusion clear point late quest diagnostic come upgrade long term growth outlook base new extend point strategy generate shareholder value accelerate growth drive operational excellence however be concern tough organic volume scenario also last month comparative study quest diagnostic forward basis multiple reflect stock be quite overvalue tough competitive landscape reimbursement headwind be other concern key pickssome better rank medical stock be edward lifescience corporation ew free report lantheus holding inc lnth free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy lantheus holding idexx laboratory carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month idexx laboratory have long term expect earning growth rate stock have gain last month zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
1033,EW,medtronic plc mdt free report mazor robotic ltd recently announce amendment exist partnership be initially sign distribute range mazor product modification company have enter next phase agreement earlier expect mazor robotic be israel base medical device company field robotic surgical guidance system meanwhile medtronic assume right exclusive worldwide distribution mazor system mazor robotic spine surgery system make third tranche investment mazor robotic early payment come back achievement certain pre agree sale marketing target advance grow demand mazor system also act favor follow third installment medtronic total investment mazor robotic rise partnership help company get platform explore development product spine market medtronic be make consistent effort expand spine business restorative therapy group rtg last report first quarter fiscal rtg report year year revenue increase constant exchange rate spine business witness low single digit growth also rtg company have announce plan launch solera voyager fixation system accord report mordor intelligence global market spinal surgery device be estimate reach worth cagr take bountiful opportunity niche space consideration believe company latest development be strategic last month medtronic have underperform broader industry last share price movement stock lose compare gain broader industry period zack rank key picksmedtronic carry zack rank sell few better rank medical stock be edward lifescience corporation ew free report lantheus holding inc lnth free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy lantheus holding idexx laboratory carry zack rank buy cansee complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month idexx laboratory have long term expect earning growth rate stock have gain last month zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
1034,EW,healthcare diagnostic company laboratory corporation america holding lh free report labcorp successfully continue expand acquisition strategy apart huge buyout covance company continue add complementary capability target tuck merger latest list be company agreement purchase analytical testing service business chromadex corp cdxc transaction be expect complete early september newly acquire entity become part labcorp covance food solution business notably chromadex be natural product company work health wellness nutritional ingredient create science base solution dietary supplement food beverage skin care sport nutrition pharmaceutical product company haven disclose deal financial term press release report american city business journal deal value have be fix report covance buy analytical testing business agreement chromadex be also able receive earnout payment accord filing security exchange commission be important make note labcorp mega buyout covance virtue company be full force expand range diagnostic offering create new industry leader laboratory testing cro contract research organization space slate act lead provider medical testing operate premier full service drug development organization company covance drug development be only cro provide full spectrum drug development capability research real world evidence study create commercial scientific advantage labcorp partner apart covance recent significant buyout be sequenom prominent player field invasive prenatal testing nipt reproductive health sequenom nipt genetic testing capability have further add impetus labcorp extensive woman health test menu inclusion have also expand company geographic reach domestically internationally particularly eu asia pacific region company acquire pathology associate medical laboratory paml former owner providence health service providence catholic health initiative chi paml be nation premier medical reference laboratory healthcare solution company acquisition be consistent company effort strengthen foothold personalize diagnostic testing market last month labcorp have be trading broader industry period stock have gain industry loss zack rank key pickslabcorp currently have zack rank hold few better rank medical stock be edward lifescience corporation ew free report lantheus holding inc lnth free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy lantheus holding idexx laboratory carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally last month lantheus holding have long term expect earning growth rate stock have surge last month idexx laboratory have long term expect earning growth rate stock have gain roughly last month simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
1035,EW,dec issue update research report edward lifescience corporation ew free report stock carry zack rank hold last month lead molecular diagnostic company have be trading broader industry stock have gain compare broader industry rise period positive note company report transcatheter heart valve therapy thvt sale growth third quarter reflect rise prior year period upside be lead strong continue adoption therapy geographical region management thvt adoption report quarter grow consistently robust performance sapien valve be also encourage company long term growth strategy recent progress technology pipeline far transcatheter heart valve be concern edward lifescience expect maintain leadership position global transcatheter aortic valve replacement tavr market tavr adoption rate japan european country continue surpass same region therapy be more popularly well establish company optimism get further boost proposal implement tavr technology treatment purpose reimbursement authority nice also company focus build pipeline strengthen foothold operate business bode well edward lifescience have also witness growth emerge portfolio mitral tricuspid repair therapy flip side natural disaster impact sale third quarter tune also higher operate expense continue be drag stiff competition currency headwind reimbursement issue be other challenge cope key pickssome better rank stock same space be masimo corporation masi free report tactile system technology tcmd free report integer holding corporation itgr free report carry zack rank buy see complete list today zack rank strong buy stock here masimo have expect growth rate year stock have rally ahead broader industry gain year tactile system have estimate annual growth rate stock have soar broader industry gain last month integer holding have project growth rate next quarter stock have surge outperform broader industry increase year time more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1036,EW,edward lifescience corporation ew free report recently acquire harpoon medical inc privately hold medical technology company focuse beating heart repair degenerative mitral regurgitation dmr agreement harpoon medical flagship beating heart repair procedure mitral valve patient harpoon system be add edward lifescience surgical heart valve therapy portfolio treat structural heart disease however harpoon system be yet receive ce mark approval financial detailsedward lifescience paid cash close deal dec moreover company be liable pay achievement certain pre decide milestone next year recent edward lifescience have be witness strength surgical heart valve therapy segment strong uptake edward intuity elite valve system progress space company receive fda approval inspiris resilium aortic valf july notably be first newly create group resilient heart valf incorporate advanced resilium tissue company plan commercially launch product unite state japan follow successful launch inspiris resilium europe earlier market potentialwe believe unhealthy lifestyle rise agee population continue result high incidence cardiovascular disease be further strengthen datum provide gbi research report global cardiovascular disease market see cagr space market be expect witness highest momentum cagr moreover report medgadget global heart valve repair replacement market be expect rise cagr thus view current market potential believe company effort help boost top line share price lifescience have be gain investor confidence consistently positive result last year company share price have outperformed broader industry stock have gain compare broader industry zack rank key picksedward lifescience carry zack rank hold few better rank medical stock be petm express inc pet free report align technology inc algn free report myriad genetic inc mygn free report notably petm align technology myriad genetic sport zack rank strong buy see complete list today zack rank stock here petm have long term expect earning growth rate stock have rally roughly year align technology have long term expect earning growth rate stock have gain year myriad genetic have long term expect earning growth rate stock have gain year time zack hide tradeswhile share many recommendation idea public certain move be hide everyone select member portfolio service peek curtain today view start now next month invite follow zack private buy sell real time value momentum stock etf option mover insider trade company be report positive earning surprise ve call accuracy even look portfolio so exclusive be normally close new investor click here zack secret trade
1037,EW,aug issue update research report mountain view base omnicell inc omcl free report company develop market end end automation solution medication use process omnicell second quarter performance be impressive year year increase earning revenue company gain revenue banking recent launch strategic partnership notably omnicell recently launch software xt hardware allow aesynt customer fully benefit xt company also launch xt series automate supply dispense system july quarter company also launch controlled substance dispenser module provide secure dispense administration controlled substance however weak margin raise concern flip side omnicell face intense competition medication management supply chain solution market also company have adopt several strategy drive top line include portfolio expansion acquisition further penetration medication adherence market thus company continue battle escalate cost overall majority last month omnicell have be trading industry latest share price movement stock have gain significantly lower broader industry addition zack rank key picksomnicell currently carry zack rank hold few top rank medical stock be edward lifescience corp ew free report lantheus holding inc lnth free report stryker corporation syk free report edward lifescience sport zack rank strong buy lantheus holding stryker carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have gain last month stryker have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
1038,EW,gainesville fl base exactech inc recently announce new product truliant knee system surgical instrumentation have be honor bronze award international design excellence award idea atlanta ga sponsored industrial designer society america idea winner receive significant international publicity exposure idea contest note hundred entry country continent significant development company knee segment truliant knee system offer advanced approach total knee replacement surgery clinically recognize platform proven implant personalize surgical workflow exclusivity truliant system be embed ergonomic instrumentation design enable surgeon make appropriate bone cut adjustment joint total knee arthroplasty last report quarter knee revenue be flat increase constant currency exactech ride solid knee businessin july exactech take step goal provide inclusive range knee replacement system launch exactechgps tka be advanced software application provide systematic computer guidance orthopedic surgeon total knee arthroplasty tka procedure exactech benefit solid prospect total knee replacement market face tough competition like zimmer biomet holding inc zbh free report offer iassist knee personalize guidance system knee replacement procedure exactech plan complete commercial launch tka software application product development be line company objective gain traction huge untapped total knee replacement market datum provide grand view research market be expect reach worth apart solid initiative knee platform exactech announce fda approval market proprietary exactechgps shoulder application unite state earlier year share price trendsover past month exactech have be trading broader industry company stock have gain higher industry believe company be currently ride high regulatory approval product launch however estimate revision trend current quarter lack luster last month notably estimate moved south compare movement opposite direction zack consensus estimate current quarter fall cent share same timeframe exactech have zack rank hold key picksa few better rank stock broader medical sector be edward lifescience corp ew free report stryker corporation syk free report notably edward lifescience sport zack rank strong buy stryker have zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate notably stock represent impressive year date return stryker represent impressive year date return stock have long term expect earning growth rate zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
1039,EW,amedisys inc am free report renown home health hospice service provider have rally last month ahead gain stock have market cap company year historical growth rate be also favorable compare broader industry also company represent return almost comparison broader industry decline last month solid prospect zack rank buy stock be attractive pick present company estimate revision trend current year have also be positive past day analyst moved estimate north movement opposite direction magnitude estimate revision increase share same time frame let find recent positive trend be sustainable recently amedisys end second quarter solid note earning revenue beating year figure also hospice company register strong growth segment amedisys be currently explore opportunity home health hospice segment company favorable demographic trend strategic acquisition encourage well moreover company have be witness growth personal care segment synergy acquisition be encourage company long term strategy evolve traditional home health hospice care company focuse bring home continuum care better serve patient diversify source payment so become less reliant medicare regard company experience improvement medicare revenue comparison decline medicare revenue home health division see last report second quarter home health industry be poise substantial growth long term drive positive demographic trend unite state company continue benefit age demographic population need higher acuity patient home nursing environment notably company be track fortify footprint market place recently announce completion national readmission prevention collaborative nrpc certification program clinical program team handle progress delivery home healthcare program additionally company strong cash balance position bolster confidence stock flip side expect synergy tenet healthcare acquisition escalate cost operate expense weigh company margin also intense competitive landscape regulatory concern continue challenge home health hospice industry other key picksother top rank medical stock be edward lifescience corp ew free report lantheus holding inc lnth free report stryker corporation syk free report edward lifescience sport zack rank strong buy lantheus holding stryker carry zack rank see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have gain last month stryker have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
1040,EW,investor edward lifescience corporation ew free report need pay close attention stock base move option market lately be dec put have highest imply volatility equity option today be imply volatility imply volatility show much movement market be expect future option high level imply volatility suggest investor underlie stock be expect big move direction other also mean be event come soon cause big rally huge sell however imply volatility be only piece puzzle putt together option trading strategy do analyst think clearly option trader be pricing big move edward lifescience share be fundamental picture company currently edward lifescience be zack rank hold medical instrument industry rank bottom zack industry rank last day analyst have increase earning estimate current quarter have drop estimate net effect have take zack consensus estimate current quarter cent share cent period give way analyst feel edward lifescience right now huge imply volatility mean trade develop oftentimes option trader look option high level imply volatility sell premium be strategy many seasoned trader use capture decay expiration hope trader be underlie stock do not move much originally expect look trade option week very own dave bartosiak give top option trade check recent live analysis option trade nflx earning report completely free see here trading netflix nflx earning option check embed video more detail
1041,EW,edward lifescience corporation ew free report report third quarter adjust earning share ep cent miss zack consensus estimate cent however adjust earning improve year year primarily drive strong sale growth company transcatheter heart valf business exclude time item net income third quarter come cent share year year respectively sale detailsedward lifescience third quarter sale improve however figure miss zack consensus estimate underlie sale increase include impact germany stocking sale customer nation choose purchase additional inventory sapien valve anticipation potential supply interruption result recent intellectual property litigation revenue be primarily drive considerable growth transcatheter heart valve sale well strong performance surgical heart valve therapy critical care product line too region edward lifescience corporation price consensus ep surprise edward lifescience corporation price consensus ep surprise edward lifescience corporation quote segment third quarter company report transcatheter heart valve therapy thvt sale reflect growth prior year quarter unite state thvt sale quarter totale year year growth be drive excellent clinical performance sapien well continue strong therapy implementation region surgical heart valve therapy sale quarter be prior year quarter be lead strong demand edward intuity elite valve system strong uptake core product outside unite state partially offset continue shift surgical aortic valf sapien valf unite state europe critical care sale be report quarter represent increase third quarter solid growth product category be drive strong growth company core product enhance surgical recovery program mainly unite state asia pacific marginsin third quarter gross margin expand basis point bps owing more profitable product mix lead grow sale transcatheter valf well favorable comparison supply chain expenditure be however partially offset expense incur due flood hurricane marium puerto rico shutdown company manufacturing plant switzerland sg expense rise year year account sale personnel related expense primarily transcatheter valve thv segment expenditure increase year year owing continue investment company transcatheter aortic valve mitral valve program adjust operate margin quarter expand bps rise revenue outweighed increase operate expense cash positionedward lifescience exit third quarter cash cash equivalent short term investment compare end second quarter long term debt quarter totale compare report previous quarter cash flow operate activity be third quarter compare previous quarter exclude capital spending free cash flow be quarter average diluted share outstanding be guidance staysedward lifescience have reaffirm full year sale expectation high end previously project range zack consensus estimate full year revenue be coincide high end guide range adjust ep expectation have also be reinstate zack consensus estimate full year adjust ep stand company guide range fourth quarter company project sale adjust effect germany stocking sale zack consensus estimate revenue be company project range company estimate adjust ep cent cent meanwhile zack consensus estimate adjust ep be cent be also company forecast range takeedward lifescience exit third quarter disappointing note earning revenue lag respective zack consensus estimate company business be affected recent natural disaster caribbean unite state edward lifescience have principal manufacturing location critical care product puerto rico dominican republic puerto rico company have discontinue production due flood affected top line extent company also have postpone number procedure houston florida management natural disaster negatively impact third quarter sale tune nevertheless strong transcatheter valve sale domestic market well overseas be major positive company also perform well gross margin front raise optimism management expect gain traction ever expand tavr market base increase preference favor transcatheter aortic valve replacement well compelling clinical evidence lead strong adoption thv therapy however tough competition cardiac device market reimbursement issue continue challenge zack rank key pickscurrently edward lifescience have zack rank hold few better rank stock broader medical sector be petm express inc pet free report abbott free report intuitive surgical inc isrg free report notably petm sport zack rank strong buy abbott intuitive surgical carry zack rank buy see complete list today zack rank stock here petm report ep cent second quarter fiscal year quarter cent also gross margin expand bps year year report quarter abbott report third quarter adjust earning continue operation cent share year year also third quarter worldwide sale come year year intuitive surgical post adjust earning share third quarter year year basis also revenue increase year year zack hide tradeswhile share many recommendation idea public certain move be hide everyone select member portfolio service peek curtain today view start now next month invite follow zack private buy sell real time value momentum stock etf option mover insider trade company be report positive earning surprise ve call accuracy even look portfolio so exclusive be normally close new investor click here zack secret trade
1042,EW,quotient limit qtnt free report be big mover last session company see share rise day move come solid volume too far more share change hand normal session stock remain volatile trade range past month time frame witness sharp increase yesterday company have see estimate revision past month zack consensus estimate current quarter have also remain unchanged recent price action be encourage so make sure keep close watch firm future have zack rank sell earning esp be quotient limit price consensus quotient limit price consensus quotient limit quotea better rank stock medical instrument industry be edward lifescience corporation ew free report carry zack rank strong buy see complete list today zack rank stock here be qtnt go predict see other think stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1043,EW,medtronic plc mdt free report have initiate voluntary product recall specific series infusion set used model medtronic insulin pump share company register drop close follow announcement company decide recall insulin pump risk device potentially deliver insulin expose respective patient threat hypoglycemia medtronic have take decision basis recent field report patient root cause analysis report vent membrane component recall infusion set be susceptible blockage fluid process prime fill tubing medtronic plan replace recall lot infusion set currently manufacture specimen cost new version have be use april include design update vent membrane company reduce risk insulin delivery infusion set be change good press release medtronic have not specifically mentioned number defective infusion set however apprehend huge chunk dispute unit be replace follow statement pamela reese medtronic senior manager communication publish medscape medical news recall apply version infusion set be used medtronic insulin pump publish list specific lot number be unwieldy be design online lot look tool product recall be anticipate act setback medtronic grow diabetes business consider large number minime infusion set already be rolled believe recall flaw bunch adversely impact company diabetes arm revenue ongoing quarter particular business space company be currently putt effort capitalize distinctive innovation strengthen foothold market base company class apart strategy move fully close loop system algorithms cgm sensor automate insulin dose medtronic have be late consistently observe strong demand graph globally new diabetes technology apprehend latest recall news positive momentum diabetes group get interrupt extent past month medtronic have be constantly trading broader industry company have lose versus industry gain period zack rank stock currently carry zack rank sell better rank medical stock include edward lifescience corporation ew free report lantheus holding inc lnth free report cheme corporation che free report edward lifescience sport zack rank strong buy lantheus holding cheme carry zack rank buy cansee complete list today zack rank stock here edward lifescience have long term expect earning growth rate gain roughly last month lantheus holding have long term expect earning growth rate rally last month cheme have long term expect earning growth rate gain last month more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1044,EW,sep issue update research report franklin lake nj base becton dickinson company bdx free report company be medical technology firm engage principally development manufacture sale medical device instrument system reagent share becton dickinson have gain year date compare industry growth zack consensus estimate current year earning have remain stable last day stock carry zack rank hold market be upbeat company strategic acquisition collaboration becton dickinson sign agreement acquire bard inc march management company be poise become biggest medical technology device company world follow buyout cash stock acquisition be value completion deal fourth quarter fiscal company plan create third business segment bd interventional notably bard be integrate vertical come strategic advantage post closure deal becton dickinson generate high single digit growth adjust earning share fiscal transaction lead pre tax annual saving worth fiscal company be able expand new area bard currently operate include fast grow vascular access segment piccs peripherally insert central catheter midline drug delivery port regard note becton dickinson announce collaboration impress instrument management system cloud base solution provider uniteor surgical tray tracking vendor management solution system provide greater visibility surgical tray management health care worker operate room sterile process department integration uniteor allow becton dickinson offer truly integrate approach complex challenge hospital health system face regard surgical tracking also company complete buyout israeli base caesarea medical electronic global infusion pump system manufacturer apart acquisition merger other catalyst include company receipt clearance fda flow cytometer system leucocount reagent assay be used residual white blood cell enumeration becton dickinson also announce global distribution complete line product mass spectrometry provide high speed high confidence identification pathogen clinical laboratory be critical step fight antimicrobial resistance company mass spectrometry solution suite include mbt biotarget mbt sepsityper well standard reagent other product further becton dickinson focus geographical expansion overseas market india china brazil turkey be boost market sentiment key picksedward lifescience corporation ew free report lantheus holding inc lnth free report be better rank medical stock edward lifescience sport zack rank strong buy lantheus holding carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1045,EW,masimo corporation masi free report have be healthy growth trajectory late have rally last month ahead gain stock have market cap irvine base masimo develop manufacture market family invasive monitoring system stock have long term expect earning growth solid estimate revision estimate revision trend current year have be favorable masimo past day estimate moved north movement opposite direction result zack consensus estimate current year moved notably positive trend signify bullish analyst sentiment masimo boast zack rank buy indicate robust fundamental expectation outperformance term let find recent positive trend be sustainable growth tide regulatory front masimo announce clearance full market release proprietary rad pulse co oximeter earlier month launch rad offer masimo noninvasive continuous monitoring measure motion low perfusion set pulse oximetry upgradeable rainbow technology consider substantial demand advanced monitoring technology global market launch reinstate investor confidence stock research report market market reveal global niche market be expect reach worth cagr compelling fundamental growth story masimo long term growth fundamental be strong company record year cagr revenue adjust earning share company have particularly witness improvement earning last year positive study result august india base study masimo sphb platform demonstrated encourage result study conclude masimo sphb allow physician exclusively focus haemoglobin trend oncosurgery earlier month netherland base study analyze performance masimo ispo rx screening newborn critical congenital heart disease also demonstrated positive result other stock consider few other top rank stock broader medical sector include edward lifescience corp ew free report idexx laboratory inc idxx free report cogentix medical inc edward lifescience sport zack rank strong buy idexx laboratory cogentix medical hold zack rank see complete list today zack rank stock here edward lifescience deliver average earning beat last quarters company have long term expect earning growth rate idexx laboratory have average earning beat trail quarters have long term expect earning growth rate cogentix medical come positive earning surprise last quarter stock represent stellar return last year trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
1046,EW,change political power unite state have be quite rough phase medtech thing start get president trump start proceed plan repeal obamacare series futile attempt republican re-sort skinny repeal obamacare fail well now republican be back latest graham cassidy bill target termination obamacare investor be busy gauge extent impact latest graham cassidy legislation medical device space have be few encourage development sub industry meanwhile company zack outpatient healthcare industry integral part medical device space currently have better prospect be evident zack industry rank place sub industry top zack industry back testing show top zack rank industry outperform bottom factor more thus be prudent investor pick stock fundamentally strong sub industry moment have choose amedisys inc am free report cheme corporation che free report base favorable zack rank buy amedisys market cap be lead provider healthcare service unite state company operate segment home health hospice personal care meanwhile cheme market cap be lead provider hospice palliative care service nation company operate segment vita roto rooter let now do comparative analysis stock make final call amedisys have vgm score compare cheme zack style score system stand value growth momentum vgm score be simply weight combination parameter be comprehensive tool allow investor filter standard score system pick winning stock amedisys also have favorable price earning growth peg ratio compare cheme amedisys also stand strong compare broader industry amedisys inc peg ratio ttm amedisys inc peg ratio ttm amedisys inc quotecheme corp peg ratio ttm cheme corp peg ratio ttm cheme corp attractive year project earning growth rate amedisys again score higher cheme industry amedisys also boast better leverage ratio compare cheme broader industry amedisys have favorable debt equity ratio compare cheme industry again long term debt capital ratio metric stand favor amedisys come comparison cheme broader industry amedisys estimate revision trend current year have also be attractive compare cheme past day estimate moved north movement opposite direction amedisys magnitude estimate revision earning increase same time frame cheme estimate moved north movement opposite direction past day magnitude estimate revision earning increase only same time frame base detailed analysis safely conclude amedisys make superior pick portfolio moment other key picksother top rank medical stock be edward lifescience corporation ew free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy idexx carry zack rank see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month idexx laboratory have long term expect earning growth rate stock have gain last year trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
1047,EW,amedisys inc am free report lead home health hospice service company be healthy growth trajectory late have rally year date ahead gain broader industry decline stock have market cap company long term expect growth rate be also favorable compare gain broader industry solid growth prospect zack rank buy stock be attractive pick present let find recent positive trend be sustainable company estimate revision trend current year have be positive past day analyst moved upward movement opposite direction magnitude estimate revision increase share same time frame late amedisys have be ride high solid potential new opportunity home health hospice service segment be also encourage company long term strategy evolve traditional home health hospice care company focuse unit bring home continuum care serve patient better service diversify source payment become less reliant medicare company have be witness growth personal care segment back synergy acquisition recently make slew strategic acquisition recent be intercity home care massachusett slate close oct home health industry be poise substantial growth long term drive positive demographic trend unite state company be expect continue benefit agee demographic population higher acuity patient home nursing environment notably company be track fortify footprint market place lately announce completion national readmission prevention collaborative certification program clinical program team handle home healthcare program additionally company strong cash balance position bolster confidence stock flip side anticipate synergy tenet healthcare acquisition escalate cost operate expense weigh company margin also intense competitive landscape regulatory concern continue challenge home health hospice industry other key picksother top rank medical stock be edward lifescience corp ew free report cheme corp che free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy cheme idexx carry zack rank see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month cheme have expect earning growth rate current year stock have gain last month idexx have long term expect earning growth rate stock have gain last month make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1048,EW,idexx laboratory inc idxx free report have be gain investor confidence consistent positive result stock have rally last year ahead gain broader industry rise moreover lead manufacturer product service primarily companion animal veterinary livestock poultry have market cap company year historical growth rate be also favorable compare industry solid prospect zack rank buy stock be attractive pick investor moment company estimate revision trend current year have be positive past day analyst revise estimate upward movement opposite direction magnitude estimate revision earning increase share same time frame also zack style score system idexx laboratory sport growth score suggest company strong growth prospect research show stock growth style score combine zack rank strong buy buy offer best upside potential regard idexx laboratory have favorable net margin net income sale industry negative company sale asset ratio compare industry ratio signify solid growth stock moreover project sale growth rate surpass industry rate let find recent positive trend be sustainable idexx laboratory continue display strong growth respect international expansion company have be significantly benefitting companion animal market emerge nation demonstrate bountiful opportunity stellar topline performance past few quarters be drive company companion animal business companion animal market fundamental remain solid tremendous global runway growth last report second quarter management unique innovation base multus modality global strategy enabled enhance commercial capability accelerate recur cag diagnostic revenue growth moreover strong top line growth quarter be drive considerable contribution other business segment also idexx laboratory recently announce addition rvetlink portfolio technology application additionally company have strong cash balance enable carry share repurchase program turn provide solid return investor flip side foreign currency fluctuation be major headwind company concern be company high reliance third party distributor idexx laboratory face higher operate expense pertain increase head count portfolio expansion higher investment target geographical expansion unite state internationally moreover competitive landscape domestic overseas market weigh company performance other key picksother top rank medical stock be edward lifescience corp ew free report cheme corp che free report amedisys inc am free report edward lifescience sport zack rank strong buy cheme amedisys carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month amedisys have long term expect earning growth rate stock have gain last month cheme have long term expect earning growth rate stock have gain last month make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1049,EW,edward lifescience corporation ew free report specialize player advanced cardiovascular disease be healthy growth trajectory late stock have rally last month ahead gain broader industry stock have market cap company year historical growth rate be also favorable compare increase broader industry gain solid prospect zack rank strong buy stock be attractive pick headquarter irvine company estimate revision trend current year have also be positive past couple month analyst moved north movement opposite direction magnitude estimate revision increase share same time frame let find recent positive trend be sustainable edward lifescience recently report second quarter performance be quite promising company beating zack consensus estimate revenue earning also raise guidance hint brighter prospect fact outlook increase be backed strong performance company product line market be also upbeat edward lifescience recent fda approval inspiris resilium aortic valve be first class resilient heart valf company also announce receipt fda approval aortic mitral valve valve procedure used sapien transcatheter heart valve believe recent fda approval several product have be boost investor confidence stock be encourage edward lifescience focus build strong pipeline further firm foothold operate business company have also witness growth emerge portfolio mitral tricuspid repair therapy latest plan company new ultra system include balloon delivery system next generation sheath technology be expect be available europe second half edward lifescience be also track initiate launch acumen hpi software suite new flotrac iq smart disposable inspiris resilium aortic valve europe japan end however stiff competition currency headwind reimbursement issue be challenge stock ahead other key picksother top rank medical stock be cheme corporation che free report amedisys inc am free report idexx laboratory inc idxx free report carry zack rank buy see complete list today zack rank stock here cheme have expect earning growth rate current year stock have gain last month amedisys have long term expect earning growth rate stock have gain last month idexx have long term expect earning growth rate stock have gain last month make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1050,EW,cheme corporation che free report have be gain investor confidence back consistent performance positive result stock have rally last year ahead gain industry rise lead manufacturer product service primarily companion animal veterinary have market cap company year historical growth rate be also favorable compare market solid prospect zack rank buy stock be attractive pick investor moment company estimate revision trend current year have also be positive past day estimate moved north movement opposite direction magnitude estimate revision earning share increase same time frame also zack style score system cheme sport growth score suggest company strong growth prospect research show stock growth style score combine zack rank strong buy offer best upside potential regard cheme have favorable net margin net income sale better industry sale asset ratio support company solid growth stock comparison industry moreover debt capital ratio be attractively place comparison industry let find recent positive trend be sustainable cheme second quarter performance be quite promising bottom line significantly improve year year basis stellar performance be drive company increase average net medicare reimbursement rate average daily census continue momentum raise outlook roto rooter segment earning share be indicative company anticipate improve operate result upcoming quarters turn boost investor optimism stock fact raise view be backed cheme expectation significant gain roto rooter business cheme vita business management note recent admission trend have be positive be expect continue come quarters second quarter vita perform well financially operationally thereby surpass company estimate additionally company strong cash balance enable carry share repurchase program provide solid return investor however headwind reimbursement related issue seasonality business competitive landscape dependence government mandate challenge cheme also tweak guidance medicare cap bill limitation be matter concern other key picksother top rank medical stock be edward lifescience corporation ew free report idexx laboratory inc idxx free report amedisys inc am free report edward lifescience sport zack rank idexx amedisys carry zack rank see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month idexx have long term expect earning growth rate stock have gain last month amedisys have long term expect earning growth rate stock have gain last month make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1051,EW,share biotelemetry inc beat free report have moved last month ahead gain broader industry rally stock have market cap company have long term growth solid prospect zack rank buy stock be attractive pick present company have deliver positive average earning surprise last quarters let find recent positive trend be sustainable one company estimate revision trend be positive past day analyst estimate moved north movement opposite direction current year zack consensus estimate have increase share cent say time frame current quarter analyst estimate moved north compare southward movement last day magnitude estimate revision current quarter rise cent cent same time frame market be upbeat biotelemetry strong top line performance past few quarters notably last report second quarter marked consecutive quarter year year revenue growth company also register growth segment expansion adjust operate margin be also encourage company consistent effort product innovation research development buoy optimism regard note research development expense increase second quarter furthermore biotelemetry acquire lifewatch ag deal value july buyout biotelemetry enhance position wireless medicine space expand product profile customer base cardiac monitoring diagnostic service space management expect acquisition yield significant synergy next month company manufacture product monitoring cardiac care patient precision raise full year revenue guidance be also encourage post acquisition lifewatch biotelemetry expect full year revenue range guidance be way higher full year report revenue be other key pickssome other top rank medical stock be edward lifescience corporation ew free report amedisys inc am free report idexx laboratory inc idxx free report edward lifescience sport zack rank amedisys idexx carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month amedisys have long term expect earning growth rate stock have gain last month idexx have long term expect earning growth rate stock have gain last month make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1052,EW,look stock be good position beat earning next report consider edward lifescience corporation ew free report firm medical instrument industry be great candidate beat company have see nice streak beating earning estimate especially look previous report fact report ew have beaten estimate least case suggest have nice short term history crush expectation earning quarters ew expect post earning cent share actually produce earning cent share beat meanwhile most recent quarter company look deliver earning cent share actually deliver earning share represent positive surprise edward lifescience corporation price ep surprise edward lifescience corporation price ep surprise edward lifescience corporation quotethank part history recent estimate have be move higher edward lifescience fact earning esp ew be positive be great sign come beat zack earning esp compare most accurate estimate broad consensus look find stock have see big revision late suggest analyst have recently become more bullish company earning prospect be case ew firm currently have zack earning esp so beat be corner be particularly true consider ew have great zack rank strong buy be harbinger outperformance signal strong earning profile see complete list today zack rank stock here add solid zack rank positive earning esp positive earning surprise happen nearly time so seem pretty likely ew see beat next report especially recent trend be guide more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1053,EW,zimmer biomet holding inc zbh free report announce global launch persona partial knee system aug be advanced addition company portfolio personalize anatomically design knee implant system acquisition biomet persona partial knee system be first develop product consolidated company persona partial knee system provide surgeon comprehensive system implant instrument offer excellent fit accuracy operate room zimmer biomet fix bearing system complement mobile bearing oxford partial knee company follow launch first surgery persona partial knee system be success last report second quarter revenue knee segment be year year cer company have be observed put consistent effort boost business take consideration grow global knee implant market believe latest development boost company sale niche regard note accord bcc research report global market joint reconstruction replacement be expect increase nearly cagr market be expect reach worth cagr european japanese market be estimate reach worth respective cagr major development zimmer biomet knee business be thelaunch ray base patient specific instrument psi knee system be world first ce marked surgical plan system enable patient specific implant position solely used ray technology past month zimmer biomet have be trading broader industry company have gain compare gain broader industry zack rank key pickszimmer biomet carry zack rank sell few better rank medical stock be edward lifescience corporation ew free report lantheus holding inc lnth free report cheme corporation che free report edward lifescience sport zack rank strong buy lantheus holding cheme carry zack rank buy cansee complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month cheme have long term expect earning growth rate stock have gain last month more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1054,EW,hologic inc holx free report have moved step forward core breast health business new product add kitty company have announce have commercially launch brevera breast biopsy system corlumina imaging technology unite state company real time breast biopsy verification system enhance patient experience streamline entire biopsy process notably brevera system claim be world first only breast biopsy solution combine tissue acquisition real time imaging sample verification advanced post biopsy handle integrate system design breast biopsy technical method increase biopsy accuracy real time imaging thus help perform fast efficient procedure cost save manner hologic new advancement be major breakthrough radiologist be hitherto conduct stereotactic breast biopsy procedure diagnose breast cancer conventional practice be time consume well uncomfortable patient brevera system image tissue sample be obtain right procedure room few second only good news be highly sophisticated technology potentially save minute patient cut procedure time almost hologic also claim brevera system proprietary corlumina imaging technology help improve multiple department health system also feature pacs integration advanced image sharing transfer patient record significantly breast health segment hologic have reshape strategy continuous innovation leadership position mammography latest brevera routine be affirm prone biopsy system management be hopeful brevera begin boost growth add more meaningful contribution also june hologic have announce fda labele genius mammography exam better standard mammography routine breast cancer screening woman dense breast hologic be pretty confident strong adoption brevera breast biopsy system market look forward company consistent effort flourish field woman health regard be important mention immense growth opportunity healthcare market hold present datum provide market market breast imaging market be expect reach cagr however more search reveal global breast biopsy market advance cagr period research market datum publish business wire last month company share price have underperform broader industry stock have lose compare broader industry fall zack rank key pickshologic carry zack rank hold few better rank medical stock be edward lifescience corporation ew free report lantheus holding inc lnth free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy lantheus holding idexx laboratory carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have surge last month idexx laboratory have long term expect earning growth rate stock have gain last month zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
1055,EW,thermo fisher scientific tmo free report have recently obtain require antitrust clearance related earlier announce purchase outstanding ordinary share patheon aug competition authority brazil approve transaction initiate day comment period expire aug additionally european commission sanction takeover aug notably thermo fisher cn luxembourg wholly own subsidiary lead scientific instrument maker agree acquire netherlands base patheon latter be global provider high quality drug solution pharmaceutical biopharma sector completion deal patheon become part thermo fisher laboratory product service segment total transaction value be fix include assumption approximately net debt acquisition be expect wrap end subject customary close condition basically patheon offer comprehensive highly customizable solution well expertise help company satisfy complex development manufacturing need be leader high growth contract development manufacturing organization cdmo market company extensive network north america europe have generate revenue approximately notably thermo fisher have be do well quite time last month company have be trading industry stock have inched industry decline period latest report second quarter revenue laboratory product service segment grow year year segment serve laboratory customer equipment consumable improve productivity range biopharma outsource service also include company research safety market customer channel thermo fisher consider patheon purchase strategic fit expand biopharma service europe management combine entity significantly strengthen acquirer unique value proposition pharmaceutical biotech customer add highly complementary service consolidation be also expect prove accretive thermo fisher adjust earning share first full year post merger completion management also expect realize total synergy approximately third year follow closure deal consist roughly cost synergy adjust operate income benefit revenue related synergy recent report global laboratory equipment service market be project reach worth cagr forecast period growth market be primarily lead increase research pharmaceutical biotechnology industry urgent need timely effective diagnosis disease expect thermo fisher cash opportunity order gain traction potentially strong new market zack rank key picksthermo fisher currently have zack rank hold better rank medical stock be edward lifescience corporation ew free report lantheus holding inc lnth free report edward lifescience sport zack rank strong buy lantheus holding carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally last month lantheus holding have long term expect earning growth rate stock have surge last month simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
1056,EW,kalamazoo mi base stryker corporation syk free report largest medical device company global orthopedic market recently announce voluntary product recall oral care lineup be offer company sage product unit add voluntary recall stryker have place temporary hold certain cloth base product decision follow complaint minor irritation allergic reaction consumer however management expect reinitiate product shipment september expect begin full supply capacity end year share price stryker slip close follow news release lead recall recall pertain cross contamination issue oral care solution be manufacture sage third party supplier notably solution be distribute market july august however stryker affirm have close business third party supplier fact sage have resume production oral care solution come temporary hold decision cloth base product fda expressed concern regard ongoing microbiological testing method product sage platform now fda have instruct stryker product be verify used new compendial microbiological method undoubtedly new method be more time consume complex previously used sage notably fda have warn stryker issue july product recall hurt recall be likely adversely impact company sale operate income full year stryker now expect organic sale growth low end previously issue guidance band add company announce net earning diluted share be expect low end range third quarter stryker estimate adjust net earning diluted share low end previously issue band stryker have be grapple supply issue spine business long prove be major drawback quarters ahead fact international growth company spine segment second quarter be partially affected supply headwind stock performance glancestryker share price movement past year have be favorable company yielded return almost better broader industry only solid performance medsurg neurotech segment last report quarter hold promise strength international segment strong momentum europe china also buoy optimism zack rank key picksstryker have zack rank hold few better rank stock broader medical sector be edward lifescience corp ew free report idexx laboratory inc idxx free report cogentix medical inc notably edward lifescience sport zack rank strong buy idexx laboratory cogentix medical have zack rank buy see complete list today zack rank stock here edward lifescience deliver average earning beat trail quarters company have long term expect earning growth rate cogentix medical register positive earning surprise last report quarter stock represent stellar return last year idexx laboratory deliver average earning beat trail quarters have long term expect earning growth rate simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
1057,EW,patterson company inc pdco free report report first quarter fiscal adjust earning cent share continue operation outpaced zack consensus estimate cent figure however come lower year quarterly figure cent net sale continue operation dip year quarter miss zack consensus estimate quarter detailscome animal health platform total sale sale increase almost year year basis sale consumable grow year year however other service product platform witness year year decline sale patterson company dental platform total sale sale decline year year approximately consumable sale dental platform drop year year sale other service product decrease sale dental equipment software dip patterson company inc price consensus ep surprise patterson company inc price consensus ep surprise patterson company inc quotefinancial conditioncash cash equivalent be jul compare apr report quarter patterson repurchase approximately share company also disburse cash dividend shareholder first quarter company affirm adjust earning range share fiscal gaap earning be expect be range diluted share zack rank key pickspatterson company currently have zack rank sell few better rank stock broader medical sector be edward lifescience corp ew free report idexx laboratory inc idxx free report cogentix medical inc edward lifescience sport zack rank strong buy idexx laboratory cogentix medical carry zack rank buy see complete list today zack rank stock here edward lifescience deliver average earning beat trail quarters cogentix medical deliver positive earning surprise last report quarter idexx laboratory deliver average earning beat trail quarters simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
1058,EW,civita solution inc civi free report recently announce have enter agreement acquire habilitative service inc target company provide service individual intellectual developmental disability state minnesota come back news feel acquisition be smart move part company habilitative service operate county minnesota provide continuum residential periodic service habilitative service support approximately adult residential site individual periodic program more employee habilitative service generate revenue approximately month period end transaction be however subject number close condition include expiration regulatory notice period party expect close transaction day past month civita solution have outperformed broader industry stock have gain compare only rise industry belong civita solution be lead national provider home community base health human service individual intellectual developmental physical behavioral disability other special need go forward be encourage company progress post acute specialty rehabilitation service srs adult day health adh service fastest grow business moreover company be witness steady contribution strategy grow organically acquisition also even company seem be implement cost restructure program efficiently weak margin continue mar financial also company recently slash guidance civita solution lower high end fiscal revenue guidance company project revenue range lower previous range zack rank stock considercivita solution have zack rank sell few better rank stock broader medical sector be edward lifescience corp ew free report idexx laboratory inc idxx free report cogentix medical inc notably edward lifescience sport zack rank strong buy idexx laboratory cogentix medical have zack rank buy see complete list today zack rank stock here edward lifescience deliver average earning beat trail quarters company have long term expect earning growth rate cogentix medical register positive earning surprise last report quarter stock represent stellar return last year idexx laboratory deliver average earning beat trail quarters have long term expect earning growth rate simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
1059,EW,aug issue update research report align technology algn free report manufacture market system clear aligner therapy intra oral scanner cad cam computer aid design manufacturing digital service used dentistry orthodontic dental record storage stock currently have zack rank hold align technology have be trading industry last month stock have gain period compare decline industry company strong invisalign technology prospect growth north america international region look encourage emea second quarter volume surge year year reflect continue adoption invisalign technology core market spain well rapid growth expansion new market include eastern europe central europe benelux report quarter volume soar year year asia pacific belt lead china follow southeast asia japan australia new great news be company have recently open new invisalign technology treatment plan facility china multimillion dollar marketing campaign invisalign technology brand promotion be also likely keep investor upbeat company receipt patent smarttrack aligner material doubt buoy optimism contrary foreign exchange headwind continue major dampener company international performance also escalate cost expense be weigh margin last month comparative study align technology forward forward month basis multiple reflect stock have be quite overvalue key pickssome better rank medical stock be edward lifescience corp ew free report lantheus holding inc lnth free report stryker corporation syk free report edward lifescience sport zack rank strong buy lantheus holding stryker carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have climb last month lantheus holding have long term expect earning growth rate stock have surge last month stryker corporation have long term expect earning growth rate stock have rally roughly last month zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
1060,EW,lead healthcare diagnostic company laboratory corporation america holding lh free report labcorp recently inked distribution agreement roswell park cancer institute molecular diagnostic subsidiary omniseq inc deal term labcorp distribute omniseq immune report card omniseq comprehensive clinical assay unite state outside company get exclusive right distribute omniseq test base physician integrate oncology member labcorp specialty testing group globally customer covance drug development arm laboratory corporation america holding price laboratory corporation america holding price laboratory corporation america holding quotealso chief scientific officer labcorp diagnostic marcia eisenberg join omniseq board director labcorp have plan participate omniseq series financing round financing be used conduct omniseq ongoing retrospective prospective clinical trial well generate further evidence clinical utility omniseq comprehensive genomic immune profile service notably immune report card be comprehensive immune profile test design inform oncologist regard checkpoint inhibitor cpi treatment decision combine result common biomarker assay relevant checkpoint inhibitor well other informative analysis omniseq assessment provide comprehensive immune profile help identify patient be likely respond cpi monotherapy other hand omniseq comprehensive assay be gene pan cancer next generation sequence tumor profile diagnostic panel help oncologist determine particular line treatment consider fact immune report card omniseq comprehensive trial have receive new york state clinical laboratory evaluation program approval expect alliance help labcorp broaden customer base cancer immunotherapy diagnostic space notably market be grow leap bound recent time datum provide radiant insight inc publish cision pr newswrite global cancer immunotherapy market be expect witness cagr hence believe labcorp latest decision widen position market be perfectly strategic part key tactical plan labcorp be consistently work hard new innovation academic institution capture grow lab testing market advanced assay tool second quarter company have open state art companion diagnostic laboratory north carolina deliver double digit increase year year revenue aid continue growth immuno oncology service company also win companion diagnostic related award first half year pipeline comprise diverse range oncology oncology indication new establish client position well consistent growth future labcorp latest partnership omniseq well decision invest latter research development add further momentum company growth trajectory zack rank key pickslabcorp currently carry zack rank hold better rank medical stock be edward lifescience corp ew free report lantheus holding inc lnth free report stryker corporation syk free report edward lifescience sport zack rank strong buy lantheus holding stryker carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have climb last month lantheus holding have long term expect earning growth rate stock have surge last month stryker corporation have long term expect earning growth rate stock have rally roughly last month
1061,EW,cvs health cvs free report release interesting datum indicate substantial potential flu vaccination market unite state datum confirm american population be take plan take flu vaccination year moreover datum also reveal rise flu vaccination take population compare previous year survey result interestingly cvs pharmacy minuteclinic location unite state recently begin offer flu vaccination notably cvs health pharmacy service witness rise last report second quarter also revenue minuteclinic rise year year believe affirmative survey datum help company gain traction space also survey finding indicate rise employ flu vaccine receiver prefer get vaccinate workplace partnership local pharmacy drugstore notably company have be track fortify footprint market place august cvs health cigna corp ci free report announce launch cigna health work collaboration leverage cvs pharmacy cvs minuteclinic retail health care service be available cigna self funded employer sponsored health plan also july minuteclinic alere escreen occupational health network employee visit minuteclinic wide range service require employer include biometric screening vaccination thus believe positive survey datum further amplify importance strategic partnership report reportsnreport global influenza drug vaccine market be project witness cagr period thus favorable survey finding further indicate array untapped opportunity available space believe age population unhealthy lifestyle rise awareness expenditure healthcare continue drive growth vaccination market however market be dominate well establish player emergent biosolution inc ebs free report moreover cvs health have be gain investor confidence consistent positive result past month company share price have outperformed broader industry stock have gain broader industry decline company have also outperformed gain market same time frame zack rank key pickcvs health currently carry zack rank hold better rank medical stock be edward lifescience corp ew free report zack rank strong buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have gain last monthsmore stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1062,EW,pennsylvania base biotelemetry inc beat free report provide ambulatory outpatient management solution monitoring clinical information regard individual health stock have rally last month ahead gain broader industry gain stock have market cap company long term growth also hold promise solid prospect zack rank buy stock be attractive pick present let find recent positive trend be sustainable company estimate revision trend moment be positive past day analyst moved north movement opposite direction current year magnitude estimate revision increase share same time frame current quarter analyst moved north compare movement opposite direction last month magnitude estimate revision current quarter rise cent same time frame biotelemetry exit second quarter promising note earning exceed zack consensus estimate revenue meeting same notably marked consecutive quarter year year revenue growth company also register growth segment expansion adjust operate margin also instill confidence investor further be encourage note company be putt effort product innovation research development regard note research development expense increase last report second quarter moreover july biotelemetry announce acquisition lifewatch ag deal value buyout biotelemetry enhance position wireless medicine space expand product profile customer base cardiac monitoring diagnostic service space raise full year revenue guidance be encourage post acquisition lifewatch biotelemetry expect full year revenue range other key picksother top rank medical stock be edward lifescience corp ew free report lantheus holding inc lnth free report cheme corporation che free report edward lifescience sport zack rank strong buy lantheus holding cheme carry zack rank see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have gain last month cheme have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1063,EW,cooper company inc coo free report recently sign asset purchase agreement acquire flagship contraception platform israel base teva pharmaceutical industry teva free report paragard intrauterine device cash transaction bolster cooper company coopersurgical csi business contraceptive device market share price cooper company inched close follow news however acquire business line be exclusively operated teva pharmaceutical manufacturing facility buffalo ny cooper company expect acquisition prove accretive earning share cent first year deal furthermore exclude acquisition related cost transaction be expect boost cooper company gross operate margin well management intrauterine device market be worth be expect multiply mid single digit paragard be only approve hormonal intrauterine device space robust csi product portfoliocooper company be well position benefit expand csi product portfolio management believe long term growth csi be drive fertility segment company have gain strong foothold courtesy reprogenetic genesis recombine buyout moreover purchase expand company international presence open opportunity market spain japan peru south america uae south africa jordan taiwan last report quarter csi revenue jump constant currency cc year year basis fiscal management trim revenue guidance csi segment csi revenue be now project range significantly lower previous range stock performance solidover past month cooper company have gain compare favorably broader industry addition moreover current level be higher gain same time frame cooper company be poise gain expand product portfolio increase penetration international market accretive acquisition be also key catalyst long haul furthermore outlook contact lens industry be favorable be likely boost stock price long haul company long term expect earning growth rate hold promise regard zack rank other key pickscooper company currently carry zack rank buy couple other top rank stock broader medical sector be edward lifescience corp ew free report idexx laboratory inc idxx free report notably edward lifescience sport zack rank strong buy idexx laboratory have zack rank see complete list today zack rank stock here edward lifescience deliver average earning beat trail quarters company have long term expect earning growth rate idexx laboratory deliver average earning beat trail quarters have long term expect earning growth rate more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1064,EW,third year row st paul mn base ecolab inc ecl free report have be select member dow jone sustainability index djsi global indicator tracking financial performance lead sustainability drive company launch djsi be consider benchmark area index be draw dow jone collaboration investment management firm strategic asset management sam ecolab have be select leader corporate sustainability djsi company claim be recognition world class service product program well successful integration corporate responsibility sustainability overall business practice be third consecutive year company have be select company fourth list ecolab be lead provider water hygiene energy technology service protect person vital resource company program service help promote safe food maintain clean environment optimize water energy use improve operational efficiency customer food energy healthcare industrial hospitality market more country ecolab have impressive run bourse last month trading industry term price performance glimpse price movement reveal ecolab share have gain industry decline company prospect global industrial global institutional business segment reflect positivity last report quarter sale segment scale year year basis furthermore ecolab boast compelling fundamental revenue adjust earning multiply rate last year however flip side unfavorable foreign currency impact venezuelan deconsolidation be expect hurt earning term also escalate cost expense be weigh margin last month comparative study ecolab forward forward month basis multiple reflect stock have be quite overvalue zack rank key picksecolab currently carry zack rank hold few better rank medical stock be edward lifescience corporation ew free report lantheus holding inc lnth free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy lantheus holding idexx laboratory carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have surge roughly last month lantheus holding have long term expect earning growth rate stock have rally last month idexx laboratory have long term expect earning growth rate stock have gain last month more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1065,EW,solidify footprint fast grow healthcare market henry schein inc hsic free report recently announce receipt office national coordinator health information technology onc health edition health module certification group llc practice management electronic health record software micromd certification deem micromd suitable end user itfully comply federal government guideline successful usage cms payment incentive program notably program include medicare quality payment program qpp medicaid ehr incentive program believe latest development boost company sale global technology value add service business interestingly segment witness increase revenue last report quarter also gross margin front segment happen be biggest contributor henry schein offer depth suite practice management software system cover dental animal health medical customer large customer base more practice inclusive micromd physician practice continue slew development company earlier announce partnership medical system simplifeye combine entity aim create mobile experience integration simplifeye henry schein micromd order allow physician provide more customize patient experience simplify practice workflow keep concern team member well connect away workplace report global healthcare market be project reach value cagr period give current market potential company development space believe henry schein be track gain traction believe agee population unhealthy lifestyle rise awareness expenditure healthcare continue drive growth healthcare market however market be dominate many well establish player nextgen division quality system inc qsii free report be prominent moreover henry schein have be gain investor confidence consistent positive result past month company share price have outperformed broader industry stock have gain higher broader industry gain company have also outperformed decline market same time frame zack rank key pickshenry schein carry zack rank hold few better rank medical stock be edward lifescience corporation ew free report lantheus holding inc lnth free report edward lifescience sport zack rank strong buy lantheus holding carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1066,EW,bid expand advanced material science range nuvasive inc nuva free report recently announce vertera spine buyout however term acquisition agreement have be keep wrapped nuvasive pioneer apply procedurally integrate solution minimally disruptive spine surgery aim market distribute vetera spine fda approve cohere cervical coalescetm lumbar interbody fusion device unite state deal also lend company dimensional porous interbody technology peek titanium material notably company have introduce few new feature modulus xlif build fully porous titanium implant create dimensional manufacturing process design match porosity stiffness bone encouragingly note company spinal hardware business comprise implant fixation product magec eos spinal brace lengthen system precice limb lengthen system register growth last report quarter nuvasive be leave stone unturned gain traction fast grow spine market regard company have be steadily focuse product development moreover company claim have active corporate development pipeline include number strategic investment acquisition partnership opportunity notably first quarter company launch first interbody device mlx tlx used lumbar fusion procedure report becker spine review global minimally invasive spine surgery market be expect witness cagr also report technavio global spinal implant market be expect witness cagr roughly period thus give current market potential believe company be right track gain traction believe agee population unhealthy lifestyle rise awareness expenditure healthcare continue drive growth minimally invasive spine surgery market however market be dominate many well establish player stryker corporation syk free report zimmer biomet holding inc zbh free report notably stryker provide range product es spinal system mantis implant lite decompression tube many more minimally invasive spine surgical solution portfolio moreover zimmer biomet range thoracolumbar product form comprehensive portfolio minimally invasive spine surgery past month nuvasive have underperform broader industry period company have lose compare gain broader industry expect company make comeback latest development zack rank key picknuvasive carry zack rank hold better rank medical stock be edward lifescience corporation ew free report sporting zack rank strong buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1067,EW,sep issue update research report cincinnatus base cheme corporation che free report stock currently carry zack rank buy last month cheme have be trading broader industry stock have gain industry decline improvement average net medicare reimbursement rate increase average daily census recently report second quarter be encourage raise outlook roto rooter segment earning share be indicative company anticipate improve operate result upcoming quarters turn boost investor optimism stock notably cheme vita business have be trouble past few quarters due certain admission coding change initiate center medicare medicaid service cms however management note recent admission trend be positive continue come quarters well term roto rooter business company continue display robust performance strength core plumbing drain clean service segment also prompt solid rise water restoration management increase expectation achieve roto rooter full year revenue growth much higher earlier project range revenue estimate be base increase job pricing approximately continue growth water restoration service however headwind reimbursement related issue seasonality business competitive landscape dependence government mandate challenge cheme also tweak guidance medicare cap bill limitation be matter concern other key picksa few other top rank medical stock be edward lifescience corporation ew free report lantheus holding inc lnth free report idexx laboratory idxx free report edward lifescience sport zack rank strong buy lantheus holding idexx laboratory carry zack rank see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have surge last month idexx laboratory have long term expect earning growth rate stock have gain last month more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1068,EW,share inogen inc ingn free report rally new week high sep close tad lower represent strong year date return approximately higher same time frame stock have zack rank hold take stable stock performance consideration expect inogen scale higher come quarters also company long term expect earning growth rate be higher broader industry majority last month company share price have considerably outperformed broader industry stock have rally last month beating industry gain just same time frame factor drive stockguidance upbeat banking solid performance last quarter inogen raise revenue adjust net income guidance moreover company narrow full year adjust ebitda guidance inogen project revenue range higher previous range represent year year growth previous range adjust ebitda be project band compare estimate earlier represent increase compare year quarter inogen expect adjust net income range previous band unique direct customer business model notably inogen have market cap company direct customer business model have lend lead position oxygen therapy market direct consumer model give company opportunity build unique brand relationship directly customer initiative support growth direct consumer line business company have announce have secure additional facility cleveland area solid result inogen report stellar second quarter beating zack consensus estimate count solid domestic international business business sale drive revenue fact company expect direct consumer sale be fastest grow channel follow domestic business business sale come quarters solid focus europe bright prospect ltot space inogen develop manufacture market portable oxygen concentrator poc company recently announce receipt ec certificate inogen platform be available sale select international country believe expand long term oxygen therapy ltot market advantage pocs traditional delivery model direct customer business model underpenetrated international market expand product portfolio be key growth catalyst favorable estimate revision trend inogen estimate revision trend have be promising full year last month estimate moved north compare movement opposite direction full year estimate rise almost share same time frame current quarter estimate moved compare downward revision last month result zack consensus estimate current quarter increase cent share same time frame inogen inc price consensus inogen inc price consensus inogen inc quotekey picksa few better rank stock broader medical sector be edward lifescience corp ew free report idexx laboratory inc idxx free report cogentix medical inc notably edward lifescience sport zack rank strong buy idexx laboratory cogentix medical have zack rank buy see complete list today zack rank stock here edward lifescience deliver average earning beat trail quarters company have long term expect earning growth rate cogentix medical register positive earning surprise last report quarter stock represent stellar return last year idexx laboratory deliver average earning beat trail quarters have long term expect earning growth rate more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1069,EW,nuvasive inc nuva free report recently receive fda approval use company redesign magec system reline small stature system company press release reline small stature be comprehensive pediatric deformity fixation system help achieve optimal construct strength reduce implant profile be only small stature system be compatible new millimeter magec rod magec system offer latest magnetic technology adjustable grow rod treat early onset scoliosis less invasive manner latest upgrade magec system help surgeon carry surgical procedure ease make more reproducible notably order strengthen footprint deformity market nuvasive announce new initiative support adult pediatric deformity research education awareness initiative part initiative company recently launch embrace journey together program program involve pediatric spinal deformity research education spinal deformity event support educate surgeon worldwide fda nod magec system reline small stature have help nuvasive progress embrace journey together program accord report market market global spinal implant market be estimate reach worth cagr look bountiful opportunity niche space believe company latest development be strategic fit past month nuvasive have underperform broader industry period company have lose compare gain broader industry expect company turn latest development zack rank key picksnuvasive carry zack rank hold few better rank medical stock be edward lifescience corporation ew free report lantheus holding inc lnth free report cheme corporation che free report edward lifescience sport zack rank strong buy lantheus holding cheme carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month cheme have long term expect earning growth rate stock have gain last month more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1070,EW,becton dickinson company bdx free report commonly know bd recently announce agreement italy base euroclone development global distribution molecular assay molecular assay be exclusively formulate detect sexually transmit pathogen fact bd have be lead player provide solution woman health sexually transmit infection sti notably company latest development closely follow recent launch bd ultra fine micro pen needle mm use pen injection device needle offer comfortable injection experience enhance customer satisfaction device be slate distribution month come back news bd euroclone plan launch molecular assay outside unite state molecular assay leverage company flagship platform bd max system detect infectious genital mycoplasmas include mycoplasma ureaplasma species be generally unidentifiable conventional method however assay be currently not available sale unite state management addition assay exist bd max portfolio company other assay bd surepath bd onclarity hpv assay be likely fortify company foothold clinical laboratory testing sti impressive stock price bd inched close follow news release last year company have outperformed broader industry stock be broader industry gain just nonetheless current return be relatively lower addition same time frame also zack rank hold company focus expand overseas market particular emerge market follow new product launch acquisition drive strategy be significant growth catalyst takebd have diversify product portfolio reduce risk exposure specific product additionally diverse revenue base increase adoption company new exist product be expect drive top line growth meanwhile latest development be likely maintain company international footprint evidently bd witness increase revenue outside unite state comparable currency neutral basis last quarter accord report ally market research global sexually transmit disease testing market be anticipate reach cagr markedly consider huge potential market believe latest development be strategic fit stock consider few better rank stock broader medical sector include edward lifescience corp ew free report idexx laboratory inc idxx free report cogentix medical inc edward lifescience sport zack rank strong buy idexx laboratory cogentix medical hold zack rank buy see complete list today zack rank stock here edward lifescience deliver average earning beat last quarters company have long term expect earning growth rate idexx laboratory pull average earning beat trail quarters have long term expect earning growth rate cogentix medical come positive earning surprise last quarter stock represent stellar return last year make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1071,EW,share price abbott free report scale new week high sep eventually close nominally lower company have gain past month much higher gain same frame abbott have also outperformed broader industry decline respect share price movement past month stock have market cap further abbott estimate revision trend current year have be favorable past day estimate moved moved estimate be share same time frame company also have trail quarter average positive earning surprise positive long term growth hold promise abbott laboratory price consensus abbott laboratory price consensus abbott laboratory quoteabbott carry zack rank hold company have impressive growth style score growth style score highlight vital metric company financial obtain clearer picture quality sustainability growth research show stock style score combine zack rank strong buy buy offer best investment opportunity growth market be upbeat abbott recent fda approval full maglev heartmate left ventricular assist device lvad company also announce receipt national reimbursement freestyle libre glucose monitoring system japan development have widen illinois base medical device major customer base diabetes management further company recently sign manage equipment service contract north west london pathology nwlp host imperial college healthcare nhs trust abbott expect alliance solidify footprint rapidly grow diagnostic market meanwhile abbott second quarter performance have be promising sale adjust earning continue operation increase year year factor be expect boost company share price key picksa few better rank medical stock be edward lifescience corporation ew free report lantheus holding inc lnth free report cheme corporation che free report edward lifescience sport zack rank strong buy lantheus holding cheme carry zack rank buy cansee complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month cheme have long term expect earning growth rate stock have gain last month simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
1072,EW,accuray inc aray free report report loss cent share fourth quarter fiscal wider zack consensus estimate loss penny however figure be relatively narrower loss cent year quarter total revenue fourth quarter increase approximately year year beat estimate year year growth be primarily drive solid prospect americas apac region accuray also report fiscal result fiscal total revenue decrease year year basis service revenue net revenue totale product revenue net revenue totale fiscal notably accuray carry zack rank sell hint probability term accuray incorporate price consensus ep surprise accuray incorporate price consensus ep surprise accuray incorporate quotesegment analysisproduct revenue revenue segment increase system order conversion backlog revenue americas apac region buoy growth segment solid performance cyberknife tomotherapy system radixact platform be key highlight segment service revenue revenue segment see modest year year increase management lackluster performance segment be primarily due lower installation gross order update report quarter gross product order totale increase year year basis end quarter product backlog be approximately higher year year gross order performance be favorably impact company flagship radixact system cyberknife system incise multileaf collimator other platform drive sale company new tomotherapy product platform also know radixact continue contribute company top line radixact represent majority accuray tomotherapy order mix report quarter sequential basis third quarter apac japan witness stellar performance radixact tomotherapy platform radixact order japan have be extremely positive date precision system accuray also announce new precision treatment plan system recently system leverage company flagship radixact cyberknife system platform company also plan build technology precision upgrade fiscal provide significant improvement treatment speed overall throughput already exist cyberknife system ibms datum management system tomotherapy accuray also announce clearance new ibms datum management system tomotherapy be centralize database share make datum accessible multiple accurate system add flexibility improve efficiency radiation therapy department margin margin percentage net revenue contract basis point bps fourth quarter be primarily due reduce product gross margin product gross margin decrease due unfavorable product channel mix operate expense fourth quarter be almost flat year period guidanceaccuray issue guidance fiscal company project full year revenue band represent growth band approximately year year basis furthermore product revenue be expect increase band year year service revenue be likely remain flat fiscal company expect increase gross order fiscal product system backlog be expect band adjust ebitda fiscal be anticipate range year year takeaccuray report wider expect loss fourth quarter fiscal primarily due lackluster performance service revenue segment company issue solid fiscal guidance recent development order newly unveil radixact system solid revenue performance apac japanese regulatory approval radixact be key positive view however unfavorable product mix decline service revenue sluggish macro economic condition pricing headwind be major concern notably china europe see sluggish revenue fourth quarter accuray significant international presence help broaden customer base however fluctuation currency exchange rate particularly strong dollar continue adversely impact company backlog top line come quarters key picksa few better rank stock broader medical sector be edward lifescience corp ew free report idexx laboratory inc idxx free report cogentix medical inc notably edward lifescience sport zack rank strong buy idexx laboratory cogentix medical have zack rank buy see complete list today zack rank stock here edward lifescience deliver average earning beat trail quarters cogentix medical register positive earning surprise last report quarter idexx laboratory deliver average earning beat trail quarters surprising tech stock keep eye tech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
1073,EW,neogen corporation neog free report report adjust earning cent share first quarter fiscal figure beat zack consensus estimate increase year quarter revenue increase year year basis beating zack consensus estimate revenue detailsfood safety segment revenue neogen food safety segment totale notably revenue segment jump first quarter overall organic growth growth be majorly fuel strength number exist product line recent acquisition furthermore increase testing toxin buoy sale segment also note sale segment be drive surge sale allergen test food such gluten peanut courtesy global food allergen regulatory effort animal safety segment animal safety segment record revenue reflect increase year quarter growth segment be mainly drive increase sale company insect control product line rise sale veterinary instrument particularly needle syringe product line flipside neogen witness decline sale cleaner disinfectant thank termination distribution agreement third quarter fiscal genomic unit genomic business unit record increase year year basis management growth business unit be fuel expansion company testing facility scotland development new genomic testing product acquisition brazil base deoxi early neogen corporation price consensus ep surprise neogen corporation price consensus ep surprise neogen corporation quotemargin detailsadjust gross margin contract basis point bps quarter largely due mixed impact acquisition quat rogama operate income be sale first quarter compare year takewe believe neogen be steadily progress back prong strategy also be encourage accretive acquisition expand international footprint drive neogen overall result fiscal moreover company have broad portfolio innovative disinfectant product more epa fda register product strengthen company global market position zack rank key pickswe note neogen carry zack rank hold few better rank medical stock be edward lifescience corporation ew free report idexx laboratory inc idxx free report amedisys inc am free report edward lifescience sport zack rank strong buy idexx amedisys carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate company deliver positive earning surprise last report quarter idexx have long term expect earning growth rate company deliver positive earning surprise last report quarter amedisys have long term expect earning growth rate company deliver positive earning surprise last report quarter more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1074,EW,surmodic inc srdx free report recently announce have receive food drug administration fda ce mark clearance low profile percutaneous transluminal angioplasty pta balloon dilation catheter aforementioned product be design peripheral angioplasty procedure surmodic share have outperformed industry past month stock have rally compare industry gain same period current level be also better return regulatory approval aforementioned product reflect surmodic peripheral angioplasty procedure particularly drug delivery space surmodic pta balloon catheter offer deliverability lesion cross leverage company proprietary serene hydrophilic coating serene hydrophilic coating be proficient avoid friction particulate company proprietary balloon catheter technology combine surmodic advanced process ensure ultra low tip entry cross profile transition achieve product performance development surmodic low profile pta catheter be step forward company strategy be provider whole product vascular solution medical device customer surmodic now have complete capability design development high volume manufacturing wide variety highly differentiate balloon catheter specialty catheter solution complete suite house capability state art facility ballinasloe ireland surmodic control step manufacturing process produce high quality reliable balloon catheter flip side company anticipate increase expense second half fiscal be increase investment related surveil dcbtrial other proprietary product estimate revision latest estimate revision trend have be favorable company current year estimate moved north compare none opposite direction last month result zack consensus estimate full year earning have moved cent share takeaccording report market research future global peripheral artery disease market be expect reach worth cagr period consider huge potential market believe latest development be strategic fit zack rank key pickssurmodic carry zack rank hold few better rank medical stock medical sector include edward lifescience corporation ew free report lantheus holding inc lnth free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy lantheus holding idexx hold zack rank buy see complete list today zack rank strong buy stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month idexx have long term expect earning growth rate stock have gain last year promising stock pick keep eye news story computer hacking identity theft become increasingly commonplace cybersecurity industry look promising investment opportunity stock buy zack just release cybersecurity investor guide locking profit help answer question new special report give information need make well inform investment choice space more importantly also highlight cybersecurity pick strong profit potential get new investing guide now
1075,EW,varian medical system var free report recently announce release fda approve treatment plan software eclipse help clinician treat more accuracy efficiency eclipse also provide treatment plan support varian hyperarc oncology system hdrt efficient automate delivery complex stereotactic radiosurgery hyperarc hdrt be new type radiosurgery treatment eclipse offer graphic process unit gpu support help physician optimize speedily calculate dose eclipse feature multus criterium optimization mco allow clinician explore application different clinical criterium accord company accord company mco focus find optimal plan faster give patient minimal trial error iteration last report third quarter varian medical revenue decline oncology system company be consistently try turn oncology system business apart latest development company recently announce fda clearance revolutionary halcyon product company receive order country system north america company sign agreement petcure oncology bring unprecedented level care pet suffering cancer accord report market market global oncology information system market be expect reach worth cagr consider huge potential market believe latest development be strategic fit past month varian medical have outperformed broader industry term price company have return compare favorably sub industry gain estimate revision estimate revision trend have be favorable company current year estimate moved north compare movement opposite direction last month result zack consensus estimate full year have increase share same period zack rank key picksvarian medicalcarry zack rank hold few better rank medical stock be edward lifescience corporation ew free report amedisys inc am free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy amedisys idexx carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month amedisys have long term expect earning growth rate stock have gain last year idexx have long term expect earning growth rate stock have gain last year promising stock pick keep eye news story computer hacking identity theft become increasingly commonplace cybersecurity industry look promising investment opportunity stock buy zack just release cybersecurity investor guide locking profit help answer question new special report give information need make well inform investment choice space more importantly also highlight cybersecurity pick strong profit potential get new investing guide now
1076,EW,medtronic plc mdt free report recently initiate post market forward pro clinical study measure performance corevalve evolut pro transcatheter aortic valve implantation tavi system regular clinical treatment study evaluate long term performance next generation self expand tavi system patient severe symptomatic aortic stenosis be intermediate high extreme risk open heart surgery notably system have recently be approve commercial use europe unite state management multus center study enroll patient site europe moreover study involve measure safety standard corevalve evolut pro valf analyze cause mortality stroke rate day clinical performance cover valve hemodynamic paravalvular regurgitation moreover company patient be continue be follow evaluate year encouragingly note march corevalve evolut pro system have receive fda approval use symptomatic patient be high extreme risk open heart surgery moreover self expand tavi system have be grant regulatory approval europe well thus believe clinical study datum display efficiency product help company gain traction coronary structural heart csh space interestingly medtronic csh revenue be constant exchange rate back high constant currency growth transcatheter aortic valf result strong customer uptake corevalve evolut pro platform unite state continue demand corevalve evolut mm valve unite state well europe notably report medgadget global heart valve repair replacement market be expect grow cagr believe unhealthy lifestyle rise agee population continue result high incidence cardiovascular disease be further support datum provide gbi research report global cardiovascular disease market see cagr space market be expect witness highest momentum cagr medtronic be base highly fragmented heart valve repair replacement market however market be dominate well establish player abbott free report boston scientific corporation bsx free report edward lifescience corporation ew free report other boston scientific lotus valve platform edward lifescience sapien xt sapien offering be worth mention here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1077,EW,world heart day be observed year september raise awareness world cardiovascular cv disease cv disease more commonly know heart disease stroke be basically disease heart blood vessel accord world heart federation cv disease be biggest killer world accounting death year number expect cross factor contribute number include uncontrolled hypertension high cholesterol level obesity smoking diabetes sedentary lifestyle theme world heart day be share power focus inspiring person world be heart healthy focus be create heart healthy environment help reduce cardiovascular risk be work home simple change lifestyle include healthy eating exercise lower alcohol consumption give smoking be way cut even prevent risk cv disease accord fda person die cardiovascular disease day unite state add american year give statistic be not surprising several healthcare company devote significant amount dollar develop treatment device cardiovascular other disease increase risk heart issue accord gbi research report more product be active development cv disease focus be main indication hypertension heart failure dyslipidemia thrombosis importantly be not just healthcare company be involved fitness segment many cv disease be preventable address behavioral risk factor food consumption smoking lack exercise person be become more conscious health have lead tech company come fitness tracker help keep track heart rate calory burn sleep pattern help management lifestyle disease diabetes obesity world heart day come let take look well position stock segment market biotelemetry inc beat free report malvern pa base biotelemetry be wireless medical technology company provide health information aim improve quality life reduce cost care company provide cardiac monitoring service original equipment manufacturing primary focus cardiac monitoring device centralize core laboratory service zack rank buy stock have strong earning track record have surpass expectation last quarters recent acquisition lifewatch have position company largest provider remote healthcare service world biotelemetry look well position rapidly evolve connect health market expect serve more patient share biotelemetry have gain year date significantly outperform industry rally edward lifescience corp ew free report edward lifescience hold lead position patient focuse innovation structural heart disease critical care monitoring company portfolio include product annuloplasty ring catheter heart valf enable treatment patient cardiovascular disease edward lifescience be focuse develop structural heart therapy estimate global transcatheter aortic valve replacement tavr opportunity cross drive increase awareness expand indication improve technology share zack rank strong buy stock hold strong position approximately global surgical heart valve segment be year date compare industry rally company have consistently surpass earning expectation last quarters novartis ag nvs free report swiss drugmaker novartis have be news lately gain approval first car cell treatment unite state company be also key player heart failure segment zack rank stock have approve drug form entresto treatment heart failure reduce ejection fraction heart failure debilitating life threaten condition be estimate affect more person world heart failure patient suffer reduce ejection fraction novartis be work generate more datum entresto heart failure more active plan study novartis also have good earning track record earning surpass expectation last quarters share zack rank stock be year date compare industry rally addition stock be several other company involved therapeutic area include company merck mrk free report nordisk nvo free report eli lilly lly free report other company be key player diabetes market accord information provide american heart association adult diabetes be time more likely die heart disease adult diabetes merck lilly be zack rank hold stock nordisk be zack rank stock see complete list today zack rank stock here hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
1078,EW,trump fail effort repeal replace obamacare trump introduce skinny repeal call do away part affordable care act aca obamacare individual mandate employer mandate cadillac taxe last month republican lose debate skinny repeal unite state witness political dilemma republican vote favor exist healthcare act probably decide support exist healthcare act base datum provide congressional budget office cbo joint committee taxation jct report abolition obamacare person be uninsured more count be expect increase cancellation withdrawal individual employer mandate have make health insurance contract health insurance coverage expensive significantly dent demand healthcare service impact medical device industry whole however medtech industry be look forward abolishment major healthcare taxe include cadillac tax medtech tax republican fail pass skinny repeal have be able delay cadillac tax thank postponement cadillac tax medical device industry be hopeful medical device tax be eradicate soon such mixed scenario feel investor place bet large cap stock deliver positive average earning surprise last report quarters be witness upward revision earning estimate stock pickwe have select medical device stock help zack stock screener hyperlink shortlist medical device stock be poise impressive return next year stock boast zack rank strong buy buy have market cap more edward lifescience corporation ew free report edward lifescience promise long term expect earning growth rate stock sport zack rank see complete list today zack rank stock here look estimate revision trend current quarter last month estimate increase cent share stock have deliver positive earning surprise last quarters average come price performance last month edward stellar return much higher broader industry gain roughly idexx laboratory inc idxx free report stock have zack rank stock have long term earning growth rate last quarters company deliver positive earning surprise average fact estimate revision trend current quarter seem favorable last month estimate increase cent share last year idexx represent return beating broader industry gain cooper company inc coo free report stock carry zack rank promise long term earning growth last quarters company deliver positive earning surprise average regard current quarter estimate increase share last month last month company represent stellar return much better broader industry rally roughly icon plc iclr free report stock carry zack rank long term earning growth estimate revision trend current quarter look promising estimate increase share last month stock have deliver positive earning surprise last quarters average come price performance last month icon represent stellar return much higher broader industry increase roughly zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
1079,EW,aug issue update research report kalamazoo mi base stryker corporation syk free report largest medical device company global orthopedic market company currently have zack rank buy stryker have impressive run bourse last month trading industry term price performance glimpse price movement reveal stryker share have gain compare favorably rise industry belong company have diverse product portfolio cushion significant sale shortfall economic downturn stryker pipeline include product hip knee mako robotic arm assist surgery mako result last quarter be solid almost global robot installation be unite state furthermore platform bone cement sport medicine bone substitute soft tissue repair trauma extremity endoscopy more fortify company market position stryker have be follow acquisition drive strategy boost growth profile june company announce definitive agreement acquire novadaq technology inc share net purchase price transaction be structure arrangement canada business corporation act be subject customary close condition include approval novadaq shareholder stryker have be focuse international growth well particular company medsurg product line have witness strong demand european australian market second quarter flip side china prove be challenge market stryker strong guidance be also catalyst third quarter company expect adjust earning range share full year company estimate adjust earning band stryker expect organic sale growth full year other key picksother top rank medical stock be edward lifescience corp ew free report steris plc ste free report align technology inc algn free report edward lifescience align technology sport zack rank strong buy steris carry zack rank buy see complete list today zack rank stock here edward lifescience have positive earning surprise trail quarters stock have gain last month align technology have long term expect earning growth rate stock have rally roughly last month steris have positive earning surprise trail quarters stock have gain last month more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1080,EW,headquarter sunnyvale accuray inc aray free report recently announce boise base summit cancer center have initiate cancer treatment radixact treatment delivery system notably radixact system leverage company flagship tomotherapy platform radixact system provide complex treatment such craniospinal total marrow irradiation add functionality summit cancer center have capability perform stereotactic radiosurgery srs stereotactic body radiotherapy sbrt spare normal tissue maintain optimal treatment efficacy radixact system have be design deliver image guide intensity modulate radiation therapy extremely precise form radiation therapy platform gain japanese regulatory approval shonin approval last quarter be expect start formal treatment fourth quarter regard glimpse preliminary fourth quarter result reveal accuray expect approximately gross product order solid growth gross order be buoy full commercial launch radixact system continue strong demand company flagship cyberknife system stock price estimate revision trendaccuray have have unimpressive run bourse last year company have lose way wider broader industry rally almost moreover current level compare unfavorably gain furthermore estimate revision stock have be unfavorable full year estimate deteriorate cent loss cent share owing bearish analyst sentiment accuray carry zack rank sell signify term takeaccuray top line growth be highly dependent cyberknife tomotherapy system sale however system involve significant capital spending many healthcare provider be reluctant spend primarily due sluggish macro economic condition mar revenue long haul however company have be gain ground series positive tiding regulatory front recently notable one accuray receive clearance fda idms datum management system july key picksa few better rank stock broader medical sector be edward lifescience corp ew free report idexx laboratory inc idxx free report stryker corporation syk free report notably edward lifescience sport zack rank strong buy idexx laboratory stryker corporation have zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate notably stock represent impressive year date return idexx laboratory have long term expect earning growth rate notably stock represent stellar year date return stryker represent impressive year date return stock have long term expect earning growth rate surprising tech stock keep eye tech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
1081,EW,base audubon pa lead musculoskeletal implant company globus medical inc gmed free report announce receipt approval excelsius gps robotic guidance navigation system fda fact positive tiding regulatory front have favore globus medical company have already clinch ce mark excelsius gps january system support minimally invasive open orthopedic neurosurgical procedure screw placement application system be exclusively design limit radiation exposure reorganize assist implant placement excelsius gps system work different imaging modality excelsius gps integrate globus medical implant instrument be compatible pre operative ct intra operative ct fluoroscopic imaging modality globus medical be gear worldwide launch include logistic supply chain manufacturing support excelsius gps system fact technology have encourage globus medical increase investment technology acquisition distribution channel share performance estimate revision trendover last month globus medical have be trading broader industry company have lose much wider broader industry decline current level also compare unfavorably decline only same time frame estimate revision trend globus medical have be unfavorable late current quarter analyst moved south compare movement opposite direction last month result magnitude current quarter estimate fall cent share same time frame viewpointa research report technavio expect global musculoskeletal disorder therapeutic market see cagr approximately believe globus medical latest regulatory progress lend competitive edge global niche space meanwhile stock have zack rank sell signify probability term contrary stock long term expect earning growth rate instill confidence investor add positive company be debt free end just report second quarter globus medical reaffirm guidance full year sale approximately adjust earning share key picksa few better rank stock broader medical sector be edward lifescience corp ew free report idexx laboratory inc idxx free report stryker corporation syk free report notably edward lifescience sport zack rank strong buy idexx laboratory stryker have zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate notably stock represent impressive year date return idexx laboratory have long term expect earning growth rate notably stock represent stellar year date return stryker represent solid year date return stock have long term expect earning growth rate surprising tech stock keep eye tech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
1082,EW,earning growth enthrall almost everyone right top brass research analyst question here be be simply earning be measure money company be make take company revenue give period time subtract cost production have earning metric be also consider most significant variable influence share price better expect earning performance normally lead rally share price however addition actual earning expectation earning play vital role determine share price movement earning estimate determine share priceswe have often see decline stock price earning growth rally price follow earning decline be largely result company earning fail meet market expectation so be earning estimate embody analyst opinion factor such sale growth product demand competitive industry environment profit margin cost control thus earning estimate serve valuable tool take investment decision earning estimate also help analyst assess cash flow determine fair value firm second quarter earning season be almost come end have picked stock have display historical earning growth be also see rise quarterly annual earning estimate aug member have report earning figure earning member be higher revenue beating ep estimate surpass top line expectation read more retail sector mixed show winning strategyin order shortlist stock have striking earning growth positive estimate revision add follow parameter zack rank less equal only zack buy strong buy be allow zack rank prove be best rating system be great way start thing year historical ep growth greater industry stock possess strong ep growth history change ep greater equal company witness year year earning growth rate more last report fiscal change estimate last week greater stock have see current quarter earning estimate revise higher last week change estimate last week greater stock have see annual earning estimate revise higher last week change estimate last week greater stock have see annual earning estimate revise higher last week criterium narrow universe stock only here be top stock sp corp sp free report be provider parking management ground transportation other ancillary service commercial institutional municipal client company have zack rank buy zack consensus estimate current year earning increase last day company estimate growth rate current year be higher industry project addition edward lifescience corp ew free report be manufacturer heart valve system repair product used replace repair patient diseased defective heart valve company sport zack rank strong buy zack consensus estimate current year earning increase last day company estimate growth rate current year be higher industry project addition magna international inc mga free report be global automotive supplier company have zack rank zack consensus estimate current year earning increase last day company estimate growth rate current year be higher industry project addition see complete list today zack rank stock here nvidia corporation nvda free report focus personal computer pc graphic graphic process unit gpu also artificial intelligence ai company have zack rank zack consensus estimate current year earning increase last day company estimate growth rate current year be higher industry project addition get rest stock list signing now week free trial research wizard start used screen own trading further also create own strategy test first take investment plunge research wizard be great place begin easy use everything be plain language very intuitive start research wizard trial today next time read economic report open research wizard plug find see gem come click here sign free trial research wizard today disclosure officer director employee zack investment research own have sell short security hold long short position option be mentioned material affiliated investment advisory firm own have sell short security hold long short position option be mentioned material disclosure performance information zack portfolio strategy be available https www zack com performancezack restaurant recommendation addition dine special place feast stock share zack special report spotlight recent ipos watch stock offer immediate promise boom sector download free
1083,EW,accelerate diagnostic inc axdx free report be big mover last session company see share rise more day move come solid volume too far more share change hand normal session reverse recent trend company stock be now past month time frame company have see negative estimate revision past few week zack consensus estimate current quarter have also moved lower past few week suggest be trouble road so make sure keep eye stock go forward see recent move higher last accelerate diagnostic currently have zack rank hold earning esp be negative accelerate diagnostic inc price consensus accelerate diagnostic inc price consensus accelerate diagnostic inc quotea better rank stock medical instrument industry be edward lifescience corporation ew free report carry zack rank strong buy see complete list today zack rank stock here be axdx go predict see other think surprising tech stock keep eye ontech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
1084,EW,sep issue update research report allscript healthcare solution inc mdrx free report company have be healthy growth trajectory late have rally last year ahead gain zack rank hold stock have market cap allscript healthcare provide information technology solution service healthcare organization higher adoption company ehr solution particularly sunrise ehr platform consistently drive company top line help counter stiff competition long run initiative eradicate ambiguity determine medicinal cost discount allscript recently launch allscript real time health system exclusive work flow solution optimize clinical financial impact medical prescription enhance prescription price transparency latest launch allscript aim provide clinician patient complete information medication price cost alternative therapy competitive price prescribe therapy different pharmacy notably allscript be first major healthcare information technology player come such solution allscript healthcare solution inc price allscript healthcare solution inc price allscript healthcare solution inc quoteon flipside company expect modest increase operate expense second half allscript product have long sale cycle involve decision make different managerial level increase company operate expense add linger global economic weakness present substantial risk allscript manufacturer life save device demand software company product be closely tie budgetary process client result company have see significant decline system sale due decline customer order key picksa few better rank stock broader medical sector be edward lifescience corp ew free report idexx laboratory inc idxx free report cogentix medical inc notably edward lifescience sport zack rank strong buy idexx laboratory cogentix medical have zack rank buy see complete list today zack rank stock here edward lifescience deliver average earning beat last quarters company have long term expect earning growth rate idexx laboratory deliver average earning beat trail quarters have long term expect earning growth rate cogentix medical come positive earning surprise last quarter stock represent stellar return last year look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1085,EW,south san francisco base fluidigm corporation fldm free report lead player analysis single cell industrial application genomic recently announce have enter licensing agreement baylor genetic agreement fluidigm license right commercialize cftr cystic fibrosis transmembrane conductance regulator library prep assay develop baylor genetic research purpose be used proprietary juno automate microfluidic system target library prep assay enable accurate identification variant exon cftr gene select intronic region combine fluidigm microfluidic solution have potential significantly simplify complex labor intensive laboratory workflow improve efficiency cftr sequence invariably improve efficiency juno automate microfluidic system help company capture considerable market share next generation sequence offer more comprehensive approach cftr genetic analysis allow complete view sequence target sequence library prep workflow however be very labor intensive application fluidigm automate microfluidic technology library preparation be streamline provide significant efficiency past month fluidigm have underperform broader industry stock have shed compare industry decline fluidigm develop manufacture market life science analytical preparatory system market such mass cytometry high throughput genomic single cell genomic company cater lead academic institution clinical research laboratory pharmaceutical biotechnology agricultural biotechnology company worldwide zack rank key pickscurrently fluidigm have zack rank hold few better rank medical stock be edward lifescience corp ew free report lantheus holding inc lnth free report align technology inc algn free report edward lifescience align technology sport zack rank strong buy lantheus holding carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have gain last month lantheus holding have long term expect earning growth rate stock have gain last month align technology have long term expect earning growth rate stock have rally roughly last month surprising tech stock keep eye ontech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
1086,EW,irvine base masimo corporation masi free report recently announce clearance full market release proprietary rad pulse co oximeter launch rad offer masimo noninvasive continuous monitoring measure motion low perfusion set pulse oximetry upgradeable rainbow technology be include compact standalone monitor incorporate advanced customizability connectivity device integration capability masimo pulse oximetry prodcut aim give accurate oxygen saturation pulse rate measurement wider adoption invasive patient monitoring technology be help company gain market share also masimo set pulse oximetry business have considerable growth opportunity international market believe masimo innovative product line drive top line growth consider bountiful opportunity advanced monitoring technology global market launch instill investor confidence stock research report market market reveal niche market be expect reach worth globally cagr additionally masimo long term growth fundamental be strong company record year cagr revenue adjust earning share masimo have particularly witness improvement earning last year masimo develop manufacture market family invasive monitoring system latest development significantly fortify company position niche market masimo carry zack rank buy year date masimo have outperformed industry term price company have return compare sub industry gain also current return be higher gain same time frame other key picksa few other top rank stock broader medical sector be edward lifescience corp ew free report idexx laboratory inc idxx free report cogentix medical inc notably edward lifescience sport zack rank strong buy idexx laboratory cogentix medical hold zack rank buy see complete list today zack rank stock here edward lifescience deliver average earning beat last quarters company have long term expect earning growth rate idexx laboratory deliver average earning beat trail quarters have long term expect earning growth rate cogentix medical come positive earning surprise last quarter stock represent stellar return last year promising stock pick keep eye news story computer hacking identity theft become increasingly commonplace cybersecurity industry look promising investment opportunity stock buy zack just release cybersecurity investor guide locking profit help answer question new special report give information need make well inform investment choice space more importantly also highlight cybersecurity pick strong profit potential get new investing guide now
1087,EW,aug issue update research report haemonetic corporation hae free report base lead provider blood management solution customer encompass blood plasma collector hospital health care provider globally stock currently carry zack rank buy past month haemonetic have be trading broader industry period stock have rally compare broader industry haemonetic exit first quarter fiscal mixed note earning beating zack consensus estimate revenue miss same encourage growth plasma haemonetic management franchise bloodcenter franchisee be quite dampener meanwhile company strong cash position boost investor confidence also year year increase report sale gross margin buoy optimism company swung operate income first quarter fiscal loss year quarter haemonetic be also optimistic strong market adoption nexsys pcs plasmapheresis system recently receive fda approval flip side last month haemonetic valuation look stretched term price earning ratio compare own industry also haemonetic have be consistently witness sluggish revenue growth blood center franchise further macroeconomic uncertainty continue challenge moreover stiff competitive landscape add wo other key picksother top rank medical stock be edward lifescience corporation ew free report myriad genetic inc mygn free report align technology inc algn free report notably edward lifescience align technology sport zack rank strong buy myriad genetic carry zack rank see complete list today zack rank stock here align technology have expect long term adjust earning growth almost stock have add roughly last month edward lifescience have long term expect earning growth rate stock have gain last month myriad genetic have long term expect earning growth rate stock have add roughly last month simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
1088,EW,bio techne corporation tech free report report fourth quarter fiscal adjust earning share consider stock base compensation expense related tax impact regular expense year quarter figure also earning surpass zack consensus estimate year year rise earning be drive increase sale full year adjust ep come compare year period quarter detailsnet sale report quarter rise organically year year outpace zack consensus estimate full year sale grow year year organically currency fluctuation have negative impact acquisition contribute revenue bio techne corp price consensus ep surprise bio techne corp price consensus ep surprise bio techne corp company have division namely biotechnology protein platform diagnostic biotechnology division register year year revenue growth fourth quarter increase organically division be impact end market issue academia biopharma also lower primegene sale china have negative impact product growth be drive sale antibody protein platform division witness growth prior year quarter organically management growth be drive new product introduction application diagnostic segment net sale be organically year quarter upside be drive large order control kit bulk reagent oem customer geographic basis fourth quarter revenue witness mid single digit growth meanwhile growth europe be impressive witness double digit growth fourth quarter asia particularly china perform well japan register low single digit growth rest apac experience solid growth quarter review margin margin contract basis point bps year year report quarter selling general administrative expense sg be year year research development expense totale year quarter lead increase operate expense amount adjust operate margin quarter contract bps year quarter balance sheetbio techneexite fiscal cash cash equivalent compare end fiscal company have total long term debt end fiscal compare end precede fiscal takebio techneexite fourth year solid note earning revenue exceed thezack consensus estimate company witness growth segment be encourage note company be currently focuse global expansion management hope complete more acquisition fiscal company be focuse product innovation research development however currency headwind poor margin raise concern zack rank other key picksbio techne currently have zack rank buy other top rank medical stock be edward lifescience corp ew free report myriad genetic inc mygn free report align technology inc algn free report edward lifescience align technology sport zack rank strong buy myriad genetic carry zack rank see complete list today zack rank stock here edward lifescience second quarter adjust earning improve year year primarily drive strong sale growth company transcatheter heart valf business stock have gain last month align technology second quarter adjust ep cent be year year revenue grow year year stock have rally roughly last month myriad genetic inc mygn free report report adjust earning share ep cent fourth quarter fiscal year year total revenue rise year year fourth quarter simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
1089,EW,nevro corp nvro free report report second quarter loss share cent compare unfavorably loss cent share year quarter figure be also much wider zack consensus estimate loss cent revenue report quarter however rise stupendous year year exceed zack consensus estimate solid result be primarily backed continue global adoption company hf therapy geographic basis second quarter revenue represent total sale gross year quarter figure also international sale total sale advanced year year constant exchange rate cer nevro corp price consensus ep surprise nevro corp price consensus ep surprise nevro corp quote company international growth be moderate capitation constraint however expect full year international growth be range high single low double digit operational updatenevro second quarter gross margin be reflect huge basis point bps expansion year year account rise gross profit company fundamental cost improvement result margin expansion company research development expense totale sale general administrative expense amount surge year year operate loss report quarter come wider operate loss prior year quarter financial updatenevro exit second quarter cash cash equivalent compare end first quarter guidancenevro reiterate revenue guidance range current zack consensus estimate remain project range takenevro exit second quarter mixed note company worldwide revenue exceed zack consensus estimate loss share remain widely zack consensus estimate year year comparison earning be unfavorable company witness strong growth company be putt effort product innovation research development however escalate cost expense affected margin zack rank key picksnevro currently carry zack rank hold better rank medical stock be edward lifescience corp ew free report insys therapeutic inc insy free report align technology inc algn free report sporting zack rank strong buy see complete list today zack rank stock here edward lifescience second quarter adjust earning soar stupendous year year primarily drive strong sale growth company transcatheter heart valf business stock have gain surprise last month insys therapeutic gross profit margin be second quarter flat year year align technology second quarter adjust ep cent be substantial year year revenue climb year year stock have surge roughly last month simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
1090,EW,model inc modn free report report fiscal third quarter adjust loss cent share be narrower year quarter loss cent include stock base compensation company incur loss cent share be narrower zack consensus estimate loss cent revenue increase year year miss zack consensus estimate notably model stock have rally year date substantially outperform gain industry belong quarter detailmodel have reportable segment namely license implementation saas maintenance license implementation revenue total revenue grow year year basis company longer sell premise perpetual license management expect revenue line continue decline fiscal saas maintenance revenue total revenue grow year year model be track shift business saas maintenance revenue model revita contribute approximately saas maintenance revenue approximately company license implementation revenue model revenue management platform continue attract prominent name life science high tech field quarter ampleon radio frequency rf power provider select model revenue cloud service significant number system become operational third quarter include nephew edward lifescience ew free report japan stryker syk free report shire icu medical medtech company be add customer base quarter high tech company call also adopt model revenue cloud model third quarter model inc price consensus ep surprise model inc price consensus ep surprise model inc quoteadjusted gross profit increase year year margin increase gross margin benefit higher percentage saas maintenance revenue adjust ebitda be compare year quarter adjust operate loss be compare year loss improve result reflect shrink cost base post revita acquisition management state have eliminate duplicate general administrative sale marketing cost well redundant product outside life science vertical post acquisition model end quarter annual expense synergy run rate be line high end expectation balance sheetmodel exit quarter cash cash equivalent balance end second quarter fiscal guidancemodel provide guidance fourth quarter fiscal expect fourth quarter gaap revenue come range gaap operate loss be project be gaap net loss be likely be cent cent share fourth quarter fiscal gaap revenue defer revenue adjustment be expect be range management continue expect annualize recur revenue arr be represent year year growth gaap loss operation be expect be range better previous guidance loss gaap net loss be expect be range cent cent share fiscal year narrower previous guide range loss cent share management still forecast end cash balance sep model now expect cash flow operation be breakeven slightly positive fourth quarter model expect ebitda be positive fiscal management expect be cash flow positive operation back half company also plan payback portion debt related revita acquisition fiscal zack rank stock model have zack rank hold better rank stock broader technology sector include alibaba group baba free report sport zack rank strong buy see complete list today zack rank stock here long term earning growth rate alibaba be project more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
1091,EW,sep issue update research report san francisco base mckesson corporation mck free report health care service information technology company stock currently carry zack rank hold past month mckesson have be trading broader industry last trading price stock have gain higher broader market gain company continue witness strong growth pharma biotech backed solid market fundamental plan growth strategy raise guidance be also encourage mckesson deliver disappointing result recently report first quarter fiscal adjust earning revenue miss zack consensus estimate quarter see strong performance distribution solution segment segment be expect remain consistent performance fiscal weak pricing trend customer consolidation boost growth company recently acquire covermymed approximately come guidance distribution solution business revenue growth be expect witness robust growth year year basis upside be expect be drive market growth acquisition mckesson expect gaap earning diluted share fiscal end mar adjust earning same period be expect range diluted share flipside pricing pressure independent retail pharmacy channel be headwind mckesson enter fiscal assumption brand inflation mid single digit first quarter slightly surpass expectation mckesson have be witness increase price competition independent retail pharmacy channel eventually result reduce volume company continue witness competitive market selling generic pharmaceutical unite state however expect overcome independent pharmacy sell side pricing impact end second quarter fiscal cutthroat competition niche market currency headwind reimbursement issue remain challenge estimate revision estimate revision trend mckesson have be unfavorable moment current quarter analyst moved south compare movement opposite direction last month result magnitude full year estimate fall key picksa few better rank medical stock medical sector be edward lifescience corporation ew free report lantheus holding inc lnth free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy lantheus holding idexx carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month idexx have long term expect earning growth rate stock have gain last year new report investor guide have become more frequent destructive ever fact re expect cause year damage cybersecurity industry be expand quickly response threat fact project year be spend protect consumer corporate asset zack have just release cybersecurity investor guide locking profit reveal promising investment candidate download new report now
1092,EW,renown information technology service provider healthcare organization allscript healthcare solution inc mdrx free report announce have enter strategic partnership elligo health research agreement company focus assist clinician conduct clinical trial study own clinic aforementioned partnership clinical trial manage clinical research organization cro be help bring new treatment patient major therapeutic area combine offer enable physician directly participate study investigator select cro clinical trial provide patient benefit more direct comprehensive care additionally physician be able generate research revenue cover investigator fee associate trial procedure allscript proprietary eparticipate service be available cro allscript professional ehr allscript touchwork ehr allscript sunrise cro market be become more more lucrative company estimate continue increase investment support bring new clinical therapy market more payment study investigator eparticipate expand reach clinical trial investment enable allscript research capable site become study investigator elligo health infrastructure service allscript physician have access clinical trial several therapeutic area include neurology pain urology pulmonology oncology woman health key area focus cro past month allscript have outperformed broader industry stock have gain compare loss industry belong allscript be lead provider healthcare information technology solution look forward management be focuse various restructure initiative such streamline operational efficiency increase cater client need believe favorable demographic trend reinforce supportive regulatory environment be expect sustain growth demand service higher client demand company population health management solution healthcare system hospital ambulatory market also drive growth long haul zack rank key picksallscript healthcare currently carry zack rank hold few better rank medical stock be edward lifescience corp ew free report lantheus holding inc lnth free report align technology inc algn free report edward lifescience align technology sport zack rank strong buy lantheus holding carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have gain last month align technology have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month surprising tech stock keep eye ontech stock have be major force market record high pick best one buy be tough simple way invest success entire sector zack have just release special report reveal thing tech company literally function more importantly reveal top stock set skyrocket increase demand device encourage get report now next wave innovation really take see stock now
1093,EW,world first pharmacy lead health wellbeing enterprise walgreen boot alliance wba free report have recently come center health wellbeing research put progressive foot forward achieve strategic goal value creation healthcare company be contain more walgreen outcome study complete past year research area center health wellbeing research provide access care patient experience adherence clinical outcome digital health member engagement health care cost hiv specialty pharmacy vaccination other twin target new online institution intend help improve patient care outcome scientific research reasonable health care cost walgreen center health wellbeing research team comprise more walgreen health service researcher clinician statistician public health practitioner actuary datum scientist notably be also quite few scientific research partner walgreen dedicate enhance healthcare value academic institutes be johns hopkin medicine johns hopkin bloomberg school public health scripps translational science institute university california san francisco school pharmacy university chicago medicine several research study have already be publish entire team such study be pharmacy patient enrolled medicare prescription drug plan company study find patient be late refill prescription receive reminder call local walgreen pharmacist demonstrated nearly greater adherence first day expect refill date context let brief few line company earlier announce strategic goal aim maximize scope scale time plan reflect significant value create opportunity company drive long term shareholder value also focus improve core performance term price performancein past month walgreen have be see outperform industry respect share price movement stock have gain ahead industry rise period zack rank key pickswalgreen currently carry zack rank hold few better rank medical stock be edward lifescience corp ew free report lantheus holding inc lnth free report align technology inc algn free report edward lifescience align technology sport zack rank strong buy lantheus holding carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have gain last month lantheus holding have long term expect earning growth rate stock have surge last month align technology have long term expect earning growth rate stock have rally roughly last month simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
1094,EW,medication supply management adherence tool provider omnicell inc omcl free report recently advanced patient management access portal pmap new enhancement help improve patient outcome notably single web base portal host functionality guide track patient note intervention appointment also provide detailed information patient respective pharmacist identify prepare document ongoing patient engagement latest enhancement pmap include target adherence intervention patient be new chronic therapy also be time med dashboard provide pharmacist individualized performance snapshot enhancement also consist single sign integration third party software help pharmasist assist patient medicare plan option immunization solution aid identify need vaccination simplify pharmacist omnicell advancement together make pmap more comprehensive web portal prompt pharmacist provide personalize care medically complex patient maintain effective service further good news be initiative lead curb healthcare cost datum provide omnicell currently more american be take more maintenance medication daily however only half chronic condition patient require medication do not take prescribe account treatment failure death annually person gradually realize importance medication adherence market potential pmap web portal seem huge expect latest feature enhancement pmap result better market adoption system most part past month omnicell share price consistently underperform industry however company have picked steam post impressive second quarter result year year increase earning revenue accordingly stock have surge significantly ahead industry gain omnicell putt effort product innovation research development expect company maintain bullish momentum go ahead zack rank key picksomnicell currently carry zack rank hold few better rank medical stock be edward lifescience corp ew free report lantheus holding inc lnth free report align technology inc algn free report edward lifescience align technology sport zack rank strong buy lantheus holding carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have gain last month lantheus holding have long term expect earning growth rate stock have soar last month align technology have long term expect earning growth rate stock have rally roughly last month simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
1095,EW,steris plc ste free report report first quarter fiscal adjust earning share ep cent year quarter adjust ep figure also surpass zack consensus estimate cent report basis quarter ep come cent year year revenue detailsteris generate revenue year year however top line beat zack consensus estimate year year decline be result foreign currency fluctuation well divest business organic revenue growth constant currency be year year primarily drive balanced growth segment steris plc price consensus ep surprise steris plc price consensus ep surprise steris plc company operate segment healthcare product healthcare specialty service apply sterilization technology life science revenue healthcare product segment inched year year report quarter be drive growth service revenue increase capital equipment revenue turn be partially offset dip consumable due divestiture revenue healthcare specialty service segment plunge report basis due divestiture however organic revenue grow reflect growth im north america csd outsource business europe other hand revenue apply sterilization technology rise organic revenue growth be back increase volume segment core medical device customer lastly revenue life science segment drop quarter growth service revenue increase consumable revenue be more offset decrease capital equipment revenue organic basis revenue nudge year year marginsadjusted gross margin improve basis point bps year year report quarter expansion be account positive impact divest low margin business improvement operational efficiency favorable foreign currency cost synergy pricing steris witness year year rise selling general administrative expense research development expense fall adjust operate margin expand bps year year basis report quarter financial detailssteris exit first quarter fiscal cash cash equivalent compare end fiscal company have long term debt end first quarter fiscal compare end fiscal company generate cash flow operation first quarter year period free cash flow period be compare prior year time frame guidancesteris continue expect organic revenue growth constant currency basis fiscal prior fiscal year adjust ep be expect range share takesteris post better expect first quarter fiscal earning revenue beating zack consensus estimate however year year decline revenue be disappointment positive note organic growth performance be strong segment further growth free cash flow reserve be indicative company strong cash balance recently company have make couple organizational change expect better align operation zack rank key pickssteris currently have zack rank buy few other top rank medical stock be edward lifescience corp ew free report insys therapeutic inc insy free report align technology inc algn free report sporting zack rank strong buy see complete list today zack rank stock here edward lifescience second quarter adjust earning improve stupendous year year primarily drive strong sale growth company transcatheter heart valf business stock have gain surprise last month insys therapeutic gross profit margin be second quarter flat year year align technology second quarter adjust ep cent be substantial year year revenue grow year year stock have surge roughly last month more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
1096,EW,bioscrip inc bio free report report net loss continue operation cent share second quarter compare net loss cent year zack consensus estimate be peg loss cent revenueswith completion company core pbm business divestment treat discontinue operation previous quarter bioscrip currently have simplified business structure focuse core infusion service revenue continue operation second quarter fall year year also miss zack consensus estimate year year decline be due company shift strategy focus grow core revenue mix couple impact cure act contract modification be partially offset synergy home solution acquisition bioscrip inc price consensus ep surprise bioscrip inc price consensus ep surprise bioscrip inc quotegross profit second quarter be year year gross margin also expand basis point bps adjust operate income be mark year year increase rise adjust operate expense adjust operate margin expand bps year year exit second quarter cash cash equivalent significantly record end first quarter guidance intactbioscrip reiterate guidance adjust ebitda range full year guidance incorporate estimate adverse effect cure act legislation company estimate regard contract company have update revenue outlook range include impact revise contract revenue zack consensus estimate revenue lie company guide range takebioscrip exit second quarter dismal note wider expect loss revenue miss zack consensus estimate management guidance include negative impact cure act legislation also add concern nonetheless be encourage company progress second quarter courtesy new multus faceted core plan be adopt improve financial position further company achieve annualize supply chain improvement roughly acquisition home solution company expect core revenue home solution continue core growth prove accretive also be upbeat company raise number immunoglobulin ig therapy stock previous quarter zack rank other key picksbioscrip have zack rank buy few other top rank medical stock be edward lifescience corporation ew free report insys therapeutic inc insy free report align technology inc algn free report notably edward lifescience insys therapeutic align technology sport zack rank strong buy see complete list today zack rank stock here insys therapeutic have long term expect earning growth rate stock post stellar quarter average earning surprise align technology have expect long term adjust earning growth almost stock have add roughly last month edward lifescience have long term expect earning growth rate stock have gain last month more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
1097,EW,biotelemetry inc beat free report report second quarter adjust earning cent share beat zack consensus estimate cent year equivalent couple cent revenue detailsrevenue increase year year almost line zack consensus estimate upside have be primarily drive increase healthcare revenue owing rise mcot patient however be partially offset impact slower medicare rate effective jan notably marked consecutive quarter year year revenue growth meanwhile research revenue increase lead imaging study volume growth full quarter impact acquisition virtualscopic partially offset lower cardiac revenue technology revenue increase higher sale wireless blood glucose monitor telcare division biotelemetry inc price consensus ep surprise biotelemetry inc price consensus ep surprise biotelemetry inc profit increase year quarter primarily drive increase revenue gross margin contract basis point bps due impact medicare rate reduction acquisition carry lower margin exist business decline be partially offset volume drive efficiency adjust operate expense totale reflect increase year quarter upside be lead increase selling marketing research development expense year year respectively meanwhile adjust operate margin expand bps financial exit second quarter cash cash equivalent compare end first quarter guidancepost acquisition lifewatch biotelemetry currently expect full year revenue range zack consensus estimate full year revenue be peg company expect revenue third quarter fourth quarter company also expect time expense related acquisition approximately be further expect be reflect third quarter result exit second quarter strong note earning exceed zack consensus estimate revenue meeting same raise full year revenue guidance be also encourage company also register growth segment be encourage note company be putt effort product innovation research development company recently complete acquisition lifewatch ag post acquisition company be look prospect solidify position cardiac monitoring however decline gross margin be matter concern zack rank key have zack rank hold few better rank medical stock be edward lifescience corporation ew free report insys therapeutic inc insy free report align technology inc algn free report notably edward lifescience insys therapeutic align technology sport zack rank strong buy see complete list today zack rank stock here insys therapeutic have long term expect earning growth rate stock post stellar quarter average earning surprise align technology have expect long term adjust earning growth almost stock have add roughly last month edward lifescience have long term expect earning growth rate stock have gain last month more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
1098,EW,lead distributor health care product service henry schein inc hsic free report be constantly focuse expand dental business account nearly half total revenue keep line henry schein dental enter agreement distribute caek inc flagship product health insurance portability accountability act hipaa software layercompliance notably caek be software service saas company focuse compliance related software healthcare industry layercompliance be cloud base tool help doctor navigate requirement hipaa notably hipaa be federal law provide privacy security standard protect patient health information layercompliance help user manage datum security program online dashboard tool help streamline process oral health care expenditure dental industry be likely rise increase population believe boost demand henry schein product service well meanwhile management have enter year agreement dentsply sirona broaden henry schein digital dentistry product line moreover second quarter henry schein announce extension agreement dentsply sirona extend agreement be valid dec henry schein include cerec cad cam restoration system schick line imaging sensor henry schein also be entitle represent entire dentsply sirona product line start sep addition henry schein continue offer planmeca shape well dental equipment consumer product longstanding partner kavo kerr brand past year henry schein have outperformed broader industry stock have gain compare gain broader industry zack rank key pickshenry schein currently carry zack rank hold few better rank medical stock be edward lifescience corp ew free report lantheus holding inc lnth free report align technology inc algn free report edward lifescience align technology sport zack rank strong buy lantheus holding carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have gain last month align technology have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
1099,EW,headquarter irvine medical device major edward lifescience corporation ew free report specialize advanced cardiovascular disease especially structural heart disease stock be healthy growth trajectory late have rally last month ahead gain broader industry stock have market cap company year historical growth rate be also favorable compare broader industry solid prospect zack rank strong buy stock be attractive pick company estimate revision trend current quarter have also be positive past day analyst moved north movement opposite direction magnitude estimate revision increase cent share same time frame let find recent positive trend be sustainable edward lifescience second quarter performance be quite promising company beating zack consensus estimate revenue earning moreover raise guidance hint brighter prospect fact guidance raise be backed strong performance company product line market be also upbeat edward lifescience recent fda approval inspiris resilium aortic valve be first class resilient heart valf company also announce receipt fda approval aortic mitral valve valve procedure used edward lifescience sapien transcatheter heart valve believe recent fda approval several product have be boost investor confidence stock be encourage edward lifescience focus build pipeline further strengthen foothold operate business company also witness growth emerge portfolio mitral tricuspid repair therapy latest plan company new ultra system include balloon delivery system next generation sheath technology be expect be available europe second half company be track initiate launch acumen hpi software suite new flotrac iq smart disposable inspiris resilium aortic valve europe japan end however stiff competition currency headwind reimbursement issue be challenge stock other key picksother top rank medical stock be idexx laboratory inc idxx free report lantheus holding inc lnth free report align technology inc algn free report align technology sport zack rank lantheus holding idexx laboratory carry zack rank buy cansee complete list today zack rank stock here align technology have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month idexx laboratory have long term expect earning growth rate stock have gain last month simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
1100,EW,initiative boost long term strategy growth strategy fresenius medical care fms free report recently sign agreement acquire outstanding share nxstage medical nxtm free report share transaction have be value be subject close approval nxstage stockholder other customary condition fresenius expect acquisition prove accretive earning year deal closure furthermore deal be expect provide annual pretax cost saving next year fresenius also expect integration cost next year time announcement management takeover boost revenue care coordination segment regard last quarter margin care coordination decline substantially year year basis owing lower profit vascular service higher cost pharmacy service believe latest development help company counter pressure margin growth strategy glanceper management latest development be significant step boost company grand long term goal fresenius have set strong long term objective growth strategy formulate few initiative attain solid market traction postulate growth strategy fresenius aim boost revenue corresponding average annual growth rate enhance core business care coordination unit meanwhile full year fresenius estimate revenue growth cc net income attributable shareholder company be likely increase share shine brightmeanwhile stock represent solid return compare favorably broader industry gain just last month furthermore fresenius promise long term expect earning growth rate almost indicate chance outperformance long haul note fresenius sport zack rank strong buy courtesy solid estimate revision trend estimate move north last month full year notably current year estimate stock rise share same time frame takefresenius provide wide range dialysis product own dialysis clinic third party clinic company offer wide array hemodyalisis peritoneal dialysis acute dialysis product well however latest development be expect fortify company foothold home dialysis market particularly renal care space datum news long island global renal dialysis market be expect see cagr reach worth key picksa few other top rank stock broader medical sector be edward lifescience corporation ew free report idexx laboratory inc idxx free report notably edward lifescience sport zack rank idexx laboratory have zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate notably stock have return last month idexx laboratory have long term expect earning growth rate additionally stock represent impressive year return more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
1101,EW,myriad genetic inc mygn free report report adjust earning share ep cent fourth quarter fiscal year year however adjust ep beat zack consensus estimate cent surpass company guide range cent include time item company report net income earning cent share quarter exhibit decline respectively fiscal company adjust ep come year number full year ep figure exceed zack consensus estimate revenuestotal revenue rise year year fourth quarter figure also outpaced company guidance top line exceed zack consensus estimate theyear year rise top line be primarily account sequential growth hereditary cancer revenue strong result genesight myriad genetic inc price consensus ep surprise myriad genetic inc price consensus ep surprise myriad genetic inc fiscal company report revenue equivalent figure fiscal top line also steer past zack consensus estimate quarter detailssegment wise molecular diagnostic test total revenue record total revenue year year mainly account rise endopredict testing revenue genesight revenue grow year year report quarter prolaris testing space company witness more market penetration thereby register revenue quarter experience fall year year however hereditary cancer testing revenue drop year year deliver third consecutive quarter sequential growth testing volume year year vectra da testing revenue come year year other testing revenue fall other hand pharmaceutical clinical service revenue accounting rest quarter be show year year decline margin trendsgross margin quarter review expand basis point bps accord management improvement gross margin be attribute improve efficiency hereditary cancer business genesight laboratory operate expense rise owing rise selling general administrative sg expense research development expense however decline report quarter overall operate margin contract stupendous bps financial positionmyriad genetic exit fiscal cash cash equivalent marketable security compare end fiscal end fiscal cash flow operation totale year comparable period consequently free cash flow gross compare fiscal guidancemyriad genetic have provide guidance fiscal company currently expect revenue range zack consensus estimate lie guide range bottom line front company expect generate adjust ep range current zack consensus estimate be higher company guidance management have provide outlook first quarter fiscal company estimate adjust earning share cent total revenue zack consensus estimate adjust ep cent revenue exceed company guide range viewmyriad genetic end fiscal solid note fourth quarter number exceed zack consensus estimate thecompany particularly observed strong growth endopredict genesight testing revenue sequential rise hereditary cancer volume flip side unfavorable foreign currency translation continue threat company considerable portion revenue come outside company face risk exchange rate fluctuation additionally macroeconomic uncertainty higher expense owing extensive pipeline testsmay impact company margin zack rank other key picksmyriad genetic have zack rank buy few other top rank medical stock be edward lifescience corporation ew free report insys therapeutic inc insy free report align technology inc algn free report notably edward lifescience insys therapeutic align technology sport zack rank strong buy see complete list today zack rank stock here insys therapeutic have long term expect earning growth rate stock post stellar quarter average earning surprise align technology have expect long term adjust earning growth almost stock have add roughly last month edward lifescience have long term expect earning growth rate stock have gain last month more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
1102,EW,dentsply sirona inc xray free report report adjust earning share ep cent second quarter miss zack consensus estimate penny earning be also lower cent record year quarter quarter detailsnet sale decrease year period also figure lag zack consensus estimate sale combine business decrease constant currency cc exchange rate report quarter sale be affected inventory reduction related change distribution strategy north america lower equipment sale end user quarter sale fall net sale europe increase sale combine business decline cc european sale rise net sale rest world decrease sale rest world combine business rise cc segment business be organized report segment dental healthcare consumable technology dental healthcare consumable comprise preventive restorative instrument endodontic laboratory dental product well consumable medical device product sale increase cc sale segment rise year year quarter technology consist dental implant cad cam system imaging system treatment center orthodontic product net sale decrease cc sale combine business fall report quarter dentsply sirona inc price consensus ep surprise dentsply sirona inc price consensus ep surprise dentsply sirona inc quotefinancial updatetotal cash cash equivalent company decrease jun dec cash generate operation first half be compare year period jun company long term debt be versus year end company anticipate adjust ep range zack rank key pickscurrently dentsply carry zack rank hold few better rank stock broader medical sector be edward lifescience corporation ew free report fresenius medical care corporation fms free report dextera surgical inc notably edward lifescience fresenius medical sport zack rank strong buy dextera have zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate notably stock have return last month fresenius medical yielded strong return year date stock have long term expect earning growth rate dextera have project sale growth current year stock promise long term expect earning growth rate more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
1103,EW,nextgen healthcare information system wholly own subsidiary irvine base quality system inc qsii free report recently complete acquisition eagledream health inc roughly cash eagledream health be cloud base analytic optimize understand clinical financial administrative datum enhance practice performance follow acquisition nextgen healthcare gain facility provide enrich care experience accelerate patient engagement ambulatory clinic health system management further expect achieve capita cost efficiency well enhance work life balance clinician staff interestingly company have be acquisition spree long earlier year nextgen healthcare have acquire entrada inc provider cloud base solution healthcare company have already start gain deal first quarter fiscal result subscription revenue be significantly strength entrada believe eagledream health acquisition also prove accretive company notably company have successfully add revenue cycle management rcm solution analytic patient management regulatory clinical tool product portfolio acquisition believe company continue pursue strategic acquisition not only expand product portfolio also strengthen competitive position report bymedgadget healthcare information system market be expect reach value cagr consider market potential quality system current development acquisition seem be strategic quality system have be gain investor confidence consistent positive result past month company share price have outperformed industry stock have gain higher industry gain company have also outperformed gain market same time frame however healthcare information system service market be highly competitive also industry be exceedingly fragmented include numerous player athenahealth inc athn free report mckesson corporation mck free report other zack rank key pickquality system currently have zack rank hold better rank medical stock be edward lifescience corporation ew free report zack rank strong buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have gain last month simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
1104,EW,idexx laboratory inc idxx free report lead manufacturer product service primarily companion animal veterinary have rally last month beating gain stock have market cap company year historical growth rate be also favorable compare broader industry also company represent return almost better broader industry gain last year solid prospect zack rank buy stock be attractive pick moment company estimate revision trend current year have also be positive past day analyst moved north movement opposite direction magnitude estimate revision earning rise share same time frame let find recent positive trend be sustainable recently idexx end second quarter solid note earning revenue beating zack consensus estimate stellar quarterly performance be drive company companion animal business companion animal market fundamental remain solid tremendous global runway growth management unique innovation base multus modality global strategy enabled enhance commercial capability accelerate recur cag diagnostic revenue growth moreover strong top line growth quarter be drive considerable contribution rest business segment also idexx recently announce addition rvetlink portfolio technology application notably rvetlink be advanced inclusive referral management solution design specialty care hospital simplify referral procedure primary care specialty care veterinarian apart idexx continue display solid growth respect international expansion company have be significantly benefitting companion animal market emerge nation demonstrate bountiful opportunity additionally company have strong cash balance enable carry share repurchase program turn provide solid return investor flip side foreign currency fluctuation be major headwind company concern be company high reliance third party distributor purchasing dynamic distributor have significant impact company sale instrument consumable rapid assay product also company face higher operate expense pertain increase head count higher investment target growth acceleration geographical expansion unite state internationally portfolio expansion moreover competitive landscape domestic overseas market weigh idexx performance other key picksother top rank medical stock be edward lifescience corp ew free report steris plc ste free report lantheus holding inc lnth free report edward lifescience sport zack rank strong buy steris lantheus holding carry zack rank see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have gain last month steris have positive earning surprise trail quarters stock have gain last month lantheus holding have long term expect earning growth rate stock have gain last month simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
1105,EW,growth stock be most exciting pick market high flyer captivate investor attention produce big gain well however also lead downside growth story be so be important find company be still see strong growth prospect business such company be well position future earning growth be edward lifescience corporation ew free report firm be medical instrument industry see ep growth last year be look great year too fact current growth estimate year call earning share growth furthermore long term growth rate be currently impressive suggest pretty good prospect long haul edward lifescience corporation price consensus edward lifescience corporation price consensus edward lifescience corporation wasn enough stock have actually see estimate rise past month current fiscal year thank rise earning estimate ew have zack rank strong buy further underscore potential outperformance company see complete list today zack rank stock here so be look fast grow stock be still see plenty opportunity horizon make sure consider ew not only do have double digit earning growth prospect impressive zack rank suggest analyst believe better day be ahead ew well simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
1106,EW,california base align technology inc algn free report designer manufacturer invisalign system have rally last month ahead gain stock have market cap company year historical growth rate be also favorable compare broader industry also company represent return almost better broader industry gain last year solid prospect zack rank strong buy stock be attractive pick present company estimate revision trend current year have also be positive past day analyst moved north movement opposite direction magnitude estimate revision increase share same time frame let find recent positive trend be sustainable recently align technology end second quarter solid note earning revenue beating zack consensus estimate moreover align technology be add standard poor index jun company have be add gic health care supply sub industry index have bolster investor confidence stock imply promising prospect ahead same month company announce encourage step strengthen position invisalign brand most popular product line keep strategy expand invest rapidly grow asia pacific region align technology announce plan build first invisalign manufacturing facility china company announce receipt patent smarttrack aligner material be exclusively used invisalign aligner treatment move bid gain traction same platform mar align technology collaborate digital design post collaboration align technology invisalign clear aligner treatment be used dentist tooth alignment procedure design protocol be also upbeat multus dollar marketing campaign initiate company invisalign brand order gain increase awareness be also optimistic company expand work flow option lead itero scanner context align technology recently launch software upgrade itero element intraoral scanner be capable compare patient scan time new timelapse technology additionally company have strong cash balance enable carry share repurchase program turn provide solid return investor however include unfavorable foreign currency affect company revenue also company be expose seasonal demand fluctuation higher operate expense pertain increase head count higher investment target growth acceleration geographical expansion portfolio expansion other key picksother top rank medical stock be edward lifescience corp ew free report steris plc ste free report lantheus holding inc lnth free report edward lifescience sport zack rank steris lantheus holding carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have gain last month steris have positive earning surprise trail quarters stock have gain last month lantheus holding have long term expect earning growth rate stock have gain last month hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1107,EW,illinois base global medical device company abbott laboratory free report recently sign manage equipment service contract north west london pathology nwlp host imperial college healthcare nhs trust abbott expect alliance solidify footprint rapidly grow diagnostic market term collaboration abbott be authorize supplier analytical equipment consumable cover abbott alinity ci alinity series diagnostic instrument aliniq provide professional service informatic solution also nwlp alliance presently cover pathology market be expect execute test year future abbott have be focuse gain traction diagnostic segment june company receive ce mark alinity hq have become fifth new diagnostic system be launch europe ongoing rollout instrument area immunoassay clinical chemistry blood screening point care interestingly abbott rake total revenue diagnostic segment recently report second quarter recent development be expect help company gain further traction space report global market molecular diagnostic be project reach value cagr consider market potential abbott current development diagnostic space collaboration seem be strategic believe agee population unhealthy lifestyle rise awareness expenditure healthcare continue drive growth diagnostic market however market be dominate well establish player quest diagnostic inc dgx free report qiagen qgen free report moreover abbott have be gain investor confidence consistent positive result past month company share price have outperformed broader industry stock have gain higher broader industry gain company have also outperformed gain market same time frame zack rank key picksabbott currently have zack rank hold better rank medical stock be edward lifescience corporation ew free report zack rank strong buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have gain last month hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1108,EW,share price sunnyvale base intuitive surgical inc isrg free report scale new week high aug eventually close bit lower company have gain last month much better rise broader industry gain take stable performance stock consideration expect intuitive surgical scale higher come quarters company positive long term growth also hold promise average volume share trade last year be remarkable approximately stock have market cap last day analyst have raise earning estimate current year have slash estimate net effect have take zack consensus estimate current quarter share market be upbeat intuitive surgical licensing agreement justright surgical deal enable intuitive surgical global license justright surgical intellectual property energy base vessel sealing tissue stapling technology use robotic field joint product development equity financing arrangement be also part agreement intuitive surgical inc price consensus intuitive surgical inc price consensus intuitive surgical inc quotealso company post impressive second quarter earning revenue register year year increase quarter company also witness growth segment international performance be also encourage believe grow adoption intuitive surgical da vinci system physician general surgery oncology urology gynecology procedure be key catalyst moreover increase procedural volume outside unite state open considerable opportunity company company be further putt effort product innovation research development regard recent fda approval da vinci instill confidence investor apart company be expect gain prominence europe asia enhance organizational capability further drive stock price zack rank key picksintuitive carry zack rank hold few better rank medical stock be edward lifescience corp ew free report lantheus holding inc lnth free report align technology inc algn free report edward lifescience align technology sport zack rank strong buy lantheus holding carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have gain last month align technology have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1109,EW,penumbra inc pen free report report second quarter loss share cent compare unfavorably earning cent year quarter loss figure be line zack consensus estimate revenue report quarter rise year year constant exchange rate cer exceed zack consensus estimate geographic basis second quarter revenue represent total sale gross year quarter figure same cer meanwhile international sale total sale advanced year year cer penumbra inc price consensus ep surprise penumbra inc price consensus ep surprise penumbra inc quotego product category revenue neuro product grow cer second quarter revenue peripheral vascular product business rise second quarter reflect increase cer year year operational updatepenumbra second quarter gross margin be reflect basis point bps contraction year year account rise cost revenue however gross profit rise research development expense totale sale general administrative expense amount year year operate loss report quarter come massively wider operate loss prior year quarter financial updatepenumbra exit second quarter cash cash equivalent compare end first quarter takepenumbra exit second quarter mixed note company report impressive top line result revenue exceed zack consensus estimate loss figure be line same year year comparison earning be unfavorable company witness strong growth geography product line company be putt effort product innovation research development however escalate cost expense affected margin penumbra be active player fast grow interventional therapy space fact company product primarily cater unmet clinical need major market neuro peripheral vascular zack rank key pickspenumbra have zack rank hold few better rank medical stock be edward lifescience corporation ew free report insys therapeutic inc insy free report align technology inc algn free report notably edward lifescience insys therapeutic align technology sport zack rank strong buy see complete list today zack rank stock here insys therapeutic have long term expect earning growth rate stock post stellar quarter average earning surprise align technology have expect long term adjust earning growth almost stock have add roughly last month edward lifescience have long term expect earning growth rate stock have gain last month more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
1110,EW,murray hill nj base bard inc announce majority shareholder have approve merger becton dickinson company bdx free report holder approximately bard share participate vote favore merger management expect complete merger fourth quarter dealon apr becton dickinson lead global medical technology company announce acquire bard agreement be expect close fourth quarter view acquisition strategic fit generate benefit complementary business geographical expansion believe development provide benefit medication management infection prevention bard customer bolster foothold global medical device market regard company have register more product internationally full year sum acquisition be expect strengthen combine entity footprint home healthcare market note research report market market reveal home healthcare market be expect reach total grow cagr however combine entity be likely face challenge regard integration new business cost associate apart increase competition delay order renewal process constricted federal spending be other concern key pickscurrently bard carry zack rank hold few better rank stock broader medical sector be edward lifescience corporation ew free report dextera surgical inc notably edward lifescience sport zack rank strong buy dextera have zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate notably stock return last month dextera have project sale growth current year stock promise long term expect earning growth rate more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
1111,EW,aug issue update research report san francisco base mckesson corporation mck free report health care service information technology company mckesson post disappointing result first quarter fiscal adjust earning revenue miss zack consensus estimate company currently have zack rank hold quarter see strong performance distribution solution segment segment be expect keep performance fiscal weak pricing trend customer consolidation boost growth company recently acquire covermymed approximately come guidance distribution solution business revenue growth be expect witness robust growth year year basis upside be expect be drive market growth acquisition mckesson expect gaap earning diluted share fiscal end mar adjust earning same period be expect range diluted share flipside pricing pressure independent retail pharmacy channel be headwind mckesson enter fiscal assumption brand inflation mid single digit first quarter slightly surpass expectation mckesson have be witness increase price competition independent retail pharmacy channel eventually result reduce volume company continue see competitive market selling generic pharmaceutical however mckesson expect overcome independent pharmacy sell side pricing impact end second quarter fiscal furthermore cutthroat competition niche market currency headwind reimbursement issue remain challenge stock performance estimate revision trendover last month mckesson have be trading broader industry company have gain compare favorably broader industry return just current level be also higher return only same time frame estimate revision trend mckesson have be unfavorable moment current quarter analyst moved south compare movement opposite direction last month result magnitude full year estimate fall same time frame key picksa few better rank stock broader medical sector be edward lifescience corporation ew free report masimo corporation masi free report idexx laboratory inc idxx free report notably edward lifescience sport zack rank strong buy idexx laboratory masimo corporation have zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate notably stock have return last month masimo yielded strong return year date stock have long term expect earning growth rate idexx laboratory have long term expect earning growth rate additionally stock represent impressive year return hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1112,EW,medical device major medtronic plc mdt free report be focuse expand core coronary structural heart business keep line company recently announce global randomize clinical trial evaluate month dual antiplatelet therapy dapt patient implanted resolute onyx drug eluting stent de percutaneous coronary intervention pci procedure dapt be combination aspirin clot medication notably resolute onyx de be first de work core wire technology evolution continuous sinusoid technology cst resolute onyx de provide enhance visibility surgeon deliver superior clinical performance accord medtronic resolute onyx month dapt study aim help inform dapt guideline newer generation de currently support bare metal stent bms stable ischemic heart disease patient require shorter dual antiplatelet regimen study also demonstrate medtronic clinical investment provide relevant dapt evidence physician current previous generation de dapt therapy guideline vary geographically well patient presentation duration dapt evaluation be make base individual clinical judgment evaluate benefit risk ratio product labele patient preference study be base approximately patient worldwide company press release resolute onyx month dapt study outcome build resolute pooled dapt interruption analysis show increase risk stent thrombosis dapt interruption discontinuation month take consideration huge grow global coronary stent market believe latest initiative medtronic be well time report transparency market research global coronary stent market be expect see cagr recent development coronary stentrecently medtronic announce de have meet primary endpoint target lesion failure tlf year treatment coronary artery disease extra small vessel also late resolute onyx de receive fda approval further post successful launch resolute onyx de medtronic have start selling japan market jul cardiovascular business report release jul note last month medtronic have outperformed index latest share price movement company have gain compare gain zack rank key picksmedtronic currently carry zack rank hold few better rank medical stock be edward lifescience corp ew free report lantheus holding inc lnth free report align technology inc algn free report edward lifescience align technology sport zack rank strong buy lantheus holding carry zack rank see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have gain last month align technology have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1113,EW,illinois base global medical device company abbott laboratory free report partner bigfoot biomedical solidify footprint rapidly grow diabetes therapeutic market leverage abbott freestyle libre glucose sense technology collaboration result innovation marketing insulin delivery system alliance help company develop patient friendly insulin delivery system calibration glucose sensor management important trial combine technological system be project initiate clinical research site abbott have be move steadily development diabetic segment recently company announce receipt health canada license freestyle libre flash glucose monitoring system further stimulate growth diabetes care sale segment be first quarter continue consumer acceptance freestyle libre internationally expect freestyle libre further contribute abbott top line canadian development french health ministry recently approve national reimbursement device report mordor intelligence global market diabetes care device be project value witness cagr moreover insulin delivery device market be expect see cagr roughly thus consider market potential abbott current development diabetes care segment collaboration seem be lucrative strategically align believe agee population unhealthy lifestyle rise awareness expenditure healthcare continue drive growth diabetes market however market be dominate many well establish player johnson johnson jnj free report be most prominent space johnson johnson also have tie base corporation successfully develop innovate insulin delivery system moreover abbott have be gain investor confidence consistent positive result past month company share price have outperformed zack categorize medical instrument sub industry stock have gain higher broader industry gain company have also outperformed gain market same time frame zack rank other key picksabbott currently have zack rank buy few other top rank medical stock be edward lifescience corporation ew free report abiom inc abmd free report notably edward lifescience sport zack rank strong buy abiom carry zack rank see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have gain last month abiom have long term expect earning growth rate stock have gain last month more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1114,EW,share pennsylvania base biotelemetry inc beat free report rally new week high aug close tad lower represent strong year date return approximately better same time frame biotelemetry provide cardiac monitoring service cardiac monitoring device manufacturing stock sport zack rank strong buy majority last month company share price have considerably outperformed broader industry stock have rally last month outshine industry return just same time frame notably biotelemetry have market cap take stable performance stock consideration expect biotelemetry scale higher come quarters company long term growth also hold promise regard growth catalystsq result solid biotelemetry exit second quarter strong note earning exceed zack consensus estimate revenue meeting same revenue increase year year primarily drive increase healthcare revenue owing rise mcot patient notably marked consecutive quarter year year revenue growth company also register growth segment be encourage note company be putt effort product innovation research development however decline gross margin be matter concern lifewatch acquisition july biotelemetry announce acquisition lifewatch ag deal value buyout biotelemetry enhance position wireless medicine space expand product profile customer base cardiac monitoring diagnostic service space management expect acquisition yield significant synergy next month company make product be utilize remotely monitoring cardiac care patient guidance strong raise full year revenue guidance be encourage post acquisition lifewatch biotelemetry currently expect full year revenue range zack consensus estimate full year revenue be peg company expect revenue third quarter fourth quarter company also expect time expense related acquisition approximately be further expect be reflect third quarter result estimate revision trend estimate revision trend biotelemetry be favorable moment full year analyst moved north compare movement opposite direction last month result full year estimate jump same time frame current quarter analyst moved north compare movement opposite direction last month zack consensus estimate current quarter rise cent same time frame biotelemetry inc price consensus biotelemetry inc price consensus biotelemetry inc quotekey picksother top rank stock broader medical sector be edward lifescience corporation ew free report masimo corporation masi free report idexx laboratory inc idxx free report notably edward lifescience sport zack rank idexx laboratory masimo corporation have zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate notably stock have return last month masimo yielded strong return year date stock have long term expect earning growth rate idexx laboratory have long term expect earning growth rate additionally stock represent impressive year return hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1115,EW,aug issue update research report haemonetic corporation hae free report base lead provider blood management solution customer encompass blood plasma collector hospital health care provider globally stock currently carry zack rank hold past month haemonetic have be trading broader industry stock now have rally compare broader industry increase company exit first quarter fiscal mixed note earning beating zack consensus estimate revenue miss same however year year increase report sale gross margin buoy optimism market be also upbeat haemonetic encourage growth plasma haemonetic management franchise company swung operate income first quarter fiscal loss year quarter haemonetic corporation price consensus haemonetic corporation price consensus haemonetic corporation quotehaemonetic have be witness strong flourish plasma franchise quite time now management have also maintain high confidence continue growth commercial plasma collection business quarter north america plasma disposable revenue increase growth continue be lead strong end market demand plasma derive company hospital business be also progress well teg line product have gain popularity worldwide teg be approve broad set indication top market teg teg manager be sanction same set indication europe australia japan flip side company have be witness sluggish revenue growth blood center franchise significantly affect haemonetic result past few quarters management also doesn expect early recovery blood center outcome macroeconomic uncertainty continue challenge haemonetic management also anticipate slower expect product adoption customer reduce revenue profit also currency fluctuation stiff competition continue hamper stock other key picksa few better rankedmedical stock be edward lifescience corp ew free report steris plc ste free report align technology inc algn free report edward lifescience align technology sport zack rank strong buy steris carry zack rank buy see complete list today zack rank stock here edward lifescience second quarter adjust earning surge stupendous year year primarily drive strong sale growth company transcatheter heart valf business stock have gain last month steris report first quarter fiscal adjust earning share cent year quarter also adjust gross margin improve basis point year year report quarter stock have gain last month align technology second quarter adjust ep cent be substantial year year revenue climb year year stock have rally roughly last month hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1116,EW,aug issue update research report palo alto base varian medical system inc var free report company be world lead provider radiotherapy radiosurgery proton therapy brachytherapy treat cancer other medical condition varian medical have unimpressive run bourse last month trading industry term price performance glimpse share price movement reveal varian medical share have lose compare unfavorably decline industry look forward varian medical oncology proton therapy business growth prospect remain impressive company be address tier mid tier market edge truebeam vitalbeam halcyon product company be winning contract not only americas also emerge international market be huge positive believe china africa present significant top line growth opportunity term company be open new office africa middle east provide growth opportunity region varian medical operate technology drive environment success depend innovation frequent product update company have be successful front evident year year growth top line company have approximately revenue opportunity various oncology imaging component product next year varied offering include truebeam edge platform insightive analytic qumulate qa rapidplan knowledge base treatment plan believe varian medical innovative product pipeline continue drive growth long term apart enjoy dominant market share conventional radiotherapy believe proton therapy also hold significant promise varian medical be probeam compact proton therapy system be superior other external beam radiotherapy precisely locate cancerous tumor cause lesser side effect surround tissue proton therapy system used same interface used company truebeam platform finally company strong overseas presence be expect enable leverage opportunity emerge market line grow demand cancer treatment overseas market varian medical sale europe africa particularly asia be grow faster rate domestic market flip side unfavorable currency translation continue be major dampener stock management fear further strengthen dollar foreign currency lead deteriorate operate result intense competition well possibility varian medical new test not generate meaningful profit outweigh cost associate development continue raise concern zack rank key picksvarian medical carry zack rank hold better rank medical stock be edward lifescience corp ew free report steris plc ste free report align technology inc algn free report edward lifescience align technology sport zack rank strong buy steris carry zack rank buy see complete list today zack rank stock here edward lifescience have positive earning surprise trail quarters stock have gain last month align technology have long term expect earning growth rate stock have rally roughly last month steris have positive earning surprise trail quarters stock have gain last month hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1117,EW,invacare corporation ivc free report recently announce global launch proprietary invacare tdx sp power wheelchair brand wheelchair come equip linx technology motion concept ultra low maxx position system new linx technology allow high end complex rehabilitation need be meet exceptional functionality ease use linx electronic system include touch screen display wireless programming remote monitoring help better clinical evaluation easy intuitive programming seamless connect functionality provider invacare produce aforementioned series wheelchair north american market taylor street manufacturing facility elyrium european customer product be assemble germany tdx sp power wheelchair base be build several invacare core patented technology include surestep suspension stability lock trac tracking technology go forward believe tdx sp wheelchair linx technology help enable long term revenue growth company share invacare have gain last month industry decline invacare be lead manufacturer distributor medical equipment used acute care setting company design manufacture distribute medical device help person move breathe rest perform essential hygiene provide medical device solution congenital acquire degenerative ailment company sell product principally home medical equipment provider retail commerce channel residential care operator distributor government health service north america europe asia pacific zack rank key pickscurrently invacare have zack rank hold few better rank stock broader medical sector be edward lifescience corporation ew free report fresenius medical care corporation fms free report idexx laboratory inc idxx free report notably edward lifescience fresenius medical sport zack rank strong buy idexx laboratory have zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate notably stock have return last month fresenius medical have yielded strong return year date stock have long term expect earning growth rate idexx laboratory have long term expect earning growth rate additionally stock represent impressive year return hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1118,EW,civita solution inc civi free report report third quarter fiscal adjust earning share ep continue operation cent surpass zack consensus estimate penny adjust earning improve year year primarily strong sale growth company post acute specialty rehabilitation service srs adult day health adh service revenue detailscivita solution third quarter revenue rise year year figure however lag zack consensus estimate company gain organic growth acquisition third quarter management organic growth be largely drive strong performance intellectual developmental disability dd also company acquire company report quarter total annual revenue moreover deal mostly cover dd srs adh service line segmental third quarter company report dd revenue reflect growth prior year quarter srs service revenue quarter totale prior year quarter risk youth ary servicesrevenue come report quarter flat third quarter level civita solutionsreport adh revenue reflect growth prior year quarter margin detailsin report quarter civita solution register gross margin basis point bps year year basis owing rise cost revenue general administrative expense decline lead enhance cost efficiency company cost restructure program accordingly adjust operate margin quarter expand bps guidancecivita solution lower high end fiscal revenue guidance company project revenue range lower previous range current zack consensus estimate revenue be peg high end company update guide range takecivita solution exit third quarter mixed note better expect earning revenue miss nonetheless be encourage company progress srs adh fastest grow business moreover company be witness steady contribution strategy grow organically acquisition however tweak fiscal guidance raise concern also even company seem be implement cost restructure program efficiently weak margin continue mar financial peer earning stock have perform well earning season be edward lifescience corp ew free report steris plc ste free report align technology inc algn free report edward lifescience second quarter adjust earning improve stupendous year year primarily drive strong sale growth company transcatheter heart valf business stock have gain last month align technology second quarter adjust ep cent be substantial year year revenue grow year year stock have rally roughly last month steris report first quarter fiscal adjust earning share cent year quarter also adjust gross margin improve bps year year report quarter stock have gain last month zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
1119,EW,irvine base masimo corporation masi free report recently report dubai health authority dha introduce masimo patient safetynet supplemental remote monitoring clinician notification system hospital dubai dha be government organization oversee healthcare system dubai patient be be monitored masimo patient safetynet latest cut edge remote monitoring wireless notification system design doctor system be intend assist hospital prevent injury death related failure rescue event frequent medical error patient safetynet aids keep inmate secure continuously invasively monitoring basic physiological condition system monitor many patient timely detect abnormality variance indicate deteriorate health moment patient health start deteriorate system automatically transmit wireless message smart phone concern technician elicit prompt possibly life sustain response caregiver have be establish patient safetynet cut traumatic critical occurrence expensive transfer intensive care unit patient safetynet system consist bedside patient monitor invasive patient sensor continuously report vital physiological statistic such total hemoglobin sphb spco oxygen content spoc pulse rate other masimo safetynet offer place company advantageous position be dominant global player pulse oximetry market additionally company complementary portfolio product service be likely assist strengthen market position achieve high productivity better compete rival edward lifescience corporation ew free report cryolife inc cry free report edap tms edap free report addition invasive parameter be expect act long term barrier entry drive substantial growth expand pulse oximetry utilization critical care area hospital represent growth driver shipment have be grow steady rate fuel new contract moreover recur revenue sale consumable be increase negative side weak macro environment raise concern competition remain intense moreover masimo partly depend original equipment manufacturer oem partner part sale conclusion valuation already factor robust growth prospect offer limit upside potential time zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
1120,EW,cvs health corporation cvs free report second quarter adjust earning share ep be nominal year year basis quarter adjust ep also exceed zack consensus estimate cent earning performance be sluggish year year disappointing retail ltc number well weaker margin time adjustment report ep continue operation first quarter surge year year net revenue quarter increase year year exceed zack consensus estimate close margin strong revenue growth pharmacy service segment be partially offset decline retail ltc performance quarter cvs health corporation price consensus ep surprise cvs health corporation price consensus ep surprise cvs health corporation quotequarter detail pharmacy service revenue increase report quarter drive growth specialty pharmacy volume higher pharmacy network claim volume well brand inflation be however partially offset increase generic dispense price compression pharmacy network claim processed quarter climb day equivalent basis backed net new business growth also mail choice processed claim count be day equivalent basis continue adoption maintenance choice offering rise specialty pharmacy claim revenue cvs health retail ltc dip year year primarily due decrease same store sale continue reimbursement pressure increase generic dispense rate front end same store sale be year year shift easter holiday second quarter first quarter have bps positive impact front end same store sale front store sale be however affected soft customer traffic effort rationalize promotional strategy be again partially offset increase basket size pharmacy same store sale also decline report quarter sale be affected approximately bps due recent generic drug introduction also pharmacy same store prescription volume be flat day equivalent basis apart marketplace change restrict cvs pharmacy participate certain network have bps negative impact same store prescription volume generic dispense rate proportion generic prescription total number prescription dispense soar bps pharmacy service segment bps retail ltc segment gross profit drop gross margin contract bps total operate margin quarter contract bps plunge operate profit cvs health exit quarter cash cash equivalent short term investment compare end first quarter year date net cash provide operate activity be year period second quarter cvs health open new retail store shut retail location further company relocate retail store jun cvs health operated retail store include pharmacy target store state well district columbia puerto rico brazil outlookcvs health have narrow adjust ep guidance earlier band zack consensus estimate be guide range however full year operate cash flow guidance have be reiterate range free cash flow range third quarter company expect deliver adjust ep projection take consideration timing medicare part operate profit third fourth quarters relative precede year current zack consensus estimate third quarter be peg way company projection takecvs health post better expect second quarter result adjust ep revenue beating zack consensus estimate however poor year year retail ltc number margin debacle result dull earning performance company quarter nonetheless year year growth top line be due strong pharmacy service segment benefit upside specialty pharmacy unimpressive bottom line scenario also prompt company narrow earning outlook zack rank key pickscvs health have zack rank hold few better rank medical stock be edward lifescience corp ew free report insys therapeutic inc insy free report align technology inc algn free report sporting zack rank strong buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have gain last month insys therapeutic have long term expect earning growth rate stock deliver stellar quarter average earning surprise align technology have expect long term adjust earning growth almost stock have surge roughly last month look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1121,EW,aug issue update research report salt lake city ut base molecular diagnostic provider myriad genetic inc mygn free report company currently carry zack rank hold past month myriad have be trading broader industry company have rally compare industry gain myriad end fiscal solid note fourth quarter number exceed zack consensus estimate company particularly observed strong growth endopredict genesight testing revenue also myriad witness third consecutive quarter rise hereditary cancer volume also receive provincial reimbursement quebec endopredict notably european league rheumatism eular meeting hold june spain crescendo bioscience wholly own subsidiary myriad release new datum meta analysis clinical study datum have demonstrated vectra da test ability predict joint damage same month company announce bracanalysis cdx companion diagnostic test have successfully identify brca mutate patient metastatic breast cancer olympiad trial have respond treatment olaparib better standard chemotherapy myriad collaboration astrazeneca beigene development companion diagnostic also raise optimism moreover myriad continue make progress kit base version prolaris mypath melanoma international market expect file ce mark prolaris moreover company have introduce elevate program target achieve incremental operate income fiscal management company have select project be anticipate deliver operate income fiscal fiscal flip side unfavorable currency translation continue be major dampener stock management fear further strengthen dollar foreign currency lead deteriorate operate result intensify competition well possibility myriad new test not generate meaningful profit outweigh cost associate development continue raise concern zack rank key pickssome better rank medical stock be edward lifescience corp ew free report steris plc ste free report align technology inc algn free report edward lifescience align technology sport zack rank strong buy steris carry zack rank buy see complete list today zack rank stock here edward lifescience have positive earning surprise trail quarters stock have gain last month align technology have long term expect earning growth rate stock have rally roughly last month steris have positive earning surprise trail quarters stock have gain last month trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
1122,EW,aug issue update research report ohio base steris plc ste free report manufacturer marketer infection prevention decontamination microbial reduction surgical support product service company currently carry zack rank buy steris post better expect result first quarter fiscal earning revenue beating zack consensus estimate however year year decline revenue be dampening positive note organic growth performance be strong segment further growth free cash flow reserve be indicative company strong cash balance also gross operate margin expand year year recently company make couple organizational change serve customer better way expect move enhance company cost structure well last month stock have gain outperformed decline broader industry however note government insurance company consistent effort curb healthcare cost have be putt pressure stock quite time be also concern current customer consolidation scenario continue affect company checked immediately competitive landscape weak cost reduction initiative be other overhang other key picksother top rank medical stock be edward lifescience corp ew free report stryker corporation syk free report align technology inc algn free report edward lifescience align technology sport zack rank strong buy stryker carry zack rank see complete list today zack rank stock here edward lifescience have positive earning surprise trail quarters stock have gain last month align technology have long term expect earning growth rate stock have rally roughly last month stryker have long term expect earning growth rate stock have gain last month trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
1123,EW,aug issue update research report elmsford ny base bioscrip inc bio free report company be lead infusion service provider strive deliver cost effective program patient stock currently have zack rank buy last month bioscrip have be trading broader industry stock have gain compare favorably decline broader industry bioscrip exit second quarter wider expect adjust net loss revenue miss management unimpressive guidance include negative impact cure act legislation add concern nonetheless market be upbeat bioscrip announcement continue offer certain core product line also stiff competition raise concern positive note be encourage company recent progress courtesy new multus faceted core plan be adopt improve financial position further company achieve annualize supply chain improvement roughly acquisition home solution bioscrip currently operate attractive market favorable industry dynamic positive fundamental particular market force develop patient management technology age population be drive growth opportunity home health service provider bioscrip healthcare landscape rapidly change company be focuse boost core infusion service platform clinically focuse customer orientated model other key picksother top rank medical stock be edward lifescience corp ew free report steris plc ste free report align technology inc algn free report edward lifescience align technology sport zack rank strong buy steris carry zack rank see complete list today zack rank stock here align technology have expect long term adjust earning growth almost stock have add roughly last month edward lifescience have long term expect earning growth rate stock have gain last month steris post stellar quarter average earning surprise stock have add roughly last month make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1124,EW,pra health science prah free report announce have price underwritten secondary public offer share common stock offer be expect close aug subject customary close condition last report sale price company common stock aug be share jun company have total cash cash investment worth compare dec month period end jun company generate cash operation pra health science be also strive effectively manage overhead function cut expense notably backlog increase approximately year year second quarter approximately share pra health science have increase last month compare industry increase believe pra have therapeutic expertise area be largest pharmaceutical development include oncology central nervous system inflammation infectious disease company provide client most flexible clinical development service offering include traditional project base phase phase iv service well embed functional outsource service company have invest medical informatic clinical technology design enhance efficiency improve study predictability provide better transparency client clinical development process pra health science be world lead global contract research organization revenue company provide outsourced clinical development service biotechnology pharmaceutical industry pra global clinical development platform include approximately office north america europe asia latin america south africa australia middle east approximately employee worldwide pra have perform approximately clinical trial worldwide addition pra have participate pivotal supportive trial lead food drug administration international regulatory approval more drug zack rank key pickscurrently pra health science have zack rank hold few better rank stock broader medical sector be edward lifescience corporation ew free report fresenius medical care corporation fms free report idexx laboratory inc idxx free report notably edward lifescience fresenius medical sport zack rank strong buy idexx laboratory have zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate notably stock have return last month fresenius medical yielded strong return year date stock have long term expect earning growth rate idexx laboratory have long term expect earning growth rate additionally stock represent impressive year return make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1125,EW,opko health inc opk free report report loss cent share second quarter earning cent year however report quarter loss be narrower zack consensus estimate loss cent revenuesin second quarter opko health report total revenue year year however revenue second quarter include payment tesaro associate commercial launch varuby europe comparison payment related rayaldee license fresenius same quarter report figure also miss zack consensus estimate gross profit second quarter be year year gross margin contract massive basis point bps research development expense totale selling general administrative expense amount year year consequently loss operation come highlight significant decline operate income prior year quarter decline be attribute rise operate expense owing company significant investment associate commercial launch rayaldee consistent investment pharmaceutical pipeline opko health inc price consensus ep surprise opko health inc price consensus ep surprise opko health inc health exit second quarter cash cash equivalent marketable security compare record end first quarter takeopko health exit second quarter mixed note narrower expect loss revenue miss nonetheless be encourage company progress business include diagnostic business bio reference laboratory pharmaceutical business andbiologic business be also upbeat company recent development genedx bio reference genetic testing unit context company expand association university california health system offer molecular genetic genomic testing service jun however rise operate expense continue mar company financial zack rank key picksopko health currently have zack rank hold few better rankedmedical stock be edward lifescience corp ew free report steris plc ste free report align technology inc algn free report edward lifescience align technology sport zack rank strong buy steris carry zack rank buy see complete list today zack rank stock here edward lifescience second quarter adjust earning improve stupendous year year primarily drive strong sale growth company transcatheter heart valf business stock have gain last month steris report first quarter fiscal adjust earning share cent year quarter also adjust gross margin improve basis point year year report quarter stock have gain last month align technology second quarter adjust ep cent be substantial year year revenue grow year year stock have rally roughly last month make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1126,EW,henry schein inc hsic free report report adjust earning share ep second quarter year year adjust ep also surpass zack consensus estimate year year upside earning be drive strong revenue growth henry schein report net income second quarter come share reflect year year growth respectively revenue detailhenry schein report revenue second quarter year year also zack consensus estimate year year improvement come back growth local currency partially offset decline owing foreign currency exchange local currency internally generate sale increase acquisition growth be henry schein inc price consensus ep surprise henry schein inc price consensus ep surprise henry schein inc company record sale north american market year year sale be international market year year segment analysis henry schein derive revenue operate segment dental medical animal health technology value add service second quarter company derive revenue global dental sale year year include growth local currency decline owing foreign currency exchange local currency internally generate sale increase acquisition growth be internal growth local currency include growth north america rise internationally company global animal health segment witness improvement revenue include growth local currency decline related foreign currency exchange local currency internally generate sale increase acquisition growth be internal growth local currency include growth north america growth internationally worldwide medical revenue scale year year growth local currency be decrease owing adverse foreign exchange revenue global technology value add service grow include growth local currency decline related foreign currency exchange be contribution acquisition quarter review margin trend gross profit increase report quarter however gross margin decline basis point bps year quarter due rise cost sale higher revenue growth rate rise selling general administrative expense adjust operate income improve year year moreover adjust operate margin remain flat year year report quarter financial positionhenry schein exit second quarter cash cash equivalent compare end first quarter year date net cash provide operate activity be compare year period quarter review company buy back approximately share almost close second quarter company have authorize future repurchase common stock ep guidance intacthenry schein reaffirm report ep guidance litigation settlement expense company still expect ep range reflect growth ep figure zack consensus estimate adjust ep be guide range takehenry schein exit second quarter solid note earning sale beating zack consensus estimate operate segment deliver strong year year growth company strong share gain north american overseas market strong revenue raise optimism however better expect earning performance be disappoint company unchanged ep guidance meanwhile year year deterioration henry schein gross operate margin be due higher cost sale expense also foreign currency fluctuation continue mar company financial zack rank key pickshenry schein have zack rank buy few other top rank medical stock be edward lifescience corporation ew free report insys therapeutic inc insy free report align technology inc algn free report notably edward lifescience insys therapeutic align technology sport zack rank strong buy see complete list today zack rank stock here insys therapeutic have long term expect earning growth rate stock post stellar quarter average earning surprise align technology have expect long term adjust earning growth almost stock have add roughly last month edward lifescience have long term expect earning growth rate stock have gain last month look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1127,EW,orthofix international ofix free report report second quarter adjust earning share ep continue operation cent line zack consensus estimate adjust earning improve year year primarily strong sale growth company biologic spine fixation strategic business unit sbu exclude time item net income second quarter come cent share show remarkable year year improvement net loss cent sale detailsorthofix second quarter sale improve constant exchange rate cer figure also beat zack consensus estimate sale be primarily drive better expect performance company sbus significant contribution biologic spine fixation orthofix international price consensus ep surprise orthofix international price consensus ep surprise orthofix international quotesbu second quarter company report biostim sale reflect same cer growth prior year quarter favorable nass coverage recommendation introduction advanced spinal fusion therapy product extensive sale force be major driver biostim business biologic sbu sale quarter totale same cer prior year quarter be lead strong demand trinity elite due expand distributor network reacquisition national hospital contract increase contribution national distributor partner extremity fixationsale be report quarter show decline cer second quarter however exclude plan subsidiary restructure loss sale due divestiture core business impact trail month growth rate business be cer orthofix report spine fixation sbu sale reflect same cer growth prior year quarter be attribute strong growth strategic initiative second quarter gross margin expand basis point bps solid top line growth be major factor have contribute improve gross margin sale marketing expense rise year year millionow increase sale mix newly add distributor biologic elevated spending extremity fixation accelerate sale growth general administrative expense be lead increase investment implement strategic initiative design company legal settlement stock base compensation company also witness rise research development expense accordingly adjust operate margin quarter contract bps result increase operate expense cash exit second quarter cash cash equivalent compare end first quarter year date net cash provide operate activity be compare year period exclude capital expenditure free cash flow be report quarter compare capital expenditure lead free cash flow year period update guidancebanking solid second quarter performance orthofix have raise full year sale expectation previous zack consensus estimate full year revenue be peg guide range adjust ep expectation have also be raise zack consensus estimate full year adjust ep stand line low end company project range company exit second quarter mixed note sale beating zack consensus estimate earning meeting same management top line be substantially drive strength biologic spine fixation business be expect continueon back improve performance sale partner expand distributorship network introduction product moreover company seem be upbeat encourage response receive spinal stim cervical stim bone growth therapy device launch earlier moreover company cetra anterior cervical plate have witness strong market adoption result sale first month launch continue slew product development launch company recently launch rival full line foot ankle internal fixation system also extremity fixation space company recently launch juniortho new brand orthopedic product currently account roughly third extremity fixation sale also believe raise full year guidance be indicative enhance prospect flip side currency fluctuation competitive landscape macroeconomic headwind continue challenge company moreover higher operate expense be also matter concern orthofix also increase dependence third party final distribution product expose company increase risk zack rank key picksorthofix have zack rank hold few better rank medical stock be edward lifescience corporation ew free report insys therapeutic inc insy free report align technology inc algn free report notably edward lifescience insys therapeutic align technology sport zack rank strong buy see complete list today zack rank stock here insys therapeutic have long term expect earning growth rate stock post stellar quarter average earning surprise align technology have expect long term adjust earning growth almost stock have add roughly last month edward lifescience have long term expect earning growth rate stock have gain last month look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1128,EW,headquarter austin tx luminex corporation lmnx free report report earning cent share second quarter surpass zack consensus estimate cent massive earning also increase year year revenue quarter increase almost year year ahead zack consensus estimate luminex have zack rank hold segment analysissystem sale revenue jump year year basis notably company ship multiplexing analyzer report quarter lead upside revenue here note system include magpix lx flexmap assay revenue assay revenue grow year year be organic royalty revenue come royalty revenue sale segment decline year year basis royalty revenue lack luster report quarter owing timing item royalty minimum audit payment consumable sale revenue segment decline management consumable revenue expectation be adversely impact funding challenge owing multus year bulk bead contract life science customer quarter tiding regulatory front luminex receive fourth fifth fda clearance ary assay platform second quarter ary bordetella ary assay luminex also gain ce ivd mark norovirus fact company be verge complete clinical study group strep soon be submit review fda lastly luminex announce japan central social insurance medical council have approve recommendation japanese ministry health labor welfare mhlw provide reimbursement proprietary verigene assay approval be verigene assay gram positive blood culture test gram negative blood culture test notably luminex be only company japan clear automate sample answer solution blood culture identification molecular diagnostic business solid molecular diagnostic group jump year year basis second quarter solid performance be fuel growth automate solution verigene ary platform furthermore segment get additional momentum recently negotiate group purchasing organization agreement be add ary platform exist verigene agreement be establish new agreement margin detail gross margin be report quarter highlight contraction basis point bps year year margin deteriorate year year basis owing anticipate shift overall product mix higher inclusion lower margin automate sample answer solution however gross margin be line expectation courtesy improvement margin verigene ary related revenue stringent cost management acquire enterprise incremental system placement continue flow new assay operate expense rise year year basis largely due incorporation nanosphere expense net revenue quarter be year year basis meanwhile sg cost be year year exclude nanosphere sg expense increase only result operate margin percentage revenue be second quarter financial condition company end second quarter approximately cash investment first quarter guidanceluminex reiterate annual revenue guidance band depict growth year year basis luminex expect gross margin next few quarters mid meanwhile company project third quarter revenue range previously issue band luminex corporation price consensus ep surprise luminex corporation price consensus ep surprise luminex corporation quoteour takeluminex second quarter see strong top line solid cash flow profitability company assay business be key growth driver long term company also witness favorable tiding regulatory front second quarter regard reimbursement approval verigene assay japan fda clearance bordetella assay be noteworthy fact luminex be verge complete clinical study group strep be close submit same fda review flipside company slash third quarter revenue guidance furthermore low consumable revenue raise concern luminex expect revenue segment be impact funding challenge related multus year bulk bead contract life science customer cutthroat competition niche space be headwind key picksa few better rank stock broader medical sector be edward lifescience corporation ew free report fresenius medical care corporation fms free report dextera surgical inc notably edward lifescience fresenius medical sport zack rank strong buy dextera have zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate notably stock return last month fresenius medical yielded strong return year date stock have long term expect earning growth rate dextera have project sale growth current year stock promise long term expect earning growth rate look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1129,EW,aug issue update research report rhode island base pharmacy retail giant cvs health corp cvs free report provide integrate offering entire spectrum pharmacy care post better expect performance second quarter cvs health be observed trading significantly ahead broader industry last month share price movement stock have lose period narrower broader industry loss positive note strong pharmacy service number benefit upside specialty pharmacy recent datum person be currently need specialty treatment have high potential cost management emphasize cvs health specialty business remain top priority customer believe be well position tap opportunity base broad differentiate offering include like specialty connect company strong pbm selling season also look encourage regard selling season magnitude bidding opportunity be flat year year company have successful quarter gross new business be net new business also reach impressive new business number include loss fep specialty contract lack impact individual med pdp prescription drug plan company have already complete client renewal soft bottom line company narrow earning outlook indicate chance recovery ahead believe omnicare target pharmacy buyout have already start benefit cvs health multiple prospect drive enterprise value significantly come day however poor year year retail ltc long term care number margin debacle drag bottom line last quarter notably highly competitive retail pharmacy market too seem threat also sluggish economic condition be concern stock currently carry zack rank hold key picksa few better rank medical stock be edward lifescience corporation ew free report myriad genetic inc mygn free report align technology inc algn free report notably edward lifescience align technology sport zack rank strong buy myriad genetic carry zack rank buy see complete list today zack rank stock here align technology have expect long term adjust earning growth almost stock have add roughly last month edward lifescience have long term expect earning growth rate stock have gain last month myriad genetic have long term expect earning growth rate stock have add roughly last month zack ipo watch listbefore look stock mentioned want get head start potential tech ipos be pop zack radar imagine be first wave investor jump company almost unlimited growth potential special report give current scoop go public time have drive valuation year other be little less obvious already show jaw drop growth download ipo watch list today free
1130,EW,chimerix inc cmrx free report report net loss continue operation cent share second quarter compare net loss cent year moreover report loss be narrower zack consensus estimate loss cent revenuesin second quarter chimerix report contract revenue year year year year decline be due fall reimbursable expense related company barda developmental contract research development expense totale general administrative expense amount year year consequently loss operation come highlight improvement operate loss prior year quarter however operate loss be attribute significant year year decline revenue chimerix inc price consensus ep surprise chimerix inc price consensus ep surprise chimerix inc exit second quarter cash cash equivalent short term investment compare record end first quarter takechimerix exit second quarter positive note narrower expect loss however revenue decline year year nonetheless be encourage company progress second quarter courtesy advancement lead product candidate brincidofovir company witness encourage enrollment multiple ascend dose study iv bcv further chimerix anticipate several important development second half start first human study cmx initiation adapt well datum iv bcv advance zack rank other key pickschimerix currently have zack rank buy few other top rank medical stock be edward lifescience corp ew free report myriad genetic inc mygn free report align technology inc algn free report edward lifescience align technology carry zack rank strong buy myriad genetic carry zack rank see complete list today zack rank stock here edward lifescience second quarter adjust earning improve year year primarily drive strong sale growth company transcatheter heart valf business stock have gain last month align technology second quarter adjust ep cent be year year revenue grow year year stock have rally roughly last month myriad genetic report adjust ep cent fourth quarter fiscal year year also total revenue rise year year fourth quarter stock have rally roughly last month simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
1131,EW,palo alto base manufacturer medical device software varian medical system inc var free report announce have sign distribution agreement toledo base bionix radiation therapy agreement varian medical distribute bionix propreitory brachytherapy applicator varian market bionix esophageal applicator app anorectal applicator ar north america applicator app be disposable brachytherapy applicator be design specifically treatment cancer app feature independently operable balloon maintain central position source catheter straight curved anatomy allow closer proximity target source maintain distance healthy tissue second applicator ar be disposable brachytherapy applicator be design specifically treatment anal rectal cancer dual balloon design ar allow exophytic tumor press closer source catheter create ability deliver very high dose tumor spare healthy tissue future trendwe note global radiotherapy market be expect reach worth cagr take bountiful prospect global niche space consideration latest development boost investor confidence share price performancea promising portfolio combine robust initiative have be favore zack rank hold company have deliver positive earning surprise last quarters note share varian medical have decline past month broader industry grow same time frame takevarian medical operate technology drive environment success depend innovation frequent product update company have be successful front evident year year expansion top line company have approximately revenue opportunity various oncology imaging component product next year apart enjoy dominant market share conventional radiotherapy believe proton therapy hold significant promise varian medical be probeam compact proton therapy system be superior other external beam radiotherapy precisely locate cancerous tumor cause lesser side effect surround tissue proton therapy system used same interface used company truebeam platform finally company strong overseas presence be expect enable leverage opportunity emerge market line grow demand cancer treatment overseas market varian medical sale europe africa particularly asia be grow faster rate domestic market do medical stock interest check theseinvestor consider better rank stock same sector such edward lifescience corporation ew free report fresenius medical care corporation fms free report idexx laboratory inc idxx free report notably edward lifescience fresenius medical sport zack rank strong buy idexx laboratory have zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate notably stock have return last month fresenius medical yielded strong return year date stock have long term expect earning growth rate idexx laboratory have long term expect earning growth rate additionally stock represent impressive year return simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
1132,EW,haemonetic corporation hae free report report adjust earning share ep cent first quarter fiscal year year figure also beat zack consensus estimate cent report basis haemonetic post net income cent share year quarter net loss loss cent total revenuerevenue inched year year constant exchange rate cer report quarter miss zack consensus estimate management hospital business cell salvage transfusion management revenue increase cer year year decline orthopat cell saver decline be more offset growth bloodtrack other hospital software product haemonetic corporation price consensus ep surprise haemonetic corporation price consensus ep surprise haemonetic corporation report quarter haemonetic witness year year same cer fall revenue north america also international revenue decline cer revenue product report operate result business franchise plasma haemostasis management cell process blood center plasma report revenue total revenue be year year cer revenue bloodcenter total revenue decline cer hemostasis management franchise revenue total revenue rise cer revenue cell process inched only cer total revenue first quarter gross margin be basis point bps year year uptick gross profit operate income be first quarter fiscal operate loss year quarter financial exit first quarter fiscal cash cash equivalent compare end precede year company long term obligation exclude current portion be report quarter end fourth quarter fiscal haemonetic generate operate cash flow end first quarter fiscal compare year quarter end first quarter fiscal company report free cash flow transformation restructure cost compare year quarter fiscal reaffirm fiscal guidance company still expect full year revenue be line fiscal revenue guidance plasma revenue growth be range inclusive sebra divestiture represent annual plasma revenue zack consensus estimate sale be peg company also expect adjust ep band zack consensus estimate be guide range management continue expect strong cash generate activity fiscal cash hand fund business activity takehaemonetic exit first quarter fiscal mixed note earning beating zack consensus estimate revenue miss same encourage growth plasma haemonetic management franchise other franchise be quite dampener meanwhile company strong cash position boost investor confidence year year increase report sale gross margin buoy optimism company be also optimistic strong market adoption nexsys pcs plasmapheresis system recently receive fda approval further company reaffirm guidance fiscal be encourage zack rank key pickshaemonetic have zack rank hold few better rank medical stock be edward lifescience corporation ew free report insys therapeutic inc insy free report align technology inc algn free report notably edward lifescience insys therapeutic align technology sport zack rank strong buy see complete list today zack rank stock here insys therapeutic have long term expect earning growth rate stock post stellar quarter average earning surprise align technology have expect long term adjust earning growth almost stock have add roughly last month edward lifescience have long term expect earning growth rate stock have gain last month look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1133,EW,bio rad laboratory inc bio free report report second quarter earning cent share huge decline year earning cent quarter figure also miss zack consensus estimate cent wide margin notably net income second quarter be hit lower sale weaker gross profit increase acquisition related expenditure new product technology higher expense implementation new system operation europe net sale quarter come year year constant exchange rate cer sale also miss zack consensus estimate year year fall sale be largely due slowdown productivity related recent go live company global erp system western europe well shift sale first quarter anticipation erp deployment bio rad laboratory inc price consensus ep surprise bio rad laboratory inc price consensus ep surprise bio rad laboratory inc quotequarter detailon segmental basis life science segment net sale come year year cer cer sale rise back strong sale droplet digital pcr ddpcr instrument reagent offset decrease process chromatography medium sale erp related disruption clinical diagnostic company register sale year year cer decline result significant slowdown european sale especially infectious disease product directly related disruption post go live new erp system gross margin second quarter be basis point bps year year decline gross profit adjust operate loss report quarter be compare operate profit year quarter company exit second quarter cash cash equivalent short term investment compare end year date net cash provide operate activity be compare year period guidance dismal second quarter performance bio rad continue expect organic sale growth approximately cer full year growth rate assume recovery substantial portion erp related sale disruption take place second quarter lower anticipate operate profit first half include addition raindance technology company have lower currency neutral operate margin projection full year range earlier guidance bottom linebio rad post disappointing quarterly show earning sale significantly lag zack consensus estimate sale growth be majorly hampered slower productivity result erp deployment western europe well lower expect sale process medium business however company reiterate organic growth expectation indicate chance recovery zack rank key picksbio rad have zack rank hold few better rank medical stock worth consider be edward lifescience corporation ew free report insys therapeutic inc insy free report align technology inc algn free report sporting zack rank strong buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have gain last month insys therapeutic have long term expect earning growth rate stock deliver stellar quarter average earning surprise align technology have expect long term adjust earning growth almost stock have rally roughly last month look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1134,EW,arlington va base evolent health inc evh free report report second quarter loss cent share be line zack consensus estimate figure improve loss cent year quarter report quarter revenue increase roughly year year approximately outpace zack consensus estimate quarter highlightsin report quarter adjust platform operation revenue account total adjust revenue represent increase compare same quarter last year surge be drive primarily increase number member platform number member rise approximately jun approximately jun increase member platform be due primarily acquisition well addition new partner growth exist market average member month fee quarter be compare same period prior year adjust cost revenue increase adjust revenue report quarter compare year period increase expense year year be primarily due cost assume acquisition additional personnel cost third party support service organization evolent health inc price consensus ep surprise evolent health inc price consensus ep surprise evolent health inc quotefinancial health cash cash equivalent be jun compare dec long term debt stand versus year end guidanceevolent health expect revenue range third quarter adjust ebitda be expect be approximately breakeven full year company anticipate revenue be range adjust ebitda be range loss loss zack rank key picksevolent health have zack rank hold better rank stock broader medical sector be edward lifescience corporation ew free report fresenius medical care corporation fms free report dextera surgical inc edward lifescience fresenius medical sport zack rank strong buy dextera have zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate notably stock have return last month fresenius medical yielded strong return last year stock have long term expect earning growth rate dextera have project sale growth current year stock promise long term expect earning growth rate look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1135,EW,envision healthcare corporation evhc free report report second quarter adjust earning cent share beating zack consensus estimate cent company be lead provider physician lead outsourced medical service consumer hospital healthcare system company report adjust revenue approximately lag zack consensus estimate however figure surpass year quarterly revenue segment service net revenue physician service be second quarter increase prior year period upside be drive contribution acquisition new contract ambulatory service net revenue report quarter be versus prior year quarter ambulatory service operated ambulatory surgery center surgical hospital jun envision healthcare corporation price consensus ep surprise envision healthcare corporation price consensus ep surprise envision healthcare corporation quotefinancial detailsa jun envision healthcare have cash cash equivalent versus dec net cash flow operation be second quarter guidance revisedenvision healthcare revise guidance reflect lower emergency medicine volume impact financial performance company expect net revenue range fiscal adjust ebitda be expect range adjust ep fiscal be expect range third quarter company expect generate adjust ebitda range anticipate adjust ep cent cent key picksenvision healthcare have zack rank sell better rank stock broader medical sector be edward lifescience corporation ew free report fresenius medical care corporation fms free report dextera surgical inc notably edward lifescience fresenius medical sport zack rank strong buy dextera have zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate notably stock have return last month fresenius medical yielded strong return last year stock have long term expect earning growth rate dextera have project sale growth current year stock promise long term expect earning growth rate look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1136,EW,cogentix medical inc be big mover last session share rise day move come company deliver robust second quarter result lead far more share change hand normal session continue recent uptrend company stock be now past month time frame company have see positive estimate revision last day zack consensus estimate moved higher same time frame suggest more solid trading ahead so make sure keep eye stock go forward see recent jump turn more strength road cognetix currently carry zack rank buy cogentix medical inc price cogentix medical inc price cogentix medical inc quoteanother top rank stock worth consider medical instrument space be edward lifescience corporation ew free report sporting zack rank strong buy see complete list today zack rank stock here trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
1137,EW,aug issue update research report st paul mn base cardiovascular system inc csii free report company be medical device manufacturer develop commercialize innovative solution treat patient suffering peripheral coronary arterial disease include arterial calcium majority last month cardiovascular system have outperformed broader industry respect price currently stock be better gain broader industry cardiovascular system deliver remarkable fourth quarter result earning revenue beating zack consensus estimate company lower operate expense drive year year improvement earning strong revenue performance also contribute upside earning moreover improvement margin be encourage overall company fiscal performance have be impressive company fiscal guidance also instill confidence investor recent development cardiovascular system have receive fda approval radial access diamondback peripheral orbital atherectomy device also year result liberty study be be present amputation prevention symposium amp flip side company operate competitive medical device industry get significantly affected product introduction failure expand business overseas hamper growth also profitability front cardiovascular bear long history net loss inception immediate recovery sight fiscal company incur net loss management still expect incur net loss first quarter fiscal zack rank key system have zack rank hold few better rank medical stock be edward lifescience corporation ew free report insys therapeutic inc insy free report align technology inc algn free report notably edward lifescience insys therapeutic align technology sport zack rank strong buy see complete list today zack rank stock here insys therapeutic have long term expect earning growth rate stock post stellar quarter average earning surprise align technology have expect long term adjust earning growth almost stock have add roughly last month edward lifescience have long term expect earning growth rate stock have gain last month trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
1138,EW,initiative boost illumigene platform cincinnatus base meridian bioscience inc vivo free report recently initiate clinical trial illumigene cmv molecular amplification test simple saliva base test detect congenital cytomegalovirus cmv infection newborn infection result developmental disability even death share merdian jump close follow news release believe latest development further buoy company stock performance term follow encourage outcome clinical trial meridian be expect submit test fda review notably be fda approve clinical trial cmv screening newborn date latest development be significant move company diagnostic segment note illumigene be flagship platform segment include isothermal dna amplification be molecular platform be suitable laboratory size centralize decentralize illumigene comprise commercialize test illumigene illumigene group streptococcus illumigene group streptococcus illumigene mycoplasma more apart enhance illumigene platform company announce expansion immunocard stat profile recently addition immunocard stat flu product platform deserve mention regard meridian reaffirm fiscal guidance be key highlight moment company expect adjust diluted earning share range cent cent however company have have unimpressive performance last month stock lose much wider broader industry decline same time frame current level be also lower return almost same time frame stock have zack rank sell key picksa few better rank stock broader medical sector be edward lifescience corporation ew free report fresenius medical care corporation fms free report idexx laboratory inc idxx free report notably edward lifescience fresenius medical sport zack rank strong buy idexx laboratory have zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate notably stock have return last month fresenius medical yielded strong return year date stock have long term expect earning growth rate idexx laboratory have long term expect earning growth rate additionally stock represent impressive year return simple trading ideasince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar proven stock pick system be ground single big idea be fortune shape life change apply portfolio start today learn more
1139,EW,surmodic inc srdx free report report earning cent share third quarter fiscal much lower year figure cent zack consensus estimate third quarter earning be peg breakeven revenue quarter fall however revenue surpass zack consensus estimate exclude hydrophilic royalty catch payment revenue rise year year basis stock have zack rank hold segment report revenue segment medical device diagnostic ivd medical device report quarter sale decline due lower hydrophilic royalty revenue royalty license fee revenue segment totale year year basis third quarter operate income segment be significantly lower year quarter year year decline be attributable increase investment related whole product strategy reduce royalty revenue ivd quarter review sale increase upside come strong growth stabilization biofx microarray antigen product sale third quarter operate income segment be relatively higher report year quarter result improve operate margin segment basis point courtesy favorable product mix solid operate leverage higher revenue dcb pivotal study surmodic receive ide approval fda transcend surveil dcb pivotal study company be expect begin enrollment platform end fiscal surveil be paclitaxel drug coat balloon be used treatment femoral popliteal disease study be formulate enroll approximately patient almost clinical site european union ex wo third quarter dollar continue compare euro company suffer loss euro denominate contingent consideration surmodic realize solid foreign exchange loss related creagh medical acquisition margin detail product gross margin expand basis point bps product sale compare prior year quarter year year margin expansion be primarily buoy manufacturing leverage favorable sale mix expense third quarter be net revenue compare year quarter surmodic expect expense rise year year basis thank whole product solution strategy new surveil drug coat balloon human clinical trial sg expense third quarter fiscal account net revenue higher year period balance sheet cash flow end third quarter company have surmodic repurchase common share report quarter share repurchase program company invest plant equipment outlooksurmodic raise guidance fiscal revenue earning company expect fiscal earning share range cent cent compare prior guidance cent cent meanwhile revenue be project range prior range revenue ivd segment be expect grow low single digit long term ivd revenue growth be expect mid single digit surmodic anticipate expense band fiscal revenue surmodic inc price consensus ep surprise surmodic inc price consensus ep surprise surmodic inc quoteour takesurmodic third quarter fiscal result be impressive beat zack consensus estimate earning revenue furthermore upbeat guidance raise investor confidence stock regulatory approval surveil reflect surmodic solid foothold develop surface technology muscular device particularly drug delivery space surmodic be strive expedite surveil drug coat balloon development program drug coat balloon platform be nascent stage flipside company expect ivd business growth mid single digit compare double digit gain realize fiscal owing anticipate top line headwind term furthermore foreign exchange wo related creagh medical buyout be major dampener key picksa few better rank stock broader medical sector be edward lifescience corporation ew free report fresenius medical care corporation fms free report dextera surgical inc notably edward lifescience fresenius medical sport zack rank strong buy dextera have zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate notably stock have return last month fresenius medical yielded strong return year date stock have long term expect earning growth rate dextera have project sale growth current year stock promise long term expect earning growth rate trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
1140,EW,headquarter menlo park pacific bioscience california inc pacb free report pioneer field single molecule long resequence technology smrt report loss cent share second quarter figure be cent wider zack consensus estimate fact figure be also wider loss cent report year quarter revenue miss zack consensus estimate decline year year basis service revenue rise year year basis gross margin second quarter be net revenue versus year quarter research development expense totale lower report year quarter pacific bioscience california inc price consensus ep surprise pacific bioscience california inc price consensus ep surprise pacific bioscience california inc quotesel general administrative sg expense totale significantly higher year balance sheetcash investment end second quarter be compare end first quarter guidance pacific bioscience reaffirm guidance product service revenue full year range company also expect gross margin growth assume revenue increase anticipate overall company expect gross margin percentage reach mid end year takepacific bioscience exit second quarter disappointing note loss wider estimate revenue miss zack consensus estimate also gap loss widen year quarter revenue decrease same poor margin also add wo however be encourage new agreement inked august pacific bioscience california novogene corp novogene purchase sequel system give dna sequence service provider capacity run sequel system time zack rank key pickspacific bioscience have zack rank hold few better rank medical stock be edward lifescience corp ew free report insys therapeutic inc insy free report align technology inc algn free report notably edward lifescience insys therapeutic align technology sport zack rank strong buy see complete list today zack rank stock here insys therapeutic have long term expect earning growth rate stock post stellar quarter average earning surprise align technology have expect long term adjust earning growth almost stock have add roughly last month edward lifescience have long term expect earning growth rate stock have gain last month today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1141,EW,medical group wmgi free report report adjust loss cent share second quarter narrower zack consensus estimate loss cent also loss narrow cent year year basis net sale second quarter totale surpass consensus mark meanwhile last quarters company deliver positive earning surprise average be currently stock have zack rank hold quarter detailwright medical currently report revenue total extremity biologic segment consolidated sale segment increase year quarter almost internationally sale extremity biologic business be year year medical group price consensus ep surprise medical group price consensus ep surprise medical group quotetotal extremity biologic include sub segment namely lower extremity upper extremity biologic sport med other lower extremity sale segment increase year year basis quarter lower extremity business sale increase second quarter management growth lower extremity be drive total ankle growth rate reduce headwind synergy result percentage point improvement first quarter growth rate internationally lower extremity sale fall year year basis upper extremity sale segment increase year year basis quarter review upper extremity business grow year year basis drive ongoing launch perform reversed glenoid expand blueprint surgical plan module become available quarter however upper extremity sale decrease year year basis internationally biologic sale segment rise year year basis quarter biologic business grow quarter management augment have impressive quarter improvement average daily revenue compare first quarter core biologic portfolio continue be challenge management expect growth biologic business second half sale force expansion initiative lower extremity cross selling program core biologic product upper extremity sale force sale segment grow internationally year year basis sport med other sale segment drop year quarter sport med other segment sale decline increase internationally second quarter margin detailsadjust gross margin percentage revenue be peg quarter expansion roughly basis point bps year year basis selling general administrative expense account total revenue second quarter totale contraction bps year quarter notably expense research development be second quarter year year basis guidancewright medical reiterate full year guidance company continue expect net sale full year band represent growth include negative impact foreign currency exchange approximately notably midpoint net sale guidance represent constant currency growth approximately company forecast full year adjust ebitda continue operation range takewright medical exit second quarter impressive note revenue earning beating zack consensus estimate also strong margin reiterate full year outlook buoy optimism company be putt effort product innovation research development medical launch invision total ankle revision system july be first system develop total ankle revision arthroplasty management perform reversed launch boost revenue later half year company deliver additional instrument set field however decrease lower extremity sale upper extremity sale internationally be matter concern key picksa few better rank medical stock be edward lifescience corporation ew free report insys therapeutic inc insy free report align technology inc algn free report notably edward lifescience insys therapeutic align technology sport zack rank strong buy see complete list today zack rank stock here insys therapeutic have long term expect earning growth rate stock post stellar quarter average earning surprise align technology have expect long term adjust earning growth almost stock have add roughly last month edward lifescience have long term expect earning growth rate stock have gain last month today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1142,EW,goleta base inogen inc ingn free report report second quarter earning cent share year year comfortably beat zack consensus estimate cent year figure cent upside be drive roughly growth revenue totale beating zack consensus estimate almost detailssale revenue surge rental revenue decline business business business business domestic sale be year year basis almost primarily drive traditional home medical equipment provider purchase consistent strength private label partner inogen inc price consensus ep surprise inogen inc price consensus ep surprise inogen inc quotemeanwhile business business international sale rise almost back solid demand company partner europe direct consumer direct consumer domestic sale advanced almost however direct consumer rental sale fall decline be attribute decrease rental reimbursement rate company increase strategic focus sale margin detailsin report quarter inogen register gross margin percentage revenue basis point bps year year basis meanwhile sale gross margin expand bps quarter percentage revenue management increase sale gross margin be drive lower material cost result decrease cost good sell quarter rental gross margin be report quarter much lower second quarter be primarily drive lower net revenue rental patient lead fall reimbursement rate however decline rental gross margin be partially offset decrease cost rental revenue particularly lead lower depreciation servicing cost adjust ebitda rise year year basis guidancebanking solid performance second quarter inogen raise revenue adjust net income guidance moreover company narrow full year adjust ebitda guidance inogen project revenue range higher previous range represent year year growth previously provide range company expect rental revenue decline courtesy lower average rental revenue patient continue focus sale adjust ebitda be now project band compare project previously thereby present increase year year inogen expect adjust net income range previously provide range represent year year growth compare previous range takeinogen report stellar second quarter beating zack consensus estimate count company witness solid growth revenue adjust earning year year basis view solid domestic international business business sale have drive stellar quarterly performance fact company expect direct consumer sale be fastest grow channel follow domestic business business sale come quarters solid focus europe context company recently sign lease expansion site ohio accelerate growth domestic direct consumer sale channel moreover second quarter company take series strategic initiative strengthen product offering market position regard company successfully integrate medsupport system acquire continue slew product development launch company receive ec certificate product jun management company also effectively launch new customer relationship management crm system jun latest development be expect enhance productivity sale bill customer service team long term flip side decline rental revenue raise concern mar company prospect moreover company generate significant portion revenue international market volatile foreign exchange rate always continue concern company zack rank key picksinogen currently carry zack rank hold few better rank medical stock be edward lifescience corporation ew free report insys therapeutic inc insy free report align technology inc algn free report notably edward lifescience insys therapeutic align technology sport zack rank strong buy see complete list today zack rank stock here insys therapeutic have long term expect earning growth rate stock post stellar quarter average earning surprise align technology have expect long term adjust earning growth almost stock have add roughly last month edward lifescience have long term expect earning growth rate stock have gain last month today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1143,EW,aug issue update research report san diego base illumina inc ilmn free report company provide tool integrate system analysis genetic variation function illumina exit second quarter solid note earning revenue beating zack consensus estimate top line be strong new product launch include veriseq nipt solution europe strength novaseq more good news be rate nipt adoption be increase outside notably last month illumina have be trading broader industry stock have grow period compare gain broader industry company raise guidance be also encourage enough indicate bullish trend continue come period also demand novaseq surpass company expectation order beating forecast more novaseq instrument have be order launch january be also look forward grail illumina own develop company focuse cancer screening market clinical market demand customer undergo oncology testing remain robust be currently look forward performance extend ra panel slate launch third quarter significantly june company announce fda approval receipt extend ra companion diagnostic kit class iii pma flip side weak margin owing novaseq launch higher array service revenue product mix sequence consumable continue act deterrent also national institutes health nih funding issue tough competitive landscape be other few concern deal zack rank key picksillumina currently have zack rank hold better rank medical stock be edward lifescience corporation ew free report insys therapeutic inc insy free report align technology inc algn free report sporting zack rank strong buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have gain last month insys therapeutic have expect long term earning growth rate stock have gain last month align technology have expect long term adjust earning growth almost stock have surge roughly last month today stock zack hottest strategy hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1144,EW,bruker corporation brkr free report report adjust earning share ep cent second quarter year figure adjust ep also beat zack consensus estimate cent exclude time adjustment bruker report net income cent share second quarter reflect increase respectively year quarter revenue detailbruker report revenue second quarter year year top line surpass zack consensus estimate exclude positive effect acquisition negative effect change foreign currency rate bruker report year year organic revenue growth second quarter geographically currency adjust european revenue increase high single digit second quarter backed encourage impact acquisition north america revenue increase low single digit lead growth best ost acquisition asia pacific organic revenue rise roughly drive continue strong performance china management company register organic revenue growth base mid teen growth calid group strength best bruker corporation price consensus ep surprise bruker corporation price consensus ep surprise bruker corporation bruker biospin group report mid single digit revenue growth lead grow uptake lower field nmr nuclear magnetic resonance bruker nano report decline year year organic revenue second quarter mainly due lower revenue semiconductor metrology product bruker calid group report year year mid teen revenue growth second quarter upside be largely drive increase rapiflex revenue strong performance consumable aftermarket service sale best revenue rise substantial organically year year basis backed higher mri oem consumer demand bruker ost acquisition nov margin trendgross margin report quarter contract basis point bps accord company adjust gross margin decline bps lead robust revenue growth lower margin best business further affected acquisition ost together have adverse impact roughly bps moreover biospin business witness drop margin year year due product mix selling general administrative expense increase research development expense rise year period other charge decline year year overall operate margin expand bps financial positionbruker exit second quarter cash cash equivalent short term investment end first quarter year date net cash provide operate activity be compare year period guidancebruker provide update guidance full year total revenue growth rate expectation year have be significantly raise new band earlier moreover organic revenue growth guidance have be raise previously continue acquisition growth expectation unchanged change foreign currency rate be expect have adverse impact revenue approximately mark improvement project previously current zack consensus estimate revenue be peg company also expect adjust operate margin increase approximately bps year year unchanged previous guidance include approximate bps headwind fiscal recent acquisition bottom line front bruker raise adjust ep projection new range current zack consensus estimate ep be peg takebruker exit second quarter solid note earning revenue beating zack consensus estimate company also raise full year guidance be indicative brighter prospect move company strategic acquisition activity have be encourage context company recently announce completion acquisition field portable platform technology platform product line acquisition widen bio detection offering encapsulate range bacterial viral toxin detection solution homeland security microbiology application be also upbeat company current focus product development latest fda approval add new species maldi biotyper system efficient microbial identification flip side currency fluctuation competitive landscape macroeconomic headwind continue challenge company zack rank other key picksbruker currently carry zack rank buy few top rank medical stock be edward lifescience corporation ew free report insys therapeutic inc insy free report align technology inc algn free report notably edward lifescience insys therapeutic align technology sport zack rank strong buy see complete list today zack rank stock here insys therapeutic have long term expect earning growth rate stock post stellar quarter average earning surprise align technology have expect long term adjust earning growth almost stock have add roughly last month edward lifescience have long term expect earning growth rate stock have gain last month today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1145,EW,allscript healthcare solution inc mdrx free report report second quarter adjust earning cent share line zack consensus estimate figure edge past year earning cent share adjust revenue exclude acquisition related defer revenue netsmart grow adjust revenue surpass zack consensus estimate adjustment allscript report revenue also outpaced estimate stock have zack rank sell quarter detailskey highlight solid growth core solution service fuel sunrise electronic health record ehr platform allscript revenue cycle management service buoy optimism second quarter furthermore increase demand careinmotion solution health plan market multiple global client asia pacific region drive revenue allscript cloud base precision medicine platform bprecise announce technology license agreement collaboration mayo clinic quarter booking booking second quarter be highest date year year basis net booking emerge software delivery unit remain be related client service solid growth booking be fuel double digit growth payer life science business furthermore netsmart register record booking quarter majority register new client software delivery support maintenance revenue segment consist software hardware subscription other transaction support maintenance revenue accord management adjust revenue segment increase quarter client service revenue segment consist recur manage service other project base client service revenue client service revenue be year year basis recur revenue segment consist subscription recur transaction support maintenance recur manage service adjust recur revenue increase year year basis recur revenue segment comprise system sale other project base client service revenue adjust recur revenue increase year year basis allscript healthcare solution inc price consensus ep surprise allscript healthcare solution inc price consensus ep surprise allscript healthcare solution inc quotemargin detailsa percentage revenue allscript register adjust gross margin second quarter compare year quarter margin contract basis point bps year year basis software gross margin percentage revenue decrease bps year year basis however client service margin second quarter increase almost bps revenue compare same period last year margin expansion be back gain efficiency scale company manage service business adjust operate expense quarter totale reflect year year increase full year company expect revenue previously issue range adjust earning share be expect grow band adjust ebitda be expect band allscript raise adjust revenue growth guidance company expect adjust revenue growth band previously issue range adjust earning share be expect increase band previously issue range most importantly allscript announce acquisition hospital health system business mckesson corporation mck free report be estimate close early fourth quarter deal be worth cash takeallscript exit second quarter favorable note adjust earning be line zack consensus estimate revenue beat same solid guidance full year strong long term outlook be key highlight moment allscript announce plan takeover hospital health system business mckesson corporation be expect close fourth quarter allscript continue reliance merger acquisition activity pose substantial integration risk furthermore intensify competition be major dampener company product have long sale cycle involve intensive decision make different managerial level add wo company expect modest increase operate expense second half year support business growth key picksbetter rank stock broader medical sector be edward lifescience corporation ew free report abiom inc abmd free report notably edward lifescience sport zack rank strong buy abiom have zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate notably stock have return last month abiom yielded strong return last year stock have long term expect earning growth rate today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1146,EW,waltham base perkinelmer inc pki free report worldwide provider product service solution diagnostic research laboratory service market report second quarter adjust earning cent share line zack consensus estimate company report adjust revenue approximately come zack consensus estimate however come year quarterly revenue segment analytical solution da revenue totale second quarter compare year quarter marked rise organically meanwhile operate profit margin percentage revenue second quarter be prior year quarter level diagnostic segment segment revenue be second quarter compare year quarter imply increase organically meanwhile operate profit margin percentage revenue segment second quarter be year quarter margin detailsadjust gross margin percentage revenue be quarter basis point bps year year downside be result impact acquisition divestiture complete adjust selling general administrative sg expense percentage revenue be bps year quarter research development expense percentage revenue rise bps quarter result company overall adjust operate margin continue operation come net revenue rise bps year year basis perkinelmer inc price consensus ep surprise perkinelmer inc price consensus ep surprise perkinelmer inc quotefinancial detail first half perkinelmer operate cash flow continue operation be compare prior year period company finished quarter approximately debt guidance company revise adjust earning guidance full year perkinelmer now expect adjust earning share band previously provide range key have zack rank hold better rank stock broader medical sector include edward lifescience corporation ew free report abiom inc abmd free report dextera surgical inc notably edward lifescience sport zack rank strong buy abiom dextera have zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate notably stock have return last month abiom yielded strong return last year stock have long term expect earning growth rate dextera have project sale growth current year stock promise long term expect earning growth rate today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1147,EW,stock market have be stellar run year thank strong corporate earning still lower interest rate improve health economy world even ongoing turmoil washington geopolitical tension north korean nuclear missile test stretched valuation fail block road fact dow jone crossed milestone first time yesterday trading session hit mark earlier year be less shy major threshold bullish trend be likely continue least term be especially true economy have be solid growth path buoy impressive labor market increase wage increase consumer spending gdp growth expand annually second quarter be double first quarter growth represent fastest growth third quarter last year economy grow notably month growth confirm year expansion mid third longest economic winning streak american history march march month february december month additionally consumer now appear be more optimistic enter second half year consumer confidence index indicated conference board surge year high july revise june be much expect further weaker dollar help blue chip company most revenue come international market surge higher read etfs ride year high consumer confidence bullish sentiment momentum investing be winning strategy seek higher return short spell be strategy look fetch profit buy hot stock have show uptrend past few week month such have present etfs stock lead outperformance current market environment further even beat broader market return come month etf picksishare edge msci usa momentum factor etf mtum free report fund provide exposure large mid cap stock exhibit relatively higher price momentum tracking msci usa momentum index charge bps fee year be popular choice aum first trust dorsey focus etf fv free report product track dorsey focus index provide target exposure first trust sector industry base etfs dorsey associate dwa believe have greatest potential outperform other etfs universe approach result little higher fee bps year have aum goldman sachs activebeta large cap equity etf gslc free report fund seek offer exposure stock well establish attribute performance good value strong momentum high quality low volatility track goldman sachs activebeta large cap equity index charge investor bps annual fee fund have amassed asset base have zack etf rank buy rating read etf investing mistake avoid spdr russell momentum focus etf oneo free report aum product target large cap security combination core factor high value high quality low size characteristic focus factor comprise high momentum characteristic follow russell momentum focuse factor index charge annual fee bps fund have zack etf rank hold rating cambrium core equity etf ccor free report be actively manage etf provide exposure high quality company industry sector have prospect long term return due ability grow earning increase dividend time hold security basket charge high expense ratio ccor have garner enough investor interest debut late have accumulate asset base read new hot etfs first half stock picksimperva inc impv free report california base company be engage development protection software service business application databasis have see solid earning estimate revision loss loss cent year past day expect earning growth stock have zack rank strong buy momentum style score see complete list today zack rank stock herelam research corporation lrcx free report california base company design manufacture market service semiconductor process equipment used fabrication integrate circuit see impressive earning estimate revision past day fiscal year expect earning growth stock have zack rank momentum style score edward lifescience corporation ew free report california base company provide product technology treat late stage cardiovascular disease see solid earning estimate revision cent year past day expect earning growth stock have zack rank momentum style score read biotech etfs continue surge higher krono worldwide inc kro free report texas base company be global producer marketer value add titanium dioxide pigment have see solid earning estimate revision cent year past day expect whopping earning growth stock have zack rank momentum style score innoviva inc california base company be focuse development financial management bio pharmaceutical see solid earning estimate revision cent year past day massive expect earning growth stock have zack rank momentum style score want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
1148,EW,hologic inc holx free report report third quarter fiscal adjust earning share ep cent year year however adjust ep beat zack consensus estimate penny remain upper end company guidance cent strong top line growth lead better expect ep increase report quarter report basis company record net income cent share reflect year year decline respectively revenue detailrevenue gross quarter year year top line also exceed zack consensus estimate company own estimation constant exchange rate cer revenue growth be solid growth hologic molecular diagnostic gyn surgical business segment drive upside top line hologic inc price consensus ep surprise hologic inc price consensus ep surprise hologic inc revenue grow year year exclude blood screening medical aesthetic revenue rise other hand international revenue be cer banking increase revenue breast health gyn surgical product exclude blood screening medical aesthetic international revenue increase constant currency segment detailrevenue diagnostic segment total revenue decline year year cer second quarter segment molecular diagnostic revenue increase cer be primarily drive increase market share utilization fully automate panther system market expansion conform testing guideline internationally result be strong acquire benefit new leadership healthy panther placement multiple new product introduction include viral load assay cytology perinatal revenue also show decline cer revenue breast health segment inched cer revenue decline reduce incremental placement gantry international revenue however climb year year revenue gyn surgical business be cer medical aesthetic business quarter report revenue total revenue revenue skeletal health accounting rest drop cer operational updatein fiscal third quarter hologic gross margin contract basis point bps adjust gross margin also decrease bps due product geographic revenue mix divestiture blood screening business full quarter revenue low margin cynosure product hologic adjust operate expense amount year year adjust operate margin contract massive bps financial updatehologic exit fiscal third quarter cash cash equivalent considerably report end second quarter total long term debt be end fiscal third quarter compare end precede quarter year date operate cash outflow be compare cash inflow same period last year fiscal guidancehologic reduce revenue guidance fiscal company currently expect revenue range earlier band new outlook reflect annualize growth previously be current zack consensus estimate remain company provide guidance management have however raise lower end earlier provide adjust ep outlook fiscal hologic currently project adjust ep range previous fiscal reflect annualize growth current zack consensus estimate adjust ep be peg fall just upper end guide range fourth quarter fiscal hologic expect revenue represent annualize growth current zack consensus estimate fourth quarter revenue be close upper end project range adjust ep be project cent annualize decline current zack consensus estimate fourth quarter adjust ep be peg cent company guidance takehologic post better expect third quarter fiscal result term earning revenue company strong cash position be encourage factor however be disappoint decrease revenue company diagnostic segment blood screening divestiture be expect mar company growth momentum day ahead overall company reduce revenue guidance fiscal lower investor confidence stock zack rank other key pickshologic currently have zack rank sell medical stock worth consider be edward lifescience corporation ew free report insys therapeutic inc insy free report align technology inc algn free report stock sport zack rank strong buy see complete list today zack rank stock here insys therapeutic have expect long term earning growth rate stock have gain last month align technology have expect long term adjust earning growth almost stock have surge roughly last month edward lifescience have long term expect earning growth rate stock have gain last month more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
1149,EW,corporation abc free report post adjust earning share third quarter fiscal beating zack consensus estimate increase year year basis upside be primarily drive strong growth consult service mwi animal health world courier business revenue improve almost report quarter however report revenue be lower zack consensus estimate revenue distribution segment report quarter revenue segment increase segment drug corp revenue be primarily back solid organic sale growth specialty group unit segment perform impressively quarter revenue rise year year increase be attribute strong oncology product sale solid performance third party logistic business other segment segment include consult service abcs world courier mwi veterinary supply revenue segment come year year basis operate expense percentage revenue third quarter be compare year quarter operate income percentage revenue contract basis point bps quarter review percentage revenue gross profit decline bps report quarter year year basis corporation hold co price consensus ep surprise corporation hold co price consensus ep surprise corporation hold co expect fiscal revenue growth range approximately significantly lower previously provide band company expect adjust diluted earning share fiscal band previously provide company expect brand drug inflation range zack rank stock have zack rank sell better rank medical stock include edward lifescience corporation ew free report abiom inc abmd free report fresenius medical care corporation fms free report fresenius medical care edward lifescience sport zack rank strong buy abiom have zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have year return abiom deliver strong return last year stock have long term expect earning growth rate fresenius medical care represent return last year company deliver solid earning surprise last report quarter more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
1150,EW,integer holding corporation itgr free report report adjust earning cent share second quarter versus cent year quarter however earning miss zack consensus estimate cent revenue rise year year second quarter also exceed zack consensus estimate sale grow report organic basis second quarter courtesy solid performance company cardio vascular business quarter detailsinteger operate segment advanced surgical orthopedic portable medical cardio vascular cardiac neuromodulation advanced surgical orthopedic portable medical revenue second quarter amount highlight decrease prior year quarter comparable organic constant currency basis advanced surgical orthopedic portable medical revenue rise year year be primarily drive stable performance portable medical space new launch orthopedic arthroscopic platform cardio vascular revenue segment totale reflect increase prior year quarter come back strong demand exist oem product line contract component comparable organic constant currency basis revenue report quarter increase prior year chiefly drive increase customer demand vascular access product cardiac neuromodulation revenue segment be decrease prior year quarter comparable organic constant currency basis cardiac neuromodulation revenue fall however relentless focus customer relationship numerous value add service opportunity economic efficiency be expect drive sale segment fact company be well position optimize total cost ownership supply chain control segment integer holding corporation price consensus ep surprise integer holding corporation price consensus ep surprise integer holding corporation full year expect revenue range adjust comparable basis adjust earning same be project range share fiscal zack rank key picksinteger have zack rank sell few better rank stock broader medical sector be edward lifescience corporation ew free report cryolife inc cry free report fresenius medical care corporation fms free report notably fresenius medical care sport zack rank strong buy edward lifescience cryolife have zack rank buy see complete list today zack rank stock here fresenius medical care represent impressive return last year company deliver solid earning surprise last report quarter edward lifescience have long term expect earning growth rate notably stock have year return cryolife yielded strong return last year stock deliver positive earning surprise last report quarter hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1151,EW,danver base abiom inc abmd free report lead developer manufacturer marketer medical product report first quarter fiscal earning cent share come ahead zack consensus estimate cent figure be also higher cent year quarter report quarter revenue increase roughly year year approximately outpace zack consensus estimate year year upside be support robust performance impella heart pump product line impella heart pump product line robust performance support year year upside quarter impella heart pump global revenue grow strong quarter impella revenue improve drive increase patient utilization outside revenue shot germany account majority international revenue grow year year basis report quarter install base impella heart pump grow hospital raise take install customer base total site install customer base impella cp heart pump grow hospital reach total overall operate income report quarter come operate margin percentage revenue compare prior year quarter abiom gross margin first quarter be compare first quarter fiscal financial conditionabiom cash cash equivalent be jun compare mar notably management announce company currently have debt abiom inc price consensus ep surprise abiom inc price consensus ep surprise abiom inc forecast fiscal revenue range mark increase fiscal level operate margin be project band takego forward believe robust demand impella product line continue drive abiom top line long term company expand product portfolio improve penetration prophylactic high risk pci cardiogenic shock patient market go forward be evident fact impella cp continue add center new publication regard device lead medical journal help promote utilization effectiveness abiom significant international presence help broaden customer base other positive fluctuation currency exchange rate adversely impact company international sale fluctuation currency exchange rate adversely impact abiom international sale company international presence broaden customer base zack rank key picksabiom have zack rank buy other better rank stock broader medical sector be edward lifescience corporation ew free report cryolife inc cry free report fresenius medical care corporation fms free report notably fresenius medical care sport zack rank strong buy edward lifescience cryolife have zack rank see complete list today zack rank stock here fresenius medical care represent impressive return last year company deliver solid earning surprise last report quarter edward lifescience have long term expect earning growth rate notably stock have year return cryolife yielded strong return last year stock deliver positive earning surprise last report quarter hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1152,EW,palo alto base lead manufacturer medical device software varian medical system inc var free report report adjust earning share third quarter fiscal steering past zack consensus estimate cent however adjust earning decline year year basis meanwhile revenue be year quarter constant currency cc revenue marginally miss zack consensus estimate varian medical report backlog end fiscal third quarter year year basis varian medical carry zack rank hold moment varian medical system inc price consensus ep surprise varian medical system inc price consensus ep surprise varian medical system inc quotesegment detailsoncology system segment revenue totale year year management oncology segment lack luster thank increase backlog mix emerge market notably cause longer backlog conversion cycle mar oncology revenue quarter review gross order quarter totale cc year quarter gross order increase cc emea apac gross order rise respectively year year basis particle therapy third quarter revenue segment be year year basis quarter company register order worth include order georgia proton therapy center atlanta segment put impressive show third quarter banking order single room probeam compact system university pennsylvania thailand product launch bode wellvarian medical have be take initiative gain customer attention broad spectrum product company unveil halcyon radiotherapy treatment system astro conference vienna third quarter halcyon radiotherapy treatment system have be design offer cost effective cancer care worldwide system streamline aspect image guide volumetric intensity modulate radiotherapy imrt halycon receive clearance ce mark european directive allow varian medical start selling system management regulatory clearance china japan follow next year quarter varian medical book several order country australia belgium india morocco romania russia turkey marginsin third quarter gross margin expand basis point bps revenue buoy increase mix service consistent varian medical long term strategy oncology system gross margin rise nearly bps drive supply chain efficiency proton therapy gross margin third quarter remain flat year year basis revenue expense research development quarter be revenue meanwhile selling general administrative sg expense quarter be year year basis rise expense be drive investment new product launch fourth quarter management estimate adjust earning share range second fourth quarter varian medical expect revenue growth range earning band stock varian medical drop close follow earning release stock have gain last month compare favorably industry decline however current level be slightly lower gain same time frame key picksa few better rank stock broader medical sector be edward lifescience corporation ew free report cryolife inc cry free report fresenius medical care corporation fms free report notably fresenius medical care sport zack rank strong buy edward lifescience cryolife have zack rank buy see complete list today zack rank stock here fresenius medical care represent impressive return last year company deliver solid earning surprise last report quarter edward lifescience have long term expect earning growth rate notably stock have year return cryolife yielded strong return last year stock deliver positive earning surprise last report quarter more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
1153,EW,edward lifescience corporation ew free report report second quarter adjust earning share ep surpass zack consensus estimate cent wide margin adjust earning also improve stupendous year year primarily drive strong sale growth company transcatheter heart valf business exclude time item net income second quarter come cent share year year respectively sale detailsedward lifescience second quarter sale improve figure also beat zack consensus estimate underlie sale increase include impact germany stocking sale customer germany elect purchase additional inventory sapien valve anticipation potential supply interruption result recent intellectual property litigation revenue be primarily drive considerable growth transcatheter heart valve sale well strong performance other product line region edward lifescience corporation price consensus ep surprise edward lifescience corporation price consensus ep surprise edward lifescience corporation quotesegment second quarter company report transcatheter heart valve therapy thvt sale reflect growth prior year quarter thvt sale quarter be year year growth be drive excellent clinical performance result be deliver sapien well continue strong therapy implementation region surgical heart valve therapy sale quarter be prior year quarter be lead strong demand edward intuity elite valve system supply recovery mitral valve sale partially offset continue shift surgical aortic valf sapien valve critical care sale be report quarter represent increase second quarter solid growth product category be drive double digit growth company enhance surgical recovery program mainly asia pacific marginsin first quarter gross margin expand basis point bps owing more profitable product mix lead grow sale transcatheter valf be however partially offset adverse foreign exchange sg expense rise year year account sale personnel related expense primarily transcatheter valve thv segment other hand expenditure increase year year owing continue investment company transcatheter mitral valve mitral valve program include expenditure clinical trial adjust operate margin quarter expand bps rise revenue outweighed increase operate expense cash positionedward lifescience exit second quarter cash cash equivalent short term investment compare end first quarter long term debt quarter totale compare report previously cash flow operate activity be second quarter compare previous quarter exclude capital spending free cash flow be quarter management repurchase share offset dilution associate valtech cardio acquisition stock base incentive compensation update guidancebanking solid second quarter performance edward lifescience have raise full year sale expectation high end previously project range zack consensus estimate full year revenue be high end guide range adjust ep expectation have also be raise zack consensus estimate full year adjust ep stand company guide range third quarter company project sale exclude effect germany stocking sale zack consensus estimate revenue be project range company estimate adjust ep cent cent meanwhile zack consensus estimate adjust ep be cent be also company forecast range takeedward lifescience exit second quarter solid note earning revenue beating zack consensus estimate strong transcatheter valve sale be major positive company also perform well gross margin front raise optimism moreover edward lifescience raise revenue earning guidance hint better day ahead however tough competition cardiac device market reimbursement issue continue challenge company nevertheless management expect gain traction ever expand tavr market base increase preference favor transcatheter aortic valve replacement well compelling clinical evidence lead strong adoption thv therapy zack rank other key pickscurrently edward lifescience sport zack rank strong buy other top rank stock worth consider broader medical sector be petm express inc pet free report becton dickinson company bdx free report quest diagnostic inc dgx free report notably petm sport zack rank becton dickinson company quest diagnostic carry zack rank buy see complete list today zack rank stock here petm have long term expect earning growth rate stock have gain last month becton dickinson company have long term expect earning growth rate stock have gain last month quest diagnostic have long term expect earning growth rate stock have gain last month more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
1154,EW,becton dickinson company bdx free report popularly know bd report third quarter fiscal earning share beat zack consensus estimate increase year year basis interestingly bd post positive earning surprise past quarters average furthermore stock currently have zack rank buy signify probability outperformance term get back quarter bd register revenue year year basis primarily owing divestiture respiratory solution business however revenue be year quarter comparable currency neutral basis revenue miss zack consensus estimate segment detailsbd medical segment bd medical generate revenue year year basis however comparable currency neutral basis revenue increase year year impressive result company medical segment reflect strong performance medication procedural solution diabetes care pharmaceutical system unit bd life science segment bd life science generate revenue year quarter revenue growth bd life science segment reflect strong performance bioscience unit solid growth diagnostic system preanalytical system unit revenue report basis revenue decrease roughly increase comparable basis bd medical segment witness stellar performance medication procedural solution diabetes care unit however massive growth segment be partially negate sluggishness medication management solution pharmaceutical system unit bd solid performance preanalytical system bioscience unit buoy growth life science segment international revenue bd witness decline revenue outside however comparable currency neutral basis revenue rise back solid growth segment becton dickinson company price consensus ep surprise becton dickinson company price consensus ep surprise becton dickinson company fiscal comparable currency neutral basis revenue be anticipate increase approximately notably exclude respiratory solution other divestiture close fiscal revenue be likely decline range year year basis owing divestiture respiratory solution business fiscal adjust earning share be expect be previously issue range represent growth approximately key picksa few other top rank stock broader medical sector be edward lifescience corporation ew free report abiom inc abmd free report dextera surgical inc notably edward lifescience sport zack rank abiom dextera have zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate notably stock have return last month abiom yielded strong return last year stock have long term expect earning growth rate dextera have project sale growth current year stock promise long term expect earning growth rate more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
1155,EW,fresenius medical care ag co kgaa fms free report report adjust earning cent american depositary share ad second quarter miss zack consensus estimate cent also earning ad remain flat year year basis last quarter company have deliver positive earning surprise quarter review revenue increase constant currency cc year year basis beat zack consensus estimate stock have zack rank strong buy fresenius medical care corporation price consensus ep surprise fresenius medical care corporation price consensus ep surprise fresenius medical care corporation quotesegment detailsrevenue detail total health care service revenue increase cc meanwhile product revenue grow cc note organic revenue contribution health care service increase year year basis glimpse product revenue reveal organic growth year year north america revenue geography north america revenue rise year year account total revenue be fuelled higher dialysis treatment increase revenue treatment dialysis business grow year year basis region cc meanwhile care coordination segment increase cc emea revenue revenue region increase year year basis primarily drive positive business development dialysis product revenue increase health care service revenue emea rise cc second quarter asia pacific revenue revenue asia pacific grow cc year year basis net health care revenue region grow organically courtesy solid growth dialysis treatment latin americarevenue revenue region increase cc business grow region witness strong rise dialysis product revenue rise year year basis courtesy higher sale dialyzer well hemodialysis solution concentrate health care service revenue increase region margin detailsdialysis margin contract basis point bps year year basis net revenue company witness high expense supply rent quarter result contraction margin however adverse impact be roughly nullify lower bad debt expense consent agreement certain pharmaceutical second quarter care coordination margin also decrease year year basis owing lower profit vascular service higher cost pharmacy service full year fresenius medical reiterate guidance company estimate revenue growth cc net income attributable shareholder company be likely increase takefresenius medical care end second quarter mixed note adjust earning miss zack consensus estimate revenue beat same company reiterate full year guidance believe be tune company long term objective growth strategy aim increase revenue corresponding average annual growth rate wide range dialysis product initiative attain market traction solid international foothold strategic acquisition divestment be major catalyst company however tough regulatory environment difficulty boost profit margin foreign legal paradigm competition niche market be major headwind key picksa few other top rank stock broader medical sector be edward lifescience corporation ew free report abiom inc abmd free report dextera surgical inc notably edward lifescience sport zack rank abiom dextera have zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate notably stock have return last month abiom yielded strong return last year stock have long term expect earning growth rate dextera have project sale growth current year stock promise long term expect earning growth rate more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
1156,EW,cardiovascular system inc csii free report report adjust earning share cent fourth quarter fiscal reflect massive improvement year quarter adjust loss cent share quarter number compare favorably zack consensus estimate loss cent year year improvement be primarily backed revenue growth lower operate expense account company cost realignment action full year adjust earning come loss cent share narrower year loss also loss figure be narrower zack consensus estimate loss cent number system post revenue fiscal fourth quarter mark year year increase figure also surpass zack consensus estimate cardiovascular system inc price consensus ep surprise cardiovascular system inc price consensus ep surprise cardiovascular system inc quotefiscal register revenue year number also revenue outpaced zack consensus estimate management company receive approval new orbital atherectomy device give physician more tool effectively routinely treat patient suffering coronary peripheral artery disease also approval diamondback coronary orbital atherectomy system micro crown japan mark company first international expansion begin calendar year date cardiovascular system sell device lead institution company add new peripheral account coronary account fiscal fourth quarter coronary device revenue improve year year peripheral device revenue rise margingross margin report quarter be basis point bps year year primarily account rise revenue meanwhile selling administrative sg expense contract research development expense be resultant adjust operate expense decrease primarily exhibit management cost realignment initiative consequently operate profit be improve loss year financial company exit fourth quarter fiscal cash cash equivalent compare end third quarter fiscal system issue first quarter fiscal fiscal guidance company expect revenue range fiscal current zack consensus estimate fiscal revenue be peg be company guidance company also expect revenue range first quarter fiscal current zack consensus estimate be peg slightly company guide range moreover company expect gross profit account revenue operate expense be estimate first quarter fiscal company expect incur net loss loss share cent first quarter fiscal current zack consensus estimate be peg breakeven company guide range system deliver remarkable fourth quarter result earning revenue beating zack consensus estimate also cardiovascular system fiscal performance have be impressive company lower operate expense drive year year improvement earning strong revenue performance also contribute upside earning moreover improvement margin be encourage company fiscal guidance also instill confidence investor company achieve several milestone quarter notably have receive fda approval radial access diamondback peripheral orbital atherectomy device year result liberty study be be present amputation prevention symposium amp zack rank key system currently have zack rank hold few better rank medical stock be edward lifescience corporation ew free report insys therapeutic inc insy free report align technology inc algn free report notably edward lifescience insys therapeutic align technology sport zack rank strong buy see complete list today zack rank stock here insys therapeutic have long term expect earning growth rate stock have gain last month align technology have expect long term adjust earning growth almost stock have add roughly last month edward lifescience have long term expect earning growth rate stock have gain last month more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
1157,EW,masimo corp masi free report report earning cent share second quarter outperform zack consensus estimate cent bottom line also improve year earning cent revenue improve year quarter beat zack consensus estimate quarter direct product revenue product revenue increase oem sale product revenue decline year quarter total product revenue decrease year year basis company rainbow product revenue report quarter totale be year year basis quarter review masimo ship approximately set pulse oximeter rainbow set pulse co oximeter exclude handheld unit company estimation worldwide install base be unit jul unit jul masimo corporation price consensus ep surprise masimo corporation price consensus ep surprise masimo corporation quotefinancial condition jul masimo total cash cash investment be compare dec company generate cash operation receive proceed stock option exercise guidancemasimo now expect total fiscal revenue approximately previously provide guidance total fiscal product revenue be project approximately previous guidance royalty revenue projection increase approximately previously provide guidance fiscal earning diluted share be expect be approximately zack rank stock considermasimo have zack rank hold better rank medical stock include edward lifescience corporation ew free report abiom inc abmd free report fresenius medical care corporation fms free report fresenius medical care edward lifescience sport zack rank strong buy abiom have zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have year return abiom deliver strong return last year stock have long term expect earning growth rate fresenius medical care represent return last year company deliver solid earning surprise last report quarter more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
1158,EW,irvine base quality system inc qsii free report report first quarter fiscal adjust earning cent share exceed zack consensus estimate year figure penny revenue totale outpace zack consensus estimate revenue also increase year year basis quality system carry zack rank hold quarter detail total software hardware related revenue increase primarily drive rise software related subscription service however massive growth section be partially offset lower software license hardware sale fall almost quarter company expect software license hardware revenue remain pressure remainder fiscal subscription revenue quarter be year year basis revenue growth segment be drive strength entrada meditouch mirth platform support maintenance revenue increase year year basis professional service increase almost come electronic datum interchange edi service revenue increase year year basis almost meanwhile company revenue cycle management rcm business improve solid recur revenue base quality system recur revenue comprise contribution subscription support maintenance rcm edi first quarter recur revenue reach record level total revenue mark increase year year basis booking update quality system register booking worth report quarter year year management delay launch streamline simplified business model quality system impede booking growth first quarter margin detail quality system gross margin expand basis point bps report quarter come operate expense company record selling general administrative sg expense year expense increase incremental personnel cost debt expense meanwhile research development cost totale year expense rise first quarter back entrada acquisition latest nga product launch fiscal company project revenue band adjust earning share be project range cent cent previously issue band cent cent management slash earning guidance incremental investment related newly acquire eagledream health platform furthermore company expect sluggishness rcm suite solution owing contraction customer base quality system inc price consensus quality system inc price consensus quality system inc quoteour takequality system post stellar first quarter fiscal beating zack consensus estimate count be particularly upbeat company solid performance total software hardware related revenue quality system solid recur revenue base be key catalyst quarters come quality system continue focus grow presence revenue cycle management rcm population health solution market however ongoing sluggishness rcm customer base intensify competition strict regulatory environment be likely mar top line furthermore downbeat guidance signal loom concern key picksa few better rank stock broader medical sector be edward lifescience corp ew free report abiom inc abmd free report fresenius medical care corp fms free report notably fresenius medical care edward lifescience sport zack rank strong buy abiom have zack rank buy see complete list today zack rank stock here fresenius medical care represent impressive return last year company deliver solid earning surprise last report quarter edward lifescience have long term expect earning growth rate notably stock have year return abiom yielded strong return last year stock have long term expect earning growth rate more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
1159,EW,cardinal health inc cah free report report fourth quarter fiscal adjust earning share beat zack consensus estimate increase year year basis revenue increase year year basis almost beating zack consensus estimate quarter segment pharmaceutical revenue rise year year basis segment witness strong growth specialty business also gain huge number pharmaceutical distribution customer however generic pharmaceutical pricing company recent investment pharmaceutical platform lead drop segmental profit however solid performance red oak sourcing platform have partially offset negative effect medical segment revenue segment increase primarily higher contribution new exist customer medical segment profit increase courtesy higher contribution new exist customer solid performance post acute segment however unfavorable performance cardinal health brand product include cordis partially offset sale segment other detail distribution selling general administrative sg expense increase year year basis report quarter cash equivalent be jun cardinal health inc price consensus cardinal health inc price consensus cardinal health inc quotefy fiscal cardinal health register adjust earning share year year basis revenue increase year year basis record delve deeper segmental revenue detail pharmaceutical segment net revenue increase fiscal medical segment net revenue revenue soar year year basis company issue fiscal guidance adjust earning share continue operation furthermore cardinal health be expect register fiscal adjust earning share least key picksa few better rank stock broader medical sector be edward lifescience corporation ew free report abiom inc abmd free report fresenius medical care corporation fms free report notably fresenius medical care edward lifescience sport zack rank strong buy abiom have zack rank buy see complete list today zack rank stock here fresenius medical care represent return last year company deliver solid earning surprise last report quarter edward lifescience have long term expect earning growth rate notably stock have year return abiom yielded strong return last year stock have long term expect earning growth rate more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
1160,EW,baxter international inc bax free report report second quarter adjust earning share cent steer past zack consensus estimate cent be way better year figure cent figure be also company guidance cent cent interestingly last quarters company deliver positive earning surprise average be baxter post sale marginally beating zack consensus estimate constant currency cc revenue increase year year basis sale be year year international sale increase cc almost baxter international inc price consensus baxter international inc price consensus baxter international inc quotemajor factor positive tiding regulatory front quarter have be favorable baxter regulatory front company receive clearance regulatory authority regard propose acquisition claris injectable notably baxter be expect close transaction end july furthermore fda approval new premixed injectable be key catalyst company new product home pd technology also get fda nod second quarter platform leverage baxter flagship amia automate peritoneal dialysis apd system sharesource telehealth platform partnership second quarter baxter sign agreement india base dorizoe lifescience expansion generic injectable pipeline duo be expect develop more generic injectable product include infective oncolytic cardiovascular medicine however financial term deal have be keep wrapped post deal closure baxter leverage dorizoe expertise accelerate launch generic molecule deal combine baxter manufacturing leadership hospital channel strength dorizoe technical expertise thereby boost baxter foothold niche spacebaxter also announce research development collaboration lead institution mayo clinic ramot tel aviv university product launch second quarter baxter launch anew version ak hd system platform offer way connectivity capability meet need potential patient segment detailshospital product sale segment climb cc year year basis hospital product sale quarter be drive solid sale fluid system select anesthesia critical care product hospital sale be also drive solid demand parenteral nutrition therapy international bio surgery product renal product sale increase cc segment renal product sale be drive solid demand center hemodialysis hd product international acute renal care sale global sale peritoneal dialysis pd therapy guidance raise full year estimate sale growth approximately cc adjust earning share continue operation be forecast band third quarter baxter estimate sale growth cc adjust earning share be forecast range cent cent long term outlookbuoyed stellar growth earning sale company raise long term outlook baxter estimate sale growth approximately compound annual basis notably adjust operate margin full year be expect be approximately revenue much higher previously issue guidance baxter expect full year adjust diluted earning band share share have have impressive run bourse year date basis company have gain roughly higher broader industry addition almost moreover current level compare favorably return same time frame together long term expect earning growth rate almost instill confidence investor currently baxter have zack rank buy other key picksa few other top rank stock broader medical sector be edward lifescience corporation ew free report cryolife inc cry free report fresenius medical care corporation fms free report notably fresenius medical care sport zack rank strong buy edward lifescience cryolife have zack rank buy see complete list today zack rank stock here fresenius medical care represent impressive return last year company deliver solid earning surprise last report quarter edward lifescience have long term expect earning growth rate notably stock have impressive year return cryolife yielded strong return last year stock deliver positive earning surprise last report quarter hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1161,EW,second quarter earning season commence last week index have good start respect earning revenue growth latest earning preview jul member total market cap have report quarterly number total earning member have go higher revenue week member be line report quarterly result time be bullish equity market be gradually demonstrate sequential improvement store medical space overall growth be steadily accelerate few precede quarters performance investor be concern healthcare space sector have be see struggle lot past half year thank political power change ongoing policy restructure related battle president donald trump finally amend earlier propose american health care act ahca totally repeal replace obamacare uncertainty medical space be towering high investor be currently adopt see policy space lack visibility befuddle bullish trend medical sector broader zack sector be maintain past few quarters accordingly second quarter expect earning growth rate stand break even level revenue growth projection compare unfavorably first quarter report earning growth rate revenue growth let take sneak peek performance major medical instrument company broader medical space expect jul edward lifescience corporation ew free report lead cardiovascular product maker be schedule report second quarter result market close jul edward lifescience post strong global sale last report quarter primarily buoy strength transcatheter heart valve tavr banking continue therapy adoption geography notable strength company be expect maintain bullish trend second quarter well edward lifescience currently carry zack rank buy have earning esp be most accurate estimate zack consensus estimate be par cent note positive zack esp serve lead indicator likely positive earning surprise bullish zack rank increase predictive power esp read more edward lifescience earning surprise store edward lifescience corporation price ep surprise edward lifescience corporation price ep surprise edward lifescience corporation quotethermo fisher scientific inc tmo free report base medical instrument manufacturer focus boost growth implementation strategy strengthen product offering be encourage initiative be likely help post solid result second quarter company have already spend research development same trend be expect year too thermo fisher be expect beat expectation report second quarter result market open have right combination key ingredient stock currently carry zack rank buy have earning esp be most accurate estimate be zack consensus estimate be lower uncover best stock buy sell re report earning esp filter read more thermo fisher earning surpass expectation thermo fisher scientific inc price ep surprise thermo fisher scientific inc price ep surprise thermo fisher scientific inc quotevarian medical system inc var free report lead provider radiotherapy radiosurgery proton therapy brachytherapy treat cancer be schedule report third quarter fiscal earning market close strengthen foothold oncology business company launch fda approve product halcyon also june company sign agreement vijametech upmc establish radiation oncology center vietnam be also upbeat varian prospect internationally primarily bank proton therapy advanced treatment option cancer patient proven model do not conclusively show varian medical be likely beat earning quarter varian currently carry zack rank hold have earning esp be most accurate estimate zack consensus estimate be par cent see complete list today zack rank stock here read more varian medical earning be surprise store varian medical system inc price ep surprise varian medical system inc price ep surprise varian medical system inc quotemore stock news tech opportunity worth driverless car artifical intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
1162,EW,athenahealth inc athn free report report adjust earning cent share second quarter fiscal steering past zack consensus estimate cent share fact figure be way better adjust earning cent share register year quarter watertown base maker bill medical practice management software post revenue also beat zack consensus estimate increase year year basis share price athenahealth inched close follow earning release fact last month athenahealth have have impressive run bourse stock climb significantly higher zack categorize medical info system sub industry return only however estimate revision stock have be unfavorable zack consensus estimate full year earning share decline cent last month athenahealth have zack rank hold quarter detail athenahealth report business service revenue year quarter however implementation other segment post revenue same quarter last year margin detail strong client base have be major growth driver company adjust gross margin second quarter be compare year company see operate margin total revenue second quarter compare year quarter notably adjust operate income report quarter be network expansion management company expand network ambulatory hospital population health platform company network expand provider unique patient record cover life end second quarter buoy stellar network expansion company be expect fortify foothold revenue cycle management rcm space drive revenue earning growth long haul athenahealth inc price consensus ep surprise athenahealth inc price consensus ep surprise athenahealth inc quoteguidance reiterate guidance fiscal fiscal company expect revenue band adjust operate income be project range annual booking fiscal be expect bottom exit second quarter fiscal solid note outshine zack consensus estimate earning revenue management company expand network ambulatory hospital population health platform athenahealth unique business model make strong niche provider rcm service small physician practice believe application athenaclinical athenaclinical streamline athenainsight athenaone athenacollector hospital health system brand promise unbreak healthcare be fortify market position term exclusiveness service provide respective market furthermore solid revenue guidance instill confidence stock key picksa few better rank stock broader medical sector be edward lifescience corporation ew free report cryolife inc cry free report edap tms sa edap free report notably edap tms sport zack rank strong buy edward lifescience cryolife have zack rank buy see complete list today zack rank stock here edap tms represent impressive return last month company deliver solid earning surprise last report quarter edward lifescience have long term expect earning growth rate notably stock boast impressive year return cryolife yielded strong return last month stock deliver positive earning surprise last report quarter make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1163,EW,genomic health inc ghdx free report report second quarter loss share cent reflect improvement year quarter loss cent quarter number be however wider zack consensus estimate loss cent net loss report quarter be compare net loss year quarter revenue detailtotal revenue quarter rise year year slightly zack consensus estimate growth international market drive top line geographically second quarter product revenue improve product revenue growth be fuel invasive breast cancer revenue growth well rise prostate test revenue international product revenue be report quarter cer basis quarter company deliver more oncotype dx test result year year genomic health inc price consensus ep surprise genomic health inc price consensus ep surprise genomic health inc quotemargin trendin quarter review genomic health gross margin expand basis point bps year year apart significant top line growth improvement gross margin be lead decline cost product revenue genomic health also witness rise operate expense owing increase selling marketing expense rise research development expense however general administrative expense decline report quarter genomic health report operate loss show year year improvement operate loss year financial updategenomic health exit second quarter cash cash equivalent short term marketable security include corporate equity investment reflect slight improvement record end first quarter takegenomic health exit second quarter disappointing note be concern company rise operate expense well nevertheless be encourage decline cost sale lead solid gross margin expansion management note strong demand genomic health oncotype test second quarter be partly account growth international prostate global invasive breast business specifically invasive breast cancer oncotype dx test prove be company only test predict major short long term outcome context jun company announce result study base oncotype dx test american society clinical oncology asco annual meeting chicago management result confirm efficiency oncotype dx test predict clinically meaningful endpoint outcome multiple cancer type be also look forward company newly initiate clinical utility program select center prepare commercial launch oncotype dx ar nucleus detect test collaboration epic science flip side management have not issue guidance be discourage moreover company sole reliance breast oncotype dx test be concern zack rank key picksgenomic health currently carry zack rank sell few better rank medical stock be edward lifescience corporation ew free report insys therapeutic inc insy free report align technology inc algn free report zack rank strong buy see complete list today zack rank stock here insys therapeutic have long term expect earning growth rate stock have gain last month align technology have expect long term adjust earning growth almost stock have add roughly last month edward lifescience have long term expect earning growth rate stock have rally last month more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
1164,EW,resm inc rmd free report announce fourth quarter fiscal adjust earning share ep cent prior year quarter level earning also beat zack consensus estimate cent include time item resm report ep cent quarter year year full year adjust ep come increase fiscal figure revenue detailrevenue report quarter increase constant exchange rate cer year year figure also exceed zack consensus estimate exclude contribution business revenue increase year year full year revenue come rally year period resm inc price consensus ep surprise resm inc price consensus ep surprise resm inc revenue americas rise year year include revenue exclude revenue americas totale reflect increase prior year quarter solid result be fuel growth device well low double digit rise software sale combine revenue emea apac region be highlight rise cer compare same period last year growth be particularly strong uk france japan australia new adjust gross margin expand basis point bps year year report quarter selling general administrative expense be year year be increase research development expense have further lead rise adjust operate expense amount accordingly adjust operate margin quarter contract bps financial updateresmed exit year cash cash equivalent compare end entire year company generate cash flow operation year figure display weak underlie earning decline net work capital balance fiscal resm paid dividend also fiscal fourth quarter earning release resm announce increase quarterly dividend cent share dividend be paid sep shareholder record aug previously declare resm temporarily suspend share repurchase program due recent acquisition however company still expect recommence buy back program second quarter fiscal guidancewhile resm have not provide definite guidance fiscal company state be well position achieve financial strategic goal company be successfully work pipeline new product connect care solution sleep apnea copd neuromuscular disease other clinical adjacency takeresm exit fourth quarter fiscal promising note earning revenue beating zack consensus estimate bright side company achieve solid high single digit global revenue growth quarter lead sale sleep device respiratory care device mask system software solution have act significant contributor company operate result yet challenge competitive bidding reimbursement issue continue plague stock foreign exchange movement dent third quarter earning cent thank weaker euro stronger australian dollar relative dollar zack rank key picksresm currently have zack rank buy other top rank stock broader medical space be edward lifescience corporation ew free report insys therapeutic inc insy free report align technology inc algn free report stock sport zack rank strong buy see complete list today zack rank stock here insys therapeutic have expect long term earning growth rate stock have gain last month align technology have expect long term adjust earning growth almost stock have surge roughly last month edward lifescience have long term expect earning growth rate stock have gain last month more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
1165,EW,dexcom inc dxcm free report report loss cent share second quarter narrower zack consensus estimate loss cent also figure improve loss cent report year quarter total revenue grow reflect increase year quarter also figure come ahead zack consensus estimate operational detailsdexcom generate gross margin percentage revenue compare same quarter prior year notably gross margin rebound year year due improvement warranty rate primarily receiver line international business display continue year year growth quarter generate revenue year year basis notably international business represent total revenue second quarter germany contribute almost international business quarter research development expense totale quarter compare year company investment include pivotal study related submission fda selling general administrative expense totale report quarter compare prior year quarter rise be primarily due year year increase head count field sale cum customer support organization higher patient focuse marketing expense dexcom inc price consensus ep surprise dexcom inc price consensus ep surprise dexcom inc quotefinancial update jun dexcom have cash cash equivalent short term marketable security versus end quarter company raise gross proceed convertible note offer paid outstanding credit facility zack rank hold company project global revenue band reflect growth approximately full year dexcom anticipate gross margin low end guidance key pickssome better rank stock broader medical sector be edward lifescience corporation ew free report abiom inc abmd free report fresenius medical care corporation fms free report notably fresenius medical care edward lifescience sport zack rank strong buy abiom have zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate notably stock have year return abiom deliver strong return last year stock have long term expect earning growth rate fresenius medical care represent impressive return last year company deliver solid earning surprise last report quarter more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
1166,EW,ecolab inc ecl free report report second quarter adjust earning exclude special gain charge tax item share come zack consensus estimate earning improve report year quarter adjust quarterly net sale be year period also net sale come zack consensus estimate upside come new business gain better pricing product innovation cost efficiency more offset higher deliver product cost quarter detailsglobal industrial segment sale grow year year almost fix currency be drive major gain paper modest increase food beverage water north america latin america lead global industrial regional growth acquisition adjust fix currency operate income decrease due higher deliver product cost global institutional segment sale increase lead strong growth specialty healthcare business line acquisition adjust fix currency operate income increase pricing sale volume gain more offset innovation cum customer investment higher deliver product cost global energy segment sale increase owing strong growth well stimulation business modest gain downstream business acquisition adjust fix currency operate income decrease due higher deliver product cost lower pricing sale other segment climb year year account strong growth pest elimination business sale segment witness robust growth north america fix currency operate income fall pricing sale volume gain be offset higher field investment ecolab inc price consensus ep surprise ecolab inc price consensus ep surprise ecolab inc third quarter ecolab project adjust diluted earning share range compare year zack rank stock ecolab carry zack rank hold few better rank stock broader medical sector be edward lifescience corporation ew free report cryolife inc cry free report fresenius medical care corporation fms free report fresenius medical care sport zack rank strong buy edward lifescience cryolife carry zack rank buy see complete list today zack rank strong buy stock here edward lifescience have long term expect earning growth rate notably stock have year return cryolife deliver strong return last year stock report positive earning surprise previous quarter fresenius medical care deliver impressive return last year company deliver positive earning surprise last report quarter make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1167,EW,cerner corp cern free report report adjust second quarter earning cent share miss zack consensus estimate penny notably earning improve year quarter company report net revenue fall short zack consensus estimate however revenue rise year year basis cerner hold zack rank buy quarter update booking second quarter be time high year year basis revenue cycle have be strong contributor company result courtesy strong sale solid contribution revwork service revenue management service population health service business also drive revenue second quarter solid growth company flagship healtheintent solution company also post impressive performance ambulatory small hospital market segment detail system sale increase solid sale be buoy license software subscription partially offset decline technology resale total service revenue include professional manage service rise year quarter reflect solid execution company service organization support maintenance revenue increase quarter slightly company full year expect growth rate cerner expect growth band segment rest year geographically domestic revenue increase year quarter revenue fall cerner corporation price consensus ep surprise cerner corporation price consensus ep surprise cerner corporation quotemargin detail gross margin second quarter be revenue basis point bps year decline be due lower mix sublicens software lackluster performance cerner technology resale business adjust operate margin second quarter be net sale bps year balance sheetcerner end second quarter total cash investment total debt cerner include capital lease obligation be third quarter cerner forecast revenue adjust earning be expect band cent cent share full year management expect revenue compare previous guidance cerner currently forecast adjust earning band compare previously estimate range key picksa few other top rank stock broader medical sector be edward lifescience corporation ew free report cryolife inc cry free report fresenius medical care corporation fms free report notably fresenius medical care sport zack rank strong buy edward lifescience cryolife have zack rank see complete list today zack rank stock here fresenius medical care represent impressive return last year company deliver solid earning surprise last report quarter edward lifescience have long term expect earning growth rate notably stock have year return cryolife yielded strong return last year stock deliver positive earning surprise last report quarter hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1168,EW,murray hill nj base bard inc report adjust earning second quarter exceed zack consensus estimate adjust earning also improve year period net sale second quarter increase year year basis figure be also better zack consensus estimate exclude impact foreign exchange net sale improve year year basis bard get acquiredon apr becton dickinson company bdx lead global medical technology company announce acquire bard bard common share cash stock agreement be expect close fourth quarter believe development provide benefit medication management infection prevention bard customer bolster foothold global medical device market regard bard register more product internationally full year quarter highlightsu net sale rise year year international sale increase foreign exchange headwind second quarter net sale outside rise year year basis segment detailsvascular product sale segment increase year year cc urology sale increase year year basis cc urology segment oncology sale segment be cc year year surgical specialty sale be cc year year sale other product line increase year year basis cc almost bard inc price consensus ep surprise bard inc price consensus ep surprise bard inc fiscal adjust earning share adjust amortization intangible be project represent year year growth range bard expect net sale growth report basis exclude impact foreign exchange net sale be project increase prior year key pickscurrently bard carry zack rank hold few better rank stock broader medical sector be edward lifescience corporation ew free report cryolife inc cry free report fresenius medical care corporation fms free report notably fresenius medical care sport zack rank strong buy edward lifescience cryolife have zack rank buy see complete list today zack rank stock here fresenius medical care represent impressive return last year company deliver solid earning surprise last report quarter edward lifescience have long term expect earning growth rate notably stock have year return cryolife yielded strong return last year stock deliver positive earning surprise last report quarter hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
1169,EW,intuitive surgical inc isrg free report post adjust earning share second quarter crush zack consensus estimate stellar revenue growth also figure improve year year basis interestingly last quarters company beat estimate average revenue increase year year drive growth recur instrument accessory service system revenue revenue also beat zack consensus estimate follow result share price be close also share intuitive surgical have return year date outperform industry gain business surgical post solid number quarter review courtesy rise customer adoption procedure growth system placement worldwide da vinci procedure volume grow approximately year year increase be attribute stellar performance general surgery worldwide urologic procedure notably company ship da vinci surgical system second quarter revenue accessory revenue segment grow quarter drive strong procedure growth increase sale stapling vessel sealing product revenue realize procedure be approximately compare year quarter system sale increase buoy higher revenue operate lease activity intuitive surgical place system order quarter year quarter management intuitive surgical note system be place operate lease transaction compare system year quarter service company register revenue year year basis due growth install base da vinci system international growthper management company post revenue outside second quarter company place system order compare year quarter first quarter include europe japan india australia china intuitive surgical inc price consensus ep surprise intuitive surgical inc price consensus ep surprise intuitive surgical inc quotefinancial update intuitive surgical end report quarter cash cash equivalent investment year year basis takewe believe grow adoption intuitive surgical da vinci system physician general surgery oncology urology gynecology procedure be key growth catalyst moreover increase procedural volume outside present significant growth opportunity company zack rank key company have zack rank hold few better rank stock broader medical sector be edward lifescience corporation ew free report cryolife inc cry free report edap tms sa edap free report notably edap tms sport zack rank strong buy edward lifescience cryolife have zack rank buy see complete list today zack rank stock here edap tms represent impressive return last month company deliver solid earning surprise last report quarter edward lifescience have long term expect earning growth rate notably stock boast impressive year return cryolife yielded strong return last month stock deliver positive earning surprise last report quarter make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
1170,EW,edward lifescience corporation ew free report be schedule report second quarter earning jul market close last quarter company have post positive earning surprise be worth note edward lifescience have outperformed zack consensus estimate precede quarters average positive earning surprise let take look thing be shape prior announcement factor playedward lifescience post strong global sale last report quarter primarily buoy strength transcatheter heart valve tavr banking continue therapy adoption geography notable strength company be expect maintain bullish trend second quarter well tavr space edward lifescience report highly encourage european post approval clinical trial result sapien transcatheter heart valve company also demonstrated successful result pertain centera valve transcatheter aortic valve replacement procedure much await europcr hold edward lifescience corporation price ep surprise edward lifescience corporation price ep surprise edward lifescience corporation quotewe be also upbeat company initiative strategic investment research development receipt regulatory approval product move latest breakthrough achieve tavr segment be fda approval sapien valve early jun bullish company ongoing performance management raise growth expectation high end project full year guidance segment moreover note company project total sale adjust earning share cent cent second quarter apart management complete acquisition israel base valtech cardio developer cardioband system transcatheter repair mitral tricuspid valf end be expect boost top line quarter be report flip side tough competition cardiac device market reimbursement issue continue challenge company also believe unfavorable foreign currency affect company gross margin be report quarter earning whispersour proven model do not conclusively show earning beat edward lifescience quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp edward lifescience have earning esp be most accurate estimate zack consensus estimate be peg uncover best stock buy sell re report earning esp filter zack rank edward lifescience have zack rank increase predictive power esp however esp make surprise prediction difficult meanwhile caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision stock considerhere be few company want consider proven model show have right combination element post earning beat quarter becton dickinson company bdx free report have earning esp zack rank see complete list today zack rank stock here align technology inc algn free report have earning esp zack rank stryker corporation syk free report have earning esp zack rank look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1171,EW,headquarter latham ny angiodynamic inc ango free report lead provider minimally invasive medical device report adjust earning cent share fourth quarter fiscal earning beat zack consensus estimate cent remain flat year year stock have deliver positive earning surprise past quarters average meanwhile net sale fall almost year year basis miss zack consensus estimate stock performance lack lustershare price angiodynamic decline close follow earning release fact company have negative return almost last month zack classify medical instrument sub industry gain current level be also significantly gain same time frame highlight angiodynamic register revenue year year however sale totale peripheral vascular pv business sale segment be report quarter lower year quarter disappointing performance management expect thrombus management platform pv product line provide company competitive advantage open significant long term opportunity note angiodynamic be lead player thrombolytic catheter space catheter direct thrombolysis company boast highly unique catheter uni fuse speedlyser pulse spray thrombus portfolio vascular access va business sale segment decline almost year year partially offset solid growth bioflo midline dialysis bioflo line product segment be expect be key catalyst oncology surgery business sale segment plunge year quarter owing lower sale ablation product nanoknife capital segment perform unimpressively primarily due market withdrawal company flagship acculis microwave tissue ablation system recall also affected company international sale precisely have overall negative impact earning management recall acculis net revenue have totale previously guide range angiodynamic inc price consensus angiodynamic inc price consensus angiodynamic inc quotefy highlightsnet sale fiscal be year angiodynamic register adjust earning cent share year year basis management year year decline sale be primarily lead unimpressive performance company va net sale oncology segment net sale however be partially offset growth pv segment net sale regard pv segment see rise year year basis pv sale be drive growth core angiographic catheter business however sale va oncology segment decline respectively year year basis margin detailsadjust gross margin increase basis point bps quarter adjust ebitda fourth quarter fiscal exclude item show attach reconciliation table be compare fourth quarter fiscal come operate expense sale marketing research development expense decline bps bps respectively percentage revenue however general administrative expense rise bps year year basis financial have strong cash flow balance fourth quarter management generate operate cash flow free cash flow additionally angiodynamic end quarter cash cash equivalent outstanding debt fiscal company expect adjust earning share band cent cent company project fiscal revenue range furthermore free cash flow be expect be report mixed fourth quarter fiscal adjust earning surpass zack consensus estimate revenue miss same company also provide encourage earning guidance fiscal major growth driver company be perpheral vascular nanoknife bioflo midline product line growth core angiographic catheter business be also likely fortify company footprint global space flipside angiodynamic recall acculis microwave tissue ablation system oncology surgery segment company also have high outstanding debt level end fourth quarter higher debt impose certain operate financial restriction limit execution company core business strategy zack rank key have zack rank hold few better rank stock broader medical sector be edward lifescience corporation ew free report cryolife inc cry free report edap tms sa edap free report notably edap tms sport zack rank strong buy edward lifescience cryolife have zack rank buy see complete list today zack rank stock here edap tms represent impressive return last month company deliver solid earning surprise last report quarter edward lifescience have long term expect earning growth rate notably stock boast impressive year return cryolife yielded strong return last month stock deliver positive earning surprise last report quarter look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
1172,EW,jul issue update research report kalamazoo mi base stryker corporation syk free report largest medical device company global orthopedic market company currently have zack rank buy company have diversify product portfolio cushion significant sale shortfall economic downturn stryker pipeline include product hip knee mako robotic arm assist surgery mako result last quarter be solid almost global robot installation be furthermore platform bone cement sport medicine bone substitute soft tissue repair trauma extremity endoscopy more fortify company market position stryker have be follow acquisition drive strategy boost growth profile june company announce definitive agreement acquire novadaq technology inc share net purchase price transaction be structure arrangement canada business corporation act be subject customary close condition include approval novadaq shareholder additionally acquisition sage product physio control add company net sale last quarter stryker have be focuse international growth well particular company medsurg product line have witness strong demand european australian market first quarter flip side china prove be challenge market stryker strong guidance be also catalyst second quarter company expect adjust earning range share full year company estimate adjust earning band stryker expect organic sale growth full year last month stock represent strong return higher zack classify medical product sub industry gain current level be also significantly higher return same time frame other key picksa few better rank stock broader medical sector be edward lifescience corporation ew free report cryolife inc cry free report edap tms sa edap free report notably edap tms sport zack rank strong buy edward lifescience cryolife have zack rank buy see complete list today zack rank stock here edap tms represent impressive return last month company deliver solid earning surprise last report quarter edward lifescience have long term expect earning growth rate notably stock represent impressive year return cryolife yielded strong return last month stock deliver positive earning surprise last report quarter trade profit big league trump policy stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
1173,EW,market be not really happy sunnyvale base base accuray inc aray free report preliminary result fourth quarter fiscal follow announcement company stock lose last trading session close meanwhile glimpse third quarter fiscal performance show loss cent share compare unfavorably zack consensus estimate earning penny total revenue quarter decrease approximately year year preliminary resultsrevenue revenue fourth quarter be forecast band fiscal revenue be project range management europe asia pacific be key growth area company gross product order accuray expect approximately gross product order fiscal gross product order be anticipate be approximately notably last quarter gross product order increase almost year year basis solid growth gross order be buoy full commercial launch radixact system continue strong demand company flagship cyberknife system balance sheet accuray forecast cash cash equivalent investment restrict cash jun mark increase mar management fourth quarter accuray reduce total debt company expect age out cancellation fourth quarter be approximately respectively estimate stock zack consensus estimate current quarter stand breakeven revenue be expect be fourth quarter note accuray fail meet earning revenue estimate past quarters full year zack consensus estimate bottom line stand loss cent come revenue estimate expect accuray revenue fiscal however company promise long term expect earning growth rate carry zack rank hold last month stock give negative return compare unfavorably zack classify medical instrument sub industry gain current level be also significantly lower return same time frame key picksa few better rank stock broader medical sector be edward lifescience corporation ew free report cryolife inc cry free report edap tms sa edap free report notably edap tms sport zack rank strong buy edward lifescience cryolife have zack rank buy see complete list today zack rank stock here edap tms represent impressive return last month company deliver solid earning surprise last report quarter edward lifescience have long term expect earning growth rate notably stock represent impressive year return cryolife yielded strong return last month stock deliver positive earning surprise last report quarter trade profit big league trump policy stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
1174,EW,jul issue update research report haemonetic corporation hae free report base lead provider blood management solution customer encompass blood plasma collector hospital health care provider globally stock currently carry zack rank hold past year haemonetic have be trading zack categorize medical product industry period stock have surge compare broader industry be particularly encourage company consistent growth plasma segment well haemonetic management franchise haemonetic have be witness strong flourish plasma franchise quite time now management have also maintain high confidence continue growth commercial plasma collection business late management declare nextgen plasma collection software have be see avid customer interest management guidance plasma revenue growth be inclusive divestiture sebra bench top handheld sealer represent annual plasma revenue fourth quarter company hospital business be also progress well teg line product have gain popularity worldwide teg be approve broad set indication top market teg teg manager be sanction same set indication europe australia japan teg be be used cardiovascular surgery company be presently pursue broader set indication begin trauma flip side company have be witness sluggish revenue growth blood center franchise have significantly affected haemonetic result past few quarters management also doesn expect early recovery blood center outcome macroeconomic uncertainty continue challenge haemonetic management also anticipate slower expect product adoption customer reduce revenue profit also currency fluctuation stiff competition continue hamper stock other key pickssome better rank medical stock be mesa laboratory inc mlab free report edward lifescience corp ew free report align technology inc algn free report mesa laboratory edward lifescience sport zack rank strong buy align technology carry zack rank buy see complete list today zack rank stock here mesa laboratory deliver positive earning surprise last quarters stock gain roughly last month edward lifescience have long term expect earning growth rate stock climb last month align technology have expect long term adjust earning growth almost stock surge approximately last month today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1175,EW,waltham base thermo fisher scientific inc tmo free report be scientific instrument maker world leader serve science company be healthy growth trajectory late andha rally past month ahead gain stock have market cap company have also considerably outperformed zack categorize medical product sub industry gain notably zack rank buy company estimate revision trend current year be favorable last day estimate have moved revision opposite direction magnitude estimate revision increase share company deliver quarter positive average earning surprise earning surprise last report first quarter strong growth prospect thermo fisher be attractive pick present growth catalyststhermo fisher continuous effort drive growth inorganically acquisition activity have be generate lot enthusiasm investor company have announce agreement acquire netherlands base patheon global provider high quality drug solution pharmaceutical biopharma sector thermo fisher expect derive lot synergy buyout help expand biopharma offering europe combination be anticipate strengthen thermo fisher foothold pharmaceutical biotech market add highly complementary service portfolio also acquisition fei have already start generate synergy contribute largely company analytical instrument portfolio have turn boost market optimism stock market be also upbeat company focus gain traction high potential emerge geography china thermo fisher have be deliver solid result market biopharma healthcare environment order meet rise demand clinical trial south korea company recently launch biopharma service unit significantly thermo fisher be continuously work cash opportunity biopharma healthcare food safety market india other key picksother top rank medical stock be mesa laboratory inc mlab free report edward lifescience corp ew free report align technology inc algn free report mesa laboratory edward lifescience sport zack rank strong buy align technology carry zack rank see complete list today zack rank stock here mesa laboratory deliver positive earning surprise last quarters stock add roughly last month edward lifescience have long term expect earning growth rate stock surge last month align technology have expect long term adjust earning growth almost stock jump nearly last month today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1176,EW,biotelemetry inc beat free report recently announce acquisition lifewatch ag deal value buyout biotelemetry enhance position wireless medicine space enlarge product profile customer base cardiac monitoring diagnostic service space stock price performance biotelemetry have be favorable last month stock have gain outperform zack classify medical service sub industry gain almost current level compare favorably return same time frame estimate revision trend current year have be positive last month estimate moved south movement opposite direction together solid long term earning growth rate instill confidence stock come back news management expect acquisition yield significant synergy next month company make product be utilize remotely monitoring cardiac care patient headquarter zug switzerland lifewatch be lead healthcare technology solution company specialize advanced digital health system wireless remote diagnostic patient monitoring service go forward biotelemetry have be gain prominence late expand payer coverage introduction innovative product furthermore note biotelemetry mar have strong financial position more cash company post stellar first quarter revenue year year basis meanwhile company expect double digit revenue growth expect approximate ebitda return fiscal quarter end jun company expect revenue growth ebitda return headquarter conshohocken pa biotelemetry provide cardiac monitoring service cardiac monitoring device manufacturing zack rank key pickscurrently biotelemetry carry zack rank hold few better rank medical stock be mesa laboratory inc mlab free report edward lifescience corp ew free report align technology inc algn free report notably mesa laboratory edward lifescience sport zack rank strong buy align technology carry zack rank buy see complete list today zack rank stock here mesa laboratory have positive earning surprise last quarters stock have add roughly last month edward lifescience have long term expect earning growth rate stock have gain last month align technology have expect long term adjust earning growth almost stock have add roughly last month today stock zack hottest strategy hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
1177,EW,jul issue update research report radnor pa base vwr corporation offer laboratory product service solution company currently carry zack rank buy last month vwr have be trading zack categorize medical dental supply industry company share have rally much gain broader medical dental supply industry period be currently look forward company impending sale ultra high purity material supplier avantor announce back upside potential stock be however limit divestiture post close be expect create major consumable focuse solution service provider high growth life science advanced technology industry acquisition build avantor strength include cgmp current good manufacturing practice process significant exposure emerge market vwr vital position americas well europe combine company therefore be serve global customer base area activity research production reflect unique advantage fast grow marketplace shareholder point view potential merger avantor seem beneficial move moment consolidation deal have be fix cash share vwr common stock represent enterprise value approximately purchase price represent approximate premium unaffected close stock price day start market speculation regard potential sale vwr purchase price also denote approximate premium trading day volume weight average price vwap approximate premium trading day vwap vwr common stock key picksother better rank medical stock be mesa laboratory inc mlab free report edward lifescience corp ew free report align technology inc algn free report mesa laboratory edward lifescience sport zack rank strong buy align technology carry zack rank see complete list today zack rank stock here mesa laboratory have positive earning surprise last quarters stock have add roughly last month edward lifescience have long term expect earning growth rate stock have jump last month align technology have expect long term adjust earning growth almost stock have surge roughly last month more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
1178,EW,davita medical group subsidiary fortune company davita inc dva free report be consistently make effort expand inorganically line recently acquire dr rahn shaw practice park avenue medical inc winter park health center inc locate orlando notably dr shaw practice have be affiliated davita medical group offersquality care patient age pediatrics geriatric acquisition be complete jul practice remain brand davita medical group company expect acquisition help strengthen foothold orlando last month davita have be observed underperform zack categorize medical outpatient home healthcare industry latest share price movement company have gain compare gain broader industry however investor confidence get boost company consistent effort expand strategic merger acquisition bolster revenue time recent everett clinic medical group medical group davita medical group division have reveal plan buy base family practice clinic open new clinic bothell woodinville year also healthcare partner unit davita medical group magan medical clinic respect multispecialty medical group los angele county san gabriel valley recently announce enter definitive agreement magan join healthcare partner davita announce enter definitive agreement magan join healthcare partner division davita late healthcare partner nevada part davita medical group announce acquisition wellhealth quality care multus specialty medical group accountable care organization affiliated entity zack rank key picksdavita currently carry zack rank sell few better rank medical stock be mesa laboratory inc mlab free report edward lifescience corp ew free report align technology inc algn free report notably mesa laboratory edward lifescience sport zack rank strong buy align technology carry zack rank buy see complete list today zack rank stock here mesa laboratory have positive earning surprise last quarters stock have add roughly last month edward lifescience have long term expect earning growth rate stock have gain last month align technology have expect long term adjust earning growth almost stock have add roughly last month more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
